{
  "questions": [
    {
      "id": "67e6cf2618b1e36f2e0000d0",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27052640",
        "http://www.ncbi.nlm.nih.gov/pubmed/17334672",
        "http://www.ncbi.nlm.nih.gov/pubmed/21880994",
        "http://www.ncbi.nlm.nih.gov/pubmed/21983866",
        "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
        "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
        "http://www.ncbi.nlm.nih.gov/pubmed/21330749",
        "http://www.ncbi.nlm.nih.gov/pubmed/25269031",
        "http://www.ncbi.nlm.nih.gov/pubmed/28514722",
        "http://www.ncbi.nlm.nih.gov/pubmed/26786929"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27052640",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1240,
          "offsetInEndSection": 1462,
          "text": "After failure of several phase III trials with previously promising agents, improvement of concepts and novel compounds are urgently needed to expand the still limited therapeutic options for the treatment of glioblastoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27052640",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 132,
          "offsetInEndSection": 256,
          "text": "Novel treatment strategies beyond the established standard of care with temozolomide-based radiotherapy are urgently needed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27052640",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 554,
          "offsetInEndSection": 797,
          "text": "So far, inhibition of angiogenesis by compounds such as bevacizumab, cediranib, enzastaurin or cilengitide as well as alternative dosing schedules of temozolomide did not prolong survival, neither at primary diagnosis nor at recurrent disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27052640",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 403,
          "offsetInEndSection": 553,
          "text": "In the last decade, phase III trials on novel compounds largely failed to introduce efficacious pharmacotherapies beyond temozolomide in glioblastoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27052640",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Glioblastoma, the most common malignant brain tumor, exhibits a poor prognosis with little therapeutic progress in the last decade."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17334672",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17334672",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 325,
          "offsetInEndSection": 549,
          "text": "We report three cases in whom patients with glioblastoma multiforme were implanted with fibrin glue-secured Gliadel after the lateral ventricles had been opened, and who later developed severe hydrocephalus leading to death."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17334672",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 550,
          "offsetInEndSection": 718,
          "text": "Although Gliadel may be an important adjunct to treatment, opening of the ventricles during surgery as part of its application should be considered a contra-indication."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17334672",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 251,
          "offsetInEndSection": 324,
          "text": "However, some precautions should be taken regarding Gliadel implantation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1304,
          "offsetInEndSection": 1423,
          "text": "VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 181,
          "offsetInEndSection": 528,
          "text": "The European Organization for Research and Treatment of Cancer (EORTC) 26981-22981/National Cancer Institute of Canada (NCIC) CE.3 clinical trial database of radiotherapy (RT) with or without temozolomide (TMZ) for newly diagnosed glioblastoma was examined to assess the impact of the interaction between AED use and chemoradiotherapy on survival."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1424,
          "offsetInEndSection": 1606,
          "text": "Future studies are needed to determine whether VPA increases TMZ bioavailability or acts as an inhibitor of histone deacetylases and thereby sensitizes for radiochemotherapy in vivo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1003,
          "offsetInEndSection": 1303,
          "text": "Patients receiving VPA alone (97 [16.9%]) appeared to derive more survival benefit from TMZ/RT (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.24-0.63) than patients receiving an EIAED only (252 [44%]) (HR 0.69, 95% CI 0.53-0.90) or patients not receiving any AED (HR 0.67, 95% CI 0.49-0.93)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21983866",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 546,
          "offsetInEndSection": 729,
          "text": "The data in the literature regarding the combined use of Gliadel with chemotherapy, concomitant with radiotherapy and adjuvant temozolomide for glioblastoma was analyzed and compared."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21983866",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 345,
          "offsetInEndSection": 545,
          "text": "objective of this study was to review the literature of efficacy and toxicities in patients with first-diagnosis glioblastoma treated with surgery, Gliadel, radiotherapy and temozolomide chemotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21983866",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 783,
          "offsetInEndSection": 938,
          "text": "The combination of Gliadel and radiotherapy with temozolomide is well tolerated and may increase survival without a substantial increase in major toxicity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21983866",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "Loco-regional chemotherapy with carmustine wafers (Gliadel) positioned at surgery and followed by radiotherapy has been shown to prolong survival in first-diagnosis glioblastoma, as well as concomitant radiochemotherapy with temozolomide."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21983866",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 239,
          "offsetInEndSection": 344,
          "text": "The combination of Gliadel with the Stupp protocol has mostly been investigated in retrospective studies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 231,
          "offsetInEndSection": 395,
          "text": "Transcriptional aberrations may play a vital role in the etiology of glioblastoma, which might be caused by both genomic alterations and other regulation molecules."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 640,
          "text": "In this study, we investigated possible cooperative deregulation of microRNAs (miRNAs) and transcription factors (TFs) in glioblastoma, under the hypothesis that miRNAs and TFs might have a combinational regulatory effect on glioblastoma genes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Glioblastoma is the most common and most lethal brain tumour in humans."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 641,
          "offsetInEndSection": 798,
          "text": "We searched glioblastoma-specific regulatory networks by integrating glioblastoma related miRNAs, TFs and genes, and identified 54 feed-forward loops (FFLs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 230,
          "text": "Illustrating the functions being disturbed during carcinogenesis and how they are deregulated is very important for us to understand its underlying mechanism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1016,
          "offsetInEndSection": 1249,
          "text": "Several retrospective studies in seizure patients with glioblastoma treated with chemotherapy have provided evidence for a moderately improved survival with the use of valproic acid, possibly due to inhibition of histone deacetylase."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 244,
          "offsetInEndSection": 430,
          "text": "Based on current evidence, prophylactic prescription of long-term antiepileptic drugs (AEDs) in patients with brain tumors in patients who did not present with seizures is not justified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2122,
          "offsetInEndSection": 2272,
          "text": "In patients with a successfully treated tumor and an overall good prognosis for long-term survival, gradual discontinuation of AEDs may be considered."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 431,
          "offsetInEndSection": 579,
          "text": "Because of the high risk of recurrence, however, AED treatment should be strongly considered after a single seizure considered to be due to a tumor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1875,
          "offsetInEndSection": 2121,
          "text": "Resection of the tumor, radiation therapy, or chemotherapy can bring refractory seizures under control or prolong the duration of seizure freedom, an effect that does not appear to be necessarily related to removal or shrinkage of the tumor mass."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21330749",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 642,
          "offsetInEndSection": 799,
          "text": "Gliadel wafer is a new approach to the treatment of glioblastoma, which involves controlled release delivery of carmustine from biodegradable polymer wafers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21330749",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 800,
          "offsetInEndSection": 886,
          "text": "It has shown promising results and provides a silver lining for glioblastoma patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21330749",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Glioblastoma is a rapidly progressive and extremely fatal form of brain tumor with poor prognosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21330749",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 528,
          "offsetInEndSection": 641,
          "text": "Targeted drug delivery strategies to circumvent the blood-brain barrier have shown efficiency in clinical trials."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21330749",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 315,
          "offsetInEndSection": 527,
          "text": "Developments in molecular and cell biology have led to better understanding of tumor development, leading to novel treatment strategies including biological therapy and immunotherapy to combat the deadly disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25269031",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "The aim of this study was to a conduct a systematic review of carmustine wafers (Gliadel wafers) for the treatment of glioblastoma multiforme (GBM) to assess the survival benefit and safety of this therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25269031",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1009,
          "offsetInEndSection": 1195,
          "text": "This systematic review suggests that carmustine wafers have demonstrated promise as an effective and tolerable treatment in comparison to other treatment strategies in patients with GBM."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25269031",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 710,
          "offsetInEndSection": 865,
          "text": "In three of the trials, patients with GBM who received carmustine wafers had significantly longer median survival than patients who did not receive wafers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25269031",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 207,
          "offsetInEndSection": 529,
          "text": "The inclusion criteria were 1) prospective or retrospective clinical trial; 2) patients who had undergone resection for primary GBM or first recurrence of GBM with or without carmustine wafer implantation; 3) patients with malignant gliomas that included GBM; 4) outcomes including survival analysis of the GBM population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25269031",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 866,
          "offsetInEndSection": 956,
          "text": "Implantation of carmustine wafers did not significantly improve progression-free survival."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28514722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 366,
          "text": "New therapeutic agents in combination with the standard Stupp protocol (a protocol about the temozolomide combined with radiotherapy treatment with glioblastoma was research by Stupp R in 2005) were assessed to evaluate whether they were superior to the Stupp protocol alone, to determine the optimum treatment regimen for patients with newly diagnosed glioblastoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28514722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 644,
          "offsetInEndSection": 1040,
          "text": "The use of novel therapeutic agents in combination with the Stupp protocol were all shown to be superior than the Stupp protocol alone for the treatment of newly diagnosed glioblastoma, ranked as follows: cilengitide 2000mg/5/week, bevacizumab in combination with irinotecan, nimotuzumab, bevacizumab, cilengitide 2000mg/2/week, cytokine-induced killer cell immunotherapy, and the Stupp protocol."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28514722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1661,
          "offsetInEndSection": 1826,
          "text": "However, we could not conclusively confirm whether cilengitide 2000mg/5/week was the optimum regime, as only one trial using this protocol was included in our study."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28514722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1539,
          "offsetInEndSection": 1660,
          "text": "All intervention drugs evaluated in our study were superior to the Stupp protocol alone when used in combination with it."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28514722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1041,
          "offsetInEndSection": 1314,
          "text": "In terms of serious adverse effects, the intervention group showed a 29% increase in the incidence of adverse events compared with the control group (patients treated only with Stupp protocol) with a statistically significant difference (RR=1.29; 95%CI 1.17-1.43; P<0.001)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2017,
          "offsetInEndSection": 2192,
          "text": "The results of this analysis do not justify the use of VPA or LEV for reasons other than seizure control in patients with newly diagnosed glioblastoma outside clinical trials."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 340,
          "text": "Several uncontrolled retrospective case series and a post hoc analysis of the registration trial for temozolomide indicated an association between valproic acid (VPA) use and improved survival outcomes in patients with newly diagnosed glioblastoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Symptomatic epilepsy is a common complication of glioblastoma and requires pharmacotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 341,
          "offsetInEndSection": 1073,
          "text": "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1668,
          "offsetInEndSection": 1941,
          "text": "Furthermore, PFS and OS of patients taking VPA both at start of and still after chemoradiotherapy were not different from those without antiepileptic drug use at both time points (PFS: HR, 0.92; 95% CI, 0.74 to 1.15; P = .467; OS: HR, 1.10; 95% CI, 0.86 to 1.40; P = .440)."
        }
      ]
    },
    {
      "id": "680d5e47353a4a2e6b000005",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8286427",
        "http://www.ncbi.nlm.nih.gov/pubmed/26380465",
        "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
        "http://www.ncbi.nlm.nih.gov/pubmed/27695175",
        "http://www.ncbi.nlm.nih.gov/pubmed/20477251",
        "http://www.ncbi.nlm.nih.gov/pubmed/24977015",
        "http://www.ncbi.nlm.nih.gov/pubmed/26770619",
        "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
        "http://www.ncbi.nlm.nih.gov/pubmed/6984375",
        "http://www.ncbi.nlm.nih.gov/pubmed/19704328"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8286427",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 343,
          "offsetInEndSection": 422,
          "text": "This article describes the symptoms of achalasia, its diagnosis, and treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8286427",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 528,
          "text": "Case studies illustrate common findings in patients with achalasia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8286427",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 205,
          "text": "The etiology of achalasia is poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8286427",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Achalasia is a motility disorder of the esophagus characterized by total loss of esophageal peristalsis and by defective lower esophageal sphincter function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8286427",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 206,
          "offsetInEndSection": 272,
          "text": "Achalasia occurs across the lifespan, but is uncommon in children."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26380465",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 242,
          "offsetInEndSection": 434,
          "text": "The current hypothesis of the disease mechanism is recurrent injury to the respiratory epithelium which leads to an uncontrolled wound healing process resulting in fibrosis rather than repair."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26380465",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown cause."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26380465",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 84,
          "offsetInEndSection": 241,
          "text": "The clinical course is unpredictable, but the disease is usually progressive with a median survival of 2-5 years as a result of advanced respiratory failure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26380465",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 435,
          "offsetInEndSection": 531,
          "text": "Despite better understanding of the pathogenesis, there is no effective therapy for the disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26380465",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 532,
          "offsetInEndSection": 689,
          "text": "In this review, we present the positive results of recently published clinical trials regarding therapy for IPF, with emphasis on pirfenidone and nintedanib."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Asthma and COPD are prevalent chronic inflammatory airway diseases that are responsible for a large global disease burden."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 303,
          "offsetInEndSection": 540,
          "text": "Eosinophilic airway inflammation is considered the most influential treatable trait of chronic airway disease, and over the last decade, several monoclonal antibodies and small molecule therapies have been developed to target this trait."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 302,
          "text": "Both diseases are complex and heterogeneous, and they are increasingly recognized as overlapping syndromes that may share similar pathophysiologic mechanisms and treatable traits."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 541,
          "offsetInEndSection": 852,
          "text": "These include monoclonal antibodies against IL-5 or IL-5 receptor alpha (mepolizumab, reslizumab, and benralizumab), IL-13 (lebrikizumab and tralokinumab), IL-4 receptor alpha (dupilumab), IgE (omalizumab), and anti-thymic stromal lymphopoietin (tezepelumab) and small molecule therapies such as prostaglandin D"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695175",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 460,
          "text": "A computed tomography (CT) scan at our hospital revealed a giant bulla, which was managed conservatively as an exacerbation of chronic obstructive pulmonary disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695175",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 746,
          "offsetInEndSection": 878,
          "text": "We highlight the etiology, presentation, diagnosis, and treatment of bullous lung disease, especially in comparison to pneumothorax."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695175",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 66,
          "offsetInEndSection": 294,
          "text": "We present the case of a 55-year-old man admitted to a referring hospital with dyspnea, cough, and increasing sputum production; he refused thoracotomy for tension pneumothorax and presented to our hospital for a second opinion."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695175",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 524,
          "offsetInEndSection": 644,
          "text": "Giant bullae can easily be misdiagnosed as a pneumothorax, but the management of the two conditions is vastly different."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695175",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 645,
          "offsetInEndSection": 696,
          "text": "Distinguishing between the two may require CT scan."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20477251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Exacerbations of chronic obstructive pulmonary disease (COPD) are an important cause of morbidity and healthcare expenditure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20477251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 718,
          "text": "Treatment with antibiotics is usually recommended for patients who have an increase in sputum volume, sputum purulence and breathlessness, but the most important determinant of bacterial infection appears to be purulence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20477251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 213,
          "offsetInEndSection": 496,
          "text": "There is also evidence for the effectiveness of antibiotics in treating COPD exacerbations in the community, but this is most convincing in patients with severe airflow obstruction and there is uncertainty regarding the value of antibiotics in patients with mild airflow obstruction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20477251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1114,
          "offsetInEndSection": 1292,
          "text": "A number of studies suggest that antibiotic courses of 5 days in duration may be as effective as those for 7 days or more in patients with mild-to-moderate exacerbations of COPD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20477251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1293,
          "offsetInEndSection": 1459,
          "text": "Guidelines do not recommend the use of prophylactic antibiotics in COPD but there is preliminary evidence to suggest that they may reduce the number of exacerbations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24977015",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Giant bullous emphysema (GBE), known as 'vanishing lung syndrome', usually occurs in association with chronic obstructive pulmonary disease (COPD)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24977015",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 148,
          "offsetInEndSection": 336,
          "text": "In this report, we describe a patient with giant emphysematous bulla occupying approximately 95% of the right hemithorax, who had history of repeated attacks of acute exacerbation of COPD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24977015",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 506,
          "offsetInEndSection": 615,
          "text": "Preoperatively he was functionally and clinically severely disabled while improved markedly after bullectomy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24977015",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 390,
          "offsetInEndSection": 505,
          "text": "Delightfully, the 5% of residual lung compressed for 4 years gradually inflated, and occupied the whole hemithorax."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24977015",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 337,
          "offsetInEndSection": 389,
          "text": "About 95% of right pulmonary parenchyma was removed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26770619",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 336,
          "text": "We present here a rare case of giant bullous emphysema in a mid-age nonsmoking female who was seen for progressive shortness of breath and cough."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26770619",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Giant bullous emphysema, or vanishing lung syndrome, typically occurs in young, thin male smokers with large bullae in one or more upper lobes occupying at least one-third of the hemithorax."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26770619",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 417,
          "offsetInEndSection": 518,
          "text": "The patient underwent successful thoracoscopic bullectomy and is currently without residual symptoms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26770619",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 337,
          "offsetInEndSection": 416,
          "text": "Chest computed tomography found a giant bulla in the middle lobe of right lung."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 181,
          "text": "Pulmonary involvement can be divided into two categories: acute or chronic compromise."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 815,
          "offsetInEndSection": 963,
          "text": "We present a case of pulmonary involvement in schistosomiasis and provide a discussion about typical imaging findings in the acute and chronic form."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 582,
          "offsetInEndSection": 742,
          "text": "The common CT findings in acute pulmonary schistosomiasis are small pulmonary nodules ranging from 2 to 15 mm and larger nodules with ground glass-opacity halo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 272,
          "text": "Chronic and recurrent infection develops in persons living or travelling in endemic areas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 743,
          "offsetInEndSection": 814,
          "text": "Katayama fever is a severe clinical manifestation of acute involvement."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6984375",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 853,
          "offsetInEndSection": 1088,
          "text": "While a conservative surgical approach to treatment of the ENT symptoms is recommended, early and active treatment of the bronchial symptoms is probably important for prevention of further lung damage and development of bronchiectasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6984375",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 645,
          "offsetInEndSection": 852,
          "text": "As primary ciliary dyskinesia can occur without situs inversus, knowledge of the typical ENT symptoms is essential for making an early diagnosis, which is important for the correct management of the disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6984375",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 327,
          "offsetInEndSection": 453,
          "text": "Daily accumulation of secretions in the nose, chronic recurrent secretory otitis media and sinusitis occurred in all subjects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6984375",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "Ear, nose and throat symptoms and signs were studied in 15 patients with Kartagener's syndrome: a triad consisting of chronic rhinosinusitis, chronic bronchitis with bronchiectasis, and situs inversus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6984375",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 326,
          "text": "The triad is caused by primary ciliary dyskinesia and characterized by absent or considerably reduced mucociliary transport."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 88,
          "offsetInEndSection": 260,
          "text": "This is a chronic, progressive condition usually affecting young male smokers and is characterized by giant emphysematous bullae, which commonly develop in the upper lobes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1441,
          "offsetInEndSection": 1544,
          "text": "The predominant findings on HRCT scans are extensive paraseptal emphysema coalescing into giant bullae."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 261,
          "offsetInEndSection": 397,
          "text": "Extensive paraseptal emphysema coalesces to form giant bullae, compressing the normal lung parenchyma and often displacing it centrally."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1287,
          "offsetInEndSection": 1440,
          "text": "All of our patients had subpleural bullae, had parenchymal fibrosis, another had extensive subcutaneous emphysema, and 1 had accompanying bronchiectasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704328",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1021,
          "offsetInEndSection": 1286,
          "text": "Five of the 7 patients had extensive upper lobe predominant bullae, 4 of the 7 patients showed severe bilateral disease with asymmetric involvement, 2 of the 7 patients demonstrated left lung predominance and whereas 1 patient showed right lung predominant disease."
        }
      ]
    },
    {
      "id": "680f4a68353a4a2e6b000007",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24696870",
        "http://www.ncbi.nlm.nih.gov/pubmed/29559781",
        "http://www.ncbi.nlm.nih.gov/pubmed/16634707",
        "http://www.ncbi.nlm.nih.gov/pubmed/34855694",
        "http://www.ncbi.nlm.nih.gov/pubmed/23109125",
        "http://www.ncbi.nlm.nih.gov/pubmed/27274384",
        "http://www.ncbi.nlm.nih.gov/pubmed/22762295",
        "http://www.ncbi.nlm.nih.gov/pubmed/25852975",
        "http://www.ncbi.nlm.nih.gov/pubmed/19033200",
        "http://www.ncbi.nlm.nih.gov/pubmed/36262632"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 530,
          "offsetInEndSection": 622,
          "text": "However, companies developing drugs for depression also face a number of serious challenges."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1324,
          "offsetInEndSection": 1510,
          "text": "The lack of complete understanding of why depression occurs also makes this area a difficult one, although it opens the door for the development of drugs with novel mechanisms of action."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 63,
          "text": "Depression represents a huge pharmaceutical market opportunity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 623,
          "offsetInEndSection": 900,
          "text": "Psychosocial treatment options remain the preferred first-line therapy ahead of medication-and when it comes to drug treatment, the abundance of generic options available has significantly contributed to halving the value of the branded antidepressant market over recent years."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 401,
          "offsetInEndSection": 529,
          "text": "The high incidence rate, combined with limited market penetration, makes depression a high potential market for pharmaceuticals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29559781",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 698,
          "offsetInEndSection": 825,
          "text": "In depression, treatment resistance to antidepressive pharmacotherapy represents one of the most important clinical challenges."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29559781",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29559781",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 826,
          "offsetInEndSection": 1011,
          "text": "Switching to monotherapy with new multimodal/multifunctional antidepressants and augmentation with new atypical antipsychotics (aripiprazole and brexpiprazole) may be promising options."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29559781",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 466,
          "offsetInEndSection": 697,
          "text": "New pharmacological options include new more sophisticated forms of monoaminergic drugs, old drugs rediscovered on the base of a better understanding of pathophysiology of mental illnesses, and drugs aimed at new treatment targets."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29559781",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1170,
          "offsetInEndSection": 1381,
          "text": "Recent advances in technology and emerging knowledge about dysfunctional brain circuits and neuroplasticity have led to the development of different new neuromodulation techniques usually used as add-on therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16634707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 320,
          "offsetInEndSection": 551,
          "text": "Further evidence for the use of neuroprotective agents can be drawn from the findings that second-generation antipsychotics, mood stabilizers and antidepressants have been shown to have neuroprotective effects in vitro and in vivo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16634707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "With the exception of dementia, the use of neuroprotective agents in psychiatric disorders is not yet well established."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16634707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 319,
          "text": "However, recent data from brain imaging studies and clinical trials support the view that neurodegenerative mechanisms may play a role in the pathophysiology of schizophrenia and affective disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16634707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 743,
          "offsetInEndSection": 873,
          "text": "This paper reviews the current options for neuroprotective treatment approaches focusing on schizophrenia and affective disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16634707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 552,
          "offsetInEndSection": 742,
          "text": "Neuroprotective agents as add-on therapies (e.g., modafinil, erythropoietin, glycine, D-serine, memantine and celecoxib) are currently being evaluated in schizophrenia and related disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34855694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1150,
          "offsetInEndSection": 1293,
          "text": "Current research with medicinal psychedelics, usually as an adjunct to psychotherapy, has shown encouraging results in treating mood disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34855694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 433,
          "offsetInEndSection": 726,
          "text": "Randomized placebo-controlled trials have found psilocybin with psychological support effective at treating depression, including treatment-resistant depression; with emergent research also signalling N,N-dimethyltryptamine/ayahuasca also as a potential option for the treatment of depression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34855694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 269,
          "text": "Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34855694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34855694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 270,
          "offsetInEndSection": 432,
          "text": "Serotonergic psychedelics have been found to modulate brain networks underlying various psychiatric disorders, as well promoting neurogenesis and neuroplasticity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109125",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 278,
          "offsetInEndSection": 562,
          "text": "The quality of studies regarding the psychopharmacological therapy of depressive disorders in childhood and adolescence has improved since the \u00abblack box\u00bb warning of the FDA concerning the occurrence of suicidality under treatment with selective serotonin reuptake inhibitors (SSRIs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109125",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Depending on symptom severity, psychopharmacological treatment can be a valuable option in the treatment of depressive disorders in childhood and adolescence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109125",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 277,
          "text": "This review provides recommendations for clinical treatment, focusing on suicidality and treatment-resistant patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109125",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 563,
          "offsetInEndSection": 692,
          "text": "In Germany, there is proof for a trend toward a more evidence-based psychopharmacological treatment approach within recent years."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27274384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1083,
          "offsetInEndSection": 1332,
          "text": "The rationale of the present review is to delineate the pharmacotherapy of the depressive phase of bipolar disorder with medications for which there is evidence in the form of observational, open-label, or double-blind randomized controlled studies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27274384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 911,
          "offsetInEndSection": 1082,
          "text": "As such, there is a pressing need for novel agents that are efficacious in acute depressive exacerbations, and also have applicable value in preventing recurrent episodes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27274384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1333,
          "offsetInEndSection": 1696,
          "text": "In the treatment of acute bipolar depression in adults, a comprehensive appraisal of the extant literature reveals that among mood stabilizers, the most robust proof of efficacy exists for divalproex sodium; while atypical antipsychotics, which include olanzapine, quetiapine, lurasidone, and cariprazine, are also effective, as demonstrated in controlled trials."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27274384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 751,
          "offsetInEndSection": 910,
          "text": "This scenario is made worse by the fact that depressive symptoms, which represent the main disease burden, are often refractory to existing psychotropic drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27274384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 317,
          "offsetInEndSection": 508,
          "text": "The depressive phase is often associated with other neuropsychiatric conditions, such as anxiety spectrum disorders, substance use disorders, stressor-related disorders, and eating disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22762295",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Interest in nonpharmaceutical supplements for treating major depressive disorder (MDD) has increased signi\ufb01cantly, both among patients and among clinicians during the past decades."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22762295",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 181,
          "offsetInEndSection": 421,
          "text": "Despite the large array of antidepressants (ADs) available, many patients continue to experience relatively modest response and remission rates, in addition to a burden of side effects that can hinder treatment compliance and acceptability."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22762295",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 753,
          "offsetInEndSection": 930,
          "text": "Based on existing data, supplementation with SAMe, as well as with various formulations of folates, appears to be efficacious and well tolerated in reducing depressive symptoms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22762295",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 422,
          "offsetInEndSection": 652,
          "text": "In this article, we review the literature on folates and S-adenosylmethionine (SAMe), 2 natural compounds linked in the 1-carbon cycle metabolic pathway, for which substantial evidence supports their involvement in mood disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22762295",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 931,
          "offsetInEndSection": 1219,
          "text": "Compared with other forms of folates, 5-methyltetrahydrofolate (L-methylfolate or 5-MTHF) may represent a preferable treatment option for MDD given its greater bioavailability in patients with a genetic polymorphism, and the lower risk of specific side effects associated with folic acid."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852975",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 206,
          "text": "Until recently, only quetiapine and an olanzapine-fluoxetine combination were approved to treat bipolar depression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852975",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 207,
          "offsetInEndSection": 333,
          "text": "Recently, lurasidone was approved to treat bipolar depression either as monotherapy or adjunctively with lithium or valproate."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852975",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Depressive episodes in bipolar disorder contribute to significant morbidity and mortality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852975",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 334,
          "offsetInEndSection": 518,
          "text": "Lurasidone was well- tolerated, and commonly observed adverse reactions (incidence \u22655% and at least twice the rate for placebo) were akathisia, extrapyramidal symptoms, and somnolence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852975",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 591,
          "offsetInEndSection": 769,
          "text": "It is taken with food to ensure maximal absorption, and dose should be adjusted in patients who receive moderate CYP450 inhibitors or inducers and in patients with renal disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19033200",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 618,
          "offsetInEndSection": 838,
          "text": "We hypothesized that a reduced antidepressant response in individuals with a constitutive reduction in 5-HTT expression could arise because of the compensatory expression of other genes that inactivate 5-HT in the brain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19033200",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1260,
          "offsetInEndSection": 1399,
          "text": "Moreover, the OCT blocker decynium-22 diminishes 5-HT clearance and exerts antidepressant-like effects in these mice but not in WT animals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19033200",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 491,
          "offsetInEndSection": 617,
          "text": "Importantly, this variant is also associated with reduced responsiveness to selective 5-HT reuptake inhibitor antidepressants."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19033200",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 266,
          "text": "Although multiple medications, along with behavioral therapies, have proven effective for some individuals, millions of people lack an effective therapeutic option."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19033200",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 267,
          "offsetInEndSection": 490,
          "text": "A common serotonin (5-HT) transporter (5-HTT/SERT, SLC6A4) polymorphism is believed to confer lower 5-HTT expression in vivo and elevates risk for multiple mood disorders including anxiety, alcoholism, and major depression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 758,
          "text": "However, these substances, by modulation of certain neurochemical pathways, have been proven to have a beneficial effect on some psychiatric disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "The utility of classical drugs used to treat psychiatric disorders (e.g., antidepressants, anxiolytics) is often limited by issues of lack of efficacy, delayed onset of action or side effects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 759,
          "offsetInEndSection": 987,
          "text": "This evidence obtained under medically controlled conditions and often associated with psychotherapy, makes these substances an alternative to conventional medicines, to which in many cases the patient does not respond properly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1610,
          "offsetInEndSection": 1869,
          "text": "In this review we focus on the basis, existing evidence and possible use of synthetic cathinones and psychedelics (specially tryptamines) for the treatment of mental illnesses and the properties that should be found in NPS to obtain new therapeutic compounds."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36262632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 988,
          "offsetInEndSection": 1228,
          "text": "Such disorders include post-traumatic stress disease and treatment-resistant depression, for which classical drugs such as MDMA, ketamine, psilocybin and LSD, among others, have already been clinically tested, reporting successful outcomes."
        }
      ]
    },
    {
      "id": "680a083218b1e36f2e00014d",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23141534",
        "http://www.ncbi.nlm.nih.gov/pubmed/26156998",
        "http://www.ncbi.nlm.nih.gov/pubmed/23570941",
        "http://www.ncbi.nlm.nih.gov/pubmed/21206757",
        "http://www.ncbi.nlm.nih.gov/pubmed/27273464",
        "http://www.ncbi.nlm.nih.gov/pubmed/27664583",
        "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
        "http://www.ncbi.nlm.nih.gov/pubmed/22138506",
        "http://www.ncbi.nlm.nih.gov/pubmed/23732542",
        "http://www.ncbi.nlm.nih.gov/pubmed/23533697"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23141534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 929,
          "offsetInEndSection": 1067,
          "text": "We propose that the pace of dendritic spine synapse maturation in early life is a critical determinant of normal intellectual development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23141534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 249,
          "offsetInEndSection": 380,
          "text": "In the SYNGAP1 mouse model of ID/ASD, we found that dendritic spine synapses develop prematurely during the early postnatal period."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23141534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 541,
          "offsetInEndSection": 755,
          "text": "Inducing SYNGAP1 mutations after critical developmental windows closed had minimal impact on spine synapse function, whereas repairing these pathogenic mutations in adulthood did not improve behavior and cognition."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23141534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 756,
          "offsetInEndSection": 928,
          "text": "These data demonstrate that SynGAP protein acts as a critical developmental repressor of neural excitability that promotes the development of life-long cognitive abilities."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23141534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 148,
          "offsetInEndSection": 248,
          "text": "However, it remains unclear how mutations that disrupt synapse function impact intellectual ability."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26156998",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1011,
          "offsetInEndSection": 1279,
          "text": "Further exploration of the effects of microglia on synapses in a second cohort of mice revealed that dendritic spine densities are increased with long-term microglial elimination, providing evidence that microglia shape the synaptic landscape in the adult mouse brain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26156998",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2145,
          "offsetInEndSection": 2391,
          "text": "Additionally, we found long-term microglial depletion globally increases dendritic spines by \u223c35% in the adult brain, indicating that microglia continue to sculpt the synaptic landscape in the postdevelopmental brain under homeostatic conditions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26156998",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1280,
          "offsetInEndSection": 1454,
          "text": "Furthermore, in these same animals, we determined that microglia play a protective role during lesioning, whereby neuronal loss was potentiated in the absence of these cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26156998",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2392,
          "offsetInEndSection": 2559,
          "text": "Microglial manipulation can therefore be used to investigate the utility of increasing dendritic spine numbers in postnatal conditions displaying synaptic aberrations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26156998",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 465,
          "text": "We previously discovered that microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling for survival in the healthy adult brain, and we have exploited this dependence to determine whether such activated microglia contribute deleteriously to functional recovery following a neuronal lesion."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23570941",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 351,
          "offsetInEndSection": 483,
          "text": "This pathway appears to be involved in neural progenitor regulation, neuronal connectivity, synaptic plasticity and learning/memory."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23570941",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 1036,
          "text": "In this review, we will discuss old and novel Notch targets and molecular mediators that contribute to Notch function in the mature brain and will summarize recent findings that explore the two facets of Notch signaling in brain physiology and pathology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23570941",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 620,
          "offsetInEndSection": 781,
          "text": "The molecular mechanisms by which Notch displays these functions in the mature brain are not fully understood, but are currently the subject of intense research."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23570941",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 350,
          "text": "In the last decade, increasing evidence has pointed out an important role of this pathway beyond embryonic development, indicating that Notch also displays a critical function in the mature brain of vertebrates and invertebrates."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23570941",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Notch signaling is an evolutionarily conserved pathway, which is fundamental for neuronal development and specification."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21206757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 567,
          "offsetInEndSection": 697,
          "text": "To determine if this response was mediated by PS1, PS2 or both we used shRNA to knockdown each PS in a murine microglia cell line."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21206757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1084,
          "offsetInEndSection": 1225,
          "text": "Taken together, our findings suggest that PS2 is the predominant \u03b3-secretase in microglia and modulates release of proinflammatory cytokines."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21206757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 180,
          "offsetInEndSection": 286,
          "text": "PS deficiency in mice results in neuroinflammation and neurodegeneration in the absence of accumulated A\u03b2."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21206757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 287,
          "offsetInEndSection": 397,
          "text": "We hypothesize that PS influences neuroinflammation through its \u03b3-secretase action in CNS innate immune cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21206757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1226,
          "offsetInEndSection": 1331,
          "text": "We propose PS2 may participate in a negative feedback loop regulating inflammatory behavior in microglia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27273464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 372,
          "offsetInEndSection": 500,
          "text": "We found that two members of the Slitrk family, Slitrk1 and Slitrk2, can regulate synapse formation between hippocampal neurons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27273464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1167,
          "offsetInEndSection": 1258,
          "text": "Altogether, our results demonstrate that Slitrk family proteins regulate synapse formation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27273464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 709,
          "offsetInEndSection": 892,
          "text": "Furthermore, decreased expression of Slitrk1 in hippocampal neurons led to a reduction in the number of excitatory, but not inhibitory, synapses formed in hippocampal neuron cultures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27273464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 270,
          "text": "This multi-step process relies on overlapping but distinct combinations of molecules that confer synaptic identity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27273464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 588,
          "offsetInEndSection": 708,
          "text": "Overexpression of Slitrk1 and Slitrk2 in hippocampal neurons increased the number of synaptic contacts on these neurons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27664583",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 140,
          "offsetInEndSection": 233,
          "text": "They trans-synaptically interact with each other and induce synapse formation and maturation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27664583",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 489,
          "offsetInEndSection": 690,
          "text": "In this review, we summarize the structure and basic synaptic function of neurexins and neuroligins, followed by behaviors and synaptic phenotypes of knock-in and knock-out mouse of these family genes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27664583",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 234,
          "offsetInEndSection": 488,
          "text": "Common variants and rare mutations, including copy number variations, short deletions, and single or small nucleotide changes in neurexin and neuroligin genes have been linked to the neurodevelopmental disorders, such as autism spectrum disorders (ASDs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27664583",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 691,
          "offsetInEndSection": 856,
          "text": "From the studies of these mice, it turns out that the effects of neurexins and neuroligins are amazingly neural circuit dependent, even within the same brain region."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27664583",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 857,
          "offsetInEndSection": 951,
          "text": "In addition, neurexins and neuroligins are commonly involved in the endocannabinoid signaling."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 665,
          "offsetInEndSection": 869,
          "text": "In this review, we will discuss new insights into the link between myelin plasticity and behaviour, as well as mechanistic aspects of myelin remodelling that may help to elucidate this intriguing process."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 138,
          "offsetInEndSection": 376,
          "text": "Once considered a static insulator, converging evidence now suggests that myelin in the central nervous system can be dynamically regulated by neuronal activity and continues to participate in nervous system plasticity beyond development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 377,
          "offsetInEndSection": 556,
          "text": "While the link between experience and myelination gains increased recognition, it is still unclear what role such adaptive myelination plays in facilitating and shaping behaviour."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 557,
          "offsetInEndSection": 664,
          "text": "Additionally, fundamental mechanisms and principles underlying myelin remodelling remain poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Myelin sheaths in the vertebrate nervous system enable faster impulse propagation, while myelinating glia provide vital support to axons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22138506",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 425,
          "text": "A hallmark of the pathology in RTT has been identified as decreased dendritic arborization, which has been interpreted to represent abnormal dendritic formation and pruning during development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22138506",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 232,
          "text": "Evidence to date suggests that these disorders display defects in synaptic organization and plasticity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22138506",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 555,
          "offsetInEndSection": 671,
          "text": "In the present work, we use Mecp2 mutant mouse models and the olfactory system to investigate dendritic development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22138506",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 833,
          "offsetInEndSection": 1015,
          "text": "We also failed to detect abnormalities in dendritic inputs at symptomatic stages when glomeruli from mutant mice appear smaller in area than the wild type (WT) (6 weeks postnatally)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22138506",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 672,
          "offsetInEndSection": 832,
          "text": "Here, we demonstrate that mitral cell dendritic development proceeds normally in mutant mice, resulting in typical dendritic morphology at early postnatal ages."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23732542",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 952,
          "offsetInEndSection": 1002,
          "text": "This phenotype disappears with synapse maturation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23732542",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1003,
          "offsetInEndSection": 1276,
          "text": "As alterations in short-term plasticity represent a new mechanism contributing to cognitive impairments in intellectual disabilities, our data provide mechanistic clues for neuronal circuit alterations in psychiatric diseases characterized by reduced expression of SNAP-25."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23732542",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 769,
          "offsetInEndSection": 951,
          "text": "Notably, synapses of 13-14 DIV neurons with reduced SNAP-25 expression show paired-pulse depression as opposed to paired-pulse facilitation occurring in their wild-type counterparts."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23732542",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 392,
          "offsetInEndSection": 560,
          "text": "We show that, unexpectedly, halved SNAP-25 levels at 13-14 DIV not only fail to impair synaptic transmission but instead enhance evoked glutamatergic neurotransmission."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23732542",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "SNAP-25 is a key component of the synaptic-vesicle fusion machinery, involved in several psychiatric diseases including schizophrenia and ADHD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 671,
          "offsetInEndSection": 871,
          "text": "TREM2 is expressed on microglial cells, the resident macrophages in the CNS, and functions to stimulate phagocytosis on one hand and to suppress cytokine production and inflammation on the other hand."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 872,
          "offsetInEndSection": 1114,
          "text": "The purpose of this paper is to discuss these recent developments including the potential role that TREM2 normally plays and how loss of function may contribute to AD pathogenesis by enhancing oxidative stress and inflammation within the CNS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 384,
          "offsetInEndSection": 605,
          "text": "Recently, a novel variant in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) has been identified that has refocused the spotlight back onto inflammation as a major contributing factor in AD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 138,
          "offsetInEndSection": 383,
          "text": "Although much attention has been devoted concerning the contribution of the microscopic lesions, senile plaques, and neurofibrillary tangles to the disease process, inflammation has long been suspected to play a major role in the etiology of AD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1115,
          "offsetInEndSection": 1267,
          "text": "In this context, an overview of the pathways linking beta-amyloid, neurofibrillary tangles (NFTs), oxidative stress, and inflammation will be discussed."
        }
      ]
    },
    {
      "id": "67e5557c18b1e36f2e0000ac",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37343519",
        "http://www.ncbi.nlm.nih.gov/pubmed/37462862",
        "http://www.ncbi.nlm.nih.gov/pubmed/27611920",
        "http://www.ncbi.nlm.nih.gov/pubmed/31415087",
        "http://www.ncbi.nlm.nih.gov/pubmed/24535888",
        "http://www.ncbi.nlm.nih.gov/pubmed/32102086",
        "http://www.ncbi.nlm.nih.gov/pubmed/21911566",
        "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
        "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
        "http://www.ncbi.nlm.nih.gov/pubmed/31369274"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37343519",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Fezolinetant is a neurokinin 3 receptor antagonist under investigation for treatment of menopausal symptoms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37343519",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 151,
          "text": "In a recent study, Lederman and colleagues"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37462862",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Fezolinetant (VEOZAH\u2122) is an oral, small molecule, neurokinin 3 receptor (NK3R) antagonist, which is being developed by Astellas Pharma Inc."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37462862",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 590,
          "offsetInEndSection": 714,
          "text": "This article summarizes the milestones in the development of fezolinetant leading to this first approval in this indication."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37462862",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 464,
          "offsetInEndSection": 589,
          "text": "Fezolinetant received its first approval in the USA in May 2023 for the treatment of moderate to severe VMS due to menopause."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37462862",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 239,
          "offsetInEndSection": 463,
          "text": "Inhibiting NK3R-mediated signalling in the central nervous system is a non-hormonal strategy to modulate the activity of neurones that are associated with thermoregulation, thereby reducing the frequency and severity of VMS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37462862",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 238,
          "text": "for the treatment of moderate to severe vasomotor symptoms (VMS) or hot flashes due to menopause."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611920",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Fexinidazole (FEX) is a nitroimidazole being developed as a new trypanocide treatment for human African trypanosomiasis/sleeping sickness."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611920",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 276,
          "offsetInEndSection": 389,
          "text": "An LC-MS/MS assay was developed for quantitation of FEX in DBS, collected via finger-prick from healthy subjects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611920",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 626,
          "offsetInEndSection": 762,
          "text": "DBS finger-prick sampling offers a simple, practical method for determining FEX, M1 and M2 concentrations in clinical studies in Africa."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611920",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 139,
          "offsetInEndSection": 275,
          "text": "Its main metabolites, fexinidazole sulfoxide (M1) and fexinidazole sulfone (M2), show the same in vitro pharmacological activity as FEX."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611920",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 390,
          "offsetInEndSection": 511,
          "text": "The DBS assay was specific, accurate and reproducible for FEX, M1 and M2 when validated against the current plasma assay."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31415087",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1458,
          "offsetInEndSection": 1490,
          "text": "Fezolinetant was well tolerated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31415087",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 686,
          "offsetInEndSection": 790,
          "text": "The primary outcome was change from baseline to week 12 in total VMS score with fezolinetant vs placebo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31415087",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1491,
          "offsetInEndSection": 1580,
          "text": "The most common fezolinetant-related adverse event was gastrointestinal disorder (n = 6)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31415087",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1113,
          "offsetInEndSection": 1304,
          "text": "At week 12, fezolinetant significantly reduced total VMS score vs placebo (-26.5 vs -12.2, P < 0.001) and decreased mean frequency of moderate/severe VMSs by five episodes per day vs placebo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31415087",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1581,
          "offsetInEndSection": 1741,
          "text": "Fezolinetant rapidly and significantly reduced moderate/severe VMSs, supporting its potential as an effective nonhormonal treatment option for menopausal women."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24535888",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 485,
          "offsetInEndSection": 576,
          "text": "Fexinidazole was assessed in 154 healthy adult male subjects of sub-Saharan African origin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24535888",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Fexinidazole is a 5-nitroimidazole recently included in a clinical efficacy trial as an oral drug for the treatment of human African trypanosomiasis (HAT)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24535888",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2218,
          "offsetInEndSection": 2338,
          "text": "These studies show that fexinidazole can be safely assessed in patients as a potential oral cure for both stages of HAT."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24535888",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 918,
          "offsetInEndSection": 1140,
          "text": "Fexinidazole was well-tolerated in a single dose from 100 to 3,600 mg, with quick absorption of the parent drug and rapid metabolism into sulfoxide [time to maximum concentration (t max) 2-5 h] and sulfone (t max 18-24 h)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24535888",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1578,
          "offsetInEndSection": 1808,
          "text": "Following the high-fat food effect finding, another study was conducted to evaluate the impact of a low-fat regimen closer to that of the target population, showing that the type of meal does not influence fexinidazole absorption."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32102086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1442,
          "offsetInEndSection": 1557,
          "text": "Fezolinetant is a well-tolerated, effective nonhormone therapy that rapidly reduces moderate/severe menopausal VMS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32102086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 323,
          "text": "This phase 2b study evaluated seven dosing regimens of fezolinetant, a selective neurokinin 3 receptor antagonist, as a nonhormone approach for the treatment of VMS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32102086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 849,
          "offsetInEndSection": 988,
          "text": "Fezolinetant reduced moderate/severe VMS frequency by -1.9 to -3.5/day at week 4 and -1.8 to -2.6/day at week 12 (all P\u200a<\u200a0.05 vs placebo)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32102086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 324,
          "offsetInEndSection": 517,
          "text": "Menopausal women aged >40-65 years with moderate/severe VMS (\u226550\u200aepisodes/wk) were randomized (double-blind) to fezolinetant 15, 30, 60, 90\u200amg BID or 30, 60, 120\u200amg QD, or placebo for 12 weeks."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32102086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 707,
          "offsetInEndSection": 794,
          "text": "Response (\u226550% reduction in moderate/severe VMS frequency) was a key secondary outcome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911566",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "Fexinidazole is a 5-nitroimidazole drug currently in clinical development for the treatment of human sleeping sickness (human African trypanosomiasis [HAT]), caused by infection with species of the protozoan parasite Trypanosoma brucei."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911566",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1276,
          "offsetInEndSection": 1481,
          "text": "The in vitro and in vivo antitrypanosomal activities of fexinidazole and its two principal metabolites provide evidence that the compound has the potential to be an effective oral treatment for both the T."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911566",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 977,
          "offsetInEndSection": 1096,
          "text": "Fexinidazole and its metabolites require up to 48 h exposure in order to induce maximal trypanocidal efficacy in vitro."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911566",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 634,
          "offsetInEndSection": 826,
          "text": "In vivo, fexinidazole is orally effective in curing both acute and chronic diseases in the mouse at doses of 100 mg/kg of body weight/day for 4 days and 200 mg/kg/day for 5 days, respectively."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911566",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 468,
          "offsetInEndSection": 633,
          "text": "The parent molecule and both metabolites have shown trypanocidal activity in vitro in the 0.7-to-3.3 \u03bcM (0.2-to-0.9 \u03bcg/ml) range against all parasite strains tested."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1421,
          "offsetInEndSection": 1546,
          "text": "donovani increased sensitivity to fexinidazole by 19-fold, indicating that a similar mechanism is involved in both parasites."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 192,
          "offsetInEndSection": 359,
          "text": "Here, we report that fexinidazole, a drug currently in phase 1 clinical trials for treating African trypanosomiasis, shows promise for treating visceral leishmaniasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1547,
          "offsetInEndSection": 1663,
          "text": "These findings illustrate the potential of fexinidazole as an oral drug therapy for treating visceral leishmaniasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 493,
          "offsetInEndSection": 641,
          "text": "Both metabolites of fexinidazole were active against Leishmania donovani amastigotes grown in macrophages, whereas the parent compound was inactive."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 642,
          "offsetInEndSection": 888,
          "text": "Pharmacokinetic studies with fexinidazole (200 mg/kg) showed that fexinidazole sulfone achieves blood concentrations in mice above the EC(99) (effective concentration inhibiting growth by 99%) value for at least 24 hours after a single oral dose."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 638,
          "text": "Fexinidazole, a 2-subsituted 5-nitroimidazole drug candidate rediscovered following extensive compound mining by the Drugs for Neglected Diseases initiative and currently in Phase I clinical study for the treatment of human African trypanosomiasis, was evaluated in experimental models of acute and chronic CD caused by different strains of Trypanosoma cruzi."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1958,
          "offsetInEndSection": 2064,
          "text": "These findings illustrate the potential of fexinidazole as a drug candidate for the treatment of human CD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 639,
          "offsetInEndSection": 702,
          "text": "We investigated the in vivo activity of fexinidazole against T."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1796,
          "offsetInEndSection": 1950,
          "text": "Fexinidazole is an effective oral treatment of acute and chronic experimental CD caused by benznidazole-susceptible, partially resistant, and resistant T."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 990,
          "offsetInEndSection": 1138,
          "text": "Our results demonstrated that fexinidazole was effective in suppressing parasitemia and preventing death in infected animals for all strains tested."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31369274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Folate receptor \u03b1 (FR\u03b1) is a well-studied tumor biomarker highly expressed in many epithelial tumors such as breast, ovarian, and lung cancers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31369274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 299,
          "text": "Mirvetuximab soravtansine (IMGN853) is the antibody-drug conjugate of FR\u03b1-binding humanized monoclonal antibody M9346A and cytotoxic maytansinoid drug DM4."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31369274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 300,
          "offsetInEndSection": 480,
          "text": "IMGN853 is currently being evaluated in multiple clinical trials, in which the immunohistochemical evaluation of an archival tumor or biopsy specimen is used for patient screening."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31369274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 614,
          "text": "Herein, we developed a zirconium-89 ("
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31369274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 481,
          "offsetInEndSection": 576,
          "text": "However, limited tissue collection may lead to inaccurate diagnosis due to tumor heterogeneity."
        }
      ]
    },
    {
      "id": "6810fef8353a4a2e6b000016",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/2199873",
        "http://www.ncbi.nlm.nih.gov/pubmed/24161312",
        "http://www.ncbi.nlm.nih.gov/pubmed/12114921",
        "http://www.ncbi.nlm.nih.gov/pubmed/15702702",
        "http://www.ncbi.nlm.nih.gov/pubmed/27875769",
        "http://www.ncbi.nlm.nih.gov/pubmed/9279523",
        "http://www.ncbi.nlm.nih.gov/pubmed/20131283",
        "http://www.ncbi.nlm.nih.gov/pubmed/3303067",
        "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
        "http://www.ncbi.nlm.nih.gov/pubmed/23090264"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2199873",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 272,
          "offsetInEndSection": 391,
          "text": "We report the case of a manic-depressive gravida on lithium therapy who developed polyhydramnios in her last trimester."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2199873",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Lithium is widely used in the treatment of bipolar affective disorders, and teratogenic effects include cardiovascular abnormalities, notably Ebstein anomaly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2199873",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 271,
          "text": "The most common side effect in the patient taking lithium is polyuria, a form of nephrogenic diabetes insipidus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2199873",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 392,
          "offsetInEndSection": 538,
          "text": "Because lithium crosses the placenta, we postulate that, by a similar mechanism, lithium may cause fetal polyuria which results in polyhydramnios."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24161312",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 264,
          "offsetInEndSection": 480,
          "text": "Prenatal antidepressant medication exposure may increase the risk for spontaneous miscarriage, preterm birth, cardiac malformations, persistent pulmonary hypertension of the newborn and postnatal adaptation syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24161312",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 481,
          "offsetInEndSection": 598,
          "text": "The use of valproate is contraindicated during pregnancy due to teratogenicity and neurocognitive delay and deficits."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24161312",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 85,
          "offsetInEndSection": 263,
          "text": "Although results from studies are inconsistent, small but significant, risks on birth outcomes occur with exposure to untreated disorders, as well as to psychotropic medications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24161312",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Women with active psychiatric disorders who become pregnant face treatment dilemmas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24161312",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 599,
          "offsetInEndSection": 757,
          "text": "This review of selected studies will highlight some of the current issues with the use of psychotropic medications during pregnancy and the postpartum period."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12114921",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 267,
          "offsetInEndSection": 382,
          "text": "Bipolar disorders that require treatment with lithium demand special consideration when the woman becomes pregnant."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12114921",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 383,
          "offsetInEndSection": 675,
          "text": "Reported neonatal problems with maternal lithium therapy include Ebstein's anomaly, poor respiratory effort and cyanosis, rhythm disturbances, nephrogenic diabetes insipidus, thyroid dysfunction, hypoglycemia, hypotonia and lethargy, hyperbilirubinemia, and large-for-gestational-age infants."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12114921",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "The purpose of this study was to review the use of lithium in pregnancy and its effects on the neonate."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12114921",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 676,
          "offsetInEndSection": 799,
          "text": "Lithium can have adverse effects on the fetus and newborn infant, but data suggest normal behavioral patterns in childhood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12114921",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 166,
          "offsetInEndSection": 266,
          "text": "Lithium is commonly used in the treatment of psychiatric disorders, specifically bipolar depression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15702702",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 387,
          "offsetInEndSection": 543,
          "text": "In the meantime sufficient data are available concerning the use of anti-depressants during pregnancy to exclude any serious damage to the fetus or newborn."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15702702",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 79,
          "offsetInEndSection": 276,
          "text": "Identifying women at risk for the development of depression, early detection of depressive symptoms and an adequate treatment are important issues in preventing severe chronic depressive disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15702702",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1154,
          "offsetInEndSection": 1320,
          "text": "A profound ultrasound screening of the organs should be performed in case of lithium exposition, whereas newer studies showed no increase in risk for Ebstein anomaly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15702702",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1321,
          "offsetInEndSection": 1475,
          "text": "A multidisciplinary approach, including psychiatry, obstetrics and neonatology should be always aimed at in case of depressive disorders during pregnancy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15702702",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Depressive disorders in women are not uncommon during the reproductive period."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27875769",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 620,
          "offsetInEndSection": 700,
          "text": "Four patients with status epilepticus took long-term valproate before pregnancy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27875769",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1232,
          "offsetInEndSection": 1423,
          "text": "Valproate during pregnancy increases the risk of major congenital malformations, but the significance of maintaining seizure control in pregnant women should be also taken into consideration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27875769",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 701,
          "offsetInEndSection": 877,
          "text": "Among them, 2 patients stopped taking valproate 3 months prior to pregnancy, and 2 patients discontinued valproate or reduced their valproate dose when pregnancy was confirmed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27875769",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1086,
          "offsetInEndSection": 1231,
          "text": "Valproate adjustment prior to or during pregnancy may result in deterioration of seizure control, which may include resultant status epilepticus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27875769",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 98,
          "offsetInEndSection": 158,
          "text": "Its administration in epileptic women remains controversial."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9279523",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 288,
          "offsetInEndSection": 410,
          "text": "We encountered a pregnant patient with hyperemesis and thyrotoxicosis, who manifested symptoms of Wernicke encephalopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9279523",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 723,
          "offsetInEndSection": 851,
          "text": "This case suggests that pregnant patients with hyperemesis should undergo careful endocrinological and neurological evaluations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9279523",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 75,
          "offsetInEndSection": 170,
          "text": "This stimulated thyroid function is occasionally termed \"gestational transient thyrotoxicosis\"."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9279523",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 287,
          "text": "The cause of this thyrotoxicosis has been clarified to closely it associate with human chorionic gonadotropin (hCG)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9279523",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 411,
          "offsetInEndSection": 562,
          "text": "Although her serum hCG concentration transiently increased in accordance with the thyrotoxicosis, it was within normal limits for the gestational week."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20131283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 273,
          "offsetInEndSection": 428,
          "text": "The present study was undertaken to investigate pregnancy outcomes in women who received leflunomide and were treated with cholestyramine during pregnancy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20131283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 272,
          "text": "Women treated with leflunomide are advised to avoid pregnancy; those who become pregnant are advised to reduce fetal exposure through a cholestyramine drug elimination procedure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20131283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1749,
          "offsetInEndSection": 1895,
          "text": "These findings can provide some reassurance to women who inadvertently become pregnant while taking leflunomide and undergo the washout procedure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20131283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1495,
          "offsetInEndSection": 1748,
          "text": "Although the sample size is small, these data do not support the notion that there is a substantial increased risk of adverse pregnancy outcomes due to leflunomide exposure among women who undergo cholestyramine elimination procedure early in pregnancy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20131283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 429,
          "offsetInEndSection": 731,
          "text": "Sixty-four pregnant women with rheumatoid arthritis (RA) who were treated with leflunomide during pregnancy (95.3% of whom received cholestyramine), 108 pregnant women with RA not treated with leflunomide, and 78 healthy pregnant women were enrolled in a prospective cohort study between 1999 and 2009."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3303067",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 215,
          "offsetInEndSection": 344,
          "text": "Lithium exposure during the first trimester seems to increase the risk of congenital heart disease, especially Ebstein's anomaly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3303067",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 594,
          "offsetInEndSection": 752,
          "text": "But toxic and withdrawal symptoms in infants born to women treated regularly until shortly before confinement are well documented for most psychoactive drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3303067",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "The literature in most European languages was consulted for guidelines regarding the drug treatment of psychiatrically disturbed pregnant or lactating women."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3303067",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 345,
          "offsetInEndSection": 483,
          "text": "As there is still insufficient evidence to prove the safeness of other psychoactive drugs for the fetus, caution seems warranted here too."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3303067",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 484,
          "offsetInEndSection": 593,
          "text": "A causal link between pharmacotherapy of the mother-to-be and malformation of the baby is difficult to prove."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 672,
          "offsetInEndSection": 796,
          "text": "We report on a woman who received Depakote (valproic acid) throughout her pregnancy for the treatment of a seizure disorder."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 276,
          "text": "The use of valproic acid during pregnancy has been associated with adverse fetal outcomes, including major and minor congenital malformations, intrauterine growth retardation (IUGR), hyperbilirubinemia, hepatotoxicity, transient hyperglycemia, and fetal and neonatal distress."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1155,
          "offsetInEndSection": 1277,
          "text": "We report the first case of septo-optic dysplasia associated with maternal exposure to valproic acid throughout pregnancy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 277,
          "offsetInEndSection": 443,
          "text": "In addition, intrauterine exposure to valproic acid has been associated with an increased risk of central nervous system abnormalities, primarily neural tube defects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 444,
          "offsetInEndSection": 671,
          "text": "Optic nerve hypoplasia has been reported in association with other prenatal anticonvulsant exposures, but the occurrence of septo-optic dysplasia as a manifestation of valproic acid embryopathy has not been reported previously."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 577,
          "text": "In course of such a treatment the patient became pregnant."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 717,
          "text": "In the 14th week of pregnancy she was admitted for symptoms suggesting pituitary tumor apoplexy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1463,
          "offsetInEndSection": 1645,
          "text": "In this case study the authors discussed therapeutic management and reviewed literature regarding gestational pituitary-tumor apoplexy with particular emphasis on surgical treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 768,
          "offsetInEndSection": 905,
          "text": "In the 20th week of pregnancy further deterioration of the patient's neurological condition and visual-field abnormalities were observed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 418,
          "offsetInEndSection": 518,
          "text": "The authors present the case of a 25-year-old woman with prolactinoma treated with dopamine agonist."
        }
      ]
    },
    {
      "id": "6810cb23353a4a2e6b000012",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28813765",
        "http://www.ncbi.nlm.nih.gov/pubmed/24171820",
        "http://www.ncbi.nlm.nih.gov/pubmed/25534557",
        "http://www.ncbi.nlm.nih.gov/pubmed/28084708",
        "http://www.ncbi.nlm.nih.gov/pubmed/21790283",
        "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
        "http://www.ncbi.nlm.nih.gov/pubmed/29059087",
        "http://www.ncbi.nlm.nih.gov/pubmed/28406319",
        "http://www.ncbi.nlm.nih.gov/pubmed/28545978",
        "http://www.ncbi.nlm.nih.gov/pubmed/27119985"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813765",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 667,
          "offsetInEndSection": 839,
          "text": "Recent evidence-based clinical practice guidelines have been published by the American Academy of Pediatrics to guide diagnosis, treatment, and prevention of bronchiolitis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813765",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Bronchiolitis is among the most common illnesses in infants and children, and is the most common cause for hospitalization in infants in the U.S."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813765",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 578,
          "offsetInEndSection": 666,
          "text": "Palivizumab prophylaxis is recommended for infants with qualifying high risk conditions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813765",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 341,
          "offsetInEndSection": 434,
          "text": "Management is supportive, with medications demonstrating limited utility in multiple studies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813765",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 435,
          "offsetInEndSection": 577,
          "text": "Preventive measures include hand hygiene, breastfeeding, avoiding tobacco smoke exposure, and isolation precautions for hospitalized patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24171820",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 663,
          "offsetInEndSection": 824,
          "text": "Palivizumab a humanized monoclonal antibody directed against the F protein of RSV is the only agent licensed to prevent severe RSV disease in high-risk children."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24171820",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 337,
          "text": "Studies conducted using molecular diagnostic assays confirmed that RSV accounts for over 50% of bronchiolitis in young children requiring hospitalization."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24171820",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Bronchiolitis is the leading cause of hospitalization of infants and young children worldwide."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24171820",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 182,
          "text": "Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis in infants."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24171820",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 825,
          "offsetInEndSection": 1035,
          "text": "Among the new antivirals being developed for treatment of RSV infections, an RNA-interference based agent has demonstrated promising results for treatment of lung transplant recipients with acute RSV infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534557",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1553,
          "offsetInEndSection": 1723,
          "text": "This educational intervention program, coordinated by doctors and pharmacists, is associated with improved treatment compliance in high-risk of RSV bronchiolitis infants."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534557",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 382,
          "text": "Palivizumab, a humanized monoclonal antibody directed against respiratory syncytial virus (RSV), is the only existent immunoprophylaxis therapy for prevention of serious lower respiratory tract disease caused by RSV in infants (up to 2\u00a0years of age), particularly in those who meet high-risk criteria (preterm infants and/or those with bronchopulmonary or congenital heart disease)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534557",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1365,
          "offsetInEndSection": 1552,
          "text": "The number of injections given at appropriate intervals remained stable between the two groups and no significant difference was found in the rate of RSV bronchiolitis rehospitalizations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534557",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 888,
          "offsetInEndSection": 1060,
          "text": "We evaluated the impact of this intervention by measuring patient compliance, defined by two criteria, and by measuring the rate of rehospitalization for RSV bronchiolitis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534557",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 508,
          "offsetInEndSection": 673,
          "text": "We aimed to assess the influence of an educational and personalized support of preterm infants treated with Palivizumab on patient compliance during the last season."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28084708",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1541,
          "offsetInEndSection": 1714,
          "text": "Children at risk of severe lower respiratory tract infection should receive immunoprophylaxis with palivizumab, a humanized monoclonal antibody, in up to five monthly doses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28084708",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Bronchiolitis is a common lower respiratory tract infection in infants and young children, and respiratory syncytial virus (RSV) is the most common cause of this infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28084708",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 598,
          "offsetInEndSection": 793,
          "text": "In 2014, the American Academy of Pediatrics updated its clinical practice guideline for diagnosis and management of RSV bronchiolitis to minimize unnecessary diagnostic testing and interventions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28084708",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 891,
          "offsetInEndSection": 1070,
          "text": "Treatment of RSV infection is mainly supportive, and modalities such as bronchodilators, epinephrine, corticosteroids, hypertonic saline, and antibiotics are generally not useful."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28084708",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 794,
          "offsetInEndSection": 890,
          "text": "Bronchiolitis remains a clinical diagnosis, and diagnostic testing is not routinely recommended."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21790283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Mepolizumab (Bosatria(\u00ae), GlaxoSmithKline) is a biologic agent developed to treat asthma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21790283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 444,
          "offsetInEndSection": 599,
          "text": "This article evaluates the currently available preclinical and clinical studies, and the impact of mepolizumab against a variety of eosinophilic disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21790283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 250,
          "offsetInEndSection": 443,
          "text": "To date, it has not been approved for use in any eosinophil-related disorder; however, several studies have suggested some therapeutic benefit across a spectrum of eosinophil-related disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21790283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 90,
          "offsetInEndSection": 249,
          "text": "It represents a humanized monoclonal antibody of IgG1 \u03ba type, which targets human IL-5 and thus prevents its interaction with the \u03b1-chain of the IL-5 receptor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 88,
          "offsetInEndSection": 235,
          "text": "As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 416,
          "offsetInEndSection": 566,
          "text": "This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Benralizumab is a monoclonal antibody that binds the \u03b1 subunit of the receptor to IL-5."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 567,
          "offsetInEndSection": 722,
          "text": "Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 236,
          "offsetInEndSection": 415,
          "text": "As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059087",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 305,
          "offsetInEndSection": 523,
          "text": "Currently approved anti-immunoglobulin E and anti-interleukin 5 biologics, which target specific pathways instead of using a 'one size fits all' strategy, are efficacious and well tolerated therapies for severe asthma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059087",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 524,
          "offsetInEndSection": 944,
          "text": "The appropriate use of these biologics, and of those in development (e.g., benralizumab and dupilumab), should be aided by further understanding of asthma phenotypes and endotypes, utilizing appropriate biomarkers.Oral corticosteroids are often added as maintenance therapy for patients with severe uncontrolled asthma, but their use is associated with significant adverse effects and should be considered a last option."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059087",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1403,
          "offsetInEndSection": 1548,
          "text": "Appropriate use of biologics in severe asthma should be supported by further understanding of biomarkers predicting response to targeted therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059087",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 945,
          "offsetInEndSection": 1191,
          "text": "The true cost of this therapy, including the cost of morbidities associated with its use, remains to be determined.Severe asthma in pediatrics poses a unique opportunity for possible prevention strategies and the potential for primary prevention."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059087",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1731,
          "offsetInEndSection": 1831,
          "text": "Finally, severe asthma in pediatrics poses a unique opportunity for potential prevention strategies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28406319",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 763,
          "offsetInEndSection": 1039,
          "text": "Expert opinion: Benralizumab was able to interfere significantly with disease-related morbidity and in particular with hospitalizations due to asthma exacerbation rates in a subset of patients with higher systemic eosinophil burden and higher doses of inhaled corticosteroids."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28406319",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 266,
          "offsetInEndSection": 465,
          "text": "However, there is research underway investigating interleukin-based monoclonal antibodies such as benralizumab, an anti-IL-5R monoclonal antibody which is currently in phase III clinical development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28406319",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Current anti-inflammatory asthma therapies including inhaled corticosteroids and leukotriene modifiers, are not always able to appropriately control the disease and other approaches are needed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28406319",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 265,
          "text": "These therapies specific target IgE (omalizumab) or IL-5 (mepolizumab)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28406319",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 466,
          "offsetInEndSection": 563,
          "text": "Areas covered: This review summarizes the existing preclinical and clinical data of benralizumab."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545978",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "Benralizumab is a humanised, anti-interleukin 5 receptor \u03b1 monoclonal antibody that directly and rapidly depletes eosinophils, reduces asthma exacerbations, and improves lung function for patients with severe eosinophilic asthma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545978",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 230,
          "offsetInEndSection": 366,
          "text": "The objective of this trial was to assess the safety and efficacy of benralizumab for patients with mild to moderate, persistent asthma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545978",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 739,
          "offsetInEndSection": 1022,
          "text": "Benralizumab resulted in an 80 mL (95% CI 0-150; p=0\u00b704) greater improvement (least-squares mean difference) in prebronchodilator FEV\nThis study suggests that active and modifiable disease processes might be ongoing in patients with mild to moderate, persistent asthma receiving ICS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545978",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 367,
          "offsetInEndSection": 738,
          "text": "In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients aged 18-75 years, weighing at least 40 kg, and with a postbronchodilator reversibility in forced expiratory volume in 1 s (FEV\nBetween Feb 2, 2015, and April 24, 2015, we enrolled 351 patients, with 211 (60%) randomly assigned (105 [50%] to placebo and 106 [50%] to benralizumab)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545978",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1023,
          "offsetInEndSection": 1264,
          "text": "Although the lung function improvement observed does not warrant use of benralizumab in this population because it did not reach the minimum clinically important difference of 10%, further studies to assess this finding should be considered."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 619,
          "offsetInEndSection": 801,
          "text": "In this article, we review the theoretical advantages of benralizumab compared to previous compounds, as well as current status of the clinical development of benralizumab in asthma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 331,
          "offsetInEndSection": 481,
          "text": "While previous monoclonal antibodies against the IL-5 ligand resulted in inconsistent improvements in asthma outcomes, benralizumab has shown promise."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 802,
          "offsetInEndSection": 905,
          "text": "Lastly, we briefly discuss the potential role of benralizumab in chronic obstructive pulmonary disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 482,
          "offsetInEndSection": 618,
          "text": "Benralizumab is a monoclonal antibody against IL-5 receptor, and has an enhanced antibody dependent cell-mediated cytotoxicity function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 330,
          "text": "Because eosinophils are key effector cells in asthmatic airway inflammation, blocking IL-5, the main cytokine responsible for its survival and activation, seems to be a rational strategy."
        }
      ]
    },
    {
      "id": "680bc7a718b1e36f2e000156",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
        "http://www.ncbi.nlm.nih.gov/pubmed/24818721",
        "http://www.ncbi.nlm.nih.gov/pubmed/33375686",
        "http://www.ncbi.nlm.nih.gov/pubmed/2046748",
        "http://www.ncbi.nlm.nih.gov/pubmed/32235439",
        "http://www.ncbi.nlm.nih.gov/pubmed/12542976",
        "http://www.ncbi.nlm.nih.gov/pubmed/22235994",
        "http://www.ncbi.nlm.nih.gov/pubmed/26110128",
        "http://www.ncbi.nlm.nih.gov/pubmed/22382701",
        "http://www.ncbi.nlm.nih.gov/pubmed/29358503"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 562,
          "text": "The hypothesis called \"cancer immunoediting is an important concept in the current cancer immunotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 976,
          "offsetInEndSection": 1090,
          "text": "Here, we focus on the cancer immunoediting hypothesis to understand the current and future cancer immunotherapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 563,
          "offsetInEndSection": 767,
          "text": "Based on the hypothesis, the immune system not only destroys cancer cells, but also selects less immunogenic cancer cells accompanied with the development of the immune suppressive tumor microenvironment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Cancer immunotherapy has become a new entity of cancer treatment with successes in various clinical trials."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 108,
          "offsetInEndSection": 457,
          "text": "Immune checkpoint inhibitors, particularly targeting PD-1 and CTLA-4 show an efficient antitumor effect via reinvigorating antitumor immune responses which are generally suppressed in the tumor microenvironment, resulting in the approval for the treatment of multiple cancer types including malignant melanoma, lung cancer, gastric cancer and so on."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 757,
          "offsetInEndSection": 935,
          "text": "Infiltration of immune cells facilitates tumor development through the production of factors that promote carcinogenesis and by enabling tumors to evade the host immune response."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Cancer-related inflammation is considered the \"seventh hallmark of cancer\"; numerous studies demonstrate that tumors develop and progress within inflammatory diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1557,
          "offsetInEndSection": 1902,
          "text": "This review will discuss the reflexive relationship between cancer and inflammation with particular focus on how by considering the role of inflammation in physiologic processes such as the maintenance of tissue homeostasis and repair may provide a logical framework for understanding the connection between the inflammatory response and cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 936,
          "offsetInEndSection": 1143,
          "text": "Small molecules including cytokines, chemokines, and growth factors play key roles in both inflammation and cancer by promoting proliferation, angiogenesis, and carcinogenesis and by recruiting immune cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 168,
          "offsetInEndSection": 376,
          "text": "Central to the development of cancer are genetic changes that endow these cancer cells with many of the hallmarks of cancer, such as self-sufficient growth and resistance to anti-growth and pro-death signals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33375686",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 354,
          "text": "ICIs use the immune system to defeat cancer by breaking the axes that allow tumors to escape immune surveillance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33375686",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 355,
          "offsetInEndSection": 432,
          "text": "Innate and adaptive immunity are involved in mechanisms against tumor growth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33375686",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 240,
          "text": "Immune checkpoint inhibitors (ICIs) have become the breakthrough treatment, with prolonged responses and improved survival results."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33375686",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 879,
          "offsetInEndSection": 968,
          "text": "Colorectal cancer (CRC) patients have gained little benefit from immunotherapy until now."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33375686",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Over the last few years, immunotherapy has been considered as a key player in the treatment of solid tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2046748",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "The cell cycle is composed of a series of steps which can be negatively or positively regulated by various factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2046748",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 307,
          "text": "Alteration or inactivation of p53 by mutation, or by its interactions with oncogene products of DNA tumour viruses, can lead to cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2046748",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 383,
          "text": "These mutations seem to be the most common genetic change in human cancers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2046748",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 116,
          "offsetInEndSection": 171,
          "text": "Chief among the negative regulators is the p53 protein."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32235439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 344,
          "offsetInEndSection": 524,
          "text": "Immune checkpoint inhibitors (ICI), which were broadly applied for melanoma treatment in the past decade, can unleash anti-tumor immune responses and result in melanoma regression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32235439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1040,
          "offsetInEndSection": 1270,
          "text": "These methods include combinations of different ICI with each other, strategies for neutralizing the immunosuppressive TME and combining ICI with other anti-cancer therapies such as radiation, oncolytic viral, or targeted therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32235439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "Although melanoma is one of the most immunogenic tumors, it has an ability to evade anti-tumor immune responses by exploiting tolerance mechanisms, including negative immune checkpoint molecules."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32235439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 525,
          "offsetInEndSection": 622,
          "text": "Patients responding to the ICI treatment showed long-lasting remission or disease control status."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32235439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 746,
          "offsetInEndSection": 893,
          "text": "Among them are intrinsic tumor properties, the dysfunction of effector cells, and the generation of immunosuppressive tumor microenvironment (TME)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12542976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Cancer is frequently considered to be a disease of the cell cycle."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12542976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 203,
          "offsetInEndSection": 381,
          "text": "Cell cycle progression is a highlyordered and tightly-regulated process that involves multiple checkpoints that assess extracellular growth signals, cell size, and DNA integrity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12542976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 820,
          "offsetInEndSection": 1062,
          "text": "Therefore, understanding the molecular mechanisms of the deregulation of cell cycle progression in cancer can provide important insights into how normal cells become tumorigenic, as well as how new cancer treatment strategies can be designed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12542976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 202,
          "text": "As such, it is not surprising that the deregulation of the cell cycle is one of the most frequent alterations during tumor development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12542976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 685,
          "offsetInEndSection": 819,
          "text": "Cancer originates from the abnormal expression or activation of positive regulators and functional suppression of negative regulators."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22235994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 524,
          "offsetInEndSection": 711,
          "text": "However, the immune system plays an integral role in almost every aspect of tumorigenesis, including tumour initiation, prevention and progression as well as the response to therapeutics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22235994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 974,
          "text": "Here we highlight more recent evidence suggesting that oncogene addiction may be integrally dependent upon host immune-mediated mechanisms, including specific immune effectors and cytokines that regulate tumour cell senescence and tumour-associated angiogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22235994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 975,
          "offsetInEndSection": 1040,
          "text": "Hence, the host immune system is essential to oncogene addiction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22235994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 256,
          "offsetInEndSection": 346,
          "text": "This phenomenon of the reversal of tumorigenesis has been described as oncogene addiction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22235994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "Despite complex genomic and epigenetic abnormalities, many cancers are irrevocably dependent on an initiating oncogenic lesion whose restoration to a normal physiological activation can elicit a dramatic and sudden reversal of their neoplastic properties."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26110128",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "The cell cycle (or cell-division cycle) is a series of events that take place in a cell, leading to its division and duplication."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26110128",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 268,
          "text": "Cell division requires cell cycle checkpoints (CPs) that are used by the cell to both monitor and regulate the progress of the cell cycle."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26110128",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 475,
          "offsetInEndSection": 833,
          "text": "We aimed to perform a narrative review, based on evaluation of the manuscripts published in MEDLINE-indexed journals using the Medical Subject Headings (MeSH) terms \"tumor suppressor's genes,\" \"skin,\" and \"cell cycle regulatory checkpoints.\" We aimed to review the current concepts regarding TSGs, CPs, and their association with selected cutaneous diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26110128",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 269,
          "offsetInEndSection": 405,
          "text": "Tumor-suppressor genes (TSGs) or antioncogenes are genes that protect the cell from a single event or multiple events leading to cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26110128",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 834,
          "offsetInEndSection": 962,
          "text": "It is important to take into account that in some cell cycle disorders, multiple genetic abnormalities may occur simultaneously."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22382701",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 628,
          "offsetInEndSection": 827,
          "text": "This article reviews the immunological responses affecting Crohn's disease and ulcerative colitis as well as the linkage of inflammatory bowel disease to the development of colitis-associated cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22382701",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 306,
          "offsetInEndSection": 486,
          "text": "The connection between inflammation and cancer has long been established and longstanding inflammatory bowel diseases are an important risk factor for developing colorectal cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22382701",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 487,
          "offsetInEndSection": 627,
          "text": "Colitis-associated colorectal cancer pathogenesis is highly influenced by specific inflammatory processes during inflammatory bowel disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22382701",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Inflammatory bowel diseases compromise of two forms of chronic intestinal inflammatory disorders: Crohn's disease and ulcerative colitis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22382701",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 828,
          "offsetInEndSection": 935,
          "text": "Finally, we discuss the prospects of using new research efforts to devise new immunotherapeutic approaches."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 839,
          "text": "In addition, preclinical and early clinical evidence suggests that chemotherapy and radiation may work synergistically with anti-PD-1/PD-L1 therapy to promote antitumor immunity, which has led to the initiation of clinical trials testing these drugs in patients with stage III NSCLC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 442,
          "offsetInEndSection": 555,
          "text": "PD-1/PD-L1 immune checkpoint inhibitors have demonstrated unprecedented efficacy in patients with stage IV NSCLC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 441,
          "text": "Although cCRT is potentially curative, 5-year overall survival has hovered around 20%, despite extensive efforts to improve outcomes with increasing doses of conformal radiation and intensification of systemic therapy with either induction or consolidation chemotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1235,
          "text": "Here, we discuss the clinical and translational implications of integrating PD-1/PD-L1 inhibitors in the management of patients with unresectable stage III NSCLC."
        }
      ]
    },
    {
      "id": "67e56f2018b1e36f2e0000b0",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12538828",
        "http://www.ncbi.nlm.nih.gov/pubmed/30924130",
        "http://www.ncbi.nlm.nih.gov/pubmed/29931593",
        "http://www.ncbi.nlm.nih.gov/pubmed/37735554",
        "http://www.ncbi.nlm.nih.gov/pubmed/19158349",
        "http://www.ncbi.nlm.nih.gov/pubmed/23683707",
        "http://www.ncbi.nlm.nih.gov/pubmed/11685722",
        "http://www.ncbi.nlm.nih.gov/pubmed/29310513",
        "http://www.ncbi.nlm.nih.gov/pubmed/15998742",
        "http://www.ncbi.nlm.nih.gov/pubmed/18956258"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12538828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1292,
          "offsetInEndSection": 1519,
          "text": "These findings suggest that amifostine alters the expression of several molecules implicated in the angiogenesis process and affects the composition of the extracellular matrix in a way that leads to inhibition of angiogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12538828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1520,
          "offsetInEndSection": 1701,
          "text": "Such an antiangiogenic action of amifostine, together with its radioprotective effects, further supports its use in combination with radiotherapy for increased therapeutic efficacy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12538828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 422,
          "offsetInEndSection": 532,
          "text": "Amifostine decreased the number of CAM vessels in a dose-dependent manner, without being toxic for the tissue."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12538828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 319,
          "offsetInEndSection": 421,
          "text": "In the present work, we studied the effect of amifostine on angiogenesis in vivo, using the CAM model."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12538828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Amifostine (WR-2721) is an inorganic thiophosphate-cytoprotective agent developed to selectively protect normal tissues against the toxicity of chemotherapy and radiation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30924130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 340,
          "text": "The main mechanisms of action of TPE include the removal of circulating autoantibodies, immune complexes, complement components, cytokines and adhesion molecules, along with sensitization of antibody-producing cells to immunosuppressant agents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30924130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 773,
          "text": "The American Society for Apheresis and the British Society of Haematology have published guidelines on the clinical use of apheresis procedures, indicating the different levels of efficacy of TPE."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30924130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 774,
          "offsetInEndSection": 984,
          "text": "Based on the evidence from current literature and our personal experience, this review discusses the indications and the suggested regimens for TPE in autoimmune haematological and non-haematological disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30924130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 341,
          "offsetInEndSection": 576,
          "text": "TPE is useful in autoimmune haematological, renal, rheumatic and neurological diseases, and is recommended for acute disorders, together with relapsed or worsened chronic diseases that are often unresponsive to conventional treatments."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30924130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Therapeutic plasma exchange (TPE) has been mainly used in the treatment of autoimmune diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29931593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Mechanisms of action of monoclonal antibodies against tissue factor pathway inhibitor (TFPI)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37735554",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 903,
          "offsetInEndSection": 1100,
          "text": "Each of these agents exploits therapeutic targets or other aspects of ITP pathophysiology currently not targeted by the existing approved agents (thrombopoietin receptor agonists and fostamatinib)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37735554",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 433,
          "offsetInEndSection": 642,
          "text": "Several agents exploiting novel targets and mechanisms in ITP are presently under clinical development, with trials primarily recruiting heavily pretreated patients and those with otherwise refractory disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37735554",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 340,
          "offsetInEndSection": 432,
          "text": "Therefore, there remains an ongoing need for novel therapeutics and drug development in ITP."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37735554",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 643,
          "offsetInEndSection": 902,
          "text": "Such agents include the neonatal Fc receptor antagonist efgartigimod, the Bruton tyrosine kinase inhibitor rilzabrutinib, the complement inhibitors sutimlimab and iptacopan and anti-CD38 monoclonal antibodies such as daratumumab and mezagitamab, among others."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37735554",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder affecting approximately 1 in 20\u2009000 people."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158349",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1286,
          "offsetInEndSection": 1565,
          "text": "Thus, our results indicate that Apt-9 activates SERCA2a by alleviating the inhibitory effect of phospholamban on this ATPase, and they suggest that phospholamban-specific aptamers warrant further investigation as potential therapeutic agents for heart failure and cardiomyopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158349",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 356,
          "offsetInEndSection": 493,
          "text": "Thus, alleviation of phospholamban-mediated inhibition of SERCA2a is a potential therapeutic option for heart failure and cardiomyopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158349",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 355,
          "text": "The sarco(endo)plasmic reticulum Ca(2+) ATPase (SERCA) 2a is responsible for Ca(2+) up-take by this organelle and is inhibited in a reversible manner by phospholamban, another SR membrane protein."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158349",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Calcium transport across the membrane of the sarcoplasmic reticulum (SR) plays an important role in the regulation of heart muscle contraction and relaxation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158349",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 723,
          "offsetInEndSection": 918,
          "text": "One of the obtained aptamers, designated Apt-9, was found to specifically bind to the cytoplasmic region of phospholamban in vitro with high affinity (dissociation constant, approximately 20 nM)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 255,
          "offsetInEndSection": 395,
          "text": "For the benzodiazepines, barbiturates, and loreclezole, actions at the GABAAR are the primary or only known mechanism of antiseizure action."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 531,
          "text": "For topiramate, felbamate, retigabine, losigamone and stiripentol, GABAAR modulation is one of several possible antiseizure mechanisms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "The GABAA receptor (GABAAR) is a major target of antiseizure drugs (ASDs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 532,
          "offsetInEndSection": 644,
          "text": "Allopregnanolone, a progesterone metabolite that enhances GABAAR function, led to the development of ganaxolone."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1112,
          "offsetInEndSection": 1254,
          "text": "Manipulation of subunit expression patterns or novel ASDs targeting the altered receptors may provide a novel approach for seizure prevention."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11685722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 656,
          "text": "Docetaxel is believed to have a twofold mechanism of antineoplastic activity: (1) inhibition of microtubular depolymerization, and (2) attenuation of the effects of bcl-2 and bcl-xL gene expression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11685722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 340,
          "offsetInEndSection": 457,
          "text": "The underlying reason for docetaxel's clinical activity against prostate cancer has been a focus of ongoing research."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11685722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 339,
          "text": "In phase I/II studies, single-agent docetaxel and the combination of docetaxel plus estramustine were effective in inducing prostate-specific antigen reductions of > or =50% in men with androgen-independent prostate cancer (AIPC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11685722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 869,
          "offsetInEndSection": 1020,
          "text": "In preclinical studies, docetaxel had a higher affinity for tubulin and was shown to be a more potent inducer of bcl-2 phosphorylation than paclitaxel."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11685722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1172,
          "offsetInEndSection": 1303,
          "text": "The pathways for docetaxel-induced apoptosis appear to differ in androgen-dependent and androgen-independent prostate cancer cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29310513",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 647,
          "text": "Thus, the aim of this study was to characterize the immunomodulatory effect of the functional S1PR1 antagonist, siponimod, in phase III clinical trials for autoimmune disorders and of the competitive sphingosine 1-phosphate receptor subtype 1 (S1PR1) antagonist, TASP0277308, in pre-clinical development in an in vivo model of TBI in mice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29310513",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 833,
          "offsetInEndSection": 1177,
          "text": "Our results demonstrated that these agents exerted significant beneficial effects on TBI pre-clinical scores in term of anti-inflammatory and immunomodulatory effects, in particular, attenuation of astrocytes and microglia activation, cytokines release, and rescue of the reduction of adhesion molecules (i.e., occludin and zonula occludens-1)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29310513",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Traumatic brain injury (TBI) provokes secondary pathological mechanisms, including ischemic and inflammatory processes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29310513",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 307,
          "text": "The new research in sphingosine 1-phosphate (S1P) receptor modulators has opened the door for an effective mechanism of reducing central nervous system (CNS) inflammatory lesion activity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29310513",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 730,
          "offsetInEndSection": 832,
          "text": "Mice were injected intraperitoneally with siponimod or TASP0277308 (1\u2009mg/kg) at 1 and 4\u2009h post-trauma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15998742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 553,
          "offsetInEndSection": 759,
          "text": "Evidence is provided that Tmr is an adenosine phosphate-isopentenyltransferase (IPT) that creates a new CK biosynthesis bypass by using 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate (HMBDP) as a substrate."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15998742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 331,
          "offsetInEndSection": 552,
          "text": "Here, we show that a CK biosynthesis enzyme, Tmr, which is encoded by the Agrobacterium T-DNA region, is targeted to and functions in plastids of infected plant cells, despite having no typical plastid-targeting sequence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15998742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 197,
          "offsetInEndSection": 330,
          "text": "Tumors are formed because the T-DNA encodes enzymes that modify the synthesis of two plant growth hormones, auxin and cytokinin (CK)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15998742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1164,
          "offsetInEndSection": 1282,
          "text": "tumefaciens modifies CK biosynthesis by sending a key enzyme into plastids of the host plant to promote tumorigenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15998742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 937,
          "offsetInEndSection": 1129,
          "text": "Consistent with the plastid localization of Tmr, HMBDP is an intermediate in the methylerythritol phosphate pathway, a plastid-localized biosynthesis route for universal isoprenoid precursors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 326,
          "text": "Therefore, inhibition of telomerase has been viewed as a promising anticancer approach due to its specificity for cancer cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1036,
          "offsetInEndSection": 1152,
          "text": "The specific mechanisms that mediate those inhibition effects include small molecules, antisense RNA, and ribozymes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 699,
          "offsetInEndSection": 892,
          "text": "These strategies include inhibition of telomerase through targeting at the telomerase reverse transcriptase (TERT) catalytic subunit, the telomerase RNA (TR) component, and associated proteins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 490,
          "offsetInEndSection": 698,
          "text": "Strategies currently being applied to induce telomerase inhibition target virtually all of the major components of the ribonucleoprotein holoenzyme and related cell signal pathways that regulate its activity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1153,
          "offsetInEndSection": 1323,
          "text": "Although the beneficial evidence of telomerase inhibition is obvious, limitations of strategies remain to be resolved to increase the feasibility of clinical application."
        }
      ]
    },
    {
      "id": "67fe5f0918b1e36f2e000144",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26559820",
        "http://www.ncbi.nlm.nih.gov/pubmed/24320032",
        "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
        "http://www.ncbi.nlm.nih.gov/pubmed/24320038",
        "http://www.ncbi.nlm.nih.gov/pubmed/29604126",
        "http://www.ncbi.nlm.nih.gov/pubmed/28918421",
        "http://www.ncbi.nlm.nih.gov/pubmed/22829586",
        "http://www.ncbi.nlm.nih.gov/pubmed/26956847",
        "http://www.ncbi.nlm.nih.gov/pubmed/31931543",
        "http://www.ncbi.nlm.nih.gov/pubmed/29457836"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559820",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Mal de debarquement (MdD) is a subjective perception of self-motion after exposure to passive motion, in most cases sea travel, hence the name."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559820",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 265,
          "offsetInEndSection": 409,
          "text": "However, in some people symptoms remain for a longer period of time or even persist and this is then called mal de debarquement syndrome (MdDS)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559820",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 907,
          "offsetInEndSection": 1087,
          "text": "We here present a systematic review of MdD(S) based on a systematic search of medical databases employing predefined criteria, using the terms \"mal de debarquement\" and \"sea legs\"."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559820",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 505,
          "offsetInEndSection": 703,
          "text": "In general, limited studies have focused on the topic, but the past few years more and more interest has been attributed to MdDS and its facets, which is reflected by an increasing number of papers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559820",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 264,
          "text": "Mal de debarquement occurs quite frequently in otherwise healthy individuals for a short period of time (several hours)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24320032",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 362,
          "offsetInEndSection": 568,
          "text": "Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of MetS, and is characterized by triglyceride accumulation and a variable degree of hepatic injury, inflammation, and repair."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24320032",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1802,
          "offsetInEndSection": 1989,
          "text": "In conclusion, the presence of metabolic alterations has a severe and multifaceted impact on the liver, and is responsible for a higher risk of liver-dependent and -independent mortality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24320032",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 361,
          "text": "This disorder is not only associated with a higher risk of appearance of type 2 diabetes and cardiovascular events, but impacts on the liver in different ways."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24320032",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1483,
          "offsetInEndSection": 1655,
          "text": "The presence of the MetS is also associated with worse outcomes in patients with cirrhosis due to any causes, and has complex interactions with hepatitis C virus infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24320032",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "The prevalence of the metabolic syndrome (MetS), a cluster of cardiovascular risk factors associated with obesity and insulin resistance, is dramatically increasing in Western and developing countries."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 131,
          "text": "NAFLD is a clinical entity related to metabolic syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 315,
          "offsetInEndSection": 501,
          "text": "The spectrum of disorders included in NAFLD are benign macrovesicular hepatic steatosis, non-alcoholic steatohepatitis, hepatic fibrosis, cirrhosis of liver and hepatocellular carcinoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 225,
          "offsetInEndSection": 314,
          "text": "Metabolic factors and genetics play important roles in the pathogenesis of this disorder."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "There is worldwide epidemic of non-alcoholic fatty liver disease (NAFLD)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1216,
          "offsetInEndSection": 1295,
          "text": "There are some studies done on incretin based therapies in patients with NAFLD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24320038",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "The metabolic syndrome (MetS) is characterized by a cluster of risk factors including central obesity, hypertension, dyslipidemia and insulin resistance, The MetS is associated with an increased risk for cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24320038",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 498,
          "offsetInEndSection": 769,
          "text": "Other risk factors than the diagnostic criteria that have been associated with MetS include lipid abnormalities, uric acid, liver function, prothrombotic factors, cytokines, adipokines, vitamin D, arterial stiffness, polycystic ovary syndrome and obstructive sleep apnea."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24320038",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 270,
          "offsetInEndSection": 497,
          "text": "Several international organizations have defined MetS using different diagnostic criteria that produced discrepancies in the results of previous studies, thus leading to the latest Joint Interim Societies (JIS) MetS definition."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24320038",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1024,
          "offsetInEndSection": 1132,
          "text": "In this narrative review, the associations of these diseases with MetS and its components will be discussed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24320038",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 770,
          "offsetInEndSection": 1023,
          "text": "Apart from CVD and T2DM, MetS has been related to non-cardiac vascular diseases and in particular to stroke, carotid artery disease, peripheral artery disease, chronic kidney disease, atherosclerotic renal artery stenosis and abdominal aortic aneurysms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29604126",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Severe skin dermatitis, multiple allergies and metabolic wasting (SAM) syndrome is a rare life-threatening inherited condition caused by bi-allelic mutations in DSG1 encoding desmoglein 1."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29604126",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 369,
          "text": "The disease was initially reported to manifest with severe erythroderma, failure to thrive, atopic manifestations, recurrent infections, hypotrichosis and palmoplantar keratoderma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29604126",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 550,
          "offsetInEndSection": 726,
          "text": "Consistent with previous data, SAM syndrome was found in all 3 patients to result from homozygous mutations in DSG1 predicted to result in premature termination of translation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29604126",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 462,
          "offsetInEndSection": 549,
          "text": "Whole exome and direct sequencing were used to identify SAM syndrome-causing mutations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29604126",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 899,
          "offsetInEndSection": 1060,
          "text": "The present data emphasize the fact that SAM syndrome is characterized by extensive phenotypic heterogeneity, suggesting the existence of potent modifier traits."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28918421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1435,
          "offsetInEndSection": 1673,
          "text": "MAS is a potentially severe manifestation that should be considered at SLE onset whenever high fever and elevated serum levels of aspartate aminotransferase, lactate dehydrogenase, C-reactive protein, ferritin and procalcitonin are noted."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28918421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Macrophage activation syndrome (MAS) is a life-threatening hyperinflammatory state mediated by uncontrolled cytokine storm and haemophagocytosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28918421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 265,
          "text": "Although rarely reported, MAS might occur in systemic lupus erythematosus (SLE), notably as an inaugural manifestation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28918421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1193,
          "offsetInEndSection": 1247,
          "text": "However, SLE-associated MAS seemed to fit this set-up."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28918421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 652,
          "text": "The patient had high-grade fever, jaundice and generalized lymphadenopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22829586",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1347,
          "offsetInEndSection": 1596,
          "text": "These results reveal a complex interplay between diet-induced metabolic effects and G6PD deficiency, where G6PD deficiency decreases weight gain and hyperinsulinemia with DIO, but elevates serum free fatty acids, without affecting glucose tolerance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22829586",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common human enzymopathy that affects cellular redox status and may lower flux into nonoxidative pathways of glucose metabolism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22829586",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 783,
          "offsetInEndSection": 920,
          "text": "Serum free fatty acids were increased by 77% and triglycerides by 90% in G6PDX mice, but not in WT mice, by DIO and high-fructose intake."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22829586",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 271,
          "offsetInEndSection": 466,
          "text": "We hypothesized that G6PD deficiency exacerbates diet-induced systemic metabolic dysfunction by increasing oxidative stress but in myocardium prevents diet-induced oxidative stress and pathology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22829586",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 467,
          "offsetInEndSection": 618,
          "text": "WT and G6PD-deficient (G6PDX) mice received a standard high-starch diet, a high-fat/high-sucrose diet to induce obesity (DIO), or a high-fructose diet."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26956847",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 207,
          "offsetInEndSection": 409,
          "text": "The (dys)metabolic syndrome is a common cluster of five pre-morbid metabolic-vascular risk factors or diseases associated with increased cardiovascular morbidity, fatty liver disease and risk of cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26956847",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 992,
          "offsetInEndSection": 1146,
          "text": "Therefore it seems reasonable to extend the term to metabolic-vascular syndrome (MVS) to signal the clinical relevance and related risk of multimorbidity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26956847",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 565,
          "offsetInEndSection": 733,
          "text": "Therefore we still include hyperglycemia, visceral obesity, dyslipidemia and hypertension as diagnostic traits in the definition according to the term 'deadly quartet'."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26956847",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 923,
          "text": "From the beginning elevated blood pressure and hyperglycemia were core traits of the metabolic syndrome associated with endothelial dysfunction and increased risk of cardiovascular disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26956847",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1232,
          "offsetInEndSection": 1439,
          "text": "According to the definition of a syndrome the rapid global rise in the prevalence of all traits and comorbidities of the MVS is mainly caused by rapid changes in life-style and sociocultural transition resp."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31931543",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Non-alcoholic fatty liver disease (NAFLD) is of increasing prevalence globally."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31931543",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 461,
          "text": "Comparable to other metabolic diseases including diabetes and dyslipidaemia, a high proportion of patients will likely benefit from permanent pharmacological therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31931543",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2333,
          "offsetInEndSection": 2523,
          "text": "Dazu z\u00e4hlen Elafibranor (PPAR-\u03b1/\u03b4-Agonist), Cenicriviroc (CCR2/CCR5-Inhibitor), Obetichols\u00e4ure (FXR-Agonist), Aramchol (SCD1-Modulator) und Resmetrion (Thyroid-Hormon-Rezeptor-beta-Agonist)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31931543",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 462,
          "offsetInEndSection": 620,
          "text": "Currently there are many compounds with different mechanisms of action in clinical development including metabolic, anti-inflammatory and anti-fibrotic drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31931543",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1191,
          "offsetInEndSection": 1402,
          "text": "The complex pathophysiology of the disease, which combines inflammation, metabolism and fibrosis, has led to the fact that even combinations of several substances are investigated with different modes of action."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Alcoholic liver disease (ALD) is characterized by lipid accumulation and liver injury."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 540,
          "offsetInEndSection": 842,
          "text": "Aberrant activation of mTORC1 was likely attributed to the defects of the DEP domain-containing mTOR-interacting protein (DEPTOR) and the nicotinamide adenine dinucleotide-dependent deacetylase sirtuin 1 (SIRT1) in the liver of chronic-plus-binge ethanol-fed mice and in the liver of patients with ALD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1969,
          "offsetInEndSection": 2198,
          "text": "The dysregulation of SIRT1-DEPTOR-mTORC1 signaling is a critical determinant of ALD pathology; targeting SIRT1 and DEPTOR and selectively inhibiting mTORC1-S6K1 signaling may have therapeutic potential for treating ALD in humans."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1786,
          "offsetInEndSection": 1968,
          "text": "Furthermore, hepatocyte-specific deletion of SIRT1 disrupted DEPTOR function, enhanced mTORC1 activity, and exacerbated alcoholic fatty liver, inflammation, and liver injury in mice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 843,
          "offsetInEndSection": 1018,
          "text": "Conversely, adenoviral overexpression of hepatic DEPTOR suppressed mTORC1 signaling and ameliorated alcoholic hepatosteatosis, inflammation, and acute-on-chronic liver injury."
        }
      ]
    },
    {
      "id": "67fbe4d718b1e36f2e00011d",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
        "http://www.ncbi.nlm.nih.gov/pubmed/12060782",
        "http://www.ncbi.nlm.nih.gov/pubmed/28949931",
        "http://www.ncbi.nlm.nih.gov/pubmed/24923803",
        "http://www.ncbi.nlm.nih.gov/pubmed/21575270",
        "http://www.ncbi.nlm.nih.gov/pubmed/26834590",
        "http://www.ncbi.nlm.nih.gov/pubmed/23510020",
        "http://www.ncbi.nlm.nih.gov/pubmed/20696312",
        "http://www.ncbi.nlm.nih.gov/pubmed/18451130",
        "http://www.ncbi.nlm.nih.gov/pubmed/10943908"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 775,
          "offsetInEndSection": 893,
          "text": "This article focuses on GWAS of alcohol addiction and provides an overview of GWAS of other substance abuse disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 344,
          "text": "Most of the GWAS of addiction performed to date have focused on alcohol dependence or smoking behavior."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 345,
          "offsetInEndSection": 518,
          "text": "Four GWAS of alcohol dependence have been published thus far, and only two single nucleotide polymorphisms have received modest support of replication in a subsequent study."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Genome-wide association studies (GWAS) currently represent the most systematic approach to genetic research into complex disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 576,
          "offsetInEndSection": 774,
          "text": "One large, single GWAS and meta-analyses of the phenotype \"smoking quantity\" have generated convincing evidence for the contribution of variants in genes for cholinergic nicotinic receptor subunits."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12060782",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 235,
          "text": "Although environmental factors contribute to drug abuse and addiction, genetic factors also play a significant role estimated at 40-60% of the total risk."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12060782",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 236,
          "offsetInEndSection": 355,
          "text": "Nonetheless, the precise identities of human genes that confer vulnerability to problem drug use remain mostly unknown."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12060782",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 907,
          "offsetInEndSection": 1162,
          "text": "Collectively, these results suggest that genetic mutations in FAAH may constitute important risk factors for problem drug use and support a potential link between functional abnormalities in the endogenous cannabinoid system and drug abuse and dependence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12060782",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 356,
          "offsetInEndSection": 634,
          "text": "Here, we describe a natural single nucleotide polymorphism in the human gene that encodes the principal endocannabinoid-inactivating enzyme, fatty acid amide hydrolase (FAAH), that in homozygous form is strongly associated with both street drug use and problem drug/alcohol use."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12060782",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Problem drug use and dependence are neurobehavioral disorders of complex origin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28949931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "In this review, we discuss the genetic etiologies of Alzheimer's disease (AD)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28949931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 402,
          "offsetInEndSection": 538,
          "text": "Pedigree analysis and twin studies suggest that genetic components are part of the etiology, rather than only being risk factors for AD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28949931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 312,
          "offsetInEndSection": 401,
          "text": "Rigorous data mining approaches justified the significant role of genes in AD prevalence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28949931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 780,
          "offsetInEndSection": 914,
          "text": "Genome-wide association and linkage analysis studies with identified multiple genomic areas have implications for the treatment of AD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28949931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 79,
          "offsetInEndSection": 191,
          "text": "Furthermore, we review genetic links to protein signaling pathways as novel pharmacological targets to treat AD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24923803",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Extensive genetic and genomic studies of the relationship between alcohol drinking preference and withdrawal severity have been performed using animal models."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24923803",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 361,
          "text": "Data from multiple such publications and public data resources have been incorporated in the GeneWeaver database with >60,000 gene sets including 285 alcohol withdrawal and preference-related gene sets."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24923803",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 523,
          "offsetInEndSection": 701,
          "text": "Combinatorial integration of functional genomics experimental results revealed a single QTL positional candidate gene in one of the loci common to both preference and withdrawal."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24923803",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 362,
          "offsetInEndSection": 522,
          "text": "Among these are evidence for positional candidates regulating these behaviors in overlapping quantitative trait loci (QTL) mapped in distinct mouse populations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24923803",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1093,
          "offsetInEndSection": 1173,
          "text": "We have demonstrated genetic and alcohol-induced regulation of Ap3m2 expression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21575270",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 332,
          "offsetInEndSection": 515,
          "text": "In this review, we summarize the current experimental and clinical evidence for the concept of oncogene addiction and describe the mechanisms explaining oncogene addiction in gliomas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21575270",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "Oncogene addiction is a phenomenon that the survival of cancer cells depends on an activated oncogene or inactivation of tumor suppressor gene, and is regarded as the 'Achilles heel' of the successful molecular targeted therapies in cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21575270",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 623,
          "offsetInEndSection": 820,
          "text": "In addition, we discuss future direction for defining complex \"oncogene addiction network\" through the integrated analysis of multiple platforms in the flow of genetic information in gliomagenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21575270",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 331,
          "text": "However, the role of oncogene addiction in gliomas has not been elucidated systematically."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21575270",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 516,
          "offsetInEndSection": 622,
          "text": "And the clinical implications for oncogene addiction in molecular targeted therapy are further emphasized."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26834590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1369,
          "offsetInEndSection": 1547,
          "text": "Although this gene has not been previously implicated in alcohol-related behaviors, its function in various neural mechanisms makes a role in alcohol-related phenomena plausible."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26834590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "Identifying the biological substrates of complex neurobehavioral traits such as alcohol dependency pose a tremendous challenge given the diverse model systems and phenotypic assessments used."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26834590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 707,
          "offsetInEndSection": 967,
          "text": "A search of over 60,000 gene sets in GeneWeaver's database revealed alcohol-related experimental results including genes identified in mouse genetic mapping studies, alcohol selected Drosophila lines, Rattus differential expression, and human alcoholic brains."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26834590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1548,
          "offsetInEndSection": 1773,
          "text": "By making diverse cross-species functional genomics data readily computable, we were able to identify and confirm a novel alcohol-related gene that may have implications for alcohol use disorders and other effects of alcohol."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26834590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 604,
          "offsetInEndSection": 706,
          "text": "Using this system we identified a gene underlying multiple alcohol-related phenotypes in four species."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23510020",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1400,
          "offsetInEndSection": 1629,
          "text": "Hopefully, the integration of neurogenetics with systems biology and high-throughput genotyping will further pave the way to decipher all of the related causes, mechanisms, and biomarkers across the spectrum of distinct AD forms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23510020",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Alzheimer's disease (AD) pathophysiology is mostly (>95%) not inherited in a Mendelian fashion."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23510020",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1149,
          "offsetInEndSection": 1399,
          "text": "Recent years have witnessed tremendous development in genetics technology that has allowed full individualized genome-wide or genomic screening embracing all of the risk and protective variants for sAD, both across populations and within individuals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23510020",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 215,
          "offsetInEndSection": 470,
          "text": "Growing evidence indicates that multiple genes contribute to sAD-characteristic endophenotypes, molecular mechanisms, signaling pathways and biomarker signatures either individually or through complex gene-gene interactions, lifestyle and the environment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23510020",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1828,
          "offsetInEndSection": 2093,
          "text": "Even though we are more at the beginning than at the end of sAD genetics, there is some reason for optimism given the recent identification of novel risk or protective variants (such as rare TREM2 and APP mutations) showing strong statistical associations with sAD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20696312",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Over the last years, a plethora of genetic findings have completely changed our views on the aetiology of Parkinson's disease (PD)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20696312",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 132,
          "offsetInEndSection": 323,
          "text": "Linkage studies and positional cloning strategies have identified mutations in a growing number of genes which cause monogenic autosomal-dominant or autosomal-recessive forms of the disorder."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20696312",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 324,
          "offsetInEndSection": 604,
          "text": "While these Mendelian forms of PD are relatively rare, high-throughput genotyping and sequencing technologies have more recently provided evidence that low-penetrance variants in at least some of these genes also play a direct role in the aetiology of the common sporadic disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20696312",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 605,
          "offsetInEndSection": 795,
          "text": "In addition, rare variants in other genes, such as the Gaucher's disease-associated glucocerebrosidase A, have also been found to be important risk factors at least in subgroups of patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20696312",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 919,
          "offsetInEndSection": 1070,
          "text": "These findings provide the 'genetic entry points' to identify molecular targets and readouts necessary to design rational disease-modifying treatments."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18451130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 281,
          "text": "This phenomenon, called \"oncogene addiction,\" provides a rationale for molecular targeted therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18451130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 282,
          "offsetInEndSection": 480,
          "text": "The efficacy of this strategy requires novel methods, including integrative genomics and systems biology, to identify the state of oncogene addiction (i.e., the \"Achilles heel\") in specific cancers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18451130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 481,
          "offsetInEndSection": 596,
          "text": "Combination therapy may also be required to prevent the escape of cancers from a given state of oncogene addiction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18451130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67,
          "text": "Cancer cells contain multiple genetic and epigenetic abnormalities."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18451130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 68,
          "offsetInEndSection": 182,
          "text": "Despite this complexity, their growth and survival can often be impaired by the inactivation of a single oncogene."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Heritable factors account for approximately 40-60% of the total variance of liability to alcohol dependence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 320,
          "text": "The present study tested whether a novel functional polymorphism in the promotor region of the X-chromosomal monoamine oxidase A gene (MAOA) was related to antisocial and anxious-depressive traits in alcoholics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 321,
          "offsetInEndSection": 480,
          "text": "Due to the X-chromosomal localization of the MAOA gene, psychobiological traits were compared separately for both genders of 298 male and 66 female alcoholics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 874,
          "offsetInEndSection": 1074,
          "text": "Taken together, these findings suggest that the 3-repeat allele of the MAOA polymorphism contributes modestly to the dimension of overand underreactive behaviors as possible antecedents of alcoholism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 481,
          "offsetInEndSection": 655,
          "text": "In males, 30 of 59 alcoholics with antisocial personality disorder carried the low-activity 3-repeat allele in contrast to only 7 of 31 anxious-depressive alcoholics (51% vs."
        }
      ]
    },
    {
      "id": "680a079718b1e36f2e000147",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34535671",
        "http://www.ncbi.nlm.nih.gov/pubmed/24941379",
        "http://www.ncbi.nlm.nih.gov/pubmed/30009514",
        "http://www.ncbi.nlm.nih.gov/pubmed/1423320",
        "http://www.ncbi.nlm.nih.gov/pubmed/23372568",
        "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
        "http://www.ncbi.nlm.nih.gov/pubmed/7517178",
        "http://www.ncbi.nlm.nih.gov/pubmed/29163501",
        "http://www.ncbi.nlm.nih.gov/pubmed/24348481",
        "http://www.ncbi.nlm.nih.gov/pubmed/29642292"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34535671",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Natural killer (NK) cells exert critical roles in anti-tumor immunity but how their functions are regulated by epitranscriptional modification (e.g., N"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24941379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Natural killer (NK) cells recognize targets stressed by malignant transformation or infection and can be long-lived."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24941379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 357,
          "offsetInEndSection": 496,
          "text": "Persistence and in vivo expansion of NK cells depends on lymphodepleting chemotherapy to make space and induce release of endogenous IL-15."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24941379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1015,
          "offsetInEndSection": 1155,
          "text": "These are exciting times; more than 35 years after NK cells were initially described, we are exploiting their capacity for clinical therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24941379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 636,
          "offsetInEndSection": 727,
          "text": "Other limitations to NK-cell therapy include poor in vivo survival and lack of specificity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24941379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 271,
          "offsetInEndSection": 356,
          "text": "In the clinic, haploidentical NK cells can be adoptively transferred to treat cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30009514",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Natural killer (NK) cells recognize targets that have been changed via malignant transformation or infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30009514",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 407,
          "text": "NK cells use a plethora of activating and inhibitory receptors to recognize these changes and attack targets, but tumour cells often evade NK cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30009514",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 408,
          "offsetInEndSection": 509,
          "text": "Therefore, major efforts are being made to hone in on NK cell antitumour properties in immunotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30009514",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1268,
          "offsetInEndSection": 1385,
          "text": "Further understanding of the biology of NK cells will inform strategies to exploit NK cells for therapeutic purposes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30009514",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 890,
          "offsetInEndSection": 953,
          "text": "One major limitation to NK cell therapy is lack of specificity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1423320",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 604,
          "offsetInEndSection": 732,
          "text": "Similarly, the role of NK cells is unclear; these seem to lyse cells with low levels of MHC class I expression more efficiently."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1423320",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 285,
          "text": "This implies that expression of MHC class I molecules on tumours is also mandatory for an effective T cell response against neoplasias."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1423320",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "It is well established that MHC class I molecules present peptides from endogenous proteins, such as virus or tumour antigens, to CD8+ T lymphocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1423320",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1912,
          "offsetInEndSection": 2123,
          "text": "Consequences of defective MHC class I expression for the survival of a malignant clone may theoretically consist of an escape from cytotoxic T cell attack or in an increased susceptibility for NK mediated lysis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1423320",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 733,
          "offsetInEndSection": 859,
          "text": "So far, human tumour specific antigens that can be presented by HLA molecules have not been identified on the molecular level."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23372568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "In recent years, our understanding of the role of natural killer (NK) cells in the response to viral infection has grown rapidly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23372568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 432,
          "offsetInEndSection": 631,
          "text": "Tremendous knowledge has been gained in this area through the study of herpes viruses, but appreciation for the significance of NK cells in the response to other types of viral infections is growing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23372568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 431,
          "text": "Not only do we realize viruses have many immune-evasion strategies to escape NK cell responses, but that stimulation of NK cell subsets during an antiviral response occurs through receptors seemingly geared directly at viral products and that NK cells can provide a memory response to viral pathogens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23372568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1314,
          "offsetInEndSection": 1581,
          "text": "This review focuses on recent advances in understanding the role of NK cells in the immune response to poxviruses, the receptors involved in activation of NK cells during poxvirus infection, and the viral evasion strategies poxviruses employ to avoid the NK response."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23372568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 632,
          "offsetInEndSection": 892,
          "text": "The function of NK cells in defense against poxviruses has emerged over several decades beginning with the early seminal studies showing the role of NK cells and the NK gene complex in susceptibility of mouse strains to ectromelia, a poxvirus pathogen of mice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Immune recognition and elimination of cancerous cells is the primary goal of cancer immunotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 503,
          "offsetInEndSection": 682,
          "text": "However, tumor antigens are often weak T cell agonists, attributable to several mechanisms, including immune self-tolerance and poor immunogenicity of self-derived tumor peptides."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 99,
          "offsetInEndSection": 221,
          "text": "However, obstacles including immune tolerance and tumor-induced immunosuppression often limit beneficial immune responses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 683,
          "offsetInEndSection": 910,
          "text": "One strategy for overcoming these mechanisms is vaccination with mimotopes, or peptide mimics of tumor antigens, which alter the antigen presentation and/or T cell activation to increase the expansion of tumor-specific T cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 358,
          "offsetInEndSection": 502,
          "text": "Immunizing with tumor antigenic peptides is a promising, straight-forward vaccine strategy hypothesized to boost preexisting antitumor immunity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7517178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "The identification of MHC-restricted and tumour-specific cytotoxic T lymphocytes (CTLs) provides strong evidence in support of T cell-mediated immune surveillance against human tumour cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7517178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 332,
          "offsetInEndSection": 585,
          "text": "In contrast to these observations there are now numerous examples to suggest that a number of tumours escape this CTL-mediated control either by down-regulating accessory molecules or by blocking the intracellular processing of tumour-specific antigens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7517178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 331,
          "text": "These CTLs recognize short peptides derived from tumour-associated antigens in conjunction with class I molecules expressed on tumour cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7517178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1477,
          "offsetInEndSection": 1660,
          "text": "These findings suggest that resistance of tumour cells to CTL-mediated immune control can be reversed if the relevant peptide epitopes are appropriately presented on the cell surface."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7517178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 586,
          "offsetInEndSection": 766,
          "text": "Recently a number of tumour cell lines have been identified which display a transcriptional deficiency of transporters associated with antigen processing (also referred to as TAP)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29163501",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 85,
          "offsetInEndSection": 239,
          "text": "The unique ability of natural killer (NK) cells to kill cancer cells independent of major histocompatibility requirement makes them suitable as ACT tools."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29163501",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Optimal adoptive cell therapy (ACT) should contribute to effective cancer treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29163501",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 240,
          "offsetInEndSection": 353,
          "text": "Herceptin, an antihuman epidermal growth factor receptor-2 (anti-HER2) monoclonal antibody, is used to treat HER2"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24348481",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1067,
          "offsetInEndSection": 1251,
          "text": "Importantly, blocking co-inhibitory molecule signaling, often referred to as immune checkpoint blockade, does not necessarily lead to an effective activation of tumor-specific T cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24348481",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 447,
          "offsetInEndSection": 578,
          "text": "Even when already activated, tumor-specific T cells can be neutralized by the expression of co-inhibitory molecules on tumor cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24348481",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 721,
          "offsetInEndSection": 896,
          "text": "In this review, we discuss recent data regarding the essential and complex role of co-inhibitory molecules in regulating the immune response within the tumor microenvironment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24348481",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 274,
          "text": "T cell activation requires the interaction of the T cell receptor with a cognate major-histocompatibility complex-peptide complex."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24348481",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 579,
          "offsetInEndSection": 720,
          "text": "These and other immunosuppressive cues in the tumor microenvironment are major factors currently hampering the application of DC vaccination."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 211,
          "text": "Natural killer (NK) cells are large lymphocytes that directly kill cancer cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 212,
          "offsetInEndSection": 358,
          "text": "However, many aggressive cancers, including breast cancer, were reported to escape the successful killing of NK cells in a tumor microenvironment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 359,
          "offsetInEndSection": 496,
          "text": "In this study, we investigated the anti-cancer effect of curcumin in coculture of human breast carcinoma MDA-MB-231 and NK (NK-92) cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 620,
          "text": "We found that curcumin had an immune-stimulatory effect on NK-92 by increasing the surface expression of the CD16\u207a and CD56"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Curcumin is known to possess various biological functions, including anti-inflammatory, antioxidative, and anti-cancer activities."
        }
      ]
    },
    {
      "id": "67e5749b18b1e36f2e0000b5",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23153524",
        "http://www.ncbi.nlm.nih.gov/pubmed/33168588",
        "http://www.ncbi.nlm.nih.gov/pubmed/24014301",
        "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
        "http://www.ncbi.nlm.nih.gov/pubmed/25685858",
        "http://www.ncbi.nlm.nih.gov/pubmed/21371446",
        "http://www.ncbi.nlm.nih.gov/pubmed/26894970",
        "http://www.ncbi.nlm.nih.gov/pubmed/31547472",
        "http://www.ncbi.nlm.nih.gov/pubmed/24009233",
        "http://www.ncbi.nlm.nih.gov/pubmed/26642065"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153524",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 278,
          "text": "Alisertib (MLN8237) an investigational agent that inhibits Aurora A Ser/Thr kinase has shown activity in PTCL patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153524",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 653,
          "offsetInEndSection": 764,
          "text": "Treatment with MLN8237 inhibited PTCL cell proliferation in CRL-2396 and TIB-48 cells with an IC50 of 80-100nM."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153524",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 765,
          "offsetInEndSection": 983,
          "text": "MLN8237 induced endo-reduplication in a dose and time dependent manner in PTCL cell lines leading to apoptosis demonstrated by flow cytometry and PARP-cleavage at concentrations achieved in early phase clinical trials."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153524",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 526,
          "offsetInEndSection": 652,
          "text": "Of the subtypes of PTCL, aurora B was over-expressed in PTCL (NOS) [73%], T-NHL [100%], ALCL (Alk-Neg) [100%] and AITL [100%]."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153524",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 370,
          "text": "Here we demonstrate that aurora A and B are highly expressed in T-cell lymphoma cell lines."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33168588",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 195,
          "offsetInEndSection": 339,
          "text": "The study found that 60% of patients had molecular responses after two cycles of blinatumomab and 71% had molecular responses after five cycles."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33168588",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "A phase II trial shows that a chemotherapy-free regimen of dasatinib and blinatumomab produces molecular responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 323,
          "offsetInEndSection": 499,
          "text": "The kinases essential for BCR signal transduction, which are emerging as targets for CLL treatment, and the specific inhibitors under development are the focus of this chapter."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 133,
          "offsetInEndSection": 230,
          "text": "Recently, inhibitors of kinases in the BCR pathway have shown promising clinical activity in CLL."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "The B cell antigen receptor (BCR) and its downstream pathways are pivotal in the pathogenesis of chronic lymphocytic leukemia (CLL)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 500,
          "offsetInEndSection": 658,
          "text": "In particular, the BTK inhibitor ibrutinib and the PI3K inhibitor idelalisib (GS-1101) are two evolving targeted therapies with the most mature clinical data."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 231,
          "offsetInEndSection": 322,
          "text": "Based upon these results, the treatment paradigm for CLL will likely undergo major changes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small-cell lung cancer (NSCLC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 339,
          "offsetInEndSection": 543,
          "text": "Cell-free DNAs (cfDNAs) were analyzed in a RET-mutant medullary thyroid cancer (MTC) patient and a CCDC6-RET fusion NSCLC patient who had dramatic response to selpercatinib and later developed resistance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 898,
          "offsetInEndSection": 1068,
          "text": "Selpercatinib and pralsetinib use an unconventional mode to bind RET that avoids the interference from gatekeeper mutations but is vulnerable to non-gatekeeper mutations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 215,
          "offsetInEndSection": 338,
          "text": "It is critical to analyze RET mutants resistant to these drugs and unravel the molecular basis to improve patient outcomes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 544,
          "offsetInEndSection": 649,
          "text": "Selpercatinib-resistant RET mutants were identified and cross-profiled with pralsetinib in cell cultures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685858",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 192,
          "offsetInEndSection": 378,
          "text": "Blockade of the IL-6 pathway has been explored in multiple preclinical and clinical studies with promising results for the treatment of different types of cancer and Castleman's disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685858",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 837,
          "text": "Results from this study led to the recent approval of siltuximab for the treatment of Castleman's disease by the FDA and EMA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685858",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 547,
          "offsetInEndSection": 711,
          "text": "Recent phase II clinical studies in patients with multicentric Castleman's disease have shown the efficacy and safety of siltuximab in patients with this condition."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685858",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 379,
          "offsetInEndSection": 491,
          "text": "Siltuximab is a human/murine chimeric immunoglobulin G1kappa (IgG1kappa) monoclonal antibody against human IL-6."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685858",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 492,
          "offsetInEndSection": 546,
          "text": "It binds to IL-6 neutralizing its biological activity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21371446",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "We studied the effects of AZD1152, an Aurora B kinase inhibitor, on Burkitt's lymphoma (BL) and Hodgkin's lymphoma (HL) in human tissues and cell cultures and in a murine xenograft model of lymphoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21371446",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1281,
          "offsetInEndSection": 1409,
          "text": "There preclinical data suggest that the inhibition of Aurora B kinase is a potentially useful therapeutic strategy in BL and HL."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21371446",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 383,
          "text": "They were aberrantly expressed in BL and HL cell lines, and in lymph nodes from patients with BL and HL."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21371446",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 464,
          "offsetInEndSection": 656,
          "text": "The promoter activity of Aurora B kinase was high in BL cell lines and the Aurora B promoter contained a positive regulatory region between -74 and -104 from the transcription initiation site."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21371446",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 657,
          "offsetInEndSection": 854,
          "text": "AZD1152-hQPA had antiproliferative effects in the BL and HL cell lines studied; inhibited the phosphorylation of histone H3 and retinoblastoma proteins, and resulted in cells with > 4N DNA content."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26894970",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 308,
          "text": "In the current study, gamabufotalin (GBT) was isolated from toad venom, and its tumor-specific cytotoxicity was investigated in human MM cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26894970",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1095,
          "offsetInEndSection": 1209,
          "text": "Taken together, our study identified the potential of GBT as a promising therapeutic agent in the treatment of MM."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26894970",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 484,
          "offsetInEndSection": 653,
          "text": "Further analysis showed that GBT especially evoked the ubiquitination and degradation of c-Myc protein, thereby globally repressing the expression of c-Myc target genes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26894970",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 395,
          "offsetInEndSection": 483,
          "text": "Mechanistic studies using functional approaches identified GBT as an inhibitor of c-Myc."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26894970",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 940,
          "offsetInEndSection": 1094,
          "text": "The antitumor effect of GBT was validated in a xenograft mouse model and the suppression of MM-induced osteolysis was verified in a SCID-hu model in vivo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31547472",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1413,
          "offsetInEndSection": 1674,
          "text": "In conclusion, these recent studies strongly support CD123 as an important therapeutic target for the treatment of BPDCN, while a possible in the treatment of AML and other hematological malignancies will have to be evaluated by in the ongoing clinical studies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31547472",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 329,
          "offsetInEndSection": 501,
          "text": "Importantly, CD123 is expressed at both the level of leukemic stem cells (LSCs) and more differentiated leukemic blasts, which makes CD123 an attractive therapeutic target."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31547472",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 862,
          "offsetInEndSection": 1084,
          "text": "Different monoclonal antibodies directed against CD123 are under evaluation as antileukemic drugs, showing promising results either for the treatment of AML minimal residual disease or of relapsing/refractory AML or BPDCN."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31547472",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 328,
          "text": "The interleukin-3 receptor alpha chain (IL-3R), more commonly referred to as CD123, is widely overexpressed in various hematological malignancies, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, hairy cell leukemia, Hodgkin lymphoma and particularly, blastic plasmacytoid dendritic neoplasm (BPDCN)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31547472",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 502,
          "offsetInEndSection": 625,
          "text": "Various agents have been developed as drugs able to target CD123 on malignant leukemic cells and on the normal counterpart."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24009233",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1261,
          "offsetInEndSection": 1377,
          "text": "Our data demonstrate a novel strategy to identify cancer membrane target antigens using humoral anti-tumor immunity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24009233",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 162,
          "offsetInEndSection": 269,
          "text": "Targeting the CLL membrane and associated signaling patterns is a current focus of therapeutic development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24009233",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1378,
          "offsetInEndSection": 1486,
          "text": "In addition, we identify LCP1 as a membrane-associated target in CLL with confirmed pathogenic significance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24009233",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 399,
          "offsetInEndSection": 491,
          "text": "We sought to use this immune response to identify novel membrane-associated targets for CLL."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24009233",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 270,
          "offsetInEndSection": 398,
          "text": "Many tumor membrane targets are simultaneously targeted by humoral immunity, thus forming recognizable immunoglobulin responses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 350,
          "offsetInEndSection": 436,
          "text": "Targeting CDKs has been the focus of considerable basic science and clinical research."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 349,
          "text": "In this article, we not only review the preclinical and clinical studies of cyclin-dependent kinase (CDK) 4/6 inhibitors in breast cancer, liposarcoma, mantel cell lymphoma, melanoma and germ cell tumors, but also examine promising preclinical data in glioblastoma, renal and ovarian cancer models that may provide directions for future development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1020,
          "offsetInEndSection": 1176,
          "text": "Palbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1177,
          "offsetInEndSection": 1362,
          "text": "Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 573,
          "text": "The CDK 4/6 inhibitors are a novel class of therapeutics that target the CDK 4/6 kinases that promote transition through the cell cycle."
        }
      ]
    },
    {
      "id": "680d5f2a353a4a2e6b000006",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21881964",
        "http://www.ncbi.nlm.nih.gov/pubmed/29879994",
        "http://www.ncbi.nlm.nih.gov/pubmed/24730627",
        "http://www.ncbi.nlm.nih.gov/pubmed/24019633",
        "http://www.ncbi.nlm.nih.gov/pubmed/9559208",
        "http://www.ncbi.nlm.nih.gov/pubmed/9927835",
        "http://www.ncbi.nlm.nih.gov/pubmed/21172808",
        "http://www.ncbi.nlm.nih.gov/pubmed/27421131",
        "http://www.ncbi.nlm.nih.gov/pubmed/37064719",
        "http://www.ncbi.nlm.nih.gov/pubmed/19529061"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881964",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "IgG4-related disease (IgG4RD) is a novel clinical disease entity characterized by elevated serum IgG4 concentration and tumefaction or tissue infiltration by IgG4-positive plasma cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881964",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 532,
          "offsetInEndSection": 817,
          "text": "Although IgG4RD forms a distinct, clinically independent disease category and is attracting strong attention as a new clinical entity, many questions and problems still remain to be elucidated, including its pathogenesis, the establishment of diagnostic criteria, and the role of IgG4."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881964",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 818,
          "offsetInEndSection": 916,
          "text": "Here we describe the concept of IgG4RD and up-to-date information on this emerging disease entity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881964",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 186,
          "offsetInEndSection": 531,
          "text": "IgG4RD may be present in a certain proportion of patients with a wide variety of diseases, including Mikulicz's disease, autoimmune pancreatitis, hypophysitis, Riedel thyroiditis, interstitial pneumonitis, interstitial nephritis, prostatitis, lymphadenopathy, retroperitoneal fibrosis, inflammatory aortic aneurysm, and inflammatory pseudotumor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29879994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 270,
          "offsetInEndSection": 634,
          "text": "The aim of this study was to analyze if serum periostin is elevated in COPD compared to healthy controls, if it is affected by smoking status, if it is linked to inflammatory cell counts in blood, sputum and endobronchial biopsies, and if periostin can predict ICS-response in COPD patients.Serum periostin levels were measured using Elecsys Periostin immunoassay."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29879994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 635,
          "offsetInEndSection": 752,
          "text": "Correlations between periostin and inflammatory cell count in blood, sputum and endobronchial biopsies were analyzed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29879994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 116,
          "offsetInEndSection": 269,
          "text": "Since periostin is associated with Th2 driven inflammation and inhaled corticosteroid (ICS)-response in asthma, it could function as a biomarker in COPD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29879994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1047,
          "offsetInEndSection": 1469,
          "text": "Linear regression analysis of serum periostin showed positive correlations age (B\u2009=\u20090.02, 95%CI 0.01-0.03) and FEV1% predicted (B\u2009=\u20090.01, 95%CI 0.01-0.02) in healthy smokers, but not in COPD patients In conclusion, COPD -smokers and -past-smokers have significantly higher periostin levels compared to healthy smokers, yet periostin is not suitable as a biomarker for Th2-driven inflammation or ICS-responsiveness in COPD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29879994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Although Th2 driven inflammation is present in COPD, it is not clearly elucidated which COPD patients are affected."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24730627",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 729,
          "offsetInEndSection": 875,
          "text": "Early diagnosis and respiratory management are important in order to prevent the development of bronchiectasis and deterioration in lung function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24730627",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 414,
          "offsetInEndSection": 504,
          "text": "The triad of situs inversus, bronchiectasis and sinusitis is known as Kartagener syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24730627",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 339,
          "text": "Impairment of mucus clearance at these sites leads to sinusitis, repeated pulmonary infections, bronchiectasis, and chronic otitis media."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24730627",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Primary ciliary dyskinesia (PCD) is a genetic disease that causes abnormalities in ciliary structure and/or function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24730627",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 876,
          "offsetInEndSection": 1014,
          "text": "We report early diagnosis of PCD on nasal mucosal biopsy in two newborns who presented with prolonged respiratory distress and rhinorrhea."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24019633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Kartagener's syndrome is a very rare congenital malformation comprising of a classic triad of sinusitis, situs inversus and bronchiectasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24019633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 425,
          "offsetInEndSection": 512,
          "text": "We present a case of 12 year old boy with sinusitis, situs inversus and bronchiectasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24019633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 140,
          "offsetInEndSection": 295,
          "text": "Primary ciliary dyskinesia is a genetic disorder with manifestations present from early life and this distinguishes it from acquired mucociliary disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24019633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 296,
          "offsetInEndSection": 424,
          "text": "Approximately one half of patients with primary ciliary dyskinesia have situs inversus and, thus are having Kartagener syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24019633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 513,
          "offsetInEndSection": 772,
          "text": "The correct diagnosis of this rare congenital autosomal recessive disorder in early life is important in the overall prognosis of the syndrome, as many of the complications can be prevented if timely management is instituted, as was done in this in this case."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9559208",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "A recurrent theme in the schema of pathogenetic mechanisms attributed to colorectal cancer (CRC) and inflammatory bowel disease (IBD) is the interaction between genes and environment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9559208",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 753,
          "offsetInEndSection": 917,
          "text": "Particular attention is given to hypotheses relating to the role of dietetic substances, mainly fibre and dairy products, and how they may affect disease formation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9559208",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 439,
          "offsetInEndSection": 561,
          "text": "In addition, both forms of IBD--Crohn's disease (CD) and ulcerative colitis (UC)--have distinctive associated host events."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9559208",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 918,
          "offsetInEndSection": 1080,
          "text": "It is argued that within the context of hypotheses proposed for possible beneficial effects of these two dietetic factors, CRC and IBD may be considered together."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9559208",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 562,
          "offsetInEndSection": 671,
          "text": "Even within CD and UC, different clinical patterns and prognoses may have different specific host mechanisms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9927835",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Kartagener's syndrome is an inherited disease characterized by a triad of symptoms--bronchiectasis, situs inversus and sinusitis--and is classified as an immotile cilia syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9927835",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 280,
          "offsetInEndSection": 459,
          "text": "We report the case of a woman with Kartagener's syndrome who underwent surgery under epidural anesthesia with postoperative epidural analgesia, both techniques proving successful."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9927835",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 179,
          "offsetInEndSection": 279,
          "text": "Patients may experience specific airway problems when undergoing anesthesia for surgical procedures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21172808",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 717,
          "offsetInEndSection": 962,
          "text": "There, Crb, acting in parallel with the epidermal growth factor receptor (Egfr) pathway, is required for tracheal cell apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin (Moe)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21172808",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1435,
          "offsetInEndSection": 1543,
          "text": "These results unveil a link between Crb and the organisation of the actin cytoskeleton during morphogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21172808",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 462,
          "text": "Here, we approach these issues by investigating the role of the apical determinant protein Crumbs (Crb) during the morphogenesis of the embryonic Drosophila tracheal system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21172808",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 288,
          "text": "How their epithelial features, such as apicobasal polarity or adhesion, are maintained and remodelled and how adhesion and polarity proteins contribute to morphogenesis are two important questions in development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21172808",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 463,
          "offsetInEndSection": 572,
          "text": "Crb accumulates differentially throughout tracheal development and is required for different tracheal events."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27421131",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 258,
          "text": "Despite clinical and histologic similarities between sarcoidosis and tuberculosis, the role of M."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27421131",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Sarcoidosis is a rare multiorgan granulomatous disease of unknown etiology, mostly affecting young adults, with predilection for hilar lymph nodes and the lung."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27421131",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 330,
          "text": "tuberculosis in the etiopathogenesis of sarcoidosis is still not clear."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27421131",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 527,
          "offsetInEndSection": 626,
          "text": "tuberculosis in the development of sarcoidosis, as evidenced by negative culture in these patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27421131",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1362,
          "offsetInEndSection": 1586,
          "text": "In this article we summarise the present knowledge about the most common localization of sarcoidosis - pulmonary sarcoidosis, with special emphasis on the current etiologic hypothesis, possibility of diagnosis and treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37064719",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1056,
          "offsetInEndSection": 1165,
          "text": "Finally, we pair EoE and ESCC murine models to examine the functional relationship between these pathologies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37064719",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1817,
          "offsetInEndSection": 2076,
          "text": "Finally, our \nOur findings provide the first functional investigation of the relationship between EoE and esophageal cancer and suggest that esophageal epithelial remodeling events occurring in response to EoE inflammation may limit esophageal carcinogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37064719",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 319,
          "offsetInEndSection": 542,
          "text": "Basal cell hyperplasia may occur in patients with gastroesophageal reflux disease (GERD), a condition in which acid from the stomach enters the esophagus, or eosinophilic esophagitis (EoE), an emerging form of food allergy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37064719",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1559,
          "offsetInEndSection": 1816,
          "text": "Senescence, glucocorticoid receptor signaling, and granulocyte-macrophage colony-stimulating factor pathways are associated with EoE-enriched clusters while pathways associated with cell proliferation and metabolism are identified in ESCC-enriched clusters."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37064719",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 683,
          "text": "While GERD is a primary risk factor for esophageal cancer, epidemiological data suggests that EoE patients do not develop esophageal cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19529061",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 602,
          "offsetInEndSection": 757,
          "text": "This case report is on a patient who presented with long standing history of sinusitis, bronchiectasis and on examination situs inversus with dextrocardia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19529061",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Kartagener Syndrome is a rare autosomal recessive disorder consisting of triad of sinusitis, bronchiectasis and situs inversus with dextrocardia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19529061",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 323,
          "offsetInEndSection": 463,
          "text": "Clinical manifestations include lifelong, chronic upper and lower respiratory tract diseases secondary to ineffective mucociliary clearance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19529061",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 464,
          "offsetInEndSection": 601,
          "text": "Early diagnosis and management of chest infections can prevent irreversible damage to lungs and prevent potential lifelong complications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19529061",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 322,
          "text": "It is the subset of disorder called primary ciliary dyskinesia in which the cilia have abnormal structure and/or function resulting in multisystem diseases of various severity."
        }
      ]
    },
    {
      "id": "6810f6f0353a4a2e6b000015",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22675341",
        "http://www.ncbi.nlm.nih.gov/pubmed/32233338",
        "http://www.ncbi.nlm.nih.gov/pubmed/26587691",
        "http://www.ncbi.nlm.nih.gov/pubmed/27042424",
        "http://www.ncbi.nlm.nih.gov/pubmed/19436648",
        "http://www.ncbi.nlm.nih.gov/pubmed/30678612",
        "http://www.ncbi.nlm.nih.gov/pubmed/25202980",
        "http://www.ncbi.nlm.nih.gov/pubmed/24247648",
        "http://www.ncbi.nlm.nih.gov/pubmed/34431633",
        "http://www.ncbi.nlm.nih.gov/pubmed/25237400"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22675341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Glucagon-Like Peptide-1 receptor agonists (GLP-1RAs), approved as glucose-lowering drugs for the treatment of type 2 diabetes, have also been shown to reduce body weight."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22675341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 657,
          "offsetInEndSection": 764,
          "text": "When compared with placebo, GLP-1RAs determine a reduction of BMI at 6 months of -1.0 [-1.3; -0.6] kg/m(2)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22675341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 511,
          "text": "An extensive Medline, Cochrane database, and Embase search for \"exenatide,\" \"liraglutide,\" \"albiglutide,\" \"semaglutide,\" and \"lixisenatide\" was performed, collecting all randomized clinical trials on humans up to December 15, 2011, with a duration of at least 24 weeks, comparing GLP-1 receptor agonists with either placebo or active drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22675341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 881,
          "offsetInEndSection": 1249,
          "text": "This result could seem modest from a clinical standpoint; however, it could be affected by many factors contributing to an underestimation of the effect of GLP-1RA on body weight, such as non adequate doses, inclusion criteria, efficacy of GLP-1RA on reducing glycosuria, and association to non-pharmacological interventions not specifically aimed to weight reduction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22675341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 512,
          "offsetInEndSection": 656,
          "text": "Twenty two (7,859 patients) and 7 (2,416 patients) trials with available results on body weight at 6 and 12 months, respectively, were included."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32233338",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 159,
          "text": "Liraglutide may be useful for weight management in adolescents with obesity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32233338",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2232,
          "offsetInEndSection": 2429,
          "text": "In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32233338",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 160,
          "offsetInEndSection": 387,
          "text": "In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32233338",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Obesity is a chronic disease with limited treatment options in pediatric patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32233338",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 388,
          "offsetInEndSection": 540,
          "text": "Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587691",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 312,
          "offsetInEndSection": 445,
          "text": "They are also effective in reducing body weight but current GLP-1RAs have to be given by subcutaneous injection daily or once weekly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587691",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 205,
          "offsetInEndSection": 311,
          "text": "The GLP-1 receptor agonists (GLP-1RAs) are established as an option for treatment of T2DM after metformin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587691",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 446,
          "offsetInEndSection": 674,
          "text": "This review focuses on the new GLP-1RAs currently undergoing development, some of which require less frequent subcutaneous administration and others that are being developed in oral formulations that may favor patient adherence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587691",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1098,
          "offsetInEndSection": 1345,
          "text": "These findings in patients with high cardiovascular risk may favor the use of SGLT2 inhibitors as a second line treatment after metformin but there should still be an important role for novel GLP-1RAs, especially when weight reduction is required."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587691",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 675,
          "offsetInEndSection": 799,
          "text": "The new GLP-1RAs may have the benefit of requiring less frequent subcutaneous dosing or being active by oral administration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27042424",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "Glucagon-like peptide-1 (GLP-1)-based therapy improves glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27042424",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 368,
          "offsetInEndSection": 555,
          "text": "As a number of GLP-1 receptor agonists (GLP-1 RAs) continue to become available, physicians will soon face the challenge of selecting the right option customized to their patient's needs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27042424",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 962,
          "text": "The following discussion, derived from an extensive literature search using the PubMed database, applying the terms incretin, GLP-1, exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide, and taspoglutide, provides a comprehensive review of existing and upcoming molecules in the GLP-1 RA class in terms of their structure, pharmacological profiles, efficacy, safety, and convenience."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27042424",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 963,
          "offsetInEndSection": 1174,
          "text": "Search Methodology: A literature search was conducted using the PubMed database, applying the terms incretin, GLP-1, exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide, and taspoglutide."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27042424",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1175,
          "offsetInEndSection": 1372,
          "text": "Relevant articles were those that discussed structural, pharmacokinetic and pharmacodynamic differences, classification, long-acting and short-acting GLP-1 RAs, phase 3 trials, and expert opinions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19436648",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and currently undergoing regulatory review for the treatment of type 2 diabetes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19436648",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 296,
          "offsetInEndSection": 470,
          "text": "In clinical trials of up to 1 year duration, liraglutide has been demonstrated to have beneficial effects on islet cell function, leading to improvements in glycemic control."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19436648",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 597,
          "offsetInEndSection": 766,
          "text": "Liraglutide is effective as monotherapy and in combination therapy with oral antidiabetic drugs, and reduces HbA1c by up to approximately 1.5% from baseline (8.2%-8.4%)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19436648",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 858,
          "offsetInEndSection": 999,
          "text": "Liraglutide is associated with body weight loss, and reductions in systolic blood pressure have been observed throughout the clinical trials."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19436648",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1204,
          "offsetInEndSection": 1307,
          "text": "Further clinical experience with liraglutide will reveal its long-term durability, safety and efficacy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30678612",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1125,
          "offsetInEndSection": 1233,
          "text": "Orlistat, with peripheral mechanisms, represents the only drug approved for weight reduction in adolescents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30678612",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1234,
          "offsetInEndSection": 1291,
          "text": "Liraglutide has been approved at higher dose for obesity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30678612",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 862,
          "offsetInEndSection": 982,
          "text": "Anti-obesity drugs with central mechanisms, such as phentermine and lorcaserin, are available in USA, but not in Europe."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30678612",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 136,
          "offsetInEndSection": 334,
          "text": "The first line treatment is lifestyle modification to weight-loss, but for those who fail to achieve the goal or have difficulty in maintaining achieved results, pharmacological treatment is needed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30678612",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 397,
          "offsetInEndSection": 656,
          "text": "We aim to review actual pharmacological management of obese patients, highlighting differences between Food and Drug Administration - and European Medicine Agency-approved molecules, and pointing out self-medications readily obtainable and widely distributed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25202980",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25202980",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 173,
          "offsetInEndSection": 293,
          "text": "It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25202980",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1338,
          "offsetInEndSection": 1474,
          "text": "Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25202980",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 294,
          "offsetInEndSection": 555,
          "text": "Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25202980",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 103,
          "offsetInEndSection": 172,
          "text": "Besides lowering blood glucose, liraglutide also reduces body weight."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247648",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 379,
          "offsetInEndSection": 535,
          "text": "Recently, the International Diabetes Federation has proposed a new set of criteria to define metabolic syndrome in children and adolescents aged 6-16 years."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247648",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 278,
          "text": "This review attempts to summarize the recent literature on metabolic syndrome in children and adolescents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247648",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 668,
          "offsetInEndSection": 753,
          "text": "Fatty liver plays a central role in the insulin-resistant state in obese adolescents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247648",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "The prevalence of obesity is on the increase, and consequently metabolic syndrome is also becoming a serious health problem in children and adolescents all over the world."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247648",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1153,
          "offsetInEndSection": 1230,
          "text": "Metabolic syndrome prevalence in children and adolescents is on the increase."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 292,
          "offsetInEndSection": 397,
          "text": "Liraglutide and semaglutide are developed for the treatment of obesity, independently of type 2 diabetes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Glucagon-like peptide-1 receptor agonists are the antidiabetic agents that are associated with the greatest weight loss beyond a marked reduction in glycated haemoglobin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1116,
          "offsetInEndSection": 1251,
          "text": "Le liraglutide et le s\u00e9maglutide sont d\u00e9velopp\u00e9s pour le traitement de l\u2019ob\u00e9sit\u00e9, ind\u00e9pendamment de la pr\u00e9sence d\u2019un diab\u00e8te de type 2."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 836,
          "offsetInEndSection": 1115,
          "text": "Les agonistes des r\u00e9cepteurs du glucagon-like peptide-1 (GLP-1) sont les agents antidiab\u00e9tiques qui, outre une baisse importante du taux d\u2019h\u00e9moglobine glyqu\u00e9e, offrent la perte pond\u00e9rale la plus marqu\u00e9e, en augmentant la sati\u00e9t\u00e9 par un effet central, pr\u00e9dominant et p\u00e9riph\u00e9rique."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 398,
          "offsetInEndSection": 835,
          "text": "Three approaches may be considered to potentiate weight loss: an increase of the drug dosage because of the demonstration of a dose-response, an add-on therapy with a sodium-glucose cotransporter type 2 inhibitor as this agent exerts a complementary action through urinary calorie loss (glucosuria) or a combination of the effects of two incretin hormones (GLP-1 and GIP), as the potent dual agonist tirzepatide currently in development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1163,
          "offsetInEndSection": 1356,
          "text": "Body mass index (BMI) was changed 27.3\u2009\u00b1\u20095.4\u00a0kg/m(2) to 25.9\u2009\u00b1\u20094.8\u00a0kg/m(2) and percent reduction of body weight was significant and maintained over 4% at 2\u00a0years after liraglutide introduction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, has been shown to possess pleiotropic effects including body weight reduction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1028,
          "offsetInEndSection": 1162,
          "text": "At 1\u00a0year after liraglutide introduction, 69 patients (80.2%) decreased body weight and 58 patients (67.4%) improved glycemic control."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 136,
          "offsetInEndSection": 280,
          "text": "However, long-term effect of liraglutide on body weight and glycemic control has not been elucidated in Japanese type 2 diabetes (T2D) subjects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1512,
          "offsetInEndSection": 1763,
          "text": "Stepwise regression analysis demonstrated that baseline BMI and previous insulin dose were positively associated with body weight reduction and baseline HbA1c was positively associated with reduction of HbA1c at 2\u00a0years after liraglutide introduction."
        }
      ]
    },
    {
      "id": "680a237618b1e36f2e000152",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34687436",
        "http://www.ncbi.nlm.nih.gov/pubmed/35587830",
        "http://www.ncbi.nlm.nih.gov/pubmed/22882019",
        "http://www.ncbi.nlm.nih.gov/pubmed/34775780",
        "http://www.ncbi.nlm.nih.gov/pubmed/20428822",
        "http://www.ncbi.nlm.nih.gov/pubmed/25398844",
        "http://www.ncbi.nlm.nih.gov/pubmed/26420896",
        "http://www.ncbi.nlm.nih.gov/pubmed/21035151",
        "http://www.ncbi.nlm.nih.gov/pubmed/31088835",
        "http://www.ncbi.nlm.nih.gov/pubmed/35456984"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34687436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "In patients with glioblastoma, the average survival time with current treatments is short, mainly due to recurrences and resistance to therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34687436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 363,
          "text": "This insufficient treatment success is, in large parts, due to the tremendous molecular heterogeneity of gliomas, which affects the overall prognosis and response to therapies and plays a vital role in gliomas' grading."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34687436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 364,
          "offsetInEndSection": 471,
          "text": "In addition, the tumor microenvironment is a major player for glioma development and resistance to therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34687436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 969,
          "offsetInEndSection": 1164,
          "text": "Moreover, there is increasing evidence that these players affect the molecular biological properties of gliomas and enable inter-cell communication that supports pro-cancerogenic cell properties."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34687436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 472,
          "offsetInEndSection": 699,
          "text": "Active communication between glioma cells and local or neighboring healthy cells and the immune environment promotes the cancerogenic processes and contributes to establishing glioma stem cells, which drives therapy resistance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35587830",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "To determine whether imaging-based risk stratification enables prognostication in diffuse glioma, NOS (not otherwise specified)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35587830",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1658,
          "offsetInEndSection": 1857,
          "text": "Imaging-based risk stratification achieved histomolecular-level prognostication in diffuse glioma, NOS, and could aid in guiding patient referral for insufficient or unsuccessful molecular diagnosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35587830",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1858,
          "offsetInEndSection": 1972,
          "text": "\u2022 Three imaging-based risk types enable distinct prognostication in diffuse glioma, NOS (not otherwise specified)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35587830",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 257,
          "offsetInEndSection": 436,
          "text": "Two neuroradiologists analyzed pre-surgical CT and MRI to assign gliomas to the three imaging-based risk types considering well-known imaging phenotypes (e.g., T2/FLAIR mismatch)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35587830",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1153,
          "offsetInEndSection": 1277,
          "text": "Prognostication according to the three imaging-based risk types was achieved for both PFS and OS (log-rank test, p < 0.001)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22882019",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "text": "A practical mathematical model for glioblastomas (brain tumours), which incorporates the two key parameters of tumour growth, namely the cancer cell diffusion and the cell proliferation rate, has been shown to be clinically useful and predictive."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22882019",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 604,
          "offsetInEndSection": 759,
          "text": "This is an input of potential importance in any future controlled clinical study of any connection between cell phone radiation and brain tumour incidence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22882019",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 835,
          "offsetInEndSection": 1083,
          "text": "Finally, based on patient parameters, the solution of the model equation of the tumour growth helps to explain why certain patients live longer than others after similar treatment protocols specifically surgical resection (removal) and irradiation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22882019",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 448,
          "offsetInEndSection": 603,
          "text": "Based on patient in vivo parameters, obtained from two brain scans, it is shown how to estimate the time, after initial detection, when the tumour started."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22882019",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 760,
          "offsetInEndSection": 834,
          "text": "It is also used to estimate more accurately survival times from detection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34775780",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 278,
          "text": "Statistical analyses have been used for many years in an attempt to predict clinical outcomes of brain metastasis patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34775780",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 942,
          "offsetInEndSection": 1100,
          "text": "Statistical models predicting brain metastasis behavior continue to evolve with the changing landscape of systemic therapy and the more aggressive use of SRS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34775780",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 454,
          "text": "Such models have attempted to predict such endpoints as survival and which patients would most benefit from stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34775780",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 756,
          "offsetInEndSection": 941,
          "text": "It also tells the history of the derivation and validation of BMV, a recently identified biomarker for survival and neurologic death in the brain metastasis population treated with SRS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34775780",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "To provide a review of the current status of predictive nomograms and brain metastasis velocity (BMV) in the prognostication of brain metastasis outcomes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20428822",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 200,
          "text": "The identification of novel molecular prognostic markers of GBM has recently been an area of great interest in neuro-oncology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20428822",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1547,
          "offsetInEndSection": 1700,
          "text": "Our data did not show statistically significant associations between MGMT promoter methylation and the outcome of GBM patients treated with temozolomide."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20428822",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1365,
          "offsetInEndSection": 1447,
          "text": "None of the patient clinical features were significantly correlated with survival."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20428822",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1062,
          "offsetInEndSection": 1364,
          "text": "Univariate and multivariate analyses did not show any statistically significant association between MGMT methylation status and patient OS (P=0.583 by the log-rank test; P=0.617 by the Cox-regression test) or progression-free survival (P=0.775 by the log-rank test; P=0.691 by the Cox-regression test)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20428822",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 364,
          "text": "The methylation status of the MGMT gene promoter is currently a promising molecular prognostic marker, but some controversial data have precluded its clinical use."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25398844",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Glioblastoma is characterized by high expression levels of proangiogenic cytokines and microvascular proliferation, highlighting the potential value of treatments targeting angiogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25398844",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 967,
          "offsetInEndSection": 1200,
          "text": "Predictive markers may allow appropriate patient enrichment, combination with chemotherapy may ultimately prove successful in improving overall survival, and novel agents targeting multiple proangiogenic pathways may prove effective."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25398844",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 580,
          "offsetInEndSection": 927,
          "text": "Despite promising phase II clinical trial results and patient benefit in terms of clinical improvement and longer progression-free survival, an overall survival benefit has not been demonstrated in four randomized phase III trials of bevacizumab or cilengitide in newly diagnosed glioblastoma or cediranib or enzastaurin in recurrent glioblastoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25398844",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 459,
          "offsetInEndSection": 579,
          "text": "The identification of biomarkers or imaging parameters to predict response and to herald resistance is of high priority."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25398844",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 287,
          "offsetInEndSection": 458,
          "text": "Ultimately, however, alternative proangiogenic signal transduction pathways are activated, leading to the development of resistance, even in tumors that initially respond."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26420896",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1127,
          "offsetInEndSection": 1217,
          "text": "Epilepsy is an independent prognostic factor for longer survival in glioblastoma patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26420896",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 311,
          "text": "We investigated the relationship between survival and epilepsy at presentation, early diagnosis, and antiepileptic drug therapy in glioblastoma patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26420896",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Epileptogenic glioblastomas are thought to convey a favorable prognosis, either due to early diagnosis or potential antitumor effects of antiepileptic drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26420896",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 312,
          "offsetInEndSection": 551,
          "text": "Multivariable Cox regression was applied to survival data of 647 consecutive patients diagnosed with de novo glioblastoma between 2005 and 2013 in order to investigate the association between epilepsy and survival in glioblastoma patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26420896",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 647,
          "offsetInEndSection": 732,
          "text": "Epilepsy correlated positively with survival (HR: 0.75 (95% CI: 0.61-0.92), P < .01)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035151",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1348,
          "offsetInEndSection": 1608,
          "text": "Recent studies conducted in GBM, both in the adjuvant and recurrent setting, have changed the natural course of the disease and opened a new area of clinical research, including imaging and response evaluation, predictive markers, and other targeted therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035151",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 446,
          "text": "In 2005, a phase III study clearly concluded in the benefit of adding temozolomide during and after radiotherapy treatment in GBM and thus defined the new standard of treatment in this devastating disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035151",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 630,
          "offsetInEndSection": 859,
          "text": "Moreover, methylation of the promoter of the O6 methylguanine DNA transferase (MGMT) gene exhibits a prognostic impact independently of therapeutic schedule but may also predict the benefit of adding temozolomide to radiotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035151",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "We review the indications and limitations of chemotherapy in glioblastoma multiform (GBM), including the role played by alkylating and other cytotoxic agents and the increased input of clinical research on targeted agents in GBM management."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035151",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 860,
          "offsetInEndSection": 1000,
          "text": "However, pitfalls in MGMT determination and lack of prospective validation have to be solved before considering MGMT as a decisional marker."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31088835",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 156,
          "offsetInEndSection": 342,
          "text": "Paradoxically, radiation is also a risk factor for GBM development, raising the possibility that radiotherapy of brain tumors could promote tumor recurrence or trigger secondary gliomas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31088835",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Glioblastomas are lethal brain tumors that are treated with conventional radiation (X-rays and gamma rays) or particle radiation (protons and carbon ions)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31088835",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 343,
          "offsetInEndSection": 494,
          "text": "In this study, we determined whether tumor suppressor losses commonly displayed by patients with GBM confer susceptibility to radiation-induced glioma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31088835",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 495,
          "offsetInEndSection": 535,
          "text": "Mice with Nestin-Cre-driven deletions of"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 428,
          "offsetInEndSection": 632,
          "text": "This is the main reason why, in recent years, scientific research has been focused on understanding the function and the composition of tumor microenvironment and its role in gliomagenesis and recurrence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 991,
          "offsetInEndSection": 1220,
          "text": "Understanding how glioma cells interact with non-neoplastic cells in tumor microenvironment is an essential step to comprehend mechanisms at the base of disease progression and to find new therapeutic strategies for GBM patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 133,
          "offsetInEndSection": 258,
          "text": "In recent years, molecular biomarkers have gained more and more importance both in the diagnosis and therapy of glial tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Despite the multidisciplinary management in the treatment of glioblastomas, the average survival of GBM patients is still 15 months."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 427,
          "text": "At the same time, it has become clear that non neoplastic cells, which constitute about 30% of glioma mass, dramatically influence tumor growth, spread, and recurrence."
        }
      ]
    },
    {
      "id": "68110110353a4a2e6b000018",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12856055",
        "http://www.ncbi.nlm.nih.gov/pubmed/2582337",
        "http://www.ncbi.nlm.nih.gov/pubmed/20659474",
        "http://www.ncbi.nlm.nih.gov/pubmed/30261763",
        "http://www.ncbi.nlm.nih.gov/pubmed/11130352",
        "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
        "http://www.ncbi.nlm.nih.gov/pubmed/29540258",
        "http://www.ncbi.nlm.nih.gov/pubmed/9806661",
        "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
        "http://www.ncbi.nlm.nih.gov/pubmed/29454747"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12856055",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 689,
          "offsetInEndSection": 826,
          "text": "The use of paracetamol in therapeutic doses generally is safe, although hepatotoxicity has occurred with recommended dosages in children."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12856055",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1190,
          "offsetInEndSection": 1316,
          "text": "The role of paracetamol in children with severe malaria or sepsis and in malnourished, febrile children needs to be clarified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12856055",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 373,
          "offsetInEndSection": 528,
          "text": "No studies showed any clear benefit for the use of paracetamol in therapeutic doses in febrile children with viral or bacterial infections or with malaria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12856055",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 827,
          "offsetInEndSection": 927,
          "text": "In developing countries where malnutrition is common, data on the safety of paracetamol are lacking."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12856055",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 986,
          "offsetInEndSection": 1069,
          "text": "No evidence shows that it is beneficial to treat febrile children with paracetamol."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2582337",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "N-acetyl cysteine (NAC) has recently been shown to have antioxidant properties, and since bleomycin produces pulmonary damage via free oxygen radical toxicity, the possible protective effect of NAC on bleomycin lung toxicity was investigated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2582337",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 874,
          "offsetInEndSection": 984,
          "text": "It is concluded that NAC inhibits bleomycin lung toxicity when administered by direct intratracheal injection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2582337",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 463,
          "offsetInEndSection": 620,
          "text": "All rats treated with bleomycin only had typical changes of bleomycin lung toxicity whereas the animals treated with bleomycin and NAC had minimal pathology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2582337",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 243,
          "offsetInEndSection": 367,
          "text": "Rats received saline (n = 7), NAC (n = 6), bleomycin (n = 7) or bleomycin and NAC (n = 6) by direct intratracheal injection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2582337",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 368,
          "offsetInEndSection": 462,
          "text": "Seven days later the animals were killed and the lungs processed for histology or morphometry."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20659474",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1293,
          "offsetInEndSection": 1368,
          "text": "Macroautophagy protects against ethanol-induced toxicity in livers of mice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20659474",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1172,
          "offsetInEndSection": 1292,
          "text": "Increasing macroautophagy pharmacologically reduced hepatotoxicity and steatosis associated with acute ethanol exposure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20659474",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 760,
          "offsetInEndSection": 980,
          "text": "Suppression of macroautophagy with pharmacologic agents or small interfering RNAs significantly increased hepatocyte apoptosis and liver injury; macroautophagy therefore protected cells from the toxic effects of ethanol."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20659474",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 235,
          "offsetInEndSection": 420,
          "text": "We investigated whether macroautophagy, an evolutionarily conserved cellular mechanism that is commonly activated in response to stress, could protect liver cells from ethanol toxicity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20659474",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1369,
          "offsetInEndSection": 1482,
          "text": "Reagents that modify macroautophagy might be developed as therapeutics for patients with alcoholic liver disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30261763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 568,
          "offsetInEndSection": 706,
          "text": "Areas covered: We review recent advances in antifibrotic therapy, of which most are currently tested in clinical trials for NAFLD or NASH."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30261763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 402,
          "offsetInEndSection": 567,
          "text": "The improved understanding of pathogenic mechanisms underlying chronic inflammation and fibrogenesis in the liver prompted recent advances in antifibrotic therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30261763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1059,
          "offsetInEndSection": 1319,
          "text": "Other antifibrotic drug candidates target cell death or inflammation, such as caspase (emricasan) or ASK1 inhibitors (selonsertib), galectin-3 inhibitors and reducing inflammatory macrophage recruitment by blocking chemokine receptors CCR2/CCR5 (cenicriviroc)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30261763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 234,
          "offsetInEndSection": 401,
          "text": "Fibrosis might progress to cirrhosis and predisposes to hepatocellular carcinoma (HCC), but is also associated with extrahepatic morbidity and mortality in NAFLD/NASH."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30261763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "Chronic injury to the liver, such as viral hepatitis, alcoholism, non-alcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), promotes extracellular matrix deposition and organ scarring, termed hepatic fibrosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11130352",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 567,
          "offsetInEndSection": 836,
          "text": "A trial could be conducted to determine whether this intervention improves the management of overdose or results in a net increase in harm (by undermining existing prevention strategies, precipitating naloxone-related complications, or resulting in riskier heroin use)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11130352",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 394,
          "offsetInEndSection": 566,
          "text": "Experts have suggested that, as part of a comprehensive overdose prevention strategy, naloxone should be provided to heroin users for peer administration after an overdose."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11130352",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 200,
          "offsetInEndSection": 393,
          "text": "Naloxone hydrochloride, an injectable opioid antagonist which reverses the respiratory depression, sedation and hypotension associated with opioids, has long been used to treat opioid overdose."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11130352",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Heroin overdose is a major cause of death among heroin users, and often occurs in the company of other users."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11130352",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 199,
          "text": "However, sudden death after injection is rare, giving ample opportunity for intervention."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1567,
          "offsetInEndSection": 1750,
          "text": "Aramchol treatment improved steatohepatitis and fibrosis by 1) decreasing SCD1, and 2) increasing the flux through the transsulfuration pathway maintaining cellular redox homeostasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1011,
          "offsetInEndSection": 1103,
          "text": "Aramchol administration reduced features of steatohepatitis and fibrosis in 0.1MCD fed mice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 654,
          "text": "The aim of this study was to investigate Aramchol's mechanism of action and its effect on fibrosis using the methionine- and choline-deficient (MCD) diet model of NASH."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1256,
          "offsetInEndSection": 1453,
          "text": "Aramchol increased the flux through the transsulfuration pathway, leading to a rise in glutathione (GSH) and GSH/GSSG ratio, the main cellular antioxidant that maintains intracellular redox status."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease (NAFLD) which sets the stage for further liver damage."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29540258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Acetaminophen (APAP) overdose is the leading cause of acute liver failure (ALF) with limited treatment options."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29540258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 217,
          "text": "It is known that liver regeneration following APAP-induced ALF is a deciding factor in the final outcome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29540258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1283,
          "offsetInEndSection": 1526,
          "text": "Taken together, these data show that massive DNA DSB occurs in high-dose APAP toxicity, and lack of prompt DSB repair after APAP overdose leads to prolonged growth arrest and proliferative senescence, resulting in inhibited liver regeneration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29540258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1113,
          "offsetInEndSection": 1282,
          "text": "Activation of p53, the major cell cycle checkpoint protein, was significantly higher with APAP600 as demonstrated by substantially higher expression of its target genes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29540258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 492,
          "offsetInEndSection": 611,
          "text": "Here we report that DNA damage and repair mechanisms regulate initiation of liver regeneration following APAP overdose."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9806661",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1781,
          "offsetInEndSection": 1926,
          "text": "Amifostine significantly decreased the amount of acute lung injury and subsequent fibrosis in the hamster model of bleomycin-induced lung injury."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9806661",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 394,
          "offsetInEndSection": 541,
          "text": "Amifostine, an aminothiol compound, is a cytoprotectant that is used with many antitumor agents and can act as a potent scavenger of free radicals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9806661",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 542,
          "offsetInEndSection": 622,
          "text": "The authors hypothesized that amifostine could ameliorate bleomycin lung injury."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9806661",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1157,
          "offsetInEndSection": 1436,
          "text": "Animals who received IT bleomycin, when compared with controls, had increased lung water measurements on Day 2 that were consistent with acute inflammation; on Day 21, they had pulmonary fibrosis, as measured by morphometric analysis, as well as increased hydroxyproline content."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9806661",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 63,
          "offsetInEndSection": 197,
          "text": "In humans, it can cause significant morbidity and mortality when used to treat malignancies such as lymphoma and testicular carcinoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 357,
          "text": "In the search for new therapeutics, the repurposing of the broad-spectrum antiprotozoal drug fexinidazole has completed Phase III trials with the anticipation that it will be the first oral treatment for HAT."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 576,
          "offsetInEndSection": 715,
          "text": "Pharmacokinetics of fexinidazole in plasma and central nervous system (CNS) compartments were similar in both infected and uninfected mice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 358,
          "offsetInEndSection": 575,
          "text": "This study used the recently validated bioluminescence imaging model to assess the dose and rate of kill effect of fexinidazole in infected mice, and the dose-dependent effect of fexinidazole on trypanosome infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 841,
          "text": "Drug distribution within the CNS was further examined by microdialysis, showing similar levels in the cortex and hippocampus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 148,
          "text": "Current treatment options are limited."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454747",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 576,
          "offsetInEndSection": 703,
          "text": "We tested the hypothesis that PAI-1 limits liver-related morbidity after APAP challenge by reducing tPA-dependent fibrinolysis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454747",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Acetaminophen (APAP)-induced liver injury in mice is associated with activation of the coagulation cascade and deposition of fibrin in liver."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454747",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 426,
          "offsetInEndSection": 575,
          "text": "Prior studies have shown that PAI-1 prevents intrahepatic hemorrhage and mortality after APAP challenge, but the downstream mechanisms are not clear."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454747",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 704,
          "offsetInEndSection": 924,
          "text": "Compared with APAP-challenged (300 mg/kg) wild-type mice, hepatic deposition of cross-linked fibrin was reduced, with intrahepatic congestion and hemorrhage increased in PAI-1-deficient mice 24 hours after APAP overdose."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454747",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 310,
          "offsetInEndSection": 425,
          "text": "PAI-1 expression is increased in both experimental APAP-induced liver injury and patients with acute liver failure."
        }
      ]
    },
    {
      "id": "680f4c63353a4a2e6b00000d",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24469437",
        "http://www.ncbi.nlm.nih.gov/pubmed/17364993",
        "http://www.ncbi.nlm.nih.gov/pubmed/11808344",
        "http://www.ncbi.nlm.nih.gov/pubmed/11831069",
        "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
        "http://www.ncbi.nlm.nih.gov/pubmed/2515622",
        "http://www.ncbi.nlm.nih.gov/pubmed/12082821",
        "http://www.ncbi.nlm.nih.gov/pubmed/8115806",
        "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
        "http://www.ncbi.nlm.nih.gov/pubmed/26940379"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24469437",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1653,
          "offsetInEndSection": 1744,
          "text": "Due to its safety, effectiveness and once-daily dosing, praziquantel is the drug of choice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24469437",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 285,
          "text": "In Africa, it predominantly manifests as urogenital disease, and the main infective agent is Schistosoma hematobium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24469437",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Schistosomiasis is the second most common socio-economically devastating parasitic disease after malaria, affecting about 240 million residents of developing countries."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24469437",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 996,
          "offsetInEndSection": 1122,
          "text": "Schistosomal glomerulopathy manifests as a clinical spectrum of asymptomatic proteinuria, nephrosis and/or nephritic syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24469437",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1353,
          "offsetInEndSection": 1453,
          "text": "Early detection by urine microscopy is hampered by low urinary excretion rates of the parasite eggs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17364993",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Imatinib is one of the most recent medications used for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17364993",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 336,
          "offsetInEndSection": 417,
          "text": "Imatinib blocks proliferation and induces apoptosis of BCR-ABL-expression in CML."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17364993",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 335,
          "text": "It is an orally administered protein-tyrosine kinase inhibitor, an enzyme which is produced by BCR-ABL fusion which results from translocation of 9:22 chromosome (Philadelphia chromosome)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17364993",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 418,
          "offsetInEndSection": 538,
          "text": "Many side effects produced by imatinib have been documented but its induction of hepatotoxcity has been rarely reported."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17364993",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 632,
          "offsetInEndSection": 771,
          "text": "We describe another case of hepatotoxicity due to imatinib in a 17-year old female with clinical, laboratory and histopathological changes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11808344",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 315,
          "text": "Imatinib (STI571), selective inhibitor of the ABL-tyrosine kinase, inhibits the activity of BCR-ABL tyrosine kinase."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11808344",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 316,
          "offsetInEndSection": 468,
          "text": "A phase I and II study of STI571 showed remarkable cytogenetic effect in patients with interferon-refractory CML, offering new hope for therapy for CML."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11808344",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 469,
          "offsetInEndSection": 604,
          "text": "It will, however, require long-term follow-up data from phase II and III clinical studies to validate the effect of STI571 on survival."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11808344",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by Philadelphia chromosome and resultant production of the constitutively activated BCR-ABL tyrosine kinase."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11808344",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 605,
          "offsetInEndSection": 688,
          "text": "As therapy for CML improves, monitoring minimal residual disease will be important."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11831069",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Imatinib (STI571 or Glivec, Novartis) is a new type of tyrosine kinase inhibitor that selectively inhibits various tyrosine kinases including ABL, BCR-ABL, KIT and PDGF receptors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11831069",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1423,
          "offsetInEndSection": 1490,
          "text": "Imatinib is the first effective systemic therapy for advanced GIST."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11831069",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 180,
          "offsetInEndSection": 447,
          "text": "Earlier studies have shown that Imatinib is highly effective in the treatment of chronic myeloid leukemia (CML), which is characterized by translocation of chromosome material from chromosome 9 to chromosome 22 with formation of the so-called Philadelphia chromosome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11831069",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 911,
          "offsetInEndSection": 1073,
          "text": "Initial case reports and various study approaches appear to indicate that treatment of GIST with Imatinib is a highly promising therapeutic option in this entity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11831069",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 679,
          "offsetInEndSection": 845,
          "text": "Gastrointestinal stromal tumors (GIST) are also suitable indications for treatment with Imatinib, the prerequisite being overexpression by the tumor of c-KIT (CD117)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Nitrofurantoin is a commonly prescribed antibiotic for urinary tract infection (UTI) treatment and prophylaxis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 291,
          "offsetInEndSection": 478,
          "text": "Therefore, treating physicians' awareness and regular monitoring is essential for early recognition, drug withdrawal, avoiding unnecessary treatment, and preventing irreversible fibrosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 479,
          "offsetInEndSection": 622,
          "text": "Here, we report the case of a 77-year-old woman who had been hospitalized with interstitial lung disease due to chronic nitrofurantoin therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 623,
          "offsetInEndSection": 797,
          "text": "Despite the severity of symptoms and the extent of radiological lung involvement, she returned to her clinical and radiological baseline shortly following the drug cessation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 290,
          "text": "Although relatively rare, nitrofurantoin can cause a spectrum of lung injuries, from acute hypersensitivity reactions that might be fatal to chronic reactions involving fibrosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "The best therapeutic approach to acute schistosomiasis (Katayama fever) is still unsettled."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 387,
          "text": "mansoni cercariae were treated with oxamniquine or praziquantel and dexamethasone or prednisolone."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1019,
          "offsetInEndSection": 1114,
          "text": "mansoni by combining these drugs has clear implications for treatment of the Katayama syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 258,
          "text": "In this paper we report a synergistic effect between schistosomicides and steroids in the treatment of the early stages of Schistosoma mansoni infection in the mouse."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 584,
          "offsetInEndSection": 697,
          "text": "Mice treated with schistosomicides alone or with schistosomicides plus steroids had worm burdens of similar size."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082821",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1057,
          "offsetInEndSection": 1202,
          "text": "Perspectives for treatment with STI571 are described, as are combinations with alpha-interferon and other cytostatics with a synergistic profile."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082821",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 380,
          "offsetInEndSection": 498,
          "text": "STI571 (signal transduction inhibition number 571) is a potent and selective inhibitor of the BCR-ABL tyrosine kinase."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082821",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 379,
          "text": "Chronic myeloid leukaemia (CML) is characterised by the occurrence of the Philadelphia (Ph) chromosome (9/22 translocation) and the formation of a fusion protein--the BCR-ABL transcript with constitutive activation of the BCR-ABL tyrosine kinase and consequent changes in the intracellular signal transduction, which is responsible for the deregulated myeloid cell proliferation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082821",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 895,
          "offsetInEndSection": 1056,
          "text": "Side effects are primarily nausea, vomiting, various rashes, oedema, most often in the periorbital region, and musculoskeletal symptoms, including muscle cramps."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082821",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 499,
          "offsetInEndSection": 725,
          "text": "In the chronic phase of the disease, normal peripheral blood values are achieved within the first month of treatment in the large majority of patients and in many patients also a cytogenic response within the following months."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8115806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 641,
          "offsetInEndSection": 739,
          "text": "In this paper, clinical, diagnostic and therapeutic features of acute schistosomiasis are updated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8115806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 502,
          "offsetInEndSection": 640,
          "text": "Clinical and experimental evidence indicate that steroids act synergistically with schistosomicides in the treatment of Katayama syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8115806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 346,
          "offsetInEndSection": 501,
          "text": "Recently, an ELISA test using KLH (keyhole limpet haemocyanin) as antigen, has proved useful in differentiating acute from chronic schistosomiasis mansoni."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8115806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Three distinct syndromes caused by schistosomiasis have been described: cercarial dermatitis or swimmer's itch, acute schistosomiasis or Katayama fever, and chronic schistosomiasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8115806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 245,
          "text": "Complications of acute schistosomiasis have also been reported."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Schistosomiasis is a helminthic infection that is endemic in tropical and subtropical regions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 815,
          "offsetInEndSection": 963,
          "text": "We present a case of pulmonary involvement in schistosomiasis and provide a discussion about typical imaging findings in the acute and chronic form."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 273,
          "offsetInEndSection": 478,
          "text": "In the lungs, granuloma formation and fibrosis around the schistosome eggs retained in the pulmonary vasculature may result in obliterative arteriolitis and pulmonary hypertension leading to cor pulmonale."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 479,
          "offsetInEndSection": 581,
          "text": "Acute schistosomiasis is associated with primary exposure and is commonly seen in nonimmune travelers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22470757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 582,
          "offsetInEndSection": 742,
          "text": "The common CT findings in acute pulmonary schistosomiasis are small pulmonary nodules ranging from 2 to 15 mm and larger nodules with ground glass-opacity halo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 486,
          "text": "Intravesical treatments offer the opportunity to directly target the painful bladder with less systemic side effects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 487,
          "offsetInEndSection": 692,
          "text": "In this review, the authors analyze the existing literature supporting the treatment of BPS/IC with conventional drugs including heparin, hyaluronic acid, chondroitin sulfate, and dimethylsulfoxide (DMSO)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 284,
          "text": "Unfortunately, many of the existing oral treatments are ineffective in most patients of BPS/IC, which is the motivation for developing new drugs and therapeutic approaches."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 865,
          "offsetInEndSection": 1092,
          "text": "Investigational treatments such as liposomes, botulinum toxin (BTX), liposomal BTX, PD-0299685 (a Ca(2+) channel \u02512\u03b4 ligand), continuous intravesical lidocaine, and AQX-1125 (a novel SHIP1 activating compound) are also covered."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940379",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1093,
          "offsetInEndSection": 1284,
          "text": "New investigational drugs offer promising improvements in clinical outcomes for BPS/IC patients; however, BPS/IC is a chronic pain disorder that is very vulnerable to a strong placebo effect."
        }
      ]
    },
    {
      "id": "680a087218b1e36f2e00014f",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
        "http://www.ncbi.nlm.nih.gov/pubmed/33817641",
        "http://www.ncbi.nlm.nih.gov/pubmed/26338180",
        "http://www.ncbi.nlm.nih.gov/pubmed/37132268",
        "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
        "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
        "http://www.ncbi.nlm.nih.gov/pubmed/34539983",
        "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
        "http://www.ncbi.nlm.nih.gov/pubmed/27556661",
        "http://www.ncbi.nlm.nih.gov/pubmed/20207611"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 670,
          "offsetInEndSection": 777,
          "text": "Multiple 2D maps of choline (Cho), creatine (Cr), and N-acetylaspartate (NAA) of the tumors were generated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 148,
          "offsetInEndSection": 413,
          "text": "In order to improve the differential diagnosis, we combined fluorine-18 2-fluoro-deoxyglucose positron emission tomography ((18)F-FDG PET), proton magnetic resonance spectroscopy ((1)H MRS) and histological data to develop a multi-parametric machine-learning model."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1238,
          "offsetInEndSection": 1420,
          "text": "The SVM and ROC analyses both demonstrated that SUVmax of the lesion was the most significant single diagnostic parameter (75% accuracy) followed by Cho concentration (67% accuracy)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "The ability to differentiate between brain tumor progression and radiation therapy induced necrosis is critical for appropriate patient management."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 778,
          "offsetInEndSection": 906,
          "text": "A support vector machine (SVM) learning model was established to take imaging biomarkers and histological data as input vectors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33817641",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 647,
          "text": "R-scores were built from 1246 radiomic features in 2 target volumes by using the Extreme Gradient Boosting algorithm to predict BMV-H groups, as defined by BMV at least 4 or leptomeningeal disease at first DBF."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33817641",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 342,
          "text": "We developed an integrated model of clinical predictors and pre-SRS MRI-derived radiomic scores (R-scores) to identify high-BMV (BMV-H) patients upon initial identification of brain metastases (BMs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33817641",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 648,
          "offsetInEndSection": 749,
          "text": "Two R-scores and 3 clinical predictors were integrated into a predictive clinico-radiomic (CR) model."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33817641",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 750,
          "offsetInEndSection": 979,
          "text": "The related R-scores showed signi\ufb01cant differences between BMV-H and low BMV (BMV-L), as defined by BMV less than 4 or no DBF (\nOur CR model provides a novel approach showing good performance to predict BMV and clinical outcomes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33817641",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Brain metastasis velocity (BMV) predicts outcomes after initial distant brain failure (DBF) following upfront stereotactic radiosurgery (SRS)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338180",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1886,
          "offsetInEndSection": 2094,
          "text": "Metabolic and textural parameters from initial [(18)F]FDG PET/CT scans could be indexes to assess tumour heterogeneity for the prediction of neoadjuvant radiation chemotherapy response and recurrence in LARC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338180",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 688,
          "offsetInEndSection": 789,
          "text": "Using three-dimensional textural analysis, about 50 textural features were calculated for PET images."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338180",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 277,
          "text": "The aim of this study was to investigate metabolic and textural parameters from pretreatment [(18)F]FDG PET/CT scans for the prediction of neoadjuvant radiation chemotherapy response and 3-year disease-free survival (DFS) in patients with locally advanced rectal cancer (LARC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338180",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1255,
          "offsetInEndSection": 1362,
          "text": "Textural parameters from histogram-based and co-occurrence analysis were significantly associated with TRG."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338180",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 790,
          "offsetInEndSection": 1051,
          "text": "Response to neoadjuvant radiation chemotherapy, as assessed by histological tumour regression grading (TRG) after surgery and 3-year DFS, was evaluated using univariate/multivariate binary logistic regression and univariate/multivariate Cox regression analyses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37132268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1056,
          "offsetInEndSection": 1155,
          "text": "Fifty-seven features were extracted, of which 13 were found to be promising predictors of response."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37132268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1719,
          "offsetInEndSection": 1871,
          "text": "Both multiparametric MRI and [ 18 F]FDG PET/CT contain promising imaging features to predict response to neoadjuvant chemoradiotherapy in LARC patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37132268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 761,
          "offsetInEndSection": 893,
          "text": "Using binary logistic regression analysis with a cutoff value of P \u2005\u2264\u20050.2, promising predictive features for response were selected."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37132268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 382,
          "text": "In this pilot study, we investigated the feasibility of response prediction using digital [ 18 F]FDG PET/computed tomography (CT) and multiparametric MRI before, during, and after neoadjuvant chemoradiation therapy in locally advanced rectal cancer (LARC) patients and aimed to select the most promising imaging modalities and timepoints for further investigation in a larger trial."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37132268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1156,
          "offsetInEndSection": 1718,
          "text": "Baseline [T2: volume, diffusion-weighted imaging (DWI): apparent diffusion coefficient (ADC) mean, DWI: difference entropy], early response (T2: volume change, DWI: ADC mean change) and end-of-treatment presurgical evaluation MRI (T2: gray level nonuniformity, DWI: inverse difference normalized, DWI: gray level nonuniformity normalized), as well as baseline (metabolic tumor volume, total lesion glycolysis) and early response PET/CT (\u0394 maximum standardized uptake value, \u0394 peak standardized uptake value corrected for lean body mass), were promising features."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 282,
          "offsetInEndSection": 565,
          "text": "There are different imaging modalities that have been used in the follow-up of rectal cancer, including computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and positron emission tomography-computed tomography (PET-CT) in clinical practice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 566,
          "offsetInEndSection": 775,
          "text": "We will systematically search PubMed, EMBASE, the Cochrane Library, and Chinese Biomedical Literature Database for diagnostic trials using CT, MRI, PET, and PET-CT to detect LR of rectal cancer in April, 2018."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1679,
          "offsetInEndSection": 1818,
          "text": "This review will help determine the diagnostic accuracy of CT, MRI, PET, and PET-CT for the diagnosis of patients with LR of rectal cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 983,
          "offsetInEndSection": 1212,
          "text": "We will use bivariate meta-analysis to estimate summary sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of CT, MRI, PET, and PET-CT, as well as different sequences of MRI."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "The risk of local recurrence (LR) continues to threat patients with rectal cancer after surgery or chemoradiotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Mutational signatures can be used to understand cancer origins and provide a unique opportunity to group tumor types that share the same origins and result from similar processes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 639,
          "offsetInEndSection": 735,
          "text": "The extraction of mutational signatures from high-throughput data still remains a daunting task."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 505,
          "offsetInEndSection": 638,
          "text": "In this context, an important question consists in the determination of the actual number of signatures that best represent the data."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1038,
          "offsetInEndSection": 1153,
          "text": "In addition, we introduce two new concepts of significant clinical relevance for evaluating the mutational profile."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1509,
          "offsetInEndSection": 1589,
          "text": "It also estimates the correct number of signatures even when other methods fail."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34539983",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1547,
          "offsetInEndSection": 1706,
          "text": "In conclusion, we established a risk signature that comprises three eRNAs, which can accurately be utilized as targets to predict prognosis in glioma patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34539983",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 761,
          "offsetInEndSection": 899,
          "text": "To construct a risk signature, we selected three eRNAs, including CRNDE, MRPS31P5, and LINC00844, for their significant prognostic values."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34539983",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 401,
          "offsetInEndSection": 613,
          "text": "Using data retrieved from the TCGA and CGGA databases, a LASSO regression analysis and multiCox proportional hazards regression analyses were performed to determine the hub eRNAs associated with glioma prognosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34539983",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 614,
          "offsetInEndSection": 760,
          "text": "Quantitative reverse transcription PCR was performed on the glioma samples to evaluate the expression characteristics of the identified hub eRNAs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34539983",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 124,
          "offsetInEndSection": 268,
          "text": "Enhancer RNA (eRNA) plays a significant role in tumor proliferation and metastasis; however, their functions in gliomas need further evaluation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1553,
          "offsetInEndSection": 1718,
          "text": "Based on these results, we conclude that a combination of multimodal imaging methods should be used to precisely assess the restaging of rectal cancer following CRT."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 884,
          "offsetInEndSection": 1099,
          "text": "Restaging after neoadjuvant chemoradiotherapy (CRT) remains a challenge with all modalities because it is difficult to reliably differentiate between the tumor mass and other radiation-induced changes in the images."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1327,
          "offsetInEndSection": 1552,
          "text": "Preoperative high-resolution MRI in combination with diffusion-weighted imaging, and/or PET-CT could provide valuable prognostic information for rectal cancer patients with locally advanced disease receiving preoperative CRT."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 511,
          "offsetInEndSection": 741,
          "text": "Magnetic resonance imaging (MRI) is often used to assess preoperative staging and the circumferential resection margin involvement, which assists in evaluating a patient's risk of recurrence and their optimal therapeutic strategy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1184,
          "offsetInEndSection": 1326,
          "text": "Although CT is most commonly used to evaluate treatment responses, its utility for identifying and following-up metastatic lesions is limited."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27556661",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "The unique radiobiological properties of protons have been understood for many years."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27556661",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 197,
          "text": "In addition, many of the clinical benefits of radiotherapy were first noted in tumors involving the skull base."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27556661",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 377,
          "offsetInEndSection": 569,
          "text": "We reviewed the physical properties of protons and the clinical studies performed to justify their use in the management of skull-base tumors and determine the benefits of proton beam therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27556661",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 570,
          "offsetInEndSection": 757,
          "text": "Published reports suggest a benefit to proton beam therapy for use in tumors of the skull base, including craniopharyngiomas, chordomas, skull-base sarcomas, and unresectable meningiomas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27556661",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 758,
          "offsetInEndSection": 822,
          "text": "Use of proton beam therapy may be beneficial in select patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 289,
          "text": "Ionizing cranial radiation is a risk factor for late occurrence of meningiomas within the radiation field."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 484,
          "offsetInEndSection": 550,
          "text": "Radiation-induced meningiomas may also have predilection to recur."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 290,
          "offsetInEndSection": 446,
          "text": "While pathologic grading of meningiomas is straightforward, significant variability often exists between pathologists in applying standard grading criteria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 61,
          "text": "Meningiomas are among the most common brain tumors in adults."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 62,
          "offsetInEndSection": 182,
          "text": "They are most commonly located over the cerebral convexities and are infrequently found in an intraventricular location."
        }
      ]
    },
    {
      "id": "6810daad353a4a2e6b000013",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26204547",
        "http://www.ncbi.nlm.nih.gov/pubmed/23844515",
        "http://www.ncbi.nlm.nih.gov/pubmed/27194400",
        "http://www.ncbi.nlm.nih.gov/pubmed/27648772",
        "http://www.ncbi.nlm.nih.gov/pubmed/24440934",
        "http://www.ncbi.nlm.nih.gov/pubmed/28506071",
        "http://www.ncbi.nlm.nih.gov/pubmed/16215086",
        "http://www.ncbi.nlm.nih.gov/pubmed/29020255",
        "http://www.ncbi.nlm.nih.gov/pubmed/25548572",
        "http://www.ncbi.nlm.nih.gov/pubmed/29450831"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26204547",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Fecal microbiota transplantation (FMT) has an incomparable efficacy to treat recurrent Clostridium difficile infection, with near 90% of success."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26204547",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 379,
          "offsetInEndSection": 612,
          "text": "Therefore a fecal microbiota transplant was performed using solid stools from a relative, diluted in saline and instilled in the distal ileon, with a good clinical response, without recurrence of diarrhea, during a 6-month follow-up."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26204547",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 304,
          "text": "We report a 57 years old woman who developed an antibiotic associated diarrhea with a positive polymerase chain reaction test for Clostridium Difficile toxin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26204547",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 305,
          "offsetInEndSection": 378,
          "text": "She was successfully treated with Vancomycin trice but diarrhea recurred."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23844515",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 611,
          "offsetInEndSection": 839,
          "text": "Fecal microbiota transplantation (FMT) holds considerable promise as a therapy for recurrent Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-up registries are stilt required."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23844515",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 494,
          "offsetInEndSection": 610,
          "text": "In recent years, fecal transplantation has been used in the English-speaking countries with cure rates of about 87%."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23844515",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 218,
          "offsetInEndSection": 357,
          "text": "difficile infections favor recurrences, new methods able to neutralize the bacterium without affecting the gut microbiota are badly needed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23844515",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Clostridium difficile is the etiologic agent of nosocomial and community-acquired diarrhea associated with exposure to antibiotics that disrupt the normal colonic flora."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23844515",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 840,
          "offsetInEndSection": 968,
          "text": "These are needed to identify the right patient, efficacy and safety profile of FMT before this approach can be widely advocated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27194400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 273,
          "offsetInEndSection": 468,
          "text": "Fecal microbiota transplantation (FMT), a highly effective treatment for recurrent Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR bacterial decolonization."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27194400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 994,
          "offsetInEndSection": 1204,
          "text": "FMT is a completely novel way to eradicate drug-resistant bacteria from the intestinal reservoir and should be further investigated to address the global problem of difficult-to-treat, MDR bacterial infections."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27194400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 469,
          "offsetInEndSection": 748,
          "text": "A total of eight case reports have been published showing FMT resulted in intestinal decolonization of extended spectrum \u03b2-lactamase (ESBL)-producing and carbapenemase-producing Enterobacteriaceae, vancomycin-resistant Enterococci, or methicillin-resistant Staphylococcus aureus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27194400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 887,
          "offsetInEndSection": 993,
          "text": "Five trials are currently underway to further investigate the use of FMT for MDR bacterial decolonization."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27194400",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Treatment options for multidrug-resistant (MDR) bacterial infections are limited and often less effective."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27648772",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Fecal microbiota transplantation (FMT) restores a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile infection (CDI)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27648772",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1387,
          "offsetInEndSection": 1552,
          "text": "Fecal microbiota transplantation should be considered in patients with recurrent episodes of mild to moderate CDI who have failed conventional antimicrobial therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27648772",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1171,
          "offsetInEndSection": 1243,
          "text": "Fecal microbiota transplantation rarely results in major adverse events."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27648772",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1008,
          "offsetInEndSection": 1170,
          "text": "Fecal microbiota transplantation may be effectively administered via antegrade (upper gastrointestinal) or retrograde (lower gastrointestinal) routes of delivery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27648772",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1553,
          "offsetInEndSection": 1633,
          "text": "There is insufficient evidence to recommend FMT for the treatment of severe CDI."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24440934",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "By systematic review, we assessed the impact of fecal microbiota transplantation (FMT) for the treatment of Clostridium difficile (CD)-associated diarrhea."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24440934",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1598,
          "offsetInEndSection": 1712,
          "text": "Hospitals should encourage the development of fecal transplantation programs to improve therapy of local patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24440934",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 156,
          "offsetInEndSection": 285,
          "text": "Fecal microbiota microbiota transplantation from a healthy donor into an individual with CD infection (CDI) can resolve symptoms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24440934",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1058,
          "offsetInEndSection": 1209,
          "text": "Almost all patients treated with donors' fecal infusion experienced recurrent episodes of CD-associated diarrhea despite standard antibiotic treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24440934",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 777,
          "offsetInEndSection": 938,
          "text": "A critical appraisal of the clinical research evidence on the effectiveness and safety of FMT for the treatment of patients with CD-associated diarrhea was made."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28506071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "The use of fecal microbiota transplantation in recurrent Clostridium difficile infection and coexistent inflammatory bowel disease remains unclear."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28506071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 586,
          "offsetInEndSection": 816,
          "text": "Fecal microbiota transplantation is relatively simple to perform, well-tolerated, safe and effective in recurrent Clostridium difficile infection with ulcerative pancolitis, as an alternative in case of antibiotic therapy failure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28506071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 334,
          "offsetInEndSection": 430,
          "text": "Fecal microbiota transplantation of an unrelated healthy donor was performed by the lower route."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28506071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 148,
          "offsetInEndSection": 333,
          "text": "A 61-year-old man with ulcerative pancolitis was diagnosed with a third recurrence of Clostridium difficile infection, previously treated with metronidazole, vancomycin and fidaxomicin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28506071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 431,
          "offsetInEndSection": 585,
          "text": "After a twelve month follow-up, the patient remains asymptomatic without Clostridium difficile infection relapses or inflammatory bowel disease flare-ups."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16215086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 364,
          "offsetInEndSection": 496,
          "text": "This paper reviews the studies that have used probiotics to treat patients with short bowel syndrome and gastrointestinal disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16215086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 363,
          "text": "Recently, there has been interest in the oral administration of probiotics for these patients with small bowel bacterial overgrowth, inflammatory bowel disease, and radiation enteritis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16215086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 79,
          "offsetInEndSection": 177,
          "text": "Treatment of diarrhea has centered on the use of antidiarrheal medications and antibiotic therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16215086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Patients with intestinal failure often have diarrhea for a variety of reasons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16215086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 574,
          "text": "Additionally, some of the specific issues regarding probiotics are addressed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29020255",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 139,
          "offsetInEndSection": 248,
          "text": "We report cure of a septic patient with proctitis by fecal microbiota transplant via rectal swabs (mini-FMT)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29020255",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Rarely, in fulminant Clostridium difficile infection (CDI), the rectal stump is persistently infected following total abdominal colectomy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29020255",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 249,
          "offsetInEndSection": 351,
          "text": "This novel procedure offers a management option for recurrent CDI following total abdominal colectomy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25548572",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI) diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25548572",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 557,
          "offsetInEndSection": 615,
          "text": "FMT resolved the symptoms and restored normal GI-function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25548572",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1242,
          "offsetInEndSection": 1441,
          "text": "The presented case suggests a possible role of microbiota in restoring and maintaining normal GI-functionality and improves our knowledge on the etiology of antibiotic-induced, noninfectious colitis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25548572",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 192,
          "offsetInEndSection": 409,
          "text": "We followed up the relief of symptoms and long-term, over-a-year microbiota stabilization in a 46-year-old man, who underwent FMT for antibiotic-induced, non-CDI colitis nine months after being treated for CDI by FMT."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25548572",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 756,
          "offsetInEndSection": 886,
          "text": "A number of mucosa-associated bacteria increased after FMT and some of these bacteria remained increased in feces up to 14 months."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile infection (CDI)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 361,
          "offsetInEndSection": 648,
          "text": "Although the exact mechanisms of FMT have yet to be fully elucidated, replacement or restoration of a 'normal' microbiota (or at least a microbiota resembling those who have never had CDI) appears to have a positive effect on the gut dysbiosis that is thought to exist in these patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1271,
          "offsetInEndSection": 1421,
          "text": "Only a few studies have directly compared clinical efficacy in groups of patients who have been treated with FMT prepared differently (e.g., fresh vs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 170,
          "offsetInEndSection": 360,
          "text": "There have been many well-conducted randomized controlled trials and thousands of patients reported in case series that describe success rates of approximately 90% following one or more FMT."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2462,
          "offsetInEndSection": 2709,
          "text": "As FMT is increasingly being proposed for a number of conditions other than CDI, harmonization of methods and techniques may be more critical to the success of FMT, and thus it will be important to standardize these as far as practically possible."
        }
      ]
    },
    {
      "id": "6810c27b353a4a2e6b000010",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22934167",
        "http://www.ncbi.nlm.nih.gov/pubmed/25345238",
        "http://www.ncbi.nlm.nih.gov/pubmed/17074941",
        "http://www.ncbi.nlm.nih.gov/pubmed/12672169",
        "http://www.ncbi.nlm.nih.gov/pubmed/22090498",
        "http://www.ncbi.nlm.nih.gov/pubmed/23042258",
        "http://www.ncbi.nlm.nih.gov/pubmed/23109125",
        "http://www.ncbi.nlm.nih.gov/pubmed/23681158",
        "http://www.ncbi.nlm.nih.gov/pubmed/17440145",
        "http://www.ncbi.nlm.nih.gov/pubmed/23425613"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22934167",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 674,
          "offsetInEndSection": 848,
          "text": "There were 11 children who were treated with sertraline, and these patients were retrospectively compared to 34 children who were not treated with sertraline by chart review."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22934167",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1224,
          "offsetInEndSection": 1326,
          "text": "This data supports the need for a controlled trial of sertraline treatment in young children with FXS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22934167",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 136,
          "offsetInEndSection": 257,
          "text": "However, there are no medication recommendations with documented efficacy for children under 5 years old of age with FXS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22934167",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1039,
          "offsetInEndSection": 1223,
          "text": "Mean rate of improvement in both expressive and receptive language development was significantly higher in the group who was treated with sertraline (P < 0.0001 and P = 0.0071, resp.)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22934167",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Young children with fragile X syndrome (FXS) often experience anxiety, irritability, and hyperactivity related to sensory hyperarousal."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25345238",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 377,
          "offsetInEndSection": 468,
          "text": "The warning was extended in 2007 to antidepressants prescribed to adults aged 25 and under."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25345238",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 815,
          "offsetInEndSection": 1011,
          "text": "This report investigates a case where a 14 year old with major depressive disorder (MDD) developed suicidal ideation shortly after being prescribed a selective serotonin reuptake inhibitor (SSRI)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25345238",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 376,
          "text": "In 2004 the Food and Drug Administration (FDA) issued a \"black-box\" warning for antidepressants in children and adolescents, stating that these drugs may increase suicidality, a term encompassing both suicidal thoughts and behavior, especially in the first few weeks of treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25345238",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1012,
          "offsetInEndSection": 1163,
          "text": "Investigating the role antidepressants may play in suicidality suggests the need to explore the neurobiological mechanisms within the serotonin system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25345238",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 469,
          "offsetInEndSection": 686,
          "text": "The evidence behind this decision stemmed from meta-analyses of antidepressant clinical trials that demonstrated a slight increase in suicidality in those receiving antidepressants versus those treated with a placebo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17074941",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1882,
          "offsetInEndSection": 2119,
          "text": "More SSRI prescriptions are associated with lower suicide rates in children and may reflect antidepressant efficacy, treatment compliance, better quality mental health care, and low toxicity in the event of a suicide attempt by overdose."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17074941",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 761,
          "text": "The FDA recently linked adverse event reports of suicidal ideation among children and adolescents in randomized controlled trials to selective serotonin reuptake inhibitors (SSRIs) and consequently required a change in labeling that included a black box warning regarding SSRI use for all age groups."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17074941",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 940,
          "offsetInEndSection": 1175,
          "text": "Therefore, this study examined the association between antidepressant medication prescription rate and suicide rate in children ages 5-14 prior to the FDA findings by analyzing associations at the county level across the United States."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17074941",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1554,
          "offsetInEndSection": 1775,
          "text": "After adjustment for sex, race, income, access to mental health care, and county-to-county variability in suicide rates, higher SSRI prescription rates were associated with lower suicide rates in children and adolescents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17074941",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 762,
          "offsetInEndSection": 939,
          "text": "Given that the age-adjusted suicide rate is about six times higher in 15-19 year olds compared with 10-14 year olds, the risk-benefit ratio may be different in younger children."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12672169",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1094,
          "offsetInEndSection": 1274,
          "text": "In summary, paroxetine is well tolerated in the treatment of depression in those between the ages of 65 and 75, although few studies have examined its use in those of 75 and older."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12672169",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Paroxetine is a potent selective serotonin reuptake inhibitor (SSRI) with indications for the treatment of depression, obsessive- compulsive disorder, panic disorder and social phobia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12672169",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1022,
          "offsetInEndSection": 1093,
          "text": "However, the safety of the drug allows its prescription in the elderly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12672169",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 337,
          "offsetInEndSection": 528,
          "text": "There is wide interindividual variation in the pharmacokinetics of paroxetine in adults as well as in the elderly with higher plasma concentrations and slower elimination noted in the latter."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12672169",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 855,
          "offsetInEndSection": 1021,
          "text": "In anxiety disorders including general anxiety disorder, panic disorder, obsessive-compulsive disorder and social anxiety, there are no studies at all in the elderly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22090498",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "Selective serotonin reuptake inhibitors (SSRIs), such as citalopram (CTM), have been widely prescribed for major depressive disorder, not only for adult populations, but also for children and pregnant mothers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22090498",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1398,
          "offsetInEndSection": 1697,
          "text": "Together, these results indicate that administration of SSRIs during a sensitive period of brain development results in long-lasting alterations in NE-LC circuit function in adults and may be useful in understanding the etiology of pervasive developmental disorders such as autism spectrum disorder."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22090498",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 468,
          "offsetInEndSection": 629,
          "text": "In contrast, perinatal SSRI exposure induces a long-lasting downregulation of the 5-HT-raphe system, which is opposite to that seen with chronic adult treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22090498",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 210,
          "offsetInEndSection": 467,
          "text": "Recent evidence suggests that chronic SSRI exposure in adults increases serotonin (5-HT) levels in the raphe system and decreases norepinephrine (NE) locus ceruleus (LC) neural activity, suggesting a robust opposing interaction between these two monoamines."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22090498",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1260,
          "offsetInEndSection": 1397,
          "text": "Moreover, these effects were only evident in male exposed rats, suggesting a sexual dimorphism in neural development after SSRI exposure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23042258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "The selective serotonin reuptake inhibitors are prescribed increasingly also during pregnancy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23042258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 356,
          "offsetInEndSection": 615,
          "text": "Fluoxetine and paroxetine use in early pregnancy has been associated with a small increased risk for specific cardiovascular malformations in some studies, fluoxetine with ventricular septal defects and paroxetine with right ventricular outflow tract defects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23042258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1557,
          "offsetInEndSection": 1733,
          "text": "Considering the important role of serotonin in central nervous system development, more studies are needed to assess the possible adverse effects on long-term neurodevelopment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23042258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1068,
          "offsetInEndSection": 1264,
          "text": "Although several studies have not confirmed an increased risk for adverse neurodevelopment, a recent study observed an increased risk for autism spectrum disorders in prenatally exposed offspring."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23042258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 686,
          "offsetInEndSection": 858,
          "text": "Data on preterm birth, low birth weight, and being small for gestational age have been conflicting; and mother's underlying depression is obviously an important confounder."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109125",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 278,
          "offsetInEndSection": 562,
          "text": "The quality of studies regarding the psychopharmacological therapy of depressive disorders in childhood and adolescence has improved since the \u00abblack box\u00bb warning of the FDA concerning the occurrence of suicidality under treatment with selective serotonin reuptake inhibitors (SSRIs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109125",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Depending on symptom severity, psychopharmacological treatment can be a valuable option in the treatment of depressive disorders in childhood and adolescence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109125",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 277,
          "text": "This review provides recommendations for clinical treatment, focusing on suicidality and treatment-resistant patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109125",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 563,
          "offsetInEndSection": 692,
          "text": "In Germany, there is proof for a trend toward a more evidence-based psychopharmacological treatment approach within recent years."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681158",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Women are increasingly prescribed selective serotonin reuptake inhibitors (SSRIs) during pregnancy, with potential implications for neurodevelopment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681158",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1002,
          "offsetInEndSection": 1141,
          "text": "The outcome of one study suggested that children with autism were more likely to have a mother who was prescribed an SSRI during pregnancy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681158",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1389,
          "offsetInEndSection": 1595,
          "text": "These data are not robust enough to discourage use of SSRIs during human pregnancy, particularly given the known adverse effects of maternal mental illness on pregnancy outcomes and infant neurodevelopment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681158",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 284,
          "offsetInEndSection": 455,
          "text": "The aim of this paper was to review the existing preclinical and clinical literature of prenatal SSRI exposure on serotonin-related behaviors and markers in the offspring."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681158",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 892,
          "offsetInEndSection": 1001,
          "text": "Human studies (n\u2009=\u20094) examining anxiety in the offspring showed no adverse effects of prenatal SSRI exposure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17440145",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2153,
          "offsetInEndSection": 2278,
          "text": "Age-stratified analyses showed that for children younger than 12 years with MDD, only fluoxetine showed benefit over placebo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17440145",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "The US Food and Drug Administration (FDA) has issued warnings that use of antidepressant medications poses a small but significantly increased risk of suicidal ideation/suicide attempt for children and adolescents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17440145",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 215,
          "offsetInEndSection": 439,
          "text": "To assess the efficacy and risk of reported suicidal ideation/suicide attempt of antidepressants for treatment of pediatric major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and non-OCD anxiety disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17440145",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2393,
          "offsetInEndSection": 2610,
          "text": "Relative to placebo, antidepressants are efficacious for pediatric MDD, OCD, and non-OCD anxiety disorders, although the effects are strongest in non-OCD anxiety disorders, intermediate in OCD, and more modest in MDD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17440145",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 642,
          "offsetInEndSection": 938,
          "text": "Studies were published and unpublished randomized, placebo-controlled, parallel-group trials of second-generation antidepressants (selective serotonin reuptake inhibitors, nefazodone, venlafaxine, and mirtazapine) in participants younger than 19 years with MDD, OCD, or non-OCD anxiety disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1262,
          "offsetInEndSection": 1438,
          "text": "Moreover, the numerous prescriptions for fluoxetine, the only SSRI currently approved for this age group in Germany, lead to the question of possible unauthorized alternatives."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1026,
          "offsetInEndSection": 1088,
          "text": "Sertraline, escitalopram, and citalopram were also prescribed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "The present analysis evaluates the prevalence and medication use in inpatients with depression during childhood and adolescence at the KinderAGATE hospitals in 2010."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 773,
          "offsetInEndSection": 950,
          "text": "In our sample male patients diagnosed with depression (58 % DPat, mean age 13.8 years) were treated more often and earlier than female patients (42 % DPat, mean age 15.3 years)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23425613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 951,
          "offsetInEndSection": 1025,
          "text": "Fluoxetine and mirtazapine were the most frequently prescribed substances."
        }
      ]
    },
    {
      "id": "680a07a418b1e36f2e000148",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11994452",
        "http://www.ncbi.nlm.nih.gov/pubmed/21439318",
        "http://www.ncbi.nlm.nih.gov/pubmed/31856298",
        "http://www.ncbi.nlm.nih.gov/pubmed/32687059",
        "http://www.ncbi.nlm.nih.gov/pubmed/28382035",
        "http://www.ncbi.nlm.nih.gov/pubmed/14727085",
        "http://www.ncbi.nlm.nih.gov/pubmed/29395860",
        "http://www.ncbi.nlm.nih.gov/pubmed/11188932",
        "http://www.ncbi.nlm.nih.gov/pubmed/24325394",
        "http://www.ncbi.nlm.nih.gov/pubmed/11570584"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11994452",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 429,
          "offsetInEndSection": 610,
          "text": "Most DP T cells are small size lymphocytes that do not exhibit an activated phenotype, and their proliferative rate is similar to that of the other peripheral T cell subpopulations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11994452",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "CD4+CD8+ double-positive (DP) T cells represent a minor subpopulation of T lymphocytes found in the periphery of adult rats."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11994452",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 719,
          "offsetInEndSection": 877,
          "text": "However, both DP T cell subsets have an intrathymic origin since they appear in the recent thymic emigrant population after injection of FITC intrathymically."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11994452",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 352,
          "text": "In this study, we show that peripheral DP T cells appear among the first T cells that colonize the peripheral lymphoid organs during fetal life, and represent approximately 40% of peripheral T cells during the perinatal period."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11994452",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 611,
          "offsetInEndSection": 718,
          "text": "Only 30-40% of DP T cells expresses CD8beta chain, the remaining cells expressing CD8alphaalpha homodimers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21439318",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 596,
          "offsetInEndSection": 823,
          "text": "In this report, we have investigated by immunofluorescence on cryosection and by flow cytometry, the phenotype and the localization of dendritic cells into Peyer's patch of C57Bl/6 mouse intestine using dendritic cells markers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21439318",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 119,
          "offsetInEndSection": 311,
          "text": "The intestinal mucosa contains numerous dendritic cells, which induce either protective immunity to infectious agents or tolerance to innocuous antigens, including food and commensal bacteria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21439318",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 312,
          "offsetInEndSection": 595,
          "text": "Although during the past few years, several subsets of human mucosal dendritic cells have been described, a precise characterization of the different mouse mucosal dendritic cells subpopulations remains to be achieved with regard to their phenotype and localization in Peyer's patch."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21439318",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Peyer's patch have been extensively studied as a major inductive site for mucosal immunity within the small intestine."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21439318",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 824,
          "offsetInEndSection": 981,
          "text": "Positive and double staining for CD11c and BDCA-2, pDC/IPC, DC-LAMP, DC-SIGN, TLR8 and Langerin have been observed revealing new mouse intestinal DC subsets."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31856298",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 179,
          "offsetInEndSection": 283,
          "text": "M cells are considered to constitute an important route for antigen uptake in the mucosal immune system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31856298",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "The small intestine hosts specialized lymphoid structures, the Peyer's patches, that face the gut lumen and are overlaid with unique epithelial cells, called microfold (M) cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31856298",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 557,
          "offsetInEndSection": 809,
          "text": "Taking advantage of the respective reporter animals, we focused on classical DCs that express Zbtb46 and analyzed how these cells interact with M cells in steady state and sample antigen for T\u00a0cell activation in the Peyer's patches following challenge."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31856298",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 284,
          "offsetInEndSection": 426,
          "text": "Here, we used intravital microscopy to define immune cell populations, which are in close contact with M cells and potentially sample antigen."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31856298",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 427,
          "offsetInEndSection": 556,
          "text": "We present live evidence that DCs enter M cell pockets and highlight the abundance of mononuclear phagocytes in these structures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32687059",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Foxp3+ regulatory T cells (Tregs) are potent suppressor cells, essential for the maintenance of immune homeostasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32687059",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 299,
          "text": "However, some Tregs populate the thymus and constitute a major subset of yet poorly understood cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32687059",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 116,
          "offsetInEndSection": 197,
          "text": "Most Tregs develop in the thymus and are then released into the immune periphery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32687059",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 300,
          "offsetInEndSection": 355,
          "text": "Here we describe a subset of thymus recirculating IL18R"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "The adaptive immune system is dependent on functionally distinct lineages of T cell antigen receptor \u03b1\u03b2-expressing T cells that differentiate from a common progenitor in the thymus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 185,
          "text": "CD4"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14727085",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 244,
          "offsetInEndSection": 551,
          "text": "Exosomes secreted from professional antigen-presenting cells (i.e., B lymphocytes and dendritic cells) are enriched in MHC class I and II complexes, costimulatory molecules, and hsp70-90 chaperones, and have therefore been more extensively studied for their immunomodulatory capacities in vitro and in vivo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14727085",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Exosomes are small membrane vesicles originating from late endosomes and secreted by hematopoietic and epithelial cells in culture."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14727085",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 552,
          "offsetInEndSection": 761,
          "text": "This review will present the main biological features pertaining to tumor or DC-derived exosomes, will emphasize their immunostimulatory function, and will discuss their implementation in cancer immunotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14727085",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 132,
          "offsetInEndSection": 243,
          "text": "Exosome proteic and lipid composition is unique and might shed some light into exosome biogenesis and function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29395860",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 587,
          "offsetInEndSection": 713,
          "text": "Located in the small intestine, Peyer's patches (PP) are primary antigen sampling and mucosal immune response inductive sites."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29395860",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1268,
          "offsetInEndSection": 1487,
          "text": "This review focuses on recent advances on the PP MPS, which have allowed, through new criteria of PP phagocyte subset identification, the characterization of PP MF origin, diversity, specificity, location and functions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29395860",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "In mammals, macrophages (MF) are present in virtually all tissues where they serve many different functions linked primarily to the maintenance of homeostasis, innate defense against pathogens, tissue repair and metabolism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29395860",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1039,
          "offsetInEndSection": 1267,
          "text": "However, taking into account that PP are privileged sites of entry for pathogens, it is important to understand how the latter are handled by and/or escape the PP MPS, especially MF, which role in killing invaders is well known."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29395860",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 714,
          "offsetInEndSection": 910,
          "text": "Surprisingly, although markers of intestinal MF, such as F4/80, have been identified more than 30\u202fyears ago, MF of PP escaped any kind of phenotypic description and remained \"unknown\" for decades."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11188932",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Dendritic cells (DCs) are the most potent antigen presenting cells and the only ones capable of inducing primary cytotoxic immune responses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11188932",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 218,
          "text": "We found that DCs secrete a population of membrane vesicles, called exosomes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11188932",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 357,
          "offsetInEndSection": 502,
          "text": "Besides MHC and co-stimulatory molecules, exosomes bear several adhesion proteins, most likely involved in their specific subjected to targeting."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11188932",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 671,
          "offsetInEndSection": 845,
          "text": "Indeed, a single injection of DC-derived exosomes sensitized with tumor peptides induced potent anti tumor immune responses in mice and the eradication of established tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11188932",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 618,
          "offsetInEndSection": 670,
          "text": "Like DCs, exosomes induced immune responses in vivo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325394",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 641,
          "offsetInEndSection": 775,
          "text": "However, it is a challenge to obtain high enough numbers of primary DCs for immunotherapy, since their frequency in blood is very low."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325394",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "The superiority of dendritic cells (DCs) as antigen-presenting cells has been exploited in numerous clinical trials, where generally monocyte-derived DCs (Mo-DCs) are injected to induce immunity in patients with cancer or infectious diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325394",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1497,
          "offsetInEndSection": 1596,
          "text": "Further, they induced potent allogeneic T-cell responses and activated antigen-experienced T cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325394",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 438,
          "offsetInEndSection": 640,
          "text": "Pre-clinical studies suggest that vaccination with combination of primary DC subsets, such as myeloid and plasmacytoid blood DCs (mDCs and pDCs, respectively), may result in stronger clinical responses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325394",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1134,
          "offsetInEndSection": 1232,
          "text": "The ex vivo-generated DCs were phenotypically and functionally comparable to peripheral blood DCs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Due to their central role in controlling immunity, dendritic cells are logical targets for priming naive cytotoxic T lymphocytes against tumour cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1109,
          "offsetInEndSection": 1299,
          "text": "Blocking of MHC class I, but not class II, molecules on hybridomas impaired T cell proliferation, secretion of Th-1-associated cytokines, as well as the cytotoxic activity of primed T cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 307,
          "offsetInEndSection": 458,
          "text": "Hybridomas were positive for major histocompatibility complex (MHC) class II, CD40, CD54, CD83, CD86, and the pro-inflammatory cytokine interleukin-12."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1300,
          "offsetInEndSection": 1536,
          "text": "These findings strongly suggest that hybridomas deliver melanoma-associated antigens via MHC class I molecules to T lymphocytes, resulting in the generation of CD8+ cytotoxic T lymphocytes with effective anti-melanoma activity in vitro."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11570584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 669,
          "text": "After 6 days, in-vitro-primed T lymphocytes revealed a strong proliferation activity and released Th-1-associated, but not Th-2-associated, cytokines."
        }
      ]
    },
    {
      "id": "67fbd58c18b1e36f2e00010e",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23225525",
        "http://www.ncbi.nlm.nih.gov/pubmed/28751258",
        "http://www.ncbi.nlm.nih.gov/pubmed/22405725",
        "http://www.ncbi.nlm.nih.gov/pubmed/37905874",
        "http://www.ncbi.nlm.nih.gov/pubmed/19378813",
        "http://www.ncbi.nlm.nih.gov/pubmed/23965852",
        "http://www.ncbi.nlm.nih.gov/pubmed/29441009",
        "http://www.ncbi.nlm.nih.gov/pubmed/23629963",
        "http://www.ncbi.nlm.nih.gov/pubmed/20356930",
        "http://www.ncbi.nlm.nih.gov/pubmed/25645281"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23225525",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Protein aggregation within the central nervous system has been recognized as a defining feature of neurodegenerative diseases since the early 20th century."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23225525",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 760,
          "offsetInEndSection": 960,
          "text": "There is emerging evidence implicating soluble oligomers, smaller protein aggregates not detectable by conventional microscopy, as potential culprits in the pathogenesis of neurodegenerative diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23225525",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 156,
          "offsetInEndSection": 334,
          "text": "Since that time, there has been a growing list of neurodegenerative disorders, including Parkinson disease, which are characterized by inclusions of specific pathogenic proteins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23225525",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 567,
          "offsetInEndSection": 759,
          "text": "However, the correlation between protein inclusion formation and cytotoxicity is inconsistent, suggesting that another form of the pathogenic proteins may be contributing to neurodegeneration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23225525",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 335,
          "offsetInEndSection": 566,
          "text": "This has led to the long-held dogma that these characteristic protein inclusions, which are composed of large insoluble fibrillar protein aggregates and visible by light microscopy, are responsible for cell death in these diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "The deposition of misfolded \u03b2-sheet enriched amyloid protein is a shared feature of many neurodegenerative diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 283,
          "offsetInEndSection": 590,
          "text": "\u03b1-Syn is misfolded and aggregated in a group of neurodegenerative diseases collectively known as \u03b1-Synucleinopathies, which include Parkinson's disease (PD), dementia with Lewy body, multiple system atrophy and also a subset of Alzheimer's disease patients with concomitant PD-like Lewy bodies and neurites."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 591,
          "offsetInEndSection": 813,
          "text": "While sharing the same pathological protein, different \u03b1-Synucleinopathies demonstrate distinct clinical and pathological phenotypes, which could result from the existence of diverse pathological \u03b1-Syn strains in patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 282,
          "text": "Recent studies demonstrated the existence of conformationally diverse strains as a common property for multiple amyloidogenic proteins including \u03b1-Synuclein (\u03b1-Syn)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 814,
          "offsetInEndSection": 957,
          "text": "In this review, we summarized the characteristics of different \u03b1-Synucleinopathies and \u03b1-Syn strains generated with recombinant \u03b1-Syn monomers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22405725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 257,
          "text": "Not only are mutations in the gene encoding TDP-43 associated with ALS and FTLD, but this protein is also a major constituent of pathological intracellular inclusions in these diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22405725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 697,
          "offsetInEndSection": 882,
          "text": "Moreover, TDP-43 is an aggregation-prone protein and, given the role of toxic protein aggregates in neurodegeneration, a toxic gain-of-function mechanism is another rational hypothesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22405725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1322,
          "offsetInEndSection": 1522,
          "text": "Thus, understanding the interplay between TDP-43 aggregation, stress granules and the effect of ALS-associated TDP-43 mutations may be the key to understanding the role of TDP-43 in neurodegeneration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22405725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 576,
          "offsetInEndSection": 696,
          "text": "Thus, a loss of these essential functions is an attractive hypothesis regarding the role of TDP-43 in neurodegeneration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22405725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 883,
          "offsetInEndSection": 981,
          "text": "Importantly, ALS related mutations modulate the propensity of TDP-43 to aggregate in cell culture."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37905874",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 312,
          "offsetInEndSection": 537,
          "text": "However, under pathological conditions, abnormal expression, post-translational modifications, conformational changes, and truncation can make these proteins prone to aggregation, triggering specific disease-related cascades."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37905874",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "The aggregation of amyloid-beta peptide and tau protein dysregulation are implicated to play key roles in Alzheimer's disease pathogenesis and are considered the main pathological hallmarks of this devastating disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37905874",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 538,
          "offsetInEndSection": 857,
          "text": "Recent studies have indicated associations between aberrant behavior of amyloid-beta and tau proteins and various neurological diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37905874",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1034,
          "offsetInEndSection": 1172,
          "text": "In this comprehensive review, we provide an overview of the connections between amyloid-beta and tau proteins and a spectrum of disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37905874",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 858,
          "offsetInEndSection": 1033,
          "text": "Additionally, these proteins have been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes, which are all leading causes of morbidity and mortality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378813",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Intra- and/or extracellular proteinaceous inclusions in the brain tissue are characteristic pathological markers of many neurodegenerative diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378813",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 371,
          "offsetInEndSection": 566,
          "text": "Alpha-synucleinopathy is a term that collectively refers to a set of diseases in which neurodegeneration is accompanied by intracellular accumulation of alpha-synuclein in neurons or glial cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378813",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 567,
          "offsetInEndSection": 800,
          "text": "Recently, TDP-43 has been identified as a major disease protein in the ubiquitinated inclusions in deseases such as amyotrophic lateral sclerosis and frontotemporal lobar degeneration with tau-negative, ubiquitin-positive inclusions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378813",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 901,
          "offsetInEndSection": 1113,
          "text": "In this article, we review the present understanding of histopathological features of basal ganglia lesions in protein conformation disorders, including tauopathy, alpha-synucleinopathy, and TDP-43 proteinopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378813",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 801,
          "offsetInEndSection": 900,
          "text": "Thus, these neurodegenerative disorders comprise a new disease class, namely, TDP-43 proteinopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23965852",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Common cellular and molecular mechanisms including protein aggregation and inclusion body formation are involved in many neurodegenerative diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23965852",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 875,
          "offsetInEndSection": 1008,
          "text": "The present article reviews abnormal protein accumulation and inclusion body formation inside and outside the central nervous system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23965852",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 384,
          "offsetInEndSection": 530,
          "text": "Recently, TDP-43 was identified as a component of ubiquitinated inclusions in amyotrophic lateral sclerosis and frontotemporal lobar degeneration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23965852",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 301,
          "text": "\u03b1-Synuclein is a major component of Lewy bodies in Parkinson's disease (PD) as well as in glial cytoplasmic inclusions in multiple system atrophy (MSA)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23965852",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 639,
          "offsetInEndSection": 759,
          "text": "However, pathological changes occur in widespread regions of the central and peripheral nervous systems in this disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29441009",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 670,
          "offsetInEndSection": 775,
          "text": "Thus, dysfunction of autophagy is suggested to lead to the accretion of noxious proteins in the AD brain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29441009",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 90,
          "offsetInEndSection": 351,
          "text": "It is characterized by a progressive and irreversible loss of cognitive abilities and formation of senile plaques, composed mainly of amyloid \u03b2 (A\u03b2), and neurofibrillary tangles (NFTs), composed of tau protein, in the hippocampus and cortex of afflicted humans."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29441009",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 352,
          "offsetInEndSection": 469,
          "text": "In brains of AD patients the metabolism of A\u03b2 is dysregulated, which leads to the accumulation and aggregation of A\u03b2."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29441009",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Alzheimer's disease (AD) is the most common cause of progressive dementia in the elderly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29441009",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 470,
          "offsetInEndSection": 541,
          "text": "Metabolism of A\u03b2 and tau proteins is crucially influenced by autophagy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629963",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 292,
          "text": "Two RNA-binding proteins, TDP-43 and FUS, aggregate in the degenerating motor neurons of ALS patients, and mutations in the genes encoding these proteins cause some forms of ALS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629963",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 586,
          "offsetInEndSection": 796,
          "text": "Recent work connecting TDP-43 and FUS to stress granules has suggested how this cellular pathway, which involves protein aggregation as part of its normal function, might be coopted during disease pathogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629963",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 293,
          "offsetInEndSection": 439,
          "text": "TDP-43 and FUS and several related RNA-binding proteins harbor aggregation-promoting prion-like domains that allow them to rapidly self-associate."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629963",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Amyotrophic lateral sclerosis (ALS) is a fatal human neurodegenerative disease affecting primarily motor neurons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629963",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 440,
          "offsetInEndSection": 585,
          "text": "This property is critical for the formation and dynamics of cellular ribonucleoprotein granules, the crucibles of RNA metabolism and homeostasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20356930",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1055,
          "offsetInEndSection": 1303,
          "text": "Collectively, these findings suggest that amyloid conformers can spread from cell to cell within the brains of afflicted individuals, thereby spreading the specific neurodegenerative phenotypes distinctive to the protein being converted to amyloid."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20356930",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 407,
          "offsetInEndSection": 590,
          "text": "Diverse polypeptides that tend to populate intrinsically unfolded states also form self-templating amyloid conformers that are associated with devastating neurodegenerative disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20356930",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 591,
          "offsetInEndSection": 790,
          "text": "Moreover, two RNA-binding proteins, FUS and TDP-43, which form cytoplasmic aggregates in amyotrophic lateral sclerosis, harbor a 'prion domain' similar to those found in several yeast prion proteins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20356930",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Prions are proteins that access self-templating amyloid forms, which confer phenotypic changes that can spread from individual to individual within or between species."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20356930",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 791,
          "offsetInEndSection": 894,
          "text": "Can these proteins and the neurodegenerative diseases to which they are linked become 'infectious' too?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25645281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Several neurodegenerative diseases such as transmissible spongiform encephalopathies, Alzheimer's and Parkinson's diseases are caused by the conversion of cellular proteins to a pathogenic conformer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25645281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 509,
          "offsetInEndSection": 843,
          "text": "This review aims to cover what is known about the intracellular trafficking of these proteins as well as their degradation mechanisms and highlight similarities in their movement through the endocytic pathway that could contribute to the pathogenic conversion and seeding of these proteins which underlies the basis of these diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25645281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 200,
          "offsetInEndSection": 508,
          "text": "Despite differences in the primary structure and subcellular localization of these proteins, which include the prion protein, \u03b1-synuclein and amyloid precursor protein (APP), striking similarity has been observed in their ability to seed and convert na\u00efve protein molecules as well as transfer between cells."
        }
      ]
    },
    {
      "id": "67fbe10618b1e36f2e000111",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30127341",
        "http://www.ncbi.nlm.nih.gov/pubmed/24065914",
        "http://www.ncbi.nlm.nih.gov/pubmed/23602925",
        "http://www.ncbi.nlm.nih.gov/pubmed/22958973",
        "http://www.ncbi.nlm.nih.gov/pubmed/17347940",
        "http://www.ncbi.nlm.nih.gov/pubmed/1623312",
        "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
        "http://www.ncbi.nlm.nih.gov/pubmed/27974283",
        "http://www.ncbi.nlm.nih.gov/pubmed/21571763",
        "http://www.ncbi.nlm.nih.gov/pubmed/23666287"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30127341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 181,
          "offsetInEndSection": 341,
          "text": "Males are more susceptible to neurodevelopmental disorders including intellectual disability, autism spectrum disorder, and attention-deficit activity disorder."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30127341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 342,
          "offsetInEndSection": 461,
          "text": "Conversely, after puberty, females are more prone to major depressive disorder and anxiety disorders compared to males."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30127341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1420,
          "offsetInEndSection": 1649,
          "text": "Overall we describe an increased rate of attention-deficit hyperactivity disorder and autism spectrum disorder, along with the increased rates of major depressive disorder and anxiety disorders in one or more of these conditions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30127341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1650,
          "offsetInEndSection": 1928,
          "text": "In addition to contributing unique insights about sexual dimorphism in neuropsychiatric disorders, awareness of the increased risk of neurodevelopmental and psychiatric disorders in sex chromosome aneuploidies can inform appropriate management of these common genetic disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30127341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "The study of sexual dimorphism in psychiatric and neurodevelopmental disorders is challenging due to the complex interplay of diverse biological, psychological, and social factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065914",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Autism spectrum disorders (ASD) are currently diagnosed in the presence of impairments in social interaction and communication, and a restricted range of activities and interests."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065914",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 180,
          "offsetInEndSection": 287,
          "text": "However, there is considerable variability in the behaviors of different individuals with an ASD diagnosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065914",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 425,
          "offsetInEndSection": 626,
          "text": "While any psychiatric condition is likely to incorporate a degree of heterogeneity, the variability in the nature and severity of behaviors observed in ASD is thought to exceed that of other disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065914",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 921,
          "offsetInEndSection": 1188,
          "text": "Using data from the Western Australian Autism Biological Registry, this study found that LBW and maternal SSRI use during pregnancy were associated with greater sleep disturbances and a greater number of gastrointestinal complaints in children with ASD, respectively."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065914",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 709,
          "offsetInEndSection": 920,
          "text": "In doing so, we examined whether two proposed risk factors - low birth weight (LBW), and in utero exposure to selective serotonin reuptake inhibitors (SSRIs) - are associated with greater behavioral homogeneity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23602925",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Children with chromosome 22q11.2 deletion syndrome (22q11.2DS), Fragile X syndrome (FXS), or Turner syndrome (TS) are considered to belong to distinct genetic groups, as each disorder is caused by separate genetic alterations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23602925",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1022,
          "offsetInEndSection": 1241,
          "text": "Girls with 22q11.2DS showed lower fractional anisotropy (FA) than controls in the association fibers of the superior and inferior longitudinal fasciculi, the splenium of the corpus callosum, and the corticospinal tract."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23602925",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1373,
          "offsetInEndSection": 1493,
          "text": "Girls with TS had lower FA in the inferior longitudinal fasciculus, right internal capsule and left cerebellar peduncle."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23602925",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1242,
          "offsetInEndSection": 1372,
          "text": "FA was abnormally lower in girls with FXS in the posterior limbs of the internal capsule, posterior thalami, and precentral gyrus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23602925",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 567,
          "offsetInEndSection": 735,
          "text": "We scanned 101 female children between 7 and 14years old: 25 with 22q11.2DS, 18 with FXS, 17 with TS, and 41 aged-matched controls using diffusion tensor imaging (DTI)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22958973",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Autism spectrum disorders (ASD) form a common group of neurodevelopmental disorders appearing to be under polygenic control, but also strongly influenced by multiple environmental factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22958973",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 361,
          "offsetInEndSection": 460,
          "text": "BTBR T+ tf/J (BTBR) mice display behaviors consistent with the three diagnostic categories for ASD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22958973",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 360,
          "text": "The brain mechanisms responsible for ASD are not understood and animal models paralleling related emotional and cognitive impairments may prove helpful in unraveling them."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22958973",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 560,
          "offsetInEndSection": 814,
          "text": "This review covers much of the data available to date on BTBR behavior, neuroanatomy and physiology in search for candidate biomarkers, which could both serve as diagnostic tools and help to design effective treatments for the behavioral symptoms of ASD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22958973",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 559,
          "text": "They show impaired social interaction and communication as well as increased repetitive behaviors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17347940",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 347,
          "offsetInEndSection": 451,
          "text": "To examine the differences between the two sexes, their prevalence and possible female subtypes in ADHD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17347940",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 346,
          "text": "Because it is a biological disorder, both boys and girls with ADHD display these same symptoms, but more boys are diagnosed with ADHD (in a ratio of 3 to 1)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17347940",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 819,
          "offsetInEndSection": 954,
          "text": "The girls were subdivided into four subtypes, in order of greater to lesser prevalence: shy, hypersociable, hyperactive and changeable."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17347940",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1184,
          "offsetInEndSection": 1541,
          "text": "a) Girls have certain specific clinical manifestations within the three common symptoms; b) methylphenidate is equally effective in both sexes; c) only boys display other disorders such as negativism and conduct disorders; and d) the brains of males and females are quite similar, but symptoms are expressed differently depending on environments and levels."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17347940",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1011,
          "offsetInEndSection": 1183,
          "text": "Only the group of boys presented other comorbidities such as negativism and conduct disorders; approximately 25% of them required treatment with atypical neuroleptic drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1623312",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 284,
          "offsetInEndSection": 495,
          "text": "It was concluded that, even within a group of cases fitting currently accepted criteria for autism, there is considerable variation in symptom profile depending on the exact type of associated medical condition."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1623312",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 283,
          "text": "Fifty-nine cases with infantile autism/autistic disorder were subclassified according to associated medical condition (fragile-X, tuberous sclerosis, neurofibromatosis, hypo-melanosis of Ito, Moebius syndrome, Rett syndrome, and a 'new' syndrome associated with a marker chromosome)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1143,
          "offsetInEndSection": 1347,
          "text": "Atypical behaviors included a preference for being alone, and selective interest in privileged objects used in a stereotyped manner, motor fretting, and attention instability were present in all children."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 488,
          "offsetInEndSection": 656,
          "text": "The aim of the present study was to describe a case series of children with Duchenne muscular dystrophy that have also the presence of autism spectrum disorders (ASDs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 385,
          "text": "In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsive disorder."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1348,
          "offsetInEndSection": 1461,
          "text": "By the administration of these scales was confirmed the presence of an autism spectrum disorders in all subjects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 795,
          "offsetInEndSection": 975,
          "text": "In order to evaluate and identify the presence and intensity of autistic symptoms have been used the Childhood Autism Rating Scale and Autism Diagnostic Observation Schedule tools."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Autism Spectrum Disorders (ASD) are characterized by: social and communication impairments, and by restricted repetitive behaviors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 132,
          "offsetInEndSection": 250,
          "text": "The aim of the present paper is to review abnormalities of oxytocin (OXT) and related congenital malformations in ASD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 465,
          "offsetInEndSection": 575,
          "text": "The development of ASD is suggested to be related to abnormalities of the oxytocin-arginin-vasopressin system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 576,
          "offsetInEndSection": 688,
          "text": "Previous results suggest that OXT and arginine vasopressin (AVP) may play a role in the etiopathogenesis of ASD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27974283",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 251,
          "offsetInEndSection": 423,
          "text": "A literature search was conducted in the PubMed database up to 2016 for articles related to the pathomechanism of ASD, abnormalities of OXT and the OXT polymorphism in ASD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "It is now well established that the prevalence of mental health difficulties in individuals with autism spectrum disorders (ASD) is considerably higher than in the general population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 184,
          "offsetInEndSection": 441,
          "text": "With recent estimates of the prevalence of autism spectrum disorders being as high as one percent, increasing numbers of children and young people are presenting to local and specialist services with mental health problems in addition to a diagnosis of ASD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 442,
          "offsetInEndSection": 586,
          "text": "Many families report that the impact of the mental health problems can be as or more impairing than the autism spectrum difficulties themselves."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 752,
          "offsetInEndSection": 989,
          "text": "This paper reports a case series of children and adolescents with ASD and an anxiety disorder who were treated with a standard cognitive behaviour therapy (CBT) rationale adapted to take account of the neuropsychological features of ASD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 990,
          "offsetInEndSection": 1086,
          "text": "Common features of the presentation of the disorders and also treatment processes are discussed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "The Autistic Spectrum Disorders (ASD) are characterized by an atypical sociability, alterations in communication, restricted interests and stereotypies, with adding affective and adaptative disabilities."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 436,
          "offsetInEndSection": 598,
          "text": "Among the individual risk factors of the suicidal behavior in ASD patients, mood and anxiety disorders are found as well as a familial affective disorder history."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 204,
          "offsetInEndSection": 325,
          "text": "The suicidal behaviors are frequently observed in the adolescents and adults with an ASD without intellectual deficience."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 715,
          "offsetInEndSection": 850,
          "text": "Laters tudies taking into account the cognitive characteristics would permit to investigate the suicidal phenomenology in ASD patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 326,
          "offsetInEndSection": 435,
          "text": "However, the clinical research on the topic is limited and the diagnosis not assessed in the emergency units."
        }
      ]
    },
    {
      "id": "680fcb72353a4a2e6b00000e",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8918594",
        "http://www.ncbi.nlm.nih.gov/pubmed/32370812",
        "http://www.ncbi.nlm.nih.gov/pubmed/23105285",
        "http://www.ncbi.nlm.nih.gov/pubmed/9150551",
        "http://www.ncbi.nlm.nih.gov/pubmed/23105292",
        "http://www.ncbi.nlm.nih.gov/pubmed/16157351",
        "http://www.ncbi.nlm.nih.gov/pubmed/2687698",
        "http://www.ncbi.nlm.nih.gov/pubmed/22067045",
        "http://www.ncbi.nlm.nih.gov/pubmed/22560084",
        "http://www.ncbi.nlm.nih.gov/pubmed/22390546"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8918594",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "The CH1 domains of antibodies belonging to the following five murine immunoglobulin (Ig) classes IgG1, IgG2a, IgG2b, IgG3 and IgA have been compared."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8918594",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 265,
          "text": "The IgG CH1 domain structures are, as would be expected, similar overall, but show local conformational variations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8918594",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 266,
          "offsetInEndSection": 469,
          "text": "When compared with IgG CH1 domain structures, the IgA CH1 domain displays several significant structural differences, which are a consequence of insertions/ deletions and specific structural constraints."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8918594",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 470,
          "offsetInEndSection": 627,
          "text": "In regions of structural differences in the IgG CH1 domains, the spatial correspondence of residues is not reflected by conventional (Kabat) sequence number."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8918594",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 628,
          "offsetInEndSection": 758,
          "text": "Thus the sequence alignment and numbering for CH1 domains has been revised to be consistent with the three-dimensional alignments."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32370812",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 399,
          "text": "Among the four subclasses of human IgG (IgG1, IgG2, IgG3, IgG4), which differ in their constant regions, particularly in their hinges and CH2 domains, IgG1 has the highest Fc\u03b3R-binding affinity, followed by IgG3, IgG2, and IgG4."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32370812",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 582,
          "offsetInEndSection": 773,
          "text": "Fc\u03b3 receptors include six subtypes (Fc\u03b3RI, Fc\u03b3RIIA, Fc\u03b3RIIB, Fc\u03b3RIIC, Fc\u03b3RIIIA, Fc\u03b3RIIIB) which differ in cellular distribution, binding affinity to Fc, and the resulting biological activity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32370812",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "The intact antibody of human immunoglobulin (IgG) is composed of the fragment for antigen binding (Fab) and the crystallizable fragment (Fc) for binding of Fc\u03b3 receptors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32370812",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 400,
          "offsetInEndSection": 581,
          "text": "As a result, different subclasses have different effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32370812",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1148,
          "offsetInEndSection": 1283,
          "text": "This review outlines fundamental strategies that are required to select IgG subclasses in developing anti-tumor therapeutic antibodies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105285",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 561,
          "offsetInEndSection": 662,
          "text": "In the present review a detailed account of different types of monoclonal gammapathies are described."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105285",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 326,
          "offsetInEndSection": 477,
          "text": "These monoclonal immunoglobulins are also called paraproteins and are frequently associated with a broad heterogeneous group of plasma cell dyscrasias."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105285",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 256,
          "text": "The neoplastic proliferation of single clones of plasma cells causes synthesis of very large amount of monoclonal immunoglobulins consisting of only one type of heavy either the gamma, alpha, mu, delta or epsilon chain or only kappa or lambda light chains."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105285",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 257,
          "offsetInEndSection": 325,
          "text": "Each monoclonal immunolobulin differs idiotypically from each other."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105285",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 478,
          "offsetInEndSection": 560,
          "text": "Occasionally their presence is observed in a few benign conditions and in old age."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9150551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 253,
          "text": "There are four main groups: the integrin family, the immunoglobulin superfamily, selectins, and cadherins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9150551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 596,
          "offsetInEndSection": 924,
          "text": "The immunoglobulin superfamily includes leukocyte function antigen-2 (LFA-2 or CD2), leukocyte function antigen-3 (LFA-3 or CD58), intercellular adhesion molecules (ICAMs), vascular adhesion molecule-1 (VCAM-1), platelet-endothelial cell adhesion molecule-1 (PE-CAM-1), and mucosal addressin cell adhesion molecule-1 (MAdCAM-1)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9150551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1018,
          "offsetInEndSection": 1136,
          "text": "Cadherins are major cell-cell adhesion molecules and include epithelial (E), placental (P), and neural (N) subclasses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9150551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 925,
          "offsetInEndSection": 1017,
          "text": "The selectin family includes E-selectin (CD62E), P-selectin (CD62P), and L-selectin (CD62L)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9150551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 333,
          "text": "The integrin family has eight subfamilies, designated as beta 1 through beta 8."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1091,
          "offsetInEndSection": 1225,
          "text": "Classification of secretory monoclonal immunoglobulin revealed monoclonal immunoglobulin Ig G in 74%, Ig A 15% and Ig M in 2.9% cases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 261,
          "offsetInEndSection": 556,
          "text": "Characterization of paraprotein (monoclonal immunoglobulin class and light chain type) was carried out by employing immunoelectrophoresis and/or immunofixation electrophoresis using heavy chain specific gamma, alpha, mu, delta and epsilon and light chain specific kappa (K), lambda (\u03bb) antisera."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 557,
          "offsetInEndSection": 637,
          "text": "Serum immunoglobulins Ig G, Ig A, and Ig M were estimated by immunoturbidometry."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 796,
          "offsetInEndSection": 898,
          "text": "Among the 245 cases, 73.1% monoclonal gammapathies were of secretory type and 7.3% were non-secretory."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105292",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 899,
          "offsetInEndSection": 1090,
          "text": "Monoclonal gammapathies were associated with 80.4% of multiple myeloma, 8.9% of solitary plasmacytoma, 4.1% of extra-medullary plasmacytoma, 3.3% of lymphoma and 2.9% of plasma cell leukemia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16157351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Human immunoglobulin D (IgD) occurs most abundantly as a membrane-bound antibody on the surface of mature B cells (mIgD)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16157351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 252,
          "text": "IgD possesses the longest hinge sequence of all the human antibody isotypes, with 64 residues connecting the Fab and Fc fragments."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16157351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 448,
          "offsetInEndSection": 616,
          "text": "Synchrotron X-ray scattering and analytical ultracentrifugation of IgD identified the solution arrangement of its Fab and Fc fragments, and thereby its hinge structure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16157351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 617,
          "offsetInEndSection": 779,
          "text": "The Guinier X-ray radius of gyration R(G) of 6.9(+/-0.1)nm showed that IgD is more extended in solution than the immunoglobulin subclass IgA1 (R(G) of 6.1-6.2nm)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16157351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1573,
          "offsetInEndSection": 1906,
          "text": "Although the linear sequence of the IgD hinge is much longer, comparison with previous scattering modelling of IgA1 and IgA2(m)1 suggests that the hinge of IgA1 and IgD are more similar than might have been expected, Both possess flexible T-shaped solution structures, probably reflecting the presence of restraining O-linked sugars."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2687698",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 316,
          "text": "On the basis of comparative studies of known antibody structures and sequences it has been argued that there is a small repertoire of main-chain conformations for at least five of the six hypervariable regions of antibodies, and that the particular conformation adopted is determined by a few key conserved residues."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2687698",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 317,
          "offsetInEndSection": 532,
          "text": "These hypotheses are now supported by reasonably successful predictions of the structures of most hypervariable regions of various antibodies, as revealed by comparison with their subsequently determined structures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22067045",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 103,
          "offsetInEndSection": 159,
          "text": "Human IgA is represented by two isotypes, IgA1 and IgA2."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22067045",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 160,
          "offsetInEndSection": 372,
          "text": "The major structural difference between these two subclasses is the presence of nine potential sites of O-glycosylation in the hinge region between the first and second constant region domains of the heavy chain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22067045",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "IgA is the most abundantly produced antibody and plays an important role in the mucosal immune system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22067045",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 930,
          "offsetInEndSection": 1186,
          "text": "Here, we report the identification and elucidation of IgA1 O-glycopeptide structural isomers that occur based on amino acid position of the attached glycans (positional isomers) and the structure of the O-glycan chains at individual sites (glycan isomers)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22067045",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1469,
          "offsetInEndSection": 1736,
          "text": "These findings represent the first definitive identification of structural isomeric IgA1 O-glycoforms, define the single-site heterogeneity for all O-glycan sites in a single sample, and have implications for defining epitopes based on clustered O-glycan variability."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560084",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 597,
          "offsetInEndSection": 855,
          "text": "One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560084",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1489,
          "offsetInEndSection": 1636,
          "text": "The distribution of IGHD subgroups was as follows: IGHD3, 39.1%; IGHD2, 21.8%; IGHD6, 12.6%; IGHD1, 10.3%; IGHD4, 8%; IGHD5, 6.9%; and IGHD7, 1.1%."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560084",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "The mutational status and configuration of immunoglobulin heavy variable (IGHV) gene rearrangements was analyzed in 85 Serbian patients with chronic lymphocytic leukemia (CLL)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560084",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1637,
          "offsetInEndSection": 1744,
          "text": "The most frequent IGHJ gene was IGHJ4 (48.9%), followed by IGHJ6 (28.4%), IGHJ3 (11.4%), and IGHJ5 (11.4%)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560084",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1343,
          "offsetInEndSection": 1488,
          "text": "Most frequently expressed was the IGHV3 subgroup (55.7%), followed by IGHV1 (27.3%), IGHV4 (12.5%), IGHV5 (2.3%), IGHV2 (1.1%), and IGHV6 (1.1%)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 962,
          "text": "We used characteristic and unique peptide sequences to determine the IgG subclass distribution and thus provided direct evidence that all four IgG subclasses can be generated during a xeno-autoantibody immune response to carbohydrate Neu5Gc-antigens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1238,
          "text": "The approach described here, therefore, provides a way to characterize these clinically significant antibodies, helping to understand their origins and significance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 230,
          "offsetInEndSection": 390,
          "text": "Using a sialoglycan microarray, we screened the binding pattern of such antibodies (anti-Neu5Gc IgG) in several samples of clinically approved human IVIG (IgG)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "Human polyclonal IgG antibodies directly against the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc) are potential biomarkers and mechanistic contributors to cancer and other diseases associated with chronic inflammation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 391,
          "offsetInEndSection": 519,
          "text": "These results were used to select an appropriate sample for a multistep affinity purification of the xeno-autoantibody fraction."
        }
      ]
    },
    {
      "id": "6805568118b1e36f2e000145",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26478806",
        "http://www.ncbi.nlm.nih.gov/pubmed/23964859",
        "http://www.ncbi.nlm.nih.gov/pubmed/23282091",
        "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
        "http://www.ncbi.nlm.nih.gov/pubmed/26416477",
        "http://www.ncbi.nlm.nih.gov/pubmed/29105160",
        "http://www.ncbi.nlm.nih.gov/pubmed/24488306",
        "http://www.ncbi.nlm.nih.gov/pubmed/33179277",
        "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
        "http://www.ncbi.nlm.nih.gov/pubmed/21067460"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26478806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 443,
          "offsetInEndSection": 604,
          "text": "Dual orexin receptor antagonists (DORAs) are a new class of insomnia medication that target wakefulness-promoting neuropeptides to regulate the sleep-wake cycle."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26478806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 605,
          "offsetInEndSection": 772,
          "text": "Suvorexant is the first DORA to be approved and has demonstrated efficacy at decreasing both time to sleep onset and increasing total sleep time compared with placebo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26478806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 773,
          "offsetInEndSection": 938,
          "text": "Suvorexant has a novel mechanism of action and may represent an alternative for patients who cannot tolerate or do not receive benefit from traditional sleep agents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26478806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 939,
          "offsetInEndSection": 1143,
          "text": "Suvorexant is generally effective and well tolerated, but has not been compared head to head with traditional sleep agents and being only newly available, lacks a longer-term 'real-world' experience base."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26478806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 276,
          "text": "Regardless, treatment of insomnia is beneficial to the patient and may benefit comorbidities if they exist."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, 1 (SB-649868), or suvorexant have shown promise for the treatment of insomnias and sleep disorders in several recent clinical trials in volunteers and primary insomnia patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 351,
          "offsetInEndSection": 466,
          "text": "We therefore initiated a drug discovery project with the aim of creating both OX2R selective antagonists and DORAs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 467,
          "offsetInEndSection": 652,
          "text": "Here we report that the OX2R selective antagonist 26 induced sleep in mice primarily by increasing NREM sleep, whereas the DORA suvorexant induced sleep largely by increasing REM sleep."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 653,
          "offsetInEndSection": 739,
          "text": "Thus, OX2R selective antagonists may also be beneficial for the treatment of insomnia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 245,
          "offsetInEndSection": 350,
          "text": "The relative contribution of antagonism of OX1R and OX2R for sleep induction is still a matter of debate."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282091",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 278,
          "offsetInEndSection": 458,
          "text": "Data from in vitro functional assays are presented, with the claimed compounds typically being dual orexin receptor antagonists (DORAs) or having moderate selectivity for orexin-1."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282091",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 459,
          "offsetInEndSection": 624,
          "text": "Structurally, the claimed compounds represent a variation on established DORA SAR themes and translate features of clinical compounds into a pyrazole-based scaffold."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282091",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 625,
          "offsetInEndSection": 821,
          "text": "Example 52, the most potent molecule in the application, has similar molecular weight and lipophilicity to suvorexant, the most advanced DORA, with broadly comparable potency in functional assays."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282091",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 61,
          "offsetInEndSection": 134,
          "text": "claims pyrazole-based antagonists of the orexin-1 and orexin-2 receptors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282091",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 135,
          "offsetInEndSection": 277,
          "text": "Utility in a number of therapeutic areas is claimed, including the treatment of sleep disorders; the most likely use of the claimed compounds."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Starting from suvorexant (trade name Belsomra), we successfully identified interesting templates leading to potent dual orexin receptor antagonists (DORAs) via a scaffold-hopping approach."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 549,
          "offsetInEndSection": 801,
          "text": "Compound 80\u2009c [{(1S,6R)-3-(6,7-difluoroquinoxalin-2-yl)-3,8-diazabicyclo[4.2.0]octan-8-yl}(4-methyl-[1,1'-biphenyl]-2-yl)methanone] is a potent and selective DORA that inhibits the stimulating effects of orexin peptides OXA and OXB at both Ox1 and Ox2."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 548,
          "text": "Structure-activity relationship optimization allowed us not only to improve the antagonistic potency on both orexin\u20051 and orexin\u20052 receptors (Ox1 and Ox2, respectively), but also to increase metabolic stability in human liver microsomes (HLM), decrease time-dependent inhibition of cytochrome P450 (CYP) 3A4, and decrease P-glycoprotein (Pgp)-mediated efflux."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 802,
          "offsetInEndSection": 1033,
          "text": "In calcium-release assays, 80\u2009c was found to exhibit an insurmountable antagonistic profile at both Ox1 and Ox2, while displaying a sleep-promoting effect in rat and dog models, similar to that of the benchmark compound suvorexant."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26416477",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 490,
          "offsetInEndSection": 683,
          "text": "This review provides a historical perspective on the discovery and development of DORAs as well as selective OX1 receptor antagonists (1-SORAs) and selective OX2 receptor antagonists (2-SORAs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26416477",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 385,
          "offsetInEndSection": 489,
          "text": "Suvorexant is a dual orexin receptor antagonist (DORA) which is available for the treatment of insomnia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26416477",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 384,
          "text": "Since these G protein-coupled receptors were deorphanised in 1998, more than 200 patents containing orexin receptor antagonists have been filed and, in 2014, suvorexant (Belsomra\u00ae) became the first of these compounds to receive approval from the FDA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26416477",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 852,
          "offsetInEndSection": 980,
          "text": "Detailed medicinal chemistry case studies are presented and future opportunities for orexin receptor antagonists are considered."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26416477",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 684,
          "offsetInEndSection": 851,
          "text": "2-SORAs are under clinical evaluation for their ability to modulate sleep, and 1-SORAs have shown promise for the treatment of addiction in pre-clinical animal models."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29105160",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 919,
          "offsetInEndSection": 1141,
          "text": "Recently approved FDCs, such as atazanavir (ATV)/COBI (Evotaz; Bristol-Myers Squibb, Princeton, NJ), darunavir (DRV)/COBI (Prezcobix; Janssen Products, Titusville NJ), and FTC/TAF (Descovy; Gilead), are also now available."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29105160",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 153,
          "offsetInEndSection": 350,
          "text": "Many single-tablet regimens (STRs), including newer fixed-dose combination (FDC) tablets, are available, offering patients several options for choosing a treatment regimen that works best for them."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29105160",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 522,
          "offsetInEndSection": 918,
          "text": "Newer STRs include dolutegravir (DTG)/lamivudine (3TC)/abacavir (ABC) (Triumeq; Viiv Healthcare, Research Triangle Park, NC), rilpivirine (RPV)/emtricitabine (FTC)/tenofovir alafenamide (TAF) (Odefsey; Gilead, Foster City, CA), RPV/FTC/tenofovir disoproxil fumarate (TDF) (Complera; Gilead), elvitegravir (EVG)/cobicistat (COBI)/FTC/TDF (Stribild; Gilead), and EVG/COBI/FTC/TAF (Genvoya; Gilead)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29105160",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Antiretroviral (ART) therapy for the treatment of human immunodeficiency virus (HIV) infection has undergone significant changes over the past 30 years."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29105160",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2127,
          "offsetInEndSection": 2441,
          "text": "This review provides an overview of the clinical efficacy and safety data for these coformulated agents, highlighting the relative impact on comparative adverse events, assessing the potential for experiencing fewer drug-drug interactions, and discussing the clinical implications regarding adherence to treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24488306",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Dual Orexin Receptor Antagonists (DORA) bind to both the Orexin 1 and 2 receptors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24488306",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 310,
          "text": "High resolution crystal structures of the Orexin 1 and 2 receptors, both class A GPCRs, were not available at the time of this study, and thus, ligand-based analyses were invoked and successfully applied to the design of DORAs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24488306",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 311,
          "offsetInEndSection": 607,
          "text": "Computational analysis, ligand based superposition, unbound small-molecule X-ray crystal structures and NMR analysis were utilized to understand the conformational preferences of key DORAs and excellent agreement between these orthogonal approaches was seen in the majority of compounds examined."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24488306",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1148,
          "offsetInEndSection": 1349,
          "text": "Using a dominant states approximation for the partition function, we made a comprehensive assessment of the free energies required to adopt both an extended and a F2F conformation of a number of DORAs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24488306",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 608,
          "offsetInEndSection": 797,
          "text": "The predominantly face-to-face (F2F) interaction observed between the distal aromatic rings was the core 3D shape motif in our design principle and was used in the development of compounds."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33179277",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 256,
          "text": "Dapagliflozin (SGLT-2 inhibitor) and sotagliflozin (SGLT1/2 inhibitor) are two of the drugs of SGLT inhibitor class which have been recommended by the National Institute for Health and Care Excellence (NICE) in people with type 1 diabetes with BMI \u226527\u00a0kg/m"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 347,
          "offsetInEndSection": 471,
          "text": "Eteplirsen has orphan drug designation in the USA and EU, and rare paediatric disease designation in the USA for use in DMD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 135,
          "offsetInEndSection": 346,
          "text": "Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Eteplirsen (Exondys\u00a051) is an antisense oligonucleotide designed to induce exon 51 skipping that is developed by Sarepta Therapeutics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 943,
          "offsetInEndSection": 1054,
          "text": "This article summarizes the milestones in the development of eteplirsen leading to this first approval for DMD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 708,
          "offsetInEndSection": 882,
          "text": "Long-term treatment with eteplirsen was associated with a decrease in the rate of decline in ambulation and pulmonary function in an open-label extension of a phase II trial."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 355,
          "text": "This review describes the pharmacological properties underlying the safety and efficacy of desvenlafaxine, a second-generation serotonin-norepinephrine reuptake inhibitor (SNRI)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1103,
          "offsetInEndSection": 1416,
          "text": "incremental benefits with desvenlafaxine, derived from straight-forward dosing, a simple metabolic profile and lack of interaction with active transporter P-gp and CYP enzymes may contribute to more consistent response, good tolerability and lower incidence of drug-drug interactions with concomitant medications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 457,
          "offsetInEndSection": 563,
          "text": "Desvenlafaxine therapy is initiated at the therapeutic dose (50 mg/day) without a need for dose titration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 811,
          "offsetInEndSection": 901,
          "text": "The efficacy of desvenlafaxine in treating major depressive disorder has been established."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 726,
          "offsetInEndSection": 810,
          "text": "Desvenlafaxine has clinically insignificant effects on the activity of CYP and P-gp."
        }
      ]
    },
    {
      "id": "67e26b0b18b1e36f2e000073",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18688681",
        "http://www.ncbi.nlm.nih.gov/pubmed/35198223",
        "http://www.ncbi.nlm.nih.gov/pubmed/23765730",
        "http://www.ncbi.nlm.nih.gov/pubmed/31752657",
        "http://www.ncbi.nlm.nih.gov/pubmed/16387374",
        "http://www.ncbi.nlm.nih.gov/pubmed/38090463",
        "http://www.ncbi.nlm.nih.gov/pubmed/32693809",
        "http://www.ncbi.nlm.nih.gov/pubmed/22427775",
        "http://www.ncbi.nlm.nih.gov/pubmed/21503250",
        "http://www.ncbi.nlm.nih.gov/pubmed/19185360"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18688681",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Takotsubo cardiomyopathy is a novel, yet well-described, reversible cardiomyopathy triggered by profound psychological or physical stress with a female predominance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18688681",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 795,
          "offsetInEndSection": 1134,
          "text": "Takotsubo cardiomyopathy is typically characterized by the following: 1) acute onset of ischemic-like chest pain or dyspnea, 2) transient apical and mid-ventricular regional wall-motion abnormality, 3) minor elevation of cardiac biomarkers, 4) dynamic electrocardiographic changes, and 5) the absence of epicardial coronary artery disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18688681",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1672,
          "offsetInEndSection": 1924,
          "text": "Whether an emotional or physical event precedes one's symptoms, it is apparent that takotsubo cardiomyopathy case presentations mimic ST-segment elevation myocardial infarction, and thus is an important entity to be recognized by the medical community."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18688681",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 536,
          "offsetInEndSection": 679,
          "text": "The following search terms were used: takotsubo cardiomyopathy, stress-induced cardiomyopathy, and left ventricular apical ballooning syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18688681",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1135,
          "offsetInEndSection": 1256,
          "text": "The pathogenesis of the syndrome is unknown but has mostly been associated with acute emotional or physiologic stressors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35198223",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 797,
          "offsetInEndSection": 930,
          "text": "In conclusion, Takotsubo cardiomyopathy should be reconsidered as benign disease with short- and long-term outcome and complications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35198223",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "Takotsubo cardiomyopathy is considered a benign syndrome that presented by transient characteristic left ventricular dysfunction with a variety of wall-motion abnormalities that resolve completely after few weeks."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35198223",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 413,
          "text": "In this report, a 67-year-old female-who was diagnosed by Takotsubo cardiomyopathy after emotional stress 2\u00a0years ago-presented by shortness of breath that associated with palpitation and chest pain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35198223",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 583,
          "offsetInEndSection": 710,
          "text": "Cardiac magnetic resonance imaging reveled outpouching aneurysm of anterior septal wall with no delayed gadolinium enhancement."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35198223",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 711,
          "offsetInEndSection": 754,
          "text": "Heart team had recommended medical therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23765730",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 240,
          "offsetInEndSection": 431,
          "text": "Right ventricular involvement, which has been infrequently reported, is present in about a quarter of cases of Tako-Tsubo cardiomyopathy and is associated with a more severe clinical outcome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23765730",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Tako-Tsubo cardiomyopathy is a transient left ventricular apical ballooning syndrome also known as stress-induced cardiomyopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23765730",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 432,
          "offsetInEndSection": 536,
          "text": "We report the case of a 55-year-old postmenopausal woman with transient biventricular apical ballooning."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23765730",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 239,
          "text": "This reversible cardiomyopathy without epicardial coronary artery disease mimics acute myocardial infarction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23765730",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 596,
          "offsetInEndSection": 721,
          "text": "Regional and global function of both ventricles was estimated using two-dimensional speckle tracking strain echocardiography."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31752657",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Takotsubo Cardiomyopathy (TTC) is an uncommon cause of acute reversible ventricular systolic dysfunction in the absence of obstructive Coronary Artery Disease (CAD)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31752657",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 166,
          "offsetInEndSection": 274,
          "text": "Typically manifesting as apical wall ballooning, TTC can rarely present atypically with apical wall sparing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31752657",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 275,
          "offsetInEndSection": 383,
          "text": "A 62-year-old female presented with complaints of chest pain and features mimicking acute coronary syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31752657",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 384,
          "offsetInEndSection": 578,
          "text": "Coronary angiogram revealed no obstructive CAD and left ventriculogram showed reduced ejection fraction, normal left ventricular apex and hypokinetic mid-ventricles consistent with atypical TTC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31752657",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 766,
          "offsetInEndSection": 883,
          "text": "This case report provides an insight into the diagnosis and management of TTC in the absence of pathognomic features."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16387374",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 271,
          "offsetInEndSection": 436,
          "text": "We present a unique case of tako-tsubo syndrome in a 71-year-old woman who developed symptomatic ventricular arrhythmias after complete resolution of cardiomyopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16387374",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Tako-tsubo syndrome appears to be an apparently reversible form of the cardiomyopathy, but little is known about the long term risk even with normalization of ventricular function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16387374",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 181,
          "offsetInEndSection": 270,
          "text": "The incidence of ventricular arrhythmias after resolution of cardiomyopathy is not known."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38090463",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Takotsubo cardiomyopathy (TC) is a recognized clinical syndrome characterized by reversible cardiomyopathy with a distinctive left ventricular apical ballooning appearance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38090463",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1229,
          "offsetInEndSection": 1378,
          "text": "Her left ventricular ejection fraction (LVEF) on presentation was 22%, and troponin T (TnT) levels were notably elevated at 430 (normal ranges < 14)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38090463",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 366,
          "offsetInEndSection": 505,
          "text": "While catecholamine-induced myocardial stunning is suggested by current evidence, the exact pathophysiological mechanisms remain uncertain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38090463",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 956,
          "offsetInEndSection": 1098,
          "text": "We present the case of a previously healthy 35-year-old female who presented with chest pain and dyspnea after discovering her father's death."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38090463",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 365,
          "text": "The clinical presentation of TC can be like that of a myocardial infarction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32693809",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Takotsubo cardiomyopathy is characterized by transient dysfunction of the medial to apical segment of the left ventricle."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32693809",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1753,
          "offsetInEndSection": 1894,
          "text": "Our case showed severe morphological myocardial change after several chest pain episodes that were considered to be takotsubo cardiomyopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32693809",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1895,
          "offsetInEndSection": 2068,
          "text": "This notable case suggests that the frequent recurrence of serious takotsubo cardiomyopathy is life threatening and can lead to irreversible serious myocardial degeneration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32693809",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 384,
          "text": "Recurrence within a few months or years has been reported and serious complications, including arrhythmia, acute cardiac shock and cardiac rupture, can arise; however, recurrence is rare and takotsubo cardiomyopathy is typically a reversible functional disorder."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32693809",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 893,
          "offsetInEndSection": 1021,
          "text": "Echocardiography revealed medial to apical dyskinesia and basal hypercontractility of the left ventricle, and cardiac tamponade."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22427775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 255,
          "offsetInEndSection": 345,
          "text": "Tako-tsubo cardiomyopathy is usually a potentially reversible form of cardiac dysfunction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22427775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "Tako-tsubo cardiomyopathy is characterized by chest pain, electrocardiographic abnormalities mimicking acute myocardial infarction, akinesis or dyskinesis of apical or mid left ventricular segments, and the absence of obstructive coronary artery disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22427775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 721,
          "text": "We report a patient with tako-tsubo cardiomyopathy, ventricular fibrillation, and hemodynamic instability requiring a left ventricular assist device (TandemHeart(\u2122)) followed by improvement of left ventricular ejection fraction to 45%."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22427775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 346,
          "offsetInEndSection": 485,
          "text": "A careful literature search revealed no previous report of a patient requiring mechanical circulatory support in tako-tsubo cardiomyopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21503250",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Tako-tsubo cardiomyopathy (transient left ventricular apical ballooning) is a reversible form of cardiomyopathy of unknown etiology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21503250",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 133,
          "offsetInEndSection": 314,
          "text": "Tako-tsubo Cardiomyopathy (TTC) is typically precipitated by sudden emotional or physical stress, and is associated with excessive sympathetic stimulation and catecholamine release."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21503250",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 388,
          "offsetInEndSection": 578,
          "text": "The diagnosis of TTC must be considered in all patients who develop a transient left ventricular apical (or mid ventricular) ballooning in the absence of obstructive coronary artery disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21503250",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 579,
          "offsetInEndSection": 766,
          "text": "Although the prevalence of TTC remains unknown, approximately 2% of all patients presenting with a presumed diagnosis of acute myocardial infarction have been found to have this syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21503250",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 315,
          "offsetInEndSection": 387,
          "text": "Its clinical presentation is similar to that of acute coronary syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19185360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Tako-Tsubo cardiomyopathy is characterized by a transient and reversible left ventricular dysfunction possibly due to a catecholamine-mediated myocardial stunning."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19185360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 421,
          "text": "Here we report on a patient with Tako-Tsubo cardiomyopathy induced low output failure in which blood flow disturbances in the thoracic aorta mimicked an acute type A aortic dissection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19185360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 236,
          "text": "This form of cardiomyopathy is rarely associated with cardiogenic shock."
        }
      ]
    },
    {
      "id": "680a080b18b1e36f2e00014b",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34780382",
        "http://www.ncbi.nlm.nih.gov/pubmed/28865512",
        "http://www.ncbi.nlm.nih.gov/pubmed/22939693",
        "http://www.ncbi.nlm.nih.gov/pubmed/21416408",
        "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
        "http://www.ncbi.nlm.nih.gov/pubmed/36286062",
        "http://www.ncbi.nlm.nih.gov/pubmed/18988199",
        "http://www.ncbi.nlm.nih.gov/pubmed/30598662",
        "http://www.ncbi.nlm.nih.gov/pubmed/33256196",
        "http://www.ncbi.nlm.nih.gov/pubmed/32863742"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34780382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Bone marrow edema (BME) is a nonspecific but relevant finding, usually indicating the presence of an underlying pathology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34780382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 332,
          "text": "The gold standard technique for detecting BME is magnetic resonance imaging (MRI), as it allows for a correct diagnosis to be made, which is extremely important given the heterogeneity of BME-related diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34780382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 333,
          "offsetInEndSection": 522,
          "text": "Depending on the severity of painful symptomatology and the MRI evidence, different treatment strategies can be followed: physical modalities, pharmacological options, and surgical therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865512",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "The overall goal of radiogenomics is the identification of genomic markers that are predictive for the development of adverse effects resulting from cancer treatment with radiation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865512",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 977,
          "offsetInEndSection": 1192,
          "text": "A major aim of research in radiogenomics is the development of a predictive instrument to enable identification of people who are at greatest risk for adverse effects resulting from cancer treatment using radiation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865512",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 597,
          "offsetInEndSection": 780,
          "text": "Work in radiogenomics has greatly benefited from creation of the Radiogenomics Consortium (RGC) that includes investigators at multiple institutions located in a variety of countries."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865512",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 490,
          "text": "The principal rationale for a focus on toxicity in radiogenomics is that for many patients treated with radiation, especially individuals diagnosed with early-stage cancers, the survival rates are high, and therefore a substantial number of people will live for a significant period of time beyond treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865512",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 781,
          "offsetInEndSection": 976,
          "text": "The common goal of the RGC membership is to share biospecimens and data so as to achieve large-scale studies with increased statistical power to enable identification of relevant genomic markers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22939693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 428,
          "text": "This review uses computed tomography (CT) with three-dimensional reconstructions to help describe some of the types and classifications of craniosynostosis, as well as describing some of the associations and the management of craniosynostosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22939693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Craniosynostosis is a complex condition, characterized by the premature fusion of one of more of the cranial sutures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22939693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 118,
          "offsetInEndSection": 184,
          "text": "They can be seen individually or as part of multisystem syndromes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21416408",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 586,
          "offsetInEndSection": 757,
          "text": "Rheumatoid arthritis (RA) is the most frequent chronic inflammatory disorder, affecting millions of people worldwide and leading to joint damage and substantial morbidity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21416408",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1351,
          "offsetInEndSection": 1519,
          "text": "Moreover, the presence and stability of miRNAs in body fluids provide fingerprints that can serve as molecular biomarkers for disease diagnosis and therapeutic outcome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21416408",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 480,
          "text": "Biomarkers can be detectable before the clinical onset of the disease, and are thus useful for prognosis; they can be measured at early stages of the disease and are useful for stratification and classification of the disease and patients; they can be monitored along the disease course and used as indicators of risk factors and pharmacological response to treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21416408",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Biomarkers are indicators of biological conditions that can be detected and measured in body fluids or tissues."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21416408",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1520,
          "offsetInEndSection": 1717,
          "text": "As a growing body of evidences reveals abnormal expression of specific miRNAs in RA tissues, the use of a blood-based miRNA signature for optimal diagnosis and treatment becomes a realistic option."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 566,
          "offsetInEndSection": 775,
          "text": "We will systematically search PubMed, EMBASE, the Cochrane Library, and Chinese Biomedical Literature Database for diagnostic trials using CT, MRI, PET, and PET-CT to detect LR of rectal cancer in April, 2018."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 282,
          "offsetInEndSection": 565,
          "text": "There are different imaging modalities that have been used in the follow-up of rectal cancer, including computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and positron emission tomography-computed tomography (PET-CT) in clinical practice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1679,
          "offsetInEndSection": 1818,
          "text": "This review will help determine the diagnostic accuracy of CT, MRI, PET, and PET-CT for the diagnosis of patients with LR of rectal cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "The risk of local recurrence (LR) continues to threat patients with rectal cancer after surgery or chemoradiotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 983,
          "offsetInEndSection": 1212,
          "text": "We will use bivariate meta-analysis to estimate summary sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of CT, MRI, PET, and PET-CT, as well as different sequences of MRI."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36286062",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 4,
          "text": "Both"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18988199",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "Positron emission tomography (PET) is a powerful and rapidly developing area of molecular imaging that is used to study and visualize human physiology by the detection of positron-emitting radiopharmaceuticals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18988199",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 358,
          "offsetInEndSection": 586,
          "text": "Unlike magnetic resonance imaging (MRI) or computerized tomography (CT), which mainly provide detailed anatomical images, PET can measure chemical changes that occur before macroscopic anatomical signs of a disease are observed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18988199",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 587,
          "offsetInEndSection": 708,
          "text": "PET is emerging as a revolutionary method for measuring body function and tailoring disease treatment in living subjects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18988199",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 828,
          "offsetInEndSection": 1029,
          "text": "This Review highlights key aspects of the synthesis of PET radiotracers with the short-lived positron-emitting radionuclides (11)C, (18)F, (15)O, and (13)N, with emphasis on the most recent strategies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18988199",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 211,
          "offsetInEndSection": 357,
          "text": "Information about metabolism, receptor/enzyme function, and biochemical mechanisms in living tissue can be obtained directly from PET experiments."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30598662",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 3,
          "text": "The"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33256196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 3,
          "text": "The"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32863742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 3,
          "text": "The"
        }
      ]
    },
    {
      "id": "6810db0a353a4a2e6b000014",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19412502",
        "http://www.ncbi.nlm.nih.gov/pubmed/21176430",
        "http://www.ncbi.nlm.nih.gov/pubmed/17653994",
        "http://www.ncbi.nlm.nih.gov/pubmed/28624931",
        "http://www.ncbi.nlm.nih.gov/pubmed/16283319",
        "http://www.ncbi.nlm.nih.gov/pubmed/28690860",
        "http://www.ncbi.nlm.nih.gov/pubmed/36989026",
        "http://www.ncbi.nlm.nih.gov/pubmed/37609293",
        "http://www.ncbi.nlm.nih.gov/pubmed/33388011",
        "http://www.ncbi.nlm.nih.gov/pubmed/14636645"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412502",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Fibromyalgia syndrome is a chronic disease of widespread and debilitating pain whose cause is unknown and whose risk factors are poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412502",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 784,
          "offsetInEndSection": 1006,
          "text": "The serotonin and norepinephrine reuptake inhibitors (SNRIs), duloxetine and milnacipran, on the other hand, have been shown in placebo-controlled trials to offer significant relief to patients suffering from fibromyalgia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412502",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1148,
          "offsetInEndSection": 1379,
          "text": "The effectiveness of the SNRIs as well as other dual acting antidepressants, such as mirtazapine, but not the SSRIs, implies that a dysfunction of both serotonin and norepinephrine neurotransmission probably exists in fibromyalgia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412502",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 275,
          "offsetInEndSection": 410,
          "text": "Although they are not officially approved for this indication, antiepileptics and antidepressants are often used to treat fibromyalgia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412502",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 525,
          "offsetInEndSection": 643,
          "text": "Because of the poor tolerability of the tricyclics, the newer antidepressants have been widely tested in fibromyalgia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21176430",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Fibromyalgia (FM) is a common syndrome characterised by widespread pain and at least 11/18 painful tender points that requires multimodal pharmacological treatment also combined with non-pharmacological therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21176430",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1110,
          "offsetInEndSection": 1277,
          "text": "Various pharmacological treatments have been used to treat FM with inconclusive results, and gradually increasing low doses is suggested in order to maximise efficacy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21176430",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1007,
          "offsetInEndSection": 1109,
          "text": "As no single drug fully manages FM symptoms, multicomponent therapy should be used from the beginning."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21176430",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 538,
          "offsetInEndSection": 650,
          "text": "Most of the drugs improve only one or two symptoms; no drug capable of overall symptom control is yet available."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21176430",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 1006,
          "text": "Furthermore, different classes of drugs with different mechanisms of action are used off-label, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), opioids, non-steroidal anti-inflammatory drugs (NSAIDs), growth hormone, corticosteroids and sedative hypnotics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 68,
          "text": "Fibromyalgia is a syndrome of unknown origin with a high prevalence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 820,
          "offsetInEndSection": 897,
          "text": "Data of 65 patients with fibromyalgia were analysed, of whom 97% were female."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 69,
          "offsetInEndSection": 142,
          "text": "Multimodal approaches seem to be the treatment of choice in fibromyalgia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 964,
          "offsetInEndSection": 1163,
          "text": "Data of 65 patients with fibromyalgia were analysed, patients significantly improved on the domains feeling good, pain, fatigue, stiffness, quality of life, catastrophizing and on the physical tests."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653994",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 260,
          "text": "A multidisciplinary program was developed and implemented for patients with fibromyalgia in the primary care setting."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28624931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 709,
          "offsetInEndSection": 813,
          "text": "The pathogenesis is not completely understood although the gene responsible for FMF has been identified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28624931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "Familial Mediterranean fever (FMF) is the most common monogenic periodic fever syndrome and characterized by recurrent episodes of fever, serositis, arthritis, dermal manifestations, and long-term renal complications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28624931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 218,
          "offsetInEndSection": 333,
          "text": "The MEFV gene was described in 1997 as the gene responsible for FMF and is inherited in autosomal recessive manner."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28624931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 814,
          "offsetInEndSection": 929,
          "text": "Whether the pyrin mutation effect in FMF is due to a loss of function or a gain of function is still controversial."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28624931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1015,
          "offsetInEndSection": 1078,
          "text": "Colchicine remains the mainstay of treatment of FMF since 1972."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16283319",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 288,
          "offsetInEndSection": 349,
          "text": "FMF is caused by mutations in MEFV gene, which encodes pyrin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16283319",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Familial Mediterranean fever (FMF) is the most frequent hereditary inflammatory disease characterized by self-limited recurrent attacks of fever and serositis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16283319",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 545,
          "offsetInEndSection": 635,
          "text": "The most devastating complication of FMF is amyloidosis, leading to chronic renal failure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16283319",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 482,
          "offsetInEndSection": 544,
          "text": "A mutated pyrin probably results in uncontrolled inflammation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16283319",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 797,
          "offsetInEndSection": 972,
          "text": "Daily colchicine is the mainstay of the therapy for the disease, resulting in complete remission or marked reduction in the frequency and duration of attacks in most patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28690860",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease that is inherited in an autosomal recessive manner and is caused by mutations in the"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36989026",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Uterine fibroids (UFs), leiomyomas or myomas, are a type of malignancy that affects the smooth muscle of the uterus, and it is most commonly detected in women of reproductive age."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36989026",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 180,
          "offsetInEndSection": 308,
          "text": "Uterine fibroids are benign monoclonal growths that emerge from uterine smooth muscle cells (myometrium) as well as fibroblasts."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36989026",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 884,
          "offsetInEndSection": 1061,
          "text": "Twenty-five percent of the reproductive women experience the symptoms of uterine fibroids, and among them, around 25% require hospitalization due to the severity of the disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36989026",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1223,
          "offsetInEndSection": 1438,
          "text": "The exact frequency of uterine fibroids varies\u00a0depending on the diagnosis, and the population investigated; nonetheless, the incidence of uterine fibroids in reproductive women ranges from 5.4 percent to 77 percent."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36989026",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1439,
          "offsetInEndSection": 1688,
          "text": "The uterine fibroid treatment included painkillers, supplementation with iron, vitamin D3, birth control, hormone therapy, gonadotropin-releasing hormone (GnRH) agonists, drugs modulating the estrogen receptors, and surgical removal of the fibroids."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37609293",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 374,
          "text": "These tumors are a leading cause of gynecological care but lack long-term therapy as the origin and development of fibroids are not well understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37609293",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 512,
          "offsetInEndSection": 636,
          "text": "However, there remains a systemic gap in our understanding of molecular and biological process that define uterine fibroids."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37609293",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 225,
          "text": "Common symptoms associated with fibroids include pelvic pain, heavy menstrual bleeding, anemia, and pelvic pressure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37609293",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 375,
          "offsetInEndSection": 511,
          "text": "Several next-generation sequencing technologies have been performed to identify the underlying genetic and epigenetic basis of fibroids."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37609293",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Uterine leiomyoma or fibroids are the most common prevalent noncancerous tumors of the uterine muscle layer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33388011",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 269,
          "text": "Heavy menstrual bleeding with resultant anemia, dysmenorrhea, chronic pelvic pain, infertility, urinary symptoms and constipation are generally associated with uterine fibroids (UFs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33388011",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 537,
          "offsetInEndSection": 677,
          "text": "Various medical therapies are now available for women with uterine fibroids, although each therapy has its own advantages and disadvantages."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33388011",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Uterine fibroids (leiomyomas or myomas) are the most frequent benign tumors in women."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33388011",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 430,
          "offsetInEndSection": 536,
          "text": "The aim of this review is to offer available and the newest medical treatment options for symptomatic UFs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33388011",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 678,
          "offsetInEndSection": 975,
          "text": "Our topic specifically explores gonadotropin-releasing hormone (GnRH) analogs and selective progesterone receptor modulators (SPRMs), but also provides the reader with useful advice on the therapies for fibroids available after the recent European Medicines Agency (EMA) warning (EMA/160220/2020)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 157,
          "offsetInEndSection": 304,
          "text": "FMF is caused by mutations in the Mediterranean fever gene (MEFV), which is expressed in blood cells of the myelomonocytic differentiation pathway."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Familial Mediterranean fever (FMF) is an autosomal recessive disorder characterized by recurrent attacks of fever, serositis, and a risk for AA amyloidosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 565,
          "offsetInEndSection": 866,
          "text": "The location of S1791 in exon 2 is of interest because (1) amyloidosis in FMF has previously been found to be strongly associated with compound exon 10 mutations and (2) it supports the notion that the mechanism causing FMF is connected to the cytoplasmic rather than nuclear function of the molecule."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 406,
          "offsetInEndSection": 564,
          "text": "In both cases, S1791 was in compound heterozygosity with MEFV mutation M694V, and the characteristic clinical syndrome of FMF including amyloidosis was found."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 305,
          "offsetInEndSection": 405,
          "text": "We identified a novel mutation S1791 in exon 2 of MEFV in two members of a family of Turkish origin."
        }
      ]
    },
    {
      "id": "67e2cfcf18b1e36f2e00009a",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
        "http://www.ncbi.nlm.nih.gov/pubmed/22338309",
        "http://www.ncbi.nlm.nih.gov/pubmed/22716221",
        "http://www.ncbi.nlm.nih.gov/pubmed/19382614",
        "http://www.ncbi.nlm.nih.gov/pubmed/16463613",
        "http://www.ncbi.nlm.nih.gov/pubmed/23757624",
        "http://www.ncbi.nlm.nih.gov/pubmed/24126422",
        "http://www.ncbi.nlm.nih.gov/pubmed/28131133",
        "http://www.ncbi.nlm.nih.gov/pubmed/21170699",
        "http://www.ncbi.nlm.nih.gov/pubmed/21113693"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Bone loss with aging places postmenopausal women at a higher risk for osteoporosis and its consequences such as fractures, pain, disability, and increased morbidity and mortality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 551,
          "offsetInEndSection": 674,
          "text": "Hormone Replacement Therapy (HRT) was a popular option for postmenopausal women before the Women's Health Initiative (WHI)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1528,
          "offsetInEndSection": 1716,
          "text": "A new target in treating postmenopausal osteoporosis is the tissue estrogen complex or the pairing of a SERM with a conjugated estrogen known as a tissue selective estrogen complex (TSEC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 675,
          "offsetInEndSection": 857,
          "text": "Several agents are available in the U.S., including bisphosphonates, hormone therapy, calcitonin, parathyroid hormone and the selective estrogen receptor modulator (SERM) raloxifene."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 239,
          "offsetInEndSection": 414,
          "text": "The Third National Health and Nutrition Examination Survey (NHANES III) estimated that up to 18% of US women aged 50 and older have osteoporosis and up to 50% have osteopenia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22338309",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 230,
          "text": "Several therapeutic agents are now available to treat postmenopausal osteoporosis and prevent fractures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22338309",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 344,
          "offsetInEndSection": 471,
          "text": "Hormone replacement therapy (HRT) should not be prescribed for osteoporosis in women who do not experience menopausal symptoms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22338309",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased fracture risk."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22338309",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 719,
          "offsetInEndSection": 909,
          "text": "All four bisphosphonates available in Belgium, except ibandronate, have been shown to reduce the risk of vertebral, non-vertebral and hip fractures in prospective, placebo-controlled trials."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22338309",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 472,
          "offsetInEndSection": 718,
          "text": "The marked benefits of raloxifene on the reduction in invasive breast cancer and vertebral fracture risk are partially counterbalanced by a lack of effect on non-vertebral fracture risk, and an increased risk of venous thromboembolism and stroke."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22716221",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 157,
          "offsetInEndSection": 349,
          "text": "The review included studies on the benefits and risks of medications and therapies used to prevent fractures in postmenopausal women and men with low bone density (osteopenia) or osteoporosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22716221",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2079,
          "offsetInEndSection": 2519,
          "text": "In 2012, the Agency for Healthcare Research and Quality (AHRQ) published an updated review on the effectiveness and safety of treatments for osteoporosis, including new therapies for the prevention of vertebral and nonvertebral fractures in postmenopausal women and men.The interventions assessed in the review included 1 biological agent, pharmacological agents, dietary and supplemental calcium and vitamin D, and weight-bearing exercise."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22716221",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 518,
          "offsetInEndSection": 955,
          "text": "AHRQ published an updated review in March 2012 that summarized the benefits and risks of osteoporosis medications in treatment and prevention of osteoporosis, including bisphosphonates (aledronate, risedronate, ibandronate, zoledronic acid), parathyroid hormone, teriparatide, calcitonin, estrogens (for prevention in postmenopausal women), selective estrogen receptor modulators (raloxifene), and denosumab(approved by the FDA in 2010)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22716221",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 3614,
          "offsetInEndSection": 3801,
          "text": "A risk reduction for vertebral fractures in postmenopausal women with osteoporosis treated with ibandronate, teriparatide, or raloxifene therapy was supported with high-strength evidence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22716221",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1794,
          "offsetInEndSection": 1906,
          "text": "It is common in postmenopausal women but men are at risk as well for fractures associated with low bone density."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19382614",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "Postmenopausal osteoporosis is associated with lack of estrogens, therefore, understandably one of the treatment options in osteoporosis is a group of medicines known as selective estrogen receptor modulators (SERMs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19382614",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1263,
          "offsetInEndSection": 1413,
          "text": "SERM with parathormone or SERM with bisphosphonate might prove to be an advantageous treatment option for women with severe or resistant osteoporosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19382614",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1166,
          "offsetInEndSection": 1262,
          "text": "Implementation of SERMs in combined therapy of osteoporosis is currently under research as well."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19382614",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 658,
          "offsetInEndSection": 832,
          "text": "Raloxifen, which is currently in use, besides the reduction of vertebral fractures risk, has beneficial influence on endometrial and breast neoplasm development risk as well."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19382614",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 540,
          "offsetInEndSection": 657,
          "text": "The first used SERM was tamoxifen, but due to its negative effect on endometrium it is not indicated in osteoporosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16463613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "The management of osteoporosis has been dominated by the use of antiresorptive agents, such as bisphosphonates and raloxifene, which have been shown to effectively reduce the risk of osteoporotic fractures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16463613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1021,
          "offsetInEndSection": 1129,
          "text": "Since 1 February 2005 teriparatide may be prescribed for postmenopausal women with serious osteoporosis i.e."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16463613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 610,
          "offsetInEndSection": 750,
          "text": "Clinically relevant studies on teriparatide in postmenopausal women and in men have shown that it significantly lowers the risk of fracture."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16463613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1130,
          "offsetInEndSection": 1442,
          "text": "with a minimum of 1 osteoporotic fracture who (a) despite treatment with bisphosphonates or raloxifene after 2 prolapsed vertebrae once again have 1 or more fractures (inadequate response); (b) can tolerate neither bisphosphonates nor raloxifene; (c) are prescribed the drug by their treating medical specialist."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16463613",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 809,
          "offsetInEndSection": 908,
          "text": "There are no clear recommendations on the order of treatment with teriparatide and bisphosphonates."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23757624",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 704,
          "offsetInEndSection": 1040,
          "text": "Pharmacologic therapy to reduce fracture risk is advisable for men with a clinical diagnosis of osteoporosis (a spine or hip fracture) or a T-score of -2.5 or below in the spine, femoral neck, total hip or 1/3 radius; however, the majority of men at high risk will only be identified using a fracture risk assessment tool, such as FRAX."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23757624",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "To review information pertinent to bone health and osteoporosis in men."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23757624",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1287,
          "offsetInEndSection": 1415,
          "text": "There are recommended strategies for identifying men at high risk of fracture, and effective agents are available for treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23757624",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1181,
          "offsetInEndSection": 1286,
          "text": "Osteoporosis in men presents an important public health problem with significant morbidity and mortality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23757624",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 401,
          "offsetInEndSection": 525,
          "text": "Bone density testing is appropriate for men age 70 and older and younger men (50-69) who have risk factors for osteoporosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126422",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "Postmenopausal osteoporosis is a major concern to public health."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126422",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 948,
          "offsetInEndSection": 1053,
          "text": "The authors aim to update denosumab role in postmenopausal osteoporosis with a physiopathological review."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126422",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 485,
          "offsetInEndSection": 817,
          "text": "Denosumab (Prolia\u00ae) is a fully human monoclonal antibody for RANKL, which selectively inhibits osteoclastogenesis, being recently approved for the treatment of postmenopausal osteoporosis in women at a high or increased risk of fracture by the FDA in the United States and by the European Medicines Agency in Europe since June 2010."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126422",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 65,
          "offsetInEndSection": 205,
          "text": "Fractures are the major clinical consequence of osteoporosis and are associated with substantial morbidity, mortality and health care costs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126422",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 818,
          "offsetInEndSection": 947,
          "text": "FREEDOM, DECIDE and STAND are the phase 3 trials comparing denosumab with placebo and alendronate in postmenopausal osteoporosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28131133",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Antiresorptive agents for treating postmenopausal osteoporosis include selective estrogen receptor modulator (SERM), bisphosphonates and denoumab."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28131133",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 415,
          "offsetInEndSection": 651,
          "text": "Results of the combination therapy for teriparatide and bisphosphonates were mixed; while small increases of bone density were observed in the combination therapy of teriparatide and estrogen/SERM and that of teriparatide and denosumab."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28131133",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 332,
          "text": "Synergistic effects of combining teriparatide with an antiresorptive agent have been proposed and studied."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28131133",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 225,
          "text": "Teriparatide is the only Food and Drug Administration-approved anabolic agent."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28131133",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 333,
          "offsetInEndSection": 414,
          "text": "This article reviews the trial designs and the outcomes of combination therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21170699",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "The Austrian Society for Bone and Mineral Research routinely publishes evidence-based guidelines for the treatment of postmenopausal osteoporosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21170699",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 650,
          "text": "Together with alendronate, risedronate, zoledronate, ibandronate, strontium ranelate, and raloxifene, denosumab constitutes an effective option in the treatment of postmenopausal osteoporosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21170699",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 363,
          "offsetInEndSection": 457,
          "text": "Denosumab has been shown to reduce vertebral, non-vertebral,and hip-fracture risk effectively."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21170699",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 362,
          "text": "The fully human monoclonal antibody denosumab (Prolia(\u00ae)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 708,
          "offsetInEndSection": 935,
          "text": "The new antiresorptive drug, denosumab, although FDA-approved only for postmenopausal women, has been shown in a study of men on ADT to increase bone density in spine, hip, and forearm and decrease vertebral fractures on x-ray."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 551,
          "offsetInEndSection": 707,
          "text": "Men on androgen deprivation therapy (ADT) are at high risk for bone loss and fracture, and all the bisphosphonates have been shown to increase bone density."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 317,
          "offsetInEndSection": 421,
          "text": "Evaluation of men will often identify secondary causes of osteoporosis as well as multiple risk factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 316,
          "text": "Methods for screening men for osteoporosis include dual energy x-ray absorptiometry and use of fracture risk calculators such as FRAX (World Health Organization) and the Garvan nomogram."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Osteoporosis in men is finally receiving some attention; it has been realized that men are more likely to die after hip fracture."
        }
      ]
    },
    {
      "id": "680a081d18b1e36f2e00014c",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26067407",
        "http://www.ncbi.nlm.nih.gov/pubmed/25518365",
        "http://www.ncbi.nlm.nih.gov/pubmed/32962914",
        "http://www.ncbi.nlm.nih.gov/pubmed/21041318",
        "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
        "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
        "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
        "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
        "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
        "http://www.ncbi.nlm.nih.gov/pubmed/17676593"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26067407",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Astrocytes perform critical homeostatic physiological functions in the central nervous system (CNS) and are robustly responsive to injury, inflammation, or infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26067407",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 367,
          "text": "We hypothesized that the components of the extracellular matrix (ECM), which are known to vary during development and in response to disease, determine astrocytic responses to injury and inflammation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26067407",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 368,
          "offsetInEndSection": 493,
          "text": "We examined the response of primary astrocyte cultures grown on different ECM proteins to a mechanical wound (i.e., scratch)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26067407",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1535,
          "offsetInEndSection": 1708,
          "text": "These findings provide new insights into the role of ECM as a source of heterogeneity of glial responses that may have important implications for neuropathological sequelae."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26067407",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1284,
          "offsetInEndSection": 1534,
          "text": "In addition, we evaluated downstream targets of integrin signaling, specifically the mammalian target of rapamycin (mTOR), and determined that activation of this pathway contributed to the response of astrocytes grown on TnC, but not on Ln, Vn or Fn."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25518365",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 308,
          "text": "Signaling pathway leading from astrocytes to neurons would be required for astrocytes to participate in neuronal functions and, here, we investigated the presence of such pathway."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25518365",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 41,
          "offsetInEndSection": 128,
          "text": "However, whether astrocytic activity has any significance in brain function is unknown."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25518365",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 40,
          "text": "Astrocytes respond to neuronal activity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25518365",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 366,
          "offsetInEndSection": 460,
          "text": "A light-sensitive protein, channelrhodopsin-2 (ChR2), was selectively expressed in astrocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25518365",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 578,
          "text": "Photostimulation of these astrocytes induced glutamate release which modulated neuronal activity and animal behavior."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32962914",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 275,
          "offsetInEndSection": 461,
          "text": "The intricate homeostatic mechanisms underpinning lipid handling and metabolism across two major CNS cell types; neurons and astrocytes, are integral for cellular health and maintenance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32962914",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Lipids play an important role in the central nervous system (CNS)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32962914",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 462,
          "offsetInEndSection": 531,
          "text": "Here, we explore the various roles of lipids in these two cell types."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32962914",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 274,
          "text": "They contribute to the structural integrity and physical characteristics of cell and organelle membranes, act as bioactive signalling molecules, and are utilised as fuel sources for mitochondrial metabolism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32962914",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 532,
          "offsetInEndSection": 853,
          "text": "Given that changes in lipid metabolism have been identified in a number of neurodegenerative diseases, we also discuss changes in lipid handling and utilisation in the context of amyotrophic lateral sclerosis (ALS), in order to identify key cellular processes affected by the disease, and inform future areas of research."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21041318",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "We briefly review the current literature where optogenetics has been used to study various aspects of astrocyte physiology in vitro and in vivo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21041318",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 251,
          "offsetInEndSection": 451,
          "text": "We demonstrate how the ability to target astrocytes with cell-specific viral vectors to express optogenetic constructs helped to unravel some previously unsuspected roles of these inconspicuous cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21041318",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 250,
          "text": "This includes both genetically engineered Ca(2+) sensors and effector proteins, such as channelrhodopsin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 642,
          "text": "We report here that the astrogliogenic role of Notch is in part mediated by direct binding of the Notch intracellular domain to the CSL DNA binding protein, forming a transcriptional activation complex onto the astrocyte marker gene, glial fibrillary acidic protein (GFAP)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 643,
          "offsetInEndSection": 869,
          "text": "In addition, we found that, in CSL-/- neural stem cell cultures, astrocyte differentiation was delayed but continued at a normal rate once initiated, suggesting that CSL is involved in regulating the onset of astrogliogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 246,
          "offsetInEndSection": 368,
          "text": "Whether the role of Notch signaling in promoting astroglial differentiation is permissive or instructive has been debated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 870,
          "offsetInEndSection": 1103,
          "text": "Importantly, although the classical CSL-dependent Notch signaling pathway is intact and able to activate the Notch canonical target promoter during the neurogenic phase, it is unable to activate the GFAP promoter during neurogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 245,
          "text": "It has recently been postulated that Notch instructively drives astrocyte differentiation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 647,
          "offsetInEndSection": 857,
          "text": "By searching for transcription factors that function at these elements, we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 342,
          "text": "Here we perform comprehensive and integrated transcriptomic and epigenomic analyses to delineate gene regulatory programs that drive the developmental trajectory from mouse embryonic stem cells to astrocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "A broad molecular framework of how neural stem cells are specified toward astrocyte fate during brain development has proven elusive."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 343,
          "offsetInEndSection": 646,
          "text": "We report molecularly distinct phases of astrogliogenesis that exhibit stage- and lineage-specific transcriptomic and epigenetic signatures with unique primed and active chromatin regions, thereby revealing regulatory elements and transcriptional programs underlying astrocyte generation and maturation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1029,
          "offsetInEndSection": 1171,
          "text": "Altogether, these findings provide integrated insights into the genetic and epigenetic mechanisms steering the trajectory of astrogliogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 704,
          "text": "However, the role of CCL-1 in the CNS and the effects on microglia remains unclear."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Microglia, which constitute the resident macrophages of the central nervous system (CNS), are generally considered as the primary immune cells in the brain and spinal cord."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1309,
          "offsetInEndSection": 1485,
          "text": "These indicate that CCL-1 has a role as a mediator in neuron-glia interaction, which may contribute to the development of neurological diseases, especially in neuropathic pain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 764,
          "offsetInEndSection": 951,
          "text": "We first showed that CCR-8, a specific receptor for CCL-1, was expressed on primary cultured microglia, as well as on astrocytes and neurons, and was upregulated in the presence of CCL-1."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 338,
          "offsetInEndSection": 620,
          "text": "Chemokine (C-C motif) ligand 1 (CCL-1), a well-characterized chemokine secreted by activated T cells, has been shown to play an important role in neuropathic pain induced by nerve injury and is also produced in various cell types in the CNS, especially in dorsal root ganglia (DRG)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 352,
          "offsetInEndSection": 496,
          "text": "These patients could suffer astrocyte-related epilepsy, as increasing evidence indicates that dysfunctions of astrocytes can result in epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1107,
          "offsetInEndSection": 1383,
          "text": "Here, we discuss the possibility that an optogenetic approach could be used to control the release of gliotransmitters and improve astrocyte function such as glutamate and K(+) uptake, and thereby offer a potential strategy to investigate and treat astrocyte-related epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 572,
          "text": "However, epilepsy drugs that affect astrocytes are not available currently."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 186,
          "offsetInEndSection": 351,
          "text": "For instance, pharmacological therapy is frequently accompanied by side effects, and current anticonvulsive drugs fail to be effective to around a third of patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Epilepsy is a neurological disorder that affects around 1% of the population worldwide."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 953,
          "offsetInEndSection": 1294,
          "text": "This review will discuss the subtle functions of FOXOs and FOXM1 in gliomas, dissecting their regulatory network with other proteins, microRNAs and their role in glioma progression, including stem cell differentiation and therapy resistance/sensitivity, alongside highlighting recent pharmacological progress for modulating their expression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 314,
          "offsetInEndSection": 540,
          "text": "The forkhead box (FOX) transcription factors comprise a collection of proteins that play various roles in numerous complex molecular cascades and have been discovered to be differentially expressed in distinct glioma subtypes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 313,
          "text": "Glioma is the most aggressive and malignant type of primary brain tumor, comprises the majority of central nervous system deaths, and is categorized into different subgroups according to its histological characteristics, including astrocytomas, oligodendrogliomas, glioblastoma multiforme (GBM), and mixed tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 813,
          "text": "Accumulating data indicates that FOXM1 acts as an oncogene in various types of cancers, and a significant part of studies has investigated its function in glioma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 541,
          "offsetInEndSection": 650,
          "text": "FOXM1 and FOXOs have been recognized as crucial transcription factors in tumor cells, including glioma cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 309,
          "offsetInEndSection": 397,
          "text": "However, the functions and regulation of VGCC in astrocytes are still poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Astrocytes express voltage-gated calcium channels (VGCCs) that are upregulated in the context of the reactive astrogliosis occurring in several CNS pathologies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 398,
          "offsetInEndSection": 594,
          "text": "Interestingly, protein kinase C epsilon (PKCepsilon), one of the known regulators of VGCC in several cell types, induces in astrocytes a stellated morphology similar to that associated to gliosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1671,
          "offsetInEndSection": 1804,
          "text": "Therefore, here we describe a novel regulatory pathway involving VGCC that participates in PKCepsilon-dependent astrocyte activation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 308,
          "text": "Moreover, the ability of selective calcium channel blockers to inhibit reactive astrogliosis has been revealed in a variety of experimental models."
        }
      ]
    },
    {
      "id": "6810ff8f353a4a2e6b000017",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21561807",
        "http://www.ncbi.nlm.nih.gov/pubmed/2943896",
        "http://www.ncbi.nlm.nih.gov/pubmed/22695290",
        "http://www.ncbi.nlm.nih.gov/pubmed/15136074",
        "http://www.ncbi.nlm.nih.gov/pubmed/16804313",
        "http://www.ncbi.nlm.nih.gov/pubmed/18425908",
        "http://www.ncbi.nlm.nih.gov/pubmed/21764126",
        "http://www.ncbi.nlm.nih.gov/pubmed/23277022",
        "http://www.ncbi.nlm.nih.gov/pubmed/16034960",
        "http://www.ncbi.nlm.nih.gov/pubmed/22845405"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21561807",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 990,
          "offsetInEndSection": 1113,
          "text": "Laparoscopic excision of ovarian endometrioma prior to IVF does not offer any additional benefit over expectant management."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21561807",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 776,
          "offsetInEndSection": 989,
          "text": "Except for pelvic clearance, there is insufficient evidence to suggest that surgical treatment of endometrioma is better than medical treatment with respect to the long-term relief of symptoms and quality of life."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21561807",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 108,
          "offsetInEndSection": 258,
          "text": "Surgical treatment is associated with a high recurrence rate and its employment for women undergoing assisted conception has recently been challenged."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21561807",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 369,
          "text": "Medical treatment has not been shown to be effective in controlling symptoms or improving fertility potential."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21561807",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1114,
          "offsetInEndSection": 1358,
          "text": "A large, well-designed, adequately powered randomized controlled study that compares the effects of surgical removal versus expectant management of endometrioma on ovarian performance and pregnancy outcomes in women undergoing IVF is warranted."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2943896",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "Seventy-nine cases of ovarian endometrioma were treated via the laparoscope."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2943896",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 367,
          "text": "Indications for laparoscopy were infertility (35 cases), pain (33), hypermenorrhea (5) and pelvic mass (4); the condition was an incidental finding in 2 cases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2943896",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 429,
          "offsetInEndSection": 608,
          "text": "The long-term results, especially the fertility outcome, have been promising: 12 of 20 women (60%) achieved a term pregnancy following a laparoscopic endometrioma procedure alone."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2943896",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 207,
          "text": "The surgical technique gradually evolved from drainage alone to fulguration and finally to excision of the endometrioma cyst wall."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2943896",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 609,
          "offsetInEndSection": 717,
          "text": "Of the eight women with endometriomas who did not conceive, six had well-documented male factor infertility."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22695290",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2070,
          "offsetInEndSection": 2298,
          "text": "Despite the available evidence that surgery for endometriomas does not improve the outcome of ART and may damage ovarian reserve, it seems that the majority of gynaecologists in the UK offer ovarian cystectomy to their patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22695290",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 289,
          "text": "It appears that the majority of gynaecologists in the UK offer surgery (mostly cystectomy) for endometriomas prior to ART, regardless of the presence of symptoms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22695290",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1378,
          "offsetInEndSection": 1569,
          "text": "Laparoscopic surgeons were almost twice as likely to 'offer surgery to all patients with endometriomas prior to ART' compared with clinicians performing laparotomy (22 versus 12%, P < 0.001)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22695290",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "What is the current management of women with ovarian endometriomas undergoing assisted reproductive treatment (ART) in the UK?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22695290",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 290,
          "offsetInEndSection": 425,
          "text": "The ideal management of endometriomas in women undergoing ART remains controversial and presents a dilemma to reproductive specialists."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15136074",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 713,
          "offsetInEndSection": 822,
          "text": "Laparoscopic cystectomy for endometriomas before commencing an IVF cycle does not improve fertility outcomes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15136074",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1051,
          "offsetInEndSection": 1211,
          "text": "Conversely, conservative surgical treatment of ovarian endometriomas in symptomatic women does not impair IVF or intracytoplasmic sperm injection success rates."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15136074",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "To investigate whether conservative surgery on ovarian endometriomas before an IVF cycle improves fertility outcomes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15136074",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 823,
          "offsetInEndSection": 1050,
          "text": "Proceeding directly to controlled ovarian hyperstimulation in women with asymptomatic ovarian endometriomas might reduce the time to pregnancy, the costs of treatment, and the hypothetical complications of laparoscopic surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15136074",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 188,
          "offsetInEndSection": 355,
          "text": "One hundred eighty-nine women with endometriomas who underwent IVF treatment: 56 women proceeded directly to IVF, and 133 first underwent conservative ovarian surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16804313",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 586,
          "offsetInEndSection": 797,
          "text": "Consideration for bilateral salpingo-oophorectomy as part of gender reassignment surgery should be given, especially in this poorly studied group of patients whose overall risk of ovarian cancer remains unknown."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16804313",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 451,
          "offsetInEndSection": 585,
          "text": "Androgen supplementation in this population may be associated with an increased risk of both ovarian cancer and of endometrial cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16804313",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 377,
          "text": "We report only the second case of ovarian cancer in a female-to-male transsexual while on androgen supplementation therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16804313",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 378,
          "offsetInEndSection": 450,
          "text": "Staining of his tumor for androgen receptors showed abundant expression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16804313",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 174,
          "offsetInEndSection": 253,
          "text": "The incidence of ovarian cancer among female-to-male transsexuals is not known."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18425908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 3429,
          "offsetInEndSection": 3572,
          "text": "However in women who may subsequently may undergo fertility treatment insufficient evidence exists to determine the favoured surgical approach."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18425908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 339,
          "text": "The laparoscopic approach to the management of endometriomata is favoured over a laparotomy approach as it offers the advantage of a shorter hospital stay, faster patient recovery and decreased hospital costs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18425908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 3068,
          "offsetInEndSection": 3359,
          "text": "There is good evidence that excisional surgery for endometriomata provides for a more favourable outcome than drainage and ablation with regard to the recurrence of the endometrioma, recurrence of pain symptoms, and in women who were previously subfertile, subsequent spontaneous pregnancy ."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18425908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 512,
          "offsetInEndSection": 712,
          "text": "The objective of this review was to determine the most effective technique of treating an ovarian endometrioma; either excision of the cyst capsule or drainage and electrocoagulation of the cyst wall."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18425908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1739,
          "offsetInEndSection": 1822,
          "text": "No randomised studies of the management of endometriomata by laparotomy were found."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764126",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 75,
          "offsetInEndSection": 251,
          "text": "Surgery is considered to play a role within the framework of the therapeutic options to cure infertile women with the disease even though its effectiveness is generally modest."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764126",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 760,
          "offsetInEndSection": 961,
          "text": "Randomized controlled trials showed that the excision technique is associated with a higher pregnancy rate and a lower rate of recurrence although it may determine severe injury to the ovarian reserve."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764126",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 572,
          "offsetInEndSection": 759,
          "text": "The comparison between the excision/stripping and the vaporization/coagulation techniques represents the main point of debate on what is the best procedure to remove ovarian endometrioma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764126",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 962,
          "offsetInEndSection": 1131,
          "text": "Improvements to this latter aspect may be represented by a combined excisional-vaporization technique or by replacing diathermy coagulation with surgical ovarian suture."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764126",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1328,
          "offsetInEndSection": 1473,
          "text": "However, available studies are mainly based on II look laparoscopies performed few weeks after the intervention and data on fertility is lacking."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23277022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 291,
          "text": "While laparoscopic excision is known to improve fertility, recurrence can cause significant ovarian damage and adverse affects on fertility."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23277022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Laparoscopic excision is considered as the 'gold standard' treatment of ovarian endometrioma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23277022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 292,
          "offsetInEndSection": 380,
          "text": "It is therefore crucial to prevent recurrence in order to conserve 'improved' fertility."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23277022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 747,
          "offsetInEndSection": 1000,
          "text": "The accumulating evidence suggests that the administration of oral contraceptives (OC), levonorgestrel-releasing intrauterine system (LNG-IUS) and a combination of gonadotropin releasing hormone (GnRH) analogue and OC may also have therapeutic benefits."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23277022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 582,
          "offsetInEndSection": 677,
          "text": "Previous medical treatment for endometriosis prior laparoscopy is a risk factor for recurrence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034960",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 316,
          "text": "The laparoscopic approach to the management of endometriomata is favoured for as it offers the advantage of a shorter hospital stay, faster patient recovery and decreased hospital costs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034960",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2220,
          "offsetInEndSection": 2504,
          "text": "There is some evidence that excisional surgery for endometriomata provides for a more favourable outcome than drainage and ablation, with regard to the recurrence of the endometrioma, recurrence of symptoms and subsequent spontaneous pregnancy in women who were previously subfertile."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034960",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 489,
          "offsetInEndSection": 822,
          "text": "The objective of this review was to determine the most effective technique of treating an ovarian endometrioma; either excision of the cyst capsule or drainage and electrocoagulation of the cyst wall, with regard to relief of pain, recurrence of the endometrioma, recurrence of symptoms and the subsequent spontaneous pregnancy rate."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034960",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1561,
          "offsetInEndSection": 1683,
          "text": "Two randomised studies of the laparoscopic management of ovarian endometriomata of greater than 3cm in size were included."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034960",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1477,
          "offsetInEndSection": 1560,
          "text": "No randomised studies of the management of endometriomata by laparotomy were found."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 649,
          "offsetInEndSection": 911,
          "text": "Cautious extrapolation of data from standard normothermic, nonintraoperative, intraperitoneal chemotherapy and data from Phase II and nonrandomized comparative studies suggest that HIPEC delivered at the time of surgery for ovarian cancer has definite potential."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "The outcome of ovarian cancer remains poor with conventional therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 431,
          "offsetInEndSection": 648,
          "text": "While standard normothermic, nonintraoperative, intraperitoneal chemotherapy has been demonstrated to be beneficial in randomized trials and meta-analyses, there are no data from randomized HIPEC trials available yet."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 430,
          "text": "Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) provides improved exposure of the entire seroperitoneal surface to the agent and utilizes the direct cytoxic and drug-enhancing effect of hyperthermia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 912,
          "offsetInEndSection": 1161,
          "text": "Data from ongoing randomized HIPEC trials to adequately answer the question of whether the addition of HIPEC actually prolongs survival in patients with peritoneal dissemination of primary and recurrent ovarian cancer are awaited in the near future."
        }
      ]
    },
    {
      "id": "67fbe21818b1e36f2e000113",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15132715",
        "http://www.ncbi.nlm.nih.gov/pubmed/8608779",
        "http://www.ncbi.nlm.nih.gov/pubmed/19138419",
        "http://www.ncbi.nlm.nih.gov/pubmed/18055323",
        "http://www.ncbi.nlm.nih.gov/pubmed/22019751",
        "http://www.ncbi.nlm.nih.gov/pubmed/21789282",
        "http://www.ncbi.nlm.nih.gov/pubmed/22649416",
        "http://www.ncbi.nlm.nih.gov/pubmed/22560341",
        "http://www.ncbi.nlm.nih.gov/pubmed/26176686",
        "http://www.ncbi.nlm.nih.gov/pubmed/22891351"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15132715",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Genetic factors play an important role in the pathogenesis of autoimmune thyroid disease (AITD) and it has been calculated that 80% of the susceptibility to develop Graves' disease is attributable to genes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15132715",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 520,
          "offsetInEndSection": 845,
          "text": "Low birth weight, iodine excess and deficiency, selenium deficiency, parity, oral contraceptive use, reproductive span, fetal microchimerism, stress, seasonal variation, allergy, smoking, radiation damage to the thyroid gland, viral and bacterial infections all play a role in the development of autoimmune thyroid disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15132715",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 347,
          "offsetInEndSection": 519,
          "text": "We have attempted to carry out a comprehensive review of all the environmental and hormonal risk factors thought to bring about AITD in genetically predisposed individuals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15132715",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 846,
          "offsetInEndSection": 996,
          "text": "The use of certain drugs (lithium, interferon-alpha, Campath-1H) also increases the risk of the development of autoimmunity against the thyroid gland."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15132715",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 207,
          "offsetInEndSection": 346,
          "text": "The concordance rate for AITD among monozygotic twins is, however, well below 1 and environmental factors thus must play an important role."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8608779",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 357,
          "text": "Other risk factors for FTC include age over 50 years and female sex."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8608779",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 82,
          "offsetInEndSection": 213,
          "text": "There are marked geographical variations in the relative proportions of FTC and PTC, most likely related to dietary iodine content."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8608779",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Follicular thyroid cancer is the second most common thyroid malignancy after PTC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8608779",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1816,
          "offsetInEndSection": 2181,
          "text": "For patients at low risk of recurrence (young, small lesions, minimally invasive tumor), serum thyroglobulin measurements may largely suffice, whereas higher risk patients with elevated serum thyroglobulin levels and patients with significant titers of interfering anti-thyroglobulin autoantibodies may also need to undergo periodic diagnostic radioiodine scanning."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8608779",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 288,
          "text": "In iodine-deficient areas, the relative rate of FTC tends to be increased."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19138419",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19138419",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1089,
          "offsetInEndSection": 1249,
          "text": "Further studies are needed to clarify the relationship between viruses and thyroid diseases, in order to develop new strategies for prevention and/or treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19138419",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 960,
          "offsetInEndSection": 1088,
          "text": "However, it remains to determine whether they are responsible for thyroid diseases or whether they are just innocent bystanders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19138419",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 276,
          "offsetInEndSection": 491,
          "text": "We have reviewed virological data for each type of thyroiditis at different levels of evidence; epidemiological data, serological data or research on circulating viruses, direct evidence of thyroid tissue infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19138419",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 635,
          "offsetInEndSection": 959,
          "text": "However, direct evidence of the presence of viruses or their components in the organ are available for retroviruses (HFV) and mumps in subacute thyroiditis, for retroviruses (HTLV-1, HFV, HIV and SV40) in Graves's disease and for HTLV-1, enterovirus, rubella, mumps virus, HSV, EBV and parvovirus in Hashimoto's thyroiditis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18055323",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 845,
          "offsetInEndSection": 1116,
          "text": "In this review we will summarise and discuss the main genetic events related to thyroid cancer initiation, the contribution of genomics and the convenience of using a new molecular classification of thyroid cancer, complementary to the clinicopathological classification."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18055323",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Thyroid cancers stand out among solid tumours because many of the tumour-initiating genetic events have been identified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18055323",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1117,
          "offsetInEndSection": 1281,
          "text": "This may help us to predict more faithfully the clinical outcome of patients with thyroid cancer and to select more appropriately candidates for targeted therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18055323",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 354,
          "offsetInEndSection": 595,
          "text": "Similarly, there is increasing evidence demonstrating that mutations leading to activation of the phosphatidylinositol 3- kinase (PI3K)/AKT effectors -PTEN and PI3KCa- are essential for the pathogenesis of follicular thyroid carcinoma (FTC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18055323",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 353,
          "text": "Mutations leading to constitutive activation of MAP kinase effectors -the tyrosine receptor kinase RET and the intracellular signalling effectors RAS and BRAF- are essential for the pathogenesis of papillary thyroid carcinoma (PTC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22019751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 666,
          "offsetInEndSection": 893,
          "text": "Although autoimmune thyroiditis is the most common cause of hypothyroidism in elderly subjects, other causes, such as drugs, neck radiotherapy, thyroidectomy or radioiodine therapy, are frequently observed among these subjects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22019751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1471,
          "offsetInEndSection": 1663,
          "text": "Thyroid cancer has similar characteristics in elderly as in general population, however the rate of aggressive forms such as the anaplastic histotype, is higher in older than younger subjects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22019751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1046,
          "offsetInEndSection": 1185,
          "text": "Other medications that may affect TSH levels are metformin, antiepileptic medications, lithium carbonate and iodine-containing medications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22019751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2158,
          "offsetInEndSection": 2479,
          "text": "In conclusion, thyroid diseases in patients older than 60 years deserve attention from different points of view: the prevalence is different from the young adult; symptoms are more nuanced and makes difficult the diagnosis; age and comorbidity often force therapeutic choices and may limit safety and efficacy of therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22019751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1664,
          "offsetInEndSection": 1793,
          "text": "Diagnosis of thyroid diseases includes a comprehensive medical history and physical examination and appropriate laboratory tests."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789282",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Dyslipidemia is a common finding in patients with thyroid disease, explained by the adverse effects of thyroid hormones in almost all steps of lipid metabolism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789282",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 588,
          "offsetInEndSection": 743,
          "text": "In thyroid disease, dyslipidemia coexists with various metabolic abnormalities and induce insulin resistance and oxidative stress via a vice-vicious cycle."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789282",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 744,
          "offsetInEndSection": 1046,
          "text": "The above associations in combination with the thyroid hormone induced hemodynamic alterations, might explain the increased risk of coronary artery disease, cerebral ischemia risk, and angina pectoris in older, and possibly ischemic stroke in younger patients with overt or subclinical hyperthyroidism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789282",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 441,
          "text": "Not only overt but also subclinical hypo- and hyperthyroidism, through different mechanisms, are associated with lipid alterations, mainly concerning total and LDL cholesterol and less often HDL cholesterol, triglycerides, lipoprotein (a), apolipoprotein A1, and apolipoprotein B."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789282",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 442,
          "offsetInEndSection": 587,
          "text": "In addition to quantitative, qualitative alterations of lipids have been also reported, including atherogenic and oxidized LDL and HDL particles."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 876,
          "offsetInEndSection": 1039,
          "text": "In addition, the BRAF(V600E) mutation, the most common genetic alteration in PTC, is present in many PTMC with extra thyroidal extension and lymph node metastasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "Most human thyroid cancers are differentiated papillary carcinomas (PTC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 386,
          "offsetInEndSection": 553,
          "text": "Although PTMC usually has an excellent long-term prognosis, it can metastasize to neck lymph nodes; however deaths related to this type of thyroid tumor are very rare."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 554,
          "offsetInEndSection": 706,
          "text": "Few data exist on molecular pathways that play a role in PTMC development; however, two molecules have been shown to be associated with aggressive PTMC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1325,
          "offsetInEndSection": 1416,
          "text": "Here, we summarize the clinical outcome, cancer genetics, and molecular mechanisms of PTMC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Epidemiological studies suggest an important link between obesity and thyroid cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 355,
          "offsetInEndSection": 514,
          "text": "The present study was undertaken to explore the possible regulatory factors which would influence leptin receptor expression in papillary thyroid cancer cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 212,
          "offsetInEndSection": 354,
          "text": "Previously we have demonstrated that leptin receptor is overexpressed in papillary thyroid cancer and is associated with tumor aggressiveness."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 857,
          "offsetInEndSection": 1036,
          "text": "Taken together, our study provides evidence that epigenetic events and insulin stimulation take part in regulation of leptin receptor expression in papillary thyroid cancer cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 211,
          "text": "The adipose tissue-derived polypeptide leptin acting via leptin receptor may modulate cell migration of thyroid cancer cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176686",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Anaplastic thyroid carcinoma (ATC) is a rare, poorly differentiated type of thyroid cancer occurring in less than 5% of all thyroid cancers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176686",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 964,
          "offsetInEndSection": 1043,
          "text": "Anaplastic thyroid carcinoma is a deadly cancer without an effective treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176686",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 346,
          "offsetInEndSection": 505,
          "text": "Several mutations in cell cycle regulation have been discovered in ATC that contribute to its undifferentiated state, one of which is the BRAF kinase mutation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176686",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1044,
          "offsetInEndSection": 1187,
          "text": "Inhibiting mutated enzymes that drive the development of this cancer is a potential drug target that may improve outcomes in patients with ATC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176686",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 599,
          "offsetInEndSection": 709,
          "text": "In this case report, a 51\u00a0y old male presented with a 2-week history of hoarseness and was diagnosed with ATC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Although tyrosine-phosphorylated or activated STAT3 (pY-STAT3) is a well-described mediator of tumorigenesis, its role in thyroid cancer has not been investigated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1573,
          "offsetInEndSection": 1690,
          "text": "Our studies show that, in the context of thyroid cancer, STAT3 is paradoxically a negative regulator of tumor growth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 346,
          "text": "We observed that 63 of 110 (57%) human primary papillary thyroid carcinoma (PTC) cases expressed nuclear pY-STAT3 in tumor cells, preferentially in association with the tumor stroma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 468,
          "offsetInEndSection": 751,
          "text": "Using human thyroid cancer-derived cell lines [harboring rearranged during transfection (RET)/PTC, v-RAF murine sarcoma viral oncogene homolog B (BRAF), or rat sarcoma virus oncogene (RAS) alterations], we determined that IL-6/gp130/JAK signaling is responsible for STAT3 activation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 983,
          "offsetInEndSection": 1153,
          "text": "Similarly, STAT3 deficiency in a murine model of BRAFV600E-induced PTC led to thyroid tumors that were more proliferative and larger than those tumors expressing STAT3wt."
        }
      ]
    },
    {
      "id": "67fc20ee18b1e36f2e00012a",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35311140",
        "http://www.ncbi.nlm.nih.gov/pubmed/35920986",
        "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
        "http://www.ncbi.nlm.nih.gov/pubmed/35269652",
        "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
        "http://www.ncbi.nlm.nih.gov/pubmed/28767130",
        "http://www.ncbi.nlm.nih.gov/pubmed/27959923",
        "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
        "http://www.ncbi.nlm.nih.gov/pubmed/32998960",
        "http://www.ncbi.nlm.nih.gov/pubmed/19107440"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35311140",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 394,
          "offsetInEndSection": 559,
          "text": "It has been observed that glioblastoma cells can recruit, manipulate and use other cells including neurons, glial cells, immune cells, and endothelial/stromal cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35311140",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 678,
          "offsetInEndSection": 858,
          "text": "Nonetheless, recent data are suggesting that the microenvironment can also be a niche in which glioblastoma cells can differentiate into glial cells losing their tumoral phenotype."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35311140",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Glioblastoma is an aggressive tumor and is associated with a dismal prognosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35311140",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 212,
          "offsetInEndSection": 393,
          "text": "The biological behavior of glioblastoma tumor cells reveals a very complex pattern of genomic alterations and is partially responsible for the clinical aggressiveness of this tumor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35311140",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 859,
          "offsetInEndSection": 996,
          "text": "Here we summarize the known interactions between micro-environment and glioblastoma cells highlighting possible therapeutic implications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35920986",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 920,
          "offsetInEndSection": 1128,
          "text": "Here we discuss the role of extracellular matrix and immune cell populations, major components of the tumor ecosystem in glioblastoma, as well as signaling pathways that regulate GSC maintenance and invasion."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35920986",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "text": "With the application of high throughput sequencing technologies at single-cell resolution, studies of the tumor microenvironment in glioblastoma, one of the most aggressive and invasive of all cancers, have revealed immense cellular and tissue heterogeneity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35920986",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 919,
          "text": "Among the heterogeneous tumor cell subpopulations of glioblastoma, glioma stem cells (GSCs), which exhibit tumorigenic properties and strong invasive capacity, are critical for tumor growth and are believed to contribute to therapeutic resistance and tumor recurrence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35920986",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 469,
          "offsetInEndSection": 650,
          "text": "The spatiotemporal interactions between malignant and immune cells generate an immunosuppressive microenvironment, contributing to the failure of effective anti-tumor immune attack."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35920986",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 468,
          "text": "A unique extracellular scaffold system adapts to and supports progressive infiltration and migration of tumor cells, which is characterized by altered composition, effector delivery, and mechanical properties."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 427,
          "text": "At the same time, it has become clear that non neoplastic cells, which constitute about 30% of glioma mass, dramatically influence tumor growth, spread, and recurrence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 991,
          "offsetInEndSection": 1220,
          "text": "Understanding how glioma cells interact with non-neoplastic cells in tumor microenvironment is an essential step to comprehend mechanisms at the base of disease progression and to find new therapeutic strategies for GBM patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 633,
          "offsetInEndSection": 856,
          "text": "The aim of this review is to summarize the most recent discovery about resident microglia, tumor-associated macrophages, lymphocytes, and the role of extracellular vesicles and their bijective interaction with glioma cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 428,
          "offsetInEndSection": 632,
          "text": "This is the main reason why, in recent years, scientific research has been focused on understanding the function and the composition of tumor microenvironment and its role in gliomagenesis and recurrence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456984",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 133,
          "offsetInEndSection": 258,
          "text": "In recent years, molecular biomarkers have gained more and more importance both in the diagnosis and therapy of glial tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35269652",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1015,
          "offsetInEndSection": 1268,
          "text": "This review article sheds light on the various components of the GBM microenvironment and their roles in tumoral development, as well as immune-related biological processes that support the interconnection/interrelationship between different cell types."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35269652",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 644,
          "offsetInEndSection": 855,
          "text": "Several studies have suggested that various GBM subtypes present different modifications in their microenvironment, although the importance of the microenvironment in treatment response has yet to be determined."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35269652",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 302,
          "offsetInEndSection": 463,
          "text": "Soluble factors, extracellular matrix components, tissue-resident cell types, resident or newly recruited immune cells together make up the GBM microenvironment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35269652",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 301,
          "text": "Treatment resistance and tumor recurrence in GBM are mostly explained by considerable alterations within the tumor microenvironment, as well as extraordinary cellular and molecular heterogeneity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35269652",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Glioma is the most common primary intracranial tumor and has the greatest prevalence of all brain tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 469,
          "offsetInEndSection": 750,
          "text": "The main aim of the review was to assess the different possible mechanisms that could explain resistance to treatment promoted by TME and GSCs in glioblastoma, including the role of M2 macrophages, micro RNAs (miRNAs), and long non-coding RNAs (lncRNAs) from exosomes from the TME."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "The invasive nature of glioblastoma is problematic in a radical surgery approach and can be responsible for tumor recurrence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1404,
          "offsetInEndSection": 1668,
          "text": "A better insight into how GBM cells interact with TME is an essential step towards comprehending the mechanisms that give rise to resistance to standard treatment, which can help to pave the way for the development of novel therapeutic strategies for GBM patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 273,
          "offsetInEndSection": 468,
          "text": "The continuous cross-talk between glioma stem cells (GSCs) and the tumor microenvironment (TME) contributes to disease progression, which renders research in this field difficult and challenging."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 751,
          "offsetInEndSection": 1008,
          "text": "A systematic review of the literature on the role of the TME in developing and promoting radioresistance and chemoresistance of GBM was performed according to PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) guidelines."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 614,
          "offsetInEndSection": 749,
          "text": "The associations between TAMs, gemistocytic cells and glioblastoma subtype were examined with immuno- and haematoxylin-eosin stainings."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1082,
          "offsetInEndSection": 1238,
          "text": "Our results suggest that M2-like TAMs hold an unfavourable prognostic value in high-grade gliomas and may contribute to a pro-tumourigenic microenvironment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 750,
          "offsetInEndSection": 1081,
          "text": "Three tissue arrays containing glioblastoma specimens were included to study IBA-1/CD204 levels in central tumour and tumour periphery and to characterize CD204\nOur data revealed that the amount of especially CD204\nThis is the first study to use automated quantitative immunofluorescence to determine the prognostic impact of TAMs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 60,
          "text": "Glioblastomas are highly aggressive and treatment resistant."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 206,
          "offsetInEndSection": 334,
          "text": "Our objective was to investigate the prognostic value of TAMs in gliomas using automated quantitative double immunofluorescence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27959923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 743,
          "offsetInEndSection": 896,
          "text": "We found that tumours with little or no immune infiltration were associated with different survival patterns according to oestrogen receptor (ER) status."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27959923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2258,
          "offsetInEndSection": 2470,
          "text": "Large differences in the cellular composition of the immune infiltrate in breast tumours appear to exist, and these differences are likely to be important determinants of both prognosis and response to treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27959923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "Immune infiltration of breast tumours is associated with clinical outcome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27959923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 897,
          "offsetInEndSection": 1082,
          "text": "In ER-negative disease, tumours lacking immune infiltration were associated with the poorest prognosis, whereas in ER-positive disease, they were associated with intermediate prognosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27959923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 200,
          "offsetInEndSection": 427,
          "text": "The aim of this study was to determine whether differences in the cellular composition of the immune infiltrate in breast tumours influence survival and treatment response, and whether these effects differ by molecular subtype."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 524,
          "offsetInEndSection": 725,
          "text": "Glioma-associated macrophages (GAMs) act critically in enhancing tumor progression and can alter drug resistance, promoting resistance to radiotherapy and establishing an immunosuppressive environment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 360,
          "text": "We assessed the impact of macrophages in the TME on the prognosis in patients with recurrent GBM."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Glioblastoma (GBM) is a common and highly malignant primary tumor of the central nervous system in adults."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1003,
          "offsetInEndSection": 1209,
          "text": "In contrast, M2 is supposed to participate in immunosuppression and tumor progression, which is formed after being exposed to the macrophage M-CSF, IL-10, IL-35 and the transforming growth factor-\u00df (TGF-\u03b2)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1210,
          "offsetInEndSection": 1562,
          "text": "Because there is currently no standard of care in recurrent GBM, novel identified targeted therapies based on the complex signaling and interactions between the glioma stem cells (GSCs) and the TME, especially resident microglia and bone-marrow-derived macrophages, may be helpful in improving the overall survival of these patients in the near future."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32998960",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 448,
          "text": "Formalin-fixed, paraffin-embedded tumor samples of 124 uniformly treated, newly diagnosed patients with glioblastoma were submitted to RNA sequencing, IHC, and immune-phenotyping to identify differences in molecular subtypes associated with treatment sensitivities."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32998960",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1361,
          "offsetInEndSection": 1655,
          "text": "The cell-type deconvolution analysis revealed that these tumors are highly enriched in M2 macrophages, resting memory CD4\nThere is a subset of tumors, frequently classified as mesenchymal or IGS cluster 23, that may be identified with IHC and could well be optimal candidates for immunotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32998960",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1161,
          "offsetInEndSection": 1360,
          "text": "Immune-phenotyping showed that mesenchymal and IGS 23 tumors exhibited a higher positive effector cell score, a higher negative suppressor cell score, and lower levels of immune checkpoint molecules."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32998960",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 449,
          "offsetInEndSection": 657,
          "text": "We detected high molecular and IHC overlapping of the The Cancer Genome Atlas (TCGA) mesenchymal subtype with instrinsic glioma subtypes (IGS) cluster 23 and of the TCGA classical subtype with IGS cluster 18."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32998960",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Molecular subtype classifications in glioblastoma may detect therapy sensitivities."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Gliomas account for more than 70% of all brain tumors, and of these, glioblastoma is the most frequent and malignant histologic type (World Health Organization [WHO] grade IV)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 378,
          "offsetInEndSection": 485,
          "text": "With the exception of pilocytic astrocytomas (WHO grade I), the prognosis of glioma patients is still poor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 280,
          "text": "There is a tendency toward a higher incidence of gliomas in highly developed, industrialized countries."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 657,
          "text": "Fewer than 3% of glioblastoma patients are still alive at 5 years after diagnosis, older age being the most significant and consistent prognostic factor of poorer outcome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107440",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 658,
          "offsetInEndSection": 769,
          "text": "Gliomas are components of several inherited tumor syndromes, but the prevalence of these syndromes is very low."
        }
      ]
    },
    {
      "id": "67f8527318b1e36f2e000104",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36389300",
        "http://www.ncbi.nlm.nih.gov/pubmed/23984569",
        "http://www.ncbi.nlm.nih.gov/pubmed/19762171",
        "http://www.ncbi.nlm.nih.gov/pubmed/9181534",
        "http://www.ncbi.nlm.nih.gov/pubmed/24163979",
        "http://www.ncbi.nlm.nih.gov/pubmed/20642659",
        "http://www.ncbi.nlm.nih.gov/pubmed/20018387",
        "http://www.ncbi.nlm.nih.gov/pubmed/23903677",
        "http://www.ncbi.nlm.nih.gov/pubmed/25000345",
        "http://www.ncbi.nlm.nih.gov/pubmed/25010615"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36389300",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1192,
          "text": "According to different anesthesia methods, they were divided into non-intubation anesthesia group (n=62) and intubation anesthesia group (n=53)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36389300",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 297,
          "offsetInEndSection": 454,
          "text": "In non-intubation anesthesia, laryngeal mask is used instead of tracheal intubation without muscle relaxants and small doses of sedative and analgesic drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36389300",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 174,
          "offsetInEndSection": 296,
          "text": "However, general anesthesia with endotracheal intubation can produce intubation and anesthetic drug related complications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36389300",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Thoracoscopic-assisted Nuss repair is a commonly used method for treating pectus excavatum, which has always been performed under tracheal intubation and general anesthesia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36389300",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1640,
          "offsetInEndSection": 1891,
          "text": "Compared with the intubation anesthesia group, the non-intubation anesthesia group had less anesthesia intubation time, lower intraoperative mean heart rate, less postoperative complications, such as pneumothorax, pleural effusion, and lung infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984569",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 403,
          "offsetInEndSection": 575,
          "text": "After induction of general anesthesia, both attempts of laryngoscope-guided and AirwayScope -guided tracheal intubation failed, but a size-2 air-Q could be easily inserted."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984569",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "We report a case of successful fiberoptic tracheal intubation through the supraglottic airway device air-Q in a 14-year-old boy in whom intubation was difficult because of Shprintzen-Goldberg syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984569",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 727,
          "offsetInEndSection": 930,
          "text": "Supraglottic airway air-Q is a useful conduit for fiberoptic tracheal intubation under general anesthesia, especially in the case of a patient with weak connective tissue in whom intubation is difficult."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984569",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 576,
          "offsetInEndSection": 726,
          "text": "Fiberoptic tracheal intubation through the air-Q was successfully performed without any difficulty and was safe for his weak airway connective tissue."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984569",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 283,
          "offsetInEndSection": 402,
          "text": "The patient showed dysmorphic facies and weakness of connective tissue, and was scheduled to undergo abdominal surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762171",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 815,
          "offsetInEndSection": 968,
          "text": "In this article, we review the literature on the airway management of intubated patients as well as of infants managed with nasal-CPAP or nasal cannulae."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762171",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "The management of endotracheal tubes and nasal cannulae covers a large part of work time of nurses involved in the care of very preterm infants."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762171",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 518,
          "offsetInEndSection": 756,
          "text": "With regard to the nasal cannulae, there is a more recent use of this device consisting in delivering end-expiratory pressure or gas flow to reduce the frequency of apneas and desaturations in preterm infants or for the management of RDS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762171",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 243,
          "offsetInEndSection": 517,
          "text": "In fact, there is limited evidence regarding several points such as the frequency of endotracheal suctioning, the level of suction pressure, the duration of suctioning, the depth of catheter insertion, the sterility, and the use of normal saline during endotracheal suction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762171",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 757,
          "offsetInEndSection": 814,
          "text": "This approach is defined high-flow nasal cannulae (HFNC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9181534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 717,
          "offsetInEndSection": 797,
          "text": "Surgical indications for tonsillectomy in the young voice patient are discussed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9181534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 798,
          "offsetInEndSection": 971,
          "text": "There are no special considerations in the evaluation and treatment of laryngeal pathology in the young adult, with the exception of limiting the use of sedative anesthesia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9181534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 533,
          "offsetInEndSection": 716,
          "text": "Treatment of these conditions must be tailored in the professional voice user because of the potential side effects of some medications and the performance imperatives of the patient."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9181534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 84,
          "offsetInEndSection": 312,
          "text": "Care of the young adult professional voice requires knowledge of the specific anatomic and physiologic changes associated with the mutational voice, as well as the effects of general growth and maturation on the vocal mechanism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9181534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 532,
          "text": "Upper respiratory infection and allergies are common in this age group."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163979",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 542,
          "offsetInEndSection": 648,
          "text": "Supraglottitis should be remembered as possible diagnosis when an adult person complains of a sore throat."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163979",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 362,
          "text": "We reviewed all patients at Tampere University Hospital over the age of 18, who had been recorded with a diagnosis of epiglottitis or supraglottitis upon discharge from the hospital between 1989 and 2009."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163979",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 88,
          "offsetInEndSection": 157,
          "text": "Supraglottitis often develops in adults more slowly than in children."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163979",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Acute epiglottitis in children has almost vanished since the start of Hib vaccinations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163979",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 363,
          "offsetInEndSection": 428,
          "text": "The most common symptoms were sore throat and pain on swallowing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20642659",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Propofol is gaining increasing popularity as induction agent for pediatric endotracheal intubation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20642659",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1360,
          "offsetInEndSection": 1647,
          "text": "Our experience with propofol as induction agent for endotracheal intubation in preterm neonates reveals distinctive cardiovascular effects, which represent an important risk factor for serious complications of prematurity like intraventricular hemorrhage or periventricular leucomalacia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20642659",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 363,
          "offsetInEndSection": 553,
          "text": "The purpose of this study was to document intubating conditions, vital signs, extubation times and outcome in preterm neonates receiving propofol as induction agent for the INSURE procedure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20642659",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 100,
          "offsetInEndSection": 224,
          "text": "Recently, propofol has been described for the first time as induction agent for endotracheal intubation in preterm neonates."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20642659",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1035,
          "offsetInEndSection": 1151,
          "text": "Propofol generally offered good intubating conditions, but we encountered severe problems with arterial hypotension."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20018387",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 469,
          "offsetInEndSection": 563,
          "text": "We present a rare case of acute epiglottitis in a fully vaccinated child due to nontypeable H."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20018387",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Once a prevalent disease, acute epiglottitis in children has become a rare entity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20018387",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 368,
          "text": "However, physicians must be aware that epiglottitis may result from vaccine failures or from infection with other pathogenic organisms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20018387",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 232,
          "text": "The introduction of the Haemophilus influenzae type b vaccine has had a dramatic impact on the number of invasive infections caused by this organism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20018387",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 468,
          "text": "Vaccinated children with epiglottitis present in a similar fashion to those who are not vaccinated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903677",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 184,
          "offsetInEndSection": 293,
          "text": "High-flow nasal cannula may be able to prevent intubations in infants and children with respiratory distress."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903677",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1663,
          "offsetInEndSection": 1785,
          "text": "A final diagnosis of bronchiolitis was observed to be protective with respect to intubation (OR, 0.40; 95% CI, 0.17-0.96)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903677",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 921,
          "offsetInEndSection": 1031,
          "text": "Multivariable logistic regression was performed to identify factors associated with intubation following HFNC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903677",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1246,
          "offsetInEndSection": 1347,
          "text": "Of the 498 patients, 42 (8%) of patients failed therapy and required intubation following HFNC trial."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903677",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2044,
          "offsetInEndSection": 2136,
          "text": "A diagnosis of acute bronchiolitis was protective with respect to intubation following HFNC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25000345",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 511,
          "offsetInEndSection": 663,
          "text": "Other nonmedical therapies include, the Stretta procedure, transoral incisionless fundoplication, and the magnetic sphincter augmentation device (LINX)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25000345",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 664,
          "offsetInEndSection": 785,
          "text": "Antireflux surgery, in experienced hands, has been repeatedly shown to be efficacious in resolving NERD-related symptoms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25000345",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 786,
          "offsetInEndSection": 970,
          "text": "Psychological therapeutic interventions and alternative medicine techniques, such as acupuncture, continue to show promise, especially in NERD patients who failed antireflux treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25000345",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "There has been a marked decline over the last several years in drug development for gastroesophageal reflux disease and specifically for nonerosive reflux disease (NERD), despite there being many areas of unmet need."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25000345",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 217,
          "offsetInEndSection": 390,
          "text": "In contrast, we have seen a proliferation, during the same period of time, in development of novel, nonmedical therapeutic strategies for NERD using cutting-edge technology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1375,
          "offsetInEndSection": 1433,
          "text": "Fourteen out of 200 patients had difficulty in intubation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 240,
          "offsetInEndSection": 453,
          "text": "In this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the STOP-Bang questionnaire for predicting difficult intubation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 580,
          "offsetInEndSection": 762,
          "text": "Cormack & Lehane grading and difficulty of intubation (Cormack & Lehane grade III or IV, need of an intubation aid, or need of three or more intubation attempts) were also evaluated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "A close relationship between obstructive sleep apnea (OSA) and difficult intubation has been suggested."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 857,
          "offsetInEndSection": 1023,
          "text": "The occurrence of difficult intubation was higher in the patients at a high risk of OSA (i.e., a STOP-Bang score of \u2265 3) than in the patients at a low risk (13.3% vs."
        }
      ]
    },
    {
      "id": "680f4ae9353a4a2e6b000009",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/2124757",
        "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
        "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
        "http://www.ncbi.nlm.nih.gov/pubmed/35713776",
        "http://www.ncbi.nlm.nih.gov/pubmed/23340416",
        "http://www.ncbi.nlm.nih.gov/pubmed/22322415",
        "http://www.ncbi.nlm.nih.gov/pubmed/25710834",
        "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
        "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
        "http://www.ncbi.nlm.nih.gov/pubmed/15638775"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2124757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 276,
          "text": "Surgery is being increasingly used in the treatment of medically intractable seizures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2124757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "We are witnessing a renaissance of the surgical treatment of epilepsy, with renewed interest in the classic procedures and development of new ones such as selective amygdalohippocampectomy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2124757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 676,
          "offsetInEndSection": 909,
          "text": "Selective amygdalohippocampectomy, anterior temporal lobectomy and hemispherectomy yield very rewarding results as regards seizure control, while corpus callosotomies frequently reduce the number and severity of generalized seizures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2124757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 444,
          "offsetInEndSection": 675,
          "text": "The various therapeutic options such as temporal lobectomy, selective amygdalohippocampectomy, extratemporal cortical resections, hemispherectomy and corpus callosotomy are described and the risks and benefits of surgery discussed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2124757",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 277,
          "offsetInEndSection": 443,
          "text": "Exact presurgical evaluation, with definition of the focus, is of the utmost importance and good results are largely dependent on case selection for surgical therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 186,
          "offsetInEndSection": 351,
          "text": "For instance, pharmacological therapy is frequently accompanied by side effects, and current anticonvulsive drugs fail to be effective to around a third of patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 572,
          "text": "However, epilepsy drugs that affect astrocytes are not available currently."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 994,
          "offsetInEndSection": 1106,
          "text": "Recently, a number of experiments have explored the treatments for epilepsy with optogenetic control of neurons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Epilepsy is a neurological disorder that affects around 1% of the population worldwide."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 352,
          "offsetInEndSection": 496,
          "text": "These patients could suffer astrocyte-related epilepsy, as increasing evidence indicates that dysfunctions of astrocytes can result in epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1748,
          "offsetInEndSection": 1874,
          "text": "Potentially more effective treatments targeting specific mechanisms of epileptogenesis and ictogenesis are being investigated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1498,
          "offsetInEndSection": 1747,
          "text": "Among newer generation AEDs, levetiracetam has a number of advantageous features, including availability of a parenteral formulation, but other agents such as gabapentin, lamotrigine, oxcarbazepine, topiramate, and zonisamide may also be considered."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 244,
          "offsetInEndSection": 430,
          "text": "Based on current evidence, prophylactic prescription of long-term antiepileptic drugs (AEDs) in patients with brain tumors in patients who did not present with seizures is not justified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 431,
          "offsetInEndSection": 579,
          "text": "Because of the high risk of recurrence, however, AED treatment should be strongly considered after a single seizure considered to be due to a tumor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 806,
          "offsetInEndSection": 1015,
          "text": "In patients who may require chemotherapy, a non-enzyme-inducing AED is preferred for initial treatment to minimize the risk of drug interactions that impact adversely on the outcome of anticancer chemotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713776",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 631,
          "offsetInEndSection": 810,
          "text": "CC can be effective in treating some seizure types and can be performed using traditional surgical techniques or with the less invasive methods of laser ablation and radiosurgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713776",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 811,
          "offsetInEndSection": 961,
          "text": "This current literature supports the use of VNS, DBS and CC, alone or in combination, as palliative treatments of drug-resistant generalized epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713776",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "To summarize current evidence and recent developments in the surgical treatment of drug-resistant generalized epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713776",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 283,
          "text": "Current surgical treatments of drug-resistant generalized epilepsy include vagus nerve stimulation (VNS), deep brain stimulation (DBS) and corpus callosotomy (CC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713776",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 284,
          "offsetInEndSection": 420,
          "text": "Neurostimulation with VNS and/or DBS has been shown to be effective in reducing seizure frequency in patients with generalized epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "Temporal lobe epilepsy is the most common type of epilepsy in adults, is often medically refractory, and due to broad actions and long-time scales, current systemic treatments have major negative side-effects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 210,
          "offsetInEndSection": 385,
          "text": "However, temporal lobe seizures tend to arise from discrete regions before overt clinical behaviour, making temporally and spatially specific treatment theoretically possible."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 386,
          "offsetInEndSection": 552,
          "text": "Here we report the arrest of spontaneous seizures using a real-time, closed-loop, response system and in vivo optogenetics in a mouse model of temporal lobe epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 553,
          "offsetInEndSection": 753,
          "text": "Either optogenetic inhibition of excitatory principal cells, or activation of a subpopulation of GABAergic cells representing <5% of hippocampal neurons, stops seizures rapidly upon light application."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 754,
          "offsetInEndSection": 924,
          "text": "These results demonstrate that spontaneous temporal lobe seizures can be detected and terminated by modulating specific cell populations in a spatially restricted manner."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22322415",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "Despite myriad anticonvulsants available and in various stages of development, there are thousands of children and adults with epilepsy worldwide still refractory to treatment and not candidates for epilepsy surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22322415",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 989,
          "offsetInEndSection": 1135,
          "text": "Ketogenic diets are also now being increasingly studied for neurological conditions other than epilepsy, including Alzheimer's disease and cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22322415",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1334,
          "offsetInEndSection": 1471,
          "text": "Dietary therapy for epilepsy continues to grow in popularity worldwide, with expanding use for adults and conditions other than epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22322415",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 831,
          "offsetInEndSection": 988,
          "text": "In 2009, two controlled trials of the ketogenic diet were published, as well as an International Expert Consensus Statement on dietary treatment of epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22322415",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 391,
          "offsetInEndSection": 668,
          "text": "In the past several years, neurologists are finding new indications to use these dietary treatments, perhaps even as first-line therapy, including infantile spasms, myoclonic-astatic epilepsy (Doose syndrome), Dravet syndrome, and status epilepticus (including FIRES syndrome)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25710834",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Current treatment options for epilepsy are inadequate, as too many patients suffer from uncontrolled seizures and from negative side effects of treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25710834",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 796,
          "offsetInEndSection": 973,
          "text": "In this Perspective, we discuss promising uses of these technologies for the study of seizures and epilepsy, as well as potential use of these strategies for clinical therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25710834",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 439,
          "offsetInEndSection": 636,
          "text": "Using such tools, it is now possible to begin to address some of the fundamental unanswered questions in epilepsy, to dissect epileptic neuronal circuits and to develop new intervention strategies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25710834",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 252,
          "text": "In addition to these clinical challenges, our scientific understanding of epilepsy is incomplete."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25710834",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 438,
          "text": "Optogenetic and designer receptor technologies provide unprecedented and much needed specificity, allowing for spatial, temporal and cell type-selective modulation of neuronal circuits."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1331,
          "offsetInEndSection": 2373,
          "text": "In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (CBT), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 318,
          "text": "We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of starting antiepileptic drug treatment following a single seizure?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 319,
          "offsetInEndSection": 392,
          "text": "What are the effects of drug monotherapy in people with partial epilepsy?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 393,
          "offsetInEndSection": 491,
          "text": "What are the effects of additional drug treatments in people with drug-resistant partial epilepsy?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 581,
          "offsetInEndSection": 671,
          "text": "What are the effects of behavioural and psychological treatments for people with epilepsy?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1331,
          "offsetInEndSection": 2373,
          "text": "In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (CBT), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 318,
          "text": "We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of starting antiepileptic drug treatment following a single seizure?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 319,
          "offsetInEndSection": 392,
          "text": "What are the effects of drug monotherapy in people with partial epilepsy?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 393,
          "offsetInEndSection": 491,
          "text": "What are the effects of additional drug treatments in people with drug-resistant partial epilepsy?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 581,
          "offsetInEndSection": 671,
          "text": "What are the effects of behavioural and psychological treatments for people with epilepsy?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1439,
          "offsetInEndSection": 1588,
          "text": "This is supplemented by the mechanisms of drug action at these important anticonvulsant targets for classical and clinically relevant compounds (e.g."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 244,
          "text": "Epilepsy describes a group of brain disorders whose symptoms and causes are diverse and complicated, but all share a common behavioural manifestation: the seizure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1051,
          "offsetInEndSection": 1243,
          "text": "Many drugs routinely used in the clinical setting, as well as several novel experimental drugs, have shown interactions with VGICs that underpin, at least in part, their anticonvulsant action."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1589,
          "offsetInEndSection": 1669,
          "text": "phenytoin, ethosuximide) as well as some important second generation drugs (e.g."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Epilepsy is one of the most prevalent neurological syndromes in the world today."
        }
      ]
    },
    {
      "id": "67fd922518b1e36f2e000143",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29594035",
        "http://www.ncbi.nlm.nih.gov/pubmed/32445205",
        "http://www.ncbi.nlm.nih.gov/pubmed/28341752",
        "http://www.ncbi.nlm.nih.gov/pubmed/32708142",
        "http://www.ncbi.nlm.nih.gov/pubmed/33050070",
        "http://www.ncbi.nlm.nih.gov/pubmed/33881837",
        "http://www.ncbi.nlm.nih.gov/pubmed/25620672",
        "http://www.ncbi.nlm.nih.gov/pubmed/29436395",
        "http://www.ncbi.nlm.nih.gov/pubmed/25110953",
        "http://www.ncbi.nlm.nih.gov/pubmed/37218976"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29594035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Macrophages are a major component of the tumor microenvironment and orchestrate various aspects of immunity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29594035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 306,
          "text": "Within tumors, macrophages can reversibly alter their endotype in response to environmental cues, including hypoxia and stimuli derived from other immune cells, as well as the extracellular matrix."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29594035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 307,
          "offsetInEndSection": 495,
          "text": "Depending on their activation status, macrophages can exert dual influences on tumorigenesis by either antagonizing the cytotoxic activity immune cells or by enhancing antitumor responses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29594035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1163,
          "offsetInEndSection": 1376,
          "text": "In this review, we discuss the molecular mechanisms underlying the pro-tumorigenic programming of macrophages and provide a comprehensive update of macrophage-targeted therapies for the treatment of solid cancers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29594035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 496,
          "offsetInEndSection": 722,
          "text": "In most solid cancers, increased infiltration with tumor-associated macrophages (TAMs) has long been associated with poor patient prognosis, highlighting their value as potential diagnostic and prognostic biomarkers in cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32445205",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 435,
          "text": "During initial stages of tumor development, macrophages can either directly promote antitumor responses by killing tumor cells or indirectly recruit and activate other immune cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32445205",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 253,
          "text": "Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the TME."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32445205",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Tumorigenesis is not only determined by the intrinsic properties of cancer cells but also by their interactions with components of the tumor microenvironment (TME)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32445205",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 436,
          "offsetInEndSection": 494,
          "text": "As genetic changes occur within the tumor or T helper 2 (T"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28341752",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 399,
          "offsetInEndSection": 554,
          "text": "In this review, we outline the importance of tumor-associated macrophages (TAM), a major component of the TME, in the response of tumors to cancer therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28341752",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 816,
          "offsetInEndSection": 1081,
          "text": "Finally, we review the many preclinical studies that have shown that the response of tumors to irradiation and anticancer drugs can be improved, sometimes markedly so, by depleting TAMs from tumors or by suppressing their polarization from an M1 to an M2 phenotype."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28341752",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 555,
          "offsetInEndSection": 815,
          "text": "We discuss the normal role of macrophages in wound healing, the major phenotypes of TAMs, and their role in blunting the efficacy of cancer treatment by radiation and anticancer drugs, both by promoting tumor angiogenesis and by suppressing antitumor immunity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28341752",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 398,
          "text": "Increasingly, however, the realization that the cancer has co-opted the normal cells of the stroma for its own survival has led to the concept that the tumor microenvironment (TME) could be targeted for effective therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28341752",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1082,
          "offsetInEndSection": 1194,
          "text": "The data clearly support the validity of clinical testing of combining targeting TAMs with conventional therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32708142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 218,
          "offsetInEndSection": 461,
          "text": "A high TAM infiltration is generally associated with poor prognosis, but macrophages are highly plastic cells that can adopt either proinflammatory/antitumor or anti-inflammatory/protumor features in response to tumor microenvironment stimuli."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32708142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Tumor-associated macrophages (TAMs) represent the most abundant innate immune cells in tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32708142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 217,
          "text": "TAMs, exhibiting anti-inflammatory phenotype, are key players in cancer progression, metastasis and resistance to therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32708142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 462,
          "offsetInEndSection": 636,
          "text": "In the context of cancer therapy, many anticancer therapeutics, apart from their direct effect on tumor cells, display different effects on TAM activation status and density."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32708142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 637,
          "offsetInEndSection": 780,
          "text": "In this review, we aim to evaluate the indirect effects of anticancer therapies in the modulation of TAM phenotypes and pro/antitumor activity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33050070",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 415,
          "text": "In particular, tumor-associated macrophages (TAMs) are the most abundant leucocyte subset in many cancers and play a major role in the creation of a protective niche for tumor cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33050070",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1005,
          "offsetInEndSection": 1196,
          "text": "Exploiting their functional plasticity, the reprogramming of TAMs aims to convert immunosuppressive and pro-tumoral macrophages into immunostimulatory and anti-tumor cytotoxic effector cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33050070",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1305,
          "offsetInEndSection": 1438,
          "text": "In this review, we summarize the current knowledge on strategies able to reprogram TAMs with single as well as combination therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33050070",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 416,
          "offsetInEndSection": 586,
          "text": "Their ability to generate an immune-suppressive environment is crucial to escape the immune system and to allow the tumor to proliferate and metastasize to distant sites."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33050070",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "In the last decade, it has been well-established that tumor-infiltrating myeloid cells fuel not only the process of carcinogenesis through cancer-related inflammation mechanisms, but also tumor progression, invasion, and metastasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33881837",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Tumor-associated macrophages (TAMs) of M2 phenotype have mediated the immunosuppression in a tumor microenvironment, facilitating the escape of tumor cells from immunosurveillance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33881837",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 181,
          "offsetInEndSection": 327,
          "text": "Reprograming the immunosuppressive M2 TAMs to immunostimulatory M1 phenotype can activate the antitumor immune responses for cancer immunotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33881837",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 328,
          "offsetInEndSection": 357,
          "text": "Herein, hollow iron oxide (Fe"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25620672",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 211,
          "text": "They are capable, due to their plasticity, of acquiring phenotypes that either combat (M1 type) or promote (M2 type) neoplastic growth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25620672",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 212,
          "offsetInEndSection": 368,
          "text": "These cells, known as tumor-associated macrophages (TAMs), play complex but pivotal roles in the outcome of photodynamic therapy (PDT) of malignant lesions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25620672",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1358,
          "offsetInEndSection": 1599,
          "text": "However, TAMs accumulating in the later post-PDT phase can acquire the M2 (healing) phenotype, and could have a role in tumor recurrence by releasing factors that promote angiogenesis and the survival/proliferation of remaining cancer cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25620672",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Macrophages are one of the principal host cell populations in solid tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25620672",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 557,
          "text": "Among the various parenchymal and stromal cell populations found in tumors, TAMs have been shown to have the greatest capacity for the uptake of systemically administered photosensitizers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29436395",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 448,
          "offsetInEndSection": 661,
          "text": "Microwell assays to measure multiplex protein secretion by single cells identified that untreated tumors have distinct TAM subpopulations secreting MMP9 or cosecreting CCL17/22, characteristic of an M2-like state."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29436395",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 941,
          "offsetInEndSection": 1119,
          "text": "Together, this study demonstrates the potential for targeting TAMs to convert a \"cold\" into an \"inflamed\" tumor microenvironment capable of eliciting protective T cell responses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29436395",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 256,
          "text": "Eliciting effective antitumor immune responses in patients who fail checkpoint inhibitor therapy is a critical challenge in cancer immunotherapy, and in such patients, tumor-associated myeloid cells and macrophages (TAMs) are promising therapeutic targets."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29436395",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 662,
          "offsetInEndSection": 837,
          "text": "Combination therapy reduced the frequency of these subsets, while simultaneously inducing a separate polyfunctional inflammatory TAM subset cosecreting TNF-\u03b1, IL-6, and IL-12."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29436395",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 257,
          "offsetInEndSection": 447,
          "text": "We demonstrate in an autochthonous, poorly immunogenic mouse model of melanoma that combination therapy with an agonistic anti-CD40 mAb and CSF-1R inhibitor potently suppressed tumor growth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110953",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Tumor associated macrophages (TAM) can promote angiogenesis, invasiveness and immunosuppression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110953",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 97,
          "offsetInEndSection": 315,
          "text": "The cytokine CSF-1 (or M-CSF) is an important factor of TAM recruitment and differentiation and several pharmacological agents targeting the CSF-1 receptor (CSF-1R) have been developed to regulate TAM in solid cancers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110953",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 316,
          "offsetInEndSection": 514,
          "text": "We show that the kinase inhibitor PLX3397 strongly dampened the systemic and local accumulation of macrophages driven by B16F10 melanomas, without affecting Gr-1(+) myeloid derived suppressor cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110953",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 893,
          "offsetInEndSection": 1029,
          "text": "These results support the combined use of CSF-1R inhibition with CD8 T cell immunotherapy, especially for macrophage-stimulating tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110953",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 515,
          "offsetInEndSection": 662,
          "text": "Removal of intratumoral macrophages was remarkably efficient and a modest, but statistically significant, delay in melanoma outgrowth was observed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1003,
          "offsetInEndSection": 1209,
          "text": "In contrast, M2 is supposed to participate in immunosuppression and tumor progression, which is formed after being exposed to the macrophage M-CSF, IL-10, IL-35 and the transforming growth factor-\u00df (TGF-\u03b2)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 726,
          "offsetInEndSection": 1002,
          "text": "M1 macrophages are characterized by increased secretion of proinflammatory cytokines, such as IL-1\u00df, tumor necrosis factor (TNF), IL-27, matrix metalloproteinase (MMPs), CCL2, and VEGF (vascular endothelial growth factor), IGF1, that can lead to the destruction of the tissue."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 107,
          "offsetInEndSection": 262,
          "text": "Ever more recent papers are focusing on understanding the role of the tumor microenvironment (TME) in affecting tumorigenesis and the subsequent prognosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 524,
          "offsetInEndSection": 725,
          "text": "Glioma-associated macrophages (GAMs) act critically in enhancing tumor progression and can alter drug resistance, promoting resistance to radiotherapy and establishing an immunosuppressive environment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 360,
          "text": "We assessed the impact of macrophages in the TME on the prognosis in patients with recurrent GBM."
        }
      ]
    },
    {
      "id": "67fc1a3818b1e36f2e000129",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
        "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
        "http://www.ncbi.nlm.nih.gov/pubmed/24117632",
        "http://www.ncbi.nlm.nih.gov/pubmed/23155537",
        "http://www.ncbi.nlm.nih.gov/pubmed/27901639",
        "http://www.ncbi.nlm.nih.gov/pubmed/19951799",
        "http://www.ncbi.nlm.nih.gov/pubmed/31644405",
        "http://www.ncbi.nlm.nih.gov/pubmed/21037442",
        "http://www.ncbi.nlm.nih.gov/pubmed/25012804",
        "http://www.ncbi.nlm.nih.gov/pubmed/28717439"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 464,
          "offsetInEndSection": 647,
          "text": "The laparoscopic Nissen fundoplication represents the surgical gold standard, but is largely underused because of the level of technical difficulty and the prevalence of side effects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 985,
          "offsetInEndSection": 1206,
          "text": "Paul, MN, USA) is designed to provide a permanent solution to GERD by augmenting the sphincter barrier with a standardized, reproducible laparoscopic procedure that does not alter gastric anatomy and is easily reversible."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "Gastroesophageal reflux disease (GERD) results from incompetency of the lower esophageal sphincter that allows the contents of the stomach to reflux into the esophagus, the airways, and the mouth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1395,
          "offsetInEndSection": 1564,
          "text": "The device decreased esophageal acid exposure, improved reflux symptoms and quality of life, and allowed cessation of proton-pump inhibitors in the majority of patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1207,
          "offsetInEndSection": 1394,
          "text": "Two single-group trials confirmed that a magnetic device designed to augment the lower esophageal sphincter can be safely and effectively implanted using a standard laparoscopic approach."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 490,
          "offsetInEndSection": 684,
          "text": "The laparoscopic Nissen fundoplication is the surgical gold standard; however, the level of technical difficulty and its side effects have limited its use to less than 1% of the GERD population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "Gastroesophageal reflux disease (GERD), commonly manifested by heartburn or regurgitation, is a chronic, progressive condition in which failed sphincter function allows the contents of the stomach to reflux into the esophagus, the airways and the mouth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 968,
          "offsetInEndSection": 1267,
          "text": "The LINX(\u2122) Reflux Management System (Torax Medical) is designed to provide a permanent solution to GERD by augmenting the physiologic function of the sphincter barrier with a simple and reproducible laparoscopic procedure that does not alter gastric anatomy and can be easily reversed if necessary."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 854,
          "offsetInEndSection": 967,
          "text": "Consequently, a significant gap in the treatment continuum for GERD remains evident in current clinical practice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 299,
          "offsetInEndSection": 489,
          "text": "The majority of patients receive adequate relief from proton pump inhibitors, but up to 40% have incomplete relief of symptoms that cannot be addressed by increasing the dose of medications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24117632",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1000,
          "text": "This paper includes commentaries on outcomes of esophageal surgery, including the mechanisms by which fundoduplication improves lower esophageal sphincter (LES) pressure; the efficacy of the Linx\u2122 management system in improving LES function; the utility of radiologic characterization of antireflux valves following surgery; the correlation between endoscopic findings and reported symptoms following antireflux surgery; the links between laparoscopic sleeve gastrectomy and decreased LES pressure, endoscopic esophagitis, and gastroesophageal reflux disease (GERD); the less favorable outcomes following fundoduplication among obese patients; the application of bioprosthetic meshes to reinforce hiatal repair and decrease the incidence of paraesophageal hernia; the efficacy of endoluminal antireflux procedures, and the limited efficacy of revisional antireflux operations, underscoring the importance of good primary surgery and diligent work-up to prevent the necessity of revisional procedures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23155537",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 935,
          "offsetInEndSection": 1176,
          "text": "The laparoscopic minimally invasive procedure improves the acceptance of patients to surgical therapy, but the long-term complication and drawbacks of anti-reflux surgery cannot be ignored, and which is even more common than open procedures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23155537",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Gastroesophageal reflux disease (GERD) is the most common gastrointestinal diagnosis recorded during visits to outpatient clinics in west countries."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23155537",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1177,
          "offsetInEndSection": 1436,
          "text": "The limitations of current therapy for GERD have encouraged a search for more effective treatment.The Linx sphincter augmentation device has been developed to address this gap with improvement of the barrier function of LES and reversible design if necessary."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23155537",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 818,
          "offsetInEndSection": 934,
          "text": "Surgical therapy is alternative management approach to the patients with PPI failure, complications, or huge hernia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23155537",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 221,
          "offsetInEndSection": 284,
          "text": "Asa dysfunction, GERD is characterized by reflux and heartburn."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27901639",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1089,
          "offsetInEndSection": 1220,
          "text": "Fundoplication was performed in 271 (82%): Dor (n\u2009=\u2009205, 76%), Toupet (n\u2009=\u200949, 18%), Thal (n\u2009=\u200913, 4.5%), and Nissen (n\u2009=\u20094, 1.5%)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27901639",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1702,
          "offsetInEndSection": 1769,
          "text": "Routine use of an additional fundoplication might not be justified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27901639",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 615,
          "offsetInEndSection": 791,
          "text": "Incidence of postoperative gastro-esophageal reflux (GER) and dysphagia between patients with and without fundoplication at the time of LHM was compared by Fisher's Exact Test."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27901639",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1595,
          "offsetInEndSection": 1701,
          "text": "There is no difference in incidence of GER and dysphagia between patients with and without fundoplication."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27901639",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Achalasia is a rare disorder in children who are commonly treated by laparoscopic Heller's myotomy (LHM)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19951799",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 73,
          "offsetInEndSection": 357,
          "text": "Specific topics include reviews of long-term outcomes after laparoscopic antireflux surgery, the use of surgically placed implantable device for LES augmentation (Linx), the use of mesh for hiatal hernioplasty, and prone and nonthoracic approaches to minimally invasive esophagectomy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19951799",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "This article covers some new areas of development in esophageal surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31644405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1219,
          "offsetInEndSection": 1364,
          "text": "Laparoscopic surgery, partial or total fundoplication, is reserved for PPIs and endoscopy indolent patients or in those with progressive disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31644405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Gastroesophageal Reflux Disease (GERD) is characterized by acid and bile reflux in the distal oesophagus, and this may cause the development of reflux esophagitis and Barrett's oesophagus (BE)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31644405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 636,
          "offsetInEndSection": 750,
          "text": "The medical treatment of GERD and BE includes the use of proton pump inhibitors (PPIs) regarding symptoms control."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31644405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 421,
          "offsetInEndSection": 635,
          "text": "The gold standard for BE diagnostics involves high-resolution white-light endoscopy, followed by uniform endoscopy findings description (Prague classification) with biopsy performance according to Seattle protocol."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31644405",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 935,
          "offsetInEndSection": 1132,
          "text": "Endoscopy treatment includes a wide range of resection and ablative techniques, such as radio-frequency ablation (RFA), often concomitantly used in everyday endoscopy practice (multimodal therapy)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21037442",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2194,
          "offsetInEndSection": 2367,
          "text": "The new laparoscopically implanted sphincter augmentation device eliminates GERD symptoms without creating undue side effects and is effective at 1 and 2 years of follow-up."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21037442",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 288,
          "offsetInEndSection": 554,
          "text": "A sphincter augmentation device (LINX Reflux Management System; Torax Medical, Shoreview, MN), designed to prevent reflux due to abnormal opening of the lower esophageal sphincter (LES), was laparoscopically implanted at the gastroesophageal junction in 44 patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21037442",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 287,
          "text": "One- and 2-year evaluation of a feasibility trial (clinicaltrials.gov registration numbers NCT01057992, NCT01058070, and 01058564) to assess the safety and efficacy of a laparoscopically implanted sphincter augmentation device for the treatment of gastroesophageal reflux disease (GERD)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21037442",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1129,
          "offsetInEndSection": 1302,
          "text": "Patients were evaluated after surgery by GERD Health-Related Quality of Life symptom score, PPI usage, endoscopy, esophageal manometry, and 24-hour esophageal pH monitoring."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21037442",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1707,
          "offsetInEndSection": 1834,
          "text": "One device was laparoscopically explanted for persistent dysphagia without disruption of the anatomy or function of the cardia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25012804",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 224,
          "offsetInEndSection": 376,
          "text": "However, no direct comparison between MSA and laparoscopic Nissen fundoplication (LNF), the gold standard surgical therapy for GERD, has been performed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25012804",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1314,
          "offsetInEndSection": 1459,
          "text": "MSA and LNF are both effective and safe treatments for GERD; however, severe dysphagia requiring endoscopic intervention is more common with MSA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25012804",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1522,
          "offsetInEndSection": 1654,
          "text": "Consideration should be paid to these distinct post-operative symptom profiles when selecting a surgical therapy for reflux disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25012804",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 536,
          "offsetInEndSection": 687,
          "text": "MSA and LNF were both effective treatments for reflux with 75 and 83 % of patients, respectively, reporting resolution of GERD at short-term follow-up."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25012804",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Laparoscopic magnetic sphincter augmentation (MSA) with the LINX device is a promising new therapy for the treatment of gastroesophageal reflux disease (GERD)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Achalasia is a chronic incurable esophageal motility disorder characterized by impaired lower esophageal sphincter (LES) relaxation and loss of esophageal peristalsis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 720,
          "offsetInEndSection": 936,
          "text": "The most effective treatment options for achalasia include pneumatic dilation, Heller myotomy and peroral endoscopic myotomy (POEM), with the latter increasingly emerging as the treatment of choice for many patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 595,
          "offsetInEndSection": 719,
          "text": "Management of achalasia mainly involves improving the esophageal outflow in order to provide symptomatic relief to patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 482,
          "offsetInEndSection": 594,
          "text": "As the underlying etiology of achalasia remains unclear, there is currently no curative treatment for achalasia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 937,
          "offsetInEndSection": 1062,
          "text": "This review focusses on evidence for current and emerging treatment options for achalasia with a particular emphasis on POEM."
        }
      ]
    },
    {
      "id": "67e285b018b1e36f2e00007b",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16821224",
        "http://www.ncbi.nlm.nih.gov/pubmed/20197675",
        "http://www.ncbi.nlm.nih.gov/pubmed/697225",
        "http://www.ncbi.nlm.nih.gov/pubmed/11807897",
        "http://www.ncbi.nlm.nih.gov/pubmed/25800473",
        "http://www.ncbi.nlm.nih.gov/pubmed/15797949",
        "http://www.ncbi.nlm.nih.gov/pubmed/8151646",
        "http://www.ncbi.nlm.nih.gov/pubmed/8517687",
        "http://www.ncbi.nlm.nih.gov/pubmed/12966522",
        "http://www.ncbi.nlm.nih.gov/pubmed/26755454"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16821224",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Turner's syndrome is defined as a congenital disease determining by quantitative and/or structural aberrations of one from two X chromosomes with frequent presence of mosaicism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16821224",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 600,
          "offsetInEndSection": 1059,
          "text": "The most frequent X chromosome aberrations in patients with phenotype of Turner syndrome are as follows: X monosomy - 45,X; mosaicism (50-75%), including 45,X/46,XX (10-15%), 45,X/46,XY (2-6%), 45,X/46,X,i(Xq), 45,X/46,X,del(Xp), 45,X/46,XX/47,XXX; aberration of X structure: total or partial deletion of short arm of X chromosome (46,X,del(Xp)) isochromosom of long arm of X chromosome (46,X,(i(Xq)), ring chromosome (46, X,r(X)), marker chromosome (46,X+m)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16821224",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 537,
          "offsetInEndSection": 599,
          "text": "Turner's syndrome occurs in 1:2000 to 1:2500 female livebirth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16821224",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1288,
          "offsetInEndSection": 1410,
          "text": "In this paper current data concerning correlation between phenotype and karyotype in patients with TS have been presented."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16821224",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 536,
          "text": "Clinically it is characterized by growth and body proportion abnormalities, gonadal dysgenesis resulting in sexual infantilism, primary amenorrhoea, infertility, characteristic stigmata, anomalies of heart, renal and bones and the presence of some diseases like Hashimoto thyroiditis with hypothyroidism, diabetes mellitus type 2, osteoporosis, hypertension."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20197675",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "Turner's syndrome, also known as 'monosomy X', is a genetic disorder that occurs in 1/2,500 female births and is hypothesized to result from haploinsufficiency of certain genes expressed from both sex chromosomes that escape X inactivation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20197675",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 435,
          "text": "While the classic karyotype related to Turner's syndrome is 45,X, the majority of those affected actually have a mosaic chromosomal complement, most often with a second normal cell line (46,XX)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20197675",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 895,
          "offsetInEndSection": 1031,
          "text": "The only possible explanation for the absence of Turner phenotype is the hidden mosaicism combined with an untreated gonadal dysgenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20197675",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1032,
          "offsetInEndSection": 1148,
          "text": "Our results support the theory that significant ascertainment bias exists in our understanding of Turner's syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20197675",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 661,
          "offsetInEndSection": 894,
          "text": "In this paper we report a molecular and cytogenetic investigation of a 26-year-old female with non-mosaic 45,X karyotype, who has a stature of 170 cm without GH treatment, and whose only apparent Turner feature is gonadal dysgenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/697225",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 84,
          "offsetInEndSection": 186,
          "text": "Turner phenotype in this family is the result of deletion of the entire short arm of one X chromosome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/697225",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Seven women in three generations of a family have been affected by Turner syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/697225",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 270,
          "offsetInEndSection": 485,
          "text": "Autoradiographic findings showed that the deleted X chromosome was late labeling in those persons with Turner syndrome, whereas the normal X chromosome was late replicating in carriers of the balanced translocation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/697225",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 187,
          "offsetInEndSection": 269,
          "text": "The short arm deletion is transmitted by carriers of a balanced X-1 translocation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/697225",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 595,
          "offsetInEndSection": 762,
          "text": "Because of the clinical implications, we believe that families of persons with structural chromosomal abnormalities should be studied to exclude familial transmission."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11807897",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Turner syndrome is a chromosomal disorder in which all or part of one X chromosome is missing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11807897",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 255,
          "offsetInEndSection": 476,
          "text": "We analyzed 15 Turner patients, 10 with a 45,X whereas the rest had a second cell line with abnormal X-chromosomes: a pseudodicentric, an isochromosome, one large and one small ring, and the last with a long arm deletion."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11807897",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 477,
          "offsetInEndSection": 786,
          "text": "Our aims were: to detect X cryptic mosaicism in patients with a 45,X constitution; to determine the parental origin of the abnormality; to infer the zygotic origin of the karyotype and to suggest the timing and mechanism of the error(s) leading to the formation of abnormal X chromosomes from maternal origin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11807897",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 908,
          "offsetInEndSection": 989,
          "text": "Parental origin of the single X chromosome was maternal in 90% of these patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11807897",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1089,
          "offsetInEndSection": 1378,
          "text": "These results allowed us to corroborate breakpoints in these abnormal X chromosomes and suggest that the pseudodicentric chromosome originated from post-zygotic sister chromatid exchange, whereas the Xq deleted chromosome probably arose after a recombination event during maternal meiosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25800473",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "Turner syndrome (TS) is a chromosomal disorder caused by complete or partial X chromosome monosomy that manifests various clinical features depending on the karyotype and on the genetic background of affected girls."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25800473",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 216,
          "offsetInEndSection": 372,
          "text": "This study aimed to systematically investigate the key clinical features of TS in relationship to karyotype in a large pediatric Turkish patient population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25800473",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 532,
          "offsetInEndSection": 654,
          "text": "The most common karyotype was 45,X (50.7%), followed by 45,X/46,XX (10.8%), 46,X,i(Xq) (10.1%) and 45,X/46,X,i(Xq) (9.5%)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25800473",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 911,
          "offsetInEndSection": 1073,
          "text": "Cardiac defects (bicuspid aortic valve, coarctation of the aorta and aortic stenosis) were the most common congenital anomalies, occurring in 25% of the TS cases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25800473",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 775,
          "offsetInEndSection": 910,
          "text": "Among patients diagnosed before age one year, the ratio of karyotype 45,X was significantly higher than that of other karyotype groups."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15797949",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Turner syndrome (TS) is the most common genetic problem affecting women and occurs when an X chromosome is completely deleted, portions of an X chromosome are deleted, or chromosomal mosaicism occurs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15797949",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1094,
          "offsetInEndSection": 1262,
          "text": "With just four informative SNP markers for the X chromosome, all TS girls with 45,X, partial X chromosome deletions, or mosaicism were identified with 100% sensitivity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15797949",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 596,
          "offsetInEndSection": 772,
          "text": "To screen for sex chromosome abnormalities, we assembled a panel of informative single nucleotide polymorphism (SNP) markers that span the X chromosome from the dbSNP database."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15797949",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 259,
          "text": "Girls with TS may also have occult Y chromosome sequences."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15797949",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 773,
          "offsetInEndSection": 1008,
          "text": "Pyrosequencing assays suitable for quantitative assessment of signal strength from single nucleotides were designed and used to genotype 46,XX; 46,XY; 45,X; and TS mosaics, examining zygosity and signal strength for individual alleles."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8151646",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "A case of mosaic Turner's syndrome with a 45,X/46,XX/47,XXX karyotype, who was also a fragile X obligate carrier as the mother of an affected boy, was identified by molecular diagnosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8151646",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 338,
          "offsetInEndSection": 395,
          "text": "Her external appearance was typical of Turner's syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8151646",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 186,
          "offsetInEndSection": 295,
          "text": "Complete haplotyping and direct DNA analysis showed that the X chromosome in all metaphases was the normal X."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8151646",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 597,
          "text": "This report shows that molecular studies in conjunction with cytogenetic analysis can help in the clinical diagnosis of a rare case and can show the uniqueness of a case such as the one here described."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8151646",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 296,
          "offsetInEndSection": 337,
          "text": "At the age of 57, she is mentally normal."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8517687",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Monosomy for the X chromosome is the most frequent cause of Turner's syndrome, a common clinical syndrome associated with particular physical and neurobehavioral features."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8517687",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1948,
          "offsetInEndSection": 2162,
          "text": "The unique nature of the naturally occurring genetic phenomenon seen in this twin pair provides an opportunity to more fully elucidate the neurobehavioral phenotype associated with X monosomy and Turner's syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8517687",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 411,
          "offsetInEndSection": 582,
          "text": "Physical features in the affected twin were relatively mild with respect to the full spectrum of physical malformations and disabilities associated with Turner's syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8517687",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 294,
          "text": "The results from comprehensive assessment of prepubertal monozygotic female twins discordant for X monosomy are presented."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8517687",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1353,
          "offsetInEndSection": 1592,
          "text": "The right frontal, right parietal-occipital, and left parietal-perisylvian regions showed the greatest discrepancy between the sisters with respect to increased cerebrospinal fluid and decreased gray matter volumes in twin with X monosomy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12966522",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Rett syndrome is caused by mutation in MECP2, a gene located on Xq28 and subject to X-inactivation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12966522",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1198,
          "text": "This is the first reported case of sex chromosome trisomy and MECP2 mutation in a female, and it illustrates the importance of allele dosage on the severity of Rett syndrome phenotype."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12966522",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 326,
          "offsetInEndSection": 497,
          "text": "Here we report the identification of a unique 47,XXX girl with relatively mild atypical Rett syndrome leading initially to a diagnosis of infantile autism with regression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12966522",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 325,
          "text": "Mutations in MECP2 are primarily de novo events in the male germ line and thus lead to an excess of affected females."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12966522",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 498,
          "offsetInEndSection": 577,
          "text": "Mutation analysis of the MECP2 gene identified a de novo MECP2 mutation, L100V."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 73,
          "offsetInEndSection": 169,
          "text": "Mutations in the MECP2 gene on chromosome Xq28 have been shown to be the cause of Rett syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 322,
          "offsetInEndSection": 398,
          "text": "Females with Rett syndrome are usually heterozygous for a mutation in MECP2."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Rett syndrome is a severe X-linked dominant neurodevelopmental disorder."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 170,
          "offsetInEndSection": 321,
          "text": "Sequencing of the MECP2 gene in a patient with clinical suspicion of Rett syndrome revealed c.1160C>T (P387L) in exon 4 of the MECP2 gene homozygously."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755454",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 665,
          "offsetInEndSection": 829,
          "text": "We hypothesize that the presence of this mutation c.1160C>T (P387L) in the homozygous form is responsible for the Rett syndrome-like phenotype seen in this patient."
        }
      ]
    },
    {
      "id": "680a07f918b1e36f2e00014a",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33922020",
        "http://www.ncbi.nlm.nih.gov/pubmed/28976890",
        "http://www.ncbi.nlm.nih.gov/pubmed/19698742",
        "http://www.ncbi.nlm.nih.gov/pubmed/23845246",
        "http://www.ncbi.nlm.nih.gov/pubmed/34849584",
        "http://www.ncbi.nlm.nih.gov/pubmed/34539752",
        "http://www.ncbi.nlm.nih.gov/pubmed/24769127",
        "http://www.ncbi.nlm.nih.gov/pubmed/23721879",
        "http://www.ncbi.nlm.nih.gov/pubmed/25766410",
        "http://www.ncbi.nlm.nih.gov/pubmed/24642372"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33922020",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 266,
          "text": "Mitochondria are double membrane-bound organelles in eukaryotic cells essential to a variety of cellular functions including energy conversion and ATP production, iron-sulfur biogenesis, lipid and amino acid metabolism, and regulating apoptosis and stress responses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33922020",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 378,
          "offsetInEndSection": 492,
          "text": "Excessive and dysfunctional/damaged mitochondria are degraded by selective autophagic pathways known as mitophagy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33922020",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 267,
          "offsetInEndSection": 377,
          "text": "Mitochondrial dysfunction is mechanistically linked to several neurodegenerative diseases, cancer, and ageing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33922020",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 493,
          "offsetInEndSection": 590,
          "text": "Both budding yeast and mammals use the well-conserved machinery of core autophagy-related genes ("
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976890",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Mitochondria are indispensable cellular organelles providing ATP and numerous other essential metabolites to ensure cell survival."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976890",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 329,
          "text": "Reactive oxygen species (ROS), which are formed as side reactions during oxidative phosphorylation or by external agents, induce molecular damage in mitochondrial proteins, lipids/membranes and DNA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976890",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 464,
          "offsetInEndSection": 568,
          "text": "One critical level of mitochondrial quality control is the removal of damaged mitochondria by mitophagy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976890",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 719,
          "offsetInEndSection": 831,
          "text": "Depending on the proteins utilized mitophagy is divided into receptor-mediated and ubiquitin-mediated mitophagy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976890",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 953,
          "offsetInEndSection": 1093,
          "text": "In contrast to receptor-mediated pathways, the Pink-Parkin-dependent pathway is currently the best characterized ubiquitin-mediated pathway."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19698742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 303,
          "offsetInEndSection": 457,
          "text": "Most intracellular ATP is generated by mitochondrial respiration, which also represents the most relevant source of intracellular reactive oxygen species."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19698742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Mitochondria are required for cellular survival, yet can also orchestrate cell death."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19698742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 588,
          "text": "Mitochondria participate in a plethora of anabolic pathways, including cholesterol, cardiolipin, heme and nucleotide biosynthesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19698742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 589,
          "offsetInEndSection": 809,
          "text": "Moreover, mitochondria integrate numerous pro-survival and pro-death signals, thereby exerting a decisive control over several biochemical cascades leading to cell death, in particular the intrinsic pathway of apoptosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19698742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 302,
          "text": "The peculiar biochemical properties of these organelles, which are intimately linked to their compartmentalized ultrastructure, provide an optimal microenvironment for multiple biosynthetic and bioenergetic pathways."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845246",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Parkin is a cytosolic ubiquitin ligase that translocates to damaged mitochondria and promotes their degradation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845246",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 113,
          "offsetInEndSection": 283,
          "text": "Recent work demonstrates that a phosphorylated form of the mitochondrial fusion protein Mitofusin 2 serves as a receptor for Parkin translocation to damaged mitochondria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34849584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Mitochondria are small cellular constituents that generate cellular energy (ATP) by oxidative phosphorylation (OXPHOS)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34849584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 303,
          "offsetInEndSection": 484,
          "text": "With respect to the latter, mutations in subunit-encoding genes and assembly factors of the first OXPHOS complex (complex I) induce isolated complex I deficiency and Leigh syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34849584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 302,
          "text": "Dysfunction of these organelles is linked to a heterogeneous group of multisystemic disorders, including diabetes, cancer, ageing-related pathologies and rare mitochondrial diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34849584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1041,
          "offsetInEndSection": 1307,
          "text": "Here, we review and discuss the role of complex I and NDUFS4 mutations in human mitochondrial disease, and review how the analysis of Ndufs4 knockout mouse models has generated new insights into the MC1ND1/Leigh syndrome pathomechanism and its therapeutic targeting."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34849584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 657,
          "offsetInEndSection": 896,
          "text": "Mutations in the nuclear DNA-encoded NDUFS4 gene, encoding the NADH:ubiquinone oxidoreductase subunit S4 (NDUFS4) of complex I, induce 'mitochondrial complex I deficiency, nuclear type 1' (MC1DN1) and Leigh syndrome in paediatric patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34539752",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "The maintenance of the mitochondrial genome depends on a suite of nucleus-encoded proteins, among which the catalytic subunit of the mitochondrial replicative DNA polymerase, Pol \u03b3\u03b1, plays a pivotal role."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34539752",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 205,
          "offsetInEndSection": 243,
          "text": "Mutations in the Pol \u03b3\u03b1-encoding gene,"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24769127",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "Since it has been recognized that mitochondria are crucial not only for energy metabolism but also for other cellular functions, there has been a growing interest in cardiolipin, the specific phospholipid of mitochondrial membranes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24769127",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 475,
          "offsetInEndSection": 586,
          "text": "Cardiolipin plays an important role in the structural organization and the function of mitochondrial membranes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24769127",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 312,
          "text": "Indeed, cardiolipin is a universal component of mitochondria in all eukaryotes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24769127",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 869,
          "text": "Specifically, we describe the formation, the migration, and the degradation of cardiolipin and we discuss how cardiolipin affects mitochondrial function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24769127",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 587,
          "offsetInEndSection": 715,
          "text": "In this article, we review the literature on cardiolipin biology, focusing on the most important discoveries of the past decade."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23721879",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 75,
          "offsetInEndSection": 207,
          "text": "Important subunits of the oxidative phosphorylation system, which supplies cells with the energy currency ATP, are encoded by mtDNA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23721879",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "Mitochondria contain mtDNA derived from the ancestral endosymbiont genome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23721879",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 374,
          "offsetInEndSection": 525,
          "text": "Mitochondrial transcription factor A (TFAM) is the main factor packaging mtDNA into nucleoids and is also essential for mtDNA transcription initiation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23721879",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 815,
          "offsetInEndSection": 946,
          "text": "In this review the structure of the mitochondrial nucleoid and its possible regulatory roles in mtDNA expression will be discussed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23721879",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 373,
          "text": "A naked mtDNA molecule is longer than a typical mitochondrion and is therefore compacted in vivo to form a nucleoprotein complex, denoted the mitochondrial nucleoid."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25766410",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 173,
          "offsetInEndSection": 332,
          "text": "The essential role of mitochondria, added to their recently documented capacity to transfer from cell to cell, obviously contributes to their current interest."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25766410",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 333,
          "offsetInEndSection": 473,
          "text": "However, determining the proper role of mitochondria in defined biological contexts was hampered by the lack of suitable experimental tools."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25766410",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 56,
          "text": "Mitochondrial activity is central to tissue homeostasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25766410",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 57,
          "offsetInEndSection": 172,
          "text": "Mitochondria dysfunction constitutes a hallmark of many genetic diseases and plays a key role in tumor progression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25766410",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1063,
          "offsetInEndSection": 1262,
          "text": "The MitoCeption technique, which can be applied to different cell systems, will therefore be a method of choice to analyze the metabolic modifications induced by exogenous mitochondria in host cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642372",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 310,
          "offsetInEndSection": 430,
          "text": "Recent studies demonstrated that ATP can be released from cells in a controlled manner through pannexin (Panx) channels."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642372",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 309,
          "text": "Extracellular ATP is an important signaling molecule throughout the inflammatory cascade, serving as a danger signal that causes activation of the inflammasome, enhancement of immune cell infiltration, and fine-tuning of several signaling cascades including those important for the resolution of inflammation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642372",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 946,
          "offsetInEndSection": 1096,
          "text": "Moreover, extracellular ATP can be broken down by ectonucleotidases into ADP, AMP, and adenosine, which is critical in the resolution of inflammation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642372",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 431,
          "offsetInEndSection": 722,
          "text": "Panx1-mediated ATP release is involved in inflammasome activation and neutrophil/macrophage chemotaxis, activation of T cells, and a role for Panx1 in inducing and propagating inflammation has been demonstrated in various organs, including lung and the central and peripheral nervous system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642372",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 723,
          "offsetInEndSection": 945,
          "text": "The recognition and clearance of dying cells and debris from focal points of inflammation is critical in the resolution of inflammation, and Panx1-mediated ATP release from dying cells has been shown to recruit phagocytes."
        }
      ]
    },
    {
      "id": "67cdc78381b102733300001a",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21786507",
        "http://www.ncbi.nlm.nih.gov/pubmed/23626552",
        "http://www.ncbi.nlm.nih.gov/pubmed/10385057",
        "http://www.ncbi.nlm.nih.gov/pubmed/8987005",
        "http://www.ncbi.nlm.nih.gov/pubmed/12390436",
        "http://www.ncbi.nlm.nih.gov/pubmed/2798270",
        "http://www.ncbi.nlm.nih.gov/pubmed/23880115",
        "http://www.ncbi.nlm.nih.gov/pubmed/27468093",
        "http://www.ncbi.nlm.nih.gov/pubmed/31951513",
        "http://www.ncbi.nlm.nih.gov/pubmed/6308196"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21786507",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Oesophageal atresia is a congenital defect of alimentary tract concerning the interruption of oesophagus with or without connection with the trachea."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21786507",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 620,
          "offsetInEndSection": 919,
          "text": "The authors from different medical specializations: clinical genetics, paediatric surgery, paediatrics and neonatology, paediatric intensive care and palliative medicine, have undertaken a discussion regarding surgical treatment of children with oesophageal atresia and chromosomal, lethal syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21786507",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 448,
          "offsetInEndSection": 619,
          "text": "The aim of this article is a retrospective analysis of the course of treatment of newborn with oesophageal atresia and Edwards syndrome and making of therapeutic decision."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21786507",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 192,
          "text": "Its incidence is 1:3000-3500 of live-born."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21786507",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 398,
          "offsetInEndSection": 447,
          "text": "About 5% of these children live more than 1 year."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23626552",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 326,
          "offsetInEndSection": 397,
          "text": "Treatment choices in advanced HCC arising in adolescence are discussed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23626552",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "This case describes the clinical course and treatment of a 17-year-old male patient with advanced hepatocellular carcinoma (HCC) arising in a non-cirrhotic liver."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23626552",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 325,
          "text": "The disease was thought to be caused by a congenital cholestatic syndrome associated with intermittent oedema in childhood, resembling the rare Aagenaes syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10385057",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 475,
          "offsetInEndSection": 648,
          "text": "All symptoms and signs should disappear within 4 weeks post-partum; prolonged post-partum courses should prompt a search for other causes, such as primary biliary cirrhosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10385057",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Cholestasis of pregnancy is the commonest liver disease unique to pregnancy and is characterized by pruritus in the mother in late pregnancy, without any skin rashes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10385057",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 227,
          "text": "This is accompanied by an elevation of the serum bile acids."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10385057",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 938,
          "offsetInEndSection": 1052,
          "text": "Preliminary studies using ursodeoxycholic acid show symptomatic and biochemical improvement in most women treated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10385057",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1053,
          "offsetInEndSection": 1206,
          "text": "There is also a suggestion of an improved foetal outcome and treatment should be considered in women who present with the condition earlier in pregnancy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8987005",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 534,
          "offsetInEndSection": 678,
          "text": "In a second family, identical multiple atresias occurred in two female siblings born 18 months apart and a third child with a duodenal stenosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8987005",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 56,
          "text": "The familial occurrence of duodenal atresia is uncommon."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8987005",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 818,
          "offsetInEndSection": 974,
          "text": "A history of family occurrence of duodenal atresia should alert the physician to the possibility of associated pathology including immune deficiency states."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8987005",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 57,
          "offsetInEndSection": 263,
          "text": "This study evaluated the inheritance patterns, the nature and associations, and the presence of immunologic deficits in duodenal atresia recurring in at least three siblings each in two nonrelated families."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8987005",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 264,
          "offsetInEndSection": 437,
          "text": "In the first family, an association with Fanconi's anemia was observed in three of seven pregnancies (2 boys, 1 girl) suggesting an autosomal recessive mode of transmission."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12390436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 338,
          "offsetInEndSection": 467,
          "text": "By the age of 12 yr she had developed liver insufficiency and, after a challenging discussion, underwent a liver transplantation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12390436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "An 8-yr-old-patient was diagnosed with COACH syndrome at the moment of her first bleeding episode from esophageal varices."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12390436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 337,
          "text": "Investigations revealed biliary cirrhosis as the cause of portal hypertension, no visible kidney cyst or impairment of renal function, cerebellar dysplasia with non-disabling ataxia, and minimal mental retardation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12390436",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 468,
          "offsetInEndSection": 754,
          "text": "She subsequently developed an abdominal aspergillosis, which required several abdominal explorations and splenectomy as well as 6 months of therapy with liposomal amphotericin B, but survived and in long-term follow-up is in good health, with completed puberty, and has finished school."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2798270",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 320,
          "text": "The average age at death was greater in females than in males."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2798270",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 321,
          "offsetInEndSection": 464,
          "text": "Cardiovascular anomalies were consistently present; ventricular septar defect and patent ductus arteriosus being the most common malformations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2798270",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 257,
          "text": "There was no sex predominance in our series, as opposed to male:female ratios of 1:3 reported in the literature."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2798270",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "The clinical features and morphological findings in 31 Japanese infants with trisomy 18 are presented."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2798270",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 103,
          "offsetInEndSection": 144,
          "text": "The majority were small-for-date infants."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880115",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Crohn's disease (CD) diagnosed in pediatric patients has been reported to have a more aggressive phenotype and course, with a greater prevalence of upper gastrointestinal involvement, than in adults."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880115",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1942,
          "offsetInEndSection": 2113,
          "text": "Our data show that although children are at increased risk of panenteric disease, they are not more likely to have more complicated disease or undergo surgery than adults."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880115",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 880,
          "offsetInEndSection": 1034,
          "text": "Within 1 year of diagnosis, a higher proportion of A1 patients had upper gastrointestinal involvement and ileocolonic (L3) disease than A2 or A3 patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880115",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 598,
          "offsetInEndSection": 879,
          "text": "For specific time intervals, we determined types and numbers of imaging studies performed and parameters of disease phenotype, including age at diagnosis according to the Montreal classification (A1 diagnosed <17 years of age, A2 diagnosed 17-40 years, and A3 diagnosed >40 years)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880115",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 273,
          "offsetInEndSection": 389,
          "text": "We aimed to discern whether, in fact, CD diagnosed in childhood has a different outcome than CD diagnosed in adults."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468093",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 739,
          "offsetInEndSection": 809,
          "text": "Hepatocellular carcinoma (HCC) develops in up to 3.5% of PBC patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468093",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 993,
          "offsetInEndSection": 1110,
          "text": "40% of PBC patients do not respond adequately to UDCA, and these patients are at high risk for serious complications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468093",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 183,
          "text": "The disease affects mainly women."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468093",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Primary biliary cholangitis (PBC) is an autoimmune disease of the liver characterized by destruction and inflammation of the intrahepatic bile ducts."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468093",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 680,
          "offsetInEndSection": 738,
          "text": "PBC can progress to cirrhosis and end-stage liver disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31951513",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 453,
          "offsetInEndSection": 577,
          "text": "Most cancers arise in the gallbladder or dilated common bile duct, suggesting that bile stasis is related to carcinogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31951513",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 176,
          "offsetInEndSection": 241,
          "text": "A major issue in patients with PBM is the risk of biliary cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31951513",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "Pancreaticobiliary maljunction (PBM) is a congenital malformation in which the pancreatic and bile ducts join outside the duodenal wall, usually forming a long common channel."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31951513",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1154,
          "offsetInEndSection": 1331,
          "text": "For early diagnosis, the presence of extrahepatic bile duct dilatation or gallbladder wall thickening may provide a clue to PBM with or without biliary dilatation, respectively."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31951513",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1425,
          "offsetInEndSection": 1594,
          "text": "Radiologists should also carefully evaluate follow-up images in PBM patients even years after prophylactic surgery because residual bile ducts remain at risk for cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1075,
          "offsetInEndSection": 1321,
          "text": "Our study suggests that neurologic injury may occur during the first two years of life in vitamin E-deficient children with cholestatic hepatobiliary disease, obligating aggressive attempts at correcting this deficiency state at a very young age."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 291,
          "offsetInEndSection": 420,
          "text": "To establish the age of onset of neuropathologic lesions, we prospectively evaluated four young children with severe cholestasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Vitamin E malabsorption and deficiency during chronic childhood cholestasis has been associated with a progressive ataxic neurologic syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 290,
          "text": "Hyporeflexia, the first sign of neurologic dysfunction, may begin prior to age 2 years, but severe symptoms do not develop until age 5 to 10 years."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308196",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 849,
          "offsetInEndSection": 1008,
          "text": "Sural nerve histology at age 6 to 25 months revealed a degenerative axonopathy involving large-caliber myelinated fibers, but without quantitative axonal loss."
        }
      ]
    },
    {
      "id": "67d7ff2c18b1e36f2e000049",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23767452",
        "http://www.ncbi.nlm.nih.gov/pubmed/15981987",
        "http://www.ncbi.nlm.nih.gov/pubmed/23567359",
        "http://www.ncbi.nlm.nih.gov/pubmed/16313685",
        "http://www.ncbi.nlm.nih.gov/pubmed/20036949",
        "http://www.ncbi.nlm.nih.gov/pubmed/23496382",
        "http://www.ncbi.nlm.nih.gov/pubmed/21159258",
        "http://www.ncbi.nlm.nih.gov/pubmed/21438963",
        "http://www.ncbi.nlm.nih.gov/pubmed/37546121",
        "http://www.ncbi.nlm.nih.gov/pubmed/12485471"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23767452",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 650,
          "offsetInEndSection": 818,
          "text": "The symptoms of gluten sensitivity may also have another genetic background of food intolerance independent of the HLADQ2, -\u200aDQ8 system and tissue transglutaminase (eg."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23767452",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 473,
          "offsetInEndSection": 649,
          "text": "The differences between celiac disease and gluten intolerance include permeability of the intestinal mucosal barrier, histology of duodenal biopsy, and mucosal gene expression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23767452",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 303,
          "offsetInEndSection": 387,
          "text": "Gluten sensitivity is a recently defined entity induced by innate immune mechanisms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23767452",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 220,
          "text": "This protein complex is involved in pathogenesis of wheat allergy, celiac disease, and gluten sensitivity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23767452",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 388,
          "offsetInEndSection": 472,
          "text": "These subjects present various intestinal and particularly extraintestinal symptoms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15981987",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Gluten enteropathy is a chronic all-life disease, characterized by typical inflammatory changes of the small bowel mucosa."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15981987",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 802,
          "offsetInEndSection": 929,
          "text": "Coeliac disease and dermatitis herpetiformis are considered to be two identical forms of the gluten enteropathy manifestations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15981987",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 212,
          "text": "It is the genetically determined autoimmune disease with permanent intolerance to gluten."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15981987",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 930,
          "offsetInEndSection": 1073,
          "text": "Coeliac disease is frequently associated with other autoimmune diseases--diabetes mellitus, autoimmune thyreoiditis, hepatitis, IgA deficiency."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15981987",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 213,
          "offsetInEndSection": 319,
          "text": "Its clinical signs are very heterogeneous and also the severity of intestinal changes varies considerably."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 895,
          "offsetInEndSection": 1120,
          "text": "There is a great interest in the role of a major dietary protein, gluten, in the production of symptoms that are very similar to those of patients with celiac disease without the enteropathy that characterizes celiac disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1121,
          "offsetInEndSection": 1311,
          "text": "Emerging research into a syndrome known as nonceliac gluten sensitivity suggests a heterogeneous condition with some features of celiac disease but often categorized as FGIDs, including IBS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 231,
          "text": "Food intolerance is a common complaint amongst patients with functional gastrointestinal (GI) disorders (FGIDs), including those with irritable bowel syndrome (IBS), functional dyspepsia, as well as gastroesophageal reflux disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 619,
          "offsetInEndSection": 727,
          "text": "Lactose intolerance is common in the general population and can mimic symptoms of FGID or coexist with FGID."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 376,
          "offsetInEndSection": 512,
          "text": "However, the prevalence of food allergy is sufficiently high that patients with FGID may also have food allergies or hypersensitivities."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16313685",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Coeliac disease is a lifelong intolerance to the gluten found in wheat, barley and rye, and some patients are also sensitive to oats."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16313685",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1942,
          "offsetInEndSection": 2050,
          "text": "However, risk of these complications diminishes very considerably in patients who are on a gluten-free diet."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16313685",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 665,
          "offsetInEndSection": 840,
          "text": "Coeliac disease is the major diagnosable food intolerance and, with the advent of a simple blood test for case finding, prevalence rates are thought to be approximately 1:100."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16313685",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1325,
          "offsetInEndSection": 1410,
          "text": "Diet is the key to management and a gluten-free diet effectively cures the condition."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16313685",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1648,
          "offsetInEndSection": 1786,
          "text": "Patients with minor symptoms, who are found incidentally to have coeliac disease, often ask whether it is necessary to adhere to the diet."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20036949",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 472,
          "text": "Gluten intolerance is a unique model of autoimmune disease in which we can recognize the main environmental factor (gluten) and the more complex genetic background."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20036949",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 82,
          "offsetInEndSection": 172,
          "text": "It is a permanent food intolerance to ingested gluten in genetically predisposed subjects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20036949",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 473,
          "offsetInEndSection": 610,
          "text": "In additional way, serological markers for monitoring the disease and a safe and effective therapy (gluten free diet) are also available."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20036949",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 611,
          "offsetInEndSection": 727,
          "text": "In deed the environmental factor such as gluten intake is necessary to trigger the disease but genetics also matter."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20036949",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 173,
          "offsetInEndSection": 307,
          "text": "In this review we analyze the biochemical markers of the disease going from laboratory findings to histology passing through genetics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 328,
          "text": "Triggered by the ingestion of gluten in genetically predisposed individuals, this enteropathy may appear at any age, and is characterized by a wide variety of clinical signs and symptoms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 329,
          "offsetInEndSection": 551,
          "text": "Among them, gastrointestinal presentations include chronic diarrhea, abdominal pain, weight loss or failure to thrive in children; but extra-intestinal manifestations are also common, and actually appear to be on the rise."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Celiac disease, with a prevalence around 1% of the general population, is the most common genetically-induced food intolerance in the world."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1094,
          "offsetInEndSection": 1275,
          "text": "A positive subject will then be confirmed by an intestinal biopsy, and will then be put on a strict gluten-free diet, that in most cases will bring a marked improvement of symptoms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 552,
          "offsetInEndSection": 765,
          "text": "They include a large variety of ailments, such as dermatitis Herpetiformis, anemia, short stature, osteoporosis, arthritis, neurologic problems, unexplained elevation of transaminases, and even female infertility."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21159258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Dermatitis herpetiformis is an autoimmune blistering disease that appears as a cutaneous manifestation of gluten intolerance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21159258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 243,
          "text": "It is one of a group of disorders that have gluten sensitivity in common, including celiac disease and gluten ataxia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21159258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 627,
          "offsetInEndSection": 845,
          "text": "Treatment of dermatitis herpetiformis is based on a life-long, strict gluten-free diet, which improves all clinical aspects of gluten sensitivity, and dapsone, a drug that is only effective for the skin manifestations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21159258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 370,
          "offsetInEndSection": 504,
          "text": "Immunological studies demonstrate the presence of specific immunoglobulin (Ig) A anti-endomysial and anti-transglutaminase antibodies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21159258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 505,
          "offsetInEndSection": 626,
          "text": "The finding of granular deposits of IgA along the dermal-epidermal junction is pathognomonic of dermatitis herpetiformis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21438963",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 588,
          "offsetInEndSection": 1023,
          "text": "Since the participation of gluten in the esophageal symptoms of CD seems clear, its intimate mechanisms have yet to be elucidated, and several hypothesis have been proposed, including the specific immune alterations characterizing CD, the reduction in nutrient absorption determining the arrival of intact gluten to distal gastrointestinal segments, and various dysregulations in the function of gastrointestinal hormones and peptides."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21438963",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 411,
          "offsetInEndSection": 587,
          "text": "In addition, several published studies have consistently shown the efficacy of a gluten-free diet in rapidly controlling esophageal symptoms and in preventing their recurrence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21438963",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Celiac disease (CD) may often be associated with various motor disorders affecting the different segments of the digestive tract, including the esophagus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21438963",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 410,
          "text": "Although it has not been universally reported, some available evidences indicate that pediatric and adult celiac patients could manifest a higher frequency of esophagitis and gastroesophageal reflux disease-related symptoms compared to nonceliac patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21438963",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1024,
          "offsetInEndSection": 1177,
          "text": "Recent studies have suggested the existence of a possible relationship between CD and eosinophilic esophagitis, which should be more deeply investigated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37546121",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 356,
          "text": "While gastrointestinal (GI) symptoms are commonly associated with CD, atypical presentations can pose diagnostic challenges, particularly when hematological abnormalities are the primary manifestation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37546121",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Celiac disease (CD) is a chronic autoimmune disorder characterized by an immune-mediated response to gluten, resulting in small intestinal mucosal damage."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37546121",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1041,
          "offsetInEndSection": 1209,
          "text": "Prompt recognition and appropriate management, including adherence to a gluten-free diet, can lead to symptom improvement and resolution of hematological abnormalities."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37546121",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 631,
          "offsetInEndSection": 720,
          "text": "GI symptoms were absent, and there was no family history of gastroenterological diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37546121",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 862,
          "offsetInEndSection": 1040,
          "text": "This case emphasizes the significance of considering CD as a potential cause for atypical hematological manifestations, such as extreme thrombocytosis secondary to severe anemia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 290,
          "offsetInEndSection": 348,
          "text": "The symptoms in both forms are dependent on gluten intake."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Gluten sensitive enteropathy has various manifestations, of which the two major forms are classical coeliac disease (cCD) and dermatitis herpetiformis (DH)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1158,
          "offsetInEndSection": 1261,
          "text": "The non-HLA DR;DQ factors are critical for the different clinical manifestations of gluten sensitivity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 157,
          "offsetInEndSection": 289,
          "text": "In cCD predominantly the small intestine is affected, whereas in DH also the skin is affected showing typical rash and IgA deposits."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 849,
          "offsetInEndSection": 1157,
          "text": "Results from the Finnish family material with 25 discordant and 85 concordant sib pairs, and from additional case-control material comprising 71 unrelated Hungarian DH and 68 cCD patients, together indicated that the HLA DQ locus did not differ between the two major outcomes of gluten sensitive enteropathy."
        }
      ]
    },
    {
      "id": "680a084018b1e36f2e00014e",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
        "http://www.ncbi.nlm.nih.gov/pubmed/26857494",
        "http://www.ncbi.nlm.nih.gov/pubmed/27377536",
        "http://www.ncbi.nlm.nih.gov/pubmed/15800022",
        "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
        "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
        "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
        "http://www.ncbi.nlm.nih.gov/pubmed/25267439",
        "http://www.ncbi.nlm.nih.gov/pubmed/37983289",
        "http://www.ncbi.nlm.nih.gov/pubmed/12529926"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "Immune cell infiltration to the brain's territory was considered for decades to reflect a pathological process in which immune cells attack the central nervous system (CNS); such a process is observed in the inflammatory autoimmune disease, multiple sclerosis (MS)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 758,
          "offsetInEndSection": 961,
          "text": "Specifically, autoimmune T cells were found to facilitate CNS healing processes, such as in the case of sterile mechanical injuries to the brain or the spinal cord, mental stress, or biochemical insults."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 962,
          "offsetInEndSection": 1212,
          "text": "Even more intriguingly, autoimmune T cells were found to be involved in supporting fundamental processes of brain functional integrity, such as in the maintenance of life-long brain plasticity, including spatial learning and memory, and neurogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1970,
          "offsetInEndSection": 2169,
          "text": "Accordingly, we propose that fighting off acute and chronic neurodegenerative conditions requires breaking peripheral immune tolerance to CNS self-antigens, in order to boost protective autoimmunity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 266,
          "offsetInEndSection": 612,
          "text": "As neuroinflammatory processes within the CNS parenchyma are also common to other CNS pathologies, regardless of their etiology, including neurodegenerative disorders such as Alzheimer's disease (AD) and Amyotrophic lateral sclerosis (ALS), these pathologies have often been compared to MS, a disease that benefits from immunosuppressive therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26857494",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 185,
          "text": "However, it remains unknown whether B cells can orchestrate Th17-mediated responses against neuro-antigens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26857494",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 355,
          "offsetInEndSection": 582,
          "text": "Notwithstanding these similarities, the application of an in vitro assay demonstrated that the B cells derived from a subset of MS patients exhibited the capability of coordinating Th17 responses directed toward neuro-antigens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26857494",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 186,
          "offsetInEndSection": 354,
          "text": "We report that MS patients and healthy donors had a similar frequency of antigen-specific Th1 and Th17 cells, and distribution of T effector and T central memory cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26857494",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 583,
          "offsetInEndSection": 691,
          "text": "These observations underscore the B cell's contribution to the putative underpinnings of multiple sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26857494",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "B cells are highly potent antigen presenting cells of their cognate antigens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377536",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "Multiple sclerosis (MS) is believed to be initiated when myelin-specific T cells infiltrate the central nervous system (CNS), triggering subsequent recruitment of inflammatory leukocytes to the CNS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377536",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 444,
          "text": "The contribution of neutrophils to CNS autoimmune disease has been underappreciated, but several studies in experimental autoimmune encephalomyelitis (EAE), an animal model of MS, indicate that neutrophils have an important role in inflammation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377536",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 590,
          "offsetInEndSection": 693,
          "text": "Neutrophils may also influence the manifestation of EAE by facilitating parenchymal brain inflammation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377536",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 445,
          "offsetInEndSection": 589,
          "text": "Neutrophils are hypothesized to contribute to the pathogenesis of EAE by producing cytokines and promoting breakdown of the blood brain barrier."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377536",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 694,
          "offsetInEndSection": 882,
          "text": "This review summarizes evidence supporting a functional role for neutrophils in EAE and MS, highlighting the differential regulation of neutrophil recruitment in the brain and spinal cord."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15800022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 467,
          "offsetInEndSection": 581,
          "text": "B cells were detected in the CSF of multiple sclerosis and IND patients, but were largely absent in NIND patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15800022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 287,
          "text": "Although intrathecal immunoglobulin G (IgG) synthesis is a key feature of the disease, little is still known about the B cell response in the CNS of multiple sclerosis patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15800022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 288,
          "offsetInEndSection": 466,
          "text": "We analysed the phenotype and kinetics of different B cell subsets in patients with multiple sclerosis, infectious disease (IND) and non-inflammatory neurological disease (NIND)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15800022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 838,
          "offsetInEndSection": 1029,
          "text": "While PB disappeared rapidly from the CSF after resolution of infection in IND patients, these cells were present at high numbers throughout the disease course in multiple sclerosis patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15800022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 582,
          "offsetInEndSection": 734,
          "text": "In the CSF, the majority of B cells had a phenotype of memory B cells and short-lived plasma blasts (PB); plasma cells were absent from the compartment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 222,
          "offsetInEndSection": 527,
          "text": "Data suggesting that B cells play a role in the pathogenesis of multiple sclerosis have been accumulating for the past five decades, demonstrating that the cerebrospinal fluid and central nervous system tissues of multiple sclerosis patients contain B cells, plasma cells, antibodies, and immunoglobulins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 221,
          "text": "Until recently, most studies have emphasized the role of T cells in the pathogenesis of multiple sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 528,
          "offsetInEndSection": 726,
          "text": "Data suggest that B cells are involved in antigen capture and presentation to T cells, cytokine production, antibody secretion, demyelination, tissue damage, and remyelination in multiple sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system with no clear etiology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 727,
          "offsetInEndSection": 894,
          "text": "These advances in the understanding of B-cell and antibody roles in the pathophysiology of multiple sclerosis provide a strong rationale for B-cell-targeted therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 293,
          "offsetInEndSection": 508,
          "text": "Prior work indicates that presence of B cells is fostered within the inflamed MS central nervous system (CNS) environment, and that B cell-rich immune cell collections may be present within the meninges of patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 692,
          "offsetInEndSection": 891,
          "text": "Elucidating the characteristics of B cells that populate the MS CNS, how they traffic into the CNS and how they may contribute to progressive forms of the disease has become of considerable interest."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1194,
          "offsetInEndSection": 1327,
          "text": "We will further describe the different barriers of the CNS and the possible mechanisms of migration of B cells across these barriers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 892,
          "offsetInEndSection": 1193,
          "text": "Here, we will review characteristics of human B cells identified within distinct CNS subcompartments of patients with MS, including the cerebrospinal fluid, parenchymal lesions, and meninges, as well as the relationship between B cell populations identified in these subcompartments and the periphery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1328,
          "offsetInEndSection": 1585,
          "text": "Finally, we will consider the range of human B cell responses (including potential for antibody production, cytokine secretion, and antigen presentation) that may contribute to propagating inflammation and injury cascades thought to underlie MS progression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 503,
          "offsetInEndSection": 707,
          "text": "A growing body of evidence shows that Tregs are not only important for maintaining immune balance at the periphery but also contribute to self-tolerance and immune privilege in the central nervous system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 941,
          "offsetInEndSection": 1185,
          "text": "Interestingly, a dysfunction of Tregs is mainly observed in the early stages of several neurodegenerative diseases, but not in their chronic stages, pointing to a causative role of inflammation in the pathogenesis of neurodegenerative diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 839,
          "offsetInEndSection": 940,
          "text": "We then discuss the evidence supporting a dysfunction of Tregs in several neurodegenerative diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 232,
          "offsetInEndSection": 502,
          "text": "A specific subset of T cells, currently recognized as FOXP3(+) CD25(+) CD4(+) regulatory T cells (Tregs), are pivotal in suppressing autoimmunity and maintaining immune homeostasis by mediating self-tolerance at the periphery as shown in autoimmune diseases and cancers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1186,
          "offsetInEndSection": 1384,
          "text": "Furthermore, we provide an overview of a number of molecules, such as hormones, neuropeptides, neurotransmitters, or ion channels, that affect the dysfunction of Tregs in neurodegenerative diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25267439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) typically characterized by the recruitment of T cells into the CNS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25267439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 430,
          "offsetInEndSection": 580,
          "text": "No differences in the frequencies of the B-cell subsets or in their ability to secrete cytokines were observed between MS and healthy volunteers (HV)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25267439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 317,
          "text": "However, certain subsets of B cells have been shown to negatively regulate autoimmune diseases and some data support a prominent role for B cells in MS physiopathology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25267439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 831,
          "text": "Altogether, our data show that, in our MS patient cohort, regulatory B cells have conserved frequency and function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25267439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 581,
          "offsetInEndSection": 715,
          "text": "Prestimulated B cells from MS patients also inhibited CD4(+)CD25(-) T cell proliferation with a similar efficiency as B cells from HV."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37983289",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1683,
          "offsetInEndSection": 1794,
          "text": "Lastly, we found that the pathological B cell responses we observed in the meninges required the presence of T."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37983289",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1970,
          "offsetInEndSection": 2064,
          "text": "Taken together, our data provide evidence that the meningeal immune response during chronic T."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37983289",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1081,
          "offsetInEndSection": 1256,
          "text": "Furthermore, the B cells found in the infected meninges produced high-affinity autoantibodies able to recognise mouse brain antigens, in a process dependent on LT\u03b2 signalling."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37983289",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1450,
          "offsetInEndSection": 1682,
          "text": "In humans, we identified the presence of autoreactive IgG antibodies in the cerebrospinal fluid (CSF) of second stage HAT patients that recognised human brain lysates and MBP, consistent with our findings in experimental infections."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37983289",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2234,
          "offsetInEndSection": 2527,
          "text": "These findings have wider implications for understanding the mechanisms underlying the formation ELAs during chronic inflammation resulting in autoimmunity in mice and humans, as observed in other autoimmune neurodegenerative disorders, including neuropsychiatric lupus and multiple sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Lymphocyte recruitment to the central nervous system (CNS) is a critical step in the pathogenesis of diseases such as multiple sclerosis (MS), meningitis and posterior uveitis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1118,
          "offsetInEndSection": 1297,
          "text": "In this article we review current understanding of endothelial cell ICAM-1 signalling and discuss the importance of these findings in relation to leucocyte trafficking to the CNS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 831,
          "offsetInEndSection": 1117,
          "text": "In particular, it has been shown that ICAM-1-mediated signalling in brain endothelial cells is a crucial regulatory step in the process of lymphocyte migration through the blood-brain barrier and as such represents an additional phase in the multistep paradigm of leucocyte recruitment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 424,
          "text": "The principle sequential stages that control lymphocyte emigration from the blood have been widely reported, but only recently has attention been directed towards the role of the vascular endothelium in actively supporting transvascular migration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 830,
          "text": "Engagement of these receptors initiates endothelial signalling cascades that result in downstream effector mechanisms which in turn influence the progression of neuroinflammation."
        }
      ]
    },
    {
      "id": "67cde41a81b102733300001d",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26543426",
        "http://www.ncbi.nlm.nih.gov/pubmed/22857835",
        "http://www.ncbi.nlm.nih.gov/pubmed/23438422",
        "http://www.ncbi.nlm.nih.gov/pubmed/21369385",
        "http://www.ncbi.nlm.nih.gov/pubmed/23732207",
        "http://www.ncbi.nlm.nih.gov/pubmed/10720930",
        "http://www.ncbi.nlm.nih.gov/pubmed/22736301",
        "http://www.ncbi.nlm.nih.gov/pubmed/24026180",
        "http://www.ncbi.nlm.nih.gov/pubmed/2669121",
        "http://www.ncbi.nlm.nih.gov/pubmed/20566568"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26543426",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "This article reviews the relationship between metabolic syndrome (MetS) and nephrolithiasis, as well as the clinical implications for patients with this dual diagnosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26543426",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 856,
          "offsetInEndSection": 1108,
          "text": "Current American Urological Association and European Association of Urology guidelines suggest investigating the etiology of nephrolithiasis in affected individuals; however, there is no specific goal of treating MetS as part of the medical management."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26543426",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 633,
          "offsetInEndSection": 855,
          "text": "Urologic complications of MetS include a 30% higher risk of nephrolithiasis, with an increased percentage of uric acid nephrolithiasis in the setting of hyperuricemia, hyperuricosuria, low urine pH, and low urinary volume."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26543426",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1306,
          "offsetInEndSection": 1419,
          "text": "These recommendations may offer a beneficial adjunctive treatment option for nephrolithiasis complicated by MetS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26543426",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1674,
          "offsetInEndSection": 1766,
          "text": "These recommendations should accompany the currently accepted management of nephrolithiasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857835",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Childhood urolithiasis is an evolving condition with an increasing incidence and prevalence over the last 2 decades."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857835",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 219,
          "offsetInEndSection": 374,
          "text": "This review describes the pathophysiology, underlying metabolic abnormalities, clinical presentation, evaluation, and management of childhood urolithiasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857835",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 375,
          "offsetInEndSection": 561,
          "text": "A comprehensive metabolic evaluation is essential for all children with renal calculi, given the high rate of recurrence and the importance of excluding inherited progressive conditions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857835",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 218,
          "text": "Over that time the underlying cause has shifted from predominantly infectious to metabolic in nature."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23438422",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Kidney stones are a common problem worldwide with substantial morbidities and economic costs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23438422",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 149,
          "text": "Medical therapy reduces stone recurrence significantly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23438422",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1111,
          "offsetInEndSection": 1185,
          "text": "Allopurinol is used in calcium oxalate stone formers with hyperuricosuria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23438422",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 244,
          "text": "Much progress has been made in the last several decades in improving therapy of stone disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23438422",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 467,
          "offsetInEndSection": 571,
          "text": "Fluid intake to promote urine volume of at least 2.5 L each day is essential to prevent stone formation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21369385",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Nephrolithiasis is associated with a variety of abnormalities in urinary composition."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21369385",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 365,
          "offsetInEndSection": 430,
          "text": "Dietary factors play an important role in kidney stone formation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21369385",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 714,
          "offsetInEndSection": 905,
          "text": "Urine flow of >1 ml/kg/h almost eliminates the risk of supersaturation for calcium oxalate, calcium phosphate and uric acid, thus protecting from the formation of corresponding kidney stones."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21369385",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 302,
          "text": "Stone disease is morbid and costly, and the recurrence rates may be as high as 30-50% after 5 years."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21369385",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 303,
          "offsetInEndSection": 364,
          "text": "Efforts to prevent stone formation are, therefore, essential."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23732207",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1267,
          "offsetInEndSection": 1414,
          "text": "In conclusion, diet is a key element in the management of the patient with kidney stones but always subordinated to present metabolic risk factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23732207",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "The composition of urine is influenced by diet and changes in dietary factors have been proposed to modify the risk of recurrent nephrolithiasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23732207",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 735,
          "offsetInEndSection": 868,
          "text": "Observational studies have shown a positive and independent association between sodium intake and the formation of new kidney stones."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23732207",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1137,
          "offsetInEndSection": 1266,
          "text": "In prospective observational studies, diets rich in magnesium were associated with a lower risk of kidney stone formation in men."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23732207",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 869,
          "offsetInEndSection": 1059,
          "text": "Consumption of animal protein creates an acid load that increases urinary excretion of calcium and uric acid and reduced citrate, all factors that could participate in the genesis of stones."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10720930",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Renal stone disease, which affects 12% of males and 5% of females by the seventh decade, occurs as an inherited disorder in 45% of patients and is most commonly associated with hypercalciuria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10720930",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 523,
          "offsetInEndSection": 730,
          "text": "These two disorders, which represent unusual forms of the renal Fanconi syndrome, are characterized by a low molecular weight proteinuria, hypercalciuria, nephrocalcinosis, nephrolithiasis and renal failure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10720930",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 193,
          "offsetInEndSection": 353,
          "text": "The biochemical basis for hereditary nephrolithiasis and hypercalciuria is unknown, and this has therefore been investigated by a \"positional cloning\" approach."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10720930",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2033,
          "offsetInEndSection": 2142,
          "text": "Thus, four hereditary disorders of nephrolithiasis are due to mutations of the novel chloride channel, CLCN5."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10720930",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1725,
          "offsetInEndSection": 2032,
          "text": "In addition, such CLCN5 mutations that would result in a functional loss have also been demonstrated in Japanese children with idiopathic low molecular weight proteinuria, hypercalciuria and nephrocalcinosis, and an Italian kindred with X-linked recessive hypophosphatemic rickets (XLRH) and hypercalciuria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "Renal cysts are a common radiological finding in both adults and children."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 186,
          "offsetInEndSection": 326,
          "text": "In this article, we discuss the major causes of renal cysts in children and adults with a particular focus on the most common genetic forms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 405,
          "offsetInEndSection": 544,
          "text": "We consider the evidence for a universal 'cilia hypothesis' for cyst formation and the evidence for non-ciliary proteins in cyst formation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 75,
          "offsetInEndSection": 185,
          "text": "They occur in a variety of conditions, and the clinical presentation, management, and prognosis varies widely."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 327,
          "offsetInEndSection": 404,
          "text": "Many cystoproteins have been localized to the cilia centrosome complex (CCC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24026180",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 666,
          "text": "However, not all patients with type 2 diabetes develop kidney stones, suggesting that uric acid stone formers may have additional urinary defects, perhaps not apparent at baseline."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24026180",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "text": "Idiopathic uric acid nephrolithiasis is characterized by elevated urinary net acid excretion and insufficient buffering by ammonium, resulting in excessively acidic urine and titration of the relatively soluble urate anion to insoluble uric acid."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24026180",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1009,
          "offsetInEndSection": 1266,
          "text": "Uric acid stone formers had a lower ammonium excretory response to acute acid loading compared with diabetic and nondiabetic nonstone formers, suggesting that an ammonium excretory defect unique to uric acid stone formers was unmasked by the acid challenge."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24026180",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 667,
          "offsetInEndSection": 848,
          "text": "We performed a metabolic study of 14 patients with idiopathic uric acid nephrolithiasis, 13 patients with type 2 diabetes, and 8 healthy control subjects of similar body mass index."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24026180",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 247,
          "offsetInEndSection": 485,
          "text": "Patients with type 2 diabetes have similar changes in urinary pH, net acid excretion, and ammonium in 24-h urine collections at baseline, even after controlling for dietary factors, and are at increased risk for uric acid nephrolithiasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669121",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Hyperoxaluria and hypercalciuria are common features of renal calcium stone disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669121",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 403,
          "offsetInEndSection": 543,
          "text": "Hyperoxaluria was associated with a higher frequency of both stone episodes and stone operations than a lower urinary oxalate concentration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669121",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1336,
          "offsetInEndSection": 1515,
          "text": "In most recurrent renal stone formers the urinary calcium concentration was increased, with an inverse relationship to serum PTH, indicating intestinal hyperabsorption of calcium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669121",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1720,
          "offsetInEndSection": 1948,
          "text": "Two different mechanisms of similar prevalence might explain enhanced secretion of PTH in normocalcaemic stone disease, namely reduced calcium absorption and a renal defect in the form of reduced tubular reabsorption of calcium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669121",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 544,
          "offsetInEndSection": 743,
          "text": "Patients with idiopathic stone disease showed increased intestinal uptake of both oxalate and calcium, which was probably of importance for their propensity to form calcium oxalate-containing stones."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20566568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 631,
          "offsetInEndSection": 768,
          "text": "In this review, we discuss the association between bariatric surgery, an increased risk of renal stone formation and oxalate nephropathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20566568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 547,
          "offsetInEndSection": 630,
          "text": "The main risk factor for nephrolithiasis is increased excretion of urinary oxalate."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20566568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 280,
          "offsetInEndSection": 546,
          "text": "Despite the fact that bariatric surgery-induced weight loss is associated with a significant decrease in morbidity and mortality and improvement in renal function, bariatric surgery has recently been shown to be associated with a significant risk of nephrolithiasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20566568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 279,
          "text": "Importantly, bariatric surgery is regarded as the only therapy that is effective in maintaining significant weight loss in morbidly obese individuals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20566568",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Medical treatment of obesity and lifestyle modification have limited effectiveness in treating it in morbidly obese individuals."
        }
      ]
    },
    {
      "id": "67e2b80618b1e36f2e00008f",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24126522",
        "http://www.ncbi.nlm.nih.gov/pubmed/21687806",
        "http://www.ncbi.nlm.nih.gov/pubmed/18447956",
        "http://www.ncbi.nlm.nih.gov/pubmed/20204066",
        "http://www.ncbi.nlm.nih.gov/pubmed/19863554",
        "http://www.ncbi.nlm.nih.gov/pubmed/12474416",
        "http://www.ncbi.nlm.nih.gov/pubmed/21607086",
        "http://www.ncbi.nlm.nih.gov/pubmed/26463167",
        "http://www.ncbi.nlm.nih.gov/pubmed/18304778",
        "http://www.ncbi.nlm.nih.gov/pubmed/21441598"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126522",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 652,
          "offsetInEndSection": 664,
          "text": "pneumophila."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126522",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Upon entry of Legionella pneumophila into amoebas and macrophages, host-mediated farnesylation of the AnkB effector enables its anchoring to the Legionella-containing vacuole (LCV) membrane."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126522",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 969,
          "offsetInEndSection": 1191,
          "text": "pneumophila to human monocyte-derived macrophages (hMDMs), the host farnesylation and ubiquitination machineries are recruited by the Dot/Icm system to the plasma membrane exclusively beneath sites of bacterial attachment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126522",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 436,
          "offsetInEndSection": 651,
          "text": "pneumophila to exhibit a starvation response and differentiate into the nonreplicative phase in response to the basal levels of cellular amino acids that are not sufficient to power intracellular proliferation of L."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126522",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1561,
          "offsetInEndSection": 1851,
          "text": "Our data represent a novel strategy by an intracellular pathogen that triggers rapid nutritional remodeling of the host cell upon attachment to the plasma membrane, and as a result, a gratuitous surplus of cellular amino acids is generated to support proliferation of the incoming pathogen."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "The tularemia-causing bacterium Francisella tularensis is a facultative intracellular organism with a complex intracellular lifecycle that ensures its survival and proliferation in a variety of mammalian cell types, including professional phagocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 524,
          "offsetInEndSection": 707,
          "text": "Studies of various strains and host cell models have led to the consensual paradigm of Francisella as a cytosolic pathogen, but also to some controversy about its intracellular cycle."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 251,
          "offsetInEndSection": 523,
          "text": "Because this cycle is essential to Francisella pathogenesis and virulence, much research has focused on deciphering the mechanisms of its intracellular survival and replication and characterizing both bacterial and host determinants of the bacterium's intracellular cycle."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687806",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 708,
          "offsetInEndSection": 964,
          "text": "In this review, we will detail major findings that have advanced our knowledge of Francisella intracellular survival strategies and also attempt to reconcile discrepancies that exist in our molecular understanding of the Francisella-phagocyte interactions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1060,
          "offsetInEndSection": 1072,
          "text": "pneumophila."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Legionella pneumophila pneumonia often exacerbates acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1099,
          "offsetInEndSection": 1215,
          "text": "pneumophila grew within A549 alveolar epithelial cells and induced subsequent cell death in a dose-dependent manner."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 346,
          "offsetInEndSection": 376,
          "text": "pneumophila undergo apoptosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 535,
          "offsetInEndSection": 770,
          "text": "pneumophila-infected A549 alveolar epithelial cells were assessed using the terminal deoxyribonucleotidyl transferase-mediated triphosphate (dUTP)-biotin nick end labeling method (TUNEL method) and colorimetric caspase activity assays."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20204066",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Listeriosis is an emerging zoonotic infection of humans and ruminants worldwide caused by Listeria monocytogenes (LM)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20204066",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 313,
          "offsetInEndSection": 426,
          "text": "This review discusses the current knowledge about listeric encephalitis, and involved host and bacterial factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20204066",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 119,
          "offsetInEndSection": 312,
          "text": "In both host species, CNS disease accounts for the high mortality associated with listeriosis and includes rhombencephalitis, whose neuropathology is strikingly similar in humans and ruminants."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20204066",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 536,
          "offsetInEndSection": 693,
          "text": "Such studies will provide a basis for the development of new therapeutic strategies that aim to prevent LM from invading the brain and spread within the CNS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20204066",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 427,
          "offsetInEndSection": 535,
          "text": "There is an urgent need to study the molecular mechanisms of neuropathogenesis, which are poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863554",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Francisella tularensis is a highly infectious intracellular bacterium that causes the fulminating disease tularemia, which can be transmitted between mammals by arthropod vectors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863554",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 783,
          "offsetInEndSection": 1007,
          "text": "The Francisella pathogenicity island, which potentially encodes a putative type VI secretion system, is essential for phagosome biogenesis and bacterial escape into the cytosol within macrophages and arthropod-derived cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863554",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 353,
          "offsetInEndSection": 479,
          "text": "tularensis into macrophages is mediated by looping phagocytosis and is associated with signalling through Syk tyrosine kinase."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863554",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 480,
          "offsetInEndSection": 782,
          "text": "Within macrophages and arthropod-derived cells, the Francisella-containing phagosome matures transiently into an acidified late endosome-like phagosome with limited fusion to lysosomes followed by rapid bacterial escape into the cytosol within 30-60 min, and bacterial proliferation within the cytosol."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863554",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1265,
          "offsetInEndSection": 1426,
          "text": "The past few years have witnessed a quantum leap in our understanding of various aspects of this organism and this review will discuss these remarkable advances."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12474416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 402,
          "offsetInEndSection": 560,
          "text": "The person with pneumonic symptoms may be a source of a droplet-borne inhalatory infection for other people who consequently develop primary pneumonic plague."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12474416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Plague is an infectious disease caused by the Yersinia pestis microorganism, which is transmitted to the human host from a natural reservoir (different rodent species) by a flea bite."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12474416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 877,
          "offsetInEndSection": 1035,
          "text": "As Yersinia pestis can be easily obtained and cultured and is highly pathogenic for humans, it poses a serious threat of being used for bioterrorism purposes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12474416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1036,
          "offsetInEndSection": 1192,
          "text": "Artificially created aerosol containing plague bacilli can cause numerous and almost simultaneous cases of primary pulmonic plague in an exposed population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12474416",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 291,
          "offsetInEndSection": 401,
          "text": "Infection by flea bite results in a bubonic or septicemic plague, possibly complicated by secondary pneumonia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21607086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Francisella tularensis is a facultative intracellular pathogen that causes the disease tularemia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21607086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 249,
          "offsetInEndSection": 454,
          "text": "There is currently no vaccine approved for human use, making genetic manipulation of this organism critical to unraveling the genetic basis of pathogenesis and developing countermeasures against tularemia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21607086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1019,
          "offsetInEndSection": 1030,
          "text": "tularensis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21607086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 118,
          "text": "tularensis subsp."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21607086",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 510,
          "offsetInEndSection": 699,
          "text": "tularensis have lagged behind those routinely used for other bacteria, primarily due to lack of research and the restricted nature of the biocontainment required for studying this pathogen."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26463167",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "During pneumonic plague, the bacterium Yersinia pestis elicits the development of inflammatory lung lesions that continue to expand throughout infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26463167",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1311,
          "offsetInEndSection": 1534,
          "text": "Unrestricted bacterial growth during the initial preinflammatory phase primes patients to be infectious once disease symptoms begin in the proinflammatory phase, and the rapid disease progression can lead to death before Y."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26463167",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1582,
          "offsetInEndSection": 1791,
          "text": "Using in vivo analyses and focusing on relevant cell types during pneumonic plague infection, we can identify host pathways that may be manipulated to extend the treatment window for pneumonic plague patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26463167",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 217,
          "offsetInEndSection": 434,
          "text": "Here, we examine spatially distinct regions of lung lesions using laser capture microdissection and transcriptome sequencing (RNA-seq) analysis to identify transcriptional differences between lesion microenvironments."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26463167",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1133,
          "offsetInEndSection": 1310,
          "text": "pestis to be transmitted via respiratory droplets and its history of weaponization has led to its classification as a select agent most likely to be used as a biological weapon."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18304778",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 523,
          "offsetInEndSection": 584,
          "text": "tularensis, designated LpnA (also known as Tul4), in the LVS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18304778",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Francisella tularensis is a highly virulent bacterium that causes tularemia, a disease that is often fatal if untreated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18304778",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 585,
          "offsetInEndSection": 720,
          "text": "An LpnA deletion mutant was comparable to the wild-type strain in its ability to grow intracellularly and cause lethal disease in mice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18304778",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 721,
          "offsetInEndSection": 959,
          "text": "Additionally, mice inoculated with a sublethal dose of the mutant strain were afforded the same protection against a subsequent lethal challenge with the LVS as were mice initially administered a sublethal dose of the wild-type bacterium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18304778",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1358,
          "offsetInEndSection": 1558,
          "text": "LpnA is clearly unnecessary for multiple functions of the LVS, but its inflammatory capacity implicates it and other Francisella lipoproteins as potentially important to the pathogenesis of tularemia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "The CRISPR/Cas system in prokaryotes provides resistance against invading viruses and plasmids."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 425,
          "text": "Subsequently, the CRISPR is transcribed and the transcript is cleaved by a Cas protein within the repeats, generating short RNAs (crRNAs) that contain the spacer sequence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 154,
          "offsetInEndSection": 253,
          "text": "Initially, fragments of invader DNA are integrated as new spacers into the repetitive CRISPR locus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 587,
          "offsetInEndSection": 777,
          "text": "In this article, we discuss our current understanding of this fascinating adaptive and heritable defense system, and describe functional similarities and differences with RNAi in eukaryotes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21441598",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 426,
          "offsetInEndSection": 586,
          "text": "Finally, crRNAs guide the Cas protein machinery to a complementary invader target, either DNA or RNA, resulting in inhibition of virus or plasmid proliferation."
        }
      ]
    },
    {
      "id": "680a21ff18b1e36f2e000151",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
        "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
        "http://www.ncbi.nlm.nih.gov/pubmed/25904790",
        "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
        "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
        "http://www.ncbi.nlm.nih.gov/pubmed/28936965",
        "http://www.ncbi.nlm.nih.gov/pubmed/31420495",
        "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
        "http://www.ncbi.nlm.nih.gov/pubmed/34182142",
        "http://www.ncbi.nlm.nih.gov/pubmed/31186721"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 962,
          "offsetInEndSection": 1212,
          "text": "Even more intriguingly, autoimmune T cells were found to be involved in supporting fundamental processes of brain functional integrity, such as in the maintenance of life-long brain plasticity, including spatial learning and memory, and neurogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "Immune cell infiltration to the brain's territory was considered for decades to reflect a pathological process in which immune cells attack the central nervous system (CNS); such a process is observed in the inflammatory autoimmune disease, multiple sclerosis (MS)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1495,
          "offsetInEndSection": 1802,
          "text": "Here, we suggest that dysregulation of the balance between peripheral immune suppression, on one hand, and protective autoimmunity, on the other, is an underlying mechanism in the emergence and progression of the neuroinflammatory response associated with chronic neurodegenerative diseases and brain aging."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 613,
          "offsetInEndSection": 757,
          "text": "Yet, over the last decade, it became clear that autoimmunity has a bright side, and that it plays a pivotal role in CNS repair following damage."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25199710",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 266,
          "offsetInEndSection": 612,
          "text": "As neuroinflammatory processes within the CNS parenchyma are also common to other CNS pathologies, regardless of their etiology, including neurodegenerative disorders such as Alzheimer's disease (AD) and Amyotrophic lateral sclerosis (ALS), these pathologies have often been compared to MS, a disease that benefits from immunosuppressive therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 692,
          "offsetInEndSection": 891,
          "text": "Elucidating the characteristics of B cells that populate the MS CNS, how they traffic into the CNS and how they may contribute to progressive forms of the disease has become of considerable interest."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 509,
          "offsetInEndSection": 691,
          "text": "A potential association is reported between such meningeal immune cell collections and the subpial pattern of cortical injury that is now considered important in progressive disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 892,
          "offsetInEndSection": 1193,
          "text": "Here, we will review characteristics of human B cells identified within distinct CNS subcompartments of patients with MS, including the cerebrospinal fluid, parenchymal lesions, and meninges, as well as the relationship between B cell populations identified in these subcompartments and the periphery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 292,
          "text": "However, potential roles of B cells in progressive forms of disease continue to be debated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732544",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 293,
          "offsetInEndSection": 508,
          "text": "Prior work indicates that presence of B cells is fostered within the inflamed MS central nervous system (CNS) environment, and that B cell-rich immune cell collections may be present within the meninges of patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25904790",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 418,
          "text": "In several models of CNS pathologies, circulating immune cells were shown to display an indispensable role in the resolution of the neuroinflammatory response."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25904790",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 419,
          "offsetInEndSection": 597,
          "text": "The recruitment of such cells to the CNS involves activation of the choroid plexus (CP) of the brain for leukocyte trafficking, through a mechanism that requires IFN-\u03b3 signaling."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25904790",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1247,
          "offsetInEndSection": 1482,
          "text": "Collectively, our results demonstrate that recruitment of immunoregulatory cells to the diseased spinal cord in ALS, needed for fighting off the pathology, can be enhanced by transiently boosting peripheral immunity to myelin antigens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25904790",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 787,
          "offsetInEndSection": 1126,
          "text": "Therapeutic immunization of mSOD1 mice with a myelin-derived peptide led to CP activation, and was followed by the accumulation of immunoregulatory cells, including IL-10-producing monocyte-derived macrophages and Foxp3(+) regulatory T cells, and elevation of the neurotrophic factors IGF-1 and GDNF in the diseased spinal cord parenchyma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25904790",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 258,
          "text": "In this disease, local neuroinflammation develops along the disease course and contributes to its rapid progression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Lymphocyte recruitment to the central nervous system (CNS) is a critical step in the pathogenesis of diseases such as multiple sclerosis (MS), meningitis and posterior uveitis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 831,
          "offsetInEndSection": 1117,
          "text": "In particular, it has been shown that ICAM-1-mediated signalling in brain endothelial cells is a crucial regulatory step in the process of lymphocyte migration through the blood-brain barrier and as such represents an additional phase in the multistep paradigm of leucocyte recruitment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1118,
          "offsetInEndSection": 1297,
          "text": "In this article we review current understanding of endothelial cell ICAM-1 signalling and discuss the importance of these findings in relation to leucocyte trafficking to the CNS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 424,
          "text": "The principle sequential stages that control lymphocyte emigration from the blood have been widely reported, but only recently has attention been directed towards the role of the vascular endothelium in actively supporting transvascular migration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 532,
          "offsetInEndSection": 650,
          "text": "ICAM-1, VCAM-1 and PECAM-1), not only act as ligands for leucocyte receptors but can also serve as signal transducers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 222,
          "offsetInEndSection": 527,
          "text": "Data suggesting that B cells play a role in the pathogenesis of multiple sclerosis have been accumulating for the past five decades, demonstrating that the cerebrospinal fluid and central nervous system tissues of multiple sclerosis patients contain B cells, plasma cells, antibodies, and immunoglobulins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 221,
          "text": "Until recently, most studies have emphasized the role of T cells in the pathogenesis of multiple sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 528,
          "offsetInEndSection": 726,
          "text": "Data suggest that B cells are involved in antigen capture and presentation to T cells, cytokine production, antibody secretion, demyelination, tissue damage, and remyelination in multiple sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 727,
          "offsetInEndSection": 894,
          "text": "These advances in the understanding of B-cell and antibody roles in the pathophysiology of multiple sclerosis provide a strong rationale for B-cell-targeted therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388801",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system with no clear etiology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1099,
          "offsetInEndSection": 1213,
          "text": "Herein, we mainly review the potential role and its mechanism of IL-35 in the pathogenesis of infectious diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 269,
          "offsetInEndSection": 422,
          "text": "Cytokines play significant roles in modulating the host immune response to the clearance of pathogenic microorganisms and maintaining immune homeostasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 268,
          "text": "It has been demonstrated that the occurrence and development of infectious diseases are closely associated with the functional status of immune system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 570,
          "offsetInEndSection": 900,
          "text": "With the progress of research in recent years, IL-35 might serve as an essential contributor in the immunopathogensis of vast infectious diseases, including hepatitis B, sepsis, tuberculosis and parasite infection, which simultaneously appear to be closely related to the severity, progression as well as prognosis of the illness."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 423,
          "offsetInEndSection": 569,
          "text": "Interleukin-35 (IL-35), as a newly identified member of IL-12 family, exerts suppressive effect on immune response by means of a specific pattern."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31420495",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "The immune function within the tumor microenvironment has become a prominent therapeutic target, with tumor-associated macrophages (TAMs) playing a critical role in immune suppression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31420495",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 198,
          "text": "We propose an"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 503,
          "offsetInEndSection": 707,
          "text": "A growing body of evidence shows that Tregs are not only important for maintaining immune balance at the periphery but also contribute to self-tolerance and immune privilege in the central nervous system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 232,
          "offsetInEndSection": 502,
          "text": "A specific subset of T cells, currently recognized as FOXP3(+) CD25(+) CD4(+) regulatory T cells (Tregs), are pivotal in suppressing autoimmunity and maintaining immune homeostasis by mediating self-tolerance at the periphery as shown in autoimmune diseases and cancers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 941,
          "offsetInEndSection": 1185,
          "text": "Interestingly, a dysfunction of Tregs is mainly observed in the early stages of several neurodegenerative diseases, but not in their chronic stages, pointing to a causative role of inflammation in the pathogenesis of neurodegenerative diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1385,
          "offsetInEndSection": 1594,
          "text": "We also emphasize the effects of the intestinal microbiome on the induction and function of Tregs and the need to study the crosstalk between the enteric nervous system and Tregs in neurodegenerative diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22899644",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1595,
          "offsetInEndSection": 1788,
          "text": "Finally, we point out the need for a systems biology approach in the analysis of the enormous complexity regulating the function of Tregs and their potential role in neurodegenerative diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34182142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 392,
          "offsetInEndSection": 591,
          "text": "This review compiles the most relevant and recent literature related to the role of epigenetic mechanisms including DNA methylation and histone modifications in immune cells of wide range of cancers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34182142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 592,
          "offsetInEndSection": 747,
          "text": "We also include recent research with respect to role of the most relevant transcription factors that epigenetically control the anti-tumor immune response."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34182142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 391,
          "text": "Though there have been extensive studies accomplished relating to epigenetic changes in cancer cells, recent focus has been shifted on epigenetic-mediated changes in the immune cells including T cells, Macrophages, Natural Killer cells and anti-tumor immune responses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34182142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "The epigenetic regulation of immune response involves reversible and heritable changes that do not alter the DNA sequence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34182142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 748,
          "offsetInEndSection": 869,
          "text": "Finally, a statement of future direction that promises to look forward for strategies to improve immunotherapy in cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 305,
          "offsetInEndSection": 517,
          "text": "In the present study, the IL-35 protein expression levels were measured in the plasma and tumor tissue of patients with prostate cancer (PCA), and its role was determined in the occurrence and progression of PCA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Interleukin (IL)-35 is a novel member of the IL-12 cytokine family, which exhibits a unique immune regulatory function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 663,
          "offsetInEndSection": 795,
          "text": "Receiver operating characteristic curves were plotted to analyze the role of IL-35 as a clinical biomarker for the diagnosis of PCA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1917,
          "offsetInEndSection": 2146,
          "text": "Therefore, increased expression of IL-35 in the plasma and tumor tissues may contribute to the progression and metastasis of PCA, and IL-35 may serve as a novel prognostic biomarker or therapeutic target for the treatment of PCA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 304,
          "text": "Previously, it was demonstrated that IL-35 expression is significantly increased in a wide range of tumor tissues, promoting angiogenesis and inhibiting the anti-tumor immune response."
        }
      ]
    },
    {
      "id": "67fc546c18b1e36f2e000130",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24392752",
        "http://www.ncbi.nlm.nih.gov/pubmed/27757389",
        "http://www.ncbi.nlm.nih.gov/pubmed/22108462",
        "http://www.ncbi.nlm.nih.gov/pubmed/34517744",
        "http://www.ncbi.nlm.nih.gov/pubmed/27358410",
        "http://www.ncbi.nlm.nih.gov/pubmed/27468879",
        "http://www.ncbi.nlm.nih.gov/pubmed/24403054",
        "http://www.ncbi.nlm.nih.gov/pubmed/23089199",
        "http://www.ncbi.nlm.nih.gov/pubmed/22403045",
        "http://www.ncbi.nlm.nih.gov/pubmed/17350985"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392752",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "The widespread use of antibiotics has been associated with the emergence of antimicrobial resistance among bacteria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392752",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 375,
          "offsetInEndSection": 514,
          "text": "Chloramphenicol is a broad spectrum antibiotic that was abandoned in developed countries due to its association with fatal aplastic anemia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392752",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 863,
          "offsetInEndSection": 957,
          "text": "However, in combination with colistin, chloramphenicol was found to have synergistic activity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392752",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 672,
          "offsetInEndSection": 764,
          "text": "Our paper reviews in vitro data on the activity of chloramphenicol against ESKAPE pathogens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392752",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 958,
          "offsetInEndSection": 1033,
          "text": "The risk-benefit related to chloramphenicol toxicity has not been analyzed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27757389",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Antibiotics have significant and long-lasting impacts on the intestinal microbiota and consequently reduce colonization resistance against"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22108462",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 474,
          "offsetInEndSection": 658,
          "text": "In the first 2 populations, use of antibiotics was associated with an increase in carriage of antibiotic-resistant bacteria, but in intensive care patients the opposite was documented."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22108462",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 193,
          "offsetInEndSection": 346,
          "text": "Yet recent well-designed studies have demonstrated that prophylactic antibiotic use is of significant benefit to patients prone to developing infections."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22108462",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 192,
          "text": "Therefore, antibiotics should usually only be prescribed for infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22108462",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 659,
          "offsetInEndSection": 732,
          "text": "These studies demonstrate that antibiotics do more than cause resistance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22108462",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 733,
          "offsetInEndSection": 821,
          "text": "The pros and cons of prophylactic antibiotic use must therefore be carefully considered."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34517744",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1313,
          "offsetInEndSection": 1509,
          "text": "This review provides an up-to-date overview of the use of PCT in different clinical settings and diseases, including a discussion about its potential to improve the care of patients with COVID-19."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34517744",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 364,
          "offsetInEndSection": 640,
          "text": "Randomized trials in patients with respiratory tract infections have shown that PCT has prognostic implications and its use, embedded in stewardship protocols, leads to reductions in the use of antibiotics in different clinical settings without compromising clinical outcomes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34517744",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 363,
          "text": "As the rise of antimicrobial resistance reaches \"alarming\" levels according to the World Health Organization, the importance of using biomarkers, such as PCT to limit unnecessary antibiotic exposure has further increased."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34517744",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 941,
          "offsetInEndSection": 1195,
          "text": "For patients with respiratory infections and sepsis, PCT can be used to determine whether to initiate antimicrobial therapy in low-risk settings and, together with clinical data, whether to discontinue antimicrobial therapy in certain high-risk settings."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34517744",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Procalcitonin (PCT) is useful for differentiating between viral and bacterial infections and for reducing the unnecessary use of antibiotics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27358410",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 816,
          "offsetInEndSection": 1001,
          "text": "Based on derived CS from documented signs/symptoms, antibiotics were prescribed inappropriately to 196/273 patients (80%; 95% CI 74% to 85%) including broad-spectrum antibiotics to 25%."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27358410",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1401,
          "offsetInEndSection": 1528,
          "text": "Based on derived CS (<3), 80% of patients were inappropriately prescribed antibiotics, particularly broad-spectrum antibiotics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27358410",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1258,
          "offsetInEndSection": 1344,
          "text": "CS was not being used in the ED to guide antibiotic prescribing for acute tonsillitis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27358410",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "To determine whether antibiotics are prescribed appropriately for acute tonsillitis in an emergency department (ED)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27358410",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1529,
          "offsetInEndSection": 1609,
          "text": "Further studies need to assess use of CS to guide antibiotic prescription in ED."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468879",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Bacterial infection is the most common complication in paediatric oncological patients during cancer treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468879",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1220,
          "offsetInEndSection": 1422,
          "text": "Patients with gram-negative bacteraemia had significantly elevated levels of PCT and IL-6 in comparison with a group of patients with gram-positive bacteraemia (p = 0.04 for PCT and p = 0.005 for IL-6)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468879",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 997,
          "offsetInEndSection": 1219,
          "text": "We identified comparably balanced sensitivity (64% - 81%) and specificity (61% - 88%) for interleukin-6 and procalcitonin, and we proved their quality to predict positive blood culture and clinical signs of sepsis as well."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468879",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 795,
          "text": "Within this sample, there were 22 cases of positive blood cultures, 16 cases of sepsis, 38 cases of fever with no signs or symptoms of sepsis, and two deaths from infectious complications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468879",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 488,
          "text": "We performed a prospective longitudinal observational study to evaluate of the role of serum biomarkers (C-reactive protein, procalcitonin, interleukin-6, presepsin) in the early diagnosis of bacteraemia (gram-negative versus gram-positive) in patients with haematological malignancies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403054",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 281,
          "text": "Thus, identifying new therapeutic targets to treat Corynebacteria infections is both medically and economically important."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403054",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 799,
          "offsetInEndSection": 999,
          "text": "Our results suggest that CG2496 is a novel therapeutic target and methiothepin is a potential lead compound or structural scaffold for developing new antibiotics specifically targeting Corynebacteria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403054",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "The bacterial genus Corynebacteria contains several pathogenic species that cause diseases such as diphtheria in humans and \"cheesy gland\" in goats and sheep."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403054",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 687,
          "offsetInEndSection": 742,
          "text": "Methiothepin was also shown to inhibit the growth of C."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403054",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 282,
          "offsetInEndSection": 412,
          "text": "CG2496, a functionally uncharacterized protein from Corynebacterium glutamicum, was evaluated using an NMR ligand-affinity screen."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089199",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1813,
          "offsetInEndSection": 1902,
          "text": "In older patients on stable warfarin therapy, antibiotics may lead to an increase in INR."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089199",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 224,
          "offsetInEndSection": 482,
          "text": "The aim of this study was to determine the effect of oral antibiotics, such as amoxicillin, azithromycin, cephalexin, ciprofloxacin, levofloxacin, and moxifloxacin, on the international normalized ratio (INR) in patients \u226565 years on stable warfarin therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089199",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1903,
          "offsetInEndSection": 2128,
          "text": "However, this may not result in clinically significant outcomes of bleeding or hospitalization, suggesting that antibiotics may be prescribed for older adults taking warfarin as long as their INR is being routinely monitored."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089199",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "Several classes of drugs, such as antibiotics, may interact with warfarin to cause an increase in warfarins anticoagulant activity and the clinical relevance of warfarin-antibiotic interactions in older adults is not clear."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089199",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1514,
          "offsetInEndSection": 1702,
          "text": "Antibiotics with a significant increase in INR were amoxicillin (P = 0.0019), azithromycin (P < 0.0001), ciprofloxacin (P = 0.002), levofloxacin (P < 0.0001) and moxifloxacin (P < 0.0001)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403045",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 680,
          "offsetInEndSection": 848,
          "text": "In cases of human infection with potentially toxigenic corynebacteria, it is important to determine the species and examine the isolate for diphtheria toxin production."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403045",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Corynebacterium ulcerans is mainly known for its ability to cause animal infections."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403045",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1049,
          "offsetInEndSection": 1190,
          "text": "For the primary prevention of disease caused by diphtheria toxin-producing corynebacteria, vaccination with diphtheria toxoid is recommended."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403045",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 849,
          "offsetInEndSection": 933,
          "text": "If toxigenicity is present, diphtheria antitoxin should be administered immediately."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403045",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 104,
          "offsetInEndSection": 213,
          "text": "ulcerans produce diphtheria toxin, which can cause life-threatening cardiopathies and neuropathies in humans."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1009,
          "offsetInEndSection": 1102,
          "text": "All the investigated strains of Clostridium perfringens were inhibited by 1 mg/L retapamulin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 365,
          "offsetInEndSection": 573,
          "text": "The in vitro activity of retapamulin and six comparators (amoxicillin, amoxicillin/clavulanic acid, ceftriaxone, imipenem, clindamycin and metronidazole) was evaluated against 232 anaerobic clinical isolates."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 364,
          "text": "The aim of this study was to determine the antimicrobial activity of retapamulin by determining the minimal inhibitory concentration (MIC) values of this new drug and comparators against a wide range of anaerobic bacteria of human origin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1224,
          "offsetInEndSection": 1448,
          "text": "Based on inhibitory concentrations, retapamulin was more active than clindamycin, metronidazole and ceftriaxone against Propionibacterium acnes and anaerobic Gram-positive cocci, as all isolates were inhibited by <or=2 mg/L."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1449,
          "offsetInEndSection": 1665,
          "text": "At <or=2 mg/L, retapamulin inhibited 90% of all 232 anaerobes tested, whereas overall resistance rates for the comparators were as follows: co-amoxiclav, 2%; metronidazole, 12%; clindamycin, 15% and ceftriaxone, 20%."
        }
      ]
    },
    {
      "id": "680f4aa6353a4a2e6b000008",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/1067597",
        "http://www.ncbi.nlm.nih.gov/pubmed/5964959",
        "http://www.ncbi.nlm.nih.gov/pubmed/21422738",
        "http://www.ncbi.nlm.nih.gov/pubmed/4664580",
        "http://www.ncbi.nlm.nih.gov/pubmed/23239357",
        "http://www.ncbi.nlm.nih.gov/pubmed/23925142",
        "http://www.ncbi.nlm.nih.gov/pubmed/17710455",
        "http://www.ncbi.nlm.nih.gov/pubmed/19674480",
        "http://www.ncbi.nlm.nih.gov/pubmed/2514275",
        "http://www.ncbi.nlm.nih.gov/pubmed/19488551"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1067597",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 346,
          "text": "Erabutoxin b is one of a family of snake venom neurotoxins, all low-molecular-weight proteins, which block neuromuscular transmission at the postsynaptic membrane."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1067597",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 799,
          "offsetInEndSection": 964,
          "text": "In 28 snake venom neurotoxins of established sequence which inhibit the acetylcholine receptor, the four disulfide bridges and seven other residues remain invariant."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1067597",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "The three-dimensional structure of erabutoxin b, a neurotoxin in the venom of the sea snake Laticauda semifasciata, has been determined from a 2.75 A resolution electron density map."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1067597",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 347,
          "offsetInEndSection": 400,
          "text": "They specifically inhibit the acetylcholine receptor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1067597",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 680,
          "offsetInEndSection": 798,
          "text": "Approximately 40% of the main chain is organized into a twisted antiparallel beta-pleated sheet of five short strands."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/5964959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 3,
          "offsetInEndSection": 177,
          "text": "The toxic principles in the venom of the sea-snake Laticauda semifasciata were separated into two components by CM-cellulose chromatography and obtained in crystalline forms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/5964959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 2,
          "text": "1."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/5964959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 216,
          "text": "They were named ;erabutoxins a and b'."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/5964959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 533,
          "offsetInEndSection": 708,
          "text": "The only difference between erabutoxins a and b was that one of the aspartic acid (or asparagine) residues in erabutoxin a was replaced by a histidine residue in erabutoxin b."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/5964959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 220,
          "offsetInEndSection": 423,
          "text": "The homogeneity of each toxin was shown by rechromatography, by disk electrophoresis, by ultracentrifuging, by toxicity measurements before and after repeated crystallizations and by N-terminal analysis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21422738",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 300,
          "text": "Amino acid sequences of the toxins indicated that the toxins are members of a superfamily consisting of short and long neurotoxins and cytotoxins found in sea snakes and terrestrial snakes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21422738",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Erabutoxins a and b are neurotoxins isolated from venom of a sea snake Laticauda semifasciata (erabu-umihebi)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21422738",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 473,
          "offsetInEndSection": 681,
          "text": "X-ray crystallography and NMR analyses showed that the toxins have a three-finger structure, in which three fingers made of three loops emerging from a dense core make a gently concave surface of the protein."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21422738",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 839,
          "offsetInEndSection": 1043,
          "text": "Classification of snakes by means of sequence comparison and that based on different morphological features were inconsistent, which led the authors to propose a hypothesis \"Evolution without divergence.\""
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21422738",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 301,
          "offsetInEndSection": 472,
          "text": "The short neurotoxins to which erabutoxins belong act by blocking the nicotinic acetylcholine receptor on the post synaptic membrane in a manner similar to that of curare."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4664580",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 404,
          "offsetInEndSection": 607,
          "text": "The toxin showed the same lethal activity to mice (0.13mug/g body wt., intramuscular injection) and the same effect on isolated frog muscle as erabutoxins a and b, the main toxic components of the venom."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4664580",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Erabutoxin c, a minor neurotoxic component of the venom of a sea snake Laticauda semifasciata, was isolated in pure form by repeated column chromatography on CM-cellulose columns."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4664580",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 913,
          "text": "Erabutoxin c consisted of 62 amino acid residues, containing one fewer lysine and one more histidine than erabutoxin a and one fewer lysine and one more aspartic acid (or asparagine) than erabutoxin b."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4664580",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1327,
          "offsetInEndSection": 1405,
          "text": "It was therefore concluded that erabutoxin c was [51-asparagine]-erabutoxin b."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4664580",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 180,
          "offsetInEndSection": 326,
          "text": "The toxin was crystallizable and monodisperse in rechromatography, disc electrophoresis and isoelectric focusing (isoelectric point, pH9.23-9.25)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23239357",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Botulinum neurotoxins (BoNTs) are the most potent human toxins known and the causative agent of botulism, and are widely used as valuable pharmaceuticals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23239357",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 503,
          "offsetInEndSection": 703,
          "text": "The quantitative and reliable potency determination of fully functional BoNTs produced as active pharmaceutical ingredient (API) requires an assay that considers all steps in the intoxication pathway."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23239357",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 259,
          "text": "The BoNTs are modular proteins consisting of a heavy chain and a light chain linked by a disulfide bond."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23239357",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1353,
          "offsetInEndSection": 1553,
          "text": "Such quantitative and reliable BoNT potency determination is a crucial step in basic research, in the development of pharmaceutical BoNTs, and in the quantitative detection of neutralizing antibodies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23239357",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 903,
          "offsetInEndSection": 1073,
          "text": "Cell-based assays are currently the only in vitro alternative that detect fully functional BoNTs in a single assay and have been utilized for years for research purposes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23925142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "Botulinum neurotoxins are one of the most potent toxins known to man."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23925142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 762,
          "offsetInEndSection": 978,
          "text": "The results show clear differences between the toxin product and the placebo, which contains the pharmaceutical excipients human serum albumin and lactose, showing that the assay detects the active form of the toxin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23925142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 374,
          "offsetInEndSection": 525,
          "text": "This report demonstrates a novel assay that utilises the endopeptidase activity of the toxin to detect Botulinum neurotoxin in a pharmaceutical sample."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23925142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 212,
          "offsetInEndSection": 373,
          "text": "At present the assay used for monitoring the activity of the toxin is the mouse bioassay, which is lengthy and has ethical issues due to the use of live animals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23925142",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 70,
          "offsetInEndSection": 211,
          "text": "Current methods of detection involve the quantification of the toxin but do not take into account the percentage of the toxin that is active."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17710455",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 693,
          "offsetInEndSection": 872,
          "text": "This considerably expands the range of snake toxins that block insect nicotinic acetylcholine receptors and may enable further pharmacological distinctions between nAChR subtypes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17710455",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Here we examine the actions of six snake neurotoxins (alpha-cobratoxin from Naja naja siamensis, erabutoxin-a and b from Laticauda semifasciata; CM12 from N."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17710455",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 371,
          "offsetInEndSection": 565,
          "text": "All toxins tested reduced responses to directly-applied ACh as well as EPSPs evoked by electrical stimulation of nerve XI with similar time courses, suggesting that their action is postsynaptic."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17710455",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 234,
          "text": "haje annulifera, toxin III 4 from Notechis scutatus and a long toxin from N."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17710455",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 566,
          "offsetInEndSection": 692,
          "text": "Thus, these nicotinic receptors in a well-characterized insect synapse are sensitive to both long and short chain neurotoxins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19674480",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Venomous animals incapacitate their prey using complex venoms that can contain hundreds of unique protein toxins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19674480",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 368,
          "offsetInEndSection": 511,
          "text": "From an evolutionary perspective, spiders are the most successful venomous animals and they maintain by far the largest pool of toxic peptides."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19674480",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 830,
          "offsetInEndSection": 1032,
          "text": "Key features of ArachnoServer include a new molecular target ontology designed especially for venom toxins, the most up-to-date taxonomic information available, and a powerful advanced search interface."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19674480",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 512,
          "offsetInEndSection": 692,
          "text": "However, at present, there are no databases dedicated to spider toxins and hence it is difficult to realise their full potential as drugs, insecticides, and pharmacological probes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19674480",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 367,
          "text": "The realisation that many of these toxins may have pharmaceutical and insecticidal potential due to their remarkable potency and selectivity against target receptors has led to an explosion in the number of new toxins being discovered and characterised."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2514275",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1770,
          "offsetInEndSection": 1957,
          "text": "Hence, the outcome of this study has important consequences for the current ideas on snake alpha-neurotoxin structure/activity relationships and the evolutionary origins of neurotoxicity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2514275",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1390,
          "offsetInEndSection": 1651,
          "text": "The alpha-conotoxin-like area of the snake alpha-neurotoxins is peripheral to the site previously considered important for binding to the cholinoceptor, even though it seems to represent the focus of evolutionary convergence between the two types of neurotoxin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2514275",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "alpha-neurotoxins from elapid snake venoms and alpha-conotoxins from marine snails bind specifically and with high affinity to nicotinic cholinoceptors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2514275",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 641,
          "text": "A systematic computer search of the three-dimensional structure of erabutoxin b (an alpha-neurotoxin from the false sea snake Laticauda semifasciata) was performed to identify the locality that most closely matched the amino acid compositions of the smaller alpha-conotoxins (from the marine snails Conus magus and Conus geographus)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2514275",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 642,
          "offsetInEndSection": 810,
          "text": "The area of greatest similarity centered on residue position 25 of erabutoxin b, a locale that is conserved throughout the snake alpha-neurotoxins and their homologues."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Botulinum toxin (BTX) is one of the most potent bacterial toxins known and its effectiveness in the treatment of some pain syndromes is well known."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 573,
          "offsetInEndSection": 810,
          "text": "Botulinum toxin, a neurotoxin with high affinity for cholinergic synapses, blocks the release of acetylcholine by nerve endings without interfering with neuronal conduction of electrical signals or synthesis and storage of acetylcholine."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 404,
          "offsetInEndSection": 511,
          "text": "Botulinum toxin is produced by fermentation of Clostridium botulinum, a Gram-positive, anaerobic bacterium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1214,
          "text": "Botulinum toxin type A is well tolerated in the treatment of chronic pain disorders in which pharmacotherapy regimens can cause side effects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1348,
          "offsetInEndSection": 1537,
          "text": "However, further studies are necessary to establish the efficacy of BTX-A in chronic pain disorders and its exact mechanism of action, as well as its potential in multifactorial treatments."
        }
      ]
    },
    {
      "id": "680a078618b1e36f2e000146",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24269728",
        "http://www.ncbi.nlm.nih.gov/pubmed/20454996",
        "http://www.ncbi.nlm.nih.gov/pubmed/28111277",
        "http://www.ncbi.nlm.nih.gov/pubmed/21969581",
        "http://www.ncbi.nlm.nih.gov/pubmed/21501576",
        "http://www.ncbi.nlm.nih.gov/pubmed/25042473",
        "http://www.ncbi.nlm.nih.gov/pubmed/2209722",
        "http://www.ncbi.nlm.nih.gov/pubmed/24925909",
        "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
        "http://www.ncbi.nlm.nih.gov/pubmed/21216828"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24269728",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1656,
          "offsetInEndSection": 1811,
          "text": "Thus, after disease onset, microglia acquired unique characteristics that do not conform to typical M1 (inflammatory) or M2 (anti-inflammatory) phenotypes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24269728",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 944,
          "offsetInEndSection": 1063,
          "text": "Flow cytometry revealed the presence of at least two phenotypically distinct microglial populations in the spinal cord."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24269728",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 304,
          "offsetInEndSection": 485,
          "text": "We immunomagnetically isolated microglia from different CNS regions of SOD1(G93A) rats at three different points in disease progression: presymptomatic, symptom onset and end-stage."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24269728",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1989,
          "offsetInEndSection": 2201,
          "text": "These novel observations suggest that microglial regional and phenotypic heterogeneity may be an important consideration when designing new therapeutic strategies targeting microglia and neuroinflammation in ALS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24269728",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 760,
          "offsetInEndSection": 943,
          "text": "At disease end-stage, microglia were characterized by high expression of galectin-3, osteopontin and VEGF, and concomitant downregulated expression of TNF\u03b1, IL-6, BDNF and arginase-1."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20454996",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 97,
          "offsetInEndSection": 405,
          "text": "Although both cell types were thought to be generated through completely distinct pathways and molecular processes, a recent study has revealed that these different cell types are intimately interconnected far beyond previously postulated limits in that they share a common post-neural crest progenitor, i.e."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20454996",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Melanocytes and Schwann cells are derived from the multipotent population of neural crest cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20454996",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 434,
          "offsetInEndSection": 711,
          "text": "This finding raises interesting questions about the lineage relationships of hitherto unrelated cell types such as melanocytes and Schwann cells, and may provide clinical insights into mechanisms of pigmentation disorders and for cancer involving Schwann cells and melanocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20454996",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 406,
          "offsetInEndSection": 433,
          "text": "the Schwann cell precursor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111277",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 428,
          "offsetInEndSection": 496,
          "text": "Granulocytes and macrophages emerged in a mutually exclusive manner."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111277",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 307,
          "text": "Conversion of B cells to macrophages was readily induced by the ectopic expression of any C/EBP, and enhanced by endogenous C/EBP\u03b1 and \u03b2 activation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111277",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 655,
          "offsetInEndSection": 784,
          "text": "The GMP-like progenitors remained self-renewing and cytokine-independent, and continuously produced macrophages and granulocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111277",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "The lymphoid-myeloid transdifferentiation potentials of members of the C/EBP family (C/EBP\u03b1, \u03b2, \u03b4, and \u03b5) were compared in v-Abl-immortalized primary B cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111277",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 654,
          "text": "C/EBP\u03b2-expressing B cells produced granulocyte-macrophage progenitor (GMP)-like progenitors when subjected to selective pressure to eliminate lymphoid cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21969581",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1160,
          "offsetInEndSection": 1331,
          "text": "Together, our findings are consistent with the notion that the conversion from pre-B cells to macrophages is mostly direct and does not involve overt retrodifferentiation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21969581",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Earlier work has shown that pre-B cells can be converted into macrophages by the transcription factor CCAAT/enhancer binding protein \u03b1 at very high frequencies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21969581",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 343,
          "offsetInEndSection": 505,
          "text": "A transcriptome analysis of transdifferentiating cells showed that most genes are up- or down-regulated continuously, acquiring a macrophage phenotype within 5 d."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21969581",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 721,
          "offsetInEndSection": 1159,
          "text": "Importantly, however, we were unable to observe the reexpression of cell-surface marker combinations that characterize hematopoietic stem and progenitor cells, including c-Kit and FMS-like tyrosine kinase 3, even when CAAT/enhancer binding protein \u03b1 was activated in pre-B cells under culture conditions that favor growth of hematopoietic stem and progenitor cells or when the transcription factor was activated in a time-limited fashion."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21969581",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 506,
          "offsetInEndSection": 720,
          "text": "In addition, we observed the transient reactivation of a subset of immature myeloid markers, as well as low levels of the progenitor markers Kit and FMS-like tyrosine kinase 3 and a few lineage-inappropriate genes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501576",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1172,
          "offsetInEndSection": 1365,
          "text": "In particular, melanocytes and glial Schwann cells were shown to arise from a common bipotent progenitor, which depends upon the peptide endothelin-3 for proliferation and self-renewal ability."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501576",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 293,
          "text": "Melanocytes, the pigmented cells of the skin, and the glial Schwann cells lining peripheral nerves are developmentally derived from an early and transient ectodermal structure of the vertebrate embryo, the neural crest, which is also at the origin of multiple neural and non-neural cell types."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501576",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2625,
          "offsetInEndSection": 2784,
          "text": "Individual Schwann cells isolated by FACS, using a glial-specific surface marker, gave rise in culture to pigment cells and myofibroblasts/smooth muscle cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501576",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2243,
          "offsetInEndSection": 2446,
          "text": "To address this question, we have studied the clonal progeny of differentiated Schwann cells and melanocytes after their isolation from the sciatic nerve and the back skin of quail embryos, respectively."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501576",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 294,
          "offsetInEndSection": 545,
          "text": "Besides melanocytes and neural cells of the peripheral nervous system, the neural crest cells give rise to mesenchymal cell types in the head, which form most of the craniofacial skeleton, dermis, fat tissue and vascular musculo-connective components."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042473",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 637,
          "offsetInEndSection": 890,
          "text": "Microglia in CSF1 overexpressing mice exhibit gene expression profiles indicating that they are not basally M1 or M2 polarized, but they do have defects in inducing expression of certain genes in response to the inflammatory stimulus lipopolysaccharide."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042473",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 135,
          "offsetInEndSection": 306,
          "text": "To examine the effects of CSF1 overexpression on microglia, transgenic mice that overexpress CSF1 in the glial fibrillary acidic protein (GFAP) compartment were generated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042473",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 891,
          "offsetInEndSection": 1018,
          "text": "These results indicate that the CSF1 overexpression observed in CNS pathologies likely has pleiotropic influences on microglia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042473",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Macrophage colony stimulating factor (CSF1) is a cytokine that is upregulated in several diseases of the central nervous system (CNS)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042473",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 307,
          "offsetInEndSection": 428,
          "text": "CSF1 overexpressing mice have increased microglial proliferation and increased microglial numbers compared with controls."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2209722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 423,
          "offsetInEndSection": 574,
          "text": "These conditions allow bone marrow precursor cells and monocytes to differentiate almost quantitatively into accessory cells and/or mature macrophages."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2209722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 256,
          "offsetInEndSection": 422,
          "text": "Here we have cultivated rat bone marrow precursor cells and human monocytes isolated from peripheral blood in tissue culture supplemented with certain growth factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2209722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "Hemopoietic cells from blood and bone marrow of mammals usually do not express lamins A/C but only lamin B, and this feature distinguishes these cells from the vast majority of somatic cells of the adult animal, which reveal lamins A/C as well as lamin B."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2209722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1049,
          "offsetInEndSection": 1234,
          "text": "Parallel in vivo experiments showed that treatment with thioglycollate caused the percentage of lamin A/C-positive peritoneal macrophages to increase from 5 to 80% between Days 0 and 6."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2209722",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 845,
          "offsetInEndSection": 1048,
          "text": "A dramatic increase in lamin A/C-positive cells was observed in the first 3 days of culture with both accessory cells and macrophages expressing lamins A/C as soon as such cell types could be identified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 156,
          "offsetInEndSection": 370,
          "text": "We show that the parasympathetic system in mice--including trunk ganglia and the cranial ciliary, pterygopalatine, lingual, submandibular, and otic ganglia--arise from glial cells in nerves, not neural crest cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 479,
          "offsetInEndSection": 631,
          "text": "We used multicolor Cre-reporter lineage tracing to show that most of these neurons arise from bi-potent progenitors that generate both glia and neurons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 632,
          "offsetInEndSection": 818,
          "text": "This nerve origin places cellular elements for generating parasympathetic neurons in diverse tissues and organs, which may enable wiring of the developing parasympathetic nervous system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 371,
          "offsetInEndSection": 478,
          "text": "The parasympathetic fate is induced in nerve-associated Schwann cell precursors at distal peripheral sites."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "The peripheral autonomic nervous system reaches far throughout the body and includes neurons of diverse functions, such as sympathetic and parasympathetic."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Microglia, which constitute the resident macrophages of the central nervous system (CNS), are generally considered as the primary immune cells in the brain and spinal cord."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 173,
          "offsetInEndSection": 337,
          "text": "Microglial cells respond to various factors which are produced following nerve injury of multiple aetiologies and contribute to the development of neuronal disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 764,
          "offsetInEndSection": 951,
          "text": "We first showed that CCR-8, a specific receptor for CCL-1, was expressed on primary cultured microglia, as well as on astrocytes and neurons, and was upregulated in the presence of CCL-1."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 704,
          "text": "However, the role of CCL-1 in the CNS and the effects on microglia remains unclear."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23747724",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 705,
          "offsetInEndSection": 763,
          "text": "Here we showed the multiple effects of CCL-1 on microglia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 306,
          "offsetInEndSection": 512,
          "text": "We characterized the repertoires derived from meningeal B cell aggregates and the corresponding parenchymal infiltrates from brain tissue derived primarily from patients with progressive multiple sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 513,
          "offsetInEndSection": 642,
          "text": "The majority of expanded antigen-experienced B cell clones derived from meningeal aggregates were also present in the parenchyma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 305,
          "text": "In the central nervous system of patients with multiple sclerosis, B cell aggregates populate the meninges, raising the central question as to whether these structures relate to the B cell infiltrates found in parenchymal lesions or instead, represent a separate central nervous system immune compartment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1001,
          "offsetInEndSection": 1230,
          "text": "This study establishes a relationship between extraparenchymal lymphoid tissue and parenchymal infiltrates and defines the arrangement of B cell clones that populate the central nervous system of patients with multiple sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 643,
          "offsetInEndSection": 824,
          "text": "We extended this investigation to include 20 grey matter specimens containing meninges, 26 inflammatory plaques, 19 areas of normal appearing white matter and cerebral spinal fluid."
        }
      ]
    },
    {
      "id": "67e098cb18b1e36f2e00006d",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17584678",
        "http://www.ncbi.nlm.nih.gov/pubmed/7991969",
        "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
        "http://www.ncbi.nlm.nih.gov/pubmed/18045856",
        "http://www.ncbi.nlm.nih.gov/pubmed/6065875",
        "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
        "http://www.ncbi.nlm.nih.gov/pubmed/17286271",
        "http://www.ncbi.nlm.nih.gov/pubmed/23710633",
        "http://www.ncbi.nlm.nih.gov/pubmed/2052626",
        "http://www.ncbi.nlm.nih.gov/pubmed/21549607"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17584678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "This review mainly focuses on the structure, function of the sarco(endo)plasmic reticulum calcium pump (SERCA) and its role in genesis of arrhythmias."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17584678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1116,
          "offsetInEndSection": 1259,
          "text": "Actually both decrease and increase of SERCA activity in the heart result in some pathological mechanisms such as heart failure and arrhythmia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17584678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 301,
          "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular stores."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17584678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 753,
          "offsetInEndSection": 898,
          "text": "During diastole, muscle relaxation occurs as Ca2+ is again removed from cytosol, predominantly by accumulation into SR via the action of SERCA2a."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17584678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 615,
          "offsetInEndSection": 752,
          "text": "In heart muscle, during systole, depolarization triggers the release of Ca2+ from the sarcoplasmic reticulum (SR) and starts contraction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7991969",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 526,
          "offsetInEndSection": 637,
          "text": "The major function of the SO seems to be in regulating the flow of bile and pancreatic juice into the duodenum."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7991969",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 741,
          "offsetInEndSection": 823,
          "text": "On the other hand it functions as \"a pump\" as well to milk bile into the duodenum."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7991969",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Sphincter of Oddi (SO) is a dynamic structure located strategically at the confluence of the bile duct, the pancreatic duct and the duodenum."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7991969",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 638,
          "offsetInEndSection": 740,
          "text": "By maintaining a basal tone, the sphincter diverts bile into the gallbladder under fasting conditions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7991969",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 323,
          "offsetInEndSection": 446,
          "text": "These studies have shown that the SO motor function is a complex phenomenon controlled by a variety of neurohumoral agents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "Gastroesophageal reflux disease (GERD) results from incompetency of the lower esophageal sphincter that allows the contents of the stomach to reflux into the esophagus, the airways, and the mouth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 985,
          "offsetInEndSection": 1206,
          "text": "Paul, MN, USA) is designed to provide a permanent solution to GERD by augmenting the sphincter barrier with a standardized, reproducible laparoscopic procedure that does not alter gastric anatomy and is easily reversible."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 464,
          "offsetInEndSection": 647,
          "text": "The laparoscopic Nissen fundoplication represents the surgical gold standard, but is largely underused because of the level of technical difficulty and the prevalence of side effects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 463,
          "text": "The majority of patients are successfully treated with proton-pump inhibitors, but up to 40% have incomplete relief of symptoms even after dose adjustment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1395,
          "offsetInEndSection": 1564,
          "text": "The device decreased esophageal acid exposure, improved reflux symptoms and quality of life, and allowed cessation of proton-pump inhibitors in the majority of patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18045856",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 395,
          "offsetInEndSection": 597,
          "text": "In this study, we used PLB-knockout (PLB-KO) mice to directly examine the effect of PLB absence on contractility, CaM kinase II activity, and intracellular Ca(2+) waves in gastric antrum smooth muscles."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18045856",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1456,
          "offsetInEndSection": 1622,
          "text": "These findings suggest that PLB is an important modulator of gastric antrum smooth muscle contractility by modulation of SR Ca(2+) release and CaM kinase II activity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18045856",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 394,
          "text": "We previously reported significant differences in contractility, SR Ca(2+) release, and CaM kinase II activity in gastric fundus smooth muscles as a result of PLB phosphorylation by CaM kinase II."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18045856",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1309,
          "offsetInEndSection": 1455,
          "text": "Similarly, the intracellular Ca(2+) wave frequency was elevated, and not further increased by caffeine, in antrum smooth muscles from PLB-KO mice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18045856",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1179,
          "offsetInEndSection": 1308,
          "text": "CaM kinase II autonomous activity was elevated, and not further increased by caffeine, in antrum smooth muscles from PLB-KO mice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6065875",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 195,
          "offsetInEndSection": 282,
          "text": "Pressure changes from balloons placed in the gastric antrum and duodenum were recorded."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6065875",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 727,
          "offsetInEndSection": 831,
          "text": "There is a definite relationship between gastric antral activity and flow through the sphincter of Oddi."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6065875",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 892,
          "offsetInEndSection": 1021,
          "text": "Mechanical or electrical stimulation of the stomach, duodenum, or upper small bowel influences the tone of the sphincter of Oddi."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6065875",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 832,
          "offsetInEndSection": 891,
          "text": "This is more obvious when food is present in the stomach.5."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6065875",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 495,
          "offsetInEndSection": 671,
          "text": "Reflex inhibition of the sphincter of Oddi is seen on electrical and mechanical stimulation of the gall-bladder but not with passive pressure changes within the gall-bladder.3."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "Gastroesophageal reflux disease (GERD), commonly manifested by heartburn or regurgitation, is a chronic, progressive condition in which failed sphincter function allows the contents of the stomach to reflux into the esophagus, the airways and the mouth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 490,
          "offsetInEndSection": 684,
          "text": "The laparoscopic Nissen fundoplication is the surgical gold standard; however, the level of technical difficulty and its side effects have limited its use to less than 1% of the GERD population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 968,
          "offsetInEndSection": 1267,
          "text": "The LINX(\u2122) Reflux Management System (Torax Medical) is designed to provide a permanent solution to GERD by augmenting the physiologic function of the sphincter barrier with a simple and reproducible laparoscopic procedure that does not alter gastric anatomy and can be easily reversed if necessary."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 299,
          "offsetInEndSection": 489,
          "text": "The majority of patients receive adequate relief from proton pump inhibitors, but up to 40% have incomplete relief of symptoms that cannot be addressed by increasing the dose of medications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 298,
          "text": "Chronic GERD affects 10% of Western society."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17286271",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1183,
          "offsetInEndSection": 1353,
          "text": "Because the SERCA pump plays a major role in muscle contraction, a number of investigations have focused on understanding its role in cardiac and skeletal muscle disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17286271",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 366,
          "offsetInEndSection": 503,
          "text": "The SERCA pump is encoded by a family of three genes, SERCA1, 2, and 3, that are highly conserved but localized on different chromosomes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17286271",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 907,
          "offsetInEndSection": 1063,
          "text": "The function of the SERCA pump is modulated by the endogenous molecules phospholamban (PLB) and sarcolipin (SLN), expressed in cardiac and skeletal muscles."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17286271",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1354,
          "offsetInEndSection": 1514,
          "text": "These studies document that SERCA pump expression and activity are decreased in aging and in a variety of pathophysiological conditions including heart failure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17286271",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1515,
          "offsetInEndSection": 1733,
          "text": "Recently, SERCA pump gene transfer was shown to be effective in restoring contractile function in failing heart muscle, thus emphasizing its importance in muscle physiology and its potential use as a therapeutic agent."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23710633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1133,
          "offsetInEndSection": 1314,
          "text": "In this review, we will highlight the molecular mechanisms underlying the regulation of SERCA2a activity and the potential therapeutic modalities for the treatment of heart failure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23710633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 408,
          "offsetInEndSection": 525,
          "text": "Sarcoplasmic/ endoplasmic reticulum Ca(2+)ATPase 2a (SERCA2a) mediates Ca(2+) reuptake into the SR in cardiomyocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23710633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 251,
          "offsetInEndSection": 407,
          "text": "Failing hearts are characterized by reduced contractile properties caused by impaired Ca(2+) cycling between the sarcoplasm and sarcoplasmic reticulum (SR)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23710633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 874,
          "offsetInEndSection": 1023,
          "text": "SERCA2a activity can be regulated at multiple levels of a signaling cascade comprised of phospholamban, protein phosphatase 1, inhibitor-1, and PKC\u03b1."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23710633",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 526,
          "offsetInEndSection": 677,
          "text": "Of note, the expression level and/or activity of SERCA2a, translating to the quantity of SR Ca(2+) uptake, are significantly reduced in failing hearts."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2052626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 270,
          "text": "It regulates the flow of bile and pancreatic juice into the duodenum and prevents reflux of duodenal contents into the ducts."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2052626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1353,
          "offsetInEndSection": 1556,
          "text": "Motility disorders characterized as an elevated basal pressure, rapid contraction frequency, paradoxical response to cholecystokinin octapeptide or excess of retrograde contractions have been identified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2052626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1006,
          "offsetInEndSection": 1194,
          "text": "The contractions and basal pressure are inhibited by ingestion of a meal or infusion of cholecystokinin octapeptide, thus enhancing the flow of bile and pancreatic juice into the duodenum."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2052626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2108,
          "offsetInEndSection": 2330,
          "text": "Improved understanding of the controlling mechanisms of sphincter of Oddi motility and the pathophysiology of sphincter of Oddi dysfunction should assist in the development of effective pharmacotherapy for these disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2052626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 937,
          "offsetInEndSection": 1005,
          "text": "These contractions are present throughout the interdigestive period."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Deep brain stimulation (DBS) is the technique of neurostimulation of deep brain structures for the treatment of conditions such as essential tremor, dystonia, Parkinson's disease and chronic pain syndromes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 207,
          "offsetInEndSection": 340,
          "text": "The procedure uses implanted deep brain stimulation electrodes connected to extension leads and an implantable pulse generator (IPG)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 617,
          "text": "We describe a patient who received bilateral globus pallidus internus DBS for dystonia with initially good clinical response, but the device eventually failed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 772,
          "offsetInEndSection": 848,
          "text": "Twiddler's syndrome was first described in patients with cardiac pacemakers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549607",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 932,
          "offsetInEndSection": 1075,
          "text": "Twiddler's syndrome should be suspected whenever there is a failure of the DBS device to relieve symptoms previously responsive to stimulation."
        }
      ]
    },
    {
      "id": "67d6be8a18b1e36f2e000022",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33433580",
        "http://www.ncbi.nlm.nih.gov/pubmed/30028313",
        "http://www.ncbi.nlm.nih.gov/pubmed/17508036",
        "http://www.ncbi.nlm.nih.gov/pubmed/28590501",
        "http://www.ncbi.nlm.nih.gov/pubmed/24837143",
        "http://www.ncbi.nlm.nih.gov/pubmed/30515001",
        "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
        "http://www.ncbi.nlm.nih.gov/pubmed/30262714",
        "http://www.ncbi.nlm.nih.gov/pubmed/14684236",
        "http://www.ncbi.nlm.nih.gov/pubmed/29018725"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 395,
          "offsetInEndSection": 570,
          "text": "Open-angle and narrow-angle forms of glaucoma are reviewed, including a description of the pathophysiology, risk factors, screening, disease monitoring, and treatment options."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 71,
          "offsetInEndSection": 144,
          "text": "Many patients with glaucoma are asymptomatic early in the disease course."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 571,
          "offsetInEndSection": 761,
          "text": "Glaucoma is a chronic progressive optic neuropathy, characterized by damage to the optic nerve and retinal nerve fiber layer, that can lead to permanent loss of peripheral or central vision."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Glaucoma is the most common cause of irreversible blindness worldwide."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 825,
          "offsetInEndSection": 921,
          "text": "Other important risk factors include older age, nonwhite race, and a family history of glaucoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30028313",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 472,
          "offsetInEndSection": 680,
          "text": "Since patients suffering from this glaucomatous optic neuropathy (GON) first notice visual impairment when they have lost > 40% of their RGCs, early diagnosis is the key to retard the progression of glaucoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30028313",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Peripheral vision loss followed by \"tunnel vision\" and eventual irreversible blindness is the fate of patients afflicted by various forms of glaucoma including primary open-angle glaucoma (POAG) and normotensive glaucoma (NTG)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30028313",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 850,
          "offsetInEndSection": 1058,
          "text": "However, retinal vascular abnormalities and a high sensitivity of RGCs and optic nerve head components to neurotoxic, inflammatory, oxidative and mechanical insults also contribute to vision loss in POAG/GON."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30028313",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 681,
          "offsetInEndSection": 849,
          "text": "Elevated intraocular pressure (IOP), low cerebrospinal and/or low intracranial fluid pressure, advancing age, and ethnicity are major risk factors associated with POAG."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30028313",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1059,
          "offsetInEndSection": 1208,
          "text": "Current treatment modalities for POAG and NTG involve lowering IOP using topical ocular drugs, combination drug products, and surgical interventions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17508036",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "The loss of retinal ganglion cells in glaucoma may lead to blindness, and current therapies are directed at reducing pressure within the eye."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17508036",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 465,
          "offsetInEndSection": 656,
          "text": "Thus, intraocular pressure-lowering strategies combined with neuroprotective therapies to protect visual neurons in the retina and brain may help to preserve vision in patients with glaucoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17508036",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 348,
          "text": "Most of the retinal ganglion cell axon lies outside the eye, and evidence from experimental primate and human glaucoma suggests that axon injury extends from the optic nerve to visual pathways in the brain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17508036",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 349,
          "offsetInEndSection": 464,
          "text": "Neurodegenerative changes in the central visual system may contribute to the pathology of glaucomatous progression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28590501",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 197,
          "text": "Here, we investigated a newborn with bilateral anophthalmia in a Chinese family."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28590501",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Anophthalmia is a rare eye development anomaly resulting in absent ocular globes or tissue in the orbit since birth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28590501",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 950,
          "offsetInEndSection": 1266,
          "text": "This study firstly reported that compound heterozygous mutations of the ALDH1A3 gene can result in anophthalmia in humans, thus highlighting those heterozygous mutations in ALDH1A3 should be considered for molecular screening in anophthalmia, particularly in cases from families without consanguineous relationships."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28590501",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 375,
          "text": "Exome sequencing revealed that compound heterozygous mutations c.287G > A (p.(Arg96His)) and c.709G > A (p.(Gly237Arg)) of the ALDH1A3 gene were present in the affected newborn."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28590501",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 376,
          "offsetInEndSection": 567,
          "text": "Both mutations were absent in all of the searched databases, including 10,000 in-house Chinese exome sequences, and these mutations were confirmed as having been transmitted from the parents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24837143",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Mutations in the myocilin gene (MYOC) are causative for 10% of cases with juvenile open-angle glaucoma and 3-4% of those with primary open-angle glaucoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24837143",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 851,
          "offsetInEndSection": 1103,
          "text": "In contrast, when Myoc(-/-) mice were crossed with \u03b2B1-crystallin-MYOC mice with ectopic overexpression of myocilin in the eye, no differences in developmental apoptosis, RGC number and INL thickness were observed when compared to wildtype littermates."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24837143",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 240,
          "offsetInEndSection": 370,
          "text": "Despite its high expression in the eye, myocilin-deficient mice have originally been reported to have no obvious ocular phenotype."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24837143",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 371,
          "offsetInEndSection": 605,
          "text": "Here we revisited the ocular phenotype of myocilin-deficient mice and detected a higher number of neurons in their inner (INL) and outer (ONL) nuclear layers, as well as a higher number of retinal ganglion cells (RGC) and their axons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24837143",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1336,
          "offsetInEndSection": 1487,
          "text": "The structural differences between Myoc(-/-) mice and wildtype littermates did not result in functional differences as measured by electroretinography."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30515001",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 313,
          "text": "Therefore, the case of a female child delivered in University Clinic Center Tuzla is presented here with bilateral anophthalmia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30515001",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Anophthalmia is congenital absence of the eyes; it may be unilateral or bilateral."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30515001",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 314,
          "offsetInEndSection": 493,
          "text": "The diagnosis was confirmed with an ocular computer tomography (CT) scan that showed under development of both globes within the orbit with a conclusion of bilateral anophthalmia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30515001",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 525,
          "offsetInEndSection": 684,
          "text": "This is unique case in the territory of Bosnia and Herzegovina, as according to the literature this is the first case of anophthalmia presented in this region."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30515001",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 494,
          "offsetInEndSection": 524,
          "text": "No other anomalies were found."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 444,
          "offsetInEndSection": 671,
          "text": "Optic nerve hypoplasia has been reported in association with other prenatal anticonvulsant exposures, but the occurrence of septo-optic dysplasia as a manifestation of valproic acid embryopathy has not been reported previously."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 797,
          "offsetInEndSection": 1074,
          "text": "The patient presented with features typical of valproic acid embryopathy, including bitemporal narrowing, hypertelorism, short palpebral fissures, epicanthal folds, microphthalmia, a flat broad nasal bridge, small mouth, hypoplastic nails, mild clinodactyly, and camptodactyly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 276,
          "text": "The use of valproic acid during pregnancy has been associated with adverse fetal outcomes, including major and minor congenital malformations, intrauterine growth retardation (IUGR), hyperbilirubinemia, hepatotoxicity, transient hyperglycemia, and fetal and neonatal distress."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 277,
          "offsetInEndSection": 443,
          "text": "In addition, intrauterine exposure to valproic acid has been associated with an increased risk of central nervous system abnormalities, primarily neural tube defects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1155,
          "offsetInEndSection": 1277,
          "text": "We report the first case of septo-optic dysplasia associated with maternal exposure to valproic acid throughout pregnancy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30262714",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 181,
          "offsetInEndSection": 266,
          "text": "A Chinese infant was born with bilateral anophthalmia and palpebral fissure closures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30262714",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Congenital anophthalmia is a rare eye anomaly which lacks a recognizable eye in the orbit."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30262714",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 180,
          "text": "It can be isolated (nonsyndromic) or be observed as a sign of other diseases (syndromic)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30262714",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 267,
          "offsetInEndSection": 372,
          "text": "Ocular and systemic examinations were performed, and genomic DNA was prepared from peripheral leukocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30262714",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 373,
          "offsetInEndSection": 428,
          "text": "The coding exons and the adjacent intrinsic sequence of"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14684236",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 571,
          "text": "A recent surge in reported cases of classical kernicterus, due in part to earlier hospital discharge and relaxation of treatment criteria for hyperbilirubinemia, and new reports of hyperbilirubinemia-induced auditory dysfunction using evoked potential based infant testing and hearing screening, underscore the need to better understand how hyperbilirubinemia causes brain damage in some infants, especially because the damage is preventable."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14684236",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1100,
          "offsetInEndSection": 1388,
          "text": "Finally, the concern is raised that partial or isolated neurologic sequelae, for example auditory neuropathy and other central auditory processing disorders, may result from excessive amount and duration of exposure to free, unconjugated bilirubin at different stages of neurodevelopment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14684236",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 572,
          "offsetInEndSection": 1099,
          "text": "Recent progress in understanding bilirubin binding and neurotoxicity resulting from unbound or \"free\" unconjugated bilirubin, how bilirubin affects the central nervous system in vivo and in vitro, and the use of new clinical tools in neonates, for example magnetic resonance imaging revealing bilateral lesions in globus pallidus and subthalamus, and abnormal brainstem auditory evoked potentials with normal inner ear function, may lead to improved detection and prevention of neurologic dysfunction and damage from bilirubin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14684236",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Bilirubin toxicity remains a significant problem despite recent advances in the care of jaundiced (hyperbilirubinemic) neonates."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 958,
          "offsetInEndSection": 1145,
          "text": "Patients suffering from glaucoma experience poor quality of life owing to the diagnosis itself, functional visual loss, inconvenience and cost of treatment, and side effects of treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1270,
          "offsetInEndSection": 1401,
          "text": "It is, therefore, important that ophthalmologists keep all the aforementioned factors in mind when managing patients with glaucoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 229,
          "offsetInEndSection": 341,
          "text": "IOP reduction by medical, laser, or surgical therapies remains the only clinically proven treatment of glaucoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Glaucoma is the most common optic neuropathy characterized by normal to raised intraocular pressure (IOP), visual field defects, loss of retinal nerve fiber layer, thinning of the neuroretinal rim, and cupping of the optic disc."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 698,
          "offsetInEndSection": 828,
          "text": "Reducing IOP and controlling its fluctuations are considered to be the most important factors in limiting progression of glaucoma."
        }
      ]
    },
    {
      "id": "680bc74618b1e36f2e000155",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
        "http://www.ncbi.nlm.nih.gov/pubmed/27430520",
        "http://www.ncbi.nlm.nih.gov/pubmed/37989956",
        "http://www.ncbi.nlm.nih.gov/pubmed/23907003",
        "http://www.ncbi.nlm.nih.gov/pubmed/27846884",
        "http://www.ncbi.nlm.nih.gov/pubmed/25746916",
        "http://www.ncbi.nlm.nih.gov/pubmed/27795534",
        "http://www.ncbi.nlm.nih.gov/pubmed/37637243",
        "http://www.ncbi.nlm.nih.gov/pubmed/33686894",
        "http://www.ncbi.nlm.nih.gov/pubmed/25496336"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Cancer immunotherapy has become a new entity of cancer treatment with successes in various clinical trials."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 768,
          "offsetInEndSection": 975,
          "text": "Therefore, in addition to immune checkpoint inhibitors, various promising cancer immunotherapies such as adoptive T-cell transfer and CAR-T therapy and combination immunotherapies are under intense scrutiny."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 976,
          "offsetInEndSection": 1090,
          "text": "Here, we focus on the cancer immunoediting hypothesis to understand the current and future cancer immunotherapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 562,
          "text": "The hypothesis called \"cancer immunoediting is an important concept in the current cancer immunotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30914573",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 108,
          "offsetInEndSection": 457,
          "text": "Immune checkpoint inhibitors, particularly targeting PD-1 and CTLA-4 show an efficient antitumor effect via reinvigorating antitumor immune responses which are generally suppressed in the tumor microenvironment, resulting in the approval for the treatment of multiple cancer types including malignant melanoma, lung cancer, gastric cancer and so on."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27430520",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 837,
          "offsetInEndSection": 1040,
          "text": "It is likely that we are poised to see significantly greater anti-cancer immunotherapy efficacy, both in improving response rates and durability for melanoma, and for other less immunogenic malignancies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27430520",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 674,
          "offsetInEndSection": 836,
          "text": "This review discusses current understanding of how these checkpoint blockade therapeutics have led to major clinical responses in patients with advanced melanoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27430520",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 108,
          "offsetInEndSection": 292,
          "text": "While prospects of tumor-selective durable immune based therapies have provided small clinical signals for many decades, recent years have demonstrated a virtual explosion in progress."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27430520",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 293,
          "offsetInEndSection": 390,
          "text": "Melanoma has led the field of cancers in which immunotherapy has produced major clinical inroads."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27430520",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 391,
          "offsetInEndSection": 535,
          "text": "The most significant and impactful immunotherapies for melanoma utilize immune checkpoint inhibition to stimulate T cell mediated tumor killing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37989956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 166,
          "offsetInEndSection": 393,
          "text": "The emergence of immune checkpoint blockade as a crucial element in current immunotherapy and combination strategies has significantly transformed the treatments of resectable and advanced (unresectable or metastatic) melanoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37989956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "In the last decade, immunotherapy has become the cornerstone in the management of patients with melanoma, the foremost cause of skin-cancer-related death in the USA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37989956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 664,
          "offsetInEndSection": 882,
          "text": "The review also explores new experimental combinations of PD-1 blockade with other immunomodulatory agents, including targeted therapies, anti-TIGIT antibodies, TLR-9 agonists, antiangiogenic agents, and mRNA vaccines."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37989956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 535,
          "offsetInEndSection": 663,
          "text": "Furthermore, we discuss the rationale for the applications of PD-1 blockade and its combination with anti-CTLA-4 and anti-LAG-3."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37989956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 394,
          "offsetInEndSection": 534,
          "text": "This paper reviews the landmark clinical trials that formed the basis of management of melanoma in the perioperative and metastatic setting."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907003",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 793,
          "offsetInEndSection": 945,
          "text": "These antibodies bring immunotherapy to the forefront and indicate that immune-modulation will be a key component of therapeutic strategies from now on."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907003",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 659,
          "offsetInEndSection": 792,
          "text": "Long term tumour control now seems achievable and thus the concept of a clinical cure is emerging by modulation of the immune system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907003",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Programmed death-1 receptor (PD-1)/its ligand (PD-L1) antibodies have changed the landscape in oncology in 2013."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907003",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 359,
          "offsetInEndSection": 478,
          "text": "Thus it is clear that these antibodies have a very broad potential and trials in many tumour types are being initiated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907003",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 479,
          "offsetInEndSection": 658,
          "text": "Breaking tolerance at the tumour site is a potent phenomenon and the potential for synergy with other checkpoint inhibitors such as ipilimumab have also been demonstrated in 2013."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27846884",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1069,
          "offsetInEndSection": 1156,
          "text": "Attempts are being made to improve responses to immunotherapy by developing biomarkers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27846884",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 3474,
          "offsetInEndSection": 3574,
          "text": "This meeting's specific focus was on advances in immunotherapy and combination therapy for melanoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27846884",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 275,
          "offsetInEndSection": 485,
          "text": "Recent advances in tumor biology and immunology has led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS) of cancer patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27846884",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 713,
          "text": "Immunotherapies in particular have emerged as highly successful approaches to treat patients with cancer including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin's disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27846884",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1580,
          "offsetInEndSection": 2349,
          "text": "However, biomarkers and assays development to guide cancer immunotherapy is highly challenging for several reasons: (i) multiplicity of immunotherapy agents with different mechanisms of action including immunotherapies that target activating and inhibitory T cell receptors (e.g., CTLA-4, PD-1, etc.); adoptive T cell therapies that include tissue infiltrating lymphocytes (TILs), chimeric antigen receptors (CARs), and T cell receptor (TCR) modified T cells; (ii) tumor heterogeneity including changes in antigenic profiles over time and location in individual patient; and (iii) a variety of immune-suppressive mechanisms in the tumor microenvironment (TME) including T regulatory cells (Treg), myeloid derived suppressor cells (MDSC) and immunosuppressive cytokines."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25746916",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 363,
          "offsetInEndSection": 704,
          "text": "In the last 5 years there has been a revolution in the clinical management of melanoma in large measure based on the development of antibodies that influence T cell regulatory pathways by overcoming checkpoint inhibition and providing co-stimulation, either of which results in significantly more effective immune-mediated tumor destruction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25746916",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 984,
          "offsetInEndSection": 1093,
          "text": "Recent progress and opportunities for future investigation of combination antibody therapy will be described."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25746916",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "The concept of using immunotherapy to treat melanoma has existed for decades."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25746916",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 362,
          "text": "The rationale comes from the knowledge that many patients with melanoma have endogenous immune responses against their tumor cells and clinically meaningful tumor regression can be achieved in a minority of patients using cytokines such as interleukin-2 and adoptive cellular therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25746916",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 705,
          "offsetInEndSection": 983,
          "text": "This review will describe the pre-clinical and clinical application of antagonistic antibodies targeting the T-cell checkpoints cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), and agonistic antibodies targeting the costimulatory pathways OX40 and 4-1BB."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27795534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 867,
          "offsetInEndSection": 1003,
          "text": "As compared with previous cancer treatments, immune checkpoint inhibitors show superior efficacy against tumors with fewer side effects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27795534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Immune checkpoint inhibitors, especially anti-programmed cell death-1 (PD-1) antibodies, have revolutionized cancer therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27795534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 628,
          "offsetInEndSection": 866,
          "text": "Since the activated lymphocytes recognize various tumor-associated antigens including a mutated antigen, immune checkpoint inhibitors exhibit continuous long-term effectiveness, despite the generation of genetic mutations in cancer cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27795534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 513,
          "offsetInEndSection": 627,
          "text": "Immune checkpoint inhibitors target lymphocytes rather than cancer cells, and evoke an anti-tumor immune reaction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27795534",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1004,
          "offsetInEndSection": 1091,
          "text": "Therefore, these novel immune checkpoint inhibitor agents are anticipated to become a 4"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37637243",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "The emergence of immunotherapy has revolutionized the traditional treatment paradigm of colorectal cancer (CRC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37637243",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 113,
          "offsetInEndSection": 325,
          "text": "Among them, immune checkpoint blockade has become the first-line treatment for metastatic colorectal cancer (mCRC) and has made significant progress in the treatment of locally advanced colorectal cancer (LACRC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37637243",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 326,
          "offsetInEndSection": 403,
          "text": "We reviewed a series of clinical trials that have made breakthrough progress."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37637243",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 404,
          "offsetInEndSection": 773,
          "text": "We will emphasize the breakthrough progress in achieving organ preservation in patients with high microsatellite instability or DNA mismatch repair deficiency (MSI-H/dMMR), and based on this, we propose the concept of selective surgery, which includes selectively removing or preserving lymph nodes, with the aim of proving our idea through more research in the future."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33686894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "Increased understanding of the interactive mechanisms between tumors and the immune system led to the development of immune checkpoint inhibitors, which have revolutioned the treatment of metastatic melanoma and subsequently many other tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33686894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 835,
          "offsetInEndSection": 1073,
          "text": "Currently, several ongoing clinical trials are investigating novel molecules, or immunotherapy combinations, in order to achieve even better survival outcomes for patients, overcoming resistance mechanisms and improving toxicity profiles."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33686894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 471,
          "offsetInEndSection": 752,
          "text": "This review summarizes the last updates about treatment with nivolumab and pembrolizumab, data on other PD-1/PDL-1 agents such as spartalizumab and atezolizumab and emerging compounds, new combinations with NKTR-214, anti LAG-3, anti IDO-1 and TVEC, new checkpoint inhibitors (e.g."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33686894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 753,
          "offsetInEndSection": 834,
          "text": "TIM-3 or TIGIT) and other new molecules for the treatment of metastatic melanoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33686894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 381,
          "offsetInEndSection": 470,
          "text": "Since then, a plethora of new molecules have enriched the armamentarium against melanoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 939,
          "offsetInEndSection": 1106,
          "text": "The current work aims to address the most recent developments regarding these innovative immunotherapies and their implementation in the treatment of metastatic NSCLC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 236,
          "text": "In the metastatic setting, major advances include the incorporation of immunotherapy and targeted therapies into the clinician's therapeutic armamentarium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 422,
          "offsetInEndSection": 516,
          "text": "The aim of immunotherapy is to specifically enhance the immune response directed to the tumor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 421,
          "text": "Standard chemotherapeutic regimens have long been reported to interfere with the immune response to the tumor; conversely, antitumor immunity may add to the effects of those therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496336",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 517,
          "offsetInEndSection": 722,
          "text": "Recently, many trials addressed the role of such therapies for metastatic NSCLC treatment: ipilimumab, tremelimumab, nivolumab and lambrolizumab are immunotherapeutic agents of main interest in this field."
        }
      ]
    },
    {
      "id": "67f857eb18b1e36f2e000105",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10535368",
        "http://www.ncbi.nlm.nih.gov/pubmed/25337310",
        "http://www.ncbi.nlm.nih.gov/pubmed/16732742",
        "http://www.ncbi.nlm.nih.gov/pubmed/19711147",
        "http://www.ncbi.nlm.nih.gov/pubmed/21733178",
        "http://www.ncbi.nlm.nih.gov/pubmed/34194605",
        "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
        "http://www.ncbi.nlm.nih.gov/pubmed/27576903",
        "http://www.ncbi.nlm.nih.gov/pubmed/10979347",
        "http://www.ncbi.nlm.nih.gov/pubmed/21491341"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10535368",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "Some patients develop atrial fibrillation after any type of surgery, some patients develop atrial fibrillation only after cardiac surgery, and still other patients never develop postoperative atrial fibrillation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10535368",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 213,
          "offsetInEndSection": 476,
          "text": "Despite the inherent difficulty in identifying the causes of postoperative atrial fibrillation, several important observations have been made during the recent past that may play a role in treating or even preventing this common and serious postoperative problem."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10535368",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 477,
          "offsetInEndSection": 608,
          "text": "This communication provides a framework within which the problem of postoperative atrial fibrillation can be evaluated and treated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25337310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "The objective of the present study is to determine the incidence of delirium and the associated factors in patients undergoing open heart surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25337310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 696,
          "offsetInEndSection": 1046,
          "text": "We found that variables, including ventilation time, increased drainage during the first 24 hours, the need for re-operation in the first 24 hours, dysrhythmias, use of inotropic agents, increased use of analgesics, increased arterial carbon dioxide, lack of visitors, and use of physical restrainers were associated with the development of delirium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25337310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 455,
          "offsetInEndSection": 576,
          "text": "A trained nurse evaluated the patients for delirium and completed the risk factor checklist on days 1 to 5 after surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25337310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1047,
          "offsetInEndSection": 1097,
          "text": "In addition, we found a delirium incidence of 29%."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25337310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1098,
          "offsetInEndSection": 1271,
          "text": "Diagnosis of cognitive disorders is of utmost value; therefore, further studies are required to clarify the risk factors because controlling them will help prevent delirium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16732742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 336,
          "offsetInEndSection": 397,
          "text": "The mean onset of delirium occurred on postoperative day 1.3."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16732742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 335,
          "text": "A total of 66 inpatients undergoing cardiac surgery were interviewed using the Delirium Rating Scale (DRS) and NEECHAM Confusion Scale (NCS) preoperatively and on days 1 and 3 postoperatively."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16732742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "The aim of the present study was to identify clinical signs detective of the postoperative delirium at the early stage for nursing management."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16732742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 627,
          "offsetInEndSection": 780,
          "text": "These results suggest that assessment of cognitive status on postoperative day is an important strategy in the early detection of postoperative delirium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16732742",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 398,
          "offsetInEndSection": 626,
          "text": "Development of delirium was detected early by cognitive impairments in the DRS subscales of perceptual disturbance, hallucination, and cognitive status, and the NCS subscales of attention, command, orientation, and verbal skill."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19711147",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 843,
          "offsetInEndSection": 901,
          "text": "The incidence of postoperative delirium was 128/582 (22%)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19711147",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1590,
          "offsetInEndSection": 1721,
          "text": "Preoperative administration of beta-blockers is associated with an increased risk of postoperative delirium after vascular surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19711147",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "To determine if there is an association between perioperative administration of beta-blockers and postoperative delirium in patients undergoing vascular surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19711147",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1722,
          "offsetInEndSection": 1827,
          "text": "Conversely, preoperative statin administration is associated with a lower risk of postoperative delirium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19711147",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1245,
          "offsetInEndSection": 1362,
          "text": "Preoperative beta-blocker administration increased the odds of postoperative delirium 2.06 times (95% CI [1.18-3.6])."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21733178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Postoperative delirium can result in increased postoperative morbidity and mortality, major demand for postoperative care and higher hospital costs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21733178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 351,
          "offsetInEndSection": 736,
          "text": "Some evidence suggests that these unwanted effects vary according to each hypnotic's specific pharmacodynamic and pharmacokinetic characteristics and its interaction with the individual patient.We designed this study to evaluate postoperative delirium rate after general anaesthesia with various hypnotics in patients undergoing surgical procedures other than cardiac or brain surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21733178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 737,
          "offsetInEndSection": 853,
          "text": "We also aimed to test whether delayed postoperative cognitive recovery increases the risk of postoperative delirium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21733178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 971,
          "offsetInEndSection": 1290,
          "text": "In all patients anaesthesia will be induced with propofol and fentanyl, and maintained with the anaesthetics desflurane, or sevoflurane, or propofol and the analgesic opioid fentanyl.The onset of postoperative delirium will be monitored with the Nursing Delirium Scale every three hours up to 72 hours post anaesthesia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21733178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 240,
          "offsetInEndSection": 350,
          "text": "Their persisting clinical action can delay postoperative cognitive recovery and favour postoperative delirium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34194605",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Delayed neurocognitive recovery (dNCR) is a major complication after anesthesia and surgery in older adults."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34194605",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 126,
          "text": "Alpha-synuclein ("
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 217,
          "text": "In such patients, postoperative delirium is also frequent."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1414,
          "offsetInEndSection": 1472,
          "text": "Postoperative delirium was noted in 54.7% of the subjects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1603,
          "offsetInEndSection": 1807,
          "text": "Both uni- and multivariate analyses showed that postoperative delirium was associated with an advanced age (more than 80 years), low preoperative NEECHAM and MMSE scores, the preoperative QOL, and E-PASS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 410,
          "offsetInEndSection": 700,
          "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "The incidences of surgery-field disorders such as femur neck fracture and colorectal cancer in elderly persons have increased with the rapid aging of society."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27576903",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1118,
          "offsetInEndSection": 1280,
          "text": "The scoring system combining multiple risk factors may be useful for predicting patients with an elevated risk for postoperative delirium after abdominal surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27576903",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Despite the presence of several diagnosis scales for delirium, no prediction scale that is specific for postoperative delirium after abdominal surgery is available."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27576903",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 259,
          "text": "We sought to create a novel delirium prediction system that is specific for abdominal surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27576903",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 624,
          "text": "Seventy-three patients (34%) were categorized in the delirium group."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27576903",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 260,
          "offsetInEndSection": 377,
          "text": "This study included 213 consecutive patients who required management in the surgical ICU following abdominal surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1146,
          "offsetInEndSection": 1268,
          "text": "Major cardiac iatrogenic complications are an important factor among patients admitted to the intensive cardiac care unit."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 299,
          "text": "To study and evaluate major cardiac iatrogenic disease as the cause of admission to the intensive cardiac care unit in the modern era."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 723,
          "offsetInEndSection": 1075,
          "text": "There was evidence of a major cardiac iatrogenic problem as the cause for admission in 64 patients (2.5%): 58 (91%) suffered from arrhythmias (mainly bradyarrhythmias) secondary to beta-blockers, amiodarone, calcium antagonists, electrolyte imbalance or a combination, and 6 (9%) had non-arrhythmic events (hypotension, syncope or acute heart failure)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 300,
          "offsetInEndSection": 479,
          "text": "We assessed 64 critically ill patients suffering from major cardiac iatrogenic problems among a total of 2,559 patients admitted to the intensive cardiac care unit during 3 years."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Iatrogenic illness, defined as a disease that results from a diagnostic procedure or from any form of therapy, is a well-recognized phenomenon in clinical practice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 659,
          "offsetInEndSection": 919,
          "text": "Postoperative cardiac morbidity was confirmed after surgery during the index hospitalization and included stroke,renal failure, ventilation>24 h, deep sternal wound infection, reoperation, arrhythmia and 30-day mortality at any location (n=59, 37.3% of total)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 294,
          "text": "The aim of this study was to examine depression and anxiety disorders and their characteristic symptoms (anhedonia/low positive affect and anxious arousal, respectively), along with measures of state negative affect (NA) and Type D personality, in relation to cardiac surgery related morbidity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 920,
          "offsetInEndSection": 1203,
          "text": "After adjustment for age, recent myocardial infarction, heart failure, hypertension, urgency of surgery and time spent on cardiopulmonary bypass generalized anxiety disorder was associated with cardiac morbidity (odds ratio [OR]=3.26, 95% confidence interval [CI] 1.10-9.67, p=0.03)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1471,
          "offsetInEndSection": 1667,
          "text": "Affective disorders, affective phenotypes, and personality traits were differentially associated with post-cardiac surgery morbidity outcomes independent of cardiac surgery morbidity risk factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1668,
          "offsetInEndSection": 1778,
          "text": "Concurrent investigation of depression and anxiety with respect to cardiac outcomes warrants further research."
        }
      ]
    },
    {
      "id": "67e291a718b1e36f2e000081",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9133488",
        "http://www.ncbi.nlm.nih.gov/pubmed/1474300",
        "http://www.ncbi.nlm.nih.gov/pubmed/12947243",
        "http://www.ncbi.nlm.nih.gov/pubmed/26372543",
        "http://www.ncbi.nlm.nih.gov/pubmed/35747039",
        "http://www.ncbi.nlm.nih.gov/pubmed/12063146",
        "http://www.ncbi.nlm.nih.gov/pubmed/23670060",
        "http://www.ncbi.nlm.nih.gov/pubmed/28280401",
        "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
        "http://www.ncbi.nlm.nih.gov/pubmed/26433894"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9133488",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 288,
          "text": "Anxiety disorders, which include generalized anxiety disorder, panic disorder, posttraumatic stress disorder, obsessive-compulsive disorder, and phobic disorders, are the psychiatric disorders most commonly found in the community, according to the results of recent epidemiologic studies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9133488",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 392,
          "offsetInEndSection": 631,
          "text": "This failure to correctly diagnose and appropriately treat anxiety disorders can result in overutilization of health care services and increased morbidity and mortality rates from either the anxiety disorder or comorbid medical conditions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9133488",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 391,
          "text": "However, failure to diagnose these disorders occurs in up to 50% of patients with an anxiety disorder."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9133488",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 632,
          "offsetInEndSection": 764,
          "text": "Reliable diagnostic tools to improve the early recognition of anxiety disorders can subsequently result in more effective treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1474300",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 119,
          "offsetInEndSection": 407,
          "text": "The accumulating data has suggested that anxiety disorders may have many consequences including decreased quality of life, economic dependence, multiple somatic complaints, maladaptive personality traits, and increased mortality due to suicide, cardiovascular, and cerebrovascular causes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1474300",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Over the past two decades, anxiety disorders have become the focus of much research after years of relative obscurity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1474300",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 408,
          "offsetInEndSection": 479,
          "text": "Aggressive management of these disorders may greatly lessen the impact."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12947243",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 181,
          "offsetInEndSection": 290,
          "text": "Anxiety disorders, especially generalized anxiety disorder and phobias, are highly prevalent in older people."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12947243",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Although anxiety disorders are the most prevalent group of disorders in the United States, little is known about the efficacy of treatments for these disorders in elderly patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12947243",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 291,
          "offsetInEndSection": 393,
          "text": "Anxiety symptoms and disorders are associated with increased mortality and disability in older people."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12947243",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 394,
          "offsetInEndSection": 533,
          "text": "Risk factors for anxiety disorders include chronic medical illness, disability, low education, low social network, and poor social support."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12947243",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 740,
          "offsetInEndSection": 832,
          "text": "Cognitive-behavioral therapy is recommended as first-line psychotherapy for these disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26372543",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 296,
          "text": "While TNF-\u03b1 inhibitors have revolutionized the treatment of rheumatic diseases, including PsA, not all patients respond to these agents while others are unsuitable or intolerant to them."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26372543",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 702,
          "offsetInEndSection": 921,
          "text": "It improved signs and symptoms of PsA, inhibited radiographic progression and was effective in dactylitis, enthesitis, and skin disease, with a safety profile consistent with the one observed in patients with psoriasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26372543",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 494,
          "offsetInEndSection": 701,
          "text": "Ustekinumab, a fully human IgG1\u03ba monoclonal antibody that targets the common subunit p40 of IL-12 and IL-23, has been shown in clinical trials, to be well-tolerated and effective in patients with active PsA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26372543",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Psoriatic arthritis (PsA) is a chronic inflammatory seronegative spondyloarthritis associated with psoriasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26372543",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 389,
          "offsetInEndSection": 493,
          "text": "In the past years, the IL-23/Th17 axis has emerged as an important mechanism in the pathogenesis of PsA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747039",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Post-traumatic stress disorder (PTSD) is an anxiety disorder that often presents after exposure to a traumatic, life-threatening event."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747039",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 507,
          "offsetInEndSection": 656,
          "text": "Psychoactive drugs such as MDMA, ketamine, and psilocybin have been shown to specifically target and decrease fear and anxiety pathways in the brain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747039",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 802,
          "offsetInEndSection": 1005,
          "text": "Historically, federal and state laws have restricted research into how psychoactive drugs can be used to treat mental illness due to the widespread belief that these drugs present more harm than benefit."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747039",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1006,
          "offsetInEndSection": 1164,
          "text": "However, the current shift in public opinion on psychedelics has propelled research to look into the benefits of these drugs for patients with mental illness."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747039",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 270,
          "offsetInEndSection": 506,
          "text": "While traditional psychopharmacology and psychotherapy are the mainstays of the treatment of PTSD currently, psychoactive drugs (otherwise known as psychedelics) are being explored for their novel role in the treatment of PTSD patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12063146",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 459,
          "text": "Using the FDA database, we assessed suicide and suicide attempt risk among patients, participating in recent clinical trials evaluating new anti-anxiety medications, with diagnosis of panic disorder (PD), social anxiety disorder or social phobia (SP), generalized anxiety disorder (GAD), post traumatic stress disorder (PTSD), and obsessive compulsive disorder (OCD)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12063146",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1096,
          "text": "Suicide risk in patients with anxiety disorders is higher than previously thought."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12063146",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Previous reports of suicide risk in patients with anxiety disorders have been inconsistent."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12063146",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1097,
          "offsetInEndSection": 1174,
          "text": "Patients with anxiety disorders warrant explicit evaluation for suicide risk."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12063146",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 460,
          "offsetInEndSection": 559,
          "text": "Overall, among 20076 participating anxious patients, 12 committed suicide and 28 attempted suicide."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23670060",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 714,
          "offsetInEndSection": 918,
          "text": "TNF-\u03b1 antagonists induced consistent benefits across health outcomes in psoriasis, but only monoclonal antibodies, infliximab and adalimumab were effective in improving QoL in patients with BD, HS and PG."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23670060",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Aim of the study was to investigate the impact of TNF-\u03b1 antagonists on health-related quality of life (HRQoL) in selected skin diseases, i.e."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23670060",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 575,
          "offsetInEndSection": 713,
          "text": "From the literature it is evident that skin diseases can affect physical, psychological, social and occupational aspects of everyday life."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23670060",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1005,
          "offsetInEndSection": 1121,
          "text": "For the majority of patients with skin diseases, the most important negative impacts on QoL were appearance related."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23670060",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 401,
          "offsetInEndSection": 574,
          "text": "Citations were screened for randomized, controlled trials of TNF-\u03b1 antagonists (adalimumab, etanercept and infliximab) versus placebo in adults with psoriasis, BD, HS or PG."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28280401",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease with a broad clinical spectrum and variable course."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28280401",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 408,
          "offsetInEndSection": 679,
          "text": "The commercialization of tumor necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab) as well as interleukin (IL)-12/23 (ustekinumab) and IL-17 (secukinumab) inhibitors is representative of a revolution in the treatment of PsA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28280401",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1287,
          "offsetInEndSection": 1445,
          "text": "However, future studies directly comparing different biological drugs and assessing the efficacy of treatment strategies specific for PsA are urgently needed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28280401",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 207,
          "offsetInEndSection": 407,
          "text": "The management of PsA has changed tremendously in the last decade, thanks to an earlier diagnosis, an advancement in pharmacological therapies, and a wider application of a multidisciplinary approach."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28280401",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 206,
          "text": "It can involve musculoskeletal structures as well as skin, nails, eyes, and gut."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1476,
          "offsetInEndSection": 1659,
          "text": "This review reports on the latest progress made in the clinical use of biologic drugs for psoriasis focusing on the new human IL-12/23 monoclonal antibody, ustekinumab, for psoriasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1352,
          "offsetInEndSection": 1475,
          "text": "In particular a phase II study and two phase III studies, PHOENIX 1 together with PHOENIX 2, show very encouraging results."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 748,
          "offsetInEndSection": 873,
          "text": "Recent studies have demonstrated that interleukins (IL) 12 and 23 play an important role in the pathophysiology of psoriasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Psoriasis is a chronic, genetically determined, immune-mediated, inflammatory skin disease affecting approximately 2% to 3% of Caucasian population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1027,
          "offsetInEndSection": 1295,
          "text": "Ustekinumab (CNTO 1275, Centocor Inc, Malvern, PA, USA) is a human monoclonal antibody that binds to the shared p40 protein subunit of human interleukins 12 and 23 with high affinity and specificity, thereby preventing interaction with their surface IL-12R\u03b21 receptor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1262,
          "offsetInEndSection": 1369,
          "text": "The presence of any pain symptom was significantly associated with having a psychiatric disorder (OR 9.68)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 304,
          "offsetInEndSection": 482,
          "text": "We investigated the frequency and types of psychiatric disorders and their relationship to systemic manifestations in a cohort of 106 classic and hypermobility type EDS patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1697,
          "offsetInEndSection": 1809,
          "text": "Our findings demonstrate a high frequency of psychiatric disorders and an association with pain symptoms in EDS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 303,
          "text": "Psychiatric disorders and psychosocial impairment are common, yet poorly characterized, findings in EDS patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1056,
          "offsetInEndSection": 1261,
          "text": "Abdominal pain [odds ratio (OR) 7.38], neuropathic pain (OR 4.07), migraines (OR 5.21), joint pain (OR 2.85) and fatigue (OR 5.55) were significantly associated with the presence of a psychiatric disorder."
        }
      ]
    },
    {
      "id": "680b7f4818b1e36f2e000154",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28026754",
        "http://www.ncbi.nlm.nih.gov/pubmed/29047032",
        "http://www.ncbi.nlm.nih.gov/pubmed/29846502",
        "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
        "http://www.ncbi.nlm.nih.gov/pubmed/30632193",
        "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
        "http://www.ncbi.nlm.nih.gov/pubmed/20383195",
        "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
        "http://www.ncbi.nlm.nih.gov/pubmed/23648276",
        "http://www.ncbi.nlm.nih.gov/pubmed/31090660"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28026754",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2012,
          "offsetInEndSection": 2190,
          "text": "This study corroborates that very deep CNNs with effective training mechanisms can be employed to solve complicated medical image analysis tasks, even with limited training data."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28026754",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 294,
          "offsetInEndSection": 441,
          "text": "In order to meet these challenges, we propose a novel method for melanoma recognition by leveraging very deep convolutional neural networks (CNNs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28026754",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 442,
          "offsetInEndSection": 698,
          "text": "Compared with existing methods employing either low-level hand-crafted features or CNNs with shallower architectures, our substantially deeper networks (more than 50 layers) can acquire richer and more discriminative features for more accurate recognition."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28026754",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1081,
          "offsetInEndSection": 1293,
          "text": "Then, we construct a fully convolutional residual network (FCRN) for accurate skin lesion segmentation, and further enhance its capability by incorporating a multi-scale contextual information integration scheme."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28026754",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1454,
          "offsetInEndSection": 1679,
          "text": "This framework enables the classification network to extract more representative and specific features based on segmented results instead of the whole dermoscopy images, further alleviating the insufficiency of training data."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047032",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 192,
          "offsetInEndSection": 277,
          "text": "CNNs have been successfully used in both skin lesion segmentation and classification."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047032",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 63,
          "offsetInEndSection": 191,
          "text": "Computer-aided diagnosis systems powered by convolutional neural networks (CNNs) can improve diagnostic accuracy and save lives."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047032",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 690,
          "offsetInEndSection": 912,
          "text": "Our results indicate that segmentation border enlargement produces, to a certain degree, better results across all metrics of interest when using a convolutional based classifier built using the transfer learning paradigm."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047032",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 913,
          "offsetInEndSection": 1165,
          "text": "Consequently, preprocessing methods which produce borders larger than the actual lesion can potentially improve classifier performance, more than both perfect segmentation, using dermatologist created ground truth masks, and no segmentation altogether."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047032",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 552,
          "offsetInEndSection": 689,
          "text": "Ostensibly, segmenting a target skin lesion will remove inessential information, non-lesion skin, and artifacts to aid in classification."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29846502",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "Deep learning convolutional neural networks (CNN) may facilitate melanoma detection, but data comparing a CNN's diagnostic performance to larger groups of dermatologists are lacking."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29846502",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 963,
          "offsetInEndSection": 1116,
          "text": "Additionally, the CNN's performance was compared with the top-five algorithms of the 2016 International Symposium on Biomedical Imaging (ISBI) challenge."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29846502",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2001,
          "offsetInEndSection": 2110,
          "text": "Irrespective of any physicians' experience, they may benefit from assistance by a CNN's image classification."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29846502",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 465,
          "offsetInEndSection": 751,
          "text": "Main outcome measures were sensitivity, specificity and area under the curve (AUC) of receiver operating characteristics (ROC) for diagnostic classification (dichotomous) of lesions by the CNN versus an international group of 58 dermatologists during level-I or -II of the reader study."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29846502",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1420,
          "offsetInEndSection": 1627,
          "text": "The CNN ROC curve revealed a higher specificity of 82.5% when compared with dermatologists in level-I (71.3%, P\u2009<\u20090.01) and level-II (75.7%, P\u2009<\u20090.01) at their sensitivities of 86.6% and 88.9%, respectively."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 670,
          "offsetInEndSection": 777,
          "text": "Multiple 2D maps of choline (Cho), creatine (Cr), and N-acetylaspartate (NAA) of the tumors were generated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 148,
          "offsetInEndSection": 413,
          "text": "In order to improve the differential diagnosis, we combined fluorine-18 2-fluoro-deoxyglucose positron emission tomography ((18)F-FDG PET), proton magnetic resonance spectroscopy ((1)H MRS) and histological data to develop a multi-parametric machine-learning model."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "The ability to differentiate between brain tumor progression and radiation therapy induced necrosis is critical for appropriate patient management."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 778,
          "offsetInEndSection": 906,
          "text": "A support vector machine (SVM) learning model was established to take imaging biomarkers and histological data as input vectors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1814,
          "offsetInEndSection": 1945,
          "text": "However, addition of two more parameters, Cho and Cr of brain parenchyma contralateral to the tumor, increased the accuracy to 92%."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30632193",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "text": "Some interesting recent studies have shown that neural network models are useful alternatives in modeling survival data when the assumptions of a classical parametric or semiparametric survival model such as the Cox (1972) model are seriously violated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30632193",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 470,
          "text": "However, to the best of our knowledge, the plausibility of adapting the emerging extreme learning machine (ELM) algorithm for single-hidden-layer feedforward neural networks to survival analysis has not been explored."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30632193",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 471,
          "offsetInEndSection": 539,
          "text": "In this paper, we present a kernel ELM Cox model regularized by an L"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1553,
          "offsetInEndSection": 1718,
          "text": "Based on these results, we conclude that a combination of multimodal imaging methods should be used to precisely assess the restaging of rectal cancer following CRT."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 884,
          "offsetInEndSection": 1099,
          "text": "Restaging after neoadjuvant chemoradiotherapy (CRT) remains a challenge with all modalities because it is difficult to reliably differentiate between the tumor mass and other radiation-induced changes in the images."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1184,
          "offsetInEndSection": 1326,
          "text": "Although CT is most commonly used to evaluate treatment responses, its utility for identifying and following-up metastatic lesions is limited."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 742,
          "offsetInEndSection": 883,
          "text": "Positron emission tomography (PET)-CT may be useful in detecting occult synchronous tumors or metastases at the time of initial presentation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24764662",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 236,
          "offsetInEndSection": 388,
          "text": "Endorectal ultrasonography (EUS) is suitable for assessing the extent of tumor invasion, particularly in early-stage or superficial rectal cancer cases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20383195",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 294,
          "text": "In this study, we examined the expression and putative functions of a novel class of non-coding RNAs known as transcribed ultraconserved regions (T-UCRs) in neuroblastoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20383195",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 760,
          "offsetInEndSection": 970,
          "text": "For the first time, our results define a T-UCR expression landscape in neuroblastoma and suggest widespread T-UCR involvement in diverse cellular processes that are deregulated in the process of tumourigenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20383195",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 466,
          "offsetInEndSection": 606,
          "text": "A functional genomics approach based on the integration of multi-level transcriptome data was adapted to gain insights into T-UCR functions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20383195",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 759,
          "text": "Assignments of T-UCRs to cellular processes such as TP53 response, differentiation and proliferation were verified using various cellular model systems."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20383195",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 465,
          "text": "Genome-wide expression profiling revealed correlations between specific T-UCR expression levels and important clinicogenetic parameters such as MYCN amplification status."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Thymidylate synthase (TS) and Topoisomerase I (Topo I) are significant biomarkers in colorectal cancer (CRC)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 265,
          "text": "We aimed to study the expression of TS and Topo I in patients with resected CRC who received adjuvant chemotherapy and correlated it with clinical outcome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 440,
          "offsetInEndSection": 542,
          "text": "Archival paraffin-embedded tumor tissues were used for immunohistochemical detection of TS and Topo I."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1436,
          "offsetInEndSection": 1546,
          "text": "Patients with resected CRC expressing Topo I seem to benefit from irinotecan-containing adjuvant chemotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 656,
          "text": "Immunohistochemistry was performed on tissue microarray slides using monoclonal antibodies against TS and Topo I."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23648276",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 972,
          "offsetInEndSection": 1157,
          "text": "We conclude that network analysis is an effective method to characterize the complexity of AED administration patterns in children with epilepsy with many promising future applications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23648276",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 301,
          "offsetInEndSection": 457,
          "text": "The current article presents a concise review of network theory and its application to the characterization of AED use in children with refractory epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23648276",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 647,
          "text": "Current and previous AEDs prescribed to 27 children with refractory, localization-related epilepsy were recorded, and network theory was applied to identify patterns of drug administration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23648276",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Network analysis is an emerging tool for the study of complex systems."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23648276",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 892,
          "offsetInEndSection": 971,
          "text": "We also identified three subnetworks of AEDs that were commonly coadministered."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "This review critically analyzes how machine learning is being used to support clinical decision-making in the management of potentially resectable pancreatic cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 697,
          "offsetInEndSection": 952,
          "text": "Three studies predicted survival time using Bayesian modeling (n = 1) and artificial neural network (n = 1), and one study explored machine learning algorithms including Bayesian network, decision trees, k-nearest neighbor, and artificial neural networks."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1229,
          "offsetInEndSection": 1512,
          "text": "The future direction of research relies on expanding our view of the multidisciplinary team to include professionals from computing and data science with algorithms developed in conjunction with clinicians and viewed as aids, not replacement, to traditional clinical decision-making."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 592,
          "offsetInEndSection": 696,
          "text": "Three studies were Markov decision-analysis models comparing neoadjuvant therapy versus upfront surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 351,
          "offsetInEndSection": 509,
          "text": "Studies were assessed using the checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist."
        }
      ]
    },
    {
      "id": "67cde43c81b102733300001e",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32059832",
        "http://www.ncbi.nlm.nih.gov/pubmed/27346786",
        "http://www.ncbi.nlm.nih.gov/pubmed/21209713",
        "http://www.ncbi.nlm.nih.gov/pubmed/30385883",
        "http://www.ncbi.nlm.nih.gov/pubmed/26361263",
        "http://www.ncbi.nlm.nih.gov/pubmed/31356255",
        "http://www.ncbi.nlm.nih.gov/pubmed/29273685",
        "http://www.ncbi.nlm.nih.gov/pubmed/25105999",
        "http://www.ncbi.nlm.nih.gov/pubmed/30215690",
        "http://www.ncbi.nlm.nih.gov/pubmed/21956421"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32059832",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 267,
          "text": "Graves' disease (GD) is characterized by thyrotoxicosis, caused by the presence of circulating thyroid stimulating antibodies (TSAb), that are determinant also in the pathogenesis of its extrathyroidal manifestations [Graves' ophthalmopathy (GO), pretibial myxedema]."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32059832",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 442,
          "offsetInEndSection": 629,
          "text": "In GD, the existing treatments are not ideal for hyperthyroidism (long-term remission with anti-thyroid-drugs only in 50% of patients; while radioiodine and surgery cause hypothyroidism)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32059832",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 958,
          "offsetInEndSection": 1049,
          "text": "Further researches are necessary to identify novel effective therapies targeting GD, or GO."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32059832",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 268,
          "offsetInEndSection": 441,
          "text": "T helper (Th)1 immune response prevails in the immune-pathogenesis of GD and GO, during the active phase, when Th1 chemokines, and their (C-X-C)R3 receptor, play a key role."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32059832",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 630,
          "offsetInEndSection": 768,
          "text": "In GD, antigen-specific therapy has been recently published, with the induction of T cell tolerance via an immunization by TSH-R peptides."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346786",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Graves' ophthalmopathy is defined as autoimmune inflammation of extraocular muscles and orbital fat or connective tissue, usually in patients with Graves' disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346786",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 264,
          "text": "About one in 20 patients with Graves' hyperthyroidism has moderate-to-severe Graves' ophthalmopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346786",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1600,
          "offsetInEndSection": 1767,
          "text": "Approaches that target the causal mechanism of Graves' ophthalmopathy (antibodies or antagonists that block thyroid-stimulating-hormone receptors) also look promising."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346786",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 411,
          "offsetInEndSection": 580,
          "text": "Intravenous methylprednisolone pulses are more effective and better tolerated than oral prednisone in the treatment of active, moderate-to-severe Graves' ophthalmopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346786",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 674,
          "offsetInEndSection": 1092,
          "text": "Two randomised controlled trials of rituximab reached seemingly contradictory conclusions-rituximab was not better with respect to the primary outcome (clinical activity score) than placebo in one trial (which, however, was confounded by rather long Graves' ophthalmopathy duration), but was slightly better than intravenous methylprednisolone pulses in the other (disease flare-ups occurred only in the latter group)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21209713",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 347,
          "text": "The two major autoimmune thyroid diseases (ATDs) include Graves' disease (GD) and autoimmune thyroiditis (AT); both of which are characterized by infiltration of the thyroid by T and B cells reactive to thyroid antigens, by the production of thyroid autoantibodies and by abnormal thyroid function (hyperthyroidism in GD and hypothyroidism in AT)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21209713",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 348,
          "offsetInEndSection": 543,
          "text": "While the exact etiology of thyroid autoimmunity is not known, it is believed to develop when a combination of genetic susceptibility and environmental encounters leads to breakdown of tolerance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21209713",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 544,
          "offsetInEndSection": 660,
          "text": "It is important to recognize thyroid dysfunction at an early stage by maintaining an appropriate index of suspicion."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30385883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 726,
          "offsetInEndSection": 813,
          "text": "This is notable because TSHR is the established primary autoantigen in Graves' disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30385883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Thyroid-associated ophthalmopathy (TAO), an autoimmune component of Graves' disease, remains a disfiguring and potentially blinding condition."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30385883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 893,
          "offsetInEndSection": 1012,
          "text": "In addition, antibodies against IGF-IR have been detected in patients with Graves' disease and in rodent models of TAO."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30385883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 313,
          "text": "The recent literature is reviewed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30385883",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 278,
          "text": "Here, the author reviews the role of insulin-like growth factor-I receptor pathway in TAO and how it might be therapeutically targeted."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26361263",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "The medical treatment of Graves' orbitopathy (GO) is usually reserved to moderate to severe disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26361263",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1104,
          "offsetInEndSection": 1252,
          "text": "Clinical practice will greatly benefit from the use of disease modifying agents in GO, as compared to steroids, currently standard treatment for GO."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26361263",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 594,
          "offsetInEndSection": 732,
          "text": "Potential targets for therapy in GO are the TSH receptor and the IGF-1 receptor on the fibroblasts, inflammatory cytokines, B and T cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26361263",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 271,
          "offsetInEndSection": 402,
          "text": "Immunosuppressive therapy alternative to corticosteroids may target the different antigens involved in pathogenic mechanisms of GO."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26361263",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1374,
          "offsetInEndSection": 1509,
          "text": "However, larger randomized controlled trials are needed for definitive data on the potential disease-modifying role of rituximab in GO."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31356255",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Thyroid eye disease is a complex autoimmune disorder which causes substantial morbidity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31356255",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 273,
          "offsetInEndSection": 384,
          "text": "Most signs and symptoms of thyroid eye disease (TED) can be explained by the expansion of the orbital contents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31356255",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 753,
          "offsetInEndSection": 883,
          "text": "In the last decade, the pathophysiology of TED has also been revised with the identification of new potential therapeutic targets."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31356255",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1362,
          "offsetInEndSection": 1437,
          "text": "This short review summarizes the recent research developments in this area."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31356255",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 385,
          "offsetInEndSection": 431,
          "text": "Steroids are the mainstay of treatment in TED."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29273685",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 388,
          "offsetInEndSection": 622,
          "text": "It usually presents as a component of the syndrome known as Graves' disease where loss of immune tolerance to the thyrotropin receptor (TSHR) results in the generation of activating antibodies against that protein and hyperthyroidism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29273685",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Thyroid-associated ophthalmopathy (TAO) is a vexing and poorly understood autoimmune process involving the upper face and tissues surrounding the eyes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29273685",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1568,
          "offsetInEndSection": 1662,
          "text": "It is possible that other autoimmune diseases might also benefit from this treatment strategy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29273685",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 727,
          "offsetInEndSection": 879,
          "text": "We have reported over the past 2 decades evidence that the insulin-like growth factorI receptor (IGF1R) may also participate in the pathogenesis of TAO."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29273685",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 623,
          "offsetInEndSection": 726,
          "text": "The role for TSHR and these antibodies in the development of TAO is considerably less well established."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25105999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1063,
          "offsetInEndSection": 1300,
          "text": "Current clinical practice for Graves' ophthalmopathy will greatly benefit from the availability of immunosuppressors that act as disease-modifying drugs, as compared to steroids, the current standard treatment for Graves' ophthalmopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25105999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "In recent years, immunosuppressive therapy, as an alternative to corticosteroids, has been proposed as novel agents which target the various antigens involved in the pathogenesis of Graves' ophthalmopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25105999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 339,
          "offsetInEndSection": 586,
          "text": "Potential targets for immune therapy in Graves' ophthalmopathy are the antigens expressed on the target organ of inflammation, namely the receptor and the insulin growth factor -1 receptor on fibroblasts, inflammatory cytokines, and B and T cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25105999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 801,
          "offsetInEndSection": 928,
          "text": "A recent open study with tocilizumab, an anti-soluble interleukin-6 receptor, has shown inactivation of Graves' ophthalmopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25105999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 587,
          "offsetInEndSection": 800,
          "text": "The most promising results are observed with small thyroid stimulating hormone receptor molecules interacting with the receptor on thyrocytes and fibroblasts and with the anti-IGF-1 receptor antibody teprotumumab."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30215690",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Thyroid-associated ophthalmopathy (TAO) is a complex disease process presumed to emerge from autoimmunity occurring in the thyroid gland, most frequently in Graves disease (GD)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30215690",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 812,
          "offsetInEndSection": 1031,
          "text": "These cells, known as fibrocytes, express relatively high levels of functional TSH receptor (TSHR) through which they can be activated by TSH and the GD-specific pathogenic antibodies that underpin thyroid overactivity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30215690",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1032,
          "offsetInEndSection": 1169,
          "text": "Fibrocytes also express insulin-like growth factor I receptor (IGF-IR) with which TSHR forms a physical and functional signaling complex."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30215690",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1279,
          "offsetInEndSection": 1390,
          "text": "Some studies suggest that IGF-IR-activating antibodies are generated in GD, whereas others refute this concept."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30215690",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1698,
          "offsetInEndSection": 1805,
          "text": "The targeting of IGF-IR with specific biologic agents may represent a paradigm shift in the therapy of TAO."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Graves' disease (GD) is a systemic autoimmune syndrome comprising manifestations in thyroid and orbital connective tissue."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 291,
          "offsetInEndSection": 426,
          "text": "These fibrocytes infiltrate orbital connective tissues in thyroid-associated ophthalmopathy and express functional TSH receptor (TSHR)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 189,
          "text": "The link between these two tissues in GD eludes our understanding."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1663,
          "offsetInEndSection": 1789,
          "text": "Fibrocytes and their fibroblast derivatives may participate in the pathogenesis of thyroid autoimmunity after TSHR activation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 740,
          "offsetInEndSection": 896,
          "text": "CD34(+)ColI(+)CXCR4(+)TSHR(+) cells can be identified in situ in thyroid tissue from donors with GD, Hashimoto's thyroiditis, or in normal-appearing tissue."
        }
      ]
    },
    {
      "id": "67e2958018b1e36f2e000084",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27528462",
        "http://www.ncbi.nlm.nih.gov/pubmed/24461634",
        "http://www.ncbi.nlm.nih.gov/pubmed/19724244",
        "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
        "http://www.ncbi.nlm.nih.gov/pubmed/24201088",
        "http://www.ncbi.nlm.nih.gov/pubmed/29536439",
        "http://www.ncbi.nlm.nih.gov/pubmed/20435227",
        "http://www.ncbi.nlm.nih.gov/pubmed/19863545",
        "http://www.ncbi.nlm.nih.gov/pubmed/24870131",
        "http://www.ncbi.nlm.nih.gov/pubmed/23683917"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528462",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Brain gene expression profiling studies of suicide and depression using oligonucleotide microarrays have often failed to distinguish these two phenotypes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528462",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 596,
          "text": "Using RNA-seq, we examined whole-exome gene and exon expression in non-psychiatric controls (CON, N=29), DSM-IV major depressive disorder suicides (MDD-S, N=21) and MDD non-suicides (MDD, N=9) in the dorsal lateral prefrontal cortex (Brodmann Area 9) of sudden death medication-free individuals post mortem."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528462",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1216,
          "offsetInEndSection": 1523,
          "text": "Hypothesis-driven GO analysis suggests lower expression of genes involved in oligodendrocyte differentiation, regulation of glutamatergic neurotransmission, and oxytocin receptor expression in both suicide and depression, and provisional evidence for altered DNA-dependent ATPase expression in suicide only."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528462",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1715,
          "offsetInEndSection": 1983,
          "text": "Results lend further support for models in which deficits in microglial, endothelial (blood-brain barrier), ATPase activity and astrocytic cell functions contribute to MDD and suicide, and identify putative pathways and mechanisms for further study in these disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528462",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 813,
          "offsetInEndSection": 1215,
          "text": "In depression, altered genes include humanin-like-8 (MTRNRL8), interleukin-8 (IL8), and serpin peptidase inhibitor, clade H (SERPINH1) and chemokine ligand 4 (CCL4), while exploratory gene ontology (GO) analyses revealed lower expression of immune-related pathways such as chemokine receptor activity, chemotaxis and cytokine biosynthesis, and angiogenesis and vascular development in (adjusted P<0.1)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461634",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1280,
          "offsetInEndSection": 1421,
          "text": "This may be useful in understanding molecular mechanisms of suicidal behaviour in severe mental disorders, although replication is warranted."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461634",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 523,
          "offsetInEndSection": 612,
          "text": "Previously reported susceptibility loci for suicide attempt in BD were also investigated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461634",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "The present study investigated associations between the strongest joint genetic risk variants for bipolar disorder (BD) and schizophrenia (SCZ) and a history of suicide attempt in patients with BD, SCZ and related psychiatric disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461634",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 522,
          "text": "A history of suicide attempt was assessed in a sample of 1009 patients with BD, SCZ and related psychosis spectrum disorders, and associations with the joint genetic risk variants for BD and SCZ (rs2239547 (ITIH3/4-region), rs10994359 (ANK3) and rs4765905 (CACNA1C)) were investigated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461634",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 883,
          "offsetInEndSection": 1045,
          "text": "The previous suicide attempt susceptibility loci were only nominally associated, but had the same direction of risk in the replication sample (sign test, p=0.02)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19724244",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 779,
          "offsetInEndSection": 1034,
          "text": "DNA samples from 90 White participants who developed TESI and a sex-matched and race-matched equal number of treated participants who denied any suicidal ideas were genotyped with 109 365 single nucleotide polymorphisms on the Illumina's Human-1 BeadChip."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19724244",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 273,
          "offsetInEndSection": 523,
          "text": "The present genome-wide association study was conducted to identify additional genetic markers associated with TESI that may help identify individuals at high risk who may benefit from closer monitoring, alternative treatments, and/or specialty care."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19724244",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 104,
          "offsetInEndSection": 272,
          "text": "We have described earlier the association between treatment-emergent suicidal ideation (TESI) and markers in genes encoding glutamate receptor subunits GRIK2 and GRIA3."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19724244",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Suicidal ideation is an uncommon but worrisome symptom than can emerge during antidepressant treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19724244",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 524,
          "offsetInEndSection": 778,
          "text": "A clinically representative cohort of outpatients with nonpsychotic major depressive disorder enrolled in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial were treated with citalopram under a standard protocol for up to 14 weeks."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Genome-wide association studies (GWAS) currently represent the most systematic approach to genetic research into complex disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 775,
          "offsetInEndSection": 893,
          "text": "This article focuses on GWAS of alcohol addiction and provides an overview of GWAS of other substance abuse disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 345,
          "offsetInEndSection": 518,
          "text": "Four GWAS of alcohol dependence have been published thus far, and only two single nucleotide polymorphisms have received modest support of replication in a subsequent study."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 344,
          "text": "Most of the GWAS of addiction performed to date have focused on alcohol dependence or smoking behavior."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21253885",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 575,
          "text": "Many more GWAS have been conducted for smoking behavior."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24201088",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 545,
          "offsetInEndSection": 695,
          "text": "The available research provides little empirical evidence for the processes underlying suicidal behaviour in adolescents and young adults with autism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24201088",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 437,
          "text": "The purpose of this review is to synthesise primary research on suicidal behaviour among adolescents and young adults with autism spectrum disorders in order to estimate prevalence and to identify and critically evaluate risk factors for suicidal behaviour in this population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24201088",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 47,
          "offsetInEndSection": 160,
          "text": "However we have very little understanding of suicidal behaviour among individuals with autism spectrum disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24201088",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 46,
          "text": "Suicide is a major problem in Western society."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24201088",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 438,
          "offsetInEndSection": 544,
          "text": "Four primary research studies were identified for this review following a comprehensive literature search."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29536439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 321,
          "text": "Genome-wide association study (GWAS) is a powerful study design to identify genetic variants of a trait and, in particular, detect the association between common single-nucleotide polymorphisms (SNPs) and common human diseases such as heart disease, inflammatory bowel disease, type 2 diabetes, and psychiatric disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29536439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 426,
          "offsetInEndSection": 554,
          "text": "We provide an overview of the concepts underlying GWAS, as well as provide guidelines for statistical methods performed in GWAS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29536439",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 322,
          "offsetInEndSection": 425,
          "text": "The standard strategy of population-based case-control studies for GWAS is illustrated in this chapter."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20435227",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 307,
          "offsetInEndSection": 500,
          "text": "Clinical assessment included analysis of this patient's full genome sequence, risk prediction for coronary artery disease, screening for causes of sudden cardiac death, and genetic counselling."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20435227",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1417,
          "offsetInEndSection": 1541,
          "text": "We discovered rare variants in three genes that are clinically associated with sudden cardiac death-TMEM43, DSP, and MYBPC3."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20435227",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 791,
          "offsetInEndSection": 956,
          "text": "We queried disease-specific mutation databases and pharmacogenomics databases to identify genes and mutations with known associations with disease and drug response."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20435227",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1238,
          "offsetInEndSection": 1416,
          "text": "Analysis of 2.6 million single nucleotide polymorphisms and 752 copy number variations showed increased genetic risk for myocardial infarction, type 2 diabetes, and some cancers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20435227",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1965,
          "offsetInEndSection": 2119,
          "text": "Although challenges remain, our results suggest that whole-genome sequencing can yield useful and clinically relevant information for individual patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 524,
          "offsetInEndSection": 650,
          "text": "Mutations in several genes are implicated in arrhythmic syndromes, including SCN5A, KCNQ1, KCNH2, RyR2, and genes causing HCM."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 881,
          "offsetInEndSection": 1190,
          "text": "This article discusses the ethical and legal arguments in favour of and against three options: genetic testing of the deceased victim only; counselling of relatives before testing the victim; counselling restricted to relatives of victims who tested positive for mutations of serious and preventable diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 340,
          "offsetInEndSection": 523,
          "text": "In these cases, genetic testing can be useful and does not require proxy consent if it is carried out at the request of judicial authorities as part of a forensic death investigation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1297,
          "offsetInEndSection": 1560,
          "text": "Although the claim for a legal duty is tenuous, recent publications and guidelines suggest that geneticists and others involved in the multidisciplinary approach of sudden death (SD) cases may, nevertheless, have an ethical duty to inform relatives of SD victims."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 339,
          "text": "Hereditary non-structural diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT), long QT, and the Brugada syndrome as well as structural disease such as hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC) cause a significant percentage of sudden cardiac deaths in the young."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870131",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "Genome-wide association studies (GWAS) are a powerful tool for investigators to examine the human genome to detect genetic risk factors, reveal the genetic architecture of diseases and open up new opportunities for treatment and prevention."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870131",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 406,
          "text": "However, despite its successes, GWAS have not been able to identify genetic loci that are effective classifiers of disease, limiting their value for genetic testing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870131",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 546,
          "offsetInEndSection": 888,
          "text": "In this regard, we review basic concepts regarding GWAS, the technologies used for capturing genetic variation, the missing heritability problem, the need for efficient study design especially for replication efforts, reducing the bias introduced into a dataset, and how to utilize new resources available, such as electronic medical records."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870131",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 407,
          "offsetInEndSection": 545,
          "text": "This chapter highlights the challenges that lie ahead for GWAS in better identifying disease risk predictors, and how we may address them."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870131",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 889,
          "offsetInEndSection": 1011,
          "text": "We also look to what lies ahead for the field, and the approaches that can be taken to realize the full potential of GWAS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1059,
          "offsetInEndSection": 1188,
          "text": "Clinical and genetic examination of family members of SUD victims was also performed and affected family members were identified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 311,
          "offsetInEndSection": 556,
          "text": "Post-mortem genetic testing, so called molecular autopsy, revealed that primary arrhythmogenic disorders including long QT syndrome and catecholaminergic polymorphic ventricular tachycardia (CPVT) may account for a certain number of these cases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 855,
          "offsetInEndSection": 975,
          "text": "In the present study, we performed mutation analyses of the major genes causing cardiac channelopathies in 15 SUD cases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 310,
          "text": "In many cases the cause of death can be elucidated by medico-legal autopsy, however, a significant number of these cases remain unexplained despite a detailed postmortem investigation and are labeled as sudden unexplained death (SUD)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683917",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1189,
          "offsetInEndSection": 1309,
          "text": "This study demonstrates that molecular genetic screening needs to become an inherent part of the postmortem examination."
        }
      ]
    },
    {
      "id": "680c174d353a4a2e6b000001",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26598646",
        "http://www.ncbi.nlm.nih.gov/pubmed/15744326",
        "http://www.ncbi.nlm.nih.gov/pubmed/22122749",
        "http://www.ncbi.nlm.nih.gov/pubmed/34495528",
        "http://www.ncbi.nlm.nih.gov/pubmed/29172462",
        "http://www.ncbi.nlm.nih.gov/pubmed/29413177",
        "http://www.ncbi.nlm.nih.gov/pubmed/28414281",
        "http://www.ncbi.nlm.nih.gov/pubmed/16730216",
        "http://www.ncbi.nlm.nih.gov/pubmed/23576281",
        "http://www.ncbi.nlm.nih.gov/pubmed/18228479"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598646",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Covalent post-translational modifications (PTMs) of proteins can regulate the structural and functional state of a protein in the absence of primary changes in the underlying sequence."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598646",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 251,
          "text": "Common PTMs include phosphorylation, acetylation, and methylation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598646",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 252,
          "offsetInEndSection": 370,
          "text": "Histone proteins are critical regulators of the genome and are subject to a highly abundant and diverse array of PTMs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598646",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 371,
          "offsetInEndSection": 609,
          "text": "To highlight the functional complexity added to the proteome by lysine methylation signaling, here we will focus on lysine methylation of histone proteins, an important modification in the regulation of chromatin and epigenetic processes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598646",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 610,
          "offsetInEndSection": 875,
          "text": "We review the signaling pathways and functions associated with a single residue, H4K20, as a model chromatin and clinically important mark that regulates biological processes ranging from the DNA damage response and DNA replication to gene expression and silencing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15744326",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Post-translational modification is a major mechanism by which protein function is regulated in eukaryotes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15744326",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 107,
          "offsetInEndSection": 374,
          "text": "Instead of single-site action, many proteins such as histones, p53, RNA polymerase II, tubulin, Cdc25C and tyrosine kinases are modified at multiple sites by modifications like phosphorylation, acetylation, methylation, ubiquitination, sumoylation and citrullination."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15744326",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 375,
          "offsetInEndSection": 565,
          "text": "Multisite modification on a protein constitutes a complex regulatory program that resembles a dynamic 'molecular barcode' and transduces molecular information to and from signaling pathways."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15744326",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 657,
          "offsetInEndSection": 915,
          "text": "Among the latter, covalent modifications specifically recruit a diverse array of modules, including the SH2 domain, 14-3-3, WW domain, Polo box, BRCT repeat, bromodomain, chromodomain, Tudor domain and motifs binding to ubiquitin and other protein modifiers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15744326",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1171,
          "text": "Multisite modification thus coordinates intermolecular and intramolecular signaling for the qualitative and quantitative control of protein function in vivo."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22122749",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Post-translational modifications (PTMs) are commonly used to modify protein function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22122749",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 255,
          "text": "Modifications such as phosphorylation, acetylation and methylation can influence the conformation of the modified protein and its interaction with other proteins or DNA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22122749",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 414,
          "offsetInEndSection": 597,
          "text": "Histone methylation events, especially on arginine- and lysine-residues, are among the best-characterized PTMs, and many of these modifications have been linked to downstream effects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22122749",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 256,
          "offsetInEndSection": 413,
          "text": "In the case of histones, PTMs on specific residues can influence chromatin structure and function by modifying the biochemical properties of key amino acids."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22122749",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 598,
          "offsetInEndSection": 805,
          "text": "The addition of a methyl group to either residue results in a slight increase in hydrophobicity, in the loss of a potential hydrogen-bond donor site and, in the alteration of the protein interaction surface."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34495528",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "N-glycosylation is a highly conserved glycan modification, and more than 7000 proteins are N-glycosylated in humans."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34495528",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 340,
          "text": "Thus, glycan modification to proteins is profoundly involved in numerous physiological and pathological processes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34495528",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 225,
          "text": "N-glycosylation has many biological functions such as protein folding, trafficking, and signal transduction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34495528",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 341,
          "offsetInEndSection": 556,
          "text": "The N-glycan precursor is biosynthesized in the endoplasmic reticulum (ER) from dolichol phosphate by sequential enzymatic reactions to generate the dolichol-linked oligosaccharide composed of 14 sugar residues, Glc"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29172462",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Posttranslational modifications (PTMs) regulate protein functions and interactions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29172462",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 84,
          "offsetInEndSection": 186,
          "text": "ADP-ribosylation is a PTM, in which ADP-ribosyltransferases use nicotinamide adenine dinucleotide (NAD"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29413177",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Lysine residues across the proteome are modified by posttranslational modifications (PTMs) that significantly enhance the structural and functional diversity of proteins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29413177",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 366,
          "text": "For lysine, the most abundant PTM is \u025b-N-acetyllysine (Kac), which plays numerous roles in regulation of important cellular functions, such as gene expression (epigenetic effects) and metabolism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29413177",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 367,
          "offsetInEndSection": 444,
          "text": "A family of enzymes, namely histone deacetylases (HDACs), removes these PTMs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29413177",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 445,
          "offsetInEndSection": 579,
          "text": "A subset of these enzymes, the sirtuins (SIRTs), represent class III HDAC and, unlike the rest of the family, these hydrolases are NAD"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28414281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 988,
          "offsetInEndSection": 1403,
          "text": "Phosphorylation is among the most significant of these protein modifications.This review will describe methods for analysis of protein phosphorylation used in the studies of such diseases as cancer and neurodegenerative diseases, as well as examples of cases when the modified proteins are involved directly to their development, and screening such significant PTM is used for the diagnosis and choice of treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28414281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 494,
          "offsetInEndSection": 813,
          "text": "However, in many cases, it is shown that the development of the disease is not associated with the appearance of new proteins, but depends on the level of gene expression or forming of proteoforms - splice variants, single amino acid substitutions (SAP variants), and post-translational modifications (PTM) of proteins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28414281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 814,
          "offsetInEndSection": 987,
          "text": "PTM may play a key role in the development of pathology because they activate a variety of regulatory or structural proteins in the majority of cell physiological processes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28414281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 387,
          "text": "Numerous studies in the framework of the global program \"Human Proteome\" were aimed at the identification of all possible proteins in various cell cultures and tissues, including cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28414281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "In recent decades, studies in the molecular origins of socially significant diseases have made a big step forward with the development and using of high-performance methods in genomics and proteomics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16730216",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Posttranslational modifications are chemical changes to proteins that take place after synthesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16730216",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 824,
          "offsetInEndSection": 915,
          "text": "We describe the enzymes catalyzing the reaction, as well as their known protein substrates."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16730216",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 710,
          "offsetInEndSection": 823,
          "text": "In this review, we discuss our current understanding on the importance of protein deimination in these processes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16730216",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 98,
          "offsetInEndSection": 272,
          "text": "One such modification, peptidylarginine to peptidylcitrulline conversion, catalysed by peptidylarginine deiminases, has recently received significant interest in biomedicine."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16730216",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 273,
          "offsetInEndSection": 360,
          "text": "Introduction of citrulline dramatically changes the structure and function of proteins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23576281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 368,
          "text": "Post-translational modifications (PTMs) of protein embedded arginines are increasingly being recognized as playing an important role in both prokaryotic and eukaryotic biology, and it is now clear that these PTMs modulate a number of cellular processes including DNA binding, gene transcription, protein-protein interactions, immune system activation, and proteolysis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23576281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 904,
          "offsetInEndSection": 1069,
          "text": "This abnormally large number of modifications to a single amino acid creates a diverse set of structural perturbations that can lead to altered biological responses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23576281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 592,
          "text": "There are currently four known enzymatic PTMs of arginine (i.e., citrullination, methylation, phosphorylation, and ADP-ribosylation), and two non-enzymatic PTMs [i.e., carbonylation, advanced glycation end-products (AGEs)]."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23576281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 593,
          "offsetInEndSection": 787,
          "text": "Enzymatic modification of arginine is tightly controlled during normal cellular function, and can be drastically altered in response to various second messengers and in different disease states."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23576281",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 788,
          "offsetInEndSection": 903,
          "text": "Non-enzymatic arginine modifications are associated with a loss of metabolite regulation during normal human aging."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228479",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "A concept that has arisen over the last decade is that proteins can, in general, be covalently modified by polypeptides, resulting in alterations in their fate and function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228479",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 532,
          "text": "Although targeting for proteasomal degradation is the best studied outcome of ubiquitylation, we now understand that modification of proteins with ubiquitin has numerous other cellular roles that alter protein function and that are unrelated to proteasomal degradation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228479",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 533,
          "offsetInEndSection": 663,
          "text": "Ubiquitylation is a complex process that is regulated at the level of both addition and removal of ubiquitin from target proteins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228479",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 847,
          "offsetInEndSection": 1000,
          "text": "Because another protein modifier, NEDD8, itself regulates aspects of the ubiquitin system, basic protocols on neddylation are also included in this unit."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228479",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 174,
          "offsetInEndSection": 262,
          "text": "The first-identified and most well studied of these modifying polypeptides is ubiquitin."
        }
      ]
    },
    {
      "id": "67e0053118b1e36f2e000067",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21769097",
        "http://www.ncbi.nlm.nih.gov/pubmed/22989627",
        "http://www.ncbi.nlm.nih.gov/pubmed/36206626",
        "http://www.ncbi.nlm.nih.gov/pubmed/14662797",
        "http://www.ncbi.nlm.nih.gov/pubmed/19129865",
        "http://www.ncbi.nlm.nih.gov/pubmed/24795696",
        "http://www.ncbi.nlm.nih.gov/pubmed/27340836",
        "http://www.ncbi.nlm.nih.gov/pubmed/25470007",
        "http://www.ncbi.nlm.nih.gov/pubmed/32574926",
        "http://www.ncbi.nlm.nih.gov/pubmed/8143741"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21769097",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Reactive oxygen species (ROS) are a family of molecules that are continuously generated, transformed and consumed in all living organisms as a consequence of aerobic life."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21769097",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 465,
          "offsetInEndSection": 738,
          "text": "This Perspective provides a focused discussion on what factors lead ROS molecules to become signal and/or stress agents, highlighting how increasing knowledge of the underlying chemistry of ROS can lead to advances in understanding their disparate contributions to biology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21769097",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 340,
          "offsetInEndSection": 464,
          "text": "However, emerging data show that ROS produced in certain situations can also contribute to physiology and increased fitness."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21769097",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 339,
          "text": "The traditional view of these reactive oxygen metabolites is one of oxidative stress and damage that leads to decline of tissue and organ systems in aging and disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21769097",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 739,
          "offsetInEndSection": 929,
          "text": "An important facet of this emerging area at the chemistry-biology interface is the development of new tools to study these small molecules and their reactivity in complex biological systems."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22989627",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 51,
          "offsetInEndSection": 247,
          "text": "The aim of this study was to examine gonadotropin regulation of antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification during the ovulatory process in rats."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22989627",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 50,
          "text": "Reactive oxygen species are involved in ovulation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22989627",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 581,
          "offsetInEndSection": 692,
          "text": "LH- or H(2)O(2)-stimulated Srx mRNA levels were suppressed by inhibitors of antioxidant agents and MAPK kinase."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22989627",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1274,
          "offsetInEndSection": 1443,
          "text": "In situ hybridization analysis demonstrated that PRDX2 mRNA was detected in oocytes and theca cells as well as granulosa cells of some antral and preovulatory follicles."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22989627",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 938,
          "offsetInEndSection": 1014,
          "text": "Immunofluorescence analysis revealed that oocytes expressed the Srx protein."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36206626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Anti-M\u00fcllerian hormone (AMH) is an ideal biomarker for the assessment of ovarian reserve."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36206626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 90,
          "offsetInEndSection": 220,
          "text": "However, its application in determining ovarian reserve reduction is restricted due to the low sensitivity of existing AMH assays."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36206626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 221,
          "offsetInEndSection": 425,
          "text": "Herein, a homebrew ultrasensitive digital AMH assay (UD-AMH) was established based on a single-molecule array (SiMoA, HD-X platform), and the analytical performance of UD-AMH was evaluated systematically."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36206626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 426,
          "offsetInEndSection": 637,
          "text": "The limit of detection (LoD) and limit of quantitation (LoQ) of UD-AMH were 0.13 and 0.14\u00a0pg/mL, respectively, which is approximately 100-fold higher than that of the current reported general clinical AMH assay."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36206626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 773,
          "offsetInEndSection": 1068,
          "text": "In addition, we found that the AMH concentrations of premature ovarian insufficiency (POI) patients were very low (2.59 (0.86, 31.79) pg/mL) and similar to those of perimenopausal women (2.37 (0.65, 35.88) pg/mL) but significantly higher than those of menopausal women (0.43 (0.28, 1.17) pg/mL)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14662797",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 187,
          "offsetInEndSection": 372,
          "text": "The presence of the GABA system and metabotropic glutamate receptors in sperm prompted us to explore the existence of ionotropic glutamate receptors and glutamate transporters in sperm."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14662797",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 373,
          "offsetInEndSection": 550,
          "text": "Immunofluorescent analysis was used to investigate the existence and location of glutamate, glutamate receptor (NR2B), and glutamate transporter (GLT1) in mouse and human sperm."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14662797",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 879,
          "offsetInEndSection": 1140,
          "text": "In addition, reverse transcription-polymerase chain reaction technique and sequencing analysis revealed that glutamate transporters (GLT1 and EAAC1) and ionotropic glutamate receptors (NR1, NR2B, GluR6, and KA2) existed in mouse sperm as well as in human sperm."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14662797",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1141,
          "offsetInEndSection": 1280,
          "text": "The present findings are the first direct evidence for the existence of ionotropic glutamate receptors and glutamate transporters in sperm."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14662797",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1281,
          "offsetInEndSection": 1402,
          "text": "It also indicates that, in sperm, glutamate receptors and transporters might have functions other than neurotransmission."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19129865",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 313,
          "text": "As part of an effort to diagnose the physiological status of Geobacter species during in situ bioremediation of uranium-contaminated groundwater, transcript levels for two genes potentially associated with oxidative stress, cydA and sodA, were quantified throughout a bioremediation field study in Rifle, CO, USA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19129865",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 498,
          "offsetInEndSection": 626,
          "text": "Therefore, the response to oxidative stress was further evaluated with Geobacter uraniireducens, an isolate from the Rifle site."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19129865",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1431,
          "offsetInEndSection": 1756,
          "text": "These results suggest that the apparently high Geobacter cydA and sodA expression during bioremediation cannot necessarily be attributed to oxidative stress and demonstrate that diagnosis of the metabolic status of subsurface microorganisms through transcript analysis should be coupled with appropriate geochemical analyses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19129865",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 635,
          "offsetInEndSection": 872,
          "text": "uraniireducens cultured with fumarate as the electron acceptor was exposed to 5% oxygen for 8 h, there was a significant increase in cydA and sodA transcripts as well as other genes associated with oxygen respiration or oxidative stress."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19129865",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 873,
          "offsetInEndSection": 998,
          "text": "Oxygen-exposed cells had lower transcript abundance for genes associated with anaerobic respiration, metabolism and motility."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24795696",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 632,
          "offsetInEndSection": 849,
          "text": "This chapter sets out the major pathways of testis generation, the metabolism of ROS, and highlights the transcriptional regulation by steroid receptors of antioxidant stress enzymes and their functional implications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24795696",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 273,
          "offsetInEndSection": 481,
          "text": "The gonadal tissue, with abundance of highly unsaturated fatty acids, high rates of cell division, and variety of testis enzymes results very vulnerable to the overexpression of reactive oxygen species (ROS)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24795696",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 850,
          "offsetInEndSection": 1199,
          "text": "It also deals with of the advantages of the system biology for an antioxidant under steroid control, the major selenoprotein expressed by germ cells in the testis, the phospholipid hydroperoxide glutathione peroxidase (PHGPx/GPx4) having multiple functions and representing the pivotal link between selenium, sperm quality, and species preservation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24795696",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 482,
          "offsetInEndSection": 631,
          "text": "In order to address this risk, testis has developed a sophisticated array of antioxidant systems comprising both enzymes and free radical scavengers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24795696",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Spermatogenesis is a complex process of male germ cells proliferation and maturation from diploid spermatogonia, through meiosis, to mature haploid spermatozoa."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27340836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 500,
          "offsetInEndSection": 582,
          "text": "The reaction was studied by means of oxidation reduction potential (ORP) measures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27340836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 352,
          "text": "It has been widely studied since its discovery in the 19th century, but important aspects of the reaction as which is the oxidant, the role of oxygen, and the oxidation state of Fe still remain unclear."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27340836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 583,
          "offsetInEndSection": 707,
          "text": "The stoichiometry was measured, showing the important role of oxygen for lowering H2O2 consumption under aerobic conditions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27340836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 708,
          "offsetInEndSection": 903,
          "text": "Evidence is provided to demonstrate that in this system Fe(2+) generates a catalyst by reacting with a substrate to produce a complex, which gives rise to singlet oxygen after reacting with H2O2."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27340836",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "The use of iron ions as catalyst of oxidation with hydrogen peroxide, known as the Fenton reaction, is important for industry and biological systems."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470007",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 314,
          "offsetInEndSection": 519,
          "text": "The probe exhibits a unique fluorescence sensing mechanism, in which a xanthene fluorophore is oxidatively transformed to a xanthone derivative by H2 O2 , thereby resulting in a clear dual-emission change."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470007",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 313,
          "text": "In this article, we report an AND logic-gate-type fluorescent probe that can concurrently sense two biological events in living cells: H2 O2 accumulation and acidification."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470007",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 706,
          "offsetInEndSection": 947,
          "text": "This unique sensing property was successfully applied to the ratiometric fluorescence imaging of autolysosome formation in selective mitochondrial autophagy (mitophagy), which highlights the utility of this novel probe in autophagy research."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470007",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 520,
          "offsetInEndSection": 705,
          "text": "This transformation is significantly accelerated under weak acidic conditions, which enables the selective and sensitive detection of H2 O2 production in an acidic cellular compartment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470007",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "The concomitant detection of two biological events facilitates the highly selective and sensitive analysis of specific biological functions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32574926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1259,
          "offsetInEndSection": 1491,
          "text": "We measured oxysterols in mitochondria from peripheral blood mononuclear cells and highlight the importance of rapid cell isolation to minimise effects of handling and storage conditions on oxysterol composition in clinical samples."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32574926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 429,
          "offsetInEndSection": 617,
          "text": "Here we describe a method for isolation of oxysterols using solid phase extraction and quantification by liquid chromatography-mass spectrometry, applied to tissue, cells and mitochondria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32574926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1868,
          "offsetInEndSection": 2016,
          "text": "This method enables subcellular oxysterol metabolism to be monitored and is versatile in its application to various biological and clinical samples."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32574926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1675,
          "offsetInEndSection": 1867,
          "text": "In summary, we describe a robust and reproducible method validated for improved recovery, quantitative linearity and detection, reproducibility and selectivity for cellular oxysterol analysis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32574926",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 930,
          "offsetInEndSection": 1065,
          "text": "Our new method, using Triton and DMSO extraction, shows improved extraction efficiency and recovery of oxysterols from cellular matrix."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8143741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 276,
          "offsetInEndSection": 817,
          "text": "Two independent methods were employed: (a) a spectrophotometric measurement of 10-N-nonyl acridine orange binding to isolated rat liver mitochondria, mitoplasts and inside-out submitochondrial particles, and (b) a flow-cytometric analysis of specific red fluorescence, emitted when two dye molecules are bound to one membrane cardiolipin; the stoichiometry of 10-N-nonyl acridine orange binding to phosphatidylserine and phosphatidylinositol, 1 mol dye/mol phospholipid, prevented dye dimerisation and subsequent red-fluorescence appearance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8143741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "The distribution of cardiolipin across the inner mitochondrial membrane was directly determined by using the ability of the fluorescent dye 10-N-nonyl-3,6-bis(dimethylamino)acridine (10-N-nonyl acridine orange) to form dimers when it interacts with the diacidic phospholipid."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8143741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 818,
          "offsetInEndSection": 1026,
          "text": "57% total cardiolipin was present in the outer leaflets of inner membranes of isolated organelles, a distribution confirmed by saturation measurements for mitoplasts and inside-out submitochondrial particles."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8143741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1185,
          "offsetInEndSection": 1401,
          "text": "Nevertheless, alterations in ATP synthesis and inhibition of mitochondrial protein synthesis revealed that cardiolipin distribution was apparently tightly correlated with mitochondrial membrane assembly and activity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8143741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1027,
          "offsetInEndSection": 1184,
          "text": "The same asymmetry was directly observed in situ with mitochondrial membranes of quiescent L1210 cells, and with mitochondrial membranes of respiring yeasts."
        }
      ]
    },
    {
      "id": "67e2a8d618b1e36f2e000088",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26832999",
        "http://www.ncbi.nlm.nih.gov/pubmed/22929299",
        "http://www.ncbi.nlm.nih.gov/pubmed/27677923",
        "http://www.ncbi.nlm.nih.gov/pubmed/31614529",
        "http://www.ncbi.nlm.nih.gov/pubmed/24946952",
        "http://www.ncbi.nlm.nih.gov/pubmed/36126008",
        "http://www.ncbi.nlm.nih.gov/pubmed/7240694",
        "http://www.ncbi.nlm.nih.gov/pubmed/22453057",
        "http://www.ncbi.nlm.nih.gov/pubmed/23405174",
        "http://www.ncbi.nlm.nih.gov/pubmed/1530123"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26832999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 527,
          "offsetInEndSection": 610,
          "text": "They cause diarrhea and sometimes invasive disease, although most are asymptomatic."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26832999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Malaria is life threatening and requires urgent diagnosis and treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26832999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 422,
          "offsetInEndSection": 526,
          "text": "Human infections with intestinal protozoa are distributed worldwide with a high global morbid-mortality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26832999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 243,
          "offsetInEndSection": 421,
          "text": "The first line treatments for Plasmodium falciparum are artemisinin combination therapies, chloroquine in most non-falciparum and intravenous artesunate if any severity criteria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26832999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 802,
          "offsetInEndSection": 911,
          "text": "Diagnostic microscopic examination has low sensitivity improving with antigen detection or molecular methods."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22929299",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "Plasmodium falciparum, the causative agent of the deadliest form of malaria, and human immunodeficiency virus type-1 (HIV-1) are among the most important health problems worldwide, being responsible for a total of 4 million deaths annually."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22929299",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 440,
          "offsetInEndSection": 600,
          "text": "Epidemiological reports have suggested that malarial infection transiently enhances HIV-1 replication and increases HIV-1 viral load in co-infected individuals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22929299",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 862,
          "offsetInEndSection": 1055,
          "text": "The few in vitro studies investigating the impact of malaria on HIV-1 have demonstrated that exposure to soluble malarial antigens can increase HIV-1 infection and reactivation in immune cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22929299",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 439,
          "text": "Due to their extensive overlap in developing regions, especially Sub-Saharan Africa, co-infections with malaria and HIV-1 are common, but the interplay between the two diseases is poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22929299",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1110,
          "offsetInEndSection": 1325,
          "text": "falciparum schizont stage parasites and peripheral blood mononuclear cells (PBMC), making it hard to decipher which malarial component(s) was responsible for the observed effects and what the target host cells were."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27677923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 987,
          "offsetInEndSection": 1139,
          "text": "Expert commentary: Anemia due to nutritional deficiencies and infectious diseases such as helminthiasis and malaria are prevalent in sub-Saharan Africa."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27677923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 136,
          "offsetInEndSection": 268,
          "text": "Concomitant nutritional deficiencies, infections or exposure to environmental toxins exacerbate chronic anemia in children with SCD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27677923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1375,
          "text": "Therefore, preventing, diagnosing and treating the underlying cause of this relative anemia will improve SCD-related outcomes in children in sub-Saharan Africa."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27677923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 534,
          "offsetInEndSection": 715,
          "text": "This review will focus on the epidemiology, clinical sequelae, and treatment of relative anemia in children with SCD living in low and middle-income countries in sub-Saharan Africa."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27677923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 818,
          "text": "Areas covered: The causes and treatment of relative anemia in children with SCD in sub-Saharan Africa."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31614529",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 881,
          "offsetInEndSection": 984,
          "text": "Hence, functional iron-deficiency anemia is a risk factor for several ailments, disorders and diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31614529",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 346,
          "offsetInEndSection": 417,
          "text": "Inflammation is of diverse etiology in anemia of chronic disease (ACD)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31614529",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1683,
          "offsetInEndSection": 1775,
          "text": "However, various novel therapies are being developed to treat persistent anemia in patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31614529",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 985,
          "offsetInEndSection": 1109,
          "text": "Therefore, therapeutic strategies depend on the symptoms, severity, comorbidities and the associated risk factors of anemia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31614529",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1110,
          "offsetInEndSection": 1235,
          "text": "Oral iron supplements can be employed to treat ID and mild anemia particularly, when gastrointestinal intolerance is minimal."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24946952",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 286,
          "text": "Trypanosoma cruzi causes American trypanosomiasis, wherein 30-40% of infected individuals develop disease manifestations, most commonly cardiomyopathy but also digestive megasyndromes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24946952",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 287,
          "offsetInEndSection": 468,
          "text": "In the case of Trypanosoma brucei, the etiological agent of African trypanosomiasis, disease progression can be rapid or slow, with early or late central nervous system involvement."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24946952",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 469,
          "offsetInEndSection": 690,
          "text": "Finally, Leishmania species cause leishmaniasis, a disease that ranges from self-healing but scarring cutaneous lesions to fatal visceral leishmaniasis in which parasites disseminate to the liver, spleen, and bone marrow."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24946952",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Trypanosomatid parasites infect over 21 million people worldwide, with a range of disease phenotypes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24946952",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 691,
          "offsetInEndSection": 879,
          "text": "This review highlights parasite factors involved in disease phenotype in all three trypanosomatid diseases, with a particular focus on recent advances using large-scale 'omics' techniques."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36126008",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 175,
          "offsetInEndSection": 255,
          "text": "Human malarial disease is caused by protozoan parasites of the genus Plasmodium."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36126008",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1390,
          "offsetInEndSection": 1447,
          "text": "Severe malaria is mainly caused by Plasmodium falciparum."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36126008",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1227,
          "offsetInEndSection": 1389,
          "text": "The World Health Organization recommends treating uncomplicated cases of malaria with artemisinin combination therapy, except in the first trimester of pregnancy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36126008",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 465,
          "offsetInEndSection": 537,
          "text": "An estimated 2,000 cases of malaria occur annually in the United States."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36126008",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1448,
          "offsetInEndSection": 1559,
          "text": "Children, pregnant patients, and people who are not from endemic regions are at highest risk of severe malaria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7240694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Fanconi's anemia, an inherited disorder characterized by bone marrow aplasia, peripheral pancytopenia, and multiple congenital defects, has a association with certain types of malignancies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7240694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 313,
          "offsetInEndSection": 517,
          "text": "We report a patient with esophageal carcinoma complicating Fanconi's anemia, summarize the various tumors associated to date with the syndrome, and discuss possible mechanisms of malignant transformation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7240694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 312,
          "text": "These include acute myelomonocytic leukemia, benign and malignant liver tumors, and squamous carcinomas of various organs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7240694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 518,
          "offsetInEndSection": 616,
          "text": "This high incidence of malignancy must be appreciated for early diagnosis and appropriate therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22453057",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 248,
          "offsetInEndSection": 562,
          "text": "This paper describes the case of an HIV-infected patient with severe falciparum malaria who was diagnosed with haemolytic anaemia after treatment with oral artemether-lumefantrine.The patient presented with fever, headache, and arthromyalgia after returning from Central African Republic where he had been working."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22453057",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 646,
          "offsetInEndSection": 771,
          "text": "Blood for malaria parasites indicated hyperparasitaemia (6%) and Plasmodium falciparum infection was confirmed by nested-PCR."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22453057",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1405,
          "offsetInEndSection": 1620,
          "text": "At present, the patient is in a good clinical condition and there is no evidence of haemolytic anaemia recurrence.This is the first report of haemolytic anaemia probably associated with oral artemether/lumefantrine."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22453057",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1621,
          "offsetInEndSection": 1753,
          "text": "Further research is warranted to better define the adverse events occurring during combination therapy with artemisinin derivatives."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22453057",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 206,
          "text": "Nevertheless, several cases of haemolytic anaemia due to i.v."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23405174",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 232,
          "offsetInEndSection": 420,
          "text": "Here, we show that Plasmodium falciparum-infected erythrocytes contain uric acid precipitates in the cytoplasm of the parasitophorous vacuole, which are released when erythrocytes rupture."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23405174",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 231,
          "text": "Malaria is characterized by cyclical fevers and high levels of inflammation, and while an early inflammatory response contributes to parasite clearance, excessive and persistent inflammation can lead to severe forms of the disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23405174",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 825,
          "offsetInEndSection": 974,
          "text": "In accordance with this, uric acid accounts for a significant proportion of the total stimulatory activity induced by parasite-infected erythrocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23405174",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1187,
          "offsetInEndSection": 1387,
          "text": "Altogether, our data implicate uric acid precipitates as a potentially important contributor to the innate immune response to Plasmodium infection and may provide a novel target for adjunct therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23405174",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1055,
          "offsetInEndSection": 1186,
          "text": "vivax-infected erythrocytes obtained directly from malaria patients underscores the in vivo and clinical relevance of our findings."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "Fanconi's anemia is an autosomal recessive disorder with a high incidence (greater than 90%) of aplastic anemia and a premalignant component with a greater than 10% risk of leukemia or solid tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 436,
          "text": "The diagnosis of Fanconi's anemia depends on increased chromosomal breakage in lymphocytes following treatment with a DNA cross-linking agent; patients have been identified who are clinically well and whose physical appearance is normal."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 564,
          "text": "Although bone marrow or cord blood transplants can be curative, treatment for the aplastic anemia usually depends on androgens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 565,
          "offsetInEndSection": 732,
          "text": "Close to 20 patients with Fanconi's anemia have delivered normal babies, and the mothers' hematologic status was not significantly adversely affected by the pregnancy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1530123",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1235,
          "offsetInEndSection": 1316,
          "text": "There are now many adults with Fanconi's anemia, some with families of their own."
        }
      ]
    },
    {
      "id": "680a07ed18b1e36f2e000149",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11849819",
        "http://www.ncbi.nlm.nih.gov/pubmed/26866491",
        "http://www.ncbi.nlm.nih.gov/pubmed/24782784",
        "http://www.ncbi.nlm.nih.gov/pubmed/6283380",
        "http://www.ncbi.nlm.nih.gov/pubmed/11104511",
        "http://www.ncbi.nlm.nih.gov/pubmed/6308151",
        "http://www.ncbi.nlm.nih.gov/pubmed/11867382",
        "http://www.ncbi.nlm.nih.gov/pubmed/9339823",
        "http://www.ncbi.nlm.nih.gov/pubmed/34603008",
        "http://www.ncbi.nlm.nih.gov/pubmed/27902931"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11849819",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1183,
          "offsetInEndSection": 1334,
          "text": "Neuronal nicotinic acetylcholine receptors are more sensitive to anesthetics than their muscle counterparts, with the exception of the alpha7 receptor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11849819",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 943,
          "offsetInEndSection": 1031,
          "text": "The main effect of anesthetic agents on nicotinic acetylcholine receptors is inhibitory."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11849819",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1335,
          "offsetInEndSection": 1557,
          "text": "Several intravenous anesthetics such as barbiturates, etomidate, and propofol exert also an inhibitory effect on the nicotinic acetylcholine receptors, but only at concentrations higher than those necessary for anesthesia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11849819",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 722,
          "text": "The muscle receptor subtypes comprise of alphabetadeltagamma (embryonal) or alphabetadeltaepsilon (adult) subunits."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11849819",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Nicotinic acetylcholine receptors are members of the ligand-gated ion channel superfamily, that includes also gamma-amino-butiric-acid(A), glycine, and 5-hydroxytryptamine(3) receptors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26866491",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 889,
          "offsetInEndSection": 1066,
          "text": "In this review the authors briefly summarize the structure and mechanism of actions of BoNT on motor and sensory neurons to explain its therapeutic effects and future potential."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26866491",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 248,
          "offsetInEndSection": 413,
          "text": "Although BoNT is an extremely toxic molecule, it is now increasingly used for the treatment of disorders related to muscle hyperactivity and glandular hyperactivity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26866491",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Botulinum neurotoxin (BoNT) produced by Clostridium botulinum is the most potent molecule known to mankind."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26866491",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 499,
          "offsetInEndSection": 651,
          "text": "Depending on the target tissue, BoNT can block the cholinergic neuromuscular or cholinergic autonomic innervation of exocrine glands and smooth muscles."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26866491",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 414,
          "offsetInEndSection": 498,
          "text": "Weakening of muscles due to peripheral action of BoNT produces a therapeutic effect."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24782784",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 744,
          "offsetInEndSection": 916,
          "text": "Panx1 channels play a relevant role in potentiation of muscle contraction because they allow release of ATP and uptake of glucose, two molecules required for this response."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24782784",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1107,
          "offsetInEndSection": 1262,
          "text": "Phosphorylation of Panx1 Thr and Ser residues might be involved in Panx1 channel activation since it is enhanced during potentiation of muscle contraction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24782784",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 508,
          "offsetInEndSection": 659,
          "text": "Innervated adult fast and slow skeletal myofibers show Panx1 reactivity in close proximity to dihydropyridine receptors in the sarcolemma of T-tubules."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24782784",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1488,
          "offsetInEndSection": 1708,
          "text": "Panx1 also forms functional channels at the cell surface of myotubes and their functional state has been associated with intracellular Ca(2+) signals and regulation of myotube plasticity evoked by electrical stimulation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24782784",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 917,
          "offsetInEndSection": 1106,
          "text": "In support of this notion, the absence of Panx1 abrogates the potentiation of muscle contraction elicited by repetitive electrical stimulation, which is reversed by exogenously applied ATP."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6283380",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 438,
          "text": "Recently, however, it has been shown that curare can also block the channels opened by ACh at the frog neuromuscular junction as well as on rat and Aplysia neurones; moreover, curare is able to depolarize rat myotubes and thus behaves as an agonist for the cholinergic receptor of this preparation (see ref."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6283380",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Curare has long been regarded as a typical competitive antagonist of acetylcholine (ACh) at the vertebrate neuromuscular junction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6283380",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 443,
          "offsetInEndSection": 630,
          "text": "Using the single channel recording technique, we have now found that, on rat myotubes, curare can both open and block in the same cell the channels controlled by the cholinergic receptor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6283380",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 439,
          "offsetInEndSection": 442,
          "text": "6)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11104511",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1886,
          "offsetInEndSection": 2094,
          "text": "Characterization of the receptors that can inhibit the release of glutamate may provide useful information for treatment of conditions characterized by excessive glutamatergic transmission in the spinal cord."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11104511",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 696,
          "offsetInEndSection": 870,
          "text": "The most substantial reduction (54.30% +/- 4.40%) was seen with omega-CgTx GVIA, indicating that N-type channels play a major role in the release of glutamate in this tissue."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11104511",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1022,
          "offsetInEndSection": 1125,
          "text": "NPY and NPY(13-36) equipotently inhibited the release of glutamate in a concentration-dependent manner."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11104511",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1711,
          "offsetInEndSection": 1885,
          "text": "These results are consistent with the hypothesis that presynaptic Y(2)-like and GABA(B) receptors regulate glutamate release by blocking Ca(2+) currents through N-type VOCCs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11104511",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1250,
          "offsetInEndSection": 1414,
          "text": "The selective GABA(B) agonist (-)baclofen inhibited K(+)-evoked [(3)H]D-aspartate release from superfused spinal cord synaptosomes by 50.00% +/- 4.80% at 10 microM."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308151",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 549,
          "offsetInEndSection": 718,
          "text": "It is also shown that in adult muscle cell, the conductance of the channel (activated either by ACh or by curare) is 50-60 pS, i.e., higher than in the myotubes (35 pS)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308151",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "The mode of action of curare, a well-known competitive antagonist of acetylcholine at the nicotinic receptor, was examined with the single channel recording technique."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308151",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 168,
          "offsetInEndSection": 264,
          "text": "Curare can open cholinergic channels in rat myotubes, as suggested by Ziskind and Dennis (1978)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308151",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 412,
          "offsetInEndSection": 548,
          "text": "In adult rat muscle, the partial agonist activity of curare can also be demonstrated, though it is much weaker than in embryonic muscle."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308151",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 265,
          "offsetInEndSection": 411,
          "text": "Moreover another curare molecule can then block the curare-activated open channel, in line with previous results concerning such a mode of action."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11867382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1561,
          "offsetInEndSection": 1829,
          "text": "Potencies of nondepolarizing muscle relaxants, studied at muscle nicotinic acetylcholine receptors expressed in a recombinant expression system, correlate highly with the clinical doses needed in adults to produce 50% twitch depression at the adductor pollicis muscle."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11867382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 469,
          "offsetInEndSection": 599,
          "text": "Functional channels were activated with 10 microM acetylcholine, alone or in combination with various concentrations of the NDMRs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11867382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 680,
          "offsetInEndSection": 772,
          "text": "All NDMRs reversibly inhibited acetylcholine-activated currents in a dose-dependent fashion."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11867382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 999,
          "offsetInEndSection": 1298,
          "text": "The rank order of potencies at the epsilon-nAChR (pancuronium > vecuronium similar mivacurium > rocuronium similar d-tubocurarine > rapacuronium similar Org 9488 > gallamine) correlated highly with the clinical doses needed to produce 50% twitch depression at the adductor pollicis muscle in adults."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11867382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 361,
          "text": "We studied the inhibition of fetal (gamma-nAChR) and adult (epsilon-nAChR) muscle-type nicotinic acetylcholine receptors by the two new nondepolarizing muscle relaxants (NDMRs) rocuronium and rapacuronium, the metabolite 3-desacetyl rapacuronium (Org 9488), and five other, longer-used NDMRs (pancuronium, vecuronium, mivacurium, d-tubocurarine, and gallamine)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9339823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 345,
          "offsetInEndSection": 478,
          "text": "The toxins act primarily at peripheral cholinergic motor nerve endings by blocking the release of the neurotransmitter acetylcholine."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9339823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 702,
          "offsetInEndSection": 908,
          "text": "However, in certain neurological diseases characterized by an abnormal increase in muscle tone or activity, for example dystonia or spasticity, a reduction in signal transmission may actually be beneficial."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9339823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1348,
          "offsetInEndSection": 1521,
          "text": "This review tries to outline in brief the characteristics of Botulinum toxins, their mechanism of action and the various indications for clinical use as a therapeutic agent."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9339823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Botulinum toxins, exotoxins of Clostridium botulinum, are the most toxic naturally occurring substances known to man."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9339823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 479,
          "offsetInEndSection": 577,
          "text": "As a consequence, action potentials in the motor nerve can no longer be transmitted to the muscle."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34603008",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "Motor neurons (MNs) are specialized neurons responsible for muscle contraction that specifically degenerate in motor neuron diseases (MNDs), such as amyotrophic lateral sclerosis (ALS), spinal and bulbar muscular atrophy (SBMA), and spinal muscular atrophy (SMA)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34603008",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 648,
          "offsetInEndSection": 860,
          "text": "Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide with beneficial effects in many neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and more recently SBMA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34603008",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 990,
          "offsetInEndSection": 1143,
          "text": "These two peptides are implicated in the activation of neuroprotective pathways exploitable in the amelioration of pathological outcomes related to MNDs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34603008",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 861,
          "offsetInEndSection": 989,
          "text": "Another neuropeptide that has a neurotrophic effect on MNs is insulin-like growth factor 1 (IGF-1), also known as somatomedin C."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34603008",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 504,
          "offsetInEndSection": 647,
          "text": "Among the different strategies to target MNs, the administration of protective neuropeptides is one of the potential therapeutic interventions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Presynaptic receptors are sites at which transmitters, locally formed mediators or hormones inhibit or facilitate the release of a given transmitter from its axon terminals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 445,
          "offsetInEndSection": 600,
          "text": "Autoreceptors are presynaptic receptors at which a given transmitter restrains its further release, though in some instances may also increase its release."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 174,
          "offsetInEndSection": 444,
          "text": "The interest in the identification of presynaptic receptors has faded in recent years and it may therefore be justified to give an overview of their occurrence in the autonomic and central nervous system; this review will focus on presynaptic receptors in human tissues."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 601,
          "offsetInEndSection": 781,
          "text": "Inhibitory autoreceptors represent a typical example of a negative feedback; they are tonically activated by the respective endogenous transmitter and/or are constitutively active."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902931",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 854,
          "text": "Autoreceptors also play a role under pathophysiological conditions, e.g."
        }
      ]
    },
    {
      "id": "67e93f2d18b1e36f2e0000db",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
        "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
        "http://www.ncbi.nlm.nih.gov/pubmed/30244358",
        "http://www.ncbi.nlm.nih.gov/pubmed/33987427",
        "http://www.ncbi.nlm.nih.gov/pubmed/18495029",
        "http://www.ncbi.nlm.nih.gov/pubmed/32238797",
        "http://www.ncbi.nlm.nih.gov/pubmed/7494397",
        "http://www.ncbi.nlm.nih.gov/pubmed/33243181",
        "http://www.ncbi.nlm.nih.gov/pubmed/10210897",
        "http://www.ncbi.nlm.nih.gov/pubmed/32775816"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Systemic sclerosis is a connective tissue disease characterized by progressive skin thickening and a wide spectrum of internal organ involvement."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 616,
          "offsetInEndSection": 771,
          "text": "The patient developed progressive lung fibrosis under several immunosuppressants and was started on nintedanib, with clinical and functional stabilization."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 973,
          "offsetInEndSection": 1214,
          "text": "It is approved for idiopathic lung fibrosis and has demonstrated good results in inhibiting migration and proliferation of systemic sclerosis dermal fibroblasts, constituting a promising agent for systemic sclerosis-associated lung fibrosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 772,
          "offsetInEndSection": 972,
          "text": "Nintedanib is a tyrosine-kinase inhibitor that blocks several profibrotic pathways, inhibiting proliferation and migration of fibroblasts and decreasing the synthesis of extracellular matrix proteins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 209,
          "text": "Pathogenesis includes vasculopathy, inflammation, and fibrosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 315,
          "offsetInEndSection": 501,
          "text": "The spectrum of disorders included in NAFLD are benign macrovesicular hepatic steatosis, non-alcoholic steatohepatitis, hepatic fibrosis, cirrhosis of liver and hepatocellular carcinoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 131,
          "text": "NAFLD is a clinical entity related to metabolic syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 770,
          "offsetInEndSection": 879,
          "text": "As there are risks of potential complications during liver biopsy, many patients do not opt for liver biopsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 691,
          "offsetInEndSection": 769,
          "text": "It is diagnosed by abnormal liver chemistry, imaging studies and liver biopsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 880,
          "offsetInEndSection": 983,
          "text": "There are some noninvasive scoring systems to find out whether patients have advanced hepatic fibrosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30244358",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "TAFRO syndrome (thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) is an atypical manifestation of multicentric Castleman's disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30244358",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 162,
          "offsetInEndSection": 426,
          "text": "Although overproduction of interleukin-6, vascular endothelial growth factor, and other cytokines may partially explain the pathophysiology of this rare syndrome, the precise mechanisms underlying the renal dysfunction associated with the condition remain unclear."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30244358",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1351,
          "offsetInEndSection": 1488,
          "text": "The glomerular lesions might be characteristic of TAFRO syndrome, and were regarded as the main cause of the patient's renal dysfunction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30244358",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 495,
          "offsetInEndSection": 572,
          "text": "He was treated with immunosuppressive agents and his renal function improved."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30244358",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 573,
          "offsetInEndSection": 695,
          "text": "Tapering of immunosuppressive agents resulted in a deterioration of renal function and an elevation of C-reactive protein."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33987427",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 107,
          "offsetInEndSection": 186,
          "text": "Fibrotic scarring occurs as the consequence of chronic injury and inflammation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33987427",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 187,
          "offsetInEndSection": 447,
          "text": "While the successful treatment of hepatitis B and C reduced the burden of liver disease related to viral hepatitis, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) are nowadays the leading causes of hepatic fibrosis worldwide."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33987427",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 448,
          "offsetInEndSection": 631,
          "text": "Although basic research activities have significantly advanced our understanding of the molecular disease pathogenesis, the present therapeutic options for fibrosis are still limited."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33987427",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 725,
          "offsetInEndSection": 877,
          "text": "This highlights the necessity of preventive strategies to avoid complications of fibrosis, particularly cirrhosis, portal hypertension and liver cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33987427",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1988,
          "offsetInEndSection": 2141,
          "text": "Tackling NAFLD-associated fibrosis from different directions by combinatorial drug treatment and effective lifestyle changes hold the greatest prospects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18495029",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 890,
          "offsetInEndSection": 1136,
          "text": "Due to the atypical distribution of the fibrosis involving both the lower and upper lobes of the lung, the microscopic pattern of the fibrosis and the history of long-term nitrofurantoin use, we concluded that this drug induced the lung fibrosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18495029",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 100,
          "offsetInEndSection": 235,
          "text": "Many adverse effects of nitrofurantoin have been documented, including aplastic anemia, polyneuritis, and liver and pulmonary toxicity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18495029",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1272,
          "offsetInEndSection": 1354,
          "text": "This case shows that the use of nitrofurantoin may cause severe pulmonary disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18495029",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1355,
          "offsetInEndSection": 1461,
          "text": "Patients with long-term use of nitrofurantoin should be monitored regularly for adverse pulmonary effects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18495029",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 798,
          "offsetInEndSection": 889,
          "text": "Microscopically, end-stage interstitial fibrosis with diffuse alveolar damage was observed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32238797",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 384,
          "offsetInEndSection": 466,
          "text": "One of the medications that can cause interstitial lung disease is nitrofurantoin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32238797",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 203,
          "offsetInEndSection": 383,
          "text": "The potential causes of interstitial lung disease are broad and includes infection, malignancy, autoimmune/connective tissues diseases, inhaled substances, and certain medications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32238797",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 975,
          "offsetInEndSection": 1226,
          "text": "CONCLUSIONS Although nitrofurantoin is one of the most commonly used antibiotics in the treatment of urinary tract infections and is often considered a relatively safe medication, long-term use can lead to the development of interstitial lung disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32238797",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "BACKGROUND Interstitial lung disease, also known as diffuse parenchymal lung disease, is a group of diseases that affects the interstitium of the lungs and can lead to progressive fibrosis of the lungs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32238797",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 467,
          "offsetInEndSection": 600,
          "text": "CASE REPORT A 88-year-old man with recurrent urinary tract infections was treated with long-term nitrofurantoin prophylactic therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7494397",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Nephropathic cystinosis is an autosomal recessive inborn error of metabolism characterized by the lysosomal storage of the disulphide amino acid cystine."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7494397",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 425,
          "offsetInEndSection": 572,
          "text": "Therapy of cystinosis with cysteamine averts the otherwise inevitable renal failure, but systemic therapy does not improve the corneal keratopathy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7494397",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 154,
          "offsetInEndSection": 302,
          "text": "It produces a variety of clinical manifestations including failure to thrive, the renal Fanconi syndrome, eye findings, and end-stage renal disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7494397",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 573,
          "offsetInEndSection": 780,
          "text": "A number of presentations in this review detail approaches to gene identification, systemic therapy with cysteamine, measurement of cystine, and pathophysiological effects at the cellular and clinical level."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7494397",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 303,
          "offsetInEndSection": 424,
          "text": "A variety of phenotypes are known; however, the molecular defect underlying any of the forms has not yet been identified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33243181",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 653,
          "offsetInEndSection": 724,
          "text": "We suspected the fibrosis to be caused by the nitrofurantoin treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33243181",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Pulmonary side effects are well known, including lung fibrosis, in elderly patients treated with long-term nitrofurantoin to prevent urinary tract infections and secondary renal injury."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33243181",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 186,
          "offsetInEndSection": 382,
          "text": "However, pulmonary side effects have only been reported rarely in paediatric cases, despite nitrofurantoin being a first line prophylactic treatment of recurrent childhood urinary tract infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33243181",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 954,
          "offsetInEndSection": 1106,
          "text": "This case underlines that risk of severe side effects should be taken in to account before initiation of long-term nitrofurantoin treatment in children."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33243181",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 617,
          "text": "A computed tomography scan of the chest showed lung fibrosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10210897",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "Nephropathic cystinosis is a hereditary disorder characterized by a specific defect in the transport of cystine across the lysosomal membrane, leading to an accumulation of protein-free cystine in tissues, including conjunctiva, liver, bone marrow and kidney."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10210897",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 260,
          "offsetInEndSection": 320,
          "text": "Renal transplantation is necessary because of renal failure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10210897",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 467,
          "offsetInEndSection": 648,
          "text": "We report on two further rare cases of two siblings suffering from cystinosis who developed a predominantly distal myopathy, proven electrophysiologically and on biopsy during life."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10210897",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 321,
          "offsetInEndSection": 466,
          "text": "With improved life-expectancy, neurological complications have been reported, including cases of distal myopathy diagnosed ante- and post-mortem."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10210897",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 649,
          "offsetInEndSection": 784,
          "text": "The reported clinical picture of a distal atrophy resembling a neurogenic disease, confirms a picture apparently typical in cystinosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "text": "Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman's disease, characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, and organomegaly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1444,
          "offsetInEndSection": 1610,
          "text": "Severe diuretic-resistant anasarca with mild proteinuria and severe glomerular endotheliopathy were common characteristics of renal dysfunction due to TAFRO syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 396,
          "text": "Renal complication of this disease can be life-threatening and sometimes requires hemodialysis, but it has not been elucidated in detail."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 397,
          "offsetInEndSection": 510,
          "text": "Case-series was designed to evaluate the renal histology of patients with TAFRO syndrome treated at our hospital."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32775816",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1146,
          "offsetInEndSection": 1286,
          "text": "Treatment with glucocorticoids and molecular-targeting agents, including tocilizumab and rituximab, improved renal dysfunction and anasarca."
        }
      ]
    },
    {
      "id": "67e2bde318b1e36f2e000093",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17324369",
        "http://www.ncbi.nlm.nih.gov/pubmed/28209226",
        "http://www.ncbi.nlm.nih.gov/pubmed/3542725",
        "http://www.ncbi.nlm.nih.gov/pubmed/23666861",
        "http://www.ncbi.nlm.nih.gov/pubmed/19275628",
        "http://www.ncbi.nlm.nih.gov/pubmed/30680373",
        "http://www.ncbi.nlm.nih.gov/pubmed/16293956",
        "http://www.ncbi.nlm.nih.gov/pubmed/16149210",
        "http://www.ncbi.nlm.nih.gov/pubmed/23914326",
        "http://www.ncbi.nlm.nih.gov/pubmed/27914359"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17324369",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Obstructive sleep apnea (OSA) is a common disorder and the major sleep-related risk factor for cerebrovascular disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17324369",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 247,
          "offsetInEndSection": 454,
          "text": "Observational studies have shown that patients with clinically significant OSA have increased incidence of cardiovascular and cerebrovascular disease, as well as increased incidence of sudden death in sleep."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17324369",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 455,
          "offsetInEndSection": 628,
          "text": "Following stroke, patients have a high prevalence of OSA, which diminishes the potential for rehabilitation, increases the risk of secondary stroke, and heightens mortality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17324369",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 246,
          "text": "There is a dose-response relationship between the severity of OSA and the odds ratio for development of systemic hypertension."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17324369",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 893,
          "offsetInEndSection": 1010,
          "text": "Circadian changes during sleep contribute to an increase in the risk of cardiovascular and cerebrovascular accidents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28209226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 323,
          "offsetInEndSection": 489,
          "text": "Evidence supports a causal association of sleep apnea with the incidence and morbidity of hypertension, coronary heart disease, arrhythmia, heart failure, and stroke."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28209226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Sleep apnea is highly prevalent in patients with cardiovascular disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28209226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 622,
          "offsetInEndSection": 883,
          "text": "In this review, we discuss the mechanisms of sleep apnea, the evidence that addresses the links between sleep apnea and cardiovascular disease, and research that has addressed the effect of sleep apnea treatment on cardiovascular disease and clinical endpoints."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28209226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 884,
          "offsetInEndSection": 1027,
          "text": "Finally, we review the recent development in sleep apnea treatment options, with special consideration of treating patients with heart disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28209226",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 490,
          "offsetInEndSection": 621,
          "text": "Several discoveries in the pathogenesis, along with developments in the treatment of sleep apnea, have accumulated in recent years."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3542725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 217,
          "offsetInEndSection": 386,
          "text": "Obesity and snoring, both of which increase with age, have been identified as risk factors for sleep-related breathing disorders, as have hypertension and heart disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3542725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Sleep-related breathing disorders may contribute to the nocturnal peak in human mortality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3542725",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 216,
          "text": "Nocturnal hypoxia has been associated with serious ventricular tachyarrhythmias as well as life-threatening bradyarrhythmias."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666861",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Obstructive sleep apnea (OSA) has been found to be an independent risk factor for stroke in large epidemiological studies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666861",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 423,
          "offsetInEndSection": 665,
          "text": "This brief review focuses on presenting some of the epidemiological evidence of the linkage between OSA and stroke, discussing mechanistic pathways and the potential effect of OSA treatment in modulating the risk for stroke in these patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666861",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 317,
          "text": "The mechanisms underlying this relationship have been investigated over the past 2-3 decades, with a particular focus on identifying pathophysiological pathways and risk modification strategies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666861",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 318,
          "offsetInEndSection": 422,
          "text": "Despite the advancements made, the specific understanding of the implicated mechanisms is still limited."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666861",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 666,
          "offsetInEndSection": 730,
          "text": "Future directions for research in this field are also discussed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19275628",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Obstructive Sleep Apnea (OSA) is a prevalent disease that has emerged as a new cerebrovascular disease (CVD) risk factor, which is independent of its association to hypertension, age and other known conditions that increase CVD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19275628",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 508,
          "offsetInEndSection": 931,
          "text": "Numerous markers of these changes have been reported in OSA patients, including increased circulating free radicals, increased lipid peroxidation, decreased antioxidant capacity, elevation of tumor necrosis factor and interleukines, increased levels of proinflammatory nuclear transcription factor kappa B, decreased circulating nitric oxide, elevation of vascular adhesion molecules and vascular endothelial growth factor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19275628",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1268,
          "text": "Further research is needed in order to better clarify the complex mechanisms that underlie the relation between OSA, atherogenesis and CVD which most likely will have significant clinical impact."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19275628",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 229,
          "offsetInEndSection": 507,
          "text": "The mechanisms involved in this relation are most likely induced by the periodic hypoxia/reoxygenation that characteristically occurs in OSA, which results in oxidative stress, endothelial dysfunction and activation of the inflammatory cascade, all of which favor atherogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19275628",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 932,
          "offsetInEndSection": 1072,
          "text": "In addition, several authors have described that Continuous Positive Airway Pressure, the standard OSA therapy, reverts these abnormalities."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30680373",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Obstructive Sleep Apnea (OSA) is a common co-morbid condition in stroke patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30680373",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 518,
          "offsetInEndSection": 709,
          "text": "In this review we present the epidemiology for OSA in stroke populations and discuss the risk factors for stroke as well as the underlying pathogenetic mechanisms linking OSA, stroke and CVD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30680373",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1100,
          "offsetInEndSection": 1333,
          "text": "Work up and treatment for OSA will not only help prevent stroke with its devastating consequences, but will also help prevent CVD, and ameliorate co-morbid conditions such as diabetes and hypertension in these vulnerable populations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30680373",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 342,
          "offsetInEndSection": 517,
          "text": "Although in the United States the prevalence of OSA has somewhat decreased from the previous years, globally its prevalence remains constant, or in some cases, is on the rise."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30680373",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 710,
          "offsetInEndSection": 1003,
          "text": "We also emphasize the more thorough evaluation and control of OSA in order to prevent the disabling side effects of a stroke, which not only compromises the physical and mental health of a person and increases the burden on families, but also adds a severe burden to national health economics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16293956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 384,
          "offsetInEndSection": 726,
          "text": "Patients with obstructive sleep apnea present risk to the general public safety by causing 8-fold increase in vehicle accidents, and they may themselves also suffer from the physiologic consequences of OSA; these include hypertension, coronary artery disease, stroke, congestive heart failure, pulmonary hypertension, and cardiac arrhythmias."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16293956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1486,
          "offsetInEndSection": 1600,
          "text": "Therefore, OSA continues to be a significant health risk both for affected individuals and for the general public."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16293956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 861,
          "offsetInEndSection": 1164,
          "text": "Although the exact mechanism has not been understood, there is some evidence that OSA is associated with frequent apneas causing mechanical effects on intrathoracic pressure, cardiac function, and intermittent hypoxemia, which may in turn cause endothelial dysfunction and increase in sympathetic drive."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16293956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 727,
          "offsetInEndSection": 860,
          "text": "Of these possible cardiovascular consequences, the association between OSA and hypertension has been found to be the most convincing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16293956",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Obstructive sleep apnea (OSA) is the most common form of sleep-disordered breathing, affecting 5-15% of the population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16149210",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2101,
          "offsetInEndSection": 2294,
          "text": "Many studies have shown that patients with obstructive apnea have an increased incidence of daytime hypertension, and this syndrome is recognized as an independent risk factor for hypertension."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16149210",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1157,
          "offsetInEndSection": 1419,
          "text": "Although the exact mechanism linking sleep apnea with cardiovascular disease is unknown, there is evidence that obstructive apnea is associated with a group of proinflammatory and prothrombic factors that are also important in the development of atherosclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16149210",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 3487,
          "offsetInEndSection": 3721,
          "text": "More studies are needed to understand the mechanisms underlying the relationship between sleep apnea and cardiovascular disease, but clinicians should be aware of this link and should attempt to identify patients with these syndromes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16149210",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Sleep-disordered breathing is very common and is associated with an increased risk of cardiovascular disease, cardiac arrhythmia and stroke."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16149210",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1092,
          "offsetInEndSection": 1156,
          "text": "Obstructive apnea can also have substantial health consequences."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23914326",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 287,
          "text": "Obstructive sleep apnea, a form of sleep-disordered breathing, is associated with multiple major stroke risk factors but is also an independent risk factor for stroke."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23914326",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 380,
          "offsetInEndSection": 527,
          "text": "Sleep apnea is amenable to treatment and should be considered a modifiable stroke risk factor, though long-term compliance remains a major barrier."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23914326",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 528,
          "offsetInEndSection": 837,
          "text": "A better understanding of the relationship between sleep apnea and stroke may prompt providers to pursue the early diagnosis and treatment of underlying sleep-disordered breathing to both improve the chance of recovery from stroke in the short term and to reduce the risk of recurrent stroke in the long term."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23914326",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Sleep-disordered breathing is an increasingly recognized disorder that is particularly prevalent among stroke patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23914326",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 288,
          "offsetInEndSection": 379,
          "text": "In addition, untreated sleep apnea is associated with poor functional outcome after stroke."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 279,
          "text": "There is a growing consensus in the scientific community that suggests a strong association between obstructive sleep apnea (OSA) and cardiovascular (CVD) conditions and events, including coronary artery disease, hypertension, arrhythmia, heart failure, and sudden cardiac death."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 349,
          "offsetInEndSection": 518,
          "text": "Our conclusion, based on our review of the literature, is that the evidence supports a strong link between OSA and cardiovascular mortality, which warrants treating OSA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 280,
          "offsetInEndSection": 348,
          "text": "We reviewed evidence on the relationship between OSA and arrhythmia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 608,
          "text": "Continuous positive airway pressure (CPAP) appears to reduce the CVD consequences of OSA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 609,
          "offsetInEndSection": 715,
          "text": "Future research is expected to clarify the benefits and optimal application of these treatment approaches."
        }
      ]
    },
    {
      "id": "680c137818b1e36f2e000158",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31119147",
        "http://www.ncbi.nlm.nih.gov/pubmed/29995496",
        "http://www.ncbi.nlm.nih.gov/pubmed/32942567",
        "http://www.ncbi.nlm.nih.gov/pubmed/31147872",
        "http://www.ncbi.nlm.nih.gov/pubmed/28560055",
        "http://www.ncbi.nlm.nih.gov/pubmed/31873723",
        "http://www.ncbi.nlm.nih.gov/pubmed/32445205",
        "http://www.ncbi.nlm.nih.gov/pubmed/27742530",
        "http://www.ncbi.nlm.nih.gov/pubmed/33839323",
        "http://www.ncbi.nlm.nih.gov/pubmed/12888360"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31119147",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1124,
          "offsetInEndSection": 1318,
          "text": "As researchers continue to examine the development of the cancer hallmarks and the pathways involved, it became evident that cancer cell-derived exosomes play a major role in almost all of them."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31119147",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "In an attempt to conceptualize the process of cancer formation, Hanahan and Weinberg [2000] have outlined six universal characteristics of tumorigenesis, and labelled them as the \"hallmarks of cancer\"."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31119147",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 385,
          "text": "These hallmarks include; unlimited proliferation, evading growth suppressors, resisting cell death, replicative immortality, inducing angiogenesis, initiating invasion and metastasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31119147",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 386,
          "offsetInEndSection": 506,
          "text": "Cancer cell signalling is crucial for initiating and controlling cellular pathways that are involved in these hallmarks."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31119147",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1319,
          "offsetInEndSection": 1417,
          "text": "This review will examine the role played by cancer cell-derived exosomes in development of cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29995496",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "The hallmarks of cancer are mechanisms that cells develop to undergo malignant transformation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29995496",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 361,
          "offsetInEndSection": 480,
          "text": "Ten hallmarks, among them proliferative signaling, angiogenesis, immune response, and genome instability, are reviewed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29995496",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 219,
          "offsetInEndSection": 360,
          "text": "The purpose of this article is to review these hallmarks, their associated targeted therapies, imaging features of responses, and toxicities."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29995496",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 218,
          "text": "The targeting of these hallmarks by newer cancer therapies results in new mechanisms of response, toxicity, and resistance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29995496",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 481,
          "offsetInEndSection": 601,
          "text": "Molecular targeted therapies, including antiangiogenic factors and immune checkpoint inhibitors, target these hallmarks."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32942567",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 769,
          "offsetInEndSection": 900,
          "text": "Their close proximity to blood vessels may provide a permissive environment, facilitating angiogenesis, invasion, and tumor growth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32942567",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 175,
          "offsetInEndSection": 414,
          "text": "It also contains non-cellular components, such as the extracellular matrix, extracellular vesicles, and cytokines, and has certain physicochemical properties, such as low pH, hypoxia, elevated interstitial pressure, and impaired perfusion."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32942567",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "The glioma microenvironment is a critical regulator of tumor progression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32942567",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 558,
          "offsetInEndSection": 768,
          "text": "This is just one of a number of names given to these mesenchymal stromal-like cells, which have phenotypic and functional properties similar to those of mesenchymal stem cells and cancer-associated fibroblasts."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32942567",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 415,
          "offsetInEndSection": 557,
          "text": "This review focuses on a particular type of cells recently identified in the glioma microenvironment: glioma-associated stromal cells (GASCs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31147872",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1859,
          "offsetInEndSection": 2000,
          "text": "This chapter will introduce hallmarks of GBM and elaborate on the contributions of pericytes to these hallmarks by examining recent findings."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31147872",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1364,
          "offsetInEndSection": 1524,
          "text": "Pericytes are multipotent perivascular cells that play a vital role within the GBM microenvironment by assisting in tumor initiation, survival, and progression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31147872",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1525,
          "offsetInEndSection": 1858,
          "text": "Due to their role in regulating the blood-brain barrier permeability, promoting angiogenesis, tumor growth, clearing extracellular matrix for infiltrating GBM cells and in helping GBM cells evade immune surveillance, pericytes could be ideal therapeutic targets for stymieing or exploiting their role within the GBM microenvironment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31147872",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2001,
          "offsetInEndSection": 2174,
          "text": "In addition, the chapter also highlights the therapeutic value of targeting pericytes, while discussing conventional and novel GBM therapies and obstacles to their efficacy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31147872",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 584,
          "offsetInEndSection": 749,
          "text": "In recent years, many investigations have highlighted the role of GBM stem cells (GSCs) and their microenvironment in the initiation and maintenance of tumor tissue."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28560055",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 364,
          "offsetInEndSection": 680,
          "text": "We define seven hallmarks of cancer: selective growth and proliferative advantage, altered stress response favoring overall survival, vascularization, invasion and metastasis, metabolic rewiring, an abetting microenvironment, and immune modulation, while highlighting some considerations for the future of the field."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28560055",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 154,
          "offsetInEndSection": 363,
          "text": "Not free of critique and with understanding of different aspects of tumorigenesis coming into clearer focus in the recent years, we attempt to draw a more organized and updated picture of the cancer hallmarks."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28560055",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "The hallmarks of cancer described by Hanahan and Weinberg have proved seminal in our understanding of cancer's common traits and in rational drug design."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31873723",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 557,
          "text": "These distinctive and complementary capabilities, defined as the \"hallmarks of cancer,\" include the ability of tumor cells and their microenvironment to sustain proliferative signaling, evade growth suppressors, resist cell death, promote replicative immortality, induce angiogenesis, support invasion and metastasis, reprogram energy metabolism, induce genomic instability and inflammation, and trigger evasion of immune responses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31873723",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 766,
          "offsetInEndSection": 1029,
          "text": "Galectins, an evolutionarily conserved family of glycan-binding proteins, have broad influence in tumor progression by rewiring intracellular and extracellular circuits either in cancer or stromal cells, including immune cells, endothelial cells, and fibroblasts."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31873723",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1030,
          "offsetInEndSection": 1240,
          "text": "In this review, we dissect the role of galectins in shaping cellular circuitries governing each hallmark of tumors, illustrating relevant examples and highlighting novel opportunities for treating human cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31873723",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 558,
          "offsetInEndSection": 765,
          "text": "These common features are hierarchically regulated through different mechanisms, including those involving glycosylation-dependent programs that influence the biological and clinical impact of each hallmark."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31873723",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Hanahan and Weinberg have proposed 10 organizing principles that enable growth and metastatic dissemination of cancer cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32445205",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Tumorigenesis is not only determined by the intrinsic properties of cancer cells but also by their interactions with components of the tumor microenvironment (TME)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32445205",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 253,
          "text": "Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the TME."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32445205",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 435,
          "text": "During initial stages of tumor development, macrophages can either directly promote antitumor responses by killing tumor cells or indirectly recruit and activate other immune cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32445205",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 436,
          "offsetInEndSection": 494,
          "text": "As genetic changes occur within the tumor or T helper 2 (T"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27742530",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "The hallmarks of cancer capture the most essential phenotypic characteristics of malignant transformation and progression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27742530",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 338,
          "offsetInEndSection": 484,
          "text": "Therefore, investigators need to be aware of available and appropriate techniques capable of determining characteristic features of each hallmark."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27742530",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1136,
          "offsetInEndSection": 1288,
          "text": "Each hallmark possesses characteristics that can be analyzed by immunoblot, RT-PCR, immunocytochemistry, immunoprecipitation, RNA microarray or RNA-seq."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27742530",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 485,
          "offsetInEndSection": 742,
          "text": "We review the methods tailored to experimental cancer researchers to evaluate cell proliferation, programmed cell death, replicative immortality, induction of angiogenesis, invasion and metastasis, genome instability, and reprogramming of energy metabolism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27742530",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 337,
          "text": "Although numerous factors involved in this multi-step process are still unknown to date, an ever-increasing number of mutated/altered candidate genes are being identified within large-scale cancer genomic projects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33839323",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "The tumor microenvironment (TME), controlled by intrinsic mechanisms of carcinogenesis and epigenetic modifications, has, in recent years, become a heavily researched topic."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33839323",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 174,
          "offsetInEndSection": 285,
          "text": "The TME can be described in terms of hypoxia, metabolic dysregulation, immune escape, and chronic inflammation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33839323",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 397,
          "text": "RNA methylation, an epigenetic modification, has recently been found to have a pivotal role in shaping the TME."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33839323",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 398,
          "offsetInEndSection": 403,
          "text": "The N"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 98,
          "offsetInEndSection": 193,
          "text": "Although a simple answer remains elusive, several hallmarks of malignancy have been identified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 402,
          "text": "These critical features include uncontrolled proliferation, insensitivity to negative growth regulation, evasion of apoptosis, lack of senescence, invasion and metastasis, angiogenesis and genomic elasticity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1071,
          "offsetInEndSection": 1190,
          "text": "Here, we suggest the hallmarks of malignancy as a conceptual framework for understanding novel breast cancer therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 680,
          "offsetInEndSection": 863,
          "text": "Further improvements in therapy must attack the other hallmarks of malignancy and will undoubtedly be accompanied by a better means of individual patient selection for such therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12888360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 864,
          "offsetInEndSection": 931,
          "text": "Indeed, each of these hallmarks presents a therapeutic opportunity."
        }
      ]
    },
    {
      "id": "67ca061181b102733300000a",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26282267",
        "http://www.ncbi.nlm.nih.gov/pubmed/27492478",
        "http://www.ncbi.nlm.nih.gov/pubmed/30171939",
        "http://www.ncbi.nlm.nih.gov/pubmed/25747039",
        "http://www.ncbi.nlm.nih.gov/pubmed/30539545",
        "http://www.ncbi.nlm.nih.gov/pubmed/28947655",
        "http://www.ncbi.nlm.nih.gov/pubmed/29302591",
        "http://www.ncbi.nlm.nih.gov/pubmed/8353487",
        "http://www.ncbi.nlm.nih.gov/pubmed/9487391",
        "http://www.ncbi.nlm.nih.gov/pubmed/23093590"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282267",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 692,
          "offsetInEndSection": 854,
          "text": "Recent studies have improved our understanding of Xist localization and the proteins with which it interacts, allowing a reappraisal of ideas about Xist function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282267",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 487,
          "offsetInEndSection": 691,
          "text": "How Xist spreads, what are its binding sites, how it recruits silencing factors and how it induces a specific topological and nuclear organization of the chromatin all remain largely unanswered questions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282267",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 855,
          "offsetInEndSection": 1125,
          "text": "We discuss recent advances in our knowledge of Xist-mediated silencing, focusing on Xist spreading, the nuclear organization of the inactive X chromosome, recruitment of the polycomb complex and the role of the nuclear matrix in the process of X chromosome inactivation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282267",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 267,
          "text": "The master regulator of this process is the long non-coding RNA Xist."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282267",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 268,
          "offsetInEndSection": 486,
          "text": "During X-inactivation, Xist accumulates in cis on the future inactive X chromosome, triggering a cascade of events that provoke the stable silencing of the entire chromosome, with relatively few genes remaining active."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27492478",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "The Xist long noncoding RNA orchestrates X chromosome inactivation, a process that entails chromosome-wide silencing and remodeling of the three-dimensional (3D) structure of the X chromosome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27492478",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 326,
          "offsetInEndSection": 640,
          "text": "Here, we show that Xist directly interacts with the Lamin B receptor, an integral component of the nuclear lamina, and that this interaction is required for Xist-mediated silencing by recruiting the inactive X to the nuclear lamina and by doing so enables Xist to spread to actively transcribed genes across the X."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27492478",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 193,
          "offsetInEndSection": 325,
          "text": "Yet, it remains unclear whether these changes in nuclear structure are mediated by Xist and whether they are required for silencing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27492478",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 641,
          "offsetInEndSection": 811,
          "text": "Our results demonstrate that lamina recruitment changes the 3D structure of DNA, enabling Xist and its silencing proteins to spread across the X to silence transcription."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 520,
          "offsetInEndSection": 718,
          "text": "The multiple pathological functions of XIST in various cancers are systematically reviewed to elucidate the molecular basis of its biological roles and to provide new directions for future research."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 436,
          "offsetInEndSection": 519,
          "text": "This review focuses on research progress on the roles of XIST in tumor development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 268,
          "offsetInEndSection": 435,
          "text": "XIST is implicated in many aspects of carcinogenesis including tumor initiation, invasion, metastasis, apoptosis, cell cycle, stemness, autophagy, and drug resistance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "The X-inactive-specific transcript (XIST/Xist) is one of the first long non-coding RNAs discovered in mammals and plays an essential role in X chromosome inactivation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 168,
          "offsetInEndSection": 267,
          "text": "XIST is dysregulated and acts as an oncogene or a tumor suppressor in different human malignancies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25747039",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 809,
          "offsetInEndSection": 937,
          "text": "Here, we review the potential roles of some of these proteins in the stepwise process of Xist RNA-mediated chromosome silencing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25747039",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 224,
          "offsetInEndSection": 424,
          "text": "Xist RNA is thought to play a role as a platform in recruiting proteins involved in gene silencing and heterochromatinization, which mediate serial changes in epigenetic modification of the chromatin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25747039",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 551,
          "offsetInEndSection": 808,
          "text": "Although the biological significance of most of them for X-inactivation has not been fully established, extensive studies of these proteins should provide a better understanding of the molecular basis of how X-inactivation mediated by Xist RNA is regulated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25747039",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "X chromosome inactivation (X-inactivation) is triggered by X-linked noncoding Xist RNA, which is expressed asymmetrically from one of the two X chromosomes in females and coats it in cis to induce chromosome-wide silencing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25747039",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 425,
          "offsetInEndSection": 550,
          "text": "During the last two decades, many proteins have been shown to be enriched on the inactivated X chromosome in mouse and human."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30539545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 186,
          "offsetInEndSection": 326,
          "text": "But the mechanism by which Xist localizes and spreads on the X chromosome and facilitates transcriptional silencing remains largely unknown."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30539545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "X-inactive specific transcript (Xist) is a long noncoding RNA that is essential for initiating and maintaining epigenetic silencing of one copy of the X chromosome in mammalian females."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30539545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 789,
          "offsetInEndSection": 993,
          "text": "This strategy is\u00a0relatively simple approach to track\u00a0Xist at different stages of cell differentiation, providing mechanistic insights into the initiation, maintenance, and establishment of X inactivation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30539545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 472,
          "offsetInEndSection": 670,
          "text": "Development of a successful method for Xist tracking is a key to better understanding of the X chromosome\u00a0silencing, as well as to gain insight into the regulatory role of other long noncoding RNAs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30539545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 671,
          "offsetInEndSection": 788,
          "text": "Here, we describe an alternative method for visualization of Xist lncRNA in cells using a CRISPR/Cas9-based approach."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28947655",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 332,
          "text": "A long non-coding RNA (lncRNA), XIST, and its associated proteins orchestrate this multi-step process, resulting in the inheritable silencing of one of the two X-chromosomes in females."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28947655",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 726,
          "offsetInEndSection": 935,
          "text": "These studies shed light on key mechanisms of XCI, such as XIST coating of the X-chromosome, recruitment of DNA, RNA and histone modification enzymes, and compaction and compartmentalization of the inactive X."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28947655",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 936,
          "offsetInEndSection": 1321,
          "text": "Here, we summarize recent studies on XCI, highlight the critical contributions of new technologies and propose a unifying model for XIST function in XCI where modular domains serve as the structural and functional units in both lncRNA-protein complexes and DNA-protein complexes in chromatin.This article is part of the themed issue 'X-chromosome inactivation: a tribute to Mary Lyon'."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28947655",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 470,
          "offsetInEndSection": 725,
          "text": "Recent technological advances in the analysis of macromolecular structure and interactions have enabled us to systematically dissect the XIST ribonucleoprotein complex, which is larger than the ribosome, and its place of action, the inactive X-chromosome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28947655",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 333,
          "offsetInEndSection": 469,
          "text": "The XIST RNA is large and complex, exemplifying the unique challenges associated with the structural and functional analysis of lncRNAs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29302591",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 359,
          "text": "Xist, the master regulator of X chromosome inactivation, is a classic example of how lncRNAs can exert multi-layered and fine-tuned regulatory functions, by acting as a molecular scaffold for recruitment of distinct protein factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29302591",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 360,
          "offsetInEndSection": 522,
          "text": "In this review, we discuss the methodologies employed to define Xist RNA structures and the tight interplay between structural clues and functionality of lncRNAs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29302591",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Recent experimental evidence indicates that lncRNAs can act as regulatory molecules in the context of development and disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29302591",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 523,
          "offsetInEndSection": 718,
          "text": "This model of modular function dictated by structure, can be also generalized to other lncRNAs, beyond the field of X chromosome inactivation, to explain common features of similarly folded RNAs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8353487",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 314,
          "offsetInEndSection": 461,
          "text": "This subnuclear localization and lack of any significant protein-coding potential suggest that XIST may act as a functional RNA within the nucleus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8353487",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "The human XIST gene, a candidate for a role in X chromosome inactivation, has recently been cloned and sequenced, yielding a 17 kb cDNA with no apparent significant, conserved open reading frame."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8353487",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 462,
          "offsetInEndSection": 639,
          "text": "In the absence of a conserved open reading frame, we have turned to evolutionary studies as a first step toward elucidating a function for XIST in the process of X inactivation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8353487",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1047,
          "offsetInEndSection": 1253,
          "text": "Other features of XIST are conserved in different species, however, including the position of a major transcription start site and active X chromosome-specific DNA methylation patterns at the gene's 5' end."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8353487",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 640,
          "offsetInEndSection": 861,
          "text": "While probes for XIST detect homologues in numerous eutherians, sequence comparisons require significant gapping and reveal identity levels intermediate between those seen for coding and non-coding regions in other genes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9487391",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 904,
          "offsetInEndSection": 1142,
          "text": "Goals for the future are to understand the mechanism of Xist regulation which underlies the establishment of appropriate X inactivation patterns and to determine how Xist RNA participates in the process of propagating inactivation in cis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9487391",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 808,
          "offsetInEndSection": 903,
          "text": "Recent results have demonstrated that Xist is both necessary and sufficient for X inactivation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9487391",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 331,
          "offsetInEndSection": 409,
          "text": "In adult cells Xist is transcribed exclusively from the inactive X chromosome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9487391",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Recent years have seen rapid progress towards understanding the molecular mechanisms involved in X chromosome inactivation (X inactivation)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9487391",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 573,
          "offsetInEndSection": 714,
          "text": "It is thus thought to represent a functional RNA molecule which acts as the primary signal responsible for the propagation of X inactivation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23093590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 354,
          "offsetInEndSection": 565,
          "text": "Here, we introduce a new version of our algorithm catRAPID to investigate Xist associations with a number of proteins involved in epigenetic regulation, nuclear scaffolding, transcription and splicing processes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23093590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "The transcriptional silencing of one of the female X-chromosomes is a finely regulated process that requires accumulation in cis of the long non-coding RNA X-inactive-specific transcript (Xist) followed by a series of epigenetic modifications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23093590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 566,
          "offsetInEndSection": 800,
          "text": "Our method correctly identifies binding regions and affinities of protein interactions, providing a powerful theoretical framework for the study of X-chromosome inactivation and other events mediated by ribonucleoprotein associations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23093590",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 244,
          "offsetInEndSection": 353,
          "text": "Little is known about the molecular machinery regulating initiation and maintenance of chromosomal silencing."
        }
      ]
    },
    {
      "id": "67e26d6218b1e36f2e000074",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25516474",
        "http://www.ncbi.nlm.nih.gov/pubmed/891079",
        "http://www.ncbi.nlm.nih.gov/pubmed/1437923",
        "http://www.ncbi.nlm.nih.gov/pubmed/23019977",
        "http://www.ncbi.nlm.nih.gov/pubmed/7979581",
        "http://www.ncbi.nlm.nih.gov/pubmed/20120828",
        "http://www.ncbi.nlm.nih.gov/pubmed/25186992",
        "http://www.ncbi.nlm.nih.gov/pubmed/22724593",
        "http://www.ncbi.nlm.nih.gov/pubmed/27498665",
        "http://www.ncbi.nlm.nih.gov/pubmed/29038968"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516474",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 234,
          "text": "However, children younger than 16 years also can develop SLE (childhood-onset lupus/juvenile-type SLE)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516474",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease with highest prevalence among women of childbearing age."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516474",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 801,
          "offsetInEndSection": 1122,
          "text": "The prevalence of the following manifestations was significantly higher for pediatric than for adult-onset disease including: lupus nephritis (43% pediatric vs 26.4% for adult-onset), hematological disorders (57% vs 36.4%), photosensitivity (20% vs 9%), butterfly rash (61% vs 35.5%) and mucosal ulceration (11.4% vs 4%)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516474",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 525,
          "offsetInEndSection": 800,
          "text": "Organ manifestations, laboratory parameters, and immunoserological characteristics were reviewed and the results were evaluated using SPSS for Windows software.Gender distribution was not significantly different between groups with disease starting in childhood vs adulthood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516474",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1123,
          "offsetInEndSection": 1265,
          "text": "For adult-onset SLE, neurological symptoms (30% vs 6%) and polyarthritis (86% vs 68%) occurred significantly more frequently than in children."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/891079",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 128,
          "offsetInEndSection": 196,
          "text": "Only 9 children were less than 9 years old at the time of diagnosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/891079",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Between 1945 and 1970, 101 children (86 girls and 15 boys) with systemic lupus erythematosus were evaluated at the Mayo Clinic."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/891079",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 197,
          "offsetInEndSection": 314,
          "text": "The most frequent presenting complaint was arthralgia; fever, fatigue, and a \"butterfly\" malar rash also were common."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/891079",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 410,
          "offsetInEndSection": 517,
          "text": "The overall survival of children with renal involvement is improved by the use of adequate steroid therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/891079",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 315,
          "offsetInEndSection": 409,
          "text": "Renal involvement, found in more than 76 per cent of patients, was a prognostically poor sign."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1437923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "We compared the clinical and serological characteristics of 15 patients with onset of systemic lupus erythematosus after the age of 50 with those of 232 younger patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1437923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 317,
          "offsetInEndSection": 570,
          "text": "Initial manifestations, which presented more frequently in the older group, included thrombocytopenia (P < 0.05), sicca syndrome (P < 0.01) and cardiomyopathy (P < 0.005), whereas butterfly rash (P < 0.05) presented more frequently in the younger group."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1437923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 571,
          "offsetInEndSection": 718,
          "text": "Analysis of cumulative clinical symptoms showed that butterfly rash (P < 0.05) and livedo reticularis (P < 0.05) were less frequent in the elderly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1437923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 719,
          "offsetInEndSection": 846,
          "text": "However, this group presented a significantly increased incidence of sicca syndrome (P < 0.005) and cardiomyopathy (P < 0.005)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1437923",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 252,
          "offsetInEndSection": 316,
          "text": "Autoimmune thyroiditis was found in 20% of the elderly patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019977",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 278,
          "offsetInEndSection": 390,
          "text": "We examined 84 patients with SLE (84% women), their mean age was 42.3 +/- 2.3 yr duration of SLE 6.5 +/- 1.2 yr."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019977",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 391,
          "offsetInEndSection": 491,
          "text": "The subacute and chronic SLE variants were diagnosed in 30 (36%) and 54 (64%) patients respectively."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019977",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 586,
          "offsetInEndSection": 770,
          "text": "Symptom complexes \"systemic inflammation\", \"butterfly rash\", \"wrist petechiae\", \"enanthema of the oral mucous membrane\", and other lesions were regarded as the markers of SLE activity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019977",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "Systemic lupus erythematosus (SLE) remains a challenging medical problem."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019977",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 277,
          "text": "The integral approach to the analysis of underlying pathogenetic processes allows identifying main symptom complexes of SLE and establishing relationship between skin lesions and activity of the disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7979581",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 847,
          "offsetInEndSection": 1001,
          "text": "The mean age at diagnosis of SLE was 40.9 years (range: 11-83) with a mean interval between first definite SLE symptom and diagnosis of 61 months (0-518)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7979581",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "text": "To assess race-specific incidence and prevalence rates for systemic lupus erythematosus (SLE) using 1991 National Census data and to ascertain the frequency of clinical/laboratory features of a geographically complete cohort of patients with SLE."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7979581",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 442,
          "offsetInEndSection": 583,
          "text": "Multiple logistic regression analysis was used to study the effects of age at diagnosis on the frequency of clinical/laboratory SLE features."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7979581",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 584,
          "offsetInEndSection": 687,
          "text": "The overall one year period prevalence rate for SLE was 24.7 (age adjusted, 95% CI: 20.7-28.8)/100,000."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7979581",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1253,
          "offsetInEndSection": 1447,
          "text": "Malar rash, thrombocytopaenia, positive anti-dsDNA antibodies, hypocomplementaemia (C4), and positive IgG anticardiolipin antibodies were all seen less commonly with increasing age at diagnosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 140,
          "offsetInEndSection": 261,
          "text": "SLE mainly affects adults and is common in women between the ages of 20 and 40 years, with a female to male ratio of 9:1."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "The prevalence of systemic lupus erythematosus (SLE) is 28 per 100,000."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 897,
          "offsetInEndSection": 1029,
          "text": "Lupus glomerulonephritis is one of the most important systemic complications, occurring in about 30% of patients with SLE in the UK."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 606,
          "offsetInEndSection": 740,
          "text": "Joint involvement is inflammatory in nature with arthralgia, arthritis and/or tendinitis and occurs in about 90% of patients with SLE."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 605,
          "text": "Cutaneous involvement is present in about 60% of cases and typically manifests as a malar or butterfly rash."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25186992",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with wide clinical features ranging from cutaneous manifestations to systemic disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25186992",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 793,
          "offsetInEndSection": 912,
          "text": "The mean age of patients with DLE was 30.18 \u00b1 11.07 years and in patients without it was 28.4 \u00b1 10.26 years (p \u200a=\u200a .6)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25186992",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 489,
          "offsetInEndSection": 597,
          "text": "Disease activity was determined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25186992",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 598,
          "offsetInEndSection": 662,
          "text": "A SLEDAI-2K score \u2265 10 was considered active and severe disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25186992",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 913,
          "offsetInEndSection": 1030,
          "text": "Three of 11 patients with DLE (27.3%) and 14 of 49 patients without DLE (28.6%) had a SLEDAI-2K score \u2265 10 (p \u200a=\u200a 1)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22724593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "We report a case of a 64-year-old man with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) syndrome that had been previously misdiagnosed as systemic sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22724593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 811,
          "offsetInEndSection": 1001,
          "text": "By contrast, the existence of systemic sclerosis-specific autoantibodies, nail fold bleeding, digital ulcer/digital pitting scar or telangiectasia is highly suggestive of systemic sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22724593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 481,
          "offsetInEndSection": 526,
          "text": "Among them, five patients had skin sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22724593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1002,
          "offsetInEndSection": 1132,
          "text": "To our knowledge, this is the first report to discuss in detail the differentiation between POEMS syndrome and systemic sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22724593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 527,
          "offsetInEndSection": 682,
          "text": "Therefore, we compared skin lesions and clinical/laboratory features of POEMS syndrome and systemic sclerosis in an attempt to distinguish these disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498665",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 297,
          "text": "We report the case of a 7-year-old female patient with facial lesions of SLE since the age of 5."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498665",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which the body\u0092s immune system mistakenly attacks healthy tissue."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498665",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 387,
          "offsetInEndSection": 521,
          "text": "The child presented with a malar rash, also known as a butterfly rash, with distribution over the cheeks but sparing the nasal bridge."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498665",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 567,
          "offsetInEndSection": 659,
          "text": "Michaels\u00ae (Soratinex\u00ae) product family in the successful resolution of facial lesions of SLE."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498665",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 136,
          "offsetInEndSection": 200,
          "text": "It can affect the skin, joints, kidneys, brain and other organs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Systemic sclerosis is a connective tissue disease characterized by progressive skin thickening and a wide spectrum of internal organ involvement."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 472,
          "offsetInEndSection": 615,
          "text": "Here, we report a 65-year-old female patient with limited cutaneous systemic sclerosis, anti-topoisomerase-positive and extensive lung disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 973,
          "offsetInEndSection": 1214,
          "text": "It is approved for idiopathic lung fibrosis and has demonstrated good results in inhibiting migration and proliferation of systemic sclerosis dermal fibroblasts, constituting a promising agent for systemic sclerosis-associated lung fibrosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 616,
          "offsetInEndSection": 771,
          "text": "The patient developed progressive lung fibrosis under several immunosuppressants and was started on nintedanib, with clinical and functional stabilization."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 210,
          "offsetInEndSection": 417,
          "text": "Although immunosuppressants such as cyclophosphamide and mycophenolate mofetil have shown some benefit in interstitial lung disease management, it is still a major cause of morbi-mortality in these patients."
        }
      ]
    },
    {
      "id": "680a21eb18b1e36f2e000150",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21720767",
        "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
        "http://www.ncbi.nlm.nih.gov/pubmed/23780694",
        "http://www.ncbi.nlm.nih.gov/pubmed/28925106",
        "http://www.ncbi.nlm.nih.gov/pubmed/24760871",
        "http://www.ncbi.nlm.nih.gov/pubmed/21343408",
        "http://www.ncbi.nlm.nih.gov/pubmed/27829268",
        "http://www.ncbi.nlm.nih.gov/pubmed/21818782",
        "http://www.ncbi.nlm.nih.gov/pubmed/27638763",
        "http://www.ncbi.nlm.nih.gov/pubmed/27821050"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21720767",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Myelin is a biologically active mutilamellar that is formed by oligodendrocytes (OLs) in the central nervous system (CNS) and ensheathes axons (Ishii et al., Proc Natl Acad Sci USA 106:14605-14610, 2009)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21720767",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 287,
          "offsetInEndSection": 480,
          "text": "In this article, we investigated whether myelin derived from rat spinal cord can influence the proliferation of neural stem cells (NSCs) and NSCs differentiation into oligodendrocytes in vitro."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21720767",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 927,
          "offsetInEndSection": 1137,
          "text": "In conclusion, these results suggested that central myelin can affect the proliferation and differentiation of NSCs, thus promoting us to understand further the complex roles of myelin in NSCs after CNS injury."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21720767",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 205,
          "offsetInEndSection": 286,
          "text": "Myelin damage is related to neurological trauma such as spinal cord injury (SCI)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21720767",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 813,
          "offsetInEndSection": 926,
          "text": "In addition, myelin can inhibit the differentiation of NSCs into O4(+) oligodendrocytes impeding them maturation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Myelin sheaths in the vertebrate nervous system enable faster impulse propagation, while myelinating glia provide vital support to axons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 377,
          "offsetInEndSection": 556,
          "text": "While the link between experience and myelination gains increased recognition, it is still unclear what role such adaptive myelination plays in facilitating and shaping behaviour."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 138,
          "offsetInEndSection": 376,
          "text": "Once considered a static insulator, converging evidence now suggests that myelin in the central nervous system can be dynamically regulated by neuronal activity and continues to participate in nervous system plasticity beyond development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 557,
          "offsetInEndSection": 664,
          "text": "Additionally, fundamental mechanisms and principles underlying myelin remodelling remain poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29054040",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 665,
          "offsetInEndSection": 869,
          "text": "In this review, we will discuss new insights into the link between myelin plasticity and behaviour, as well as mechanistic aspects of myelin remodelling that may help to elucidate this intriguing process."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23780694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "The myelin sheath is a multilayered membrane in the nervous system, which has unique biochemical properties."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23780694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 232,
          "offsetInEndSection": 374,
          "text": "The proteins of the myelin sheath are involved in a number of neurological diseases, including autoimmune diseases and inherited neuropathies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23780694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 231,
          "text": "Myelin carries a set of specific high-abundance proteins, the structure and function of which are still poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23780694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 911,
          "offsetInEndSection": 1079,
          "text": "A detailed understanding of myelin protein structure and function at the molecular level will be required to fully grasp their physiological roles in the myelin sheath."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23780694",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 375,
          "offsetInEndSection": 910,
          "text": "In this review, we briefly discuss the structural properties and functions of selected myelin-specific proteins (P0, myelin oligodendrocyte glycoprotein, myelin-associated glycoprotein, myelin basic protein, myelin-associated oligodendrocytic basic protein, P2, proteolipid protein, peripheral myelin protein of 22 kDa, 2',3'-cyclic nucleotide 3'-phosphodiesterase, and periaxin); such properties include, for example, interactions with lipid bilayers and the presence of large intrinsically disordered regions in some myelin proteins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28925106",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Myelin allows for the rapid and precise timing of action potential propagation along neuronal circuits and is essential for healthy auditory system function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28925106",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 485,
          "text": "In this article, we discuss what is currently known about myelin in the auditory system with a focus on the timing of myelination during auditory system development, the role of myelin in supporting peripheral and central auditory circuit function, and how various myelin pathologies compromise auditory information processing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28925106",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 750,
          "text": "Additionally, in keeping with the increasing recognition that myelin is dynamic and is influenced by experience throughout life, we review the growing evidence that auditory sensory deprivation alters myelin along specific segments of the brain's auditory circuit."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28925106",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 816,
          "text": "Develop Neurobiol 78: 80-92, 2018."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28925106",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 751,
          "offsetInEndSection": 781,
          "text": "\u00a9 2017 Wiley Periodicals, Inc."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760871",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Schwann cells, the myelinating glia of the peripheral nervous system (PNS), originate from multipotent neural crest cells that also give rise to other cells, including neurons, melanocytes, chondrocytes, and smooth muscle cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760871",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 448,
          "offsetInEndSection": 735,
          "text": "We show here that histone deacetylases 1 and 2 (HDAC1/2) are essential for the specification of neural crest cells into Schwann cell precursors and satellite glia, which express the early determinants of their lineage myelin protein zero (P0) and/or fatty acid binding protein 7 (Fabp7)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760871",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 229,
          "offsetInEndSection": 306,
          "text": "The transcription factor Sox10 is required for peripheral glia specification."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760871",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1040,
          "offsetInEndSection": 1287,
          "text": "Consistently, in vivo genetic deletion of HDAC1/2 in mouse neural crest cells led to strongly decreased Sox10 expression, no detectable Pax3, virtually no satellite glia, and no Schwann cell precursors in dorsal root ganglia and peripheral nerves."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760871",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1410,
          "offsetInEndSection": 1601,
          "text": "Therefore, by controlling the expression of Pax3 and the concerted action of Pax3 and Sox10 on their target genes, HDAC1/2 direct the specification of neural crest cells into peripheral glia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21343408",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Myelin consists of tightly compacted membranes that form an insulating sheath around axons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21343408",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 246,
          "text": "The function of myelin for rapid saltatory nerve conduction is dependent on its unique composition, highly enriched in glycosphingolipids and cholesterol."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21343408",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 247,
          "offsetInEndSection": 383,
          "text": "Cholesterol emerged as the only integral myelin component that is essential and rate limiting for the development of CNS and PNS myelin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21343408",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 662,
          "offsetInEndSection": 764,
          "text": "In this review, the authors summarize the role of cholesterol in myelin biogenesis and myelin disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21343408",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 568,
          "offsetInEndSection": 661,
          "text": "In Schwann cells of the PNS, protein trafficking and myelin compaction depend on cholesterol."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27829268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 148,
          "offsetInEndSection": 321,
          "text": "In the central nervous system, polarized oligodendrocytes form myelin by wrapping processes in a spiral pattern around neuronal axons through myelin-related gene regulation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27829268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Myelin is a specialized structure of the nervous system that both enhances electrical conductance and insulates neurons from external risk factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27829268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 800,
          "offsetInEndSection": 998,
          "text": "Although the majority of works on FMRP have been performed in neurons, it is also found in the developing or mature glial cells including oligodendrocytes, where its function is not well understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27829268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 518,
          "offsetInEndSection": 663,
          "text": "Therefore, many research interests have been focused to identify RNA binding proteins and their regulatory mechanism in myelinating compartments."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27829268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 999,
          "offsetInEndSection": 1297,
          "text": "Here, we will review evidences suggesting abnormal translational regulation of myelin proteins with accompanying white matter problem and neurological deficits in fragile X syndrome, which can have wider mechanistic and pathological implication in many other neurological and psychiatric disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818782",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "During normal brain development, axons are myelinated by mature oligodendrocytes (OLGs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818782",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 89,
          "offsetInEndSection": 368,
          "text": "Under pathological, demyelinating conditions within the central nervous system (CNS), axonal remyelination is only partially successful because oligodendrocyte precursor cells (OPCs) largely remain in an undifferentiated state resulting in a failure to generate myelinating OLGs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818782",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1239,
          "offsetInEndSection": 1386,
          "text": "We conclude that TG2 plays a prominent role in remyelination of the CNS, probably through stimulating OPC differentiation into myelin-forming OLGs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818782",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 496,
          "offsetInEndSection": 618,
          "text": "Therefore, we hypothesized that TG2 contributes to differentiation of OPCs into OLGs and thereby stimulates remyelination."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818782",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 619,
          "offsetInEndSection": 962,
          "text": "In vivo studies, using the cuprizone model for de- and remyelination in TG2(-/-) and wild-type mice, showed that during remyelination expression of proteolipid protein mRNA, as a marker for remyelination, in the corpus callosum lags behind in TG2(-/-) mice resulting in less myelin formation and, moreover, impaired recovery of motor behavior."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27638763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "Formation of myelin sheaths by Schwann cells (SCs) enables rapid and efficient transmission of action potentials in peripheral axons, and disruption of myelination results in disorders that involve decreased sensory and motor functions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27638763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 457,
          "text": "Given that construction of SC myelin requires high levels of lipid and protein synthesis, mitochondria, which are pivotal in cellular metabolism, may be potential regulators of the formation and maintenance of SC myelin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27638763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 609,
          "offsetInEndSection": 713,
          "text": "However, evidence for the importance of SC mitochondria in myelination has been limited, until recently."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27638763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 962,
          "offsetInEndSection": 1123,
          "text": "Here, we review current knowledge about the involvement of SC mitochondria in the formation and dysfunction of myelinated axons in the peripheral nervous system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27638763",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 714,
          "offsetInEndSection": 961,
          "text": "Several studies have recently used genetic approaches that allow SC-specific ablation of mitochondrial metabolic activity in living animals to show the critical roles of SC mitochondria in the development and maintenance of peripheral nerve axons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "The transcription factor SOX10 is essential for all stages of Schwann cell development including myelination."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 299,
          "text": "SOX10 cooperates with other transcription factors to activate the expression of key myelin genes in Schwann cells and is therefore a context-dependent, pro-myelination transcription factor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1732,
          "offsetInEndSection": 1974,
          "text": "Our computational strategy revealed a putative novel function for SOX10 in Schwann cells, which suggests a model where SOX10 activates the expression of genes that inhibit myelination during non-myelinating stages of Schwann cell development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 425,
          "offsetInEndSection": 577,
          "text": "While genome-wide studies have successfully revealed SOX10 target genes, these efforts mainly focused on myelinating stages of Schwann cell development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1432,
          "offsetInEndSection": 1731,
          "text": "Functional studies in Schwann cells revealed that: (1) all eight loci are expressed prior to myelination and down-regulated subsequent to myelination; (2) seven of the eight loci harbor validated SOX10 binding sites; and (3) seven of the eight loci are down-regulated upon repressing SOX10 function."
        }
      ]
    },
    {
      "id": "67fa3c5818b1e36f2e000109",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20122157",
        "http://www.ncbi.nlm.nih.gov/pubmed/33835457",
        "http://www.ncbi.nlm.nih.gov/pubmed/34864895",
        "http://www.ncbi.nlm.nih.gov/pubmed/21937656",
        "http://www.ncbi.nlm.nih.gov/pubmed/24044569",
        "http://www.ncbi.nlm.nih.gov/pubmed/28718905",
        "http://www.ncbi.nlm.nih.gov/pubmed/27980099",
        "http://www.ncbi.nlm.nih.gov/pubmed/28707064",
        "http://www.ncbi.nlm.nih.gov/pubmed/25376489",
        "http://www.ncbi.nlm.nih.gov/pubmed/22442327"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20122157",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Biological knowledge is represented in scientific literature that often describes the function of genes/proteins (bioentities) in terms of their interactions (biointeractions)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20122157",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 296,
          "text": "Such bioentities are often related to biological concepts of interest that are specific of a determined research field."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20122157",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1140,
          "offsetInEndSection": 1343,
          "text": "Text mining tools combining the extraction of interacting bioentities and biological concepts with network displays can be helpful in developing reasonable hypotheses in different scientific backgrounds."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20122157",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 297,
          "offsetInEndSection": 498,
          "text": "Therefore, the study of the current literature about a selected topic deposited in public databases, facilitates the generation of novel hypotheses associating a set of bioentities to a common context."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20122157",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 499,
          "offsetInEndSection": 733,
          "text": "We created a text mining system (LAITOR: Literature Assistant for Identification of Terms co-Occurrences and Relationships) that analyses co-occurrences of bioentities, biointeractions, and other biological terms in MEDLINE abstracts."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33835457",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 266,
          "offsetInEndSection": 451,
          "text": "CircFunBase is such a web-accessible database that aims to provide a high-quality functional circRNA resource including experimentally validated and computationally predicted functions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33835457",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 452,
          "offsetInEndSection": 519,
          "text": "CircFunBase provides visualized circRNA-miRNA interaction networks."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33835457",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Circular RNA (or circRNA) is a type of single-stranded covalently closed circular RNA molecule and play important roles in diverse biological pathways."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33835457",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 771,
          "text": "Moreover, other circRNA related databases are outlined."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33835457",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 265,
          "text": "A comprehensive functionally annotated circRNA database will help to understand the circRNAs and their functions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864895",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 407,
          "offsetInEndSection": 555,
          "text": "Here, we present RCandy, a platform-independent R package for rapid, simple and flexible visualization of recombination events in bacterial genomes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864895",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 626,
          "text": "RCandy is an R package freely available for use under the MIT license."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864895",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Homologous recombination is an important evolutionary process in bacteria and other prokaryotes, which increases genomic sequence diversity and can facilitate adaptation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864895",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 406,
          "text": "Exploration and visualization of such recombination events can reveal valuable biological insights, but it remains challenging."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864895",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 704,
          "offsetInEndSection": 825,
          "text": "The source code comes together with a detailed vignette available on GitHub at https://github.com/ChrispinChaguza/RCandy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937656",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Borna disease virus (BDV), a nonsegmented, negative-strand RNA virus, infects a wide variety of mammalian species and readily establishes a long-lasting, persistent infection in brain cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937656",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1636,
          "offsetInEndSection": 1863,
          "text": "Our results revealed that the newly established BDV vector constitutes an alternative tool not only for stable expression of foreign genes in the CNS but also for understanding the mechanism of the release of enveloped virions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937656",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 694,
          "offsetInEndSection": 911,
          "text": "The recombinant BDV (rBDV) carrying green fluorescent protein (GFP) between the P and M genes, rBDV P/M-GFP, expressed GFP efficiently in cultured cells and rodent brains for a long period of time without attenuation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937656",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 482,
          "offsetInEndSection": 693,
          "text": "In this study, we established a novel BDV vector in which an additional transcription cassette has been inserted into an intercistronic noncoding region between the viral phosphoprotein (P) and matrix (M) genes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937656",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 912,
          "offsetInEndSection": 1158,
          "text": "Furthermore, we generated a nonpropagating rBDV, \u0394GLLP/M, which lacks the envelope glycoprotein (G) and a splicing intron within the polymerase gene (L), by the transcomplementation system with either transient or stable expression of the G gene."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24044569",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Exosomes are nanovesicles secreted into the extracellular environment upon internal vesicle fusion with the plasma membrane."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24044569",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 222,
          "offsetInEndSection": 369,
          "text": "For this reason, and because they are released in easily accessible body fluids such as blood and urine, they represent a precious biomedical tool."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24044569",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 499,
          "offsetInEndSection": 705,
          "text": "This article focuses on the exploitation of exosomes as diagnostic tools for human tumors and discusses possible applications of the same strategies to other pathologies, such as neurodegenerative diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24044569",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 370,
          "offsetInEndSection": 498,
          "text": "A growing body of evidence suggests that exosomes may be used as biomarkers for the diagnosis and prognosis of malignant tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24044569",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 221,
          "text": "The molecular content of exosomes is a fingerprint of the releasing cell type and of its status."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28718905",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Exosomes are small extracellular membrane-based vesicles with a variety of cargoes that are involved in numerous physiological and pathological processes in the nervous system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28718905",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 314,
          "text": "Accumulating evidence has implicated that exosomes are emerging as a novel form of intercellular communication within the nervous system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28718905",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 534,
          "offsetInEndSection": 649,
          "text": "Third, we discuss the roles and prospects of exosomes in the diagnosis and treatment of neurodegenerative diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28718905",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 315,
          "offsetInEndSection": 428,
          "text": "In this review, we first illustrate exosome metabolism including its formation, secretion, transport, and uptake."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28718905",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 429,
          "offsetInEndSection": 533,
          "text": "Second, we compare exosomes to synaptic vesicles in terms of intercellular messengers and communicators."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27980099",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 595,
          "offsetInEndSection": 772,
          "text": "BioGRID curates the biomedical literature for major model organism species, including humans, with a recent emphasis on central biological processes and specific human diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27980099",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1147,
          "offsetInEndSection": 1330,
          "text": "BioGRID data are directly downloadable without restriction in a variety of standardized formats and are freely distributed through partner model organism databases and meta-databases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27980099",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 773,
          "offsetInEndSection": 953,
          "text": "To facilitate network-based approaches to drug discovery, BioGRID now incorporates 27 501 chemical-protein interactions for human drug targets, as drawn from the DrugBank database."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27980099",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "The Biological General Repository for Interaction Datasets (BioGRID: https://thebiogrid.org) is an open access database dedicated to the annotation and archival of protein, genetic and chemical interactions for all major model organism species and humans."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27980099",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 256,
          "offsetInEndSection": 451,
          "text": "As of September 2016 (build 3.4.140), the BioGRID contains 1 072 173 genetic and protein interactions, and 38 559 post-translational modifications, as manually annotated from 48 114 publications."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707064",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 323,
          "text": "In this study, we developed a dipstick immunoassay using a folate-specific monoclonal antibody (mAb), allowing rapid and low-cost detection of folates."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707064",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Folates (vitamin B9) are essential for all organisms as cofactors for one-carbon metabolism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707064",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 93,
          "offsetInEndSection": 171,
          "text": "However, measurement of folates is technically complicated and time-consuming."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707064",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 324,
          "offsetInEndSection": 431,
          "text": "The indicator range of the dipstick for 5-formylterahydrofolate (5-CHO-THF), 5-methyltetrahydrofolate (5-CH"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376489",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 714,
          "offsetInEndSection": 988,
          "text": "It is expected that these new findings will give an innovation boost for the development of scaffolds for bone repair and reconstruction, which began with the use of bioinert materials, followed by bioactive materials and now leading to functional regenerative tissue units."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376489",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 989,
          "offsetInEndSection": 1463,
          "text": "These new developments have become possible with the discovery of the morphogenic activity of bioinorganic polymers, biocalcit, bio-polyphosphate and biosilica that are formed by a biogenic, enzymatic mechanism, a driving force along with the development of novel rapid-prototyping three-dimensional (3D) printing methods and bioprinting (3D cell printing) techniques that may allow a fabrication of customized implants for patients suffering in bone diseases in the future."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376489",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 460,
          "text": "New discoveries revealed that fundamental steps in biomineralization are enzyme driven, not only during hydroxyapatite deposition, but also during initial bioseed formation, involving the transient deposition and subsequent transformation of calcium carbonate to calcium phosphate mineral."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376489",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "In recent years a paradigm shift in understanding of human bone formation has occurred that starts to change current concepts in tissue engineering of bone and cartilage."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376489",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 713,
          "text": "The principal enzymes mediating these reactions, carbonic anhydrase and alkaline phosphatase, open novel targets for pharmacological intervention of bone diseases like osteoporosis, by applying compounds acting as potential activators of these enzymes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442327",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Melioidosis is an emerging infectious disease caused by the soil bacterium Burkholderia pseudomallei."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442327",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 435,
          "offsetInEndSection": 673,
          "text": "The YLF/BTFC multiplex assay (targeting the Yersinia-like fimbrial/Burkholderia thailandensis-like flagellum and chemotaxis region) also showed high diagnostic sensitivity and provides additional information on possible geographic origin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442327",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 387,
          "text": "In a direct comparison of published and newly developed TaqMan PCR assays, we found the TTS1-orf2 assay to be superior in detecting B."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442327",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "text": "In diagnostic and forensic settings, molecular detection assays need not only high sensitivity with low limits of detection but also high specificity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442327",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 388,
          "offsetInEndSection": 434,
          "text": "pseudomallei directly from clinical specimens."
        }
      ]
    },
    {
      "id": "6810c54b353a4a2e6b000011",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
        "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
        "http://www.ncbi.nlm.nih.gov/pubmed/21301338",
        "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
        "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
        "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
        "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
        "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
        "http://www.ncbi.nlm.nih.gov/pubmed/27905012",
        "http://www.ncbi.nlm.nih.gov/pubmed/22696384"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 186,
          "offsetInEndSection": 351,
          "text": "For instance, pharmacological therapy is frequently accompanied by side effects, and current anticonvulsive drugs fail to be effective to around a third of patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 88,
          "offsetInEndSection": 185,
          "text": "The two main therapies, pharmacology and the electrical stimulation, both have some shortcomings."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Epilepsy is a neurological disorder that affects around 1% of the population worldwide."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 994,
          "offsetInEndSection": 1106,
          "text": "Recently, a number of experiments have explored the treatments for epilepsy with optogenetic control of neurons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451697",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 573,
          "offsetInEndSection": 691,
          "text": "Although electrical stimulation has benefited many patients, the electrode stimulates unselective neurons or circuits."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 244,
          "text": "Epilepsy describes a group of brain disorders whose symptoms and causes are diverse and complicated, but all share a common behavioural manifestation: the seizure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1244,
          "offsetInEndSection": 1438,
          "text": "We review the physiological roles of voltage gated ion channels that are selective for sodium, potassium and calcium conductance and attempt to highlight their role in the pathology of epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 898,
          "offsetInEndSection": 1050,
          "text": "VGICs as well as being important for physiological function are critical in producing hyperexcitability such as that associated with seizure discharges."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1439,
          "offsetInEndSection": 1588,
          "text": "This is supplemented by the mechanisms of drug action at these important anticonvulsant targets for classical and clinically relevant compounds (e.g."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1051,
          "offsetInEndSection": 1243,
          "text": "Many drugs routinely used in the clinical setting, as well as several novel experimental drugs, have shown interactions with VGICs that underpin, at least in part, their anticonvulsant action."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21301338",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "There is a need for newer anti-epileptic drugs (AEDs) with improved efficacy and tolerability."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21301338",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 735,
          "text": "Two additional AEDs, lacosamide and eslicarbazepine acetate, have been licensed recently for a more traditional indication, refractory partial-onset seizures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21301338",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 736,
          "offsetInEndSection": 936,
          "text": "Although newly introduced agents given as adjunctive therapy have been found to be superior to placebo in reducing seizure frequency, the ultimate goal of sustained seizure freedom is rarely achieved."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21301338",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 439,
          "text": "Two recently introduced AEDs, stiripentol and rufinamide, have been licensed exclusively for orphan indications, that is severe myoclonic epilepsy of infancy (stiripentol, Europe) and Lennox-Gastaut syndrome (rufinamide, Europe and the USA)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21301338",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 197,
          "text": "This article reviews AEDs introduced since 2007 and investigational compounds in clinical development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 256,
          "text": "Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people are not well controlled by a single antiepileptic drug (AED) and usually require treatment with a combination of two or more AEDs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 257,
          "offsetInEndSection": 429,
          "text": "In recent years, many newer AEDs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2868,
          "offsetInEndSection": 3057,
          "text": "The results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1231,
          "offsetInEndSection": 1392,
          "text": "The primary outcomes were 50% or greater reduction in seizure frequency and seizure freedom; the secondary outcomes were treatment withdrawal and adverse events."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 550,
          "offsetInEndSection": 655,
          "text": "To investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1748,
          "offsetInEndSection": 1874,
          "text": "Potentially more effective treatments targeting specific mechanisms of epileptogenesis and ictogenesis are being investigated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 244,
          "offsetInEndSection": 430,
          "text": "Based on current evidence, prophylactic prescription of long-term antiepileptic drugs (AEDs) in patients with brain tumors in patients who did not present with seizures is not justified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 431,
          "offsetInEndSection": 579,
          "text": "Because of the high risk of recurrence, however, AED treatment should be strongly considered after a single seizure considered to be due to a tumor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1498,
          "offsetInEndSection": 1747,
          "text": "Among newer generation AEDs, levetiracetam has a number of advantageous features, including availability of a parenteral formulation, but other agents such as gabapentin, lamotrigine, oxcarbazepine, topiramate, and zonisamide may also be considered."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 806,
          "offsetInEndSection": 1015,
          "text": "In patients who may require chemotherapy, a non-enzyme-inducing AED is preferred for initial treatment to minimize the risk of drug interactions that impact adversely on the outcome of anticancer chemotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 318,
          "text": "We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of starting antiepileptic drug treatment following a single seizure?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1331,
          "offsetInEndSection": 2373,
          "text": "In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (CBT), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 581,
          "offsetInEndSection": 671,
          "text": "What are the effects of behavioural and psychological treatments for people with epilepsy?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 393,
          "offsetInEndSection": 491,
          "text": "What are the effects of additional drug treatments in people with drug-resistant partial epilepsy?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 319,
          "offsetInEndSection": 392,
          "text": "What are the effects of drug monotherapy in people with partial epilepsy?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 318,
          "text": "We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of starting antiepileptic drug treatment following a single seizure?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1331,
          "offsetInEndSection": 2373,
          "text": "In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (CBT), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 581,
          "offsetInEndSection": 671,
          "text": "What are the effects of behavioural and psychological treatments for people with epilepsy?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 393,
          "offsetInEndSection": 491,
          "text": "What are the effects of additional drug treatments in people with drug-resistant partial epilepsy?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 319,
          "offsetInEndSection": 392,
          "text": "What are the effects of drug monotherapy in people with partial epilepsy?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 279,
          "text": "Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and they usually require treatment with a combination of two or more AEDs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 280,
          "offsetInEndSection": 450,
          "text": "In recent years, many newer AEDs have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2824,
          "offsetInEndSection": 3016,
          "text": "The results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1161,
          "offsetInEndSection": 1322,
          "text": "The primary outcomes were 50% or greater reduction in seizure frequency and seizure freedom; the secondary outcomes were treatment withdrawal and adverse events."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 591,
          "offsetInEndSection": 694,
          "text": "To investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27905012",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 346,
          "text": "Epilepsy is characterized by the hyperexcitability of various neuronal circuits that results due to the imbalance between glutamate-mediated excitation of voltage-gated cation channels and \u03b3-amino butyric acid (GABA)-mediated inhibition of anion channels leading to aberrant, sporadic oscillations or fluctuations in neuronal electrical activity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27905012",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 591,
          "offsetInEndSection": 774,
          "text": "The only alternative to medicines is to identify and surgically remove the seizure foci in the brain or to abort the seizures just as they begin using an implanted cerebral electrode."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27905012",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 347,
          "offsetInEndSection": 590,
          "text": "Epilepsy with a risk of mortality and around 65 million sufferers of all ages all over the world is limited therapeutically with high rates of adverse reactions, lack of complete seizure control, and over 30% patients with refractory epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27905012",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 955,
          "offsetInEndSection": 1033,
          "text": "Thus, a better target-specific approach is needed to study and treat epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27905012",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 890,
          "offsetInEndSection": 954,
          "text": "Epilepsy animal models also constitute the identical constraint."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people are not well controlled by a single antiepileptic drug and usually require treatment with a combination of two or more antiepileptic drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 266,
          "offsetInEndSection": 453,
          "text": "In recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2694,
          "offsetInEndSection": 2883,
          "text": "The results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1103,
          "offsetInEndSection": 1264,
          "text": "The primary outcomes were 50% or greater reduction in seizure frequency and seizure freedom; the secondary outcomes were treatment withdrawal and adverse events."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 454,
          "offsetInEndSection": 559,
          "text": "To investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy."
        }
      ]
    },
    {
      "id": "67fd5d6518b1e36f2e000138",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30542515",
        "http://www.ncbi.nlm.nih.gov/pubmed/1320666",
        "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
        "http://www.ncbi.nlm.nih.gov/pubmed/8370584",
        "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
        "http://www.ncbi.nlm.nih.gov/pubmed/17456751",
        "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
        "http://www.ncbi.nlm.nih.gov/pubmed/15924253",
        "http://www.ncbi.nlm.nih.gov/pubmed/10850866",
        "http://www.ncbi.nlm.nih.gov/pubmed/26257825"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30542515",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Glioblastoma, the most frequent and lethal form of glioma, displays chromosome instability and recurrent somatic copy number alterations (SCNA)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30542515",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 235,
          "text": "Chromothripsis and whole genome duplication (WGD) have been recently identified in cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30542515",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 236,
          "offsetInEndSection": 314,
          "text": "In the present study, we analyzed SCNA and determine the ploidy pattern in 123"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1320666",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 247,
          "offsetInEndSection": 441,
          "text": "Loss of genetic material on chromosome 10 and amplification of the epidermal growth factor receptor (EGFR) gene are the most frequently reported genetic abnormalities in glioblastoma multiforme."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1320666",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1041,
          "offsetInEndSection": 1146,
          "text": "Of the 58 glioblastoma patients, 72% showed loss of chromosome 10 and 38% showed EGFR gene amplification."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1320666",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 924,
          "offsetInEndSection": 1040,
          "text": "Both the loss of genetic material on chromosome 10 and EGFR gene amplification were restricted to the glioblastomas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1320666",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 442,
          "offsetInEndSection": 923,
          "text": "In order to examine a possible correlation between these two genetic aberrations, the authors studied 106 gliomas (58 glioblastomas, 14 anaplastic astrocytomas, five astrocytomas, nine pilocytic astrocytomas, seven mixed gliomas, six oligodendrogliomas, two ependymomas, one subependymoma, one subependymal giant-cell astrocytoma, and three gangliogliomas) with Southern blot analysis for loss of heterozygosity on both arms of chromosome 10 and for amplification of the EGFR gene."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1320666",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1228,
          "offsetInEndSection": 1372,
          "text": "Without exception, the glioblastomas that exhibited EGFR gene amplification had also lost genetic material on chromosome 10 (p less than 0.001)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 253,
          "text": "Loss of heterozygosity (LOH) at markers of the long arm of chromosome 10 is the most common genetic alteration in glioblastoma, being detectable in up to 80% of cases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1062,
          "offsetInEndSection": 1180,
          "text": "Thus, we have investigated mechanisms of structural alterations of the chromosome region 10q23.3-26.3 in glioblastoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Glioblastoma is the most frequent and aggressive brain tumor in the adult population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1281,
          "offsetInEndSection": 1485,
          "text": "We resume that more detailed studies of glioblastoma at the molecular genetic level are essential in search for potential markers suitable for predicting the disease outcome and the response to treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 589,
          "offsetInEndSection": 643,
          "text": "LOH was detected in 62.1% of the glioblastoma samples."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8370584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 342,
          "offsetInEndSection": 519,
          "text": "The most common genetic alteration detected involved allele losses of chromosome 10 loci; these losses were observed in all glioblastomas and in three of the anaplastic gliomas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8370584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 197,
          "offsetInEndSection": 341,
          "text": "The frequency of allele loss was highest among the glioblastomas, suggesting that genetic alterations accumulate during glial tumor development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8370584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 520,
          "offsetInEndSection": 790,
          "text": "In order to delineate which chromosome 10 region or regions were deleted in association with glial tumor development, a deletion mapping analysis was performed, and this revealed the partial loss of chromosome 10 in eight glioblastomas and two of the anaplastic gliomas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8370584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "A panel of glial tumors consisting of 11 low grade gliomas, 9 anaplastic gliomas, and 29 glioblastomas were analyzed for loss of heterozygosity by examining at least one locus for each chromosome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8370584",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 978,
          "offsetInEndSection": 1134,
          "text": "These data suggest the existence of multiple chromosome 10 tumor suppressor gene loci whose inactivation is involved in the malignant progression of glioma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 439,
          "offsetInEndSection": 631,
          "text": "Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 251,
          "offsetInEndSection": 438,
          "text": "Primary glioblastomas are characterized by EGFR and MDM2 amplification/overexpression, PTEN mutations, and p16 deletions, whereas secondary glioblastomas frequently contain p53 mutations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1090,
          "offsetInEndSection": 1353,
          "text": "These results are in accordance with the view that LOH on 10q is a major factor in the evolution of glioblastoma multiform as the common phenotypic end point of both genetic pathways, whereas LOH on 10p is largely restricted to the primary (de novo) glioblastoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 250,
          "text": "There is increasing evidence that these glioblastoma subtypes develop through different genetic pathways."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 831,
          "offsetInEndSection": 970,
          "text": "The majority (88%) of primary glioblastomas with LOH#10 showed LOH at all informative markers, suggesting loss of the entire chromosome 10."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17456751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1090,
          "offsetInEndSection": 1315,
          "text": "During progression to glioblastoma, additional mutations accumulate, including loss of heterozygosity 10q25-qter ( approximately 70%), which is the most frequent genetic alteration in both primary and secondary glioblastomas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17456751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Glioblastoma is the most frequent and most malignant human brain tumor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17456751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 823,
          "offsetInEndSection": 1005,
          "text": "In the pathway to secondary glioblastoma, TP53 mutations are the most frequent and earliest detectable genetic alteration, already present in 60% of precursor low-grade astrocytomas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17456751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 676,
          "offsetInEndSection": 822,
          "text": "Secondary glioblastomas develop through progression from low-grade diffuse astrocytoma or anaplastic astrocytoma and manifest in younger patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17456751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 320,
          "text": "Primary and secondary glioblastoma constitute distinct disease subtypes, affecting patients of different age and developing through different genetic pathways."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Glioblastoma is the most common and most lethal brain tumour in humans."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 231,
          "offsetInEndSection": 395,
          "text": "Transcriptional aberrations may play a vital role in the etiology of glioblastoma, which might be caused by both genomic alterations and other regulation molecules."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 640,
          "text": "In this study, we investigated possible cooperative deregulation of microRNAs (miRNAs) and transcription factors (TFs) in glioblastoma, under the hypothesis that miRNAs and TFs might have a combinational regulatory effect on glioblastoma genes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 641,
          "offsetInEndSection": 798,
          "text": "We searched glioblastoma-specific regulatory networks by integrating glioblastoma related miRNAs, TFs and genes, and identified 54 feed-forward loops (FFLs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 799,
          "offsetInEndSection": 973,
          "text": "Follow up functional enrichment analysis of these FFLs uncovered some functions important to carcinogenesis but also some unique functions specific to the FFLs we identified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15924253",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 100,
          "offsetInEndSection": 236,
          "text": "Loss of heterozygosity of chromosome 10 and mutations in the tumor suppressor gene PTEN on 10q are molecular hallmarks of glioblastomas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15924253",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Glioblastoma multiforme WHO grade IV is the most common and malignant variant of astrocytic tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15924253",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 737,
          "offsetInEndSection": 821,
          "text": "In 70 glioblastomas, 5 (7%) PIK3CA mutations and 10 (14%) PTEN mutations were found."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15924253",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 939,
          "offsetInEndSection": 1016,
          "text": "In all but one glioblastoma, mutations were seen either in PIK3CA or in PTEN."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15924253",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1017,
          "offsetInEndSection": 1132,
          "text": "In conclusion, the frequency of PIK3CA mutations in glioblastomas appears to be much lower than initially reported."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10850866",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 535,
          "text": "Primary glioblastomas are characterized by EGFR amplification/overexpression, PTEN mutation, homozygous p16 deletion, and loss of heterozygosity (LOH) on entire chromosome 10, whereas secondary glioblastomas frequently contain p53 mutations and show LOH on chromosome 10q."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10850866",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1302,
          "text": "LOH on chromosome 1p was detected in 12% of primary and 15% of secondary glioblastomas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10850866",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 748,
          "offsetInEndSection": 904,
          "text": "LOH on chromosome 19q was frequently found in secondary glioblastomas (7 of 13, 54%) but rarely detected in primary glioblastomas (1 of 17, 6%, p = 0.0094)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10850866",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 536,
          "offsetInEndSection": 747,
          "text": "In this study, we analyzed LOH on chromosomes 19q, 1p, and 13q, using polymorphic microsatellite markers in 17 primary glioblastomas and in 13 secondary glioblastomas that progressed from low-grade astrocytomas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10850866",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 968,
          "offsetInEndSection": 1214,
          "text": "These results suggest that tumor suppressor gene(s) located on chromosome 19q are frequently involved in the progression from low-grade astrocytoma to secondary glioblastoma, but do not play a major role in the evolution of primary glioblastomas."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 391,
          "offsetInEndSection": 597,
          "text": "Genome-wide alterations involving copy number changes and loss of heterozygosity were identified in 17 glioma samples with positive FISH results for 1p19q co-deletions (n\u2009=\u20099) or EGFR amplification (n\u2009=\u20098)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 866,
          "offsetInEndSection": 997,
          "text": "The genomic architecture of EGFR amplified gliomas was much more complex, with a high number of gains and losses across the genome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 998,
          "offsetInEndSection": 1138,
          "text": "Recurrent alterations in EGFR amplified gliomas were both focal, such as CDKN2A homozygous deletions, and large, such as chromosome 10 loss."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1139,
          "offsetInEndSection": 1229,
          "text": "Microarray enabled a broader picture of the genomic alterations occurring in glioma cases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257825",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 598,
          "offsetInEndSection": 698,
          "text": "Gliomas positive for 1p19q co-deletions did not have other frequently recurrent genomic alterations."
        }
      ]
    },
    {
      "id": "67fb046e18b1e36f2e00010c",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
        "http://www.ncbi.nlm.nih.gov/pubmed/36102999",
        "http://www.ncbi.nlm.nih.gov/pubmed/28028563",
        "http://www.ncbi.nlm.nih.gov/pubmed/36000541",
        "http://www.ncbi.nlm.nih.gov/pubmed/32620751",
        "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
        "http://www.ncbi.nlm.nih.gov/pubmed/25145264",
        "http://www.ncbi.nlm.nih.gov/pubmed/28865998",
        "http://www.ncbi.nlm.nih.gov/pubmed/32291635",
        "http://www.ncbi.nlm.nih.gov/pubmed/12721663"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2833,
          "offsetInEndSection": 2888,
          "text": "Evaluation of zanidatamab continues in ongoing studies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 403,
          "offsetInEndSection": 562,
          "text": "The aim of this study was to evaluate the safety and anti-tumour activity of zanidatamab across a range of solid tumours with HER2 expression or amplification."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 290,
          "offsetInEndSection": 402,
          "text": "Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1524,
          "offsetInEndSection": 1625,
          "text": "Part 3 of the study evaluates the use of zanidatamab in combination with chemotherapy and is ongoing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 950,
          "offsetInEndSection": 1140,
          "text": "The primary objectives of part 1 were to identify the maximum tolerated dose, optimal biological dose, or recommended dose of zanidatamab; all patients were included in the primary analyses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36102999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 244,
          "offsetInEndSection": 496,
          "text": "Serum zanidatamab concentrations were obtained from 305 patients with advanced or metastatic breast cancer, gastroesophageal adenocarcinoma (GEA), biliary tract cancer, and other HER2-expressing cancers from four ongoing phase I and II clinical trials."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36102999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "To characterize the pharmacokinetics (PK) of zanidatamab including evaluation of the impact of intrinsic and extrinsic patient factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36102999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1526,
          "offsetInEndSection": 1690,
          "text": "Both weight-based (30\u00a0mg/kg Q3W) and two-tiered flat dosing (1800/2400\u00a0mg Q3W, 70\u00a0kg threshold) strategies are expected to provide similar exposures of zanidatamab."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36102999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 136,
          "offsetInEndSection": 243,
          "text": "To investigate alternative dosing regimens to improve caregiver convenience and reduce zanidatamab wastage."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36102999",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 552,
          "text": "Zanidatamab PK were described using population methods."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28028563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 736,
          "offsetInEndSection": 880,
          "text": "Whole genome, next generation sequencing (WGS) has been recently used to define DMD patient mutations, but has not been used in dystrophic dogs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28028563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 224,
          "text": "Truncating mutations in the DMD gene cause loss of dystrophin and the classical DMD clinical syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28028563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1127,
          "offsetInEndSection": 1318,
          "text": "WGS was then used to detect a 7 base pair deletion in DMD exon 42 (c.6051-6057delTCTCAAT mRNA), predicting a frameshift in gene transcription and truncation of dystrophin protein translation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28028563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Dystrophin is a key cytoskeletal protein coded by the Duchenne muscular dystrophy (DMD) gene located on the X-chromosome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28028563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 314,
          "offsetInEndSection": 517,
          "text": "The mdx mouse model and the golden retriever muscular dystrophy (GRMD) canine model have been used extensively to study DMD disease pathogenesis and show efficacy and side effects of putative treatments."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36000541",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 368,
          "text": "Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, respectively, and have shown encouraging antitumor activity in early phase studies in multiple cancers, including GEA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36000541",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 529,
          "offsetInEndSection": 893,
          "text": "Here, we describe the design of HERIZON-GEA-01, a global, randomized, open-label, active-comparator, Phase III study to evaluate and compare the efficacy and safety of zanidatamab plus chemotherapy with or without tislelizumab to the standard of care (trastuzumab plus chemotherapy) as first-line treatment for patients with advanced/metastatic HER2-positive GEAs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36000541",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 894,
          "offsetInEndSection": 1077,
          "text": "HERIZON-GEA-01: A phase III study of zanidatamab + chemotherapy\u00a0\u00b1 tislelizumab for first-line treatment of advanced or metastatic #HER2-positive gastroesophageal adenocarcinoma (GEA)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36000541",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 528,
          "text": "Preliminary data suggest\u00a0that dual targeting of the HER2 and PD-1 pathways could further improve upon the results achieved with targeting either pathway alone."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36000541",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "HER2-positive gastroesophageal adenocarcinomas (GEAs) are common cancers with high mortality and the treatment options for advanced/metastatic disease are limited."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32620751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 394,
          "text": "Here, we report the identification of Nemo-like kinase (NLK) as a potential target for DBA therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32620751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 944,
          "offsetInEndSection": 1042,
          "text": "We propose that NLK mediates aberrant erythropoiesis in DBA and is a potential target for therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32620751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 565,
          "offsetInEndSection": 712,
          "text": "Chemical and genetic inhibition of NLK increases erythroid expansion in mouse and human progenitors, including bone marrow cells from DBA patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32620751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 395,
          "offsetInEndSection": 511,
          "text": "To identify new DBA targets, we screen for small molecules that increase erythroid expansion in mouse models of DBA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32620751",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 713,
          "offsetInEndSection": 943,
          "text": "In DBA models and patient samples, aberrant NLK activation is initiated at the Megakaryocyte/Erythroid Progenitor (MEP) stage of differentiation and is not observed in non-erythroid hematopoietic lineages or healthy erythroblasts."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 376,
          "text": "Antisense oligonucleotides (AONs) are designed to induce the skipping of exon(s), in order to restore the reading frame, and therefore, allow for dystrophin expression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 377,
          "offsetInEndSection": 482,
          "text": "Eteplirsen and golodirsen, AONs for DMD exons 51 and 53 skipping, have been recently approved by the FDA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 483,
          "offsetInEndSection": 569,
          "text": "Viltolarsen, an AON for DMD exon 53 skipping, was approved in Japan earlier this year."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 207,
          "text": "Exon skipping has emerged as a promising therapy for DMD."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Duchenne muscular dystrophy (DMD) is one of\u00a0the most common lethal muscle-wasting disorders affecting young boys caused by mutations in the DMD gene."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Gomafu/MIAT/Rncr2 is a long noncoding RNA that has been proposed to control retinal cell specification, stem cell differentiation and alternative splicing of schizophrenia-related genes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 394,
          "offsetInEndSection": 545,
          "text": "Knockdown of Celf3 led to the down-regulation of Gomafu, and cross-link RNA precipitation analysis confirmed specific binding between Celf3 and Gomafu."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 187,
          "offsetInEndSection": 295,
          "text": "However, how Gomafu controls these biological processes at the molecular level has remained largely unknown."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 546,
          "offsetInEndSection": 696,
          "text": "In the neuroblastoma cell line Neuro2A, Celf3 formed novel nuclear bodies (named CS bodies) that colocalized with SF1, another Gomafu-binding protein."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145264",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 828,
          "offsetInEndSection": 999,
          "text": "These observations suggest that Gomafu indirectly modulates the function of the splicing factors SF1 and Celf3 by sequestering these proteins into separate nuclear bodies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865998",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 719,
          "offsetInEndSection": 882,
          "text": "Here, we designed morpholino AOs targeting DMD exon 51 using the in\u00a0silico tool and quantitatively evaluated the effects in immortalized DMD muscle cells in\u00a0vitro."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865998",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder, is caused by mutations in the dystrophin (DMD) gene."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865998",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 320,
          "text": "Exon skipping is a therapeutic approach that uses antisense oligonucleotides (AOs) to modulate splicing and restore the reading frame, leading to truncated, yet functional protein expression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865998",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 321,
          "offsetInEndSection": 519,
          "text": "In 2016, the US Food and Drug Administration (FDA) conditionally approved the first phosphorodiamidate morpholino oligomer (morpholino)-based AO drug, eteplirsen, developed for DMD exon 51 skipping."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865998",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1204,
          "offsetInEndSection": 1338,
          "text": "Significant in\u00a0vivo efficacy of the most effective morpholino, determined in\u00a0vitro, was confirmed in mice carrying the human DMD gene."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291635",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 440,
          "offsetInEndSection": 716,
          "text": "As miRNAs can regulate the expression of a broad spectrum of genes, are used as biomarkers, and can serve as therapeutic tools, we decided to identify and characterize differentially expressed miRNAs and their targets in FRDA cells compared to unaffected control (CTRL) cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291635",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1640,
          "offsetInEndSection": 1790,
          "text": "Our comprehensive transcriptome analyses identified miRNA-224-5p and miRNA-10a-5p as negative regulators of the FXN and BDNF expression, respectively."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291635",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1270,
          "offsetInEndSection": 1435,
          "text": "We also validated the ability of miRNA-10a-5p to bind and regulate the levels of brain-derived neurotrophic factor (BDNF), an important modulator of neuronal growth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291635",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1155,
          "offsetInEndSection": 1269,
          "text": "Further studies confirmed that miRNA-224-5p indeed targets FXN, resulting in decreases in mRNA and protein levels."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291635",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1436,
          "offsetInEndSection": 1639,
          "text": "We observed a significant decrease in the levels of miRNA-10a-5p and increase in the levels of BDNF upon correction of FRDA cells via zinc-finger nuclease (ZFN)-mediated excision of expanded GAA repeats."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 320,
          "offsetInEndSection": 449,
          "text": "Northern blot and 76-tissue array analyses showed that TNNI3K is highly expressed in heart, but is undetectable in other tissues."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 225,
          "text": "In an effort to identify such novel genes we identified a novel cardiac-specific kinase gene TNNI3K localized on 1p31.1 based on bioinformatics analyses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 777,
          "offsetInEndSection": 878,
          "text": "Our data suggest that TNNI3K is a cardiac-specific kinase and play important roles in cardiac system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Cardiac-restricted genes play important roles in cardiovascular system."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 319,
          "text": "Sequence analysis suggested that TNNI3K is a distant family member of integrin-linked kinase."
        }
      ]
    },
    {
      "id": "67d6bbfa18b1e36f2e000020",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22908365",
        "http://www.ncbi.nlm.nih.gov/pubmed/24856744",
        "http://www.ncbi.nlm.nih.gov/pubmed/18685551",
        "http://www.ncbi.nlm.nih.gov/pubmed/28273857",
        "http://www.ncbi.nlm.nih.gov/pubmed/1441463",
        "http://www.ncbi.nlm.nih.gov/pubmed/27272704",
        "http://www.ncbi.nlm.nih.gov/pubmed/26936099",
        "http://www.ncbi.nlm.nih.gov/pubmed/28872274",
        "http://www.ncbi.nlm.nih.gov/pubmed/27187878",
        "http://www.ncbi.nlm.nih.gov/pubmed/24849622"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22908365",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 324,
          "text": "HIV testing is the essential entry point to health care and social services that improve the quality of life and survival for persons who learn that they have HIV."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22908365",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 459,
          "offsetInEndSection": 700,
          "text": "In 2006, CDC recommended that all persons aged 13\u201364 years be screened for HIV in health-care settings in which the prevalence of undiagnosed HIV infection is >0.1%, and that persons with increased risk for HIV be retested at least annually."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22908365",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "June 27 is National HIV Testing Day, which promotes testing as an important strategy to detect, treat, and prevent human immunodeficiency virus (HIV) infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22908365",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 325,
          "offsetInEndSection": 458,
          "text": "Persons who receive appropriate treatment, monitoring, and health care also reduce their chances of transmitting the virus to others."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856744",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "text": "Universal human immunodeficiency virus (HIV) screening was recommended in 2012, and major improvements in HIV testing have occurred in the past decade, but identification of HIV infected individuals remains inadequate in the United States."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856744",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 240,
          "offsetInEndSection": 483,
          "text": "We report the case of a seronegative HIV-infected man who despite clinical and laboratory findings of acquired immunodeficiency syndrome,repeatedly tested nonreactive to third-generation HIV enzyme immunoassays (EIAs) and Western blot testing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856744",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 603,
          "offsetInEndSection": 975,
          "text": "The fourth-generation HIV EIA was positive presumably because it detects p24 HIV antigen as well as antibodies, unlike rapid HIV tests and third-generation HIV EIAs.This case highlights not only the importance of frontline providers to understand the different testing methodologies for HIV screening and their limitations but the importance of clinical suspicion as well."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856744",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 484,
          "offsetInEndSection": 602,
          "text": "Serologic diagnosis in this case required fourth-generation EIA testing due to the seronegativity of standard testing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18685551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "Early diagnosis of human immunodeficiency virus (HIV) infection enables infected persons to obtain medical care that can improve the quality and length of their lives and adopt behaviors to prevent further HIV transmission."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18685551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 366,
          "offsetInEndSection": 539,
          "text": "Among all persons with HIV infection diagnosed in 2005, 38% received a diagnosis of acquired immunodeficiency syndrome (AIDS) within 1 year of their first positive HIV test."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18685551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1632,
          "offsetInEndSection": 1766,
          "text": "New strategies are warranted to increase HIV testing, particularly among persons who are disproportionately affected by HIV infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18685551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 540,
          "offsetInEndSection": 741,
          "text": "To reduce the number of persons with undiagnosed HIV infection, CDC issued recommendations in September 2006 to implement HIV screening as part of routine medical care for all persons aged 13-64 years."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18685551",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1508,
          "offsetInEndSection": 1631,
          "text": "Health-care providers should routinely screen all patients aged 13-64 years for HIV in accordance with CDC recommendations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28273857",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "The diagnosis of acute human immunodeficiency virus (HIV) infection (AHI) plays a unique role in preventing the spread of HIV and ending the epidemic."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28273857",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 335,
          "text": "Acutely infected individuals are thought to contribute substantially to forward transmissions of HIV; however, diagnosing AHI in resource-limited settings has proven to be a challenge."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28273857",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 336,
          "offsetInEndSection": 550,
          "text": "While fourth generation antigen-antibody combination assays have been successful in high-resource settings, rapid point of care (POC) versions of these assays have yet to demonstrate high sensitivity to detect AHI."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28273857",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1246,
          "offsetInEndSection": 1443,
          "text": "We recommend that investigators design future studies carefully, keeping in mind how diagnostic performance may be influenced by prevalence, population, patient case mixes, and reference standards."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28273857",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 800,
          "offsetInEndSection": 1085,
          "text": "In this commentary, we aimed to review the quality of studies evaluating a new fourth generation rapid test for detecting AHI, to identify general methodological limitations and biases in diagnostic accuracy studies, and to recommend strategies for avoiding them in future evaluations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1441463",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Primary care physicians play an important role in identifying and treating bacterial infections in adults infected with the human immunodeficiency virus (HIV)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1441463",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 427,
          "offsetInEndSection": 601,
          "text": "Because M tuberculosis disease is preventable and curable and yet communicable, physicians should maintain a high degree of suspicion for tuberculosis in HIV-infected adults."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1441463",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 602,
          "offsetInEndSection": 750,
          "text": "In comparison, the goal of treating M avium complex in patients with advanced HIV disease is to reduce constitutional symptoms and improve survival."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1441463",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 160,
          "offsetInEndSection": 294,
          "text": "Mycobacterium avium complex and Mycobacterium tuberculosis are pathogens that can cause systemic or local infection in these patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1441463",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 426,
          "text": "We review the epidemiology, pathogenesis, clinical presentation, and principles of treatment for these two mycobacterial pathogens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27272704",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "Detection of acute HIV infection is vital in preventing onward transmission."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27272704",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 234,
          "text": "HIV point-of-care testing (POCT) has improved uptake of HIV testing but has been limited to third-generation assays, which only detect chronic HIV infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27272704",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1102,
          "offsetInEndSection": 1242,
          "text": "This new POCT shows improved sensitivity for detection of p24 antigen and may be of value for clinical use in detecting acute HIV infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27272704",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 507,
          "offsetInEndSection": 604,
          "text": "We aimed to assess the sensitivity of the new Alere HIV Combo POCT to detect acute HIV infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27272704",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 235,
          "offsetInEndSection": 506,
          "text": "Previous evaluation of the fourth-generation Alere Determine HIV-1/2 Ag/Ab Combo POCT showed only 50% sensitivity for HIV core protein p24 (p24 antigen) detection, which is suboptimal for diagnosis of acute HIV infection with limited advantage over third-generation POCT."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26936099",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1064,
          "offsetInEndSection": 1182,
          "text": "HIV infection may now be detected approximately 2 weeks postexposure, with a reduced number of false-positive results."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26936099",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 219,
          "text": "The first HIV antibody test, developed in 1985, was designed to screen blood products, not to diagnose AIDS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26936099",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 470,
          "offsetInEndSection": 661,
          "text": "The second-generation HIV test added recombinant antigens, and the third-generation HIV tests included IgM detection, reducing the test-negative window to approximately 3 weeks postinfection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26936099",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "A concern during the early AIDS epidemic was the lack of a test to identify individuals who carried the virus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26936099",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 946,
          "offsetInEndSection": 1063,
          "text": "The fifth-generation HIV assay provides separate antigen and antibody results and will require yet another algorithm."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28872274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 852,
          "offsetInEndSection": 1018,
          "text": "In the laboratory, reference HIV testing was conducted using two fourth-generation immunoassays with all positives in the confirmatory test considered true positives."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28872274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 686,
          "offsetInEndSection": 851,
          "text": "Participants were offered community-based HIV testing in the home by trained field workers using a serial algorithm with two rapid diagnostic tests (RDTs) in series."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28872274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 361,
          "offsetInEndSection": 433,
          "text": "We discuss implications of the findings on rapid HIV testing programmes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28872274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 360,
          "text": "We describe the overall accuracy and performance of a serial rapid HIV testing algorithm used in community-based HIV testing in the context of a population-based household survey conducted in two sub-districts of uMgungundlovu district, KwaZulu-Natal, South Africa, against reference fourth-generation HIV-1/2 antibody and p24 antigen combination immunoassays."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28872274",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 685,
          "text": "Peripheral blood samples were collected for HIV-related testing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27187878",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 762,
          "offsetInEndSection": 963,
          "text": "Laboratory diagnostic methods include microscopic identification of acid-fast mycobacteria from any body fluid (especially sputum), as well as isolation and characterisation of mycobacteria in culture."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27187878",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 98,
          "offsetInEndSection": 253,
          "text": "However active, prompt and accurate diagnosis is the key element in the public health response to tuberculosis and the cornerstone of tuberculosis control."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27187878",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1447,
          "offsetInEndSection": 1705,
          "text": "Laboratory diagnostic testing of cellular immunity against pathogenic mycobacteria employs the tuberculin skin test (TST, Mantoux tuberculin test) or the more specific interferon \u03b3 test to determine \u03b3 interferon released by T lymphocytes stimulated in vitro."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27187878",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1172,
          "offsetInEndSection": 1344,
          "text": "In patients who are highly suspected of having TB, but whose sputum specimens tested negative for mycobacteria, a nucleic acid amplification test is additionally performed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27187878",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Diagnosis of tuberculosis (TB) is difficult, since symptoms are often very unspecific or lacking."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 395,
          "text": "The HIV home test has the potential to help curb the HIV epidemic by improving detection of persons living with HIV and enabling them to seek follow-up care but it has not yet been evaluated in adolescents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1159,
          "offsetInEndSection": 1316,
          "text": "While advances in drug regimens have transformed HIV into a chronic disease, infected individuals need to be identified and subsequently engaged in care [4]."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 603,
          "offsetInEndSection": 760,
          "text": "This commentary summarizes the need to systematically evaluate positive and untoward/unanticipated effects of HIV home testing, particularly in young adults."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Adolescents and young adults are the fastest growing age group of human immunodeficiency virus (HIV) positive individuals in the US, and many who are infected do not know their HIV status."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 901,
          "offsetInEndSection": 971,
          "text": "Almost 40 % of new HIV infections in the US are in this age group [2]."
        }
      ]
    },
    {
      "id": "680fe1e3353a4a2e6b00000f",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20569258",
        "http://www.ncbi.nlm.nih.gov/pubmed/30380071",
        "http://www.ncbi.nlm.nih.gov/pubmed/24661571",
        "http://www.ncbi.nlm.nih.gov/pubmed/32472759",
        "http://www.ncbi.nlm.nih.gov/pubmed/28551783",
        "http://www.ncbi.nlm.nih.gov/pubmed/15587301",
        "http://www.ncbi.nlm.nih.gov/pubmed/27245382",
        "http://www.ncbi.nlm.nih.gov/pubmed/15347815",
        "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
        "http://www.ncbi.nlm.nih.gov/pubmed/30183645"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20569258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 665,
          "offsetInEndSection": 1012,
          "text": "Here, we use examples of recent advances in our understanding of mutational/pathogenic mechanisms to guide our thinking about possible locations outwith gene-coding sequences for those disease-causing or disease-associated variants that are likely so often to have been overlooked because of the inadequacy of current mutation screening protocols."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20569258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 200,
          "offsetInEndSection": 402,
          "text": "However, for a variety of reasons, this figure is likely to represent only a small proportion of the clinically relevant genetic variants that remain to be identified in the human genome (the 'mutome')."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20569258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "The number of known mutations in human nuclear genes, underlying or associated with human inherited disease, has now exceeded 100,000 in more than 3700 different genes (Human Gene Mutation Database)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20569258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 512,
          "offsetInEndSection": 664,
          "text": "In particular, whole-genome sequencing (WGS) has the potential to identify all disease-causing or disease-associated DNA variants in a given individual."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20569258",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1013,
          "offsetInEndSection": 1231,
          "text": "Such considerations are important not only for improving mutation-screening strategies but also for enhancing the interpretation of findings derived from genome-wide association studies, whole-exome sequencing and WGS."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30380071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 148,
          "offsetInEndSection": 395,
          "text": "The somatic mutations, recording the unique genetic cell-lineage 'history' of each proliferating normal cell, are important but remain to be investigated because of their ultra-low frequency hidden in the genetic background of heterogeneous cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30380071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 603,
          "text": "Luckily, the recent development of single-cell genomics biotechnologies enables the screening and collection of the somatic mutations, especial single nucleotide variations (SNVs), occurring in normal cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30380071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication per cell-division."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30380071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 604,
          "offsetInEndSection": 811,
          "text": "Here, we established DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/), which provides most comprehensive catalogue of somatic SNVs in single cells from various normal tissues."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30380071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1085,
          "offsetInEndSection": 1317,
          "text": "DSMNC, which serves as a timely and valuable collection of somatic mutations in individual normal cells, has made it possible to analyze the burdens and signatures of somatic mutations in various types of heterogeneous normal cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661571",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Genome-wide association studies (GWAS) have identified more than 8900 genetic variants, mainly single-nucleotide polymorphisms (SNPs), associated with hundreds of human traits and diseases, which define risk-associated loci."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661571",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 375,
          "offsetInEndSection": 562,
          "text": "However, the vast majority of sequence variants map to non-coding intergenic and intronic regions, and it has been much more challenging to assess the functional nature of these variants."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661571",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 225,
          "offsetInEndSection": 374,
          "text": "Variants that map to coding regions can affect protein sequence, translation rate, and alternative splicing, all of which influence protein function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661571",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 884,
          "offsetInEndSection": 1096,
          "text": "We review here these recent findings, discuss their implication for the post-GWAS era, and relate their importance to the interpretation of disease-associated mutations identified through whole-genome sequencing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661571",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 746,
          "offsetInEndSection": 883,
          "text": "Many non-coding genetic variants within risk-associated loci alter gene expression by modulating the activity of cis-regulatory elements."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32472759",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 223,
          "offsetInEndSection": 435,
          "text": "These studies have surprisingly revealed that the majority of genetic variation is not present within the coding region but rather in the non-coding region of the genome, which is also termed as \"Medical Genome\"."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32472759",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "Latest advancements in genomics involving individuals from different races and geographical locations has led to the identification of thousands of common as well as rare genetic variants and copy number variations (CNVs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32472759",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 436,
          "offsetInEndSection": 678,
          "text": "This short review describes how mutations/variations within; regulatory sequences, architectural proteins and transcriptional regulators give rise to the aberrant gene expression profiles that drives cellular transformations and malignancies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28551783",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 775,
          "text": "Simple mtDNA mutations are point mutations, which are frequently found in mitochondrial tRNA loci, causing mischarging of mitochondrial tRNAs or deletion, duplication, or reduction in mtDNA content."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28551783",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 776,
          "offsetInEndSection": 1004,
          "text": "Because mtDNA has multiple copies and a specific replication mechanism in cells or tissues, it can be heterogenous, resulting in characteristic phenotypic presentations such as heteroplasmy, genetic drift, and threshold effects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28551783",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1372,
          "offsetInEndSection": 1664,
          "text": "Clinical manifestations of mitochondrial mutations, which result from structural defects, functional impairment, or both, are increasingly detected but are not clear because of the complex interplay between the mitochondrial and nuclear genomes, even in homoplasmic mitochondrial populations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28551783",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1665,
          "offsetInEndSection": 1960,
          "text": "Additionally, various factors such as individual susceptibility, nutritional state, and exposure to chemicals can influence phenotypic presentation, even for the same mtDNA mutation.In this chapter, we summarize our current understanding of mtDNA mutations and their role in cardiac involvement."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28551783",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 531,
          "offsetInEndSection": 576,
          "text": "mtDNA mutations can be inherited or sporadic."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15587301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 297,
          "offsetInEndSection": 440,
          "text": "The most common variability of the genome are the SNPs (single nucleotide polymorphisms), every person having between 3 and 10 million of them."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15587301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 441,
          "offsetInEndSection": 727,
          "text": "SNPs may or not be harmless, and studies are in progress in cases and controls studies to answer the question of whether they determine why some persons have a given disease and others do not, and if they have something to do with that the individual variation in the response to drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15587301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 728,
          "offsetInEndSection": 891,
          "text": "We discuss in the same context the haplotype map project (HapMap) as a tool to facilitate the study of possible associations of genome changes and common diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15587301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Genomic medicine is simply the routine use of genomic analysis, preferably by direct DNA studies, to improve the quality of medical care."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15587301",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 138,
          "offsetInEndSection": 296,
          "text": "A likely consequence will be to increase the predictive and prevention capacities of medicine, including common diseases, such as cancer, diabetes and others."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27245382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Single nucleotide polymorphisms (SNPs) are important biomolecular markers in health and disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27245382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 766,
          "offsetInEndSection": 1036,
          "text": "In addition to a comprehensive review of the literature, we also demonstrate that several SNPs reside within the same regions as these Down syndrome-linked SNPs, and propose that these closely located nucleotide changes may provide new candidates for future exploration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27245382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 402,
          "offsetInEndSection": 540,
          "text": "Our survey highlights that the combination of SNPs may be a more reliable predictor of the Down syndrome phenotype than single SNPs alone."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27245382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 541,
          "offsetInEndSection": 765,
          "text": "We also describe recent links between SNPs in p53 and its related pathway proteins and Down syndrome, as well as highlight several proteins that help to associate apoptosis and p53 signaling with the Down syndrome phenotype."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27245382",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 207,
          "offsetInEndSection": 401,
          "text": "Here, we highlight associations between SNPs in several important enzymes involved in the one-carbon folate metabolic pathway and the elevated maternal risk of having a child with Down syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15347815",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 437,
          "text": "Compared with other molecular markers, single-nucleotide polymorphisms (SNPs) exhibit extremely low mutation rates, making them rare in recently emerged pathogens, but they are less prone to homoplasy and thus extremely valuable for phylogenetic analyses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15347815",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 438,
          "offsetInEndSection": 793,
          "text": "Despite their phylogenetic potential, ascertainment bias occurs when SNP characters are discovered through biased taxonomic sampling; by using whole-genome comparisons of five diverse strains of Bacillus anthracis to facilitate SNP discovery, we show that only polymorphisms lying along the evolutionary pathway between reference strains will be observed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15347815",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1502,
          "offsetInEndSection": 1719,
          "text": "Our use of nonhomoplastic whole-genome SNP characters allows branch points and clade membership to be estimated with great precision, providing greater insight into epidemiological, ecological, and forensic questions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15347815",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 936,
          "offsetInEndSection": 1147,
          "text": "Using a set of 990 SNP markers, we also show how divergent branches in our topologies collapse to single points but provide accurate information on internodal distances and points of origin for ancestral clades."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15347815",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Phylogenetic reconstruction using molecular data is often subject to homoplasy, leading to inaccurate conclusions about phylogenetic relationships among operational taxonomic units."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 440,
          "text": "The database essentially consists of a collection of text files providing specific annotations for human single nucleotide polymorphisms (SNPs), namely whether they are predicted to abolish, create or change the affinity of one or several transcription factor (TF) binding sites."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 441,
          "offsetInEndSection": 585,
          "text": "A SNP's effect on TF binding is estimated based on a position weight matrix (PWM) model for the binding specificity of the corresponding factor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "SNP2TFBS is a computational resource intended to support researchers investigating the molecular mechanisms underlying regulatory variation in the human genome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 762,
          "offsetInEndSection": 1057,
          "text": "SNP2TFBS is also accessible over a web interface, enabling users to view the information provided for an individual SNP, to extract SNPs based on various search criteria, to annotate uploaded sets of SNPs or to display statistics about the frequencies of binding sites affected by selected SNPs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 586,
          "offsetInEndSection": 761,
          "text": "These data files are regenerated at regular intervals by an automatic procedure that takes as input a reference genome, a comprehensive SNP catalogue and a collection of PWMs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30183645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 128,
          "offsetInEndSection": 257,
          "text": "The main objective is to find single nucleotide polymorphisms (SNPs) that influence a particular phenotype (i.e., disease trait)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30183645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Genome-Wide Association Studies (GWAS) are used to identify statistically significant genetic variants in case-control studies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30183645",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 304,
          "text": "GWAS typically use a p-value threshold of 5*10"
        }
      ]
    },
    {
      "id": "680d5dd8353a4a2e6b000004",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29495398",
        "http://www.ncbi.nlm.nih.gov/pubmed/7776900",
        "http://www.ncbi.nlm.nih.gov/pubmed/21041995",
        "http://www.ncbi.nlm.nih.gov/pubmed/12957828",
        "http://www.ncbi.nlm.nih.gov/pubmed/30915128",
        "http://www.ncbi.nlm.nih.gov/pubmed/24228714",
        "http://www.ncbi.nlm.nih.gov/pubmed/28566124",
        "http://www.ncbi.nlm.nih.gov/pubmed/23477202",
        "http://www.ncbi.nlm.nih.gov/pubmed/24610704",
        "http://www.ncbi.nlm.nih.gov/pubmed/16488965"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29495398",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Melatonin is a natural indoleamine produced by the pineal gland that has many functions, including regulation of the circadian rhythm."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29495398",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 600,
          "offsetInEndSection": 786,
          "text": "The studies discussed in this review should serve as a solid foundation for researchers and physicians to support basic and clinical studies on melatonin as a promising anticancer agent."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29495398",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 135,
          "offsetInEndSection": 230,
          "text": "Many studies have reported the anticancer effect of melatonin against a myriad of cancer types."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29495398",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 599,
          "text": "This review summarizes the anticancer role of melatonin in each cancer hallmark."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29495398",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 431,
          "offsetInEndSection": 518,
          "text": "Melatonin anticancer activity is mediated by interfering with various cancer hallmarks."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7776900",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 324,
          "text": "Melatonin may be related to a variety of biologic functions important in maintaining health and preventing disease, including breast and prostate cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7776900",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1502,
          "offsetInEndSection": 1710,
          "text": "The conclusion is that study results are consistent with our hypothesis and indicate that melatonin might be a useful parameter in testing similar psycho-social interventions.(ABSTRACT TRUNCATED AT 250 WORDS)"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7776900",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "The objective of this study was to test the hypothesis that the regular practice of mindfulness meditation is associated with increased physiological levels of melatonin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7776900",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 325,
          "offsetInEndSection": 448,
          "text": "Previous studies have shown melatonin production is photosensitive and we suggest here that it also may be psychosensitive."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7776900",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 449,
          "offsetInEndSection": 648,
          "text": "A cross-sectional study of 12-hour (20:00-08:00) urinary 6-sulphatoxymelatonin was conducted from which we analyzed data from 8 women who regularly meditate (RM) and 8 women who do not meditate (NM)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21041995",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 242,
          "text": "Symptoms related to hypermelatoninemia have been reported in individuals supplemented with melatonin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21041995",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Melatonin, a major photoperiod-dependent hormone, regulates circadian rhythms and biological rhythms and acts as a prominent sleep promoter."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21041995",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 794,
          "offsetInEndSection": 898,
          "text": "She was shown to have hypermelatoninemia (>1,000 pg/ml, normal range 0-150 pg/ml) during these episodes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21041995",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1111,
          "offsetInEndSection": 1315,
          "text": "We did not determine the exact mechanism of hypermelatoninemia in this patient; however, it might have been related to irregular control of pinealocytes by the suprachiasmatic nucleus or related pathways."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21041995",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 243,
          "offsetInEndSection": 327,
          "text": "However, spontaneous endogenous hypermelatoninemia has not been reported previously."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12957828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Melatonin (5-methoxy-N-acetyltryptamine), dubbed the hormone of darkness, is released following a circadian rhythm with high levels at night."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12957828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1533,
          "offsetInEndSection": 1823,
          "text": "We conclude that an accurate characterization of melatonin receptors mediating specific functions in native tissues can only be made using receptor specific ligands, with the understanding that receptor ligands may change efficacy in both native tissues and heterologous expression systems."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12957828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 721,
          "offsetInEndSection": 956,
          "text": "We also review melatonin-mediated responses through activation of melatonin receptors (MT1, MT2, and MT3) highlighting their involvement in modulation of CNS, hypothalamic-hypophyseal-gonadal axis, cardiovascular, and immune functions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12957828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 510,
          "offsetInEndSection": 720,
          "text": "Here we describe the pharmacological characteristics of melatonin receptor ligands and their various efficacies (agonist, antagonist, or inverse agonist), which can vary depending on tissue and cellular milieu."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12957828",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1407,
          "offsetInEndSection": 1532,
          "text": "Activation of the MT3 melatonin receptor reduces intraocular pressure and inhibits leukotriene B4-induced leukocyte adhesion."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30915128",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 241,
          "text": "Melatonin receptors MT1 and MT2 (genes officially named MTNR1A and MTNR1B, respectively) play crucial roles in melatonin-mediated regulation of circadian rhythms, the immune system, and control of reproduction in seasonally breeding animals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30915128",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1807,
          "offsetInEndSection": 1959,
          "text": "Our studies demonstrated that the mammalian melatonin receptors MT1 and MT2 are involved in testosterone synthesis via mediating multiple cell pathways."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30915128",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1669,
          "offsetInEndSection": 1806,
          "text": "These results suggested that the melatonin receptors MTNR1A and MTNR1B are essential to repress hCG-induced ER stress and cell apoptosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30915128",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 352,
          "offsetInEndSection": 578,
          "text": "To understand the biological function of melatonin receptors in hCG-induced testosterone synthesis, we generated melatonin receptor knockdown cells using specific siRNA and performed testosterone detection after hCG treatment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30915128",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 579,
          "offsetInEndSection": 703,
          "text": "We found that knockdown of melatonin receptors, especially MTNR1A, led to an obvious decrease (>\u200960%) of testosterone level."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24228714",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Numerous physiological functions of the pineal gland hormone melatonin are mediated via activation of two G-protein-coupled receptors, MT1 and MT2."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24228714",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 637,
          "offsetInEndSection": 807,
          "text": "Moreover, the existing models of MT1 and MT2 receptors as well as the current status in the emerging field of melatonin receptor oligomerization are critically discussed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24228714",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 148,
          "offsetInEndSection": 358,
          "text": "The melatonergic drugs on the market, ramelteon and agomelatine, as well as the most advanced drug candidates under clinical evaluation, tasimelteon and TIK-301, are high-affinity nonselective MT1/MT2 agonists."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24228714",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 808,
          "offsetInEndSection": 1106,
          "text": "In addition to the already existing indications, such as insomnia, circadian sleep disorders, and depression, new potential therapeutic applications of melatonergic ligands including cardiovascular regulation, appetite control, tumor growth inhibition, and neurodegenerative diseases are presented."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24228714",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 476,
          "offsetInEndSection": 636,
          "text": "Herein, we review recent advances in the field focusing on high-affinity agonists and antagonists and those displaying selectivity toward MT1 and MT2 receptors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28566124",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 4152,
          "offsetInEndSection": 4284,
          "text": "Furthermore, we have supported the idea of melatonin being a safe drug for topical treatment, even in previous unknown high dosages."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28566124",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 3968,
          "offsetInEndSection": 4151,
          "text": "We have supported the suggestion of melatonin as a sun protective agent, and added the clinical relevant feature, that melatonin also has a protective effect against natural sunlight."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28566124",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 3193,
          "offsetInEndSection": 3268,
          "text": "These results support that melatonin is a safe drug for dermal application."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28566124",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1174,
          "offsetInEndSection": 1353,
          "text": "The databases were searched up to January 2013 to identify studies evaluating melatonin's protective effect against UVR-induced erythema in humans, and damage on a cellular level."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28566124",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 826,
          "offsetInEndSection": 977,
          "text": "- To clinically assess the protective effect of topical treatment with melatonin against natural sun exposure, and determine the optimal concentration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23477202",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Alpha-Lactalbumin is the main whey protein in human milk rising 2,44 g/L in mature milk."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23477202",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 771,
          "offsetInEndSection": 866,
          "text": "However, the in vivo synthesis of HAMLET complex during milk digestion has not been proved yet."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23477202",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 89,
          "offsetInEndSection": 342,
          "text": "It has a key function in the synthesis of lactose from glucose and galactose in the mammary gland although this compound has also other beneficial effects on the infant health due to the high proportion of essential aminoacids (tryptophan and cysteine)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23477202",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 867,
          "offsetInEndSection": 1144,
          "text": "Infant formula have been improved considerably during the last decades not only adapting nutrient concentrations to infants requirements but also by the addition of new bioactive ingredients such as alpha-lactalbumin, to have the same functional effect as in breast fed babies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23477202",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 343,
          "offsetInEndSection": 559,
          "text": "It seems also to increase iron absorption in the digestive track, and in in vitro experiments, linked to oleic acid (HAMLET complex), has shown anticarcinogenic effects against cellular tumor such as human papilloma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24610704",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 254,
          "offsetInEndSection": 432,
          "text": "Melatonin is thought to play a role in governing the body's natural sleep-wake cycle through physiological processes regulated in the suprachiasmatic nucleus of the hypothalamus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24610704",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "Tasimelteon (HETLIOZ\u2122) is an orally bioavailable agonist of the melatonin MT1 and MT2 receptors that has been approved in the US for the treatment of non-24-hour sleep-wake disorder."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24610704",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 433,
          "offsetInEndSection": 537,
          "text": "The hormone is secreted by the pineal gland, with onset typically occurring when daylight begins to dim."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24610704",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 915,
          "offsetInEndSection": 1145,
          "text": "Because the rhythm of endogenous melatonin is considered to be a measure of the human circadian phase, the carefully timed administration of melatonin analogues, such as tasimelteon, can potentially promote circadian readjustment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24610704",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1146,
          "offsetInEndSection": 1303,
          "text": "This article summarizes the milestones in the development of tasimelteon leading to this first approval for the treatment of non-24-hour sleep-wake disorder."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1458,
          "offsetInEndSection": 1556,
          "text": "These findings indicate that the meibomian gland secretes a number of proteins into the tear film."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 349,
          "offsetInEndSection": 478,
          "text": "Meibomian gland secretions were collected from the lower eyelids of adult volunteers and placed in a chloroform-methanol mixture."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 878,
          "offsetInEndSection": 1008,
          "text": "The methodological approach to date has permitted the identification of more than 90 proteins in human meibomian gland secretions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 238,
          "text": "The authors hypothesise that many of these proteins originate from the meibomian gland."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16488965",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Human tears contain hundreds of proteins that may exert a significant influence on tear film stability, ocular surface integrity, and visual function."
        }
      ]
    },
    {
      "id": "67d7208218b1e36f2e00002e",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20426708",
        "http://www.ncbi.nlm.nih.gov/pubmed/21061765",
        "http://www.ncbi.nlm.nih.gov/pubmed/24170634",
        "http://www.ncbi.nlm.nih.gov/pubmed/19689518",
        "http://www.ncbi.nlm.nih.gov/pubmed/21317611",
        "http://www.ncbi.nlm.nih.gov/pubmed/24800325",
        "http://www.ncbi.nlm.nih.gov/pubmed/17989730",
        "http://www.ncbi.nlm.nih.gov/pubmed/29377341",
        "http://www.ncbi.nlm.nih.gov/pubmed/21715249",
        "http://www.ncbi.nlm.nih.gov/pubmed/1958563"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20426708",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1054,
          "offsetInEndSection": 1261,
          "text": "Androgenetic alopecia is a progressive condition and although the current available treatments are effective in arresting the progression of the disease, they allow only partial regrowth of hair at its best."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20426708",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 498,
          "offsetInEndSection": 604,
          "text": "Polymorphism of the androgen receptor gene was first identified in association with androgenetic alopecia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20426708",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 336,
          "offsetInEndSection": 413,
          "text": "In androgenetic alopecia, hair follicles undergo progressive miniaturization."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20426708",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Androgenetic alopecia affects up to 80% of males by the age of 80."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20426708",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 414,
          "offsetInEndSection": 497,
          "text": "Genetic factors and androgens play a major role in the pathogenesis of the disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21061765",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Androgenic alopecia (AGA), or pattern hair loss, is a common condition that affects both men and women has been gradually increasing."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21061765",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 415,
          "text": "These basic science studies, combined with more recent clinical studies, have led to a better understanding of the pathogenesis of AGA in both men and women."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21061765",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 257,
          "text": "The discovery of the androgen receptor (AR) gene and related genes has expanded the knowledge on the genetics of hair loss."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21061765",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 562,
          "offsetInEndSection": 722,
          "text": "Food and Drug Administration (FDA) medications (minoxidil and finasteride), a novel device was FDA-approved for the treatment of hair loss, the laser hair comb."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21061765",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 723,
          "offsetInEndSection": 856,
          "text": "Further studies are needed to verify the accuracy and validity of the genetic screening test and the efficacy of the laser hair comb."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24170634",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Androgenetic alopecia (AGA), or male pattern hair loss, affects up to 96% of Caucasian men."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24170634",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 308,
          "text": "Characterized by gradual thinning and eventual loss of hair along frontotemporal, parietal, and vertex areas of the scalp, AGA is associated with low self-esteem, depression, and dissatisfaction with body appearance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24170634",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 309,
          "offsetInEndSection": 493,
          "text": "In this systematic review of the literature, six primary research studies conducted in the United States are evaluated for their clinical application to primary care provider practice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24170634",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 739,
          "offsetInEndSection": 904,
          "text": "Further research in novel and established treatments is recommended, along with an evidence-based clinical practice guideline for practitioners in the United States."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24170634",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 494,
          "offsetInEndSection": 738,
          "text": "Topical minoxidil 2%-5% 1 mL twice daily or finasteride 1 mg daily are recommended as first line treatments, followed by the use of Food and Drug Administration-cleared HairMax LaserComb\u00ae in patients who do not respond to first line modalities."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19689518",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Ichthyosis follicularis, alopecia and photophobia (IFAP) is a rare genodermatosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19689518",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 564,
          "offsetInEndSection": 645,
          "text": "We describe the clinical features and discuss the differential diagnosis of IFAP."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19689518",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 333,
          "offsetInEndSection": 563,
          "text": "Missense mutations of the gene, MBTPS2, which codes for an intramembrane zinc metalloprotease essential for cholesterol homeostasis and endoplasmic reticulum stress response, are associated with the IFAP phenotype in this kindred."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19689518",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 272,
          "text": "We present the largest kindred of IFAP reported to date in the medical literature clearly demonstrating X-linked inheritance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19689518",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 146,
          "text": "Most patients have been men without significant family history."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 388,
          "text": "The aim of this study was to define the clinical and histopathological features of alopecia arising in the setting of anti-TNF therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1326,
          "offsetInEndSection": 1626,
          "text": "In conclusion, anti-TNF therapy-related alopecia may closely mimic psoriatic alopecia and alopecia areata but can be histologically distinguished from alopecia areata by epidermal psoriasiform changes and dermal plasma cells and from primary psoriasis by the presence of plasma cells and eosinophils."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 252,
          "text": "Anti-TNF drug-induced alopecia is a less well-known side effect of this class of drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 389,
          "offsetInEndSection": 512,
          "text": "Clinical and histopathological features of 3 patients who developed scalp alopecia during anti-TNF treatment were examined."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317611",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1237,
          "offsetInEndSection": 1325,
          "text": "Two patients showed significant improvement of the alopecia with topical treatment only."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24800325",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 63,
          "text": "Psoriasis is a chronic disease that affects more than the skin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24800325",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 64,
          "offsetInEndSection": 375,
          "text": "It has an impact on every facet of an individual's life and is associated with numerous comorbidities, such as obesity, diabetes, cardiovascular disease, psoriatic arthritis, metabolic syndrome, squamous cell carcinoma, lymphoma, depression, anxiety and other immune-related conditions, such as Crohn's disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24800325",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 580,
          "offsetInEndSection": 721,
          "text": "Lifestyle choices, such as smoking, alcohol consumption, inadequate nutrition and physical exercise are behaviours that need to be addressed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24800325",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 487,
          "offsetInEndSection": 579,
          "text": "Hypertension and cardiovascular disease are precursors for myocardial infarction and stroke."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24800325",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 376,
          "offsetInEndSection": 486,
          "text": "Obesity is inextricably linked with type 2 diabetes, hypertension, hyperlipidemia, and cardiovascular disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989730",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Androgenetic alopecia (AGA), a hereditary disorder that involves the progressive thinning of hair in a defined pattern, is driven by androgens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989730",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 450,
          "offsetInEndSection": 636,
          "text": "To investigate mechanisms of AGA, we cultured DP cells (DPC) from balding and non-balding scalp and confirmed previous reports that balding DPC grow slower in vitro than non-balding DPC."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989730",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 281,
          "text": "The hair follicle dermal papilla (DP) expresses androgen receptors (AR) and plays an important role in the control of normal hair growth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989730",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 282,
          "offsetInEndSection": 449,
          "text": "In AGA, it has been proposed that the inhibitory actions of androgens are mediated via the DP although the molecular nature of these interactions is poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989730",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1112,
          "offsetInEndSection": 1375,
          "text": "Premature senescence of balding DPC in vitro in association with expression of p16(INK4a)/pRB suggests that balding DPC are sensitive to environmental stress and identifies alternative pathways that could lead to novel therapeutic strategies for treatment of AGA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29377341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1052,
          "offsetInEndSection": 1265,
          "text": "Exposome factors including nutrition, medication, occupational factors, pollutants, climatic factors, and psychosocial and lifestyle factors may impact on the course and severity of acne and on treatment efficacy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29377341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 447,
          "offsetInEndSection": 571,
          "text": "Acne exposome was defined as the sum of all environmental factors influencing the occurrence, duration and severity of acne."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29377341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 282,
          "text": "To assess the impact of environmental factors on acne and to provide a comprehensive overview of the acne exposome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29377341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "Acne vulgaris is one of the main reasons for dermatological consultations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29377341",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1266,
          "offsetInEndSection": 1367,
          "text": "Identifying and reducing the impact of exposome is important for an adequate acne disease management."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715249",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy associated with psoriasis, and included among the seronegative spondyloarthropathies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715249",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1343,
          "offsetInEndSection": 1431,
          "text": "Current views on the pathogenesis of PsA are reviewed from a dermatological perspective."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715249",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1151,
          "offsetInEndSection": 1342,
          "text": "New ideas regarding the involvement of the IL-23/Th17 axis have emerged, and the dramatic effects of targeting therapies have highlighted the physiological role of key cytokines in psoriasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715249",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 321,
          "text": "The presence of cutaneous psoriasis is very important for correct and early diagnosis of PsA, because the cutaneous lesions precede the appearance of joint manifestations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715249",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 679,
          "text": "PsA has several unique characteristics, such as enthesopathy, dactylitis and abnormal bone remodeling."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1958563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 538,
          "offsetInEndSection": 720,
          "text": "Because autoimmune disease results from a pathological perturbation of normal immune function, it follows that expression of these diseases will also demonstrate a dimorphic pattern."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1958563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 946,
          "offsetInEndSection": 1160,
          "text": "To explain autoimmune dimorphism it therefore becomes necessary firstly to describe the cellular and hormonal interactions found in normal immune regulation and thereafter extrapolate these to autoimmune phenomena."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1958563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 721,
          "offsetInEndSection": 945,
          "text": "Examples of this autoimmune dimorphism include (but are not limited to) lupus, rheumatoid arthritis and multiple sclerosis with the two former more prevalent in females than males and the latter more severe during pregnancy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1958563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 384,
          "offsetInEndSection": 537,
          "text": "Furthermore, growth hormone and prolactin secretions which are different in males and females may also be partly responsible for the observed dimorphism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1958563",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 192,
          "offsetInEndSection": 383,
          "text": "This dimorphism extends to both the humoral and cell mediated systems and appears to be mechanistically based on the differences in type and concentration of sex steroids in males vs females."
        }
      ]
    },
    {
      "id": "67fc381f18b1e36f2e00012f",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
        "http://www.ncbi.nlm.nih.gov/pubmed/36040798",
        "http://www.ncbi.nlm.nih.gov/pubmed/35810190",
        "http://www.ncbi.nlm.nih.gov/pubmed/37788736",
        "http://www.ncbi.nlm.nih.gov/pubmed/25818589",
        "http://www.ncbi.nlm.nih.gov/pubmed/29181082",
        "http://www.ncbi.nlm.nih.gov/pubmed/17611626",
        "http://www.ncbi.nlm.nih.gov/pubmed/23415641",
        "http://www.ncbi.nlm.nih.gov/pubmed/37268606",
        "http://www.ncbi.nlm.nih.gov/pubmed/34529939"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Melanoma cells can switch between a melanocytic and a mesenchymal-like state."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 703,
          "offsetInEndSection": 793,
          "text": "Single-cell migration assays confirmed the intermediate migratory phenotype of this state."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 156,
          "offsetInEndSection": 377,
          "text": "Here, to search for such states and decipher their underlying gene regulatory network (GRN), we studied 10 melanoma cultures using single-cell RNA sequencing (RNA-seq) as well as 26 additional cultures using bulk RNA-seq."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 794,
          "offsetInEndSection": 953,
          "text": "Using time-series sampling of single cells after knockdown of SOX10, we unravelled the sequential and recurrent arrangement of GRNs during phenotype switching."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 378,
          "offsetInEndSection": 548,
          "text": "Although each culture exhibited a unique transcriptome, we identified shared GRNs that underlie the extreme melanocytic and mesenchymal states and the intermediate state."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36040798",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Cellular stress contributes to the capacity of melanoma cells to undergo phenotype switching into highly migratory and drug-tolerant dedifferentiated states."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36040798",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 295,
          "text": "Such dedifferentiated melanoma cell states are marked by loss of melanocyte-specific gene expression and increase of mesenchymal markers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36040798",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1372,
          "text": "In conclusion, this study describes the significance of melanoma state and the underlying functional properties explaining the aggressiveness of such states."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36040798",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 519,
          "offsetInEndSection": 699,
          "text": "In this study we describe that loss of MITF is associated with a distinct transcriptional program, MITF promoter hypermethylation, and poor patient survival in metastatic melanoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36040798",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 700,
          "offsetInEndSection": 837,
          "text": "From a comprehensive collection of melanoma cell lines, we observed that MITF-methylated cultures were subdivided in 2 distinct subtypes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35810190",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 60,
          "text": "Melanoma cells display distinct intrinsic phenotypic states."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35810190",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 688,
          "offsetInEndSection": 883,
          "text": "Through integrative analyses we demonstrate highly complex multi-omic regulation of melanoma cell intrinsic programs that provide key insights into the molecular maintenance of phenotypic states."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35810190",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 61,
          "offsetInEndSection": 359,
          "text": "Here, we seek to characterize the molecular regulation of these states using multi-omic analyses of whole exome, transcriptome, microRNA, long non-coding RNA and DNA methylation data together with reverse-phase protein array data on a panel of 68 highly annotated early passage melanoma cell lines."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35810190",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 360,
          "offsetInEndSection": 687,
          "text": "We demonstrate that clearly defined cancer cell intrinsic transcriptomic programs are maintained in melanoma cells ex vivo and remain highly conserved within melanoma tumors, are associated with distinct immune features within tumors, and differentially correlate with checkpoint inhibitor and adoptive T cell therapy efficacy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35810190",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 884,
          "offsetInEndSection": 989,
          "text": "These findings have implications for cancer biology and the identification of new therapeutic strategies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37788736",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 682,
          "offsetInEndSection": 885,
          "text": "Here, we present recent investigations of phenotypic plasticity from a systems-level perspective using two exemplars: epithelial-mesenchymal plasticity in carcinomas and phenotypic switching in melanoma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37788736",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 886,
          "offsetInEndSection": 1410,
          "text": "We highlight how an integrated computational-experimental approach has helped unravel insights into specific dynamical hallmarks of phenotypic plasticity in different cancers to address the following questions: a) how many distinct cell-states or phenotypes exist?; b) how reversible are transitions among these cell-states, and what factors control the extent of reversibility?; and c) how might cell-cell communication be able to alter rates of cell-state switching and enable diverse patterns of phenotypic heterogeneity?"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37788736",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 266,
          "offsetInEndSection": 399,
          "text": "Despite growing acceptance for phenotypic plasticity as a hallmark of cancer, the dynamics of this process remains poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37788736",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 400,
          "offsetInEndSection": 681,
          "text": "In particular, the knowledge necessary for a predictive understanding of how individual cancer cells and populations of cells dynamically switch their phenotypes in response to the intensity and/or duration of their current and past environmental stimuli remains far from complete."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37788736",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1411,
          "offsetInEndSection": 1599,
          "text": "Understanding these dynamic features of phenotypic plasticity may be a key component in shifting the paradigm of cancer treatment from reactionary to a more predictive, proactive approach."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25818589",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 673,
          "offsetInEndSection": 898,
          "text": "MITF expression in melanoma is heterogeneous, and recent findings highlight the relevance of this heterogeneity for the response of melanoma to MAPK pathway targeting drugs, as well as for MITF's role in melanoma progression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25818589",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 357,
          "text": "MITF's relevance for this cell lineage is maintained in melanoma, where it is an important regulator of survival and balances melanoma cell proliferation with terminal differentiation (pigmentation)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25818589",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 899,
          "offsetInEndSection": 1052,
          "text": "This review aims to provide an updated overview on the regulation of MITF function and plasticity in melanoma with a focus on its link to MAPK signaling."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25818589",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 464,
          "offsetInEndSection": 672,
          "text": "Furthermore, the regulation of MITF expression and function is strongly linked to the BRAF/MEK/ERK/MAP-kinase (MAPK) pathway, which is deregulated in >90% of melanomas and central target of current therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25818589",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Malignant melanoma is a neoplasm of melanocytes, and the microphthalmia-associated transcription factor (MITF) is essential for the existence of melanocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29181082",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 180,
          "offsetInEndSection": 266,
          "text": "The exact course of events in which melanocytes become melanoma cells remains unclear."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29181082",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 179,
          "text": "It involves a malignant transformation of melanocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29181082",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 613,
          "offsetInEndSection": 812,
          "text": "This is just one of the possible roles of SOX10, which contributes to melanomagenesis by regulating the SOX10-MITF pathway, but also to melanoma cell survival, proliferation and metastasis formation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29181082",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Melanoma is one of the most dangerous and lethal skin cancers, with a considerable metastatic potential and drug resistance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29181082",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 813,
          "offsetInEndSection": 915,
          "text": "The aim of this review is to describe the broad influence of the SOX10-MITF pathway on melanoma cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17611626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 603,
          "offsetInEndSection": 922,
          "text": "In order to gain an improved understanding of the molecular basis of melanoma progression, we have compared gene expression profiles from a series of melanoma cell lines representing discrete stages of malignant progression that recapitulate critical characteristics of the primary lesions from which they were derived."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17611626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 399,
          "text": "Gene expression profiling has revolutionized our ability to molecularly classify primary human tumors and significantly enhanced the development of novel tumor markers and therapies; however, progress in the diagnosis and treatment of melanoma over the past 3 decades has been limited, and there is currently no approved therapy that significantly extends lifespan in patients with advanced disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17611626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1809,
          "text": "Further analysis of expression signatures associated with melanoma progression using functional annotations categorized these transcripts into three classes of genes: 1) Upregulation of activators of cell cycle progression, DNA replication and repair (CDCA2, NCAPH, NCAPG, NCAPG2, PBK, NUSAP1, BIRC5, ESCO2, HELLS, MELK, GINS1, GINS4, RAD54L, TYMS, and DHFR), 2) Loss of genes associated with cellular adhesion and melanocyte differentiation (CDH3, CDH1, c-KIT, PAX3, CITED1/MSG-1, TYR, MELANA, MC1R, and OCA2), 3) Upregulation of genes associated with resistance to apoptosis (BIRC5/survivin)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17611626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1810,
          "offsetInEndSection": 2011,
          "text": "While these broad classes of transcripts have previously been implicated in the progression of melanoma and other malignancies, the specific genes identified within each class of transcripts are novel."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17611626",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1041,
          "offsetInEndSection": 1214,
          "text": "This clustering identifies two distinctive molecular subclasses of melanoma segregating aggressive metastatic tumor cell lines from less-aggressive primary tumor cell lines."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23415641",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 650,
          "offsetInEndSection": 865,
          "text": "This review summarizes the critical role of BRAF in melanoma pathophysiology, the clinical and pathological determinants of BRAF mutation status and finally addresses the current state of the art of BRAF inhibitors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23415641",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 323,
          "offsetInEndSection": 489,
          "text": "A majority of cutaneous melanomas show activating mutations in the NRAS or BRAF proto-oncogenes, components of the Ras-Raf-Mek-Erk (MAPK) signal transduction pathway."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23415641",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Melanoma is an aggressive form of skin cancer that causes the greatest number of skin cancer-related deaths worldwide."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23415641",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 490,
          "offsetInEndSection": 649,
          "text": "The discovery of activating BRAF mutations in \u223c50% of all melanomas has proved to be a turning point in the therapeutic management of the disseminated disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23415641",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 119,
          "offsetInEndSection": 322,
          "text": "In its early stages malignant melanoma can be cured by surgical resection, but once it has progressed to the metastatic stage it is extremely difficult to treat and does not respond to current therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37268606",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 579,
          "offsetInEndSection": 655,
          "text": "This state is conserved across human melanoma cell lines and patient tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37268606",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 961,
          "offsetInEndSection": 1138,
          "text": "Because the melanocytic cell state is linked to poor outcomes in patients, these data indicate a metabolic vulnerability in melanoma that depends on the lipid droplet organelle."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37268606",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 425,
          "offsetInEndSection": 578,
          "text": "Single-cell RNA-sequencing of these tumors show a concordance between genes regulating pigmentation and those involved in lipid and oxidative metabolism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37268606",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 220,
          "offsetInEndSection": 424,
          "text": "Here, we use a zebrafish melanoma model to identify a transcriptional program linking the melanocytic cell state to a dependence on lipid droplets, the specialized organelle responsible for lipid storage."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37268606",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Melanoma exhibits numerous transcriptional cell states including neural crest-like cells as well as pigmented melanocytic cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "text": "Melanomas can have multiple coexisting cell states, including proliferative (PRO) versus invasive (INV) subpopulations that represent a \"go or grow\" trade-off; however, how these populations interact is poorly understood."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 771,
          "offsetInEndSection": 884,
          "text": "Isolation of clusters from patients with metastatic melanoma revealed a subset with heterotypic PRO-INV clusters."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 222,
          "offsetInEndSection": 456,
          "text": "Using a combination of zebrafish modeling and analysis of patient samples, we show that INV and PRO cells form spatially structured heterotypic clusters and cooperate in the seeding of metastasis, maintaining cell state heterogeneity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 539,
          "offsetInEndSection": 656,
          "text": "Intravital imaging demonstrated cooperation in which INV cells facilitate dissemination of less metastatic PRO cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 885,
          "offsetInEndSection": 1051,
          "text": "Our data suggest a framework for the co-existence of these two divergent cell populations, in which heterotypic clusters promote metastasis via cell-cell cooperation."
        }
      ]
    },
    {
      "id": "67c9e46881b1027333000004",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34788790",
        "http://www.ncbi.nlm.nih.gov/pubmed/20981248",
        "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
        "http://www.ncbi.nlm.nih.gov/pubmed/24106273",
        "http://www.ncbi.nlm.nih.gov/pubmed/19344285",
        "http://www.ncbi.nlm.nih.gov/pubmed/34535671",
        "http://www.ncbi.nlm.nih.gov/pubmed/24497360",
        "http://www.ncbi.nlm.nih.gov/pubmed/23161490",
        "http://www.ncbi.nlm.nih.gov/pubmed/21315458",
        "http://www.ncbi.nlm.nih.gov/pubmed/37124497"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788790",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Somatic mutations and gene fusions can produce immunogenic neoantigens mediating anticancer immune responses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788790",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 435,
          "offsetInEndSection": 629,
          "text": "Here, we present nextNEOpi (nextflow NEOantigen prediction pipeline) a comprehensive and fully automated bioinformatic pipeline to predict tumor neoantigens from raw DNA and RNA sequencing data."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788790",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 630,
          "offsetInEndSection": 773,
          "text": "In addition, nextNEOpi quantifies neoepitope- and patient-specific features associated with tumor immunogenicity and response to immunotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788790",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 434,
          "text": "However, their computational prediction from sequencing data requires complex computational workflows to identify tumor-specific aberrations, derive the resulting peptides, infer patients' Human Leukocyte Antigen types and predict neoepitopes binding to them, together with a set of features underlying their immunogenicity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788790",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 774,
          "offsetInEndSection": 869,
          "text": "nextNEOpi source code and documentation are available at https://github.com/icbi-lab/nextNEOpi."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20981248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "Cancer-testis antigens (CTAs) represent an expanding class of tumor-associated proteins defined on the basis of their tissue-restricted expression to testis or ovary germline cells and frequent ectopic expression in tumor tissue."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20981248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1183,
          "offsetInEndSection": 1382,
          "text": "The current review will describe the history and identification of this family of proteins, as well as what is known of their function, expression in normal and malignant tissues, and immunogenicity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20981248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 230,
          "offsetInEndSection": 464,
          "text": "The expression of CTA in MHC class I-deficient germline cells makes these proteins particularly attractive as immunotherapeutic targets because they serve as essentially tumor-specific antigens for MHC class I-restricted CD8+ T cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20981248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 465,
          "offsetInEndSection": 624,
          "text": "Moreover, because CTAs are expressed in many types of cancer, any therapeutic developed to target these antigens might have efficacy for multiple cancer types."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20981248",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 911,
          "offsetInEndSection": 1182,
          "text": "Additionally, both humoral and cell-mediated immune responses to SSX proteins have been demonstrated in patients with tumors of varying histological origin, which indicates that natural immune responses can be spontaneously generated to these antigens in cancer patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 683,
          "offsetInEndSection": 910,
          "text": "One strategy for overcoming these mechanisms is vaccination with mimotopes, or peptide mimics of tumor antigens, which alter the antigen presentation and/or T cell activation to increase the expansion of tumor-specific T cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 503,
          "offsetInEndSection": 682,
          "text": "However, tumor antigens are often weak T cell agonists, attributable to several mechanisms, including immune self-tolerance and poor immunogenicity of self-derived tumor peptides."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 358,
          "offsetInEndSection": 502,
          "text": "Immunizing with tumor antigenic peptides is a promising, straight-forward vaccine strategy hypothesized to boost preexisting antitumor immunity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1472,
          "offsetInEndSection": 1650,
          "text": "We propose that the identification of mimotopes based on stimulation of the naturally responding T cell repertoire will dramatically improve the efficacy of mimotope vaccination."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22936035",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1092,
          "offsetInEndSection": 1242,
          "text": "Most of this research has been performed using T cell clones, which may not be accurate representations of the naturally occurring antitumor response."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106273",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Vaccines that incorporate peptide mimics of tumor antigens, or mimotope vaccines, are commonly used in cancer immunotherapy and function by eliciting increased numbers of T cells that cross-react with the native tumor antigen."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106273",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 562,
          "offsetInEndSection": 710,
          "text": "The TCR from this high affinity T cell clone was rarely identified in ex vivo evaluation of tumor-specific T cells elicited by mimotope vaccination."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106273",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 346,
          "offsetInEndSection": 561,
          "text": "Using a high affinity tumor-specific T cell clone, we identified a panel of mimotope vaccines for the dominant peptide antigen from a mouse colon tumor that elicits a range of tumor protection following vaccination."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106273",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1256,
          "text": "These results suggest that targeting a dominant fraction of tumor-specific T cells generates potent immunity and that consideration of the available T cell repertoire is necessary for targeted T cell therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106273",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 711,
          "offsetInEndSection": 816,
          "text": "Conversely, a low affinity clone found in the tumor and following immunization was frequently identified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19344285",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Mimotopes are peptides mimicking protein, carbohydrates or lipid epitopes and can be generated by phage display technology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19344285",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 763,
          "offsetInEndSection": 929,
          "text": "Therefore, the mimotope concept is applicable to both fields for epitope-specific vaccination and analysis of conformational B-cell epitopes for the allergen/antigen."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19344285",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 257,
          "offsetInEndSection": 424,
          "text": "Coupled to carriers or presented in a multiple antigenic peptide form mimotopes achieve immunogenicity and induce epitope-specific antibody responses upon vaccination."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19344285",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 930,
          "offsetInEndSection": 1006,
          "text": "Mimotope technology is a relatively young theme in allergology and oncology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19344285",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 124,
          "offsetInEndSection": 256,
          "text": "When selected by antibodies, they represent exclusively B-cell epitopes and are devoid of antigen/allergen-specific T-cell epitopes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34535671",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Natural killer (NK) cells exert critical roles in anti-tumor immunity but how their functions are regulated by epitranscriptional modification (e.g., N"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24497360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 318,
          "offsetInEndSection": 450,
          "text": "Indeed, NETs may represent an important source of autoantigens and immunostimulatory proteins in systemic lupus erythematosus (SLE)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24497360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Neutrophils are sentinel cells of the innate immune system with a primary role of clearing extracellular pathogens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24497360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 116,
          "offsetInEndSection": 317,
          "text": "The release of weblike structures decorated with granular proteins called neutrophil extracellular traps (NETs) has recently been implicated in the pathogenesis of inflammatory and autoimmune diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24497360",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 451,
          "offsetInEndSection": 636,
          "text": "In this chapter, we describe protocols to isolate human peripheral neutrophils, to generate and isolate NETs, and to detect SLE antigens in NETs using immunofluorescence and immunoblot."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 434,
          "text": "Mimotopes, or peptide mimics of tumor antigens, elicit increased numbers of T cells that crossreact with the native tumor antigen, resulting in potent antitumor responses."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Vaccination with antigens expressed by tumors is one strategy for stimulating enhanced T-cell responses against tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 435,
          "offsetInEndSection": 544,
          "text": "Unfortunately, mimotopes may also elicit cells that do not crossreact or have low affinity for tumor antigen."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 795,
          "offsetInEndSection": 978,
          "text": "We hypothesized that boosting the mimotope vaccine with the native tumor antigen would focus the T-cell response elicited by the mimotope toward high affinity, tumor-specific T cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 262,
          "text": "However, these peptide vaccines rarely result in efficient expansion of tumor-specific T cells or responses that protect against tumor growth."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21315458",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Slitrks are a family of structurally related transmembrane proteins belonging to the leucine-rich repeat (LRR) superfamily."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21315458",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 124,
          "offsetInEndSection": 226,
          "text": "Six family members exist (Slitrk1-6) and all are highly expressed in the central nervous system (CNS)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21315458",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 227,
          "offsetInEndSection": 373,
          "text": "Slitrks have been implicated in mediating basic neuronal processes, ranging from neurite outgrowth and dendritic elaboration to neuronal survival."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21315458",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 374,
          "offsetInEndSection": 625,
          "text": "Recent studies in humans and genetic mouse models have led to the identification of Slitrks as candidate genes that might be involved in the development of neuropsychiatric conditions, such as obsessive compulsive spectrum disorders and schizophrenia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21315458",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 626,
          "offsetInEndSection": 853,
          "text": "Although these system-level approaches have suggested that Slitrks play prominent roles in CNS development, key questions remain regarding the molecular mechanisms through which they mediate neuronal signaling and connectivity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Neoepitopes have attracted much attention as targets for immunotherapy against cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1113,
          "offsetInEndSection": 1170,
          "text": "The present study proposes a novel source of neoepitopes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 87,
          "offsetInEndSection": 205,
          "text": "Therefore, efficient neoepitope screening technology is an essential step in the development of personalized vaccines."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 615,
          "offsetInEndSection": 837,
          "text": "The present study reports CIRC_neo (circRNA-derived neoepitope prediction pipeline), which is a comprehensive and automated bioinformatic pipeline for the prediction of circRNA-derived neoepitopes from RNA sequencing data."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1171,
          "offsetInEndSection": 1287,
          "text": "The study focused on cancer-specific circRNAs, which have greatly expanded the source pool for neoepitope discovery."
        }
      ]
    },
    {
      "id": "67fbe2ab18b1e36f2e000116",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32506848",
        "http://www.ncbi.nlm.nih.gov/pubmed/23456483",
        "http://www.ncbi.nlm.nih.gov/pubmed/30396206",
        "http://www.ncbi.nlm.nih.gov/pubmed/33014527",
        "http://www.ncbi.nlm.nih.gov/pubmed/33010179",
        "http://www.ncbi.nlm.nih.gov/pubmed/31574849",
        "http://www.ncbi.nlm.nih.gov/pubmed/26962464",
        "http://www.ncbi.nlm.nih.gov/pubmed/28951745",
        "http://www.ncbi.nlm.nih.gov/pubmed/17333068",
        "http://www.ncbi.nlm.nih.gov/pubmed/33178308"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32506848",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 428,
          "offsetInEndSection": 561,
          "text": "Randomized controlled trials incorporating acupotomy versus intra-articular sodium hyaluronate for knee osteoarthritis were included."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32506848",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "To evaluate the clinical efficacy and safety of acupotomy in treatment of knee osteoarthritis (OA)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32506848",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1723,
          "offsetInEndSection": 1775,
          "text": "Acupotomy is a safe and effective treatment for KOA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32506848",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 893,
          "offsetInEndSection": 1573,
          "text": "The pooled analysis indicated that acupotomy showed a significant improvement for short-term effect [cure rate: odds ratio (OR) = 2.04, 95% confidence interval (CI) (1.46, 2.85), P < 0.01; total effective rate: OR = 2.25, 95% CI (1.55, 3.28), P < 0.01; pain score: standard mean difference (SMD) = \uff0d1.02; 95% CI (\uff0d1.72, \uff0d0.31); P = 0.005; Western Ontario and McMaster Universities Questionnaire (WOMAC) score: SMD = \uff0d0.74; 95% CI (\uff0d1.11, \uff0d0.37); P < 0.01]; and also for long-term effect [total effective rate: OR = 2.99, 95%CI (1.88, 4.76), Z = 4.64, P < 0.01; pain score: SMD = \uff0d1.68; 95% CI (\uff0d2.14, \uff0d1.22); P < 0.001; WOMAC score: SMD = \uff0d0.91; 95% CI (\uff0d1.40, \uff0d0.41); P < 0.001]."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32506848",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1574,
          "offsetInEndSection": 1722,
          "text": "In addition, there was no obvious difference between acupotomy group and control group in adverse events [OR = 2.13, 95%CI (0.14, 32.28), P = 0.58]."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23456483",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1740,
          "offsetInEndSection": 1946,
          "text": "Our preliminary clinical experience showed promising results upon the use of hyaluronan gel, considering that it significantly reduced pain in the short term, facilitating a more comfortable rehabilitation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23456483",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1156,
          "offsetInEndSection": 1385,
          "text": "The percentage of patients who reported pain decreased significantly over time (p\u00a0=\u00a00.0419) in the hyaluronan-treated group (suggesting limited contractions and better comfort during rehabilitation), but not in the control group."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23456483",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 212,
          "offsetInEndSection": 425,
          "text": "The aim of our cohort study was to assess clinical outcomes following treatment of posttraumatic elbow stiffness using arthroscopic arthrolysis with or without the associated use of a hyaluronan anti-adhesion gel."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23456483",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 211,
          "text": "It has been shown that arthroscopic treatment leads to excellent restoration of elbow motion, although it is still a demanding procedure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23456483",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1652,
          "offsetInEndSection": 1739,
          "text": "No adverse event or complication related to the application of hyaluronan gel occurred."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30396206",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 792,
          "offsetInEndSection": 899,
          "text": "A total of eight reports that use C-RFA in the treatment of chronic knee pain were identified and analyzed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30396206",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1005,
          "offsetInEndSection": 1218,
          "text": "C-RFA is an emerging procedure with encouraging early results; however, additional long-term prospective clinical trials are necessary to further characterize how C-RFA can best be used to treat chronic knee pain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30396206",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 620,
          "offsetInEndSection": 791,
          "text": "The objective of this review article is to provide the rationale, available evidence, indications, and outcomes associated with C-RFA for the treatment of chronic knee OA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30396206",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 255,
          "offsetInEndSection": 417,
          "text": "Surgical intervention often provides reliable pain relief but not all patients are surgical candidates and there are some patients who prefer not to have surgery."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30396206",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Knee osteoarthritis (OA) is a common condition associated with pain and physical impairment in a large segment of the population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33014527",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1514,
          "offsetInEndSection": 1789,
          "text": "These findings indicated that the combination therapy mitigated knee joint immobility, promoted chondrocyte proliferation and alleviated cartilage degeneration in KOA rabbits, and these effects may be mediated by specifically regulating the GSK3\u03b2-cyclin D1-CDK4/CDK6 pathway."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33014527",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 338,
          "offsetInEndSection": 486,
          "text": "However, whether combining acupotomy with ASCs will reverse cartilage degeneration by promoting chondrocyte proliferation in KOA rabbits is unknown."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33014527",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 337,
          "text": "Acupotomy, a biomechanical therapy guided by traditional Chinese medicine theory, alleviates cartilage degradation and is widely used in the clinic to treat KOA by correcting abnormal mechanics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33014527",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 487,
          "offsetInEndSection": 723,
          "text": "The present study aimed to investigate the effects of combination therapy of acupotomy and ASCs on chondrocyte proliferation and to determine the underlying mechanism in rabbits with KOA induced by knee joint immobilization for 6 weeks."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33014527",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Adipose-derived stem cells (ASCs) are highly chondrogenic and can be used to treat knee osteoarthritis (KOA) by alleviating cartilage defects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33010179",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 665,
          "offsetInEndSection": 816,
          "text": "The combination of acupotomy therapy and ultrasonic drug penetration has demonstrated to be effective and promising to treat knee joint osteoarthritis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33010179",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 231,
          "text": "We explore a minimally invasive surgery combining the use of ultrasonic drug penetration to treat early stage of knee joint osteoarthritis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33010179",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 232,
          "offsetInEndSection": 355,
          "text": "In total, 75 patients were participated in acupotomy therapy and ultrasonic drug penetration to treat joint osteoarthritis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33010179",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Knee joint osteoarthritis is a chronic disease that affects the health in aging population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33010179",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 479,
          "offsetInEndSection": 579,
          "text": "There was a significant difference in the WOMAC score between the two groups of patients (P\u2009<\u20090.05)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31574849",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 765,
          "offsetInEndSection": 975,
          "text": "The systematic review will provide high-quality evidence to assess the efficacy and safety of acupotomy for KOA by pain, stiffness, and dysfunction of knee joint, and quality of life, as well as adverse events."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31574849",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 976,
          "offsetInEndSection": 1097,
          "text": "The systematic review will provide evidence to assess the effectiveness and safety of acupotomy therapy for KOA patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31574849",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 261,
          "offsetInEndSection": 374,
          "text": "The aim of this study is to evaluate the efficacy and safety of acupotomy for the treatment of patients with KOA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31574849",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Knee osteoarthritis (KOA) is the most common form of arthritis, leading to pain disability in seniors and increased health care utilization."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31574849",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 185,
          "text": "Acupotomy has been widely used to treat KOA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 319,
          "offsetInEndSection": 559,
          "text": "Traditional pharmacologic therapies such as acetaminophen, non-steroidal anti-inflammatory drugs, and opioids are effective in relieving pain but are incapable of reversing cartilage damage and are frequently associated with adverse events."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1338,
          "offsetInEndSection": 1487,
          "text": "This review highlights current research progress on pharmacologic and regenerative therapies for OA including key advances and potential limitations."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 154,
          "offsetInEndSection": 318,
          "text": "Due to the poor self-healing capacity of articular cartilage and lack of specific diagnostic biomarkers, OA is a challenging disease with limited treatment options."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 848,
          "offsetInEndSection": 1210,
          "text": "Furthermore, regenerative therapies (such as autologous chondrocyte implantation (ACI), new generation of matrix-induced ACI, cell-free scaffolds, induced pluripotent stem cells (iPS cells or iPSCs), and endogenous cell homing) are also emerging as promising alternatives as they have potential to enhance cartilage repair, and ultimately restore healthy tissue."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1211,
          "offsetInEndSection": 1337,
          "text": "However, despite currently available therapies and research advances, there remain unmet medical needs in the treatment of OA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28951745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Osteoarthritis is an inflammatory disease in which all joint-related elements, articular cartilage in particular, are affected."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28951745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 128,
          "offsetInEndSection": 362,
          "text": "The poor regeneration capacity of this tissue together with the lack of pharmacological treatment has led to the development of regenerative medicine methodologies including microfracture and autologous chondrocyte implantation (ACI)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28951745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 363,
          "offsetInEndSection": 402,
          "text": "The effectiveness of ACI has been shown"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17333068",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 244,
          "text": "When it comes to local articular cartilage defects, modern medicine is limited to short-term pain relief and inflammation control."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17333068",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Articular cartilage disorders and injuries often result in lifelong chronic pain and compromised quality of life."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17333068",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 366,
          "offsetInEndSection": 449,
          "text": "Cell-based therapies to regenerate articular cartilage have been in use since 1994."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17333068",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 450,
          "offsetInEndSection": 604,
          "text": "Such therapies provide a healthy population of cells to the injured site and require differentiated chondrocytes from the uninjured site as base material."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17333068",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 605,
          "offsetInEndSection": 745,
          "text": "Their usage often leads to donor site morbidity and they generate rigid fibrous cartilage where more flexible hyaline cartilage is required."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1478,
          "offsetInEndSection": 1708,
          "text": "The control group treatments included acupuncture (8 studies), electroacupuncture (10 studies), sodium hyaluronate (8 studies), radiofrequency electrotherapy (1 study), and nonsteroidal anti-inflammatory drugs (NSAIDs, 5 studies)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1709,
          "offsetInEndSection": 1966,
          "text": "The results from the meta-analysis showed that acupotomy led to superior improvements in the VAS pain score (MD\u2009=\u2009-1.11; 95% confidence interval (CI), -1.51 to -0.71; \nChinese acupotomy therapy may relieve pain and improve function in patients with knee OA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 425,
          "text": "We included only randomized controlled trials (RCTs) that used acupotomy therapy as the major intervention in adults with knee OA, were published in either Chinese and English, included more than 20 subjects in each group, and included pain and function in the outcome measures."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1332,
          "offsetInEndSection": 1477,
          "text": "The typical acupotomy treatment involved releasing soft tissue adhesions and was performed once a week for 1-5 weeks until the pain was relieved."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178308",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 426,
          "offsetInEndSection": 544,
          "text": "Knee OA was defined by the American College of Rheumatology or Chinese Orthopedic Association criteria in all studies."
        }
      ]
    },
    {
      "id": "67eaf14c18b1e36f2e0000de",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
        "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
        "http://www.ncbi.nlm.nih.gov/pubmed/15228586",
        "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
        "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
        "http://www.ncbi.nlm.nih.gov/pubmed/30349051",
        "http://www.ncbi.nlm.nih.gov/pubmed/14730707",
        "http://www.ncbi.nlm.nih.gov/pubmed/18786246",
        "http://www.ncbi.nlm.nih.gov/pubmed/37349788",
        "http://www.ncbi.nlm.nih.gov/pubmed/34385359"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 647,
          "offsetInEndSection": 857,
          "text": "By searching for transcription factors that function at these elements, we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "A broad molecular framework of how neural stem cells are specified toward astrocyte fate during brain development has proven elusive."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 342,
          "text": "Here we perform comprehensive and integrated transcriptomic and epigenomic analyses to delineate gene regulatory programs that drive the developmental trajectory from mouse embryonic stem cells to astrocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 343,
          "offsetInEndSection": 646,
          "text": "We report molecularly distinct phases of astrogliogenesis that exhibit stage- and lineage-specific transcriptomic and epigenetic signatures with unique primed and active chromatin regions, thereby revealing regulatory elements and transcriptional programs underlying astrocyte generation and maturation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1029,
          "offsetInEndSection": 1171,
          "text": "Altogether, these findings provide integrated insights into the genetic and epigenetic mechanisms steering the trajectory of astrogliogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 642,
          "text": "We report here that the astrogliogenic role of Notch is in part mediated by direct binding of the Notch intracellular domain to the CSL DNA binding protein, forming a transcriptional activation complex onto the astrocyte marker gene, glial fibrillary acidic protein (GFAP)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 643,
          "offsetInEndSection": 869,
          "text": "In addition, we found that, in CSL-/- neural stem cell cultures, astrocyte differentiation was delayed but continued at a normal rate once initiated, suggesting that CSL is involved in regulating the onset of astrogliogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 246,
          "offsetInEndSection": 368,
          "text": "Whether the role of Notch signaling in promoting astroglial differentiation is permissive or instructive has been debated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 245,
          "text": "It has recently been postulated that Notch instructively drives astrocyte differentiation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12205678",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 870,
          "offsetInEndSection": 1103,
          "text": "Importantly, although the classical CSL-dependent Notch signaling pathway is intact and able to activate the Notch canonical target promoter during the neurogenic phase, it is unable to activate the GFAP promoter during neurogenesis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15228586",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 180,
          "offsetInEndSection": 393,
          "text": "Astrocyte RANTES/CCL5 has been shown to be induced by interleukin-1 (IL-1), with interferon-gamma (IFNgamma) as a primer, but whether type I interferons play any role in the expression of RANTES/CCL5 is not known."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15228586",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1521,
          "offsetInEndSection": 1690,
          "text": "Together, our results demonstrate that IFNbeta plays a positive regulatory role in the expression of RANTES/CCL5 in human astrocytes through several distinct mechanisms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15228586",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 394,
          "offsetInEndSection": 529,
          "text": "In this report, we studied the detailed mechanism of RANTES/CCL5 induction in primary human astrocytes activated with IL-1 and IFNbeta."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15228586",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "In the CNS, astrocytes are significant sources of RANTES/CCL5 (regulated upon activation, normal T cell expressed and secreted), a CC-chemokine with important biological function."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15228586",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1056,
          "offsetInEndSection": 1315,
          "text": "Transfection with mutated RANTES/CCL5 promoter-reporter constructs revealed that kappaB, interferon-stimulated response element (ISRE) and CAATT-enhancer binding protein-beta (C/EBPbeta) sites all contributed to IL-1/IFNbeta-induced RANTES/CCL5 transcription."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 790,
          "offsetInEndSection": 1047,
          "text": "Experimental validation of a pilot set of predicted binding sites in multiple systems revealed that SOX10 directly regulates a previously unreported alternative promoter at SOX6, which encodes a transcription factor that inhibits glial cell differentiation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "The transcription factor SOX10 is essential for all stages of Schwann cell development including myelination."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1975,
          "offsetInEndSection": 2153,
          "text": "Importantly, the computational and functional datasets we present here will be valuable for the study of transcriptional regulation, SOX protein function, and glial cell biology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 299,
          "text": "SOX10 cooperates with other transcription factors to activate the expression of key myelin genes in Schwann cells and is therefore a context-dependent, pro-myelination transcription factor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821050",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1245,
          "offsetInEndSection": 1431,
          "text": "Remarkably, this analysis enriched for genomic segments that map to loci involved in the negative regulation of gliogenesis including SOX5, SOX6, NOTCH1, HMGA2, HES1, MYCN, ID4, and ID2."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 314,
          "offsetInEndSection": 540,
          "text": "The forkhead box (FOX) transcription factors comprise a collection of proteins that play various roles in numerous complex molecular cascades and have been discovered to be differentially expressed in distinct glioma subtypes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 541,
          "offsetInEndSection": 650,
          "text": "FOXM1 and FOXOs have been recognized as crucial transcription factors in tumor cells, including glioma cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 953,
          "offsetInEndSection": 1294,
          "text": "This review will discuss the subtle functions of FOXOs and FOXM1 in gliomas, dissecting their regulatory network with other proteins, microRNAs and their role in glioma progression, including stem cell differentiation and therapy resistance/sensitivity, alongside highlighting recent pharmacological progress for modulating their expression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 813,
          "text": "Accumulating data indicates that FOXM1 acts as an oncogene in various types of cancers, and a significant part of studies has investigated its function in glioma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 313,
          "text": "Glioma is the most aggressive and malignant type of primary brain tumor, comprises the majority of central nervous system deaths, and is categorized into different subgroups according to its histological characteristics, including astrocytomas, oligodendrogliomas, glioblastoma multiforme (GBM), and mixed tumors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30349051",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "Self-renewal and pluripotency in human embryonic stem cells (hESCs) depends upon the function of a remarkably small number of master transcription factors (TFs) that include OCT4, SOX2, and NANOG."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30349051",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 591,
          "offsetInEndSection": 814,
          "text": "In hESCs, ZNF207 partners with master pluripotency TFs to govern self-renewal and pluripotency while simultaneously controlling commitment of cells towards ectoderm through direct regulation of neuronal TFs, including OTX2."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30349051",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 197,
          "offsetInEndSection": 327,
          "text": "Endogenous factors that regulate and maintain the expression of master TFs in hESCs remain largely unknown and/or uncharacterized."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30349051",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 432,
          "offsetInEndSection": 590,
          "text": "We identify known OCT4 regulators, plus a subset of potential regulators including a zinc finger protein, ZNF207, that plays diverse roles during development."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30349051",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 896,
          "offsetInEndSection": 1022,
          "text": "Thus, a distinct isoform of ZNF207 functions in hESCs at the nexus that balances pluripotency and differentiation to ectoderm."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14730707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1315,
          "offsetInEndSection": 1712,
          "text": "These human glial precursors offer several advantages as tools for understanding glial biology because they can be passaged extensively in the presence of mitogens, afford the potential to study the temporal changes in glutamate transporter expression in a tightly controlled fashion, and are cultured in the absence of neuronal coculture, allowing for the independent study of astroglial biology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14730707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 230,
          "text": "Five glutamate transporters in the human brain (EAAT1-5) are present on both astroglia and neurons."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14730707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1084,
          "offsetInEndSection": 1314,
          "text": "EAAT3 and EAAT4 expression is reduced as glial maturation progresses both in astrocyte precursors and early-differentiated astrocytes and is consistent with their role in adult tissues as primarily neuronal glutamate transporters."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14730707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 231,
          "offsetInEndSection": 430,
          "text": "We characterize the profile of three different human astroglial progenitors in vitro: human glial restricted precursors (HGRP), human astrocyte precursors (HAPC), and early-differentiated astrocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14730707",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 732,
          "offsetInEndSection": 991,
          "text": "EAAT2, the transporter responsible for the bulk of glutamate transport in the adult brain, is not expressed as a full-length protein, nor does it appear to have functional significance (as determined by the EAAT2 inhibitor dihydrokainate) in these precursors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18786246",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1319,
          "offsetInEndSection": 1538,
          "text": "In sum, the process of combining differential expression profiling and comparative genomics successfully led to further defining the role of Sox10, a critical transcription factor for the development of peripheral glia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18786246",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Sox10, a member of the Sry-related HMG-Box gene family, is a critical transcription factor for several important cell lineages, most notably the neural crest stem cells and the derivative peripheral glial cells and melanocytes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18786246",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1539,
          "offsetInEndSection": 1682,
          "text": "Our strategy utilizing relatively accessible techniques and tools should be applicable to studying the function of other transcription factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18786246",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 724,
          "offsetInEndSection": 907,
          "text": "Subsequent comparative genomics analyses led to potential binding sites for Sox10 protein conserved across several mammalian species within the genomic region proximal to these genes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18786246",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 381,
          "offsetInEndSection": 515,
          "text": "We describe identification of multiple direct regulatory target genes of Sox10 through a procedure based on function and conservation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37349788",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Glioma stem cells (GSCs) are responsible for glioma recurrence and drug resistance, yet the mechanisms underlying their maintenance remains unclear."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37349788",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 290,
          "text": "This study aimed to identify enhancer-controlled genes involved in GSCs maintenance and elucidate the mechanisms underlying their regulation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37349788",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1474,
          "offsetInEndSection": 1697,
          "text": "E2F4 was identified as a transcription factor that regulates enhancer-controlled genes related to the ATR pathway activation, with MCM8 having the highest hazard ratio among genes positively correlated with E2F4 expression."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37349788",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1113,
          "offsetInEndSection": 1396,
          "text": "We found that upregulated genes in GSCs were associated with ataxia-telangiectasia-mutated-and-Rad3-related kinase (ATR) pathway activation, and that seven enhancer-controlled genes related to ATR pathway activation (LIN9, MCM8, CEP72, POLA1, DBF4, NDE1, and CDKN2C) were identified."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37349788",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1397,
          "offsetInEndSection": 1473,
          "text": "Expression of these genes corresponded to poor prognosis in glioma patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34385359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Sox10 is a well known factor to control oligodendrocyte (OL) differentiation, and its expression is regulated by Olig2."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34385359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 221,
          "offsetInEndSection": 316,
          "text": "To study whether and how Akt may regulate OL development, we generated OL lineage cell-specific"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34385359",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 220,
          "text": "As an important protein kinase, Akt has been implicated in diseases with white matter abnormalities."
        }
      ]
    },
    {
      "id": "67c9e7ee81b1027333000007",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21042593",
        "http://www.ncbi.nlm.nih.gov/pubmed/22313602",
        "http://www.ncbi.nlm.nih.gov/pubmed/15220823",
        "http://www.ncbi.nlm.nih.gov/pubmed/27642012",
        "http://www.ncbi.nlm.nih.gov/pubmed/29790124",
        "http://www.ncbi.nlm.nih.gov/pubmed/23445625",
        "http://www.ncbi.nlm.nih.gov/pubmed/19946260",
        "http://www.ncbi.nlm.nih.gov/pubmed/22313737",
        "http://www.ncbi.nlm.nih.gov/pubmed/30964753",
        "http://www.ncbi.nlm.nih.gov/pubmed/36672434"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21042593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 821,
          "offsetInEndSection": 1055,
          "text": "Microarray analysis of the effects of Ets-1 over-expression in these ovarian cancer cells shows that Ets-1 up-regulates key enzymes involved in glycolysis and associated feeder pathways, fatty acid metabolism, and antioxidant defense."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21042593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1522,
          "offsetInEndSection": 1681,
          "text": "Collectively our findings demonstrate that Ets-1 is involved in the regulation of cellular metabolism and response to oxidative stress in ovarian cancer cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21042593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1185,
          "offsetInEndSection": 1367,
          "text": "At the functional level, we have found that Ets-1 expression is directly correlated with cellular oxygen consumption whereby increased expression causes decreased oxygen consumption."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21042593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Cancer cells predominantly utilize glycolysis for ATP production even in the presence of abundant oxygen, an environment that would normally result in energy production through oxidative phosphorylation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21042593",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1368,
          "offsetInEndSection": 1521,
          "text": "Ets-1 over-expression also caused increased sensitivity to glycolytic inhibitors, as well as growth inhibition in a glucose-depleted culture environment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22313602",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1019,
          "offsetInEndSection": 1169,
          "text": "Remarkably, high stromal MCT4 levels (score = 2) were specifically associated with decreased overall survival (< 18% survival at 10 y post-diagnosis)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22313602",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1296,
          "offsetInEndSection": 1457,
          "text": "High stromal levels of MCT4 were strictly correlated with a loss of stromal Cav-1 (p-value < 10 (-14) ), a known marker of early tumor recurrence and metastasis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22313602",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 719,
          "offsetInEndSection": 1018,
          "text": "Here, we used MCT4 immuno-staining of human breast cancer tissue microarrays (TMAs; > 180 triple-negative patients) to directly assess the prognostic value of the \"Reverse Warburg Effect.\" MCT4 expression is a functional marker of hypoxia, oxidative stress, aerobic glycolysis, and L-lactate efflux."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22313602",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1170,
          "offsetInEndSection": 1295,
          "text": "In contrast, patients with absent stromal MCT4 expression (score = 0), had 10-y survival rates of ~97% (p-value < 10 (-32) )."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22313602",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 166,
          "offsetInEndSection": 299,
          "text": "In this model, cancer cells secrete hydrogen peroxide (H2O2), initiating oxidative stress and aerobic glycolysis in the tumor stroma."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15220823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "The morphology of pancreatic endocrine tumors (PETs) is similar to that of endocrine tumors elsewhere in the body."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15220823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 743,
          "offsetInEndSection": 885,
          "text": "In sporadic PETs, the most consistent and recurring chromosomal abnormality is allelic loss of chromosome 11q, which includes the MEN-1 locus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15220823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 886,
          "offsetInEndSection": 994,
          "text": "Loss of a sex chromosome has been shown to be associated with metastasis, local invasion, and poor survival."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15220823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 549,
          "text": "Current thinking indicates that PETs arise from totipotential stem cells as well as preexisting endocrine cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15220823",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 586,
          "offsetInEndSection": 742,
          "text": "The hereditary forms are associated with multiple endocrine neoplasia type 1 (MEN-1), von Hippel-Lindau syndrome, neurofibromatosis, and tuberous sclerosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27642012",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 179,
          "offsetInEndSection": 245,
          "text": "This lack of correlation is often referred to as 'Peto's Paradox'."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27642012",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 178,
          "text": "There is no correlation, however, between body size and cancer risk."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27642012",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "A major constraint on the evolution of large body sizes in animals is an increased risk of developing cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27642012",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 246,
          "offsetInEndSection": 331,
          "text": "Here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29790124",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 593,
          "offsetInEndSection": 834,
          "text": "PTL does not seem to clearly influence disease-free survival (DFS) in localised colon cancer even though the opposite prognostic value of RS tumors on DFS depending on RAS/BRAF mutational status has been recently suggested in these patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29790124",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 353,
          "text": "Primary tumor location (PTL) seems to act as a master prognostic factor pooling different clinical, pathological, and molecular poor prognostic factors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29790124",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 835,
          "offsetInEndSection": 1029,
          "text": "In metastatic CRC (mCRC), the poor prognosis associated with RS tumors is confirmed in the most recent publications in the era of double and triple chemotherapeutic regimens and targeted agents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29790124",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1030,
          "offsetInEndSection": 1471,
          "text": "Concerning the predictive value of PTL, in patients with RAS wild-type mCRC in the first-line setting, anti-epidermal growth factor receptor (EGFR) therapy combined with chemotherapy appears to be more effective than bevacizumab in LS CRC, while patients with RS CRC benefit less from anti-EGFR therapy, and intensive chemotherapy plus bevacizumab may be more appropriate but EGFR antibodies remain an option if objective response is needed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29790124",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Colorectal cancer (CRC) is a heterogeneous disease, and the search for clinical and molecular prognostic and predictive factors is thus necessary to better tailor each individual patient's management."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23445625",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 569,
          "offsetInEndSection": 732,
          "text": "The PET/CT findings were compared with conventional imaging studies and the rate of over-staging or down-staging and changes in clinical management were evaluated."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23445625",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 184,
          "offsetInEndSection": 330,
          "text": "The aim of this study was to evaluate the effect of PET/CT on the preoperative staging and clinical management of patients with colorectal cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23445625",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1864,
          "offsetInEndSection": 1980,
          "text": "The results of our study conclude that PET/CT should not be routinely used for primary staging of colorectal cancer."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23445625",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1377,
          "offsetInEndSection": 1434,
          "text": "Therefore, the false positivity rate of PET/CT was 6.25%."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23445625",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "The use of positron emission tomography-computed tomography (PET/CT) for the preoperative staging of patients with colon and rectal cancer has increased steadily over the last decade."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19946260",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 193,
          "offsetInEndSection": 453,
          "text": "This study evaluates the association of Forkhead-box protein A1 (FOXA1) and GATA-binding protein 3 (GATA3) expressions with Oncotype DX recurrences scores in 77 cases of patients with ER-positive node-negative breast carcinomas diagnosed at Indiana University."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19946260",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1143,
          "offsetInEndSection": 1372,
          "text": "The correlation between FOXA1 expression and Oncotype DX recurrence scores remained significant after adjusting for multiple comparisons and controlling for confounders such as histological type, grade, and progesterone receptor."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19946260",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 773,
          "offsetInEndSection": 889,
          "text": "FOXA1 expression correlated negatively with Oncotype DX recurrence scores (P=0.004), and histologic type (P=0.0004)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19946260",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1373,
          "offsetInEndSection": 1549,
          "text": "A statistically significant correlation between the Oncotype DX recurrence scores and FOXA1 expression in our diverse cohort of ER-positive breast cancer patients was observed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19946260",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 890,
          "offsetInEndSection": 1081,
          "text": "Oncotype DX recurrences score also correlated negatively with progesterone receptor (P=0.035) with 100% of progesterone receptor-negative cases having high or intermediate Oncotype DX scores."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22313737",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 926,
          "offsetInEndSection": 1069,
          "text": "These results suggest that FOXA1 functions as a tumor suppressor through modulation of proliferation and migration of endometrial cancer cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22313737",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 403,
          "offsetInEndSection": 520,
          "text": "In the present study, we investigated the expression of FOXA1 in endometrial cancers by immunohistochemical analysis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22313737",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 673,
          "offsetInEndSection": 820,
          "text": "In ER-positive Ishikawa endometrial cancer cells, small interfering RNA-mediated downregulation of FOXA1 promoted cell proliferation and migration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22313737",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Endometrial cancer is the most common malignancy of the female genital tract and is associated with poor prognosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22313737",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 521,
          "offsetInEndSection": 672,
          "text": "Nuclear immunoreactivity for FOXA1 was detected in 40 of 109 cases (37%), and was found to be negatively associated with lymph node status (P = 0.033)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30964753",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "The association between physical activity (PA) and colorectal cancer (CRC) patients' survival is inconsistent."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30964753",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1098,
          "offsetInEndSection": 1243,
          "text": "The inverse association between prediagnosis PA and cancer mortality was more pronounced for colon cancer than that for rectal cancer (P\u2009=\u20090.08)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30964753",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1420,
          "offsetInEndSection": 1578,
          "text": "Our meta-analysis provides comprehensive evidence that PA performed before or after cancer diagnosis is related to reduced mortality risk among CRC survivors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30964753",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 703,
          "offsetInEndSection": 928,
          "text": "Among CRC survivors, the highest versus the lowest levels of prediagnosis PA showed decreased risks of TM (summary HR\u2009=\u20090.81, 95% CI: 0.76-0.87, I\u2009=\u20091.8%) and CRCSM (summary HR\u2009=\u20090.85, 95% CI: 0.77-0.98, I\u2009=\u20090), respectively."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30964753",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 929,
          "offsetInEndSection": 1097,
          "text": "Significant risk reductions for TM and CRCSM were also demonstrated for postdiagnosis PA (HR\u2009=\u20090.63, 95% CI: 0.54-0.74; and HR\u2009=\u20090.64, 95% CI: 0.47-0.88, respectively)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1008,
          "offsetInEndSection": 1100,
          "text": "Excess body fat results in an approximately 17% increased risk of cancer-specific mortality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1816,
          "offsetInEndSection": 1860,
          "text": "Obesity increases cancer risk and mortality."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1101,
          "offsetInEndSection": 1415,
          "text": "The relationship between obesity and the risk associated with the development of cancer and its recurrence is not fully understood and involves altered fatty acid metabolism, extracellular matrix remodeling, the secretion of adipokines and anabolic and sex hormones, immune dysregulation, and chronic inflammation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1981,
          "offsetInEndSection": 2146,
          "text": "Future studies are warranted to further elucidate the complex relationship between obesity and cancer with the identification of targets for effective interventions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672434",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 248,
          "offsetInEndSection": 418,
          "text": "This review focuses on epidemiology, the relationship between obesity and the risk associated with the development and recurrence of cancer and the management of obesity."
        }
      ]
    },
    {
      "id": "67d71d8f18b1e36f2e00002b",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18430081",
        "http://www.ncbi.nlm.nih.gov/pubmed/31076745",
        "http://www.ncbi.nlm.nih.gov/pubmed/25700419",
        "http://www.ncbi.nlm.nih.gov/pubmed/33465423",
        "http://www.ncbi.nlm.nih.gov/pubmed/28707191",
        "http://www.ncbi.nlm.nih.gov/pubmed/28396132",
        "http://www.ncbi.nlm.nih.gov/pubmed/25486992",
        "http://www.ncbi.nlm.nih.gov/pubmed/27753689",
        "http://www.ncbi.nlm.nih.gov/pubmed/28274145",
        "http://www.ncbi.nlm.nih.gov/pubmed/19651859"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18430081",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Clostridia belong to those bacteria which are considered as obligate anaerobe, e.g."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18430081",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 439,
          "offsetInEndSection": 602,
          "text": "Here we show that manipulation of the regulatory mechanism of this defence mechanism can trigger aerotolerance in the obligate anaerobe Clostridium acetobutylicum."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18430081",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 84,
          "offsetInEndSection": 130,
          "text": "oxygen is harmful or lethal to these bacteria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18430081",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1000,
          "offsetInEndSection": 1272,
          "text": "Several genes encoding the putative enzymes were upregulated and identified as members of the clostridial PerR regulon, including the heat shock protein Hsp21, a reverse rubrerythrin which was massively produced and became the most abundant protein in the absence of PerR."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18430081",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 603,
          "offsetInEndSection": 799,
          "text": "Deletion of a peroxide repressor (PerR)-homologous protein resulted in prolonged aerotolerance, limited growth under aerobic conditions and rapid consumption of oxygen from an aerobic environment."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31076745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Clostridium is a large genus of obligate anaerobes belonging to the Firmicutes phylum of bacteria, most of which have a Gram-positive cell wall structure."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31076745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 664,
          "offsetInEndSection": 877,
          "text": "This analysis allowed us to 1) confirm that the group is composed of more than one genus, 2) detect major differences between pathogens classified as a single species within the group of authentic Clostridium spp."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31076745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 431,
          "offsetInEndSection": 569,
          "text": "Currently, species belonging to the genus are placed in the unnatural order defined as Clostridiales, which includes the class Clostridia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31076745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1160,
          "offsetInEndSection": 1431,
          "text": "Our analysis shows that the current taxonomic classification of Clostridium species hinders the prediction of functions and traits, suggests a new classification for this fascinating class of bacteria, and highlights the importance of phylogenomics for taxonomic studies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31076745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 284,
          "text": "The genus includes significant human and animal pathogens, causative of potentially deadly diseases such as tetanus and botulism."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25700419",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "We report here the closed genome of Clostridium pasteurianum ATCC 6013, a saccharolytic, nitrogen-fixing, and spore-forming Gram-positive obligate anaerobe."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25700419",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 157,
          "offsetInEndSection": 307,
          "text": "The organism is of biotechnological interest due to the production of solvents (butanol and 1,3-propanediol) but can be associated with food spoilage."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25700419",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 353,
          "text": "The genome comprises a total of 4,351,223\u00a0bp."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465423",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 498,
          "offsetInEndSection": 729,
          "text": "In this review, we primarily discuss the phages infecting three well-studied anaerobes in the gut: Bifidobacterium, Clostridia and Bacteroides, with a particular focus on the challenges in isolating and characterizing these phages."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465423",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 730,
          "offsetInEndSection": 882,
          "text": "We contrast the lessons learned from these to other anaerobic work on phages infecting facultative anaerobes of the gut: Enterococcus and Lactobacillus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465423",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 378,
          "offsetInEndSection": 497,
          "text": "Studying the phages infecting anaerobes is difficult, as they are often technically demanding to isolate and propagate."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465423",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 883,
          "offsetInEndSection": 1074,
          "text": "Phages from the gut do appear to adhere to the lessons learned from aerobic work, but the additional challenges of working on them has required ingenious new approaches to enable their study."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465423",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Bacterial viruses (bacteriophages, phages) of the gut have increasingly become a focus in microbiome studies, with an understanding that they are likely key players in health and disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707191",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1490,
          "offsetInEndSection": 1500,
          "text": "difficile."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707191",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 945,
          "offsetInEndSection": 1113,
          "text": "The presence of a toxin-producing bacteria or toxins (A or B) only equates with disease if diarrhea or a diseased colon (toxic megacolon, ileus, and sepsis) is present."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707191",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65,
          "text": "Review tests available for detection of Clostridium difficile (C."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707191",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1114,
          "offsetInEndSection": 1321,
          "text": "Nucleic acid amplification testing (NAAT), when used in the stool from patients with diarrhea, appears to be the most efficient study to detect the gene that encodes for toxin A and B and thus to diagnose C."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707191",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1598,
          "offsetInEndSection": 1654,
          "text": "difficile should only be done on patients with diarrhea."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28396132",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Clostridium difficile infection (CDI) is the main cause of nosocomial diarrhea in industrialized countries and the source of a growing number of cases of diarrhea in the community."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28396132",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 181,
          "offsetInEndSection": 314,
          "text": "The outbreak of the hypervirulent strain belonging to ribotype 027 has increased the incidence and severity of CDI in some countries."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28396132",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 583,
          "offsetInEndSection": 786,
          "text": "The diagnostic techniques of choice are algorithms based on the detection of glutamate dehydrogenase and molecular detection of the genes of the toxins with or without the direct detection of the toxins."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28396132",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 787,
          "offsetInEndSection": 893,
          "text": "The recommended treatment for CDI depends on the type of infection and the characteristics of the patient."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28396132",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 315,
          "offsetInEndSection": 431,
          "text": "Although CDI usually courses as a mild diarrhea it can lead to severe forms such as toxic megacolon or septic shock."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25486992",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Clostridium difficile infection (CDI) represents the most prevalent cause of antibiotic-associated gastrointestinal infections in health care facilities in the developed world."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25486992",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1166,
          "offsetInEndSection": 1270,
          "text": "difficile in these models, including in mice challenged with a strain of the hypervirulent ribotype 027."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25486992",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 484,
          "text": "Standard therapy for CDI involves administration of antibiotics that are associated with a high rate of disease recurrence, highlighting the need for novel treatment paradigms that target the toxins rather than the organism itself."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25486992",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 793,
          "offsetInEndSection": 1015,
          "text": "In this study, we show that the antitoxin antibodies are protective in multiple murine models of CDI, including systemic and local (gut) toxin challenge models, as well as primary and recurrent models of infection in mice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25486992",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 485,
          "offsetInEndSection": 709,
          "text": "A combination of human monoclonal antibodies, actoxumab and bezlotoxumab, directed against TcdA and TcdB, respectively, has been shown to decrease the rate of recurrence in patients treated with standard-of-care antibiotics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753689",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 255,
          "offsetInEndSection": 460,
          "text": "Bezlotoxumab is a monoclonal antibody against toxin B that has successfully completed phase III studies, demonstrating a significant reduction in recurrent CDI when given with standard of care antibiotics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753689",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Clostridium difficile infection has attained high prominence given its prevalence and impacts on patients and healthcare institutions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753689",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1079,
          "text": "difficile strain has also shown promise to prevent recurrent CDI."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753689",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 996,
          "offsetInEndSection": 1013,
          "text": "A nontoxigenic C."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753689",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 197,
          "offsetInEndSection": 254,
          "text": "difficile infection (CDI) are undergoing clinical trials."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28274145",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "Clostridium difficile infections are characterized by a high recurrence rate despite antibiotic treatments and there is an urgent need to develop new treatments such as fecal transplantation and immonotherapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28274145",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 539,
          "offsetInEndSection": 607,
          "text": "difficile infection in animal models and in clinical trials as well."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28274145",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1185,
          "offsetInEndSection": 1257,
          "text": "difficile infection and pave the way for further clinical investigation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28274145",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 897,
          "offsetInEndSection": 965,
          "text": "difficile and new approaches to deliver them in the digestive tract."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28274145",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 445,
          "offsetInEndSection": 538,
          "text": "difficile toxins and surface proteins to treat or prevent primary or recurrent episodes of C."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 285,
          "text": "Here, we report the role of CodY in Bacillus anthracis, the etiologic agent of anthrax."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "In gram-positive bacteria, CodY is an important regulator of genes whose expression changes upon nutrient limitation and acts as a repressor of virulence gene expression in some pathogenic species."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 449,
          "text": "Disruption of codY completely abolished virulence in a toxinogenic, noncapsulated strain, indicating that the activity of CodY is required for full virulence of B."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 564,
          "offsetInEndSection": 843,
          "text": "These differences could reflect direct control for some genes, as suggested by the presence of CodY binding sequences in their promoter regions, or indirect effects via the CodY-dependent control of other regulatory proteins or metabolic rearrangements in the codY mutant strain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19651859",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 563,
          "text": "Global transcriptome analysis of a codY mutant and the parental strain revealed extensive differences."
        }
      ]
    },
    {
      "id": "67cdb26a81b1027333000017",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23326927",
        "http://www.ncbi.nlm.nih.gov/pubmed/24025022",
        "http://www.ncbi.nlm.nih.gov/pubmed/25962253",
        "http://www.ncbi.nlm.nih.gov/pubmed/24622320",
        "http://www.ncbi.nlm.nih.gov/pubmed/22547464",
        "http://www.ncbi.nlm.nih.gov/pubmed/25941565",
        "http://www.ncbi.nlm.nih.gov/pubmed/28811850",
        "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
        "http://www.ncbi.nlm.nih.gov/pubmed/25255411",
        "http://www.ncbi.nlm.nih.gov/pubmed/22977310"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326927",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "A new mechanism of action in the form of sodium-glucose co-transporter-(SGLT-)2 inhibitors will be available shortly for the treatment of type 2 diabetic patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326927",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 331,
          "offsetInEndSection": 431,
          "text": "SGLT-2 inhibitors also have a positive impact on body weight and blood pressure of type 2 diabetics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326927",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 432,
          "offsetInEndSection": 552,
          "text": "In the available registration trials conducted to date, the SGLT-2 inhibitors appeared overall as a safe class of drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326927",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 174,
          "offsetInEndSection": 330,
          "text": "Fasting and postprandial blood glucose and HbA(1c) concentrations are indirectly reduced by the inhibition of glucose reabsorption and increased glycosuria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326927",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 703,
          "offsetInEndSection": 820,
          "text": "Long-term trials are currently underway to verify safety and in particular cardiovascular effects of this drug class."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 428,
          "text": "Clinical trials of SGLT2 inhibitors in patients with type 2 diabetes mellitus demonstrate a significant clinical effect in decreasing serum glucose, hemoglobin A1C, body weight, systolic blood pressure, improving \u03b2-cell function, and minimizing the risk of hypoglycemia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "The sodium glucose cotransporter 2 (SGLT2) is expressed primarily in the kidneys and is involved in the reabsorption of filtered glucose in the renal tubule."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 429,
          "offsetInEndSection": 636,
          "text": "This report reviews the potentially beneficial effects of SGLT2 inhibitors in type 2 diabetes mellitus, specifically focusing on canagliflozin, the only SGLT2 inhibitor approved for use in the United States."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25962253",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "SGLT2 (Sodium Glucose co-Transporter 2 Inhibitors) inhibitors are a new group of oral medications for the treatment of type 2 diabetes mellitus patients."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25962253",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 952,
          "offsetInEndSection": 1115,
          "text": "The following review describes the relevant pathophysiology addressed by these novel medications, evidence for efficacy and the safety profile of SGLT2 Inhibitors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25962253",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 328,
          "offsetInEndSection": 542,
          "text": "SGLT2 inhibitors were found to be effective in lowering HbA1c levels in double-blinded studies, both as monotherapy and in combination with other oral hypoglycemic medications of various other mechanisms of action."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25962253",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 653,
          "text": "SGLT2 Inhibitors are not a risk factor for hypoglycemia and are suitable for combination with insulin therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25962253",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 154,
          "offsetInEndSection": 327,
          "text": "These medications interfere with the process of glucose reabsorption in the proximal convoluted tubules in the kidneys, therefore increasing both glucose and water diuresis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24622320",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "The two main sodium-glucose cotransporters (SGLTs), SGLT1 and SGLT2, provide new therapeutic targets to reduce hyperglycaemia in patients with diabetes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24622320",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 361,
          "offsetInEndSection": 588,
          "text": "Inhibitors with varying specificities for these transporters (eg, dapagliflozin, canagliflozin, and empagliflozin) can slow the rate of intestinal glucose absorption and increase the renal elimination of glucose into the urine."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24622320",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1117,
          "offsetInEndSection": 1347,
          "text": "However, the insulin-independent mechanism of action of SGLT inhibitors seems to offer durable glucose-lowering efficacy with low risk of clinically significant hypoglycaemia at any stage in the natural history of type 2 diabetes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24622320",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1348,
          "offsetInEndSection": 1444,
          "text": "SGLT inhibition might also be considered in conjunction with insulin therapy in type 1 diabetes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24622320",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 589,
          "offsetInEndSection": 814,
          "text": "Results of randomised clinical trials have shown the blood glucose-lowering efficacy of SGLT inhibitors in type 2 diabetes when administered as monotherapy or in addition to other glucose-lowering therapies including insulin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22547464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 363,
          "text": "SGLT2 inhibitors enhance renal glucose excretion by inhibiting renal glucose re-absorption and reduce plasma glucose level, as well as they decrease the body weight."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22547464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 103,
          "offsetInEndSection": 197,
          "text": "Therefore, inhibition of SGLTs may provide a novel therapeutic strategy for diabetes mellitus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22547464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 608,
          "offsetInEndSection": 742,
          "text": "Results suggest that the beneficial effects of SGLT2 inhibition might be achieved without the development of significant side effects."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22547464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Sodium-glucose co-transporters (SGLTs) have a key role in the re-absorption of glucose in the kidneys."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22547464",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 537,
          "text": "Numerous SGLT2 inhibitors have been developed and evaluated in clinical trials."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941565",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Sodium glucose cotransporter type 2 (SGLT2) inhibitors are a new class of drug developed to treat type 2 diabetes mellitus (T2DM)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941565",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 458,
          "offsetInEndSection": 623,
          "text": "Empagliflozin has shown a good efficacy and safety profile from clinical trials when given as monotherapy, and as an add-on therapy to other glucose-lowering agents."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941565",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 287,
          "text": "They target the kidney by reducing renal glucose reabsorption and promoting urinary glucose excretion, which reduces hyperglycemia in individuals with T2DM."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941565",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 288,
          "offsetInEndSection": 457,
          "text": "The SGLT2 inhibitor empagliflozin has gained approval in the EU and in the USA for the treatment of adults with T2DM (there is no current indication in type 1 diabetes)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941565",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 624,
          "offsetInEndSection": 801,
          "text": "This short commentary reviews the key efficacy and safety data from empagliflozin phase III trials and examines the potential role this agent may have in the management of T2DM."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28811850",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs that improve glycemic control by inhibiting reabsorption of glucose filtered through the renal glomerulus."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28811850",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 608,
          "offsetInEndSection": 831,
          "text": "Recent evidence shows that these SGLT2 inhibitors with low SGLT2/SGLT1 selectivity elevate the level of circulating glucagon like peptide-1 (GLP-1), an incretin hormone that promotes insulin secretion in pancreatic \u03b2 cells."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28811850",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 832,
          "offsetInEndSection": 1050,
          "text": "This effect probably occurs partly via inhibition of intestinal SGLT1, and the elevation of active GLP-1 levels is especially apparent when these drugs are co-administered with dipeptidyl peptidase 4 (DPP4) inhibitors."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28811850",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 379,
          "offsetInEndSection": 607,
          "text": "SGLT2 inhibitors such as canagliflozin and sotagliflozin (a SGLT1/SGLT2 dual inhibitor) also have a mild or moderate intestinal and renal SGLT1 inhibitory effect because of their relatively weak selectivity for SGLT2 over SGLT1."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28811850",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1051,
          "offsetInEndSection": 1297,
          "text": "These findings suggest that a combination of canagliflozin or sotagliflozin and a DPP4 inhibitor can provide a beneficial effect associated with elevation of circulating active GLP-1 and may serve as a treatment for patients with type 2 diabetes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve glycemic control by a reversible inhibition of the sodium-glucose cotransporters in the renal proximal tubules resulting in increased urinary glucose."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1103,
          "offsetInEndSection": 1233,
          "text": "SGLT2 inhibitors such as canagliflozin may predispose patients not only to diabetic ketoacidosis but also to prolonged glucosuria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 677,
          "offsetInEndSection": 821,
          "text": "Due to the reversible inhibition of SGLT2 by this class of medication, a quick recovery of glucosuria after cessation of medication is expected."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 676,
          "text": "DKA associated with SGLT2 inhibitors frequently develops in the absence of hyperglycemia, which makes the diagnosis more challenging."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 975,
          "offsetInEndSection": 1102,
          "text": "This case of DKA associated with SGLT2 inhibitor use was unique due to her hypoglycemic presentation and persistent glucosuria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25255411",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 309,
          "text": "Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of antihyperglycemic agents for the treatment of T2DM with a novel insulin-independent mechanism of action that targets the kidney."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25255411",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 310,
          "offsetInEndSection": 479,
          "text": "The SGLT2 inhibitors decrease renal glucose reabsorption, thereby increasing urinary glucose excretion and lowering plasma glucose levels in patients with hyperglycemia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25255411",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 480,
          "offsetInEndSection": 715,
          "text": "SGLT2 inhibitor canagliflozin has demonstrated efficacy in improving glycemic control and reducing body weight and blood pressure as monotherapy or as add-on to other antihyperglycemic agents across a broad range of patients with T2DM."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25255411",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 866,
          "text": "Canagliflozin is generally well tolerated, with increased incidences of specific adverse events that are related to the mechanism of SGLT2 inhibition."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25255411",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "The kidney plays a key role in glucose homeostasis and the pathophysiology of type 2 diabetes mellitus (T2DM)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 367,
          "offsetInEndSection": 527,
          "text": "The purpose of this review is to explore the physiology of SGLT2 and discuss several SGLT2 inhibitors which have clinical data in patients with type 2 diabetes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 743,
          "offsetInEndSection": 1073,
          "text": "SGLT2 inhibitors correct a novel pathophysiological defect, have an insulin-independent action, are efficacious with glycosylated hemoglobin reduction ranging from 0.5% to 1.5%, promote weight loss, have a low incidence of hypoglycemia, complement the action of other antidiabetic agents, and can be used at any stage of diabetes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 243,
          "offsetInEndSection": 366,
          "text": "Inhibition of SGLT2 leads to glucosuria and provides a unique mechanism to lower elevated blood glucose levels in diabetes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 2110,
          "offsetInEndSection": 2248,
          "text": "SGLT2 inhibitors represent a promising approach for the treatment of diabetes, and could potentially be an addition to existing therapies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 242,
          "text": "The sodium-glucose cotransporter type 2 (SGLT2) mediates most of the glucose reabsorption from the proximal renal tubule."
        }
      ]
    },
    {
      "id": "67e2b0a018b1e36f2e00008b",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22836745",
        "http://www.ncbi.nlm.nih.gov/pubmed/30088449",
        "http://www.ncbi.nlm.nih.gov/pubmed/33088545",
        "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
        "http://www.ncbi.nlm.nih.gov/pubmed/24772739",
        "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
        "http://www.ncbi.nlm.nih.gov/pubmed/19636526",
        "http://www.ncbi.nlm.nih.gov/pubmed/20877608",
        "http://www.ncbi.nlm.nih.gov/pubmed/19947304",
        "http://www.ncbi.nlm.nih.gov/pubmed/8007629"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22836745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Nitrofurantoin is commonly used for the treatment and prophylaxis of recurrent urinary tract infections (UTIs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22836745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 267,
          "text": "Although relatively rare, nitrofurantoin is one of the commonest causes of drug-induced pulmonary disease, which can be potentially serious and even fatal."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22836745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 555,
          "offsetInEndSection": 746,
          "text": "We report three cases of nitrofurantoin-induced lung disease in patients who were on long-term nitrofurantoin for UTI prophylaxis and present a brief review of the literature on this subject."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22836745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 268,
          "offsetInEndSection": 380,
          "text": "Knowledge of such potential adverse effects is essential to enable early recognition and withdrawal of the drug."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22836745",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 381,
          "offsetInEndSection": 461,
          "text": "Patients on long-term nitrofurantoin should be reviewed and monitored regularly."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30088449",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Uropathogenic Escherichia coli (UPEC) is a major cause of Urinary Tract Infections (UTIs)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30088449",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 203,
          "text": "Due to increasing antibiotic-resistance among UPEC bacteria, new treatment options for UTIs are urgently needed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30088449",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 204,
          "offsetInEndSection": 318,
          "text": "To identify new agents targeting growing bacteria that may be used for the treatment of antibiotic-resistant UTIs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30088449",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1826,
          "offsetInEndSection": 1944,
          "text": "Our findings provide possible effective drug candidates for the more effective treatment of antibiotic-resistant UTIs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30088449",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 537,
          "offsetInEndSection": 629,
          "text": "We identified 33 antibiotics which were active against log-phase clinical UPEC strain UTI89."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33088545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Nitrofurantoin is a common treatment for urinary tract infections."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33088545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 189,
          "text": "Acute lung injury resulting from nitrofurantoin is a rare, life-threatening complication with women being at greater risk."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33088545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 295,
          "text": "Symptoms include respiratory distress with fevers, rash, eosinophilia, and new-onset atrial fibrillation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33088545",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 296,
          "offsetInEndSection": 396,
          "text": "Treatment includes discontinuing the drug and possibly glucocorticoids for persistent oxygen demand."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Bacterial vaginosis is the most common cause of vaginitis, affecting over 3 million women in the United States annually."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 274,
          "text": "Depopulation of lactobacilli from the normal vaginal flora and overgrowth of Gardnerella vaginalis and other anaerobic species are the presumed etiology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 275,
          "offsetInEndSection": 372,
          "text": "To date, no scientific evidence shows that bacterial vaginosis is a sexually transmitted disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 373,
          "offsetInEndSection": 429,
          "text": "Malodorous vaginal discharge is the most common symptom."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1510,
          "offsetInEndSection": 1636,
          "text": "The association between bacterial vaginosis and adverse pregnancy outcomes has satisfied many criteria for a causal inference."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24772739",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 68,
          "text": "Nitrofurantoin is a drug commonly used for urinary tract infections."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24772739",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 295,
          "offsetInEndSection": 478,
          "text": "We present a case of an elderly lady receiving nitrofurantoin for her urinary tract infection who developed sudden acute lung injury to which she finally succumbed within a few weeks."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24772739",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 69,
          "offsetInEndSection": 103,
          "text": "It acts by damaging bacterial DNA."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24772739",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 104,
          "offsetInEndSection": 294,
          "text": "It is given in dose of 50-100 mg orally and is generally considered a safe drug but has occasionally been known to cause pulmonary toxicity which is usually reversible and only rarely fatal."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Nitrofurantoin is a commonly prescribed antibiotic for urinary tract infection (UTI) treatment and prophylaxis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 290,
          "text": "Although relatively rare, nitrofurantoin can cause a spectrum of lung injuries, from acute hypersensitivity reactions that might be fatal to chronic reactions involving fibrosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 479,
          "offsetInEndSection": 622,
          "text": "Here, we report the case of a 77-year-old woman who had been hospitalized with interstitial lung disease due to chronic nitrofurantoin therapy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 291,
          "offsetInEndSection": 478,
          "text": "Therefore, treating physicians' awareness and regular monitoring is essential for early recognition, drug withdrawal, avoiding unnecessary treatment, and preventing irreversible fibrosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809109",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 623,
          "offsetInEndSection": 797,
          "text": "Despite the severity of symptoms and the extent of radiological lung involvement, she returned to her clinical and radiological baseline shortly following the drug cessation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19636526",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Recurrent urinary tract infections are a frequent problem in urological practice."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19636526",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 991,
          "offsetInEndSection": 1159,
          "text": "However, in a subanalysis of randomized and controlled studies, it was shown that women with recurrent urinary tract infections might profit from consuming cranberries."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19636526",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 382,
          "offsetInEndSection": 581,
          "text": "A review of the literature in PubMed as well as the recently published Cochrane database systematic review confirmed that daily consumption of cranberries prevents recurrent urinary tract infections."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19636526",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 82,
          "offsetInEndSection": 219,
          "text": "Long-term antibiotic prophylaxis can cause resistance of some intestinal bacteria, and after therapy is stopped, infections often resume."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19636526",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 582,
          "offsetInEndSection": 781,
          "text": "In vitro studies have shown that binding of the P fimbriae of Escherichia coli to the uroepithelial tissue can be inhibited in the presence of proanthocyanidins, the active ingredient of cranberries."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20877608",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Overactive bladder (OAB), as defined by the International Continence Society, is characterized by a symptom complex including urinary urgency with or without urge incontinence, usually associated with frequency and nocturia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20877608",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 719,
          "text": "In about 75%, OAB symptoms are due to idiopathic detrusor activity; neurological disease, bladder outflow obstruction (BOO) intrinsic bladder pathology and other chronic pelvic floor disorders are implicated in the others."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20877608",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 225,
          "offsetInEndSection": 443,
          "text": "OAB syndrome has an incidence reported from six European countries ranging between 12-17%, while in the United States; a study conducted by the National Overactive Bladder Evaluation program found the incidence at 17%."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20877608",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 963,
          "offsetInEndSection": 1096,
          "text": "Antimuscarinics are the drug class of choice for OAB symptoms; with proven efficacy, and adverse event profiles that differ somewhat."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20877608",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 833,
          "offsetInEndSection": 962,
          "text": "The first-line treatments are lifestyle interventions, bladder training, pelvic floor muscle exercises and anticholinergic drugs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19947304",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 213,
          "offsetInEndSection": 297,
          "text": "pyogenes causes the widest range of disease in humans among all bacterial pathogens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19947304",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 30,
          "offsetInEndSection": 209,
          "text": "pyogenes (beta-haemolytic group A Streptococcus) is a natural colonizer of the human oropharynx mucous membrane and one of the most common agents of infectious diseases in humans."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19947304",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 298,
          "offsetInEndSection": 450,
          "text": "It is responsible for various skin infections such as impetigo contagiosa and erysipelas, and localized mucous membrane infections of the oropharynx (e."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19947304",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 484,
          "offsetInEndSection": 593,
          "text": "Betahaemolytic group A Streptococcus causes also invasive diseases such as sepses including puerperal sepsis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19947304",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 611,
          "offsetInEndSection": 656,
          "text": "pyogenes induces toxin-mediated syndromes, i."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 293,
          "text": "The most common species recovered from the sputum specimens of these patients were Haemophilus influenzae, followed by Streptococcus pneumoniae (S."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 294,
          "offsetInEndSection": 332,
          "text": "pneumoniae), Staphylococcus aureus (S."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 693,
          "offsetInEndSection": 801,
          "text": "It is concluded that ofloxacin, 400 mg once daily, is useful for patients with respiratory tract infections."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "The efficacy and safety of oral ofloxacin, 400 mg once daily, for the treatment of patients with lower respiratory tract infections were studied."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 513,
          "offsetInEndSection": 611,
          "text": "All these bacteria were susceptible to ofloxacin except for one strain of methicillin resistant S."
        }
      ]
    },
    {
      "id": "67e090be18b1e36f2e00006c",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12846937",
        "http://www.ncbi.nlm.nih.gov/pubmed/20890386",
        "http://www.ncbi.nlm.nih.gov/pubmed/24069959",
        "http://www.ncbi.nlm.nih.gov/pubmed/25400981",
        "http://www.ncbi.nlm.nih.gov/pubmed/22529959",
        "http://www.ncbi.nlm.nih.gov/pubmed/29076071",
        "http://www.ncbi.nlm.nih.gov/pubmed/24621781",
        "http://www.ncbi.nlm.nih.gov/pubmed/15076628",
        "http://www.ncbi.nlm.nih.gov/pubmed/8264800",
        "http://www.ncbi.nlm.nih.gov/pubmed/1482192"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12846937",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 384,
          "offsetInEndSection": 458,
          "text": "Probiotic microorganisms are administered in food supplements and yogurts."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12846937",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 594,
          "offsetInEndSection": 666,
          "text": "It is important to understand that all probiotic products are different."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12846937",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Probiotics are live, microbial food supplements that benefit the host animal by improving intestinal microbial balance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12846937",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 737,
          "offsetInEndSection": 822,
          "text": "Therapeutic results have been achieved with various probiotics in different diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12846937",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1191,
          "offsetInEndSection": 1269,
          "text": "coli Nissle strain, and recently with multiple organism probiotic supplements."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20890386",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 266,
          "offsetInEndSection": 450,
          "text": "Current evidence indicates that probiotic effects are strain-specific, they do not act through the same mechanisms, and nor are all probiotics indicated for the same health conditions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20890386",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1065,
          "offsetInEndSection": 1116,
          "text": "Safety of probiotic formulations is also discussed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20890386",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 115,
          "offsetInEndSection": 265,
          "text": "Many probiotics are derived from our intestinal bacteria, and have been shown to provide clinical benefit in a variety of gastrointestinal conditions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20890386",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 777,
          "offsetInEndSection": 890,
          "text": "In this review we focus on a few selected probiotics - a bacterial mixture (VSL#3), a Gram-negative probiotic (E."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20890386",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 891,
          "offsetInEndSection": 955,
          "text": "coli Nissle 1917), two Gram-positive probiotic bacteria (LGG, L."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24069959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 480,
          "text": "Here, we focussed on expanding the potential of lacticin 3147, one of the most studied lantibiotics and one which possesses potent activity against a wide range of Gram positive species including many nosocomial pathogens."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24069959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 633,
          "offsetInEndSection": 754,
          "text": "Initial screening revealed that polymyxin B and polymyxin E (colistin) exhibited synergistic activity with lacticin 3147."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24069959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 481,
          "offsetInEndSection": 632,
          "text": "More specifically, our aim was to investigate if lacticin 3147 activity could be enhanced when combined with a range of different clinical antibiotics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24069959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1114,
          "offsetInEndSection": 1342,
          "text": "Combining lacticin 3147 with low levels of a polymyxin could provide a means of broadening target specificity of the lantibiotic, while also reducing polymyxin use due to the lower concentrations required as a result of synergy."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24069959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 257,
          "text": "Lantibiotics are post-translationally modified, ribosomally synthesised antimicrobial peptides with a broad spectrum antimicrobial activity."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400981",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 352,
          "offsetInEndSection": 574,
          "text": "In the frame of the studies aimed at finding alternative therapies or at increasing the efficacy of the current ones and/or reducing their side effects, the investigation on the use of probiotics plays an interesting role."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400981",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 653,
          "offsetInEndSection": 754,
          "text": "Several clinical trials indicated that administration of probiotics can reduce the side effects of H."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400981",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1124,
          "offsetInEndSection": 1212,
          "text": "In conclusion, the use of probiotics appears promising as an adjuvant for the current H."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400981",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 852,
          "offsetInEndSection": 1051,
          "text": "The results of these trials vary, likely reflecting the variety of probiotics assessed and that of the eradication treatment, as well as the differences in the geographic area that imply different H."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400981",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 47,
          "offsetInEndSection": 250,
          "text": "pylori), and the evidence of its relationship with gastric diseases, antibiotic-based therapies were developed, which efficacy was however limited by antibiotic resistance and lack of patient compliance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22529959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1670,
          "offsetInEndSection": 1763,
          "text": "Probiotics are generally beneficial in treatment and prevention of gastrointestinal diseases."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22529959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1498,
          "offsetInEndSection": 1628,
          "text": "Across all diseases and probiotic species, positive significant effects of probiotics were observed for all age groups, single vs."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22529959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 350,
          "text": "Meta-analyses on the effects of probiotics on specific gastrointestinal diseases have generally shown positive effects on disease prevention and treatment; however, the relative efficacy of probiotic use for treatment and prevention across different gastrointestinal diseases, with differing etiology and mechanisms of action, has not been addressed."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22529959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1919,
          "offsetInEndSection": 2120,
          "text": "When choosing to use probiotics in the treatment or prevention of gastrointestinal disease, the type of disease and probiotic species (strain) are the most important factors to take into consideration."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22529959",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 351,
          "offsetInEndSection": 660,
          "text": "We included randomized controlled trials in humans that used a specified probiotic in the treatment or prevention of Pouchitis, Infectious diarrhea, Irritable Bowel Syndrome, Helicobacter pylori, Clostridium difficile Disease, Antibiotic Associated Diarrhea, Traveler's Diarrhea, or Necrotizing Enterocolitis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29076071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 696,
          "offsetInEndSection": 885,
          "text": "Bacteroides strains are not commonly used to treat CDI; however, as they comprise a large proportion of the intestinal microbiota, they can contribute to bile acid-mediated inhibition of C."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29076071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1214,
          "offsetInEndSection": 1368,
          "text": "The findings of this study are important due to the discovery of a new bacterial strain that in the presence of available bile acids inhibits growth of C."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29076071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 376,
          "offsetInEndSection": 554,
          "text": "Therefore, it is necessary to evaluate alternative treatment methods, such as bacteriotherapy, as well as the mechanism through which beneficial bacteria inhibit the growth of C."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29076071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1380,
          "offsetInEndSection": 1473,
          "text": "These results will facilitate development of novel bacteriotherapy strategies to control CDI."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29076071",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 618,
          "offsetInEndSection": 695,
          "text": "difficile by Bacteroides strains which can produce bile salt hydrolase (BSH)."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24621781",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 275,
          "text": "Lantibiotic compounds are ribosomally synthesized antimicrobial peptides against which bacteria are not able to produce resistance, hence making them a good alternative to antibiotics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24621781",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 276,
          "offsetInEndSection": 419,
          "text": "Nisin is the oldest and the most widely used lantibiotic, in food preservation, without having developed any significant resistance against it."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24621781",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 527,
          "offsetInEndSection": 683,
          "text": "Identification of novel lantibiotic biosynthetic clusters from an ever increasing database of bacterial genomes, can provide a major lead in this direction."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24621781",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 420,
          "offsetInEndSection": 526,
          "text": "Having their antimicrobial potential and a limited number, there is a need to identify novel lantibiotics."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24621781",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 913,
          "offsetInEndSection": 1054,
          "text": "This strategy resulted in identification of 54 bacterial strains containing the LanT homologs, which are not the known lantibiotic producers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15076628",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 66,
          "offsetInEndSection": 295,
          "text": "Bifidobacteria are particularly attractive as probiotics agent because they constitute the predominant colonic flora of breastfed infants and are thought to play a role in the decreased incidence of diarrhea in breastfed infants."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15076628",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1722,
          "offsetInEndSection": 1915,
          "text": "These results provide some evidence that viable Bifidobacterium lactis strain Bb 12, added to an acidified infant formula, has some protective effect against acute diarrhea in healthy children."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15076628",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65,
          "text": "Probiotics may be useful in preventing acute infectious diarrhea."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15076628",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 296,
          "offsetInEndSection": 585,
          "text": "This was a multicenter, double-blind, controlled study to evaluate the efficacy of a milk formula supplemented with viable Bifidobacterium lactis strain Bb 12 (BbF) in the prevention of acute diarrhea in infants younger than 8 months living in residential nurseries or foster care centers."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15076628",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 586,
          "offsetInEndSection": 671,
          "text": "Ninety healthy children received either the BbF or a conventional formula (CF) daily."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8264800",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 339,
          "offsetInEndSection": 600,
          "text": "Prominent members of the lantibiotics are nisin of Lactococcus lactis, which can be used as a food preservative, subtilin of Bacillus subtilis, which is similar to nisin, and epidermin of Staphylococcus epidermidis, which is considered in the treatment of acne."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8264800",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Lantibiotics are defined as peptide antibiotics containing the unusual amino acids mesolanthionine, 3-methyllanthionine, dehydroalanine, and dehydrobutyrine."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8264800",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 698,
          "offsetInEndSection": 877,
          "text": "Genes probably encoding these biosynthetic enzymes and regulatory factors have been identified adjacent to the structural genes of the lantibiotics subtilin, nisin, and epidermin."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8264800",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 210,
          "text": "They are synthesized by some gram-positive bacteria."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8264800",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 211,
          "offsetInEndSection": 338,
          "text": "Their inhibitory effect on certain other gram-positive bacteria is explained by detergent-like damage of cytoplasmic membranes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Nisin produced by Lactococcus lactis 6F3 is used as a food preservative and is the most important member of a group of peptide-antibiotics containing lanthionine bridges (lantibiotics) (N."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 849,
          "text": "Over their entire sequences, these genes were homologous to genes recently identified as important for the biosynthesis of lantibiotics, that is, subtilin from Bacillus subtilis ATCC 6633 and epidermin from Staphylococcus epidermidis T\u00fc 3298."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 507,
          "text": "Bacteriol."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 307,
          "offsetInEndSection": 467,
          "text": "Nisin is ribosomally synthesized, and its structural gene, nisA, encodes a prepeptide that is posttranslationally modified, revealing the active lantibiotic (C."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1482192",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 969,
          "offsetInEndSection": 1087,
          "text": "The nisT open reading frame is homologous to proteins of the HlyB (hemolysin B protein of Escherichia coli) subfamily."
        }
      ]
    },
    {
      "id": "67d7fded18b1e36f2e000042",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29417387",
        "http://www.ncbi.nlm.nih.gov/pubmed/28057084",
        "http://www.ncbi.nlm.nih.gov/pubmed/15341718",
        "http://www.ncbi.nlm.nih.gov/pubmed/36759100",
        "http://www.ncbi.nlm.nih.gov/pubmed/6769152",
        "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
        "http://www.ncbi.nlm.nih.gov/pubmed/25145720",
        "http://www.ncbi.nlm.nih.gov/pubmed/18372219",
        "http://www.ncbi.nlm.nih.gov/pubmed/15894210",
        "http://www.ncbi.nlm.nih.gov/pubmed/36868166"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29417387",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 481,
          "offsetInEndSection": 556,
          "text": "The patient was diagnosed with FHCS due to Chlamydia trachomatis infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29417387",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 137,
          "offsetInEndSection": 221,
          "text": "Here, we report a case of FHCS caused by Chlamydia trachomatis in a 50-year-old man."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29417387",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 424,
          "offsetInEndSection": 480,
          "text": "A urine specimen was positive for Chlamydia trachomatis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29417387",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Fitz-Hugh-Curtis syndrome (FHCS) is characterized by perihepatic and pelvic inflammation and occurs mostly in women of childbearing age."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29417387",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 557,
          "offsetInEndSection": 705,
          "text": "In conclusion, FHCS cannot be excluded when men present with right upper quadrant abdominal pain without significant signs of biliary tract disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28057084",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 99,
          "offsetInEndSection": 159,
          "text": "Chlamydia trachomatis is one of its most common aetiologies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28057084",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 753,
          "offsetInEndSection": 877,
          "text": "Fitz-Hugh-Curtis syndrome is a common cause of right upper quadrant pain which is often under diagnosed in poor communities."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28057084",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 374,
          "offsetInEndSection": 576,
          "text": "A 32\u00a0year old African female presented with acute right upper quadrant abdominal pain and vaginal discharge, for which she had previously received treatment in another health center with no improvement."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28057084",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 878,
          "offsetInEndSection": 1032,
          "text": "Hence, it should be included as a differential diagnosis in patients presenting with right upper quadrant pain, especially in females of reproductive age."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28057084",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Fitz-Hugh-Curtis syndrome is defined as perihepatitis associated with pelvic inflammatory disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15341718",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "Chronic symptoms of abdominal pain and irregular bowel habits in women evoke a broad differential diagnosis including irritable bowel syndrome, infection, malabsorption, and inflammatory bowel disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15341718",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 320,
          "text": "Endometriosis, a common disorder in young women that can involve the intestinal tract, deserves consideration as well."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15341718",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 321,
          "offsetInEndSection": 452,
          "text": "Intestinal endometriosis is typically asymptomatic; however, when symptoms occur, they can mimic those of irritable bowel syndrome."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15341718",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 453,
          "offsetInEndSection": 575,
          "text": "Identifying intestinal endometriosis can be challenging, but historical points and key clinical features aid in diagnosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36759100",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 220,
          "text": "Endometriosis is a common cause of cyclical pelvic pain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36759100",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 66,
          "offsetInEndSection": 163,
          "text": "Fibroids can be asymptomatic or present with heavy menstrual bleeding, pelvic pressure, and pain."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36759100",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65,
          "text": "Fibroids, endometriosis, and ovarian cysts are common conditions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36759100",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 431,
          "offsetInEndSection": 547,
          "text": "Fibroids can be managed medically or surgically depending on the patient's symptoms and desire for future fertility."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36759100",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 221,
          "offsetInEndSection": 272,
          "text": "Ovarian cysts are generally diagnosed incidentally."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6769152",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "The Fitz-Hugh--Curtis syndrome is an extragenital manifestation of gonorrhea, characterized by fibrinous inflammation of the subphrenic area with violinstring-like adhesions between the liver surface and the parietal peritoneum."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6769152",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 229,
          "offsetInEndSection": 510,
          "text": "When such patients present with acute upper right quadrant pain, the differential diagnosis to other abdominal emergencies (cholecystitis, peptic ulcer disease etc.) may be difficult, because it will not always be possible to isolate the causative agent from the external genitals."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6769152",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 586,
          "offsetInEndSection": 648,
          "text": "Two case reports are discussed in the light of the literature."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6769152",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 511,
          "offsetInEndSection": 585,
          "text": "In such cases only a laparoscopic approach will allow a correct diagnosis."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Bacterial vaginosis is the most common cause of vaginitis, affecting over 3 million women in the United States annually."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1510,
          "offsetInEndSection": 1636,
          "text": "The association between bacterial vaginosis and adverse pregnancy outcomes has satisfied many criteria for a causal inference."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 1637,
          "offsetInEndSection": 1803,
          "text": "Treatment of bacterial vaginosis in women with previous history of preterm labor results in fewer preterm deliveries than in untreated women from the same population."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 275,
          "offsetInEndSection": 372,
          "text": "To date, no scientific evidence shows that bacterial vaginosis is a sexually transmitted disease."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11025268",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 274,
          "text": "Depopulation of lactobacilli from the normal vaginal flora and overgrowth of Gardnerella vaginalis and other anaerobic species are the presumed etiology."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145720",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 374,
          "text": "Symptoms for up to 50 percent of women experiencing fibroids include heavy menstrual bleeding, pelvic pressure or pain and gastrointestinal and genitourinary changes."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145720",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 821,
          "text": "Given the high prevalence of fibroids and the potential for women's health implications, it is essential that clinicians are aware of the latest evidence regarding fibroids to provide the highest quality of care for women whose health is affected by this condition."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145720",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Uterine fibroids are the most common type of benign gynecologic mass, and are present in up to 80 percent of women."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145720",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 375,
          "offsetInEndSection": 451,
          "text": "Diagnosis is made by history and symptoms, physical examination and imaging."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145720",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 116,
          "offsetInEndSection": 207,
          "text": "Research exploring risk factors for fibroids presents conflicting or inconclusive findings."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18372219",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 859,
          "offsetInEndSection": 1022,
          "text": "Abnormal bleeding occurs in 30% of symptomatic women, and abnormal bleeding, bloating and pelvic discomfort due to mass effect constitute the most common symptoms."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18372219",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 211,
          "offsetInEndSection": 500,
          "text": "Clinically, they present with a variety of symptoms: menstrual disturbances including menorrhagia, dysmenorrhoea and intermenstrual bleeding; pelvic pain unrelated to menstruation; and pressure symptoms such as a sensation of bloatedness, increased urinary frequency and bowel disturbance."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18372219",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 210,
          "text": "However, in other women, they cause significant morbidity and affect quality of life."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18372219",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 501,
          "offsetInEndSection": 764,
          "text": "In addition, they may compromise reproductive function, possibly contributing to subfertility, early pregnancy loss and later pregnancy complications such as pain, preterm labour, malpresentations, increased need for caesarean section, and postpartum haemorrhage."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18372219",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Uterine fibroids, the most common tumours in women of reproductive age, are asymptomatic in at least 50% of afflicted women."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15894210",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "The objective of this short review is to identify the particularities of women with endometriosis, especially those complaining of pain and with the most severe lesions."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15894210",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 652,
          "offsetInEndSection": 789,
          "text": "Endometriosis is often associated with other painful conditions such as irritable bowel syndrome, interstitial cystitis and fibromyalgia."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15894210",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 440,
          "offsetInEndSection": 651,
          "text": "The woman with endometriosis seems more sensitive to pain through various mechanisms, such as central hypersensitivity and decrease threshold to somatoceptive pain and several associated psychological disorders."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15894210",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 346,
          "offsetInEndSection": 439,
          "text": "The abnormalities of the endometrium, with exacerbated biological activities, are an example."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15894210",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 170,
          "offsetInEndSection": 345,
          "text": "Genetic aberrations play, with a high probability, a major role in the development of this disease, its severity, its tendency to recur and also in its capacity to degenerate."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 547,
          "offsetInEndSection": 738,
          "text": "The independent traditional risk factors, various clinical outcomes, and increased prevalence among certain populations and geographical regions have led increasing interest in HPV infection."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Human papillomaviruses (HPVs) infect epithelial cells of human beings, and their replication cycle is associated with epithelial differentiation."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 272,
          "offsetInEndSection": 366,
          "text": "HPV infection was involved in the development of lesions on the feet, genital warts and hands."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 857,
          "offsetInEndSection": 1021,
          "text": "This review concludes present knowledge about HPV infection, virulence strains, clinical significance of HPVs, and mode of transmission, and vaccination strategies."
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
          "beginSection": "abstract",
          "endSection": "abstract",
          "offsetInBeginSection": 367,
          "offsetInEndSection": 546,
          "text": "The evidence of HPV infection revealed the role of HPVs in neck and head squamous cell carcinoma, esophageal cancer, cervical cancer, head and neck cancer, brain and lung tumours."
        }
      ]
    }
  ]
}